Antigen binding polypeptides, antigen binding polypeptide complexes and methods of use thereof

ABSTRACT

Disclosed are antigen binding polypeptides and antigen binding polypeptide complexes (e.g., antibodies and antigen binding fragments thereof) having certain structural features. Also disclosed are polynucleotides and vectors encoding such polypeptides and polypeptide complexes; host cells, chimeric antigen receptors (CARs), immune cells, pharmaceutical compositions and kits containing such polypeptides and polypeptide complexes; and methods of using such polypeptides and polypeptide complexes.

CROSS REFERENCE TO RELATED APPLICATIONS

This application claims the priority benefit of U.S. ProvisionalApplication No. 63/249,833, filed Sep. 29, 2021; U.S. ProvisionalApplication No. 63/249,794, filed Sep. 29, 2021; U.S. ProvisionalApplication No. 63/249,919, filed Sep. 29, 2021; U.S. ProvisionalApplication No. 63/249,722, filed Sep. 29, 2021; U.S. ProvisionalApplication No. 63/291,305, filed Dec. 17, 2021; and U.S. ProvisionalApplication No. 63/292,382, filed Dec. 21, 2021; which are allincorporated herein by reference in their entireties.

REFERENCE TO SEQUENCE LISTING SUBMITTED ELECTRONICALLY

The content of the electronically submitted sequence listing (Name:4850_0030001_SeqListing_ST26; Size: 1,196,609 bytes; Date of Creation:Sep. 26, 2022) is herein incorporated by reference in its entirety.

FIELD

The present disclosure relates to antigen binding polypeptides andantigen binding polypeptide complexes (e.g., antibodies and antigenbinding fragments thereof) having certain structural features. Thepresent disclosure also relates to polynucleotides and vectors encodingsuch polypeptides and polypeptide complexes; host cells, chimericantigen receptors (CARs), immune cells, pharmaceutical compositions andkits containing such polypeptides and polypeptide complexes; and methodsof using such polypeptides and polypeptide complexes.

BACKGROUND

Immunotherapy is the treatment of disease by activating or suppressingthe immune system. In recent years, immunotherapy has become of greatinterest to researchers and clinicians, particularly in its promise totreat cancer and infectious disease. Therapeutic antibodies are animportant type of immunotherapy. Therapeutic antibodies can bemonospecific, meaning that they have specificity to one antigen orepitope. Therapeutic antibodies have also been engineered to havespecificity for two different antigens or epitopes (i.e., bispecificantibodies) or for multiple different antigens or epitopes (trispecificantibodies, tetraspecific antibodies, etc.). In addition, monospecific,bispecific and multispecific antibodies have been combined to formmulti-targeting strategies to treat complex human diseases, such ascancer and infectious disease.

However, the development of therapeutic antibodies can be challenging,especially manufacturing and late stage development. For example, theproduction of bispecific or multispecific antibodies often requiresmultiple genes or plasmids for cell line development. These multiplegenes or plasmids must be delivered into the same cell to make thecorrect molecules. Furthermore, bispecific and multispecific antibodiescan have mispairing between the heavy and light chains, which can reduceproduct yield, increase cell line colony screen workload, and createproduct heterogeneity.

There is a need for multispecific and multifunctional antigen bindingpolypeptides and antigen binding polypeptide complexes that can bind tospecific combinations of target molecules for selectivity orbreadth/neutralization, bring together two or more cell types, bringtogether targets and deliver activation signals, modify the diseasemicroenvironment, and enhance avidity of binding for improved potency.The present invention meets this unmet need.

In addition, human immunodeficiency virus (HIV) poses a major infectiousdisease burden with immense medical and economic impact around theworld. Globally, −38 million people have been infected with HIV, andmore than 30 million individuals have succumbed to acquiredimmunodeficiency syndrome (AIDS), a chronic condition of weakened immunesystem caused by HIV infection. “Global Health Sector Strategy OnHIV—2016-2021-Towards Ending AIDS,” World Health Organization, June2016. There are two major forms of HIV: HIV-1 and HIV-2. HIV-1 is themore prevalent form worldwide, while HIV-2 is less pathogenic and mostlyconfined to West Africa.

The major structural proteins of HIV are Gag, Pol and Env. Gag (groupspecific antigen) is the structural protein for the viral core. Pol is apolyprotein containing the enzymes critical for viral replication:protease (PR), reverse transcriptase (RT), and integrase (IN). Env(envelope) encodes glycoproteins that form the virus's exteriorenvelope. Env is synthesized as a precursor glycoprotein, gp160, and isthen processed into gp120 and gp41. Env interacts with the primaryreceptor CD4 and a coreceptor (such as chemokine receptor CCR5) to fuseviral and target-cell membranes.

The genetic heterogeneity and glycan shielding of Env have resisted thedevelopment of natural immunity to HIV and posed challenges totraditional vaccine development. It has also prompted a search foralternative approaches to HIV prevention, one of the highest prioritiesin global health.

Despite a significant collection of anti-HIV/AIDS drugs available, HIVpatients still face daily challenges in taking multiple medicines withstrict regimens. Inevitably, most patients will bear the consequences ofemergence of drug-resistant viral variants, and develop other healthissues from the toxicities of taking anti-HIV medicines long term, suchas cardiovascular disease, kidney disease, diabetes, bone disease, liverdisease, cognitive disorders, etc. Alternative treatment options areurgently needed for HIV/AIDS patients.

Broadly neutralizing HIV-1 antibodies (bnAbs) are antibodies thatneutralize multiple HIV-1 viral strains. bnAbs target conserved epitopesof the virus, meaning that the targeted epitopes may be more likely toremain even if the virus mutates. As such, bnAbs have been investigatedrecently for HIV/AIDS treatment and prevention. Human clinical studieshave revealed two factors critical for efficacy of bnAbs. First, thereis the need to exceed a minimally effective dose, or trough level ofcirculating bnAbs to prevent infection. Second, there is a need toprevent the emergence of viral escape through resistance mutations.

Early human clinical studies using bnAbs demonstrated the feasibilityand safety of this approach with transient reductions of viral load andacceptable tolerability and immunogenicity. Burton et al., Annu Rev.Immunol. 34:635-659 (2016); Mascola et al., Immunol. Rev. 254:225-244(2013); Wu et al., Science. 329:856-861 (2010). However, resistant HIVstrains emerged rapidly following treatment with individual bnAbs invitro and in vivo. More recently, a phase II clinical trial with theVRC01 bnAb highlighted the importance of maintaining adequatecirculating antibody levels to reduce acquisition rates, suggesting thatcombination antibody therapy which enhances potency and minimizes escapemutations will be required for effective prevention. Corey et al., N.Engl. J. Med. 384:1003-1014 (2021).

Multispecific antibodies address the limitations of bnAbs by providing asingle antibody type that recognizes multiple independent binding siteson HIV-1 envelope protein. Xu et al., Science. 358(6359):85-90 (2017).Treatment with multispecific antibodies also ensures that independentbinding specificities are maintained with the same pharmacokinetics,while treatment with multiple single-target antibodies results indifferent antibody half-lives that wane at different rates. Furthermore,multispecific antibodies simplify manufacturing and regulatory processesby using one product for clinical development instead of a combinationof multiple products.

Accordingly, multispecific anti-HIV antibodies provide an importanttechnological platform for developing neutralizing antibody-basedtherapeutics for treating HIV/AIDS, offering a class of medicines withlow long-term toxicities and significantly less frequent treatmentregimen. Multispecific antibodies also use completely different targetson HIV from the current standard of care HIV/AIDS medicine,complementing to the existing medicines by providing patientsalternatives for their disease control and health management.Multispecific antibodies may also offer a meaningful way for HIVprevention in the current absence of an effective HIV vaccine.

In addition, the development of therapeutic antibodies can bechallenging, especially manufacturing and late stage development. Forexample, the production of multispecific antibodies often requiresmultiple genes or plasmids for cell line development. These multiplegenes or plasmids must be delivered into the same cell to make thecorrect molecules. Furthermore, multispecific antibodies can havemispairing between the heavy and light chains, which can reduce productyield, increase cell line colony screen workload, and create productheterogeneity.

As such, there is a need for multispecific and multifunctionalantibodies, antigen binding polypeptides and antigen binding polypeptidecomplexes that can bind to HIV proteins for selectivity orbreadth/neutralization, bring together two or more cell types, bringtogether targets and deliver activation signals, modify the HIVmicroenvironment, and enhance avidity of binding for improved potency.The present invention meets this unmet need.

BRIEF SUMMARY

Provided herein is an antigen binding polypeptide having a structurerepresented by VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1;VL1-L1-VL2-L2-VH2-L3-VH1; or VH1-L1-VH2-L2-VL2-L3-VL1; wherein VL1 is afirst immunoglobulin light chain variable region; VL2 is a secondimmunoglobulin light chain variable region; VH1 is a firstimmunoglobulin heavy chain variable region; VH2 is a secondimmunoglobulin heavy chain variable region; and L1, L2 and L3 are aminoacid linkers.

Provided herein is an antigen binding polypeptide complex comprising afirst polypeptide and a second polypeptide; wherein the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1;VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1; or VH1-L1-VH2-L2-VL2-L3-VL1;wherein the second polypeptide has a structure represented byVL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1; orVH1-L1-VH2-L2-VL2-L3-VL1; wherein VL1 is a first immunoglobulin lightchain variable region; VL2 is a second immunoglobulin light chainvariable region; VH1 is a first immunoglobulin heavy chain variableregion; VH2 is a second immunoglobulin heavy chain variable region; andL1, L2 and L3 are amino acid linkers.

Provided herein is an antigen binding polypeptide having a structurerepresented by VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc; or VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc;wherein VL1 is a first immunoglobulin light chain variable region; VL2is a second immunoglobulin light chain variable region; VH1 is a firstimmunoglobulin heavy chain variable region; VH2 is a secondimmunoglobulin heavy chain variable region; Fc is a region comprising animmunoglobulin heavy chain constant region 2 (CH2), an immunoglobulinheavy chain constant region 3 (CH3), and optionally, an immunoglobulinhinge; and L1, L2, L3 and L4 are amino acid linkers.

Provided herein is an antigen binding polypeptide complex comprising afirst polypeptide and a second polypeptide; wherein the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-Fc;VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; wherein the second polypeptide has astructure represented by Fc; VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc; or VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc;wherein VL1 is a first immunoglobulin light chain variable region; VL2is a second immunoglobulin light chain variable region; VH1 is a firstimmunoglobulin heavy chain variable region; VH2 is a secondimmunoglobulin heavy chain variable region; Fc is a region comprising animmunoglobulin heavy chain constant region 2 (CH2), an immunoglobulinheavy chain constant region 3 (CH3), and optionally, an immunoglobulinhinge; and L1, L2, L3 and L4 are amino acid linkers.

Provided herein is an antigen binding polypeptide having a structurerepresented by VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL;VL1-VL2-VH2-VH1-CL-CH1; VH1-VH2-VL2-VL1-CL-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-CL; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-CL;VL1-L1-VL2-L2-VH2-L3- VH1-L4-CL-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; wherein VL1 is a firstimmunoglobulin light chain variable region; VL2 is a secondimmunoglobulin light chain variable region; VH1 is a firstimmunoglobulin heavy chain variable region; VH2 is a secondimmunoglobulin heavy chain variable region; CH1 is an immunoglobulinheavy chain constant region 1; CL is an immunoglobulin light chainconstant region; and L1, L2, L3, L4 and L5 are amino acid linkers.

Provided herein is an antigen binding polypeptide complex comprising afirst polypeptide and a second polypeptide; wherein the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; wherein the second polypeptidehas a structure represented by VL1-VL2-VH2-VH1-CH1; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1- VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; or VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; wherein VL1is a first immunoglobulin light chain variable region; VL2 is a secondimmunoglobulin light chain variable region; VH1 is a firstimmunoglobulin heavy chain variable region; VH2 is a secondimmunoglobulin heavy chain variable region; CH1 is an immunoglobulinheavy chain constant region 1; CL is an immunoglobulin light chainconstant region; and L1, L2, L3, L4 and L5 are amino acid linkers.

Provided herein is an antigen binding polypeptide having a structurerepresented by VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc; wherein VL1 is a firstimmunoglobulin light chain variable region; VL2 is a secondimmunoglobulin light chain variable region; VH1 is a firstimmunoglobulin heavy chain variable region; VH2 is a secondimmunoglobulin heavy chain variable region; CH1 is an immunoglobulinheavy chain constant region 1; CL is an immunoglobulin light chainconstant region; and Fc is a region comprising an immunoglobulin heavychain constant region 2 (CH2), an immunoglobulin heavy chain constantregion 3 (CH3), and optionally, an immunoglobulin hinge; and L1, L2, L3,L4 and L5 are amino acid linkers.

Provided herein is an antigen binding polypeptide complex comprising afirst polypeptide and a second polypeptide; wherein the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc; wherein the second polypeptidehas a structure represented by Fc; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fe;VL1-L1-VL2-L2-VH2- L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc; wherein VL1 is a firstimmunoglobulin light chain variable region; VL2 is a secondimmunoglobulin light chain variable region; VH1 is a firstimmunoglobulin heavy chain variable region; VH2 is a secondimmunoglobulin heavy chain variable region; CH1 is an immunoglobulinheavy chain constant region 1; CL is an immunoglobulin light chainconstant region; Fc is a region comprising an immunoglobulin heavy chainconstant region 2 (CH2), an immunoglobulin heavy chain constant region 3(CH3), and optionally, an immunoglobulin hinge; and L1, L2, L3, L4 andL5 are amino acid linkers.

Provided herein is an antigen binding polypeptide complex comprising afirst polypeptide and a second polypeptide; wherein the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1;VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1;VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3- VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc; wherein the second polypeptidehas a structure represented by Fc; VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1;VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fc;VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1- L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1- L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc; wherein VL1 is a firstimmunoglobulin light chain variable region; VL2 is a secondimmunoglobulin light chain variable region; VH1 is a firstimmunoglobulin heavy chain variable region; VH2 is a secondimmunoglobulin heavy chain variable region; CH1 is an immunoglobulinheavy chain constant region 1; CL is an immunoglobulin light chainconstant region; Fc is a region comprising an immunoglobulin heavy chainconstant region 2 (CH2), an immunoglobulin heavy chain constant region 3(CH3), and optionally, an immunoglobulin hinge; and L1, L2, L3, L4 andL5 are amino acid linkers.

Provided herein is an antigen binding polypeptide or antigen bindingpolypeptide complex comprising a polypeptide having a structurerepresented by VL1-VL2-VH2-VH1-Fc-Fc; VH1-VH2-VL2-VL1-Fc-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-Fc-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-Fc-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc-L5-Fc; or VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc-L5-Fc; wherein VL1 is a first immunoglobulin light chain variableregion; VL2 is a second immunoglobulin light chain variable region; VH1is a first immunoglobulin heavy chain variable region; VH2 is a secondimmunoglobulin heavy chain variable region; Fc is a region comprising animmunoglobulin heavy chain constant region 2 (CH2), an immunoglobulinheavy chain constant region 3 (CH3), and optionally, an immunoglobulinhinge; and L1, L2, L3, L4 and L5 are amino acid linkers.

Provided herein is an antigen binding polypeptide or antigen bindingpolypeptide complex comprising a polypeptide having a structurerepresented by VL1-VL2-VH2-VH1-CH3; VH1-VH2-VL2-VL1-CH3;VL1-L1-VL2-L2-VH2-L3-VH1-CH3; VH1-L1-VH2-L2-VL2-L3-VL1-CH3;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH3; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH3;VL1-VL2-VH2-VH1-CH3-CH3; VH1-VH2-VL2-VL1-CH3-CH3;VL1-L1-VL2-L2-VH2-L3-VH1-CH3-CH3; VH1-L1-VH2-L2-VL2-L3-VL1-CH3-CH3;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH3-CH3;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH3-CH3;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH3-L5-CH3; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CH3-L5-CH3; wherein VL1 is a firstimmunoglobulin light chain variable region; VL2 is a secondimmunoglobulin light chain variable region; VH1 is a firstimmunoglobulin heavy chain variable region; VH2 is a secondimmunoglobulin heavy chain variable region; CH3 is an immunoglobulinheavy chain constant region 3; and L1, L2, L3, L4 and L5 are amino acidlinkers.

Provided herein is an antigen binding polypeptide complex comprising afirst polypeptide and a second polypeptide; wherein the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1;VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1; or VH1-L1-VH2-L2-VL2-L3-VL1;wherein the second polypeptide has a structure represented byVL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3; VL3-L4-VL4-L5-VH4-L6-VH3; orVH3-L4-VH4-L5-VL4-L6-VL3; wherein VL1 is a first immunoglobulin lightchain variable region; VL2 is a second immunoglobulin light chainvariable region; VL3 is a third immunoglobulin light chain variableregion; VL4 is a fourth immunoglobulin light chain variable region; VH1is a first immunoglobulin heavy chain variable region; VH2 is a secondimmunoglobulin heavy chain variable region; VH3 is a thirdimmunoglobulin heavy chain variable region; VH4 is a fourthimmunoglobulin heavy chain variable region; and L1, L2, L3, L4, L5 andL6 are amino acid linkers.

Provided herein is an antigen binding polypeptide complex comprising afirst polypeptide and a second polypeptide; wherein the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-Fc;VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; wherein the second polypeptide has astructure represented by VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc;VL3-L5-VL4-L6-VH4-L7-VH3-Fc; VH3-L5-VH4-L6-VL4-L7-VL3-Fc;VL3-L5-VL4-L6-VH4-L7-VH3-L8-Fc; or VH3-L5-VH4-L6-VL4-L7-VL3-L8-Fc;wherein VL1 is a first immunoglobulin light chain variable region; VL2is a second immunoglobulin light chain variable region; VL3 is a thirdimmunoglobulin light chain variable region; VL4 is a fourthimmunoglobulin light chain variable region; VH1 is a firstimmunoglobulin heavy chain variable region; VH2 is a secondimmunoglobulin heavy chain variable region; VH3 is a thirdimmunoglobulin heavy chain variable region; VH4 is a fourthimmunoglobulin heavy chain variable region; Fc is a region comprising animmunoglobulin heavy chain constant region 2 (CH2), an immunoglobulinheavy chain constant region 3 (CH3), and optionally, an immunoglobulinhinge; and L1, L2, L3, L4, L5, L6, L7 and L8 are amino acid linkers.

Provided herein is an antigen binding polypeptide complex comprising afirst polypeptide and a second polypeptide; wherein the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; wherein the second polypeptidehas a structure represented by VL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1;VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL;VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL;VL3-L6-VL4-L7-VH4-L8-VH3- L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1; wherein VL1 is a firstimmunoglobulin light chain variable region; VL2 is a secondimmunoglobulin light chain variable region; VL3 is a thirdimmunoglobulin light chain variable region; VL4 is a fourthimmunoglobulin light chain variable region; VH1 is a firstimmunoglobulin heavy chain variable region; VH2 is a secondimmunoglobulin heavy chain variable region; VH3 is a thirdimmunoglobulin heavy chain variable region; VH4 is a fourthimmunoglobulin heavy chain variable region; CH1 is an immunoglobulinheavy chain constant region 1; CL is an immunoglobulin light chainconstant region; and L1, L2, L3, L4, L5, L6, L7, L8, L9 and L10 areamino acid linkers.

Provided herein is an antigen binding polypeptide complex comprising afirst polypeptide and a second polypeptide; wherein the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc; wherein the second polypeptidehas a structure represented by VL3-VL4-VH4-VH3-CH1-Fc;VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc;VL3-VL4-VH4-VH3-CH1-CL-Fc; VH3-VH4-VL4-VL3-CH1-CL-Fc;VL3-VL4-VH4-VH3-CL-CH1-Fc; VH3-VH4-VL4-VL3-CL-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8- VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc; wherein VL1 is a firstimmunoglobulin light chain variable region; VL2 is a secondimmunoglobulin light chain variable region; VL3 is a thirdimmunoglobulin light chain variable region; VL4 is a fourthimmunoglobulin light chain variable region; VH1 is a firstimmunoglobulin heavy chain variable region; VH2 is a secondimmunoglobulin heavy chain variable region; VH3 is a thirdimmunoglobulin heavy chain variable region; VH4 is a fourthimmunoglobulin heavy chain variable region; Fc is a region comprising animmunoglobulin heavy chain constant region 2 (CH2), an immunoglobulinheavy chain constant region 3 (CH3), and optionally, an immunoglobulinhinge; CH1 is an immunoglobulin heavy chain constant region 1; CL is animmunoglobulin light chain constant region; and L1, L2, L3, L4, L5, L6,L7, L8, L9 and L10 are amino acid linkers.

Provided herein is an antigen binding polypeptide complex comprising afirst polypeptide and a second polypeptide; wherein the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1;VH1-VH2-VL2-VL1; VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fc;VL1-VL2-VH2-VH1-CH1; VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL;VH1-VH2-VL2-VL1-CL; VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL;VL1-VL2-VH2-VH1-CL-CH1; VH1-VH2-VL2-VL1-CL-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1;VL1-L1-VL2-L2-VH2-L3-VH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1;VL1-L1-VL2-L2-VH2-L3-VH1- L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc; wherein the second polypeptidehas a structure represented by VL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3;VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc; VL3-VL4-VH4-VH3-CH1;VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL;VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1;VH3-VH4-VL4-VL3-CL-CH1; VL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc;VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fc;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3;VH3-L6-VH4-L7-VL4-L8-VL3; VL3-L6-VL4-L7-VH4-L8-VH3-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc; wherein VL1 is a firstimmunoglobulin light chain variable region; VL2 is a secondimmunoglobulin light chain variable region; VL3 is a thirdimmunoglobulin light chain variable region; VL4 is a fourthimmunoglobulin light chain variable region; VH1 is a firstimmunoglobulin heavy chain variable region; VH2 is a secondimmunoglobulin heavy chain variable region; VH3 is a thirdimmunoglobulin heavy chain variable region; VH4 is a fourthimmunoglobulin heavy chain variable region; Fc is a region comprising animmunoglobulin heavy chain constant region 2 (CH2), an immunoglobulinheavy chain constant region 3 (CH3), and optionally, an immunoglobulinhinge; CH1 is an immunoglobulin heavy chain constant region 1; CL is animmunoglobulin light chain constant region; and L1, L2, L3, L4, L5, L6,L7, L8, L9 and L10 are amino acid linkers.

Also provided herein is an antigen binding polypeptide or antigenbinding polypeptide complex that specifically binds to a viral peptideor an HIV protein.

Also provided herein is an antibody or antigen binding fragment thereofcomprising an antigen binding polypeptide or antigen binding polypeptidecomplex described herein.

Provided herein is a polypeptide having at least 90% identity, at least95% identity, or 100% identity to any one of SEQ ID NOs:32-43, 62-79,130-138, 633, 635, 637, 639, 641, 643, 645, 647, 649, 651, 653, 655,657, 659, 661, 663, 665, 667, 669, 671, 673, 675, 677, and 679. Alsoprovided herein is a polypeptide having at least 90% identity, at least95% identity, or 100% identity to the amino acid sequence of SEQ IDNOs:32 or 33 that does not contain the eight histidine residues at theC-terminus. Also provided herein is a polypeptide encoded by apolynucleotide having at least 90% identity, at least 95% identity, or100% identity to any one of SEQ ID NOs:44-55, 80-97, 139-147, 634, 636,638, 640, 642, 644, 646, 648, 650, 652, 654, 656, 658, 660, 662, 664,666, 668, 670, 672, 674, 676, 678, and 680.

Provided herein is a polynucleotide encoding an antigen bindingpolypeptide or antigen binding polypeptide complex described herein.Also provided herein is a polynucleotide having at least 90% identity,at least 95% identity, or 100% identity to any one of SEQ ID NOs:44-55,80-97, 139-147, 634, 636, 638, 640, 642, 644, 646, 648, 650, 652, 654,656, 658, 660, 662, 664, 666, 668, 670, 672, 674, 676, 678, and 680.Also provided herein is a polynucleotide encoding a polypeptide havingat least 90% identity, at least 95% identity, or 100% identity to anyone of SEQ ID NOs:32-43, 62-79, 130-138, 633, 635, 637, 639, 641, 643,645, 647, 649, 651, 653, 655, 657, 659, 661, 663, 665, 667, 669, 671,673, 675, 677, and 679, or a polynucleotide encoding a polypeptidehaving at least 90% identity, at least 95% identity, or 100% identity toan amino acid sequence of SEQ ID NO:32 or 33 that does not contain theeight histidine residues at the C-terminus.

Provided herein is a vector comprising a polynucleotide describedherein.

Provided herein is a host cell comprising a polynucleotide or vectordescribed herein.

Provided herein is a chimeric antigen receptor (CAR) comprising anantigen binding polypeptide or antigen binding polypeptide complexdescribed herein. Also provided herein is an immune cell comprising aCAR described herein.

Provided herein is a pharmaceutical composition comprising (i) anantigen binding polypeptide, antigen binding polypeptide complex,antibody or antigen binding fragment thereof, polypeptide,polynucleotide, vector, host cell, CAR or immune cell described herein,or a combination thereof, and (ii) a pharmaceutically acceptablecarrier.

Provided herein is a kit comprising an antigen binding polypeptide,antigen binding polypeptide complex, antibody or antigen bindingfragment thereof, polypeptide, polynucleotide, vector, host cell, CAR orimmune cell described herein, or a combination thereof.

Also provided herein are certain methods of use of an antigen bindingpolypeptide, antigen binding polypeptide complex, antibody or antigenbinding fragment thereof, polypeptide, polynucleotide, vector, hostcell, CAR or immune cell described herein, or a combination thereof.

BRIEF DESCRIPTION OF THE DRAWINGS

Some aspects of the invention are herein described, by way of exampleonly, with reference to the accompanying drawings. With specificreference now to the drawings in detail, it is stressed that theparticulars shown are by way of example and for purposes of illustrativediscussion of aspects of the invention.

FIGS. 1A-1F show configurations of exemplary bispecific molecules of theinvention from the N-terminus to the C-terminus of the single chainantigen binding polypeptide(s). FIGS. 1A and 1D: bispecific moleculeswithout Fc region. FIG. 1B: bispecific, tetravalent molecule with Fcregion. FIGS. 1C, 1E and 1F: bispecific molecules with Fc region. Asused in FIGS. 1A-1F, VL1 refers to a first immunoglobulin light chainvariable region, VL2 refers to a second immunoglobulin light chainvariable region, VH1 refers to a first immunoglobulin heavy chainvariable region, and VH2 refers to a second immunoglobulin heavy chainvariable region. In FIGS. 1B, 1C and 1F, CH2 refers to an immunoglobulinheavy chain constant region 2, and CH3 refers to an immunoglobulin heavychain constant region 3. In FIGS. 1A and 1F, l1, l2 and l3 refer toamino acid linkers. In FIG. 1D, L1, L2 and L3 refer to amino acidlinkers. In FIGS. 1C and 1F, the circle symbol refers to aknob-into-hole modification.

FIG. 2 shows SD S-PAGE results of Nickel-NTA (Ni-NTA)-purifiedbispecific molecules with histidine tags, as depicted in FIG. 1A.

FIGS. 3A-3B show ELISA results of bispecific molecule aCD19aCD38-His orisotype control (Control IgG) binding to CD19 (FIG. 3A) and CD38 (FIG.3B).

FIG. 4 shows SDS-PAGE results of protein A-purified bispecific,tetravalent molecules with LALAPA Fc, as depicted in FIG. 1B.

FIGS. 5A-5B show ELISA results of bispecific, tetravalentaCD28aCD3LALAPAFc, aCD3aCD28LALAPAFc, or isotype control (Control IgG)binding to CD3 (FIG. 5A) and CD28 (FIG. 5B). Molecule structures aredepicted in FIG. 1C.

FIG. 6 shows nuclear factor of activated T-cells (NFAT) pathwayactivation by bispecific, tetravalent aCD28aCD3L1LALAPAFc oraCD3aCD28L1LALAPAFc, or anti-CD3 and anti-CD28 mAbs using NFATpromoter-luciferase expressing human Jurkat T cells.

FIGS. 7A-7B show ELISA results of bispecific aCD28aCD3LALAPAFc oraCD3aCD28LALAPAFc, or isotype control (Control IgG) binding to CD3 (FIG.7A) and CD28 (FIG. 7B). Molecule structures are depicted in FIG. 1C.

FIGS. 8A-8C show configurations of exemplary tetraspecific molecules ofthe invention. VL1 refers to a first immunoglobulin light chain variableregion. VL2 refers to a second immunoglobulin light chain variableregion. VL3 refers to a third immunoglobulin light chain variableregion. VL4 refers to a fourth immunoglobulin light chain variableregion. VH1 refers to a first immunoglobulin heavy chain variableregion. VH2 refers to a second immunoglobulin heavy chain variableregion. VH3 refers to a third immunoglobulin heavy chain variableregion. VH4 refers to a fourth immunoglobulin heavy chain variableregion. CH1 refers to an immunoglobulin heavy chain constant region 1.CH2 refers to an immunoglobulin heavy chain constant region 2. CH3refers to an immunoglobulin heavy chain constant region 3. CL refers toan immunoglobulin light chain constant region. The circle symbol inFIGS. 8A-8C refers to a knob-into-hole modification.

FIGS. 9A-9D show ELISA results of tetraspecificaCD28aCD3CD19CD38LALAPAFc, aCD3aCD28CD19CD38LALAPAFc,aCD28aCD3CD19CD38LALAPAFc, or aCD28aCD3CD38CD19LALAPAFc, or isotypecontrol (Control IgG) binding to CD3 (FIG. 9A), CD28 (FIG. 9B), CD19(FIG. 9C), and CD38 (FIG. 9D). Molecule structures are depicted in FIG.8A.

FIG. 10 shows NFκB pathway activation by tetraspecificaCD28aCD3/aCD19CD38L1LALAPAFc or aCD3aCD28/CD19CD38L1LALAPAFc, oranti-CD3 mAbs using NFκB promoter-luciferase expressing human Jurkat Tcells.

FIGS. 11A-11B show activation (CD69+) by tetraspecific moleculesaCD28aCD3/aCD19CD38L1LALAPAFc or aCD3aCD28/CD19CD38L1LALAPAFc, oranti-CD3 mAb, of CD4+(FIG. 11A) or CD8+(FIG. 11B) T cells from threedifferent donors.

FIG. 12 shows both orientation and linker can affect expression oftetraspecific molecules.

FIGS. 13A-13D show ELISA results of tetraspecificaCD28aCD3CD19CD38LALAPAFc with different linker lengths as depicted inFIG. 12 , or isotype control (Control IgG) binding to CD3 (FIG. 13A),CD28 (FIG. 13B), CD19 (FIG. 13C), and CD38 (FIG. 13D).

FIGS. 14A-14D show ELISA results of tetraspecificaCD28aCD3CH1/CD19CD38CL LALAPAFc with different linkers as depicted inFIG. 8B, or isotype control (Control IgG) binding to CD3 (FIG. 14A),CD28 (FIG. 14B), CD38 (FIG. 14C), and CD19 (FIG. 14D).

FIGS. 15A-15D show ELISA results of tetraspecificaCD28aCD3CD38CD19LALAPAFc, aCD28aCD3CD38CD19LALAPAFc,aCD28aCD3CD38CD19LALAPAFc, or aCD3aCD28CD19CD38LALAPAFc, or isotypecontrol (Control IgG) binding to CD3 (FIG. 15A), CD28 (FIG. 15B), CD38(FIG. 15C), and CD19 (FIG. 15D). Molecule structures are depicted inFIG. 8C.

FIGS. 15E-15H show ELISA results of tetraspecificaCD28aCD3L1/aCD38aCD19L1_HHLL, aCD28aCD3L1/aCD19aCD38L1_HHLL,aCD3aCD28L1/aCD38aCD19L1_HHLL, aCD3aCD28L1/aCD19aCD38L1_HHLL, or isotypecontrol (Control HuIgG) binding to CD3 (FIG. 15E), CD28 (FIG. 15F), CD38(FIG. 15G), and CD19 (FIG. 15H).

FIGS. 16A-16D show configurations of exemplary bispecific molecules ofthe invention. VL1 refers to a first immunoglobulin light chain variableregion. VL2 refers to a second immunoglobulin light chain variableregion. VL3 refers to a third immunoglobulin light chain variableregion. VL4 refers to a fourth immunoglobulin light chain variableregion. VH1 refers to a first immunoglobulin heavy chain variableregion. VH2 refers to a second immunoglobulin heavy chain variableregion. VH3 refers to a third immunoglobulin heavy chain variableregion. VH4 refers to a fourth immunoglobulin heavy chain variableregion. CH3 refers to an immunoglobulin heavy chain constant region 3.

FIGS. 17A-17E show exemplary configurations of trispecific antibodymolecules of the invention. FIG. 17A: bispecific arm paired withscFv-Fc. FIG. 17B: bispecific arm paired with Fab-Fc. FIG. 17C:bispecific arm paired with single-chain Fab (scFab). FIG. 17D:bispecific arm paired with scFv-single chain CL-CH1-Fc. FIG. 17E:bispecific arm fused to CH1 and paired with scFv-CL-Fc.

FIGS. 18A-18C show ELISA results of trispecific aCD28aCD3/aCD38scFv,aCD28aCD3/aCD38Fab, aCD28aCD3/aCD38scFab, aCD28aCD3/aCD38CLCH1, orisotype control (Control IgG) binding to CD3 (FIG. 18A), CD28 (FIG.18B), and CD38 (FIG. 18C). Molecule structures are depicted in FIGS.17A-17D.

FIG. 19 shows the activation (CD69+) by trispecific antibodiesaCD28aCD3L1/aCD38scFv, aCD3aCD28/aCD38scFv, aCD28aCD3/aCD38scFab,aCD3aCD28/aCD38scFab, PMA/IO positive or negative isotype (Control IgG)control, of CD2+ T cells from three different donors.

FIGS. 20A-20C show in vitro cytolysis of lymphoma tumor cells Z-138 by Tcells mediated by trispecific antibodies aCD28aCD3L1/aCD38scFv,aCD3aCD28/aCD38 scFv, aCD28aCD3/aCD38scFab, aCD3aCD28/aCD38scFab, PMA/IOor isotype (Control IgG) control from three different donors (FIGS.20A-20C, respectively).

FIGS. 21A-21D show ELISA results of trispecificaCD28aCD3CL1CH1/aCD38scFvCL, aCD28aCD3CL1CH1/aCD19scFvCL, or isotypecontrol (Control IgG) binding to CD3 (FIG. 21A), CD28 (FIG. 21B), CD19(FIG. 21C), and CD38 (FIG. 21 D). Molecule structures are depicted inFIG. 17E.

FIG. 22 shows non-limiting examples of different configurations ofpentaspecific antibody molecules. vL1 is a first immunoglobulin lightchain variable region. vL2 is a second immunoglobulin light chainvariable region. vL3 is a third immunoglobulin light chain variableregion. vL4 is a fourth immunoglobulin light chain variable region. vL5is a fifth immunoglobulin light chain variable region. vH1 is a firstimmunoglobulin heavy chain variable region. vH2 is a secondimmunoglobulin heavy chain variable region. vH3 is a thirdimmunoglobulin heavy chain variable region. vH4 is a fourthimmunoglobulin heavy chain variable region. vH5 is a fifthimmunoglobulin heavy chain variable region. CH2 is an immunoglobulinheavy chain constant region 2. CH3 is an immunoglobulin heavy chainconstant region 3. The circle symbol in the CH3 region indicates aknob-into-hole modification.

FIGS. 23A-23D show ELISA results of pentaspecificaCD28aCD3LHaCD38/aCD19aCD20, aCD28aCD3LHaCD38/aCD20aCD19,aCD28aCD3HLaCD38/aCD19aCD20, aCD28aCD3HLaCD38/aCD20aCD19, or isotypecontrol (Control IgG) binding to CD3 (FIG. 23A), CD28 (FIG. 23B), CD38(FIG. 23C), and CD19 (FIG. 23D). Molecule structures are depicted inFIG. 22 .

FIG. 24 shows additional non-limiting examples of differentconfigurations of tetraspecific antibody molecules.

FIG. 25 depicts an exemplary configuration of a masked tetraspecificantibody. Variable domains (Fv) of the antibody are shown as heavychain/light chain pairs, with Fv1-Fv3 targeting tumor associatedantigens (TAAs) or immune costimulatory receptors, and a fourth Fvtargeting CD3 (αCD3 or aCD3). In some aspects, linkers between Fv3 andαCD3 contain one or more protease recognition sites.

FIG. 26 shows SDS-PAGE results of in vitro cleavage of exemplary maskedtetraspecific molecules as depicted. Molecules were treated with eitherMTP or MMP9 protease as specified.

FIG. 27 shows ELISA binding results of exemplary masked tetraspecificmolecules as depicted in FIG. 26 , or negative isotype (Control IgG1),with or without protease treatment. Molecules cleaved or not cleaved byMTP or MMP9 as specified were tested for binding affinity to Trop2 andcMet.

FIG. 28 shows ELISA binding results of exemplary masked tetraspecificmolecules as depicted in FIG. 26 , or negative isotype (Control IgG1),with or without protease treatment. Molecules cleaved or not cleaved byMTP or MMP9 as specified were tested for binding affinity to CD28.

FIG. 29 shows ELISA binding results of exemplary masked tetraspecificmolecules as depicted in FIG. 26 , or negative isotype (Control IgG1),with or without protease treatment. Molecules cleaved or not cleaved byMTP or MMP9 as specified were tested for binding affinity to CD3.

FIG. 30 shows cytolysis of HCC1954 tumor cells by PBMCs (E:T:10:1)mediated by exemplary masked tetraspecific molecules as depicted in FIG.2 , or negative isotype (Control IgG1), from PBMCs of two donors(KP63250 and KP63251).

FIG. 31 shows ELISA binding results of exemplary non-maskedtetraspecific molecules as depicted, or negative isotype (hIgG1LALPA)control, to their respective targets of hTrop2, hcMet, hCD28, and hCD3.

FIG. 32 shows CD69+ activation by exemplary non-masked tetraspecificmolecules, or negative isotype (IgG1LALPA) control, of CD2+ T cells fromPBMCs of two different donors.

FIG. 33 shows an additional non-limiting example of a tetraspecificantibody molecule.

FIG. 34A shows a further non-limiting example of a tetravalent,bispecific antibody configuration, called MX846. MX846 was analyzed forbinding to CD3 by biolayer interferometry (BLI) (FIG. 34B), and to CD20by flow cytometry (FIG. 34C).

FIG. 35A shows a further non-limiting example of a tetravalent,trispecific antibody configuration, called MX855. MX855 was analyzed forbinding to CD3 and CD28 by biolayer interferometry (BLI) (FIG. 35B), andto CD20 by flow cytometry (FIG. 35C).

FIG. 36A shows a further non-limiting example of a tetraspecificantibody configuration, called MX851. MX851 was analyzed for binding toCD3, CD28 and BCMA by biolayer interferometry (BLI) (FIG. 36B), and toCD20 by flow cytometry (FIG. 36C).

FIG. 37A shows a further non-limiting example of a tetraspecificantibody configuration, called MX853. MX853 was analyzed for binding toCD3, CD28 and BCMA by biolayer interferometry (BLI) (FIG. 37B), and toCD20 by flow cytometry (FIG. 37C).

FIGS. 38A-38B show killing of Mantle Cell lymphoma cell line Z-138 byT-cells mediated by tetravalent, tetraspecific MX851 (FIG. 38A) andtetravalent, trispecific MX855 (FIG. 38B).

FIG. 39A shows a further non-limiting example of a trispecific antibodyconfiguration, called MX894 (VRC01scFv/PGT121×10e8v4L1IgG1LS). MX894 wasanalyzed for binding to 10e8 fusion peptide (FIG. 39B), and CD4site-dependent (FIG. 39C) and CD4 site-independent (FIG. 39D) HIV spikeprotein by biolayer interferometry (BLI).

FIG. 40A shows a further non-limiting example of a tetraspecificantibody configuration, called MX873 (VRC26.25×10-1074L9/VRC01×PGT121L1IgG1LS). MX873 was analyzed for binding to CD4 site-dependent (FIG. 40B)and CD4 site-independent (FIG. 40C) HIV spike protein by biolayerinterferometry (BLI).

FIG. 41A shows a further non-limiting example of a tetraspecificantibody configuration, called MX875 (10-1074×VRC26.25L9/VRC01×PGT121L1IgG1LS). MX875 was analyzed for binding to CD4 site-dependent (FIG. 41B)and CD4 site-independent (FIG. 41C) HIV spike protein by biolayerinterferometry (BLI).

FIG. 42A shows a further non-limiting example of a tetraspecificantibody configuration, called MX877(STAR_VRC26.25×PGT128L9/STAR_VRC01×PGT121L1 IgG1LS). MX877 was analyzedfor binding to CD4 site-dependent (FIG. 42B) and CD4 site-independent(FIG. 42C) HIV spike protein by biolayer interferometry (BLI).

DETAILED DESCRIPTION OF THE INVENTION

The invention is directed to antigen binding polypeptides and antigenbinding polypeptide complexes (e.g., antibodies or antigen bindingfragments thereof) having improved features. In some aspects, theinvention enables the generation of multispecific and multifunctionalantigen binding polypeptides and antigen binding polypeptide complexesthrough the expression of complementary self-assembling heavy and lightchains expressed with a single polypeptide per arm and, optionally, withthe addition of specific amino acid linkers. Because of thismultifunctionality, antigen binding polypeptides and antigen bindingpolypeptide complexes of the invention can bind to specific combinationsof target molecules for selectivity or breadth/neutralization, bringtogether two or more cell types, bring together targets and deliveractivation signals, modify the disease microenvironment, and enhanceavidity of binding for improved potency.

Various terms relating to aspects of disclosure are used throughout thespecification and claims Such terms are to be given their ordinarymeaning in the art, unless otherwise indicated. Other specificallydefined terms are to be construed in a manner consistent with thedefinition provided herein.

Definitions

As used herein, the term “antigen binding polypeptide” refers to apolypeptide having the ability to specifically bind to one or moresubstances that induce an immune response (i.e., one or more antigens orepitopes).

As used herein, the term “antigen binding polypeptide complex” refers toa group of two, three, four, or more associated polypeptides, wherein atleast one polypeptide has the ability to specifically bind to one ormore antigens. An antigen binding polypeptide complex, includes, but isnot limited to, an antibody or antigen binding fragment thereof.

The term “antibody” includes, without limitation, a glycoproteinimmunoglobulin which binds specifically to an antigen and comprises atleast two heavy (H) chains and two light (L) chains interconnected bydisulfide bonds. Each H chain comprises a heavy chain variable region(abbreviated herein as VH) and a heavy chain constant region. The heavychain constant region comprises three constant domains, CH1, CH2 andCH3. Each light chain comprises a light chain variable region(abbreviated herein as VL) and a light chain constant region. The lightchain constant region comprises one constant domain, CL. The VH and VLregions can be further subdivided into regions of hypervariability,termed complementarity determining regions (CDRs), interspersed withregions that are more conserved, termed framework regions (FR). Each VHand VL comprises three CDRs and four FRs, arranged from amino-terminusto carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3,CDR3, FR4. The variable regions of the heavy and light chains contain abinding domain that interacts with an antigen. The constant regions ofthe antibodies may mediate the binding of the immunoglobulin to hosttissues or factors, including various cells of the immune system (e.g.,effector cells) and the first component (C1q) of the classicalcomplement system. A heavy chain may have the C-terminal lysine or not.Unless specified otherwise herein, the amino acids in the variableregions are numbered using the Kabat numbering system and those in theconstant regions are numbered using the EU system.

The term “monoclonal antibody,” as used herein, refers to an antibodythat is produced by a single clone of B-cells and binds to the sameepitope. In contrast, the term “polyclonal antibody” refers to apopulation of antibodies that are produced by different B-cells and bindto different epitopes of the same antigen. The term “antibody” includes,by way of example, monoclonal and polyclonal antibodies; chimeric andhumanized antibodies; human or non-human antibodies; wholly syntheticantibodies; and single chain antibodies. A non-human antibody can behumanized by recombinant methods to reduce its immunogenicity in man.

The antibody can be an antibody that has been altered (e.g., bymutation, deletion, substitution, conjugation to a non-antibody moiety).For example, an antibody can include one or more variant amino acids(compared to a naturally occurring antibody) which change a property(e.g., a functional property) of the antibody. For example, several suchalterations are known in the art which affect, e.g., half-life, effectorfunction, and/or immune responses to the antibody in a patient. The termantibody also includes artificial polypeptide constructs which compriseat least one antibody-derived antigen binding site.

An “antigen binding fragment” of an antibody refers to one or morefragments or portions of an antibody that retain the ability to bindspecifically to the antigen bound by the whole antibody. It has beenshown that the antigen-binding function of an antibody can be performedby fragments or portions of a full-length antibody. An antigen bindingfragment can contain the antigenic determining regions of an intactantibody (e.g., the complementarity determining regions (CDRs)).Examples of antigen binding fragments of antibodies include, but are notlimited to, Fab, Fab′, F(ab′)₂, and Fv fragments, linear antibodies, andsingle chain antibodies. An antigen binding fragment of an antibody canbe derived from any animal species, such as rodents (e.g., mouse, rat,or hamster) and humans or can be artificially produced.

Furthermore, although the two domains of the Fv fragment, VL and VH, arecoded for by separate genes, they can be joined, using recombinantmethods, by a synthetic linker that enables them to be made as a singleprotein chain in which the VL and VH regions pair to form monovalentmolecules (known as single chain Fv (scFv); see, e.g., Bird et al.(1988) Science 242:423-426; and Huston et al. (1988) Proc. Natl. Acad.Sci. USA 85:5879-5883). Such single chain antibodies are also intendedto be encompassed within the term “antigen-binding fragment” of anantibody.

Antigen binding fragments are obtained using conventional techniquesknown to those with skill in the art, and the fragments are screened forutility in the same manner as are intact antibodies. Antigen bindingfragments can be produced by recombinant DNA techniques, or by enzymaticor chemical cleavage of intact immunoglobulins.

As used herein, the term “variable region” typically refers to a portionof an antibody, generally, a portion of a light or heavy chain,typically about the amino-terminal 110 to 120 amino acids, or 110 to 125amino acids in the mature heavy chain and about 90 to 115 amino acids inthe mature light chain, which differ extensively in sequence amongantibodies and are used in the binding and specificity of a particularantibody for its particular antigen. The variability in sequence isconcentrated in those regions called complementarity determining regions(CDRs) while the more highly conserved regions in the variable domainare called framework regions (FR). Without wishing to be bound by anyparticular mechanism or theory, it is believed that the CDRs of thelight and heavy chains are primarily responsible for the interaction andspecificity of an antibody with antigen. In some aspects, the variableregion is a mammalian variable region, e.g., a human, mouse or rabbitvariable region. In some aspects, the variable region comprises rodentor murine CDRs and human framework regions (FRs). In some aspects, thevariable region is a primate (e.g., non-human primate) variable region.In some aspects, the variable region comprises rodent or murine CDRs andprimate (e.g., non-human primate) framework regions (FRs).

The terms “complementarity determining region” or “CDR”, as used herein,refer to each of the regions of an antibody variable domain which arehypervariable in sequence and/or form structurally defined loops(hypervariable loops) and/or contain the antigen-contacting residues.Antibodies can comprise six CDRs, e.g., three in the VH and three in theVL.

The terms “VL”, “VL region,” and “VL domain” are used hereininterchangeably to refer to the light chain variable region of anantigen binding polypeptide, antigen binding polypeptide complex,antibody or antigen binding fragment thereof. In some aspects, a VLregion is referred to herein as VL1 to denote a first light chainvariable region, VL2 to denote a second light chain variable region, VL3to denote a third light chain variable region, VL4 to denote a fourthlight chain variable region, and so on. An enumerated VL region (e.g.,VL1) can have the same or different antigen binding properties and/orthe same or different sequence as another enumerated VL region (e.g.,VL2).

The terms “VH”, “VH region,” and “VH domain” are used hereininterchangeably to refer to the heavy chain variable region of anantigen binding polypeptide, antigen binding polypeptide complex,antibody or antigen binding fragment thereof. In some aspects, a VHregion is referred to herein as VH1 to denote a first heavy chainvariable region, VH2 to denote a second heavy chain variable region, VH3to denote a third heavy chain variable region, VH4 to denote a fourthheavy chain variable region, and so on. An enumerated VH region (e.g.,VH1) can have the same or different antigen binding properties and/orthe same or different sequence as another enumerated VH region (e.g.,VH2).

As used herein, “Kabat numbering” and like terms are recognized in theart and refer to a system of numbering amino acid residues in the heavyand light chain variable regions of an antibody or antigen bindingfragment thereof. In some aspects, CDRs can be determined according tothe Kabat numbering system (see, e.g., Kabat E A & Wu T T (1971) Ann NYAcad Sci 190: 382-391 and Kabat E A et al., (1991) Sequences of Proteinsof Immunological Interest, Fifth Edition, U.S. Department of Health andHuman Services, NIH Publication No. 91-3242). Using the Kabat numberingsystem, CDRs within an antibody heavy chain molecule are typicallypresent at amino acid positions 31 to 35, which optionally can includeone or two additional amino acids, following 35 (referred to in theKabat numbering scheme as 35A and 35B) (CDR1), amino acid positions 50to 65 (CDR2), and amino acid positions 95 to 102 (CDR3). Using the Kabatnumbering system, CDRs within an antibody light chain molecule aretypically present at amino acid positions 24 to 34 (CDR1), amino acidpositions 50 to 56 (CDR2), and amino acid positions 89 to 97 (CDR3).

As used herein, the terms “constant region” or “constant domain” areused interchangeably to refer to a portion of an antigen bindingpolypeptide, antigen binding polypeptide complex, antibody or antigenbinding fragment thereof, e.g., a carboxyl terminal portion of a lightand/or heavy chain which is not directly involved in binding of anantibody to antigen but which can exhibit various effector functions,such as interaction with the Fc region. The constant region generallyhas a more conserved amino acid sequence relative to a variable region.In some aspects, an antigen binding polypeptide, antigen bindingpolypeptide complex, antibody or antigen binding fragment thereofcomprises a constant region or portion thereof that is sufficient forantibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependentcellular phagocytosis (ADCP), and complement-dependent cytotoxicity(CDC).

As used herein, the terms “fragment crystallizable region,” “Fc region,”or “Fc domain” are used interchangeably herein to refer to the tailregion of an antibody that interacts with cell surface receptors calledFc receptors and some proteins of the complement system. Fc regionstypically comprise CH2 and CH3 regions, and, optionally, animmunoglobulin hinge. Examples of an Fc region include, but are notlimited to, an amino acid sequence of any one of SEQ ID NOs:391-404, oran amino acid sequence having at least 80%, at least 85%, at least 90%,at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%identity to any one of SEQ ID NOs:391-404. Examples of a CH2 regioninclude, but are not limited to, an amino acid sequence of any one ofSEQ ID NOs:410-415, or an amino acid sequence having at least 80%, atleast 85%, at least 90%, at least 95%, at least 96%, at least 97%, atleast 98%, or at least 99% identity to any one of SEQ ID NOs:410-415.Examples of a CH3 region include, but are not limited to, an amino acidsequence of any one of SEQ ID NOs:416-419, or an amino acid sequencehaving at least 80%, at least 85%, at least 90%, at least 95%, at least96%, at least 97%, at least 98%, or at least 99% identity to any one ofSEQ ID NOs:416-419.

As used herein, the terms “immunoglobulin hinge,” “hinge,” “hingedomain” or “hinge region” are used interchangeably to refer to a stretchof heavy chains between the Fab and Fc portions of an antigen bindingpolypeptide, antigen binding polypeptide complex, antibody or antigenbinding fragment thereof. A hinge provides structure, position andflexibility, which assist with normal functioning of antibodies (e.g.,for crosslinking two antigens or binding two antigenic determinants onthe same antigen molecule). An immunoglobulin hinge is divided intoupper, middle and lower hinge regions that can be separated based onstructural and/or genetic components. An immunoglobulin hinge of theinvention can contain one, two or all three of these regions.Structurally, the upper hinge region stretches from the C terminal endof CH1 to the first hinge disulfide bond. The middle hinge regionstretches from the first cysteine to the last cysteine in the hinge. Thelower hinge region extends from the last cysteine to the glycine of CH2.The cysteines present in the hinge form interchain disulfide bonds thatlink the immunoglobulin monomers.

As used herein, the term “Fab” refers to a region of an antibody thatbinds to an antigen. It is typically composed of one constant and onevariable domain of each of the heavy and the light chain.

As used herein, the term “heavy chain” refers to a portion of an antigenbinding polypeptide, antigen binding polypeptide complex, antibody orantigen binding fragment thereof typically composed of a heavy chainvariable region (VH), a heavy chain constant region 1 (CH1), a heavychain constant region 2 (CH2), and a heavy chain constant region 3(CH3). A typical antibody is composed of two heavy chains and two lightchains. When used in reference to an antibody, a heavy chain can referto any distinct type, e.g., alpha (α), delta (δ), epsilon (ε), gamma(γ), and mu (μ), based on the amino acid sequence of the constantregion, which gives rise to IgA, IgD, IgE, IgG, and IgM classes ofantibodies, respectively, including subclasses of IgG, e.g., IgG1, IgG2,IgG3, and IgG4. Heavy chain amino acid sequences are known in the art.In some aspects, the heavy chain is a human heavy chain.

As used herein, the term “light chain” refers to a portion of an antigenbinding polypeptide, antigen binding polypeptide complex, antibody orantigen binding fragment thereof typically composed of a light chainvariable region (VL) and a light chain constant region (CL). A typicalantibody is composed of two light chains and two heavy chains. When usedin reference to an antibody, a light chain can refer to any distincttype, e.g., kappa (κ) or lambda (λ), based on the amino acid sequence ofthe constant region. Light chain amino acid sequences are known in theart. In some aspects, the light chain is a human light chain.

The term “chimeric” antibody or antigen binding fragment thereof refersto an antibody or antigen binding fragments thereof wherein the aminoacid sequence is derived from two or more species. Typically, thevariable region of both light and heavy chains corresponds to thevariable region of antibodies or antigen binding fragments thereofderived from one species of mammals (e.g., mouse, rat, rabbit, etc.)with the desired specificity, affinity and capability, while theconstant regions are homologous to the sequences in antibodies orantigen binding fragments thereof derived from another (usually human)to avoid eliciting an immune response in that species.

The term “humanized” antibody or antigen binding fragment thereof refersto forms of non-human (e.g., murine) antibodies or antigen bindingfragments that are specific immunoglobulin chains, chimericimmunoglobulins, or fragments thereof that contain minimal non-human (eg, murine) sequences. Typically, humanized antibodies or antigen bindingfragments thereof are human immunoglobulins in which residues from acomplementary determining region (CDR) are replaced by residues from aCDR of a non-human species (e.g., mouse, rat, rabbit, hamster) that havethe desired specificity, affinity, and capability (Jones et al., Nature321:522-525 (1986); Riechmann et al., Nature 332:323-327 (1988);Verhoeyen et al., Science 239:1534-1536 (1988)). In some aspects, the Fvframework region (FR) residues of a human immunoglobulin are replacedwith the corresponding residues in an antibody or fragment from anon-human species that has the desired specificity, affinity, andcapability. The humanized antibody or antigen binding fragment thereofcan be further modified by the substitution of additional residueseither in the Fv framework region and/or within the replaced non-humanresidues to refine and optimize antibody or antigen-binding fragmentthereof specificity, affinity, and/or capability. In general, ahumanized antibody or antigen binding fragment thereof will comprisesubstantially all of at least one, and typically two or three, variabledomains containing all or substantially all of the CDR regions thatcorrespond to the non-human immunoglobulin whereas all or substantiallyall of the FR regions are those of a human immunoglobulin consensussequence. A humanized antibody or antigen binding fragment thereof canalso comprise at least a portion of a constant region, typically that ofa human immunoglobulin. Examples of methods used to generate humanizedantibodies are known and described, for example, in U.S. Pat. No.5,225,539; Roguska et al., Proc. Natl. Acad. Sci., USA, 91(3):969-973(1994), and Roguska et al., Protein Eng. 9(10):895-904 (1996).

The term “human” antibody or antigen binding fragment thereof, as usedherein, means an antibody or antigen binding fragment thereof having anamino acid sequence derived from a human immunoglobulin gene locus,where such antibody or antigen binding fragment is made usingrecombinant techniques known in the art. This definition of a humanantibody or antigen binding fragment thereof includes intact orfull-length antibodies and fragments thereof.

A polypeptide, polypeptide complex, antibody, antigen binding fragmentthereof, polynucleotide, vector or host cell which is “isolated” is apolypeptide, polypeptide complex, antibody, antigen binding fragmentthereof, polynucleotide, vector or host cell which is in a form notfound in nature. Isolated polypeptides, polypeptide complexes,antibodies, antigen binding fragments thereof, polynucleotides, vectorsor host cells include those which have been purified to a degree thatthey are no longer in a form in which they are found in nature. In someaspects, a polypeptide, polypeptide complex, antibody, antigen bindingfragment thereof, polynucleotide, vector or host cell which is isolatedis substantially pure. As used herein, “substantially pure” refers tomaterial which is at least 50% pure (i.e., free from contaminants), atleast 90% pure, at least 95% pure, at least 98% pure, or at least 99%pure.

The terms “polypeptide,” “peptide,” and “protein” are usedinterchangeably herein to refer to polymers of amino acids of anylength. The polymer can be linear or branched, it can comprise modifiedamino acids, and it can be interrupted by non-amino acids. The termsalso encompass an amino acid polymer that has been modified naturally orby intervention; for example, disulfide bond formation, glycosylation,lipidation, acetylation, phosphorylation, or any other manipulation ormodification, such as conjugation with a labeling component. Alsoincluded within the definition are, for example, polypeptides containingone or more analogs of an amino acid (including, for example, unnaturalamino acids, etc.), as well as other modifications known in the art. Itis understood that, because the polypeptides of this invention are basedupon antibodies, in some aspects, the polypeptides can occur as singlechains or associated chains.

The use of the alternative (e.g., “or”) should be understood to meaneither one, both, or any combination thereof of the alternatives. Asused herein, the indefinite articles “a” or “an” should be understood torefer to “one or more” of any recited or enumerated component.

As used herein, the term “and/or” is to be taken as specific disclosureof each of the two specified features or components with or without theother. Thus, the term “and/or” as used in a phrase such as “A and/or B”herein is intended to include “A and B,” “A or B,” “A” (alone), and “B”(alone). Likewise, the term “and/or” as used in a phrase such as “A, B,and/or C” is intended to encompass each of the following aspects: A, B,and C; A, B, or C; A or C; A or B; B or C; A and C; A and B; B and C; A(alone); B (alone); and C (alone).

It is understood that wherever aspects are described herein with thelanguage “comprising,” “having,” or the like, otherwise analogousaspects described in terms of “consisting of” and/or “consistingessentially of” are also provided.

As used herein, the term “about” refers to a value or composition thatis within an acceptable error range for the particular value orcomposition as determined by one of ordinary skill in the art, whichwill depend in part on how the value or composition is measured ordetermined, i.e., the limitations of the measurement system. Forexample, “about” can mean within 1 or more than 1 standard deviation perthe practice in the art. Alternatively, “about” can mean a range of upto 10% or 20% (i.e., ±10% or ±20%). For example, about 3 mg can includeany number between 2.7 mg and 3.3 mg (for 10%) or between 2.4 mg and 3.6mg (for 20%). Furthermore, particularly with respect to biologicalsystems or processes, the terms can mean up to an order of magnitude orup to 5-fold of a value. When particular values or compositions areprovided in the application and claims, unless otherwise stated, themeaning of “about” should be assumed to be within an acceptable errorrange for that particular value or composition.

As described herein, any numerical range, concentration range,percentage range, ratio range or integer range is to be understood toinclude the value of any integer within the recited range and, whenappropriate, fractions thereof (such as one-tenth and one-hundredth ofan integer), unless otherwise indicated.

Unless defined otherwise, all technical and scientific terms used hereinhave the same meaning as commonly understood by one of ordinary skill inthe art to which this disclosure is related. For example, the ConciseDictionary of Biomedicine and Molecular Biology, Juo, Pei-Show, 2nd ed.,2002, CRC Press; The Dictionary of Cell and Molecular Biology, 5th ed.,2013, Academic Press; and the Oxford Dictionary Of Biochemistry AndMolecular Biology, 2006, Oxford University Press, provide one of skillwith a general dictionary of many of the terms used in this disclosure.

Units, prefixes, and symbols are denoted in their Système Internationalde Unites (SI) accepted form. Numeric ranges are inclusive of thenumbers defining the range. The headings provided herein are notlimitations of the various aspects of the disclosure, which can be hadby reference to the specification as a whole. Accordingly, the termsdefined herein are more fully defined by reference to the specificationin its entirety.

Various aspects are described in further detail in the followingsections.

Antigen Binding Polypeptides and Antigen Binding Polypeptide Complexes

In some aspects, the invention is directed to antigen bindingpolypeptides and antigen binding polypeptide complexes having certainstructural features.

In some aspects, the invention is directed to antigen bindingpolypeptides and antigen binding polypeptide complexes having astructure represented by VL1-VL2-VH2-VH1 or VH1-VH2-VL2-VL1. In someaspects, the antigen binding polypeptide or antigen binding polypeptidecomplex contains an amino acid linker between any two regions denoted ina structure described herein. In some aspects, the antigen bindingpolypeptide or antigen binding polypeptide complex can contain an Fcregion, CH1 region, CL region, CH3 region or any combination thereof. Insome aspects, the Fc region, CH1 region, CL region and/or CH3 is locatedat the carboxy terminus of the antigen binding polypeptide, and isoptionally linked to polypeptide by at least one amino acid linker Insome aspects, the Fc region comprises an amino acid sequence of any oneof SEQ ID NOs:391-404 or an amino acid sequence having at least 80%, atleast 85%, at least 90%, at least 95%, at least 96%, at least 97%, atleast 98%, or at least 99% identity to any one of SEQ ID NOs:391-404. Insome aspects, the CH1 region comprises an amino acid sequence of any oneof SEQ ID NOs:405-409 or an amino acid sequence having at least 80%, atleast 85%, at least 90%, at least 95%, at least 96%, at least 97%, atleast 98%, or at least 99% identity to any one of SEQ ID NOs:405-409. Insome aspects, the CL region comprises an amino acid sequence of SEQ IDNO:420 or 421 or an amino acid sequence having at least 80%, at least85%, at least 90%, at least 95%, at least 96%, at least 97%, at least98% or at least 99% identity to SEQ ID NO:420 or 421. In some aspects,the antigen binding polypeptide complex is an antibody or antigenbinding fragment thereof.

In some aspects, the antigen binding polypeptide has a structurerepresented by VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1;VL1-L1-VL2-L2-VH2-L3-VH1; or VH1-L1-VH2-L2-VL2-L3-VL1; wherein VL1 is afirst immunoglobulin light chain variable region; VL2 is a secondimmunoglobulin light chain variable region; VH1 is a firstimmunoglobulin heavy chain variable region; VH2 is a secondimmunoglobulin heavy chain variable region; and L1, L2 and L3 are aminoacid linkers. In some aspects, the antigen binding polypeptide has thestructure represented by VL1-VL2-VH2-VH1. In some aspects, the antigenbinding polypeptide has the structure represented by VH1-VH2-VL2-VL1. Insome aspects, the antigen binding polypeptide has the structurerepresented by VL1-L1-VL2-L2-VH2-L3-VH1. In some aspects, the antigenbinding polypeptide has the structure represented byVH1-L1-VH2-L2-VL2-L3-VL1.

In some aspects, the antigen binding polypeptide complex comprises afirst polypeptide and a second polypeptide; wherein the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1;VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1; or VH1-L1-VH2-L2-VL2-L3-VL1;wherein the second polypeptide has a structure represented byVL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1; orVH1-L1-VH2-L2-VL2-L3-VL1; wherein VL1 is a first immunoglobulin lightchain variable region; VL2 is a second immunoglobulin light chainvariable region; VH1 is a first immunoglobulin heavy chain variableregion; VH2 is a second immunoglobulin heavy chain variable region; andL1, L2 and L3 are amino acid linkers. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1, and thesecond polypeptide has a structure represented by VL1-VL2-VH2-VH1;VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1; or VH1-L1-VH2-L2-VL2-L3-VL1.In some aspects, the first polypeptide has a structure represented byVH1-VH2-VL2-VL1, and the second polypeptide has a structure representedby VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1; orVH1-L1-VH2-L2-VL2-L3-VL1. In some aspects, the first polypeptide has astructure represented by VL1-L1-VL2-L2-VH2-L3-VH1, and the secondpolypeptide has a structure represented by VL1-VL2-VH2-VH1;VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1; or VH1-L1-VH2-L2-VL2-L3-VL1.In some aspects, the first polypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1, and the second polypeptide has a structurerepresented by VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1;VL1-L1-VL2-L2-VH2-L3-VH1; or VH1-L1-VH2-L2-VL2-L3-VL1.

In some aspects, the antigen binding polypeptide further comprises atleast one Fc region which is optionally positioned at its carboxyterminus. The Fc region can be linked to the polypeptide via at leastone amino acid linker. For example, the antigen binding polypeptide mayhave a structure represented by VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc; or VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc;wherein VL1 is a first immunoglobulin light chain variable region; VL2is a second immunoglobulin light chain variable region; VH1 is a firstimmunoglobulin heavy chain variable region; VH2 is a secondimmunoglobulin heavy chain variable region; Fc is a region comprising animmunoglobulin heavy chain constant region 2 (CH2), an immunoglobulinheavy chain constant region 3 (CH3), and optionally, an immunoglobulinhinge; and L1, L2, L3 and L4 are amino acid linkers.

In some aspects, the antigen binding polypeptide complex as definedherein further comprises at least one Fc region, which is optionallypositioned at the carboxy terminus of the first polypeptide and/orsecond polypeptide. The Fc region can be linked to the first polypeptideand/or second polypeptide via at least one amino acid linker. Forexample, the antigen binding complex may comprise a first polypeptideand a second polypeptide, wherein the first polypeptide has a structurerepresented by VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc; or VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc;wherein the second polypeptide has a structure represented by Fc;VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; wherein VL1 is a first immunoglobulinlight chain variable region; VL2 is a second immunoglobulin light chainvariable region; VH1 is a first immunoglobulin heavy chain variableregion; VH2 is a second immunoglobulin heavy chain variable region; Fcis a region comprising an immunoglobulin heavy chain constant region 2(CH2), an immunoglobulin heavy chain constant region 3 (CH3), andoptionally, an immunoglobulin hinge; and L1, L2, L3 and L4 are aminoacid linkers. In some aspects, the first polypeptide has a structurerepresented by VL1-VL2-VH2-VH1-Fc and the second polypeptide has astructure represented by Fc; VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fe;VL1-L1-VL2-L2-VH2-L3-VH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc; or VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc. Insome aspects, the first polypeptide has a structure represented byVH1-VH2-VL2-VL1-Fc and the second polypeptide has a structurerepresented by Fc; VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-Fe; VH1-L1-VH2-L2-VL2-L3-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc; or VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc. Insome aspects, the first polypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-Fe and the second polypeptide has a structurerepresented by Fc; VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc; or VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc. Insome aspects, the first polypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-Fc and the second polypeptide has a structurerepresented by Fc; VL1-VL2-VH2-VH1-Fe; VH1-VH2-VL2-VL1-Fe;VL1-L1-VL2-L2-VH2-L3-VH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fe; or VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc. Insome aspects, the first polypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc and the second polypeptide has astructure represented by Fc; VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc; or VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fe. Insome aspects, the first polypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc and the second polypeptide has astructure represented by Fc; VL1-VL2-VH2-VH1-Fe; VH1-VH2-VL2-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc; or VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fe.

In some aspects, the antigen binding polypeptide further comprises atleast one CH1 region and/or CL region which is optionally positioned atits carboxy terminus. In some aspects, the antigen binding polypeptidefurther comprises at its carboxy terminus the structure CH1-CL. In someaspects, the antigen binding polypeptide further comprises at itscarboxy terminus the structure CL-CH1. The CH1 region and/or CL regioncan be linked to the polypeptide via at least one amino acid linker.When both the CH1 region and CL region are present, they can be linkedto each other via at least one amino acid linker. For example, theantigen binding polypeptide may have a structure represented byVL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; wherein VL1 is a firstimmunoglobulin light chain variable region; VL2 is a secondimmunoglobulin light chain variable region; VH1 is a firstimmunoglobulin heavy chain variable region; VH2 is a secondimmunoglobulin heavy chain variable region; CH1 is an immunoglobulinheavy chain constant region 1; CL is an immunoglobulin light chainconstant region; and L1, L2, L3, L4 and L5 are amino acid linkers.

In some aspects, the antigen binding polypeptide complex as definedherein further comprises at least one CH1 region and/or CL region, whichis optionally positioned at the carboxy terminus of the firstpolypeptide and/or second polypeptide. For example, the carboxy terminusof the first polypeptide and/or second polypeptide may comprise a CH1region. For example, the carboxy terminus of the first polypeptideand/or second polypeptide may comprise a CL region. For example, thecarboxy terminus of the first polypeptide and/or second polypeptide maycomprise both a CH1 and a CL region. In some aspects, the carboxyterminus of the first polypeptide and/or second polypeptide comprisesthe structure CH1-CL. In some aspects, the carboxy terminus of the firstpolypeptide and/or second polypeptide comprises the structure CL-CH1.The CH1 region and/or CL region can be linked to the first polypeptideand/or second polypeptide via at least one amino acid linker. When boththe CH1 region and CL region are present, they can be linked to eachother via at least one amino acid linker. For example, the antigenbinding complex may comprise a first polypeptide and a secondpolypeptide; wherein the first polypeptide has a structure representedby VL1-VL2-VH2-VH1-CH1; VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL;VH1-VH2-VL2-VL1-CL; VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL;VL1-VL2-VH2-VH1-CL-CH1; VH1-VH2-VL2-VL1-CL-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL; VH1-L1-VH2-L2-VL2- L3-VL1-L4-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; wherein the second polypeptidehas a structure represented by VL1-VL2-VH2-VH1-CH1; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; or VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1;wherein VL1 is a first immunoglobulin light chain variable region; VL2is a second immunoglobulin light chain variable region; VH1 is a firstimmunoglobulin heavy chain variable region; VH2 is a secondimmunoglobulin heavy chain variable region; CH1 is an immunoglobulinheavy chain constant region 1; CL is a light chain constant region; andL1, L2, L3, L4 and L5 are amino acid linkers. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-CH1 and thesecond polypeptide has a structure represented by VL1-VL2-VH2-VH1-CH1;VL1-VL2-VH2-VH1-CH1; VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL;VH1-VH2-VL2-VL1-CL; VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL;VL1-VL2-VH2-VH1-CL-CH1; VH1-VH2-VL2-VL1-CL-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3- VH1-L4-CL-L5-CH1; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1-CH1 and thesecond polypeptide has a structure represented by VL1-VL2-VH2-VH1-CH1;VL1-VL2-VH2-VH1-CH1; VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL;VH1-VH2-VL2-VL1-CL; VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL;VL1-VL2-VH2-VH1-CL-CH1; VH1-VH2-VL2-VL1-CL-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1;VL1-L1- VL2-L2-VH2-L3-VH1-L4-CL; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5- CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-CL and thesecond polypeptide has a structure represented by VL1-VL2-VH2-VH1-CH1;VL1-VL2-VH2-VH1-CH1; VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL;VH1-VH2-VL2-VL1-CL; VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL;VL1-VL2-VH2-VH1-CL-CH1; VH1-VH2-VL2-VL1-CL-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL; VH1-L1- VH2-L2-VL2-L3-VL1-L4-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1-CL and thesecond polypeptide has a structure represented by VL1-VL2-VH2-VH1-CH1;VL1-VL2-VH2-VH1-CH1; VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL;VH1-VH2-VL2-VL1-CL; VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL;VL1-VL2-VH2-VH1-CL-CH1; VH1-VH2-VL2-VL1-CL-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL;VL1-L1-VL2- L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; or VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1. In some aspects,the first polypeptide has a structure represented byVL1-VL2-VH2-VH1-CH1-CL and the second polypeptide has a structurerepresented by VL1-VL2-VH2-VH1-CH1; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1- VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5- CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1-CH1-CL andthe second polypeptide has a structure represented byVL1-VL2-VH2-VH1-CH1; VL1-VL2-VH2-VH1-CH1; VH1-VH2-VL2-VL1-CH1;VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL; VL1-VL2-VH2-VH1-CH1-CL;VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1; VH1-VH2-VL2-VL1-CL-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL; VH1- L1-VH2-L2-VL2-L3-VL1-L4-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-CL-CH1 andthe second polypeptide has a structure represented byVL1-VL2-VH2-VH1-CH1; VL1-VL2-VH2-VH1-CH1; VH1-VH2-VL2-VL1-CH1;VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL; VL1-VL2-VH2-VH1-CH1-CL;VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1; VH1-VH2-VL2-VL1-CL-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; or VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1. Insome aspects, the first polypeptide has a structure represented byVH1-VH2-VL2-VL1-CL-CH1 and the second polypeptide has a structurerepresented by VL1-VL2-VH2-VH1-CH1; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1- L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1 and the second polypeptide has astructure represented by VL1-VL2-VH2-VH1-CH1; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2- VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1 and the second polypeptide has astructure represented by VL1-VL2-VH2-VH1-CH1; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1- L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CL and the second polypeptide has astructure represented by VL1-VL2-VH2-VH1-CH1; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; or VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1. Insome aspects, the first polypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL and the second polypeptide has astructure represented by VL1-VL2-VH2-VH1-CH1; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1- L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL and the second polypeptide has astructure represented by VL1-VL2-VH2-VH1-CH1; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1- VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5- CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL and the second polypeptide has astructure represented by VL1-VL2-VH2-VH1-CH1; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1 and the second polypeptide has astructure represented by VL1-VL2-VH2-VH1-CH1; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1- L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1 and the second polypeptide has astructure represented by VL1-VL2-VH2-VH1-CH1; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2- VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1.

In some aspects, the antigen binding polypeptide further comprises atleast two of an Fc region, a CH1 region and a CL region optionallypositioned at its carboxy terminus. In some aspects, the antigen bindingpolypeptide further comprises at its carboxy terminus the structureCH1-Fc. In some aspects, the antigen binding polypeptide furthercomprises at its carboxy terminus the structure CL-Fc. In some aspects,the antigen binding polypeptide further comprises at its carboxyterminus the structure CL-CH1-Fc. In some aspects, the antigen bindingpolypeptide further comprises at its carboxy terminus the structureCH1-CL-Fc. The Fc region, CH1 region and/or CL region can be linked tothe polypeptide via at least one amino acid linker. The Fc region, CH1region and/or CL region can be linked to each other via at least oneamino acid linker. For example, the C-terminal structure may have astructure represented by VL1-VL2-VH2-VH1-CH1-Fc; VH1-VH2-VL2-VL1-CH1-Fc;VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc; VL1-VL2-VH2-VH1-CH1-CL-Fc;VH1-VH2-VL2-VL1-CH1-CL-Fc; VL1-VL2-VH2-VH1-CL-CH1-Fc;VH1-VH2-VL2-VL1-CL-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL- L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc; wherein VL1 is a firstimmunoglobulin light chain variable region; VL2 is a secondimmunoglobulin light chain variable region; VH1 is a firstimmunoglobulin heavy chain variable region; VH2 is a secondimmunoglobulin heavy chain variable region; CH1 is an immunoglobulinheavy chain constant region 1; CL is an immunoglobulin light chainconstant region; and Fc is a region comprising an immunoglobulin heavychain constant region 2 (CH2), an immunoglobulin heavy chain constantregion 3 (CH3), and optionally, an immunoglobulin hinge; and L1, L2, L3,L4 and L5 are amino acid linkers.

In some aspects, the antigen binding polypeptide complex as definedherein further comprises at least two of an Fc region, a CH1 region anda CL region which is optionally positioned at the carboxy terminus ofthe first polypeptide and/or second polypeptide. For example, thecarboxy terminus of the first polypeptide and/or second polypeptide maycomprise the structure CH1-Fc. For example, the carboxy terminus of thefirst polypeptide and/or second polypeptide may comprise the structureCL-Fc. For example, the carboxy terminus of the first polypeptide and/orsecond polypeptide may comprise the structure CL-CH1-Fc. For example,the carboxy terminus of the first polypeptide and/or second polypeptidemay comprise the structure CH1-CL-Fc. In some aspects, the firstpolypeptide may comprise at its C-terminus at least two of an Fc region,a CH1 region and a CL region and the second polypeptide may comprise atits C-terminus an Fc region. The Fc region, CH1 region and/or CL regioncan be linked to the first polypeptide and/or second polypeptide via atleast one amino acid linker. The Fc region, CH1 region and/or CL regioncan be linked to each other via at least one amino acid linker. Forexample, the antigen binding complex may comprise a first polypeptideand a second polypeptide; wherein the first polypeptide has a structurerepresented by VL1-VL2-VH2-VH1-CH1-Fc; VH1-VH2-VL2-VL1-CH1-Fc;VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc; VL1-VL2-VH2-VH1-CH1-CL-Fc;VH1-VH2-VL2-VL1-CH1-CL-Fc; VL1-VL2-VH2-VH1-CL-CH1-Fc;VH1-VH2-VL2-VL1-CL-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4- CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc; wherein the second polypeptidehas a structure represented by Fc; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2- L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc; wherein VL1 is a firstimmunoglobulin light chain variable region; VL2 is a secondimmunoglobulin light chain variable region; VH1 is a firstimmunoglobulin heavy chain variable region; VH2 is a secondimmunoglobulin heavy chain variable region; CH1 is an immunoglobulinheavy chain constant region 1; CL is an immunoglobulin light chainconstant region; Fc is a region comprising an immunoglobulin heavy chainconstant region 2 (CH2), an immunoglobulin heavy chain constant region 3(CH3), and optionally, an immunoglobulin hinge; and L1, L2, L3, L4 andL5 are amino acid linkers. In some aspects, the first polypeptide has astructure represented by VL1-VL2-VH2-VH1-CH1-Fc and the secondpolypeptide has a structure represented by Fc; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3- VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1-CH1-Fc andthe second polypeptide has a structure represented by Fc;VL1-VL2-VH2-VH1-CH1-Fc; VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc;VH1-VH2-VL2-VL1-CL-Fc; VL1-VL2-VH2-VH1-CH1-CL-Fc;VH1-VH2-VL2-VL1-CH1-CL-Fc; VL1-VL2-VH2-VH1-CL-CH1-Fc;VH1-VH2-VL2-VL1-CL-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4- CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-CL-Fc and thesecond polypeptide has a structure represented by Fc;VL1-VL2-VH2-VH1-CH1-Fc; VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc;VH1-VH2-VL2-VL1-CL-Fc; VL1-VL2-VH2-VH1-CH1-CL-Fc;VH1-VH2-VL2-VL1-CH1-CL-Fc; VL1-VL2-VH2-VH1-CL-CH1-Fc;VH1-VH2-VL2-VL1-CL-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1-CL-Fc and thesecond polypeptide has a structure represented by Fc;VL1-VL2-VH2-VH1-CH1-Fc; VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc;VH1-VH2-VL2-VL1-CL-Fc; VL1-VL2-VH2-VH1-CH1-CL-Fc;VH1-VH2-VL2-VL1-CH1-CL-Fc; VL1-VL2-VH2-VH1-CL-CH1-Fc;VH1-VH2-VL2-VL1-CL-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-CH1-CL-Fc andthe second polypeptide has a structure represented by Fc;VL1-VL2-VH2-VH1-CH1-F c; VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc;VH1-VH2-VL2-VL1-CL-Fc; VL1-VL2-VH2-VH1-CH1-CL-Fc;VH1-VH2-VL2-VL1-CH1-CL-Fc; VL1-VL2-VH2-VH1-CL-CH1-Fc;VH1-VH2-VL2-VL1-CL-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1-CH1-CL-Fc andthe second polypeptide has a structure represented by Fc;VL1-VL2-VH2-VH1-CH1-F c; VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc;VH1-VH2-VL2-VL1-CL-Fc; VL1-VL2-VH2-VH1-CH1-CL-Fc;VH1-VH2-VL2-VL1-CH1-CL-Fc; VL1-VL2-VH2-VH1-CL-CH1-Fc;VH1-VH2-VL2-VL1-CL-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-CL-CH1-Fc andthe second polypeptide has a structure represented by Fc;VL1-VL2-VH2-VH1-CH1-Fe; VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc;VH1-VH2-VL2-VL1-CL-Fc; VL1-VL2-VH2-VH1-CH1-CL-Fc;VH1-VH2-VL2-VL1-CH1-CL-Fc; VL1-VL2-VH2-VH1-CL-CH1-Fc;VH1-VH2-VL2-VL1-CL-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1-CL-CH1-Fc andthe second polypeptide has a structure represented by Fc;VL1-VL2-VH2-VH1-CH1-Fe; VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc;VH1-VH2-VL2-VL1-CL-Fc; VL1-VL2-VH2-VH1-CH1-CL-Fc;VH1-VH2-VL2-VL1-CH1-CL-Fc; VL1-VL2-VH2-VH1-CL-CH1-Fc;VH1-VH2-VL2-VL1-CL-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc and the second polypeptide has astructure represented by Fc; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc and the second polypeptide has astructure represented by Fc; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4- CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc and the second polypeptide has astructure represented by Fc; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4- CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc and the second polypeptide has astructure represented by Fc; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4- CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc and the second polypeptide hasa structure represented by Fc; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3- VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc and the second polypeptide hasa structure represented by Fc; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc and the second polypeptide hasa structure represented by Fc; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL- L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc and the second polypeptide hasa structure represented by Fc; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc.

In some aspects, the antigen binding polypeptide complex comprises afirst polypeptide and a second polypeptide; wherein the firstpolypeptide has a structure represented by: VL1-VL2-VH2-VH1;VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1;VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3- VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc; wherein the second polypeptidehas a structure represented by Fc; VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1;VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fc;VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1- L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1- L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc; wherein VL1 is a firstimmunoglobulin light chain variable region; VL2 is a secondimmunoglobulin light chain variable region; VH1 is a firstimmunoglobulin heavy chain variable region; VH2 is a secondimmunoglobulin heavy chain variable region; CH1 is an immunoglobulinheavy chain constant region 1; CL is an immunoglobulin light chainconstant region; Fc is a region comprising an immunoglobulin heavy chainconstant region 2 (CH2), an immunoglobulin heavy chain constant region 3(CH3), and optionally, an immunoglobulin hinge; and L1, L2, L3, L4 andL5 are amino acid linkers. In some aspects, the first polypeptide has astructure represented by VL1-VL2-VH2-VH1 and the second polypeptide hasa structure represented by Fc; VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1;VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fe;VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fe;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1- L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fe;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fe;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fe;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fe;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL- L5-CH1-Fe; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fe. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1 and thesecond polypeptide has a structure represented by Fc; VL1-VL2-VH2-VH1;VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1;VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fe;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fe;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fe; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3- VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fe;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fe;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fe. In some aspects, the firstpolypeptide has a structure represented by VL1-L1-VL2-L2-VH2-L3-VH1 andthe second polypeptide has a structure represented by Fc;VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1;VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-Fe; VH1-L1-VH2-L2-VL2-L3-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fe; VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc;VL1-VL2-VH2-VH1-CH1; VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL;VH1-VH2-VL2-VL1-CL; VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL;VL1-VL2-VH2-VH1-CL-CH1; VH1-VH2-VL2-VL1-CL-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL;VL1-L1-VL2-L2-VH2- L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VH1-L1-VH2-L2-VL2-L3-VL1 andthe second polypeptide has a structure represented by Fc;VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1;VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc;VL1-VL2-VH2-VH1-CH1; VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL;VH1-VH2-VL2-VL1-CL; VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL;VL1-VL2-VH2-VH1-CL-CH1; VH1-VH2-VL2-VL1-CL-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1;VL1-L1- VL2-L2-VH2-L3-VH1-L4-CL; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5- CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-Fc and thesecond polypeptide has a structure represented by Fc; VL1-VL2-VH2-VH1;VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1;VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1- L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL- L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has the structure represented by VH1-VH2-VL2-VL1-Fc and thesecond polypeptide has a structure represented by Fc; VL1-VL2-VH2-VH1;VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1;VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3- VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VL1-L1-VL2-L2-VH2-L3-VH1-Fcand the second polypeptide has a structure represented by Fc;VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1;VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc;VL1-VL2-VH2-VH1-CH1; VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL;VH1-VH2-VL2-VL1-CL; VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL;VL1-VL2-VH2-VH1-CL-CH1; VH1-VH2-VL2-VL1-CL-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL;VL1-L1-VL2-L2-VH2- L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VH1-L1-VH2-L2-VL2-L3-VL1-Fcand the second polypeptide has a structure represented by Fc;VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1;VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc;VL1-VL2-VH2-VH1-CH1; VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL;VH1-VH2-VL2-VL1-CL; VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL;VL1-VL2-VH2-VH1-CL-CH1; VH1-VH2-VL2-VL1-CL-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1;VL1-L1- VL2-L2-VH2-L3-VH1-L4-CL; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5- CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc and the second polypeptide has astructure represented by Fc; VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1;VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fc;VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2- L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc and the second polypeptide has astructure represented by Fc; VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1;VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fc;VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1- L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL- L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-CH1 and thesecond polypeptide has a structure represented by Fc; VL1-VL2-VH2-VH1;VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1;VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3- VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1-CH1 and thesecond polypeptide has a structure represented by Fc; VL1-VL2-VH2-VH1;VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1;VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3- VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-CL and thesecond polypeptide has a structure represented by Fc; VL1-VL2-VH2-VH1;VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1;VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4- Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc; VH1-VH2-VL2-VL1-CH1-Fc;VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc; VL1-VL2-VH2-VH1-CH1-CL-Fc;VH1-VH2-VL2-VL1-CH1-CL-Fc; VL1-VL2-VH2-VH1-CL-CH1-Fc;VH1-VH2-VL2-VL1-CL-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1-CL and thesecond polypeptide has a structure represented by Fc; VL1-VL2-VH2-VH1;VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1;VL1-VL2-VH2-VH1-Fe; VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fe;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1- L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL- L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-CH1-CL andthe second polypeptide has a structure represented by Fc;VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1;VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fe;VL1-L1-VL2-L2-VH2-L3-VH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc;VL1-VL2-VH2-VH1-CH1; VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL;VH1-VH2-VL2-VL1-CL; VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL;VL1-VL2-VH2-VH1-CL-CH1; VH1-VH2-VL2-VL1-CL-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL; VH1-L1-VH2-L2-VL2- L3-VL1-L4-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL- Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1-CH1-CL andthe second polypeptide has a structure represented by Fc;VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1;VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc;VL1-VL2-VH2-VH1-CH1; VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL;VH1-VH2-VL2-VL1-CL; VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL;VL1-VL2-VH2-VH1-CL-CH1; VH1-VH2-VL2-VL1-CL-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL;VL1-L1-VL2- L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1;VL1-VL2-VH2-VH1-CH1-Fc; VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc;VH1-VH2-VL2-VL1-CL-Fc; VL1-VL2-VH2-VH1-CH1-CL-Fc;VH1-VH2-VL2-VL1-CH1-CL-Fc; VL1-VL2-VH2-VH1-CL-CH1-Fc;VH1-VH2-VL2-VL1-CL-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-CL-CH1 andthe second polypeptide has a structure represented by Fc;VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1;VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc;VL1-VL2-VH2-VH1-CH1; VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL;VH1-VH2-VL2-VL1-CL; VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL;VL1-VL2-VH2-VH1-CL-CH1; VH1-VH2-VL2-VL1-CL-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1;VL1-L1- VL2-L2-VH2-L3-VH1-L4-CL; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5- CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1-CL-CH1 andthe second polypeptide has a structure represented by Fc;VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1;VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fe; VH1-VH2-VL2-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc;VL1-VL2-VH2-VH1-CH1; VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL;VH1-VH2-VL2-VL1-CL; VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL;VL1-VL2-VH2-VH1-CL-CH1; VH1-VH2-VL2-VL1-CL-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL; VH1- L1-VH2-L2-VL2-L3-VL1-L4-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fe;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fe;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL- L5-CH1-Fe; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fe. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1 and the second polypeptide has astructure represented by Fc; VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1;VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fc;VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fe; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fe;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fe; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2- L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1- L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fe; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fe;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fe;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fe. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1 and the second polypeptide has astructure represented by Fc; VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1;VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fc;VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fe; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L.4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2- L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fe;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL- Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CL and the second polypeptide has astructure represented by Fc; VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1;VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fc;VH1-VH2-VL2-VL1-Fe; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2- L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1;VL1-VL2-VH2-VH1-CH1-Fc; VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc;VH1-VH2-VL2-VL1-CL-Fc; VL1-VL2-VH2-VH1-CH1-CL-Fc;VH1-VH2-VL2-VL1-CH1-CL-Fc; VL1-VL2-VH2-VH1-CL-CH1-Fc;VH1-VH2-VL2-VL1-CL-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL and the second polypeptide has astructure represented by Fc; VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1;VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fc;VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1- L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fe; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL- Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL and the second polypeptide has astructure represented by Fc; VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1;VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fc;VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1- VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5- CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL and the second polypeptide has astructure represented by Fc; VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1;VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fc;VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2- VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fe; VH1-VH2-VL2-VL1-CH1-Fc;VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc; VL1-VL2-VH2-VH1-CH1-CL-Fc;VH1-VH2-VL2-VL1-CH1-CL-Fc; VL1-VL2-VH2-VH1-CL-CH1-Fe;VH1-VH2-VL2-VL1-CL-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1 and the second polypeptide has astructure represented by Fc; VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1;VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fc;VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2- VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fe; VH1-VH2-VL2-VL1-CH1-Fc;VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc; VL1-VL2-VH2-VH1-CH1-CL-Fc;VH1-VH2-VL2-VL1-CH1-CL-Fc; VL1-VL2-VH2-VH1-CL-CH1-Fe;VH1-VH2-VL2-VL1-CL-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1 and the second polypeptide has astructure represented by Fc; VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1;VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fc;VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2- VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fe; VH1-VH2-VL2-VL1-CH1-Fc;VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc; VL1-VL2-VH2-VH1-CH1-CL-Fc;VH1-VH2-VL2-VL1-CH1-CL-Fc; VL1-VL2-VH2-VH1-CL-CH1-Fe;VH1-VH2-VL2-VL1-CL-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-CH1-Fc andthe second polypeptide has a structure represented by Fc;VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1;VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fe; VH1-VH2-VL2-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-Fe; VH1-L1-VH2-L2-VL2-L3-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc;VL1-VL2-VH2-VH1-CH1; VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL;VH1-VH2-VL2-VL1-CL; VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL;VL1-VL2-VH2-VH1-CL-CH1; VH1-VH2-VL2-VL1-CL-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL; VH1- L1-VH2-L2-VL2-L3-VL1-L4-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL- L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1-CH1-Fc andthe second polypeptide has a structure represented by Fc;VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1;VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc;VL1-VL2-VH2-VH1-CH1; VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL;VH1-VH2-VL2-VL1-CL; VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL;VL1-VL2-VH2-VH1-CL-CH1; VH1-VH2-VL2-VL1-CL-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL; VH1-L1-VH2-L2-VL2- L3-VL1-L4-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL- Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-CL-Fc and thesecond polypeptide has a structure represented by Fc; VL1-VL2-VH2-VH1;VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1;VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2- VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1;VL1-VL2-VH2-VH1-CH1-Fc; VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc;VH1-VH2-VL2-VL1-CL-Fc; VL1-VL2-VH2-VH1-CH1-CL-Fc;VH1-VH2-VL2-VL1-CH1-CL-Fc; VL1-VL2-VH2-VH1-CL-CH1-Fc;VH1-VH2-VL2-VL1-CL-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1-CL-Fc and thesecond polypeptide has a structure represented by Fc; VL1-VL2-VH2-VH1;VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1;VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1- VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5- CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-CH1-CL-Fc andthe second polypeptide has a structure represented by Fc;VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1;VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc;VL1-VL2-VH2-VH1-CH1; VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL;VH1-VH2-VL2-VL1-CL; VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL;VL1-VL2-VH2-VH1-CL-CH1; VH1-VH2-VL2-VL1-CL-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1-CH1-CL-Fc andthe second polypeptide has a structure represented by Fc;VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1;VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-Fe; VH1-L1-VH2-L2-VL2-L3-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc;VL1-VL2-VH2-VH1-CH1; VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL;VH1-VH2-VL2-VL1-CL; VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL;VL1-VL2-VH2-VH1-CL-CH1; VH1-VH2-VL2-VL1-CL-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL; VH1-L1-VH2- L2-VL2-L3-VL1-L4-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-CL-CH1-Fc andthe second polypeptide has a structure represented by Fc;VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1;VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc;VL1-VL2-VH2-VH1-CH1; VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL;VH1-VH2-VL2-VL1-CL; VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL;VL1-VL2-VH2-VH1-CL-CH1; VH1-VH2-VL2-VL1-CL-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3- VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1-CL-CH1-Fc andthe second polypeptide has a structure represented by Fc;VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1;VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc;VL1-VL2-VH2-VH1-CH1; VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL;VH1-VH2-VL2-VL1-CL; VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL;VL1-VL2-VH2-VH1-CL-CH1; VH1-VH2-VL2-VL1-CL-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL;VL1-L1-VL2-L2-VH2- L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc and the second polypeptide has astructure represented by Fc; VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1;VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fc;VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1- L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1- L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc and the second polypeptide has astructure represented by Fc; VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1;VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fc;VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4- Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc; VH1-VH2-VL2-VL1-CH1-Fc;VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc; VL1-VL2-VH2-VH1-CH1-CL-Fc;VH1-VH2-VL2-VL1-CH1-CL-Fc; VL1-VL2-VH2-VH1-CL-CH1-Fc;VH1-VH2-VL2-VL1-CL-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc and the second polypeptide has astructure represented by Fc; VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1;VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fc;VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2- L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc and the second polypeptide has astructure represented by Fc; VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1;VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fc;VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1- L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL- L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc and the second polypeptide hasa structure represented by Fc; VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1;VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fc;VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1- L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL- L5-CH1-Fe; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc and the second polypeptide hasa structure represented by Fc; VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1;VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fe;VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1- L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fe;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fe;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL- L5-CH1-Fe; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fe. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc and the second polypeptide hasa structure represented by Fc; VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1;VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fe;VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1- L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fe;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fe;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL- L5-CH1-Fe; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fe. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc and the second polypeptide hasa structure represented by Fc; VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1;VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fe;VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1- L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fe;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL- L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fe.

In other aspects, the invention is directed to an antigen bindingpolypeptide comprising at least two Fc regions at the carboxy terminusor an antigen binding polypeptide complex comprising a polypeptidecomprising at least two Fc regions at its carboxy terminus. The at leasttwo Fc regions can be linked to the polypeptide via at least one aminoacid linker. The at least two Fc regions can be linked to each other viaat least one amino acid linker. For example, the antigen bindingpolypeptide or antigen binding polypeptide complex may comprise apolypeptide having a structure represented by VL1-VL2-VH2-VH1 orVH1-VH2-VL2-VL1 which has two Fc regions. In some aspects, one or bothFc regions comprise an amino acid sequence of any one of SEQ IDNOs:391-404 or an amino acid sequence having at least 80%, at least 85%,at least 90%, at least 95%, at least 96%, at least 97%, at least 98% orat least 99% identity to any one of SEQ ID NOs:391-404. In some aspects,an antigen binding polypeptide or antigen binding polypeptide complexcomprises a polypeptide having a structure represented byVL1-VL2-VH2-VH1-Fc-Fc; VH1-VH2-VL2-VL1-Fc-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-Fc-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-Fc-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc- Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc-L5-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc-L5-Fc; wherein VL1 is a firstimmunoglobulin light chain variable region; VL2 is a secondimmunoglobulin light chain variable region; VH1 is a firstimmunoglobulin heavy chain variable region; VH2 is a secondimmunoglobulin heavy chain variable region; Fc is a region comprising animmunoglobulin heavy chain constant region 2 (CH2), an immunoglobulinheavy chain constant region 3 (CH3), and optionally, an immunoglobulinhinge; and L1, L2, L3, L4 and L5 are amino acid linkers.

In other aspects, the invention is directed to an antigen bindingpolypeptide comprising at least two CH3 regions or an antigen bindingpolypeptide complex comprising a polypeptide comprising at least two CH3regions. For example, the antigen binding polypeptide or antigen bindingpolypeptide complex may comprise a polypeptide having a structurerepresented by VL1-VL2-VH2-VH1 or VH1-VH2-VL2-VL1 which has two CH3regions. In some aspects, one or both CH3 regions comprise an amino acidsequence of any one of SEQ ID NOs:416-419, or an amino acid sequencehaving at least 80%, at least 85%, at least 90%, at least 95%, at least96%, at least 97%, at least 98%, or at least 99% identity to any one ofSEQ ID NOs:416-419. In some aspects, the antigen binding polypeptide orantigen binding polypeptide complex comprises a polypeptide having astructure represented by VL1-VL2-VH2-VH1-CH3; VH1-VH2-VL2-VL1-CH3;VL1-L1-VL2-L2-VH2-L3-VH1-CH3; VH1-L1-VH2-L2-VL2-L3-VL1-CH3; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH3; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH3;VL1-VL2-VH2-VH1-CH3-CH3; VH1-VH2-VL2-VL1-CH3-CH3;VL1-L1-VL2-L2-VH2-L3-VH1-CH3-CH3; VH1-L1-VH2-L2-VL2-L3-VL1-CH3-CH3; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH3-CH3; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH3-CH3;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH3-L5-CH3; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CH3-L5-CH3; wherein VL1 is a firstimmunoglobulin light chain variable region; VL2 is a secondimmunoglobulin light chain variable region; VH1 is a firstimmunoglobulin heavy chain variable region; VH2 is a secondimmunoglobulin heavy chain variable region; CH3 is an immunoglobulinheavy chain constant region 3; and L1, L2, L3, L4 and L5 are amino acidlinkers.

Any one of the first polypeptides described herein may be combined withany one of the second and/or third polypeptides described herein to forman antigen binding polypeptide complex of the invention.

All the disclosures relating to the antigen binding polypeptidestructures described herein and the antigen binding polypeptide complexstructures described herein apply to and can be combined with all the VHand VL regions described herein including all the target antigensdescribed herein and all the VH and VL sequences and CDR sequencesdescribed herein.

In some aspects, the invention is directed to antigen bindingpolypeptides or antigen binding polypeptide complexes (e.g., antibodiesor antigen binding fragments thereof) that specifically bind a viralpeptide, protein, polypeptide, or a fragment thereof. In some aspects,the viral peptide, protein, polypeptide, or a fragment thereof isinfluenza virus neuraminidase, influenza virus hemagglutinin, humanrespiratory syncytial virus (RSV)-viral proteins, RSV F glycoprotein,RSV G glycoprotein, herpes simplex virus (HSV) viral proteins, herpessimplex virus glycoproteins gB, gC, gD, and gE, Chlamydia MOMP and PorBantigens, core protein, matrix protein or other protein of Dengue virus,measles virus hemagglutinin, herpes simplex virus type 2 glycoproteingB, poliovirus 1 VP1, envelope glycoproteins of HIV 1, hepatitis Bsurface antigen, diptheria toxin, Streptococcus 24M epitope, gonococcalpilin, pseudorabies virus g50 (gpD), pseudorabies virus II (gpB),pseudorabies virus III (gpC), pseudorabies virus glycoprotein H,pseudorabies virus glycoprotein E, transmissible gastroenteritisglycoprotein 195, transmissible gastroenteritis matrix protein, swinerotavirus glycoprotein 38, swine parvovirus capsid protein,Serpulinahydodysenteriae protective antigen, bovine viral diarrheaglycoprotein 55, Newcastle disease virus hemagglutinin-neuraminidase,swine flu hemagglutinin, swine flu neuraminidase, foot and mouth diseasevirus, hog colera virus, swine influenza virus, African swine fevervirus, Mycoplasma liyopneutiioniae, infectious bovine rhinotracheitisvirus, infectious bovine rhinotracheitis virus glycoprotein E,glycoprotein G, infectious laryngotracheitis virus, infectiouslaryngotracheitis virus glycoprotein G or glycoprotein I, a glycoproteinof La Crosse virus, neonatal calf diarrhoea virus, Venezuelan equineencephalomyelitis virus, punta toro virus, murine leukemia virus, mousemammary tumor virus, hepatitis B virus core protein and hepatitis Bvirus surface antigen or a fragment or derivative thereof, antigen ofequine influenza virus or equine herpes virus, including equineinfluenza virus type A/Alaska 91 neuraminidase, equine influenza virustypeA/Miami 63 neuraminidase, equine influenza virus type A/Kentucky 81neuraminidase equine herpes virus type 1 glycoprotein B, and equineherpes virus type 1 glycoprotein D, antigen of bovine respiratorysyncytial virus or bovine parainfluenza virus, bovine respiratorysyncytial virus attachment protein (BRSV G), bovine respiratorysyncytial virus fusion protein (BRSV F), bovine respiratory syncytialvirus nucleocapsid protein (BRSVN), bovine parainfluenza virus type 3fusion protein, bovine parainfluenza virus type 3 hemagglutininneuraminidase, bovine E viral diarrhoea virus glycoprotein 48 andglycoprotein 53, glycoprotein E of Dengue virus, or glycoprotein ElE2 ofhuman hepatitis C virus. In some aspects, the antigen bindingpolypeptide or antigen binding polypeptide complex specifically binds atleast one epitope on at least one viral protein selected from: influenzavirus neumminidase, influenza virus hemagglutinin, human respiratorysyncytial virus (RSV)-viral proteins, RSV F glycoprotein, RSV Gglycoprotein, herpes simplex virus (HSV) viral proteins, herpes simplexvirus glycoproteins gB, gC, gD, and gE, Chlamydia MOMP and PorBantigens, core protein, matrix protein or other protein of Dengue virus,measles virus hemagglutinin, herpes simplex virus type 2 glycoproteingB, poliovirus 1 VP1, envelope glycoproteins of HIV 1, hepatitis Bsurface antigen, diptheria toxin, Streptococcus 24M epitope, gonococcalpilin, pseudorabies virus g50 (gpD), pseudorabies virus II (gpB),pseudorabies virus III (gpC), pseudorabies virus glycoprotein H,pseudorabies virus glycoprotein E, transmissible gastroenteritisglycoprotein 195, transmissible gastroenteritis matrix protein, swinerotavirus glycoprotein 38, swine parvovirus capsid protein,Serpulinahydodysenteriae protective antigen, bovine viral diarrheaglycoprotein 55, Newcastle disease virus hemagglutinin-neumminidase,swine flu hemagglutinin, swine flu neuraminidase, foot and mouth diseasevirus, hog colera virus, swine influenza virus, African swine fevervirus, Mycoplasma liyopneutiioniae, infectious bovine rhinotracheitisvirus, infectious bovine rhinotracheitis virus glycoprotein E,glycoprotein G, infectious laryngotracheitis virus, infectiouslaryngotracheitis virus glycoprotein G or glycoprotein I, a glycoproteinof La Crosse virus, neonatal calf diarrhoea virus, Venezuelan equineencephalomyelitis virus, punta toro virus, murine leukemia virus, mousemammary tumor virus, hepatitis B virus core protein and hepatitis Bvirus surface antigen or a fragment or derivative thereof, antigen ofequine influenza virus or equine herpes virus, including equineinfluenza virus type A/Alaska 91 neuraminidase, equine influenza virustypeA/Miami 63 neuraminidase, equine influenza virus type A/Kentucky 81neuraminidase equine herpes virus type 1 glycoprotein B, and equineherpes virus type 1 glycoprotein D, antigen of bovine respiratorysyncytial virus or bovine parainfluenza virus, bovine respiratorysyncytial virus attachment protein (BRSV G), bovine respiratorysyncytial virus fusion protein (BRSV F), bovine respiratory syncytialvirus nucleocapsid protein (BRSVN), bovine parainfluenza virus type 3fusion protein, bovine parainfluenza virus type 3 hemagglutininneuraminidase, bovine E viral diarrhoea virus glycoprotein 48 andglycoprotein 53, glycoprotein E of Dengue virus, glycoprotein ElE2 ofhuman hepatitis C virus. In some aspects, the antigen bindingpolypeptide or polypeptide comprised within the antigen binding complexmay comprise a VL1, VL2, VL3, VL4, VH1, VH2, VH3, and/or VH4 thatspecifically binds to a viral peptide, protein, polypeptide, or afragment thereof such as influenza virus neuraminidase, influenza virushemagglutinin, human respiratory syncytial virus (RSV)-viral proteins,RSV F glycoprotein, RSV G glycoprotein, herpes simplex virus (HSV) viralproteins, herpes simplex virus glycoproteins gB, gC, gD, and gE,Chlamydia MOMP and PorB antigens, core protein, matrix protein or otherprotein of Dengue virus, measles virus hemagglutinin, herpes simplexvirus type 2 glycoprotein gB, poliovirus 1 VP1, envelope glycoproteinsof HIV 1, hepatitis B surface antigen, diptheria toxin, Streptococcus24M epitope, gonococcal pilin, pseudorabies virus g50 (gpD),pseudorabies virus II (gpB), pseudorabies virus III (gpC), pseudorabiesvirus glycoprotein H, pseudorabies virus glycoprotein E, transmissiblegastroenteritis glycoprotein 195, transmissible gastroenteritis matrixprotein, swine rotavirus glycoprotein 38, swine parvovirus capsidprotein, Serpulinahydodysenteriae protective antigen, bovine viraldiarrhea glycoprotein 55, Newcastle disease virushemagglutinin-neuraminidase, swine flu hemagglutinin, swine fluneuraminidase, foot and mouth disease virus, hog colera virus, swineinfluenza virus, African swine fever virus, Mycoplasma liyopneutiioniae,infectious bovine rhinotracheitis virus, infectious bovinerhinotracheitis virus glycoprotein E, glycoprotein G, infectiouslaryngotracheitis virus, infectious laryngotracheitis virus glycoproteinG or glycoprotein I, a glycoprotein of La Crosse virus, neonatal calfdiarrhoea virus, Venezuelan equine encephalomyelitis virus, punta torovirus, murine leukemia virus, mouse mammary tumor virus, hepatitis Bvirus core protein and hepatitis B virus surface antigen or a fragmentor derivative thereof, antigen of equine influenza virus or equineherpes virus, including equine influenza virus type A/Alaska 91neuraminidase, equine influenza virus typeA/Miami 63 neuraminidase,equine influenza virus type A/Kentucky 81 neuraminidase equine herpesvirus type 1 glycoprotein B, and equine herpes virus type 1 glycoproteinD, antigen of bovine respiratory syncytial virus or bovine parainfluenzavirus, bovine respiratory syncytial virus attachment protein (BRSV G),bovine respiratory syncytial virus fusion protein (BRSV F), bovinerespiratory syncytial virus nucleocapsid protein (BRSVN), bovineparainfluenza virus type 3 fusion protein, bovine parainfluenza virustype 3 hemagglutinin neuraminidase, bovine E viral diarrhoea virusglycoprotein 48 and glycoprotein 53, glycoprotein E of Dengue virus,glycoprotein ElE2 of human hepatitis C virus or a combination thereof.For example, the antigen binding polypeptide or polypeptide comprisedwithin the antigen binding complex may comprise a VL1 that specificallybinds to influenza virus neuraminidase, influenza virus hemagglutinin,human respiratory syncytial virus (RSV)-viral proteins, RSV Fglycoprotein, RSV G glycoprotein, herpes simplex virus (HSV) viralproteins, herpes simplex virus glycoproteins gB, gC, gD, and gE,Chlamydia MOMP and PorB antigens, core protein, matrix protein or otherprotein of Dengue virus, measles virus hemagglutinin, herpes simplexvirus type 2 glycoprotein gB, poliovirus 1 VP1, envelope glycoproteinsof HIV 1, hepatitis B surface antigen, diptheria toxin, Streptococcus24M epitope, gonococcal pilin, pseudorabies virus g50 (gpD),pseudorabies virus II (gpB), pseudorabies virus III (gpC), pseudorabiesvirus glycoprotein H, pseudorabies virus glycoprotein E, transmissiblegastroenteritis glycoprotein 195, transmissible gastroenteritis matrixprotein, swine rotavirus glycoprotein 38, swine parvovirus capsidprotein, Serpulinahydodysenteriae protective antigen, bovine viraldiarrhea glycoprotein 55, Newcastle disease virushemagglutinin-neuraminidase, swine flu hemagglutinin, swine fluneuraminidase, foot and mouth disease virus, hog colera virus, swineinfluenza virus, African swine fever virus, Mycoplasma liyopneutiioniae,infectious bovine rhinotracheitis virus, infectious bovinerhinotracheitis virus glycoprotein E, glycoprotein G, infectiouslaryngotracheitis virus, infectious laryngotracheitis virus glycoproteinG or glycoprotein I, a glycoprotein of La Crosse virus, neonatal calfdiarrhoea virus, Venezuelan equine encephalomyelitis virus, punta torovirus, murine leukemia virus, mouse mammary tumor virus, hepatitis Bvirus core protein and hepatitis B virus surface antigen or a fragmentor derivative thereof, antigen of equine influenza virus or equineherpes virus, including equine influenza virus type A/Alaska 91neuraminidase, equine influenza virus typeA/Miami 63 neuraminidase,equine influenza virus type A/Kentucky 81 neuraminidase equine herpesvirus type 1 glycoprotein B, and equine herpes virus type 1 glycoproteinD, antigen of bovine respiratory syncytial virus or bovine parainfluenzavirus, bovine respiratory syncytial virus attachment protein (BRSV G),bovine respiratory syncytial virus fusion protein (BRSV F), bovinerespiratory syncytial virus nucleocapsid protein (BRSVN), bovineparainfluenza virus type 3 fusion protein, bovine parainfluenza virustype 3 hemagglutinin neuraminidase, bovine E viral diarrhoea virusglycoprotein 48 and glycoprotein 53, glycoprotein E of Dengue virus,glycoprotein ElE2 of human hepatitis C virus or a combination thereof.For example, the antigen binding polypeptide or polypeptide comprisedwithin the antigen binding complex may comprise a VL2 that specificallybinds to influenza virus neuraminidase, influenza virus hemagglutinin,human respiratory syncytial virus (RSV)-viral proteins, RSV Fglycoprotein, RSV G glycoprotein, herpes simplex virus (HSV) viralproteins, herpes simplex virus glycoproteins gB, gC, gD, and gE,Chlamydia MOMP and PorB antigens, core protein, matrix protein or otherprotein of Dengue virus, measles virus hemagglutinin, herpes simplexvirus type 2 glycoprotein gB, poliovirus 1 VP1, envelope glycoproteinsof HIV 1, hepatitis B surface antigen, diptheria toxin, Streptococcus24M epitope, gonococcal pilin, pseudorabies virus g50 (gpD),pseudorabies virus II (gpB), pseudorabies virus III (gpC), pseudorabiesvirus glycoprotein H, pseudorabies virus glycoprotein E, transmissiblegastroenteritis glycoprotein 195, transmissible gastroenteritis matrixprotein, swine rotavirus glycoprotein 38, swine parvovirus capsidprotein, Serpulinahydodysenteriae protective antigen, bovine viraldiarrhea glycoprotein 55, Newcastle disease virushemagglutinin-neuraminidase, swine flu hemagglutinin, swine fluneuraminidase, foot and mouth disease virus, hog colera virus, swineinfluenza virus, African swine fever virus, Mycoplasma liyopneutiioniae,infectious bovine rhinotracheitis virus, infectious bovinerhinotracheitis virus glycoprotein E, glycoprotein G, infectiouslaryngotracheitis virus, infectious laryngotracheitis virus glycoproteinG or glycoprotein I, a glycoprotein of La Crosse virus, neonatal calfdiarrhoea virus, Venezuelan equine encephalomyelitis virus, punta torovirus, murine leukemia virus, mouse mammary tumor virus, hepatitis Bvirus core protein and hepatitis B virus surface antigen or a fragmentor derivative thereof, antigen of equine influenza virus or equineherpes virus, including equine influenza virus type A/Alaska 91neuraminidase, equine influenza virus typeA/Miami 63 neuraminidase,equine influenza virus type A/Kentucky 81 neuraminidase equine herpesvirus type 1 glycoprotein B, and equine herpes virus type 1 glycoproteinD, antigen of bovine respiratory syncytial virus or bovine parainfluenzavirus, bovine respiratory syncytial virus attachment protein (BRSV G),bovine respiratory syncytial virus fusion protein (BRSV F), bovinerespiratory syncytial virus nucleocapsid protein (BRSVN), bovineparainfluenza virus type 3 fusion protein, bovine parainfluenza virustype 3 hemagglutinin neuraminidase, bovine E viral diarrhoea virusglycoprotein 48 and glycoprotein 53, glycoprotein E of Dengue virus,glycoprotein ElE2 of human hepatitis C virus or a combination thereof.For example, the antigen binding polypeptide or polypeptide comprisedwithin the antigen binding complex may comprise a VL3 that specificallybinds to influenza virus neuraminidase, influenza virus hemagglutinin,human respiratory syncytial virus (RSV)-viral proteins, RSV Fglycoprotein, RSV G glycoprotein, herpes simplex virus (HSV) viralproteins, herpes simplex virus glycoproteins gB, gC, gD, and gE,Chlamydia MOMP and PorB antigens, core protein, matrix protein or otherprotein of Dengue virus, measles virus hemagglutinin, herpes simplexvirus type 2 glycoprotein gB, poliovirus 1 VP1, envelope glycoproteinsof HIV 1, hepatitis B surface antigen, diptheria toxin, Streptococcus24M epitope, gonococcal pilin, pseudorabies virus g50 (gpD),pseudorabies virus II (gpB), pseudorabies virus III (gpC), pseudorabiesvirus glycoprotein H, pseudorabies virus glycoprotein E, transmissiblegastroenteritis glycoprotein 195, transmissible gastroenteritis matrixprotein, swine rotavirus glycoprotein 38, swine parvovirus capsidprotein, Serpulinahydodysenteriae protective antigen, bovine viraldiarrhea glycoprotein 55, Newcastle disease virushemagglutinin-neuraminidase, swine flu hemagglutinin, swine fluneuraminidase, foot and mouth disease virus, hog colera virus, swineinfluenza virus, African swine fever virus, Mycoplasma liyopneutiioniae,infectious bovine rhinotracheitis virus, infectious bovinerhinotracheitis virus glycoprotein E, glycoprotein G, infectiouslaryngotracheitis virus, infectious laryngotracheitis virus glycoproteinG or glycoprotein I, a glycoprotein of La Crosse virus, neonatal calfdiarrhoea virus, Venezuelan equine encephalomyelitis virus, punta torovirus, murine leukemia virus, mouse mammary tumor virus, hepatitis Bvirus core protein and hepatitis B virus surface antigen or a fragmentor derivative thereof, antigen of equine influenza virus or equineherpes virus, including equine influenza virus type A/Alaska 91neuraminidase, equine influenza virus typeA/Miami 63 neuraminidase,equine influenza virus type A/Kentucky 81 neuraminidase equine herpesvirus type 1 glycoprotein B, and equine herpes virus type 1 glycoproteinD, antigen of bovine respiratory syncytial virus or bovine parainfluenzavirus, bovine respiratory syncytial virus attachment protein (BRSV G),bovine respiratory syncytial virus fusion protein (BRSV F), bovinerespiratory syncytial virus nucleocapsid protein (BRSVN), bovineparainfluenza virus type 3 fusion protein, bovine parainfluenza virustype 3 hemagglutinin neuraminidase, bovine E viral diarrhoea virusglycoprotein 48 and glycoprotein 53, glycoprotein E of Dengue virus,glycoprotein ElE2 of human hepatitis C virus or a combination thereof.For example, the antigen binding polypeptide or polypeptide comprisedwithin the antigen binding complex may comprise a VL4 that specificallybinds to influenza virus neuraminidase, influenza virus hemagglutinin,human respiratory syncytial virus (RSV)-viral proteins, RSV Fglycoprotein, RSV G glycoprotein, herpes simplex virus (HSV) viralproteins, herpes simplex virus glycoproteins gB, gC, gD, and gE,Chlamydia MOMP and PorB antigens, core protein, matrix protein or otherprotein of Dengue virus, measles virus hemagglutinin, herpes simplexvirus type 2 glycoprotein gB, poliovirus 1 VP1, envelope glycoproteinsof HIV 1, hepatitis B surface antigen, diptheria toxin, Streptococcus24M epitope, gonococcal pilin, pseudorabies virus g50 (gpD),pseudorabies virus II (gpB), pseudorabies virus III (gpC), pseudorabiesvirus glycoprotein H, pseudorabies virus glycoprotein E, transmissiblegastroenteritis glycoprotein 195, transmissible gastroenteritis matrixprotein, swine rotavirus glycoprotein 38, swine parvovirus capsidprotein, Serpulinahydodysenteriae protective antigen, bovine viraldiarrhea glycoprotein 55, Newcastle disease virushemagglutinin-neuraminidase, swine flu hemagglutinin, swine fluneuraminidase, foot and mouth disease virus, hog colera virus, swineinfluenza virus, African swine fever virus, Mycoplasma liyopneutiioniae,infectious bovine rhinotracheitis virus, infectious bovinerhinotracheitis virus glycoprotein E, glycoprotein G, infectiouslaryngotracheitis virus, infectious laryngotracheitis virus glycoproteinG or glycoprotein I, a glycoprotein of La Crosse virus, neonatal calfdiarrhoea virus, Venezuelan equine encephalomyelitis virus, punta torovirus, murine leukemia virus, mouse mammary tumor virus, hepatitis Bvirus core protein and hepatitis B virus surface antigen or a fragmentor derivative thereof, antigen of equine influenza virus or equineherpes virus, including equine influenza virus type A/Alaska 91neuraminidase, equine influenza virus typeA/Miami 63 neuraminidase,equine influenza virus type A/Kentucky 81 neuraminidase equine herpesvirus type 1 glycoprotein B, and equine herpes virus type 1 glycoproteinD, antigen of bovine respiratory syncytial virus or bovine parainfluenzavirus, bovine respiratory syncytial virus attachment protein (BRSV G),bovine respiratory syncytial virus fusion protein (BRSV F), bovinerespiratory syncytial virus nucleocapsid protein (BRSVN), bovineparainfluenza virus type 3 fusion protein, bovine parainfluenza virustype 3 hemagglutinin neuraminidase, bovine E viral diarrhoea virusglycoprotein 48 and glycoprotein 53, glycoprotein E of Dengue virus,glycoprotein ElE2 of human hepatitis C virus or a combination thereof.For example, the antigen binding polypeptide or polypeptide comprisedwithin the antigen binding complex may comprise a VH1 that specificallybinds to influenza virus neumminidase, influenza virus hemagglutinin,human respiratory syncytial virus (RSV)-viral proteins, RSV Fglycoprotein, RSV G glycoprotein, herpes simplex virus (HSV) viralproteins, herpes simplex virus glycoproteins gB, gC, gD, and gE,Chlamydia MOMP and PorB antigens, core protein, matrix protein or otherprotein of Dengue virus, measles virus hemagglutinin, herpes simplexvirus type 2 glycoprotein gB, poliovirus 1 VP1, envelope glycoproteinsof HIV 1, hepatitis B surface antigen, diptheria toxin, Streptococcus24M epitope, gonococcal pilin, pseudorabies virus g50 (gpD),pseudorabies virus II (gpB), pseudorabies virus III (gpC), pseudorabiesvirus glycoprotein H, pseudorabies virus glycoprotein E, transmissiblegastroenteritis glycoprotein 195, transmissible gastroenteritis matrixprotein, swine rotavirus glycoprotein 38, swine parvovirus capsidprotein, Serpulinahydodysenteriae protective antigen, bovine viraldiarrhea glycoprotein 55, Newcastle disease virushemagglutinin-neumminidase, swine flu hemagglutinin, swine fluneuraminidase, foot and mouth disease virus, hog colera virus, swineinfluenza virus, African swine fever virus, Mycoplasma liyopneutiioniae,infectious bovine rhinotracheitis virus, infectious bovinerhinotracheitis virus glycoprotein E, glycoprotein G, infectiouslaryngotracheitis virus, infectious laryngotracheitis virus glycoproteinG or glycoprotein I, a glycoprotein of La Crosse virus, neonatal calfdiarrhoea virus, Venezuelan equine encephalomyelitis virus, punta torovirus, murine leukemia virus, mouse mammary tumor virus, hepatitis Bvirus core protein and hepatitis B virus surface antigen or a fragmentor derivative thereof, antigen of equine influenza virus or equineherpes virus, including equine influenza virus type A/Alaska 91neuraminidase, equine influenza virus typeA/Miami 63 neuraminidase,equine influenza virus type A/Kentucky 81 neuraminidase equine herpesvirus type 1 glycoprotein B, and equine herpes virus type 1 glycoproteinD, antigen of bovine respiratory syncytial virus or bovine parainfluenzavirus, bovine respiratory syncytial virus attachment protein (BRSV G),bovine respiratory syncytial virus fusion protein (BRSV F), bovinerespiratory syncytial virus nucleocapsid protein (BRSVN), bovineparainfluenza virus type 3 fusion protein, bovine parainfluenza virustype 3 hemagglutinin neuraminidase, bovine E viral diarrhoea virusglycoprotein 48 and glycoprotein 53, glycoprotein E of Dengue virus,glycoprotein ElE2 of human hepatitis C virus or a combination thereof.For example, the antigen binding polypeptide or polypeptide comprisedwithin the antigen binding complex may comprise a VH2 that specificallybinds to influenza virus neuraminidase, influenza virus hemagglutinin,human respiratory syncytial virus (RSV)-viral proteins, RSV Fglycoprotein, RSV G glycoprotein, herpes simplex virus (HSV) viralproteins, herpes simplex virus glycoproteins gB, gC, gD, and gE,Chlamydia MOMP and PorB antigens, core protein, matrix protein or otherprotein of Dengue virus, measles virus hemagglutinin, herpes simplexvirus type 2 glycoprotein gB, poliovirus 1 VP1, envelope glycoproteinsof HIV 1, hepatitis B surface antigen, diptheria toxin, Streptococcus24M epitope, gonococcal pilin, pseudorabies virus g50 (gpD),pseudorabies virus II (gpB), pseudorabies virus III (gpC), pseudorabiesvirus glycoprotein H, pseudorabies virus glycoprotein E, transmissiblegastroenteritis glycoprotein 195, transmissible gastroenteritis matrixprotein, swine rotavirus glycoprotein 38, swine parvovirus capsidprotein, Serpulinahydodysenteriae protective antigen, bovine viraldiarrhea glycoprotein 55, Newcastle disease virushemagglutinin-neuraminidase, swine flu hemagglutinin, swine fluneuraminidase, foot and mouth disease virus, hog colera virus, swineinfluenza virus, African swine fever virus, Mycoplasma liyopneutiioniae,infectious bovine rhinotracheitis virus, infectious bovinerhinotracheitis virus glycoprotein E, glycoprotein G, infectiouslaryngotracheitis virus, infectious laryngotracheitis virus glycoproteinG or glycoprotein I, a glycoprotein of La Crosse virus, neonatal calfdiarrhoea virus, Venezuelan equine encephalomyelitis virus, punta torovirus, murine leukemia virus, mouse mammary tumor virus, hepatitis Bvirus core protein and hepatitis B virus surface antigen or a fragmentor derivative thereof, antigen of equine influenza virus or equineherpes virus, including equine influenza virus type A/Alaska 91neuraminidase, equine influenza virus typeA/Miami 63 neuraminidase,equine influenza virus type A/Kentucky 81 neuraminidase equine herpesvirus type 1 glycoprotein B, and equine herpes virus type 1 glycoproteinD, antigen of bovine respiratory syncytial virus or bovine parainfluenzavirus, bovine respiratory syncytial virus attachment protein (BRSV G),bovine respiratory syncytial virus fusion protein (BRSV F), bovinerespiratory syncytial virus nucleocapsid protein (BRSVN), bovineparainfluenza virus type 3 fusion protein, bovine parainfluenza virustype 3 hemagglutinin neuraminidase, bovine E viral diarrhoea virusglycoprotein 48 and glycoprotein 53, glycoprotein E of Dengue virus,glycoprotein ElE2 of human hepatitis C virus or a combination thereof.For example, the antigen binding polypeptide or polypeptide comprisedwithin the antigen binding complex may comprise a VH3 that specificallybinds to influenza virus neumminidase, influenza virus hemagglutinin,human respiratory syncytial virus (RSV)-viral proteins, RSV Fglycoprotein, RSV G glycoprotein, herpes simplex virus (HSV) viralproteins, herpes simplex virus glycoproteins gB, gC, gD, and gE,Chlamydia MOMP and PorB antigens, core protein, matrix protein or otherprotein of Dengue virus, measles virus hemagglutinin, herpes simplexvirus type 2 glycoprotein gB, poliovirus 1 VP1, envelope glycoproteinsof HIV 1, hepatitis B surface antigen, diptheria toxin, Streptococcus24M epitope, gonococcal pilin, pseudorabies virus g50 (gpD),pseudorabies virus II (gpB), pseudorabies virus III (gpC), pseudorabiesvirus glycoprotein H, pseudorabies virus glycoprotein E, transmissiblegastroenteritis glycoprotein 195, transmissible gastroenteritis matrixprotein, swine rotavirus glycoprotein 38, swine parvovirus capsidprotein, Serpulinahydodysenteriae protective antigen, bovine viraldiarrhea glycoprotein 55, Newcastle disease virushemagglutinin-neumminidase, swine flu hemagglutinin, swine fluneuraminidase, foot and mouth disease virus, hog colera virus, swineinfluenza virus, African swine fever virus, Mycoplasma liyopneutiioniae,infectious bovine rhinotracheitis virus, infectious bovinerhinotracheitis virus glycoprotein E, glycoprotein G, infectiouslaryngotracheitis virus, infectious laryngotracheitis virus glycoproteinG or glycoprotein I, a glycoprotein of La Crosse virus, neonatal calfdiarrhoea virus, Venezuelan equine encephalomyelitis virus, punta torovirus, murine leukemia virus, mouse mammary tumor virus, hepatitis Bvirus core protein and hepatitis B virus surface antigen or a fragmentor derivative thereof, antigen of equine influenza virus or equineherpes virus, including equine influenza virus type A/Alaska 91neuraminidase, equine influenza virus typeA/Miami 63 neuraminidase,equine influenza virus type A/Kentucky 81 neuraminidase equine herpesvirus type 1 glycoprotein B, and equine herpes virus type 1 glycoproteinD, antigen of bovine respiratory syncytial virus or bovine parainfluenzavirus, bovine respiratory syncytial virus attachment protein (BRSV G),bovine respiratory syncytial virus fusion protein (BRSV F), bovinerespiratory syncytial virus nucleocapsid protein (BRSVN), bovineparainfluenza virus type 3 fusion protein, bovine parainfluenza virustype 3 hemagglutinin neuraminidase, bovine E viral diarrhoea virusglycoprotein 48 and glycoprotein 53, glycoprotein E of Dengue virus,glycoprotein ElE2 of human hepatitis C virus or a combination thereof.The antigen binding polypeptide described herein or the polypeptides ofthe antigen binding polypeptide complex described herein may compriseany combination of VL1, VL2, VL3, VL4, VH1, VH2, VH3, and/or VH4 thatbind the targets described herein. In some aspects, the antigen bindingpolypeptide or antigen binding polypeptide complex (e.g., antibodies orantigen binding fragments thereof) specifically binds to a viralpeptide, protein, polypeptide, or a fragment of influenza virusneuraminidase. In some aspects, the antigen binding polypeptide orantigen binding polypeptide complex (e.g., antibodies or antigen bindingfragments thereof) specifically binds to a viral peptide, protein,polypeptide, or a fragment of influenza virus hemagglutinin. In someaspects, the antigen binding polypeptide or antigen binding polypeptidecomplex (e.g., antibodies or antigen binding fragments thereof)specifically binds to a viral peptide, protein, polypeptide, or afragment of a human respiratory syncytial virus (RSV)-viral protein. Insome aspects, the antigen binding polypeptide or antigen bindingpolypeptide complex (e.g., antibodies or antigen binding fragmentsthereof) specifically binds to a viral peptide, protein, polypeptide, ora fragment of RSV F glycoprotein. In some aspects, the antigen bindingpolypeptide or antigen binding polypeptide complex (e.g., antibodies orantigen binding fragments thereof) specifically binds to a viralpeptide, protein, polypeptide, or a fragment of RSV G glycoprotein. Insome aspects, the antigen binding polypeptide or antigen bindingpolypeptide complex (e.g., antibodies or antigen binding fragmentsthereof) specifically binds to a viral peptide, protein, polypeptide, ora fragment of a herpes simplex virus (HSV) viral protein. In someaspects, the antigen binding polypeptide or antigen binding polypeptidecomplex (e.g., antibodies or antigen binding fragments thereof)specifically binds to a viral peptide, protein, polypeptide, or afragment of the herpes simplex virus glycoprotein gB, gC, gD, or gE. Insome aspects, the antigen binding polypeptide or antigen bindingpolypeptide complex (e.g., antibodies or antigen binding fragmentsthereof) specifically binds to a viral peptide, protein, polypeptide, ora fragment of Chlamydia MOMP. In some aspects, the antigen bindingpolypeptide or antigen binding polypeptide complex (e.g., antibodies orantigen binding fragments thereof) specifically binds to a viralpeptide, protein, polypeptide, or a fragment of a PorB antigen. In someaspects, the antigen binding polypeptide or antigen binding polypeptidecomplex (e.g., antibodies or antigen binding fragments thereof)specifically binds to a viral peptide, protein, polypeptide, or afragment of core protein, matrix protein or other protein of Denguevirus. In some aspects, the antigen binding polypeptide or antigenbinding polypeptide complex (e.g., antibodies or antigen bindingfragments thereof) specifically binds to a viral peptide, protein,polypeptide, or a fragment of measles virus hemagglutinin. In someaspects, the antigen binding polypeptide or antigen binding polypeptidecomplex (e.g., antibodies or antigen binding fragments thereof)specifically binds to a viral peptide, protein, polypeptide, or afragment of simplex virus type 2 glycoprotein gB. In some aspects, theantigen binding polypeptide or antigen binding polypeptide complex(e.g., antibodies or antigen binding fragments thereof) specificallybinds to a viral peptide, protein, polypeptide, or a fragment ofpoliovirus 1 VP1. In some aspects, the antigen binding polypeptide orantigen binding polypeptide complex (e.g., antibodies or antigen bindingfragments thereof) specifically binds to a viral peptide, protein,polypeptide, or a fragment of an envelope glycoprotein of HIV 1. In someaspects, the antigen binding polypeptide or antigen binding polypeptidecomplex (e.g., antibodies or antigen binding fragments thereof)specifically binds to a viral peptide, protein, polypeptide, or afragment of hepatitis B surface antigen. In some aspects, the antigenbinding polypeptide or antigen binding polypeptide complex (e.g.,antibodies or antigen binding fragments thereof) specifically binds to aviral peptide, protein, polypeptide, or a fragment of diptheria toxin.In some aspects, the antigen binding polypeptide or antigen bindingpolypeptide complex (e.g., antibodies or antigen binding fragmentsthereof) specifically binds to a viral peptide, protein, polypeptide, ora fragment of Streptococcus 24M epitope. In some aspects, the antigenbinding polypeptide or antigen binding polypeptide complex (e.g.,antibodies or antigen binding fragments thereof) specifically binds to aviral peptide, protein, polypeptide, or a fragment of gonococcal pilin.In some aspects, the antigen binding polypeptide or antigen bindingpolypeptide complex (e.g., antibodies or antigen binding fragmentsthereof) specifically binds to a viral peptide, protein, polypeptide, ora fragment of pseudorabies virus g50 (gpD). In some aspects, the antigenbinding polypeptide or antigen binding polypeptide complex (e.g.,antibodies or antigen binding fragments thereof) specifically binds to aviral peptide, protein, polypeptide, or a fragment of pseudorabies virusII (gpB). In some aspects, the antigen binding polypeptide or antigenbinding polypeptide complex (e.g., antibodies or antigen bindingfragments thereof) specifically binds to a viral peptide, protein,polypeptide, or a fragment of pseudorabies virus III (gpC). In someaspects, the antigen binding polypeptide or antigen binding polypeptidecomplex (e.g., antibodies or antigen binding fragments thereof)specifically binds to a viral peptide, protein, polypeptide, or afragment of pseudorabies virus glycoprotein H. In some aspects, theantigen binding polypeptide or antigen binding polypeptide complex(e.g., antibodies or antigen binding fragments thereof) specificallybinds to a viral peptide, protein, polypeptide, or a fragment ofpseudorabies virus glycoprotein E. In some aspects, the antigen bindingpolypeptide or antigen binding polypeptide complex (e.g., antibodies orantigen binding fragments thereof) specifically binds to a viralpeptide, protein, polypeptide, or a fragment of transmissiblegastroenteritis glycoprotein 195. In some aspects, the antigen bindingpolypeptide or antigen binding polypeptide complex (e.g., antibodies orantigen binding fragments thereof) specifically binds to a viralpeptide, protein, polypeptide, or a fragment of transmissiblegastroenteritis matrix protein. In some aspects, the antigen bindingpolypeptide or antigen binding polypeptide complex (e.g., antibodies orantigen binding fragments thereof) specifically binds to a viralpeptide, protein, polypeptide, or a fragment of swine rotavirusglycoprotein 38. In some aspects, the antigen binding polypeptide orantigen binding polypeptide complex (e.g., antibodies or antigen bindingfragments thereof) specifically binds to a viral peptide, protein,polypeptide, or a fragment of swine parvovirus capsid protein. In someaspects, the antigen binding polypeptide or antigen binding polypeptidecomplex (e.g., antibodies or antigen binding fragments thereof)specifically binds to a viral peptide, protein, polypeptide, or afragment of Serpulinahydodysenteriae protective antigen. In someaspects, the antigen binding polypeptide or antigen binding polypeptidecomplex (e.g., antibodies or antigen binding fragments thereof)specifically binds to a viral peptide, protein, polypeptide, or afragment of bovine viral diarrhea glycoprotein 55. In some aspects, theantigen binding polypeptide or antigen binding polypeptide complex(e.g., antibodies or antigen binding fragments thereof) specificallybinds to a viral peptide, protein, polypeptide, or a fragment ofNewcastle disease virus hemagglutinin-neuraminidase. In some aspects,the antigen binding polypeptide or antigen binding polypeptide complex(e.g., antibodies or antigen binding fragments thereof) specificallybinds to a viral peptide, protein, polypeptide, or a fragment of swineflu hemagglutinin. In some aspects, the antigen binding polypeptide orantigen binding polypeptide complex (e.g., antibodies or antigen bindingfragments thereof) specifically binds to a viral peptide, protein,polypeptide, or a fragment of swine flu neuraminidase. In some aspects,the antigen binding polypeptide or antigen binding polypeptide complex(e.g., antibodies or antigen binding fragments thereof) specificallybinds to a viral peptide, protein, polypeptide, or a fragment of footand mouth disease virus. In some aspects, the antigen bindingpolypeptide or antigen binding polypeptide complex (e.g., antibodies orantigen binding fragments thereof) specifically binds to a viralpeptide, protein, polypeptide, or a fragment of hog colera virus. Insome aspects, the antigen binding polypeptide or antigen bindingpolypeptide complex (e.g., antibodies or antigen binding fragmentsthereof) specifically binds to a viral peptide, protein, polypeptide, ora fragment of swine influenza virus. In some aspects, the antigenbinding polypeptide or antigen binding polypeptide complex (e.g.,antibodies or antigen binding fragments thereof) specifically binds to aviral peptide, protein, polypeptide, or a fragment of African swinefever virus. In some aspects, the antigen binding polypeptide or antigenbinding polypeptide complex (e.g., antibodies or antigen bindingfragments thereof) specifically binds to a viral peptide, protein,polypeptide, or a fragment of Mycoplasma liyopneutiioniae. In someaspects, the antigen binding polypeptide or antigen binding polypeptidecomplex (e.g., antibodies or antigen binding fragments thereof)specifically binds to a viral peptide, protein, polypeptide, or afragment of. In some aspects, the antigen binding polypeptide or antigenbinding polypeptide complex (e.g., antibodies or antigen bindingfragments thereof) specifically binds to a viral peptide, protein,polypeptide, or a fragment of infectious bovine rhinotracheitis virus.In some aspects, the antigen binding polypeptide or antigen bindingpolypeptide complex (e.g., antibodies or antigen binding fragmentsthereof) specifically binds to a viral peptide, protein, polypeptide, ora fragment of infectious bovine rhinotracheitis virus glycoprotein E. Insome aspects, the antigen binding polypeptide or antigen bindingpolypeptide complex (e.g., antibodies or antigen binding fragmentsthereof) specifically binds to a viral peptide, protein, polypeptide, ora fragment of glycoprotein G. In some aspects, the antigen bindingpolypeptide or antigen binding polypeptide complex (e.g., antibodies orantigen binding fragments thereof) specifically binds to a viralpeptide, protein, polypeptide, or a fragment of infectiouslaryngotracheitis virus. In some aspects, the antigen bindingpolypeptide or antigen binding polypeptide complex (e.g., antibodies orantigen binding fragments thereof) specifically binds to a viralpeptide, protein, polypeptide, or a fragment of an infectiouslaryngotracheitis virus glycoprotein G or glycoprotein I. In someaspects, the antigen binding polypeptide or antigen binding polypeptidecomplex (e.g., antibodies or antigen binding fragments thereof)specifically binds to a viral peptide, protein, polypeptide, or afragment of a glycoprotein of La Crosse virus. In some aspects, theantigen binding polypeptide or antigen binding polypeptide complex(e.g., antibodies or antigen binding fragments thereof) specificallybinds to a viral peptide, protein, polypeptide, or a fragment ofneonatal calf diarrhoea virus. In some aspects, the antigen bindingpolypeptide or antigen binding polypeptide complex (e.g., antibodies orantigen binding fragments thereof) specifically binds to a viralpeptide, protein, polypeptide, or a fragment of Venezuelan equineencephalomyelitis virus. In some aspects, the antigen bindingpolypeptide or antigen binding polypeptide complex (e.g., antibodies orantigen binding fragments thereof) specifically binds to a viralpeptide, protein, polypeptide, or a fragment of punta toro virus. Insome aspects, the antigen binding polypeptide or antigen bindingpolypeptide complex (e.g., antibodies or antigen binding fragmentsthereof) specifically binds to a viral peptide, protein, polypeptide, ora fragment of murine leukemia virus. In some aspects, the antigenbinding polypeptide or antigen binding polypeptide complex (e.g.,antibodies or antigen binding fragments thereof) specifically binds to aviral peptide, protein, polypeptide, or a fragment of mouse mammarytumor virus. In some aspects, the antigen binding polypeptide or antigenbinding polypeptide complex (e.g., antibodies or antigen bindingfragments thereof) specifically binds to a viral peptide, protein,polypeptide, or a fragment of hepatitis B virus core protein orhepatitis B virus surface antigen. In some aspects, the antigen bindingpolypeptide or antigen binding polypeptide complex (e.g., antibodies orantigen binding fragments thereof) specifically binds to a viralpeptide, protein, polypeptide, or a fragment of equine influenza virusor equine herpes virus, such as equine influenza virus type A/Alaska 91neuraminidase, equine influenza virus typeA/Miami 63 neuraminidase,equine influenza virus type A/Kentucky 81 neuraminidase equine herpesvirus type 1 glycoprotein B, and equine herpes virus type 1 glycoproteinD. In some aspects, the antigen binding polypeptide or antigen bindingpolypeptide complex (e.g., antibodies or antigen binding fragmentsthereof) specifically binds to a viral peptide, protein, polypeptide, ora fragment of bovine respiratory syncytial virus or bovine parainfluenzavirus. In some aspects, the antigen binding polypeptide or antigenbinding polypeptide complex (e.g., antibodies or antigen bindingfragments thereof) specifically binds to a viral peptide, protein,polypeptide, or a fragment of bovine respiratory syncytial virusattachment protein (BRSV G). In some aspects, the antigen bindingpolypeptide or antigen binding polypeptide complex (e.g., antibodies orantigen binding fragments thereof) specifically binds to a viralpeptide, protein, polypeptide, or a fragment of bovine respiratorysyncytial virus fusion protein (BRSV F). In some aspects, the antigenbinding polypeptide or antigen binding polypeptide complex (e.g.,antibodies or antigen binding fragments thereof) specifically binds to aviral peptide, protein, polypeptide, or a fragment of bovine respiratorysyncytial virus nucleocapsid protein (BRSVN). In some aspects, theantigen binding polypeptide or antigen binding polypeptide complex(e.g., antibodies or antigen binding fragments thereof) specificallybinds to a viral peptide, protein, polypeptide, or a fragment of bovineparainfluenza virus type 3 fusion protein. In some aspects, the antigenbinding polypeptide or antigen binding polypeptide complex (e.g.,antibodies or antigen binding fragments thereof) specifically binds to aviral peptide, protein, polypeptide, or a fragment of ovineparainfluenza virus type 3 hemagglutinin neuraminidase. In some aspects,the antigen binding polypeptide or antigen binding polypeptide complex(e.g., antibodies or antigen binding fragments thereof) specificallybinds to a viral peptide, protein, polypeptide, or a fragment of bovineE viral diarrhoea virus glycoprotein 48 or glycoprotein 53. In someaspects, the antigen binding polypeptide or antigen binding polypeptidecomplex (e.g., antibodies or antigen binding fragments thereof)specifically binds to a viral peptide, protein, polypeptide, or afragment of glycoprotein E of Dengue virus. In some aspects, the antigenbinding polypeptide or antigen binding polypeptide complex (e.g.,antibodies or antigen binding fragments thereof) specifically binds to aviral peptide, protein, polypeptide, or a fragment of glycoprotein ElE2of human hepatitis C virus. Any of the antigen binding polypeptidestructures and any of the antigen binding polypeptide complex structuresdescribed herein may be used to target one or more of the viral targetsdescribed herein.

Sequences from antibodies or antibody fragments to known spike proteinepitopes on any virus or overexpressed receptors on a cancer cell can beinserted into the constructs disclosed herein to produce multispecificmultivalent polypeptides and polypeptide complexes which bind to theepitopes on the virus or virus variants and to T cells which engage thevirus or cancer cell. The Immune Epitope Database and Analysis Resourceprovides lists of epitope sequences associated with specific antigensand infectious organism. Known VL/VH pairs and CDRs are selected andchosen to insert into a plasmid or plasmids encoding a fully functionalmultispecific multivalent antibody. In a preferred embodiment, thesource of a preferred initial antibody or monoclonal antibody is from ahighly resistant subject that has developed broadly neutralizingantibodies resistant across evolving infectious viruses or cancer cells.

Viral antigens present in Influenza A virus include matrix protein 1,hemagglutinin, nucleoprotein RNA-directed RNA polymerase catalyticsubunit, polymerase acidic protein, nuclear export protein, andpolymerase basic protein 2. Epitope sequences are inclusive of, forexample, those selected from GILGFVFTL (SEQ ID NO:422); PKYVKFQNTLKLAT(SEQ ID NO:423); SRYWAIRTR (SEQ ID NO:424); CTELKLSDY (SEQ ID NO:425);ELRSRYWAI (SEQ ID NO:426); ILRGSVAHK (SEQ ID NO:427); VSDGGPNLY (SEQ IDNO:428); FMYSEFHFI (SEQ ID NO:429); AIMDKNIIL (SEQ ID NO:430); NMLSTVLGV(SEQ ID NO:431); FLKDVMESM (SEQ ID NO:432); LPFEKSTVM (SEQ ID NO:433);and FVRQCFNPM (SEQ ID NO:434) etc. as disclosed in the above database.

Viral antigens present in Influenza B virus are selected from the groupconsisting of nucleoprotein, hemagglutinin; non-structural protein 1;neuraminidase and matrix protein 1. Epitopes from such proteins areselected from, for example, KLGEFYNQMM (SEQ ID NO:435); AVLLSNEGIINSEDE(SEQ ID NO:436); AVLLSNEGIINSEDEH (SEQ ID NO:437); AYDQSGRL (SEQ IDNO:438); AYDQSGRLV (SEQ ID NO:439); FPIMHDRTKI+OX(M4) (SEQ ID NO:440);ITKNLNSLSELEVKN (SEQ ID NO:441); ITKNLNSLSELEVKNLQ (SEQ ID NO:442);LAVLLSNEGIINSEDE (SEQ ID NO:443); LAVLLSNEGIINSEDEH (SEQ ID NO:444); andLPQSGRIVV (SEQ ID NO:445), as disclosed in the above database.

Antigens are selected from the group consisting of Influenza viruses andsurface glycoproteins: H5N1 influenza: H1N1:H1N2:H3N2:HA (hemagglutininsurface glycoprotein); NA (neuraminidase surface glycoprotein); H5 andH7. Others include: Respiratory syncytial virus (RSV). Antigensassociated with RSV include protein M2-1; matrix protein, fusionglycoprotein FO; nucleoprotein and small hydrophobic protein. Epitopespresent on these proteins are inclusive of SYIGSINNI (SEQ ID NO:446);NAITNAKII (SEQ ID NO:447); KYKNAVTEL (SEQ ID NO:448);NSELLSLINDMPITNDQKKLMSNN (SEQ ID NO:449); NPKASLLSL (SEQ ID NO:450);VYNTVISYI (SEQ ID NO:451); TYMLTNSELL (SEQ ID NO:452): WAICKRIPNKKPG(SEQ ID NO:453); and KNRGIIKTFSN (SEQ ID NO:454) etc.;

Chlamydia. Antigens associated with Chlamydia trachomatis include majorouter membrane porin, serovar D; chaperonin GroEL; uncharacterizedprotein (UniProt:Q9Z7F3) probably oxidoreductase CT_610 and inclusionmembrane protein A. Epitope sequences include, for example, TLNPTI (SEQID NO:455); ATLVVNRIRGGF (SEQ ID NO:456); LNPTIA (SEQ ID NO:457);SANNDAEIGNLI (SEQ ID NO:458); PETISDPENRNKPSAE (SEQ ID NO:459); AEGQLG(SEQ ID NO:460); ARKLLLDNL (SEQ ID NO:461); ASFVNPIYL (SEQ ID NO:462);DVVDGMNFNRGY (SEQ ID NO:463); NMFTPYIGV (SEQ ID NO:464), andNLVGLIGVKGSSIAADQLPNVGIT (SEQ ID NO:465) etc.;

Adenovirdiae. Antigens associated with human adenovirus C include earlyEIA protein; hexon protein; DNA-binding protein; EIB 55 kDa protein andDNA polymerase. Epitope sequences include, for example, SGPSNTPPEI (SEQID NO:466), TDLGQNLLY (SEQ ID NO:467); LTDLGQNLLY (SEQ ID NO:468);FALSNAEDL (SEQ ID NO:469); DEPTLLYVLFEVFDV (SEQ ID NO:470); KYSPSNVKI(SEQ ID NO:471); MPNRNYIAF (SEQ ID NO:472); VDCYINLGARWSLDY (SEQ IDNO:473); VNIRNCCYI (SEQ ID NO:474); RNFQPMSRQVVDDTKYKDYQQVGILHQHNN (SEQID NO:475); LPKLTPFAL (SEQ ID NO:476); and FQRPTISSNSHAIFR (SEQ IDNO:477) etc;

Mastadenovirus. Human mastadenovirus C has various antigens associatedwith viral infection. These include early E1A protein; hexon protein;DNA binding protein; E1B 55 kDa protein; DNA polymerase and fiberprotein. Epitope sequences are inclusive of, for example, SGPSNTPPEI(SEQ ID NO:478); TDLGQNLLY (SEQ ID NO:479); LTDLGQNLLY (SEQ ID NO:480);FALSNAEDL (SEQ ID NO:481); DEPTLLYVLFEVFDV (SEQ ID NO:482); KYSPSNVKI(SEQ ID NO:483); MPNRPNYIAF (SEQ ID NO:484); VDCYINLGARWSLDY (SEQ IDNO:485); LPKLTPFAL (SEQ ID NO:486); FQRPTISSNSHAIFR (SEQ ID NO:487) andGKYTTETFATNSYTPSYIAQE (SEQ ID NO:488) etc;

Aviadenovirus. Fowl adenovirus C has hexon protein as one of theantigens with epitopes DYDDYNIGTT (SEQ ID NO:489); KISGVFPNP (SEQ IDNO:490); PLAPKESMFN (SEQ ID NO:491); andETLLIEDDVSGQGKELGVNLNPAGPITADEQGL (SEQ ID NO:492) etc;

Herpesviridae. Antigens depend upon particular organism with humanherpesvirus 5 (human cytomegalovirus) and human herpesvirus 4 (EpsteinBarr Virus) being predominant focus with antigens ranging from 65 kDaphosphoprotein; mRNA export factor ICP27 homolog; envelope glycoproteinB; latent membrane protein 2; Epstein-Barr nuclear antigen 3; M123;trans-activitor protein BZLF1; immediate early protein IE1; Epstein-Barrnuclear antigen 4; Epstein-Barr nuclear antigen 1; DNA polymeraseprocessivity factor; ribonucleoside-diphosphate reductase largesubunit-like protein; replication and transcription activator; andlatent membrane protein 1 with epitope sequences selected from, forexample, NLVPMVATV (SEQ ID NO:493); GLCTLVAML (SEQ ID NO:494);TPRVTGGGAM (SEQ ID NO:495); SSIEFARL (SEQ ID NO:496); CLGGLLTMV (SEQ IDNO:497); FLRGRAYGL (SEQ ID NO:498); TPHFMPTNL (SEQ ID NO:499); RAKFKQLL(SEQ ID NO:500); RPPIFIRRL (SEQ ID NO:501); VLEETSVML (SEQ ID NO:502);IVTDFSVIK (SEQ ID NO:503); IPSINVHHY (SEQ ID NO:504); QYDPVAALF (SEQ IDNO:505); HPVGEADYFEY (SEQ ID NO:506); VTEHDTLLY (SEQ ID NO:507);HGIRNASFI (SEQ ID NO:508); AVFDRKSDAK (SEQ ID NO:509); TPLHEQHGM (SEQ IDNO:510); YSEHPTFTSQY (SEQ ID NO:511); YVLDHLIVV (SEQ ID NO:512);YLLEMLWRL (SEQ ID NO:513); FLYALALLL (SEQ ID NO:514); QAKWRLQTL (SEQ IDNO:515); ELRRKMMYM (SEQ ID NO:516); and RPHERNGFTVL (SEQ ID NO:517) etc;

Herpes simplex virus 1 (human herpesvirus 1). Antigens include envelopeglycoprotein B; ribonucleoside-diphosphate reductase large subunit;envelope glycoprotein D; tegument protein UL46; mRNA export factor;capsid vertex component 2 and ribonucleoside-diphosphate reductase smallsubunit. Epitope sequences include SSIEFARL (SEQ ID NO:518); QTFDRGRL(SEQ ID NO:519); SLKMADPNRFRGKDLP (SEQ ID NO:520);QPPSLPITVYYAVLERACTSVLLNAPSEAPQIVR (SEQ ID NO:521); RLNELLAYV (SEQ IDNO:522); RMLGDVMAV (SEQ ID NO:523); KYALADASLKMADPNRFRGKDLP (SEQ IDNO:524); SLPITVTTA (SEQ ID NO:525); DPEDSALL (SEQ ID NO:526); andDYATLGVGV (SEQ ID NO:527) etc;

Herpes simplex virus 2 (human herpesvirus 2). Antigens include Tegumentprotein VP22; envelope glycoprotein B; tegument protein VP16; Tegumentprotein UL47; tegument protein UL46; tegument protein VP16; envelopeglycoprotein G; capsid vertex component 2; capsid scaffolding protein;envelope glycoprotein D; mRNA export factor; major viral transcriptionfactor ICP4 homolog with antigen epitope sequences selected from, forexample, RPRGEVRFL (SEQ ID NO:528); SSIEFARL (SEQ ID NO:529);EEVDMTPADALDDFD (SEQ ID NO:530); GLADTVVAC (SEQ ID NO:531); ASDSLNNEY(SEQ ID NO:532); DFEFEQMFTDAMG (SEQ ID NO:533); EVDMTPADAL (SEQ IDNO:534); PEEFEGAGDGEPPEDDDS (SEQ ID NO:535); FLWEDQTLL (SEQ ID NO:536);FLVDAIVRVA (SEQ ID NO:537); GPADAPPGSPAPPPPEHRGG (SEQ ID NO:538);GPHETITAL (SEQ ID NO:539); KYALADPSLKMADPNRFRGKNLP (SEQ ID NO:540);NNYGSTIEGLL (SEQ ID NO:541); PEEFEGAGDGEPPEDDDSAT (SEQ ID NO:542);PPLYATGRLSQAQLMPSPPM (SEQ ID NO:543); TQPELVPEDPED (SEQ ID NO:544);YTSTLLPPELSDTTN (SEQ ID NO:545): DPSLKMADPNRFRGKNLPVL (SEQ ID NO:546);PELVPEDPEDSALLEDPAGT (SEQ ID NO:547); HGPSLYRTF (SEQ ID NO:548);NKRVFCAAVGRLA (SEQ ID NO:549); PMRARPRGEVRFL (SEQ ID NO:550); VFCAAVGRL(SEQ ID NO:551); and LGNRLCGPATAAWAG (SEQ ID NO:552) and as furtherdisclosed in the Immune Epitope database.

Herpes simplex virus 5 (human herpesvirus 5). Antigens include 65 kDaphosphoprotein; immediate early protein IE1; envelope glycoprotein H;other human herpesvirus 5 protein and envelope glycoprotein B. Epitopesequences include NLVPMVATV (SEQ ID NO:553); TMYGGISLL (SEQ ID NO:554);VLEETSVML (SEQ ID NO:555); LDPHAFHLLL (SEQ ID NO:556); RIFAELEGV (SEQ IDNO:557); RPHERNGFTVL (SEQ ID NO:558); VFPTKDVAL (SEQ ID NO:559);VLAELVKQI (SEQ ID NO:560); VLPHETRLL (SEQ ID NO:561); KRLDVCRAKMGYM (SEQID NO:562); GGGAMAGASTSAGRKRKS (SEQ ID NO:563); AALFFFDID (SEQ IDNO:564); AGILARNLVPMVATV (SEQ ID NO:565); ALFFFDIDLL (SEQ ID NO:566);ANETIYNTTLKYGDV (SEQ ID NO:567); ARAKKDELRRKMMYM (SEQ ID NO:568);ARNLVPMVATVQGQN (SEQ ID NO:569); ASTAAPPYTNEQAYQMLLAL (SEQ ID NO:570);AVGGAVASV (SEQ ID NO:571); DEEEAIVAYT (SEQ ID NO:572); DEEEAIVAYTL (SEQID NO:573); DPVAALFFF (SEQ ID NO:574); EEAIVAYTL (SEQ ID NO:575);EECQLPSLKIFIAGNSAY (SEQ ID NO:576) or EEEAIVAYTL (SEQ ID NO:577) andothers disclosed in public databases such as the Immune Epitopedatabase;

Other antigens include Herpes simplex virus 6; Leviviridae; Levivirus;Enterobacteria phase MS2; Allolevirus; Poxviridae; Chordopoxvirinae(cowpox virus or vaccinia virus); antigens include CPXV202 protein;intermediate transcription factor 3 small subunit; putative nuclease G5;interferon antagonist C7; protein A47; major core protein 4b; DNAdirected RNA polymerase 147 kDa polypeptide; mRNA capping enzymeregulatory subunit; envelope protein H3; protein B6; telomere bindingprotein I1; protein K3; poxin; protein A19; assembly protein G7; proteinF12; protein A46; protein A6; DNA polymerase; profiling; RNA bindingprotein E3; and serine protease inhibitor 1. The antigens have epitopesequences selected from TSYKFESV (SEQ ID NO:578); ITYRFYLI (SEQ IDNO:579); ILDDNLYKV (SEQ ID NO:580); KVDDTFYYV (SEQ ID NO:581); AAFEFINSL(SEQ ID NO:582); KSYNYMLL (SEQ ID NO:583); MPAYIRNTL (SEQ ID NO:584);RVYEALYYV (SEQ ID NO:585); IGMFNLTFI (SEQ ID NO:586); SLSAYIIRV (SEQ IDNO:587); LMYDIINSV (SEQ ID NO:588); RLYDYFTRV (SEQ ID NO:589);YSLPNAGDVI (SEQ ID NO:590); YSQVNKRYI (SEQ ID NO:591); VSLDYINTM (SEQ IDNO:592); TLPEVISTI (SEQ ID NO:593); FLTSVINRV (SEQ ID NO:594); GFFDFVNFV(SEQ ID NO:595); VLYDEFVTI (SEQ ID NO:596); FPYEGGKVF (SEQ ID NO:597);LMDENTYAM (SEQ ID NO:598); NLFDIPLLTV (SEQ ID NO:599); VGPSNSPTF (SEQ IDNO:600); YAPVSPIVI (SEQ ID NO:601) and HVDGKILFV (SEQ ID NO:602) etc;

Parapoxvirus (orf virus). Antigens include uncharacterized protein;ORF011 putative EEV envelope phospholipase; ORF052 putative IMV membraneprotein; ORF110 EEV glycoprotein; ORF094 putative phosphorylated IMVmembrane protein; ORF056RNA polymerase subunit RP0147; ORF101 RNApolymerase subunit RP0132 having epitope sequences AAFEFRDL (SEQ IDNO:603); AIIKYTDL (SEQ ID NO:604); AIYAFRLT (SEQ ID NO:605); AIYGFGVTF(SEQ ID NO:606); ANVDFMEYV (SEQ ID NO:607); and EQFSFSNV (SEQ IDNO:608). Other antigens and their associated antibodies and antibodyfragments which bind to epitopes include Avipoxvirus; Capripoxvirus;Leporiipoxvirus; Suipoxvirus; Molluscipoxvirus; Entomopoxvirinae;Papovaviridae; Polyomavirus; Papillomavirus; Paramyxoviridae;Paramyxovirus; Parainfluenza virus 1; Morbillivirus; Measles virus;Rubulavirus; Mumps virus; Pneumonovirinae; Pneumovirus; Metapneumovirus;Avian pneumovirus; Human metapneumovirus; Picornaviridae, andEnterovirus (enterovirus A, coxsackievirus A). Antigen includes genomepolyprotein having epitopes selected from TYTFGEHKQEKDLEY (SEQ IDNO:609); TEDSHPPYKQTQPGA (SEQ ID NO:610); PESRESLAWQTATNP (SEQ IDNO:611); FGEHKQEKDL (SEQ ID NO:612); AGGTGTEDSHPPYKQ (SEQ ID NO:613);FGEHKQEKDL (SEQ ID NO:614); AGGTGTEDSHPPYKQ (SEQ ID NO:615);FGEHKQEKDLEYGAC (SEQ ID NO:616); HYRAHARDGVFDYYT (SEQ ID NO:617); KQEDK(SEQ ID NO:618); GDPIADMIDQTVNNQ (SEQ ID NO:619); YPTFGEHLQANDLDY (SEQID NO:620); LEGTTNPNT (SEQ ID NO:621); VSSHRLDDTGEVPALQ (SEQ ID NO:622);RIYMRMKHVR (SEQ ID NO:623); TSKSKYPLVV (SEQ ID NO:624); andDGYPTFGEHKQEKDL (SEQ ID NO:625) etc;

Rhinovirus and Hepatovirus. Human hepatitis A virus (hepatovirus A) withgenome polyproteins as an antigen with epitopes YMYAVS GAL (SEQ IDNO:626); FWRGDLVFDFQV (SEQ ID NO:627); MNMSKQGIFQTVGSGLDHILSLA (SEQ IDNO:628); TVSTEQNVPDPQVGI (SEQ ID NO:629); ASICQMFCFWRGDLVFDFQV (SEQ IDNO:630); DHMSIYKFMGRSHFLCTFTF (SEQ ID NO:631); FPELKPGESTHTSDHMSIYK (SEQID NO:632) and as additionally disclosed in the IED. Others areinclusive of Cardiovirus; Andapthovirus, Reoviridae, Orthoreovirus;Orbivirus; Rotavirus; Cypovirus; Fijivirus, phytoreovirus; oryzavirus;retroviridae; mammalian type B retrovirus; mammalian type Cretroviruses; avian type C retroviruses; type D retrovirus group;BLV-HTLV retroviruses; Lentivirus; Human immunodeficiency virus 1; Humanimmunodeficiency virus 2; HTLV-I and II viruses; Herpes simplex virus;Epstein Barr virus; Cytomegalovirus; Hepatitis virus (HCV, HAV, HBV,HDV, HEV); Toxoplasma gondii virus, Treponema pallidium virus; HumanT-lymphotrophic virus; Encephalitis virus; West Nile virus; Denguevirus; Varicella Zoster virus; Rubeola, mumps, rubella, spumavirus,flaviviridae, hepatitis C virus; hepadnaviridae, hepatitis B virus;togaviridae, alphavirus sindbis virus; rubivirus; rubella virus,rhabdovridae, vesiculovirus; lyssavirus, ephemerovirus, cytohabdovirus,necleorhabdovirus, arenaviridae, arenavirus, lymphocytic choriomenigitisvirus; Ippy virus; Lassa virus; and Torovirus etc.

Thus, the recited multispecific and multivalent antibody constructs haveembedded sequences that target and bind to epitopes on viral peptides,proteins, polypeptides or glycosylated versions thereof in a subject inneed of treatment thereof, wherein said viral peptides, proteins,polypeptides or glycosylated versions thereof are selected from thegroup consisting of influenza virus neuraminidase, influenza virushemagglutinin, human respiratory syncytial virus (RSV)-viral proteins,RSV F glycoprotein, RSV G glycoprotein, herpes simplex virus (HSV) viralproteins, herpes simplex virus glycoproteins gB, gC, gD and gE,Chlamydia MOMP and PorB antigens, core protein, matrix protein or otherprotein of Dengue virus, measles virus hemagglutinin, herpes simplexvirus type 2 glycoprotein gB, poliovirus 1 VP1, envelope glycoproteinsof HIV 1, hepatitis B surface antigen, diphtheria toxin, Streptococcus24 M epitope, gonococcal pilin, pseudorabies virus g50 (gpD),pseudorabies virus II (gpB), pseudorabies virus III (gpC), pseudorabidesvirus glycoprotein H, pseudorabies virus glycoprotein E, transmissiblegastroenteritis glycoprotein 195, transmissible gastroenteritis matrixprotein, swine rotavirus glycoprotein 38, swine parvovirus capsideprotein, serpulinahydodysenteriae protective antigen, govine viraldiarrhea glycoprotein 55, Newcastle disease virushemagglutinin-neuroaminidase, swine flu hemagglutinin, swine flueneuraminidase, foot and mouth disease virus, hog colera virus, swineinfluenza virus, African swine fever virus, Mycoplasma liyopneutiinniae,infections bovine rhinotracheitis virus, infection bovinerhinotracheitis virus glycoprotein e, glycoprotein G, infectioulslaryngotracheitis virus, infectious laryngotracheitis virus glycoproteinG or glycoprotein I, a glycoprotein of Las Cross virus, neonatal calfdiarrhea virus, Venezuelan equine encephalomyelitis virus, punta torovirus, murine leukemia virus, mouse mammary tumor virus, hepatitis Bvirus core protein and hepatitis B virus surface antigen or a fragmentor derivative thereof, antigen of equine influenza virus or equineherpes virus, including equine influenza virus type A/Alaska 91neuraminidase, equine influenza virus typeA/Miami 63 neuraminidase,equine influenza virus type A/Kentucky 81 neuraminidase equine herpesvirus type 1 glycoprotein B, and equine herpes virus type 1 glycoproteinD, antigen of bovine respiratory syncytial virus or bovine parainfluenzavirus, bovine respiratory syncytial virus attachment protein (BRSV G),bovine respiratory syncytial virus fusion protein (BRSV F), bovinerespiratory syncytial virus nucleocapside protein (BRSVN), bovineparainfluenza virus type 3 fusion protein, bovine parainfluenza virustype 3 hemagglutinin neuraminidase, bovine viral diarrhea virusglycoprotein 48 and glycoprotein 53, glycoprotein E of Dengue virus, andglycoprotein ElE2 of human hepatitis C virus. All the antigen bindingpolypeptide structures described herein and all the antigen bindingpolypeptide complex structures described herein can specifically bind toone or more of the viral antigen targets described herein, namely one ormore of (such as two or more, three or more or four of): influenza virusneuraminidase, influenza virus hemagglutinin, human respiratorysyncytial virus (RSV)-viral proteins, RSV F glycoprotein, RSV Gglycoprotein, herpes simplex virus (HSV) viral proteins, herpes simplexvirus glycoproteins gB, gC, gD and gE, Chlamydia MOMP and PorB antigens,core protein, matrix protein or other protein of Dengue virus, measlesvirus hemagglutinin, herpes simplex virus type 2 glycoprotein gB,poliovirus 1 VP1, envelope glycoproteins of HIV 1, hepatitis B surfaceantigen, diphtheria toxin, Streptococcus 24 M epitope, gonococcal pilin,pseudorabies virus g50 (gpD), pseudorabies virus II (gpB), pseudorabiesvirus III (gpC), pseudorabides virus glycoprotein H, pseudorabies virusglycoprotein E, transmissible gastroenteritis glycoprotein 195,transmissible gastroenteritis matrix protein, swin rotavirusglycoprotein 38, swine parvovirus capside protein,serpulinahydodysenteriae protective antigen, govine viral diarrheaglycoprotein 55, Newcastle disease virus hemagglutinin-neuroaminidase,swine flu hemagglutinin, swine flue neuraminidase, foot and mouthdisease virus, hog colera virus, swine influenza virus, African swinefever virus, Mycoplasma liyopneutiinniae, infections bovinerhinotracheitis virus, infection bovine rhinotracheitis virusglycoprotein e, glycoprotein G, infectiouls laryngotracheitis virus,infectious laryngotracheitis virus glycoprotein G or glycoprotein I, aglycoprotein of Las Cross virus, neonatal calf diarrhea virus,Venezuelan equine encephalomyelitis virus, punta toro virus, murineleukemia virus, mouse mammary tumor virus, hepatitis B virus coreprotein and hepatitis B virus surface antigen or a fragment orderivative thereof, antigen of equine influenza virus or equine herpesvirus, including equine influenza virus type A/Alaska 91 neuraminidase,equine influenza virus typeA/Miami 63 neuraminidase, equine influenzavirus type A/Kentucky 81 neuraminidase equine herpes virus type 1glycoprotein B, and equine herpes virus type 1 glycoprotein D, antigenof bovine respiratory syncytial virus or bovine parainfluenza virus,bovine respiratory syncytial virus attachment protein (BRSV G), bovinerespiratory syncytial virus fusion protein (BRSV F), bovine respiratorysyncytial virus nucleocapside protein (BRSVN), bovine parainfluenzavirus type 3 fusion protein, bovine parainfluenza virus type 3hemagglutinin neuraminidase, bovine viral diarrhea virus glycoprotein 48and glycoprotein 53, glycoprotein E of Dengue virus, and glycoproteinElE2 of human hepatitis C virus. In some aspects, the antigen bindingpolypeptide described herein or the antigen binding polypeptide complexdescribed herein comprises a VL1 that specifically binds to influenzavirus neuraminidase, influenza virus hemagglutinin, human respiratorysyncytial virus (RSV)-viral proteins, RSV F glycoprotein, RSV Gglycoprotein, herpes simplex virus (HSV) viral proteins, herpes simplexvirus glycoproteins gB, gC, gD and gE, Chlamydia MOMP and PorB antigens,core protein, matrix protein or other protein of Dengue virus, measlesvirus hemagglutinin, herpes simplex virus type 2 glycoprotein gB,poliovirus 1 VP1, envelope glycoproteins of HIV 1, hepatitis B surfaceantigen, diphtheria toxin, Streptococcus 24 M epitope, gonococcal pilin,pseudorabies virus g50 (gpD), pseudorabies virus II (gpB), pseudorabiesvirus III (gpC), pseudorabides virus glycoprotein H, pseudorabies virusglycoprotein E, transmissible gastroenteritis glycoprotein 195,transmissible gastroenteritis matrix protein, swin rotavirusglycoprotein 38, swine parvovirus capside protein,serpulinahydodysenteriae protective antigen, govine viral diarrheaglycoprotein 55, Newcastle disease virus hemagglutinin-neuroaminidase,swine flu hemagglutinin, swine flue neuraminidase, foot and mouthdisease virus, hog colera virus, swine influenza virus, African swinefever virus, Mycoplasma liyopneutiinniae, infections bovinerhinotracheitis virus, infection bovine rhinotracheitis virusglycoprotein e, glycoprotein G, infectiouls laryngotracheitis virus,infectious laryngotracheitis virus glycoprotein G or glycoprotein I, aglycoprotein of Las Cross virus, neonatal calf diarrhea virus,Venezuelan equine encephalomyelitis virus, punta toro virus, murineleukemia virus, mouse mammary tumor virus, hepatitis B virus coreprotein and hepatitis B virus surface antigen or a fragment orderivative thereof, antigen of equine influenza virus or equine herpesvirus, including equine influenza virus type A/Alaska 91 neuraminidase,equine influenza virus typeA/Miami 63 neuraminidase, equine influenzavirus type A/Kentucky 81 neuraminidase equine herpes virus type 1glycoprotein B, and equine herpes virus type 1 glycoprotein D, antigenof bovine respiratory syncytial virus or bovine parainfluenza virus,bovine respiratory syncytial virus attachment protein (BRSV G), bovinerespiratory syncytial virus fusion protein (BRSV F), bovine respiratorysyncytial virus nucleocapside protein (BRSVN), bovine parainfluenzavirus type 3 fusion protein, bovine parainfluenza virus type 3hemagglutinin neuraminidase, bovine viral diarrhea virus glycoprotein 48and glycoprotein 53, glycoprotein E of Dengue virus, or glycoproteinElE2 of human hepatitis C virus. In some aspects, the antigen bindingpolypeptide described herein or the antigen binding polypeptide complexdescribed herein comprises a VL2 that specifically binds to influenzavirus neuraminidase, influenza virus hemagglutinin, human respiratorysyncytial virus (RSV)-viral proteins, RSV F glycoprotein, RSV Gglycoprotein, herpes simplex virus (HSV) viral proteins, herpes simplexvirus glycoproteins gB, gC, gD and gE, Chlamydia MOMP and PorB antigens,core protein, matrix protein or other protein of Dengue virus, measlesvirus hemagglutinin, herpes simplex virus type 2 glycoprotein gB,poliovirus 1 VP1, envelope glycoproteins of HIV 1, hepatitis B surfaceantigen, diphtheria toxin, Streptococcus 24 M epitope, gonococcal pilin,pseudorabies virus g50 (gpD), pseudorabies virus II (gpB), pseudorabiesvirus III (gpC), pseudorabides virus glycoprotein H, pseudorabies virusglycoprotein E, transmissible gastroenteritis glycoprotein 195,transmissible gastroenteritis matrix protein, swin rotavirusglycoprotein 38, swine parvovirus capside protein,serpulinahydodysenteriae protective antigen, govine viral diarrheaglycoprotein 55, Newcastle disease virus hemagglutinin-neuroaminidase,swine flu hemagglutinin, swine flue neuraminidase, foot and mouthdisease virus, hog colera virus, swine influenza virus, African swinefever virus, Mycoplasma liyopneutiinniae, infections bovinerhinotracheitis virus, infection bovine rhinotracheitis virusglycoprotein e, glycoprotein G, infectiouls laryngotracheitis virus,infectious laryngotracheitis virus glycoprotein G or glycoprotein I, aglycoprotein of Las Cross virus, neonatal calf diarrhea virus,Venezuelan equine encephalomyelitis virus, punta toro virus, murineleukemia virus, mouse mammary tumor virus, hepatitis B virus coreprotein and hepatitis B virus surface antigen or a fragment orderivative thereof, antigen of equine influenza virus or equine herpesvirus, including equine influenza virus type A/Alaska 91 neuraminidase,equine influenza virus typeA/Miami 63 neuraminidase, equine influenzavirus type A/Kentucky 81 neuraminidase equine herpes virus type 1glycoprotein B, and equine herpes virus type 1 glycoprotein D, antigenof bovine respiratory syncytial virus or bovine parainfluenza virus,bovine respiratory syncytial virus attachment protein (BRSV G), bovinerespiratory syncytial virus fusion protein (BRSV F), bovine respiratorysyncytial virus nucleocapside protein (BRSVN), bovine parainfluenzavirus type 3 fusion protein, bovine parainfluenza virus type 3hemagglutinin neuraminidase, bovine viral diarrhea virus glycoprotein 48and glycoprotein 53, glycoprotein E of Dengue virus, or glycoproteinElE2 of human hepatitis C virus. In some aspects, the antigen bindingpolypeptide described herein or the antigen binding polypeptide complexdescribed herein comprises a VH1 that specifically binds to influenzavirus neuraminidase, influenza virus hemagglutinin, human respiratorysyncytial virus (RSV)-viral proteins, RSV F glycoprotein, RSV Gglycoprotein, herpes simplex virus (HSV) viral proteins, herpes simplexvirus glycoproteins gB, gC, gD and gE, Chlamydia MOMP and PorB antigens,core protein, matrix protein or other protein of Dengue virus, measlesvirus hemagglutinin, herpes simplex virus type 2 glycoprotein gB,poliovirus 1 VP1, envelope glycoproteins of HIV 1, hepatitis B surfaceantigen, diphtheria toxin, Streptococcus 24 M epitope, gonococcal pilin,pseudorabies virus g50 (gpD), pseudorabies virus II (gpB), pseudorabiesvirus III (gpC), pseudorabides virus glycoprotein H, pseudorabies virusglycoprotein E, transmissible gastroenteritis glycoprotein 195,transmissible gastroenteritis matrix protein, swin rotavirusglycoprotein 38, swine parvovirus capside protein,serpulinahydodysenteriae protective antigen, govine viral diarrheaglycoprotein 55, Newcastle disease virus hemagglutinin-neuroaminidase,swine flu hemagglutinin, swine flue neuraminidase, foot and mouthdisease virus, hog colera virus, swine influenza virus, African swinefever virus, Mycoplasma liyopneutiinniae, infections bovinerhinotracheitis virus, infection bovine rhinotracheitis virusglycoprotein e, glycoprotein G, infectiouls laryngotracheitis virus,infectious laryngotracheitis virus glycoprotein G or glycoprotein I, aglycoprotein of Las Cross virus, neonatal calf diarrhea virus,Venezuelan equine encephalomyelitis virus, punta toro virus, murineleukemia virus, mouse mammary tumor virus, hepatitis B virus coreprotein and hepatitis B virus surface antigen or a fragment orderivative thereof, antigen of equine influenza virus or equine herpesvirus, including equine influenza virus type A/Alaska 91 neuraminidase,equine influenza virus typeA/Miami 63 neuraminidase, equine influenzavirus type A/Kentucky 81 neuraminidase equine herpes virus type 1glycoprotein B, and equine herpes virus type 1 glycoprotein D, antigenof bovine respiratory syncytial virus or bovine parainfluenza virus,bovine respiratory syncytial virus attachment protein (BRSV G), bovinerespiratory syncytial virus fusion protein (BRSV F), bovine respiratorysyncytial virus nucleocapside protein (BRSVN), bovine parainfluenzavirus type 3 fusion protein, bovine parainfluenza virus type 3hemagglutinin neuraminidase, bovine viral diarrhea virus glycoprotein 48and glycoprotein 53, glycoprotein E of Dengue virus, or glycoproteinElE2 of human hepatitis C virus. In some aspects, the antigen bindingpolypeptide described herein or the antigen binding polypeptide complexdescribed herein comprises a VH2 that specifically binds to influenzavirus neuraminidase, influenza virus hemagglutinin, human respiratorysyncytial virus (RSV)-viral proteins, RSV F glycoprotein, RSV Gglycoprotein, herpes simplex virus (HSV) viral proteins, herpes simplexvirus glycoproteins gB, gC, gD and gE, Chlamydia MOMP and PorB antigens,core protein, matrix protein or other protein of Dengue virus, measlesvirus hemagglutinin, herpes simplex virus type 2 glycoprotein gB,poliovirus 1 VP1, envelope glycoproteins of HIV 1, hepatitis B surfaceantigen, diphtheria toxin, Streptococcus 24 M epitope, gonococcal pilin,pseudorabies virus g50 (gpD), pseudorabies virus II (gpB), pseudorabiesvirus III (gpC), pseudorabides virus glycoprotein H, pseudorabies virusglycoprotein E, transmissible gastroenteritis glycoprotein 195,transmissible gastroenteritis matrix protein, swin rotavirusglycoprotein 38, swine parvovirus capside protein,serpulinahydodysenteriae protective antigen, govine viral diarrheaglycoprotein 55, Newcastle disease virus hemagglutinin-neuroaminidase,swine flu hemagglutinin, swine flue neuraminidase, foot and mouthdisease virus, hog colera virus, swine influenza virus, African swinefever virus, Mycoplasma liyopneutiinniae, infections bovinerhinotracheitis virus, infection bovine rhinotracheitis virusglycoprotein e, glycoprotein G, infectiouls laryngotracheitis virus,infectious laryngotracheitis virus glycoprotein G or glycoprotein I, aglycoprotein of Las Cross virus, neonatal calf diarrhea virus,Venezuelan equine encephalomyelitis virus, punta toro virus, murineleukemia virus, mouse mammary tumor virus, hepatitis B virus coreprotein and hepatitis B virus surface antigen or a fragment orderivative thereof, antigen of equine influenza virus or equine herpesvirus, including equine influenza virus type A/Alaska 91 neuraminidase,equine influenza virus typeA/Miami 63 neuraminidase, equine influenzavirus type A/Kentucky 81 neuraminidase equine herpes virus type 1glycoprotein B, and equine herpes virus type 1 glycoprotein D, antigenof bovine respiratory syncytial virus or bovine parainfluenza virus,bovine respiratory syncytial virus attachment protein (BRSV G), bovinerespiratory syncytial virus fusion protein (BRSV F), bovine respiratorysyncytial virus nucleocapside protein (BRSVN), bovine parainfluenzavirus type 3 fusion protein, bovine parainfluenza virus type 3hemagglutinin neuraminidase, bovine viral diarrhea virus glycoprotein 48and glycoprotein 53, glycoprotein E of Dengue virus, or glycoproteinElE2 of human hepatitis C virus. The antigen binding polypeptide andantigen binding polypeptide complex described herein may comprise anycombination of VH1, VH2, VL1 and VL2 that bind the targets describedherein. For example, said viral peptides, proteins, polypeptides orglycosylated versions thereof are selected from the group consisting of:influenza virus neuraminidase, influenza virus hemagglutinin, herpessimplex virus (HSV) viral proteins, core protein, matrix protein orother protein of Dengue virus, and swine influenza viral proteins. Allthe antigen binding polypeptide structures described herein and all theantigen binding polypeptide complex structures described herein canspecifically bind to one or more of the viral antigen targets describedherein, namely one or more of (such as two or more, three or more orfour of): influenza virus neuraminidase, influenza virus hemagglutinin,herpes simplex virus (HSV) viral proteins, core protein, matrix proteinor other protein of Dengue virus, and swine influenza viral proteins. Insome aspects, the antigen binding polypeptide and the antigen bindingpolypeptide complex can specifically bind to influenza virusneuraminidase. In some aspects, the antigen binding polypeptide or theantigen binding polypeptide complex comprises a VL1 that specificallybinds to influenza virus neuraminidase. In some aspects, the antigenbinding polypeptide or the antigen binding polypeptide complex comprisesa VL2 that specifically binds to influenza virus neuraminidase. In someaspects, the antigen binding polypeptide or the antigen bindingpolypeptide complex comprises a VH1 that specifically binds to influenzavirus neuraminidase. In some aspects, the antigen binding polypeptide orthe antigen binding polypeptide complex comprises a VH2 thatspecifically binds to influenza virus neuraminidase. In some aspects,the antigen binding polypeptide and the antigen binding polypeptidecomplex can specifically bind to influenza virus hemagglutinin. In someaspects, the antigen binding polypeptide or the antigen bindingpolypeptide complex comprises a VL1 that specifically binds to influenzavirus hemagglutinin. In some aspects, the antigen binding polypeptide orthe antigen binding polypeptide complex comprises a VL2 thatspecifically binds to influenza virus hemagglutinin. In some aspects,the antigen binding polypeptide or the antigen binding polypeptidecomplex comprises a VH1 that specifically binds to influenza virushemagglutinin. In some aspects, the antigen binding polypeptide or theantigen binding polypeptide complex comprises a VH2 that specificallybinds to influenza virus hemagglutinin. In some aspects, the antigenbinding polypeptide and the antigen binding polypeptide complex canspecifically bind to herpes simplex virus (HSV) viral proteins. In someaspects, the antigen binding polypeptide or the antigen bindingpolypeptide complex comprises a VL1 that specifically binds to herpessimplex virus (HSV) viral proteins. In some aspects, the antigen bindingpolypeptide or the antigen binding polypeptide complex comprises a VL2that specifically binds to herpes simplex virus (HSV) viral proteins. Insome aspects, the antigen binding polypeptide or the antigen bindingpolypeptide complex comprises a VH1 that specifically binds to herpessimplex virus (HSV) viral proteins. In some aspects, the antigen bindingpolypeptide or the antigen binding polypeptide complex comprises a VH2that specifically binds to herpes simplex virus (HSV) viral proteins. Insome aspects, the antigen binding polypeptide and the antigen bindingpolypeptide complex can specifically bind to gue virus. In some aspects,the antigen binding polypeptide or the antigen binding polypeptidecomplex comprises a VL1 that specifically binds to Dengue virus. In someaspects, the antigen binding polypeptide or the antigen bindingpolypeptide complex comprises a VL2 that specifically binds to Denguevirus. In some aspects, the antigen binding polypeptide or the antigenbinding polypeptide complex comprises a VH1 that specifically binds toDengue virus. In some aspects, the antigen binding polypeptide or theantigen binding polypeptide complex comprises a VH2 that specificallybinds to Dengue virus. In some aspects, the antigen binding polypeptideand the antigen binding polypeptide complex can specifically bind toswine influenza virus. In some aspects, the antigen binding polypeptidedescribed herein or the antigen binding polypeptide complex describedherein comprises a VL1 that specifically binds to swine influenza virus.In some aspects, the antigen binding polypeptide described herein or theantigen binding polypeptide complex described herein comprises a VL2that specifically binds to swine influenza virus. In some aspects, theantigen binding polypeptide described herein or the antigen bindingpolypeptide complex described herein comprises a VH1 that specificallybinds to swine influenza virus. In some aspects, the antigen bindingpolypeptide described herein or the antigen binding polypeptide complexdescribed herein comprises a VH2 that specifically binds to swineinfluenza virus.

In other aspects, the invention is directed to an antigen bindingpolypeptide or antigen binding polypeptide complex that specificallybinds to A2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC,B7H1, B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2,CCL3, CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19, CCL20, CCL21,CCL25 CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27, CD28, CD30, CD38,CD39, CD40, CD40L, CD47, CD52, CD70, CD80, CD86, CD123, CD133, CD137,CD137L, CD160, CD272, CEACAM5, CLEC9, CLEC91, CRTH2, CSF-1, CSF-2,CSF-3, CXCL1, CXCL2, CXCL4, CXCL12, CXCL13, CXCR3, cMet, CTLA4, DLL3,DLL4, DNGR-1, E-cadherin, EGFR, ENTPD1, EpCAM, FCER1, FCER1A, FCER2,FGFR, FLAP, FOLH1, Gi24, GITR, GITRL, GPR5, GP100, GPRC5D, HER2, HER3,ICOSL, ICOS, HHLA2, HMGB1, HVEM, IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1,ILIA, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8,IL9, IL9R, IL10, rhIL1O, IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17,IL17Rb, IL18, IL22, IL23, IL25, IL7, IL33, IL35, ITGB4, ITK, KIR, LAG3,LAMP1, leptin, LPFS2, MHC class II, MUC-1, MUC-16, NCR3LG1, NKG2D,NKp46, NTPDase-1, OX40, OX40L, PD-1, PD-L1, PD-L2, PROM1, S152,SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1, STEAP2, Syk kinase, STEAP1,TROP2, TACI, TDO, TGFbeta, T14, TIGIT, TIM3, TLR, TLR2, TLR4, TLR5,TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP, TSLPR, TWEAK, VEGF,VISTA, Vstm3, or WUCAM, or a combination thereof. In some aspects, theantigen binding polypeptide or antigen binding polypeptide complexspecifically binds at least one epitope on at least one antigen selectedfrom the group consisting of A2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA,BlyS, BTK, BTLA, B7DC, B7H1, B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1,B7-4, C3, C5, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17,CCL19, CCL20, CCL21, CCL25 CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24,CD27, CD28, CD30, CD38, CD39, CD40, CD40L, CD47, CD52, CD70, CD80, CD86,CD123, CD133, CD137, CD137L, CD160, CD272, CEACAM5, CLEC9, CLEC91,CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12, CXCL13, CXCR3,cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin, EGFR, ENTPD1, EpCAM, FCER1,FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24, GITR, GITRL, GPR5, GP100,GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1, HVEM, IDO, IFNa, IgE,IGF1R, IL2Rbeta, IL1, ILIA, IL1B, 1L1F10, IL2, IL4, IL4Ra, IL5, IL5R,IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O, IL12, IL13, IL13Ra1,IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23, IL25, IL7, IL33, IL35,ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II, MUC-1,MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L, PD-1, PD-L1,PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1, STEAP2,Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3, TLR,TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP, TSLPR,TWEAK, VEGF, VISTA, Vstm3, and WUCAM. In some aspects, the antigenbinding polypeptide or polypeptide comprised within the antigen bindingcomplex may comprise a VL1, VL2, VL3, VL4, VH1, VH2, VH3, and/or VH4that specifically binds to A2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA,BlyS, BTK, BTLA, B7DC, B7H1, B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1,B7-4, C3, C5, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17,CCL19, CCL20, CCL21, CCL25 CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24,CD27, CD28, CD30, CD38, CD39, CD40, CD40L, CD47, CD52, CD70, CD80, CD86,CD123, CD133, CD137, CD137L, CD160, CD272, CEACAM5, CLEC9, CLEC91,CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12, CXCL13, CXCR3,cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin, EGFR, ENTPD1, EpCAM, FCER1,FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24, GITR, GITRL, GPR5, GP100,GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1, HVEM, IDO, IFNa, IgE,IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R,IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O, IL12, IL13, IL13Ra1,IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23, IL25, IL7, IL33, IL35,ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II, MUC-1,MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L, PD-1, PD-L1,PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1, STEAP2,Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3, TLR,TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP, TSLPR,TWEAK, VEGF, VISTA, Vstm3, or WUCAM. For example, the antigen bindingpolypeptide or polypeptide comprised within the antigen binding complexmay comprise a VL1 that specifically binds to A2AR, APRIL, ATPDase,BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1, B7H2, B7H3, B7H4, B7H5,B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8,CCL11, CCL15, CCL17, CCL19, CCL20, CCL21, CCL25 CCR3, CCR4, CD3, CD16A,CD19, CD20, CD24, CD27, CD28, CD30, CD38, CD39, CD40, CD40L, CD47, CD52,CD70, CD80, CD86, CD123, CD133, CD137, CD137L, CD160, CD272, CEACAM5,CLEC9, CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12,CXCL13, CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin, EGFR,ENTPD1, EpCAM, FCER1, FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24, GITR,GITRL, GPR5, GP100, GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1, HVEM,IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2, IL4,IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O, IL12,IL13, IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23, IL25, IL7,IL33, IL35, ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II,MUC-1, MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L, PD-1,PD-L1, PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1,STEAP2, Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3,TLR, TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP,TSLPR, TWEAK, VEGF, VISTA, Vstm3, or WUCAM. For example, the antigenbinding polypeptide or polypeptide comprised within the antigen bindingcomplex may comprise a VL2 that specifically binds to A2AR, APRIL,ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1, B7H2, B7H3,B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3, CCL4, CCL5,CCL7, CCL8, CCL11, CCL15, CCL17, CCL19, CCL20, CCL21, CCL25 CCR3, CCR4,CD3, CD16A, CD19, CD20, CD24, CD27, CD28, CD30, CD38, CD39, CD40, CD40L,CD47, CD52, CD70, CD80, CD86, CD123, CD133, CD137, CD137L, CD160, CD272,CEACAM5, CLEC9, CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4,CXCL12, CXCL13, CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin,EGFR, ENTPD1, EpCAM, FCER1, FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24,GITR, GITRL, GPR5, GP100, GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1,HVEM, IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2,IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O,IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23,IL25, IL7, IL33, IL35, ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHCclass II, MUC-1, MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L,PD-1, PD-L1, PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2,STEAP1, STEAP2, Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14,TIGIT, TIM3, TLR, TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55,TREM1, TSLP, TSLPR, TWEAK, VEGF, VISTA, Vstm3, or WUCAM. For example,the antigen binding polypeptide or polypeptide comprised within theantigen binding complex may comprise a VL3 that specifically binds toA2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1,B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3,CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19, CCL20, CCL21, CCL25CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27, CD28, CD30, CD38, CD39,CD40, CD40L, CD47, CD52, CD70, CD80, CD86, CD123, CD133, CD137, CD137L,CD160, CD272, CEACAM5, CLEC9, CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1,CXCL2, CXCL4, CXCL12, CXCL13, CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1,E-cadherin, EGFR, ENTPD1, EpCAM, FCER1, FCER1A, FCER2, FGFR, FLAP,FOLH1, Gi24, GITR, GITRL, GPR5, GP100, GPRC5D, HER2, HER3, ICOSL, ICOS,HHLA2, HMGB1, HVEM, IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1, ILIA, IL1B,IL1F10, IL2, IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8, IL9, IL9R,IL10, rhIL1O, IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb, IL18,IL22, IL23, IL25, IL7, IL33, IL35, ITGB4, ITK, KIR, LAG3, LAMP1, leptin,LPFS2, MHC class II, MUC-1, MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1,OX40, OX40L, PD-1, PD-L1, PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC,SPG64, ST2, STEAP1, STEAP2, Syk kinase, STEAP1, TROP2, TACI, TDO,TGFBETA, T14, TIGIT, TIM3, TLR, TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa,TNFRSF7, Tp55, TREM1, TSLP, TSLPR, TWEAK, VEGF, VISTA, Vstm3, or WUCAM.For example, the antigen binding polypeptide or polypeptide comprisedwithin the antigen binding complex may comprise a VL4 that specificallybinds to A2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC,B7H1, B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2,CCL3, CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19, CCL20, CCL21,CCL25 CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27, CD28, CD30, CD38,CD39, CD40, CD40L, CD47, CD52, CD70, CD80, CD86, CD123, CD133, CD137,CD137L, CD160, CD272, CEACAM5, CLEC9, CLEC91, CRTH2, CSF-1, CSF-2,CSF-3, CXCL1, CXCL2, CXCL4, CXCL12, CXCL13, CXCR3, cMet, CTLA4, DLL3,DLL4, DNGR-1, E-cadherin, EGFR, ENTPD1, EpCAM, FCER1, FCER1A, FCER2,FGFR, FLAP, FOLH1, Gi24, GITR, GITRL, GPR5, GP100, GPRC5D, HER2, HER3,ICOSL, ICOS, HHLA2, HMGB1, HVEM, IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1,ILIA, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8,IL9, IL9R, IL10, rhIL1O, IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17,IL17Rb, IL18, IL22, IL23, IL25, IL7, IL33, IL35, ITGB4, ITK, KIR, LAG3,LAMP1, leptin, LPFS2, MHC class II, MUC-1, MUC-16, NCR3LG1, NKG2D,NKp46, NTPDase-1, OX40, OX40L, PD-1, PD-L1, PD-L2, PROM1, S152,SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1, STEAP2, Syk kinase, STEAP1,TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3, TLR, TLR2, TLR4, TLR5,TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP, TSLPR, TWEAK, VEGF,VISTA, Vstm3, or WUCAM. For example, the antigen binding polypeptide orpolypeptide comprised within the antigen binding complex may comprise aVH1 that specifically binds to A2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA,BlyS, BTK, BTLA, B7DC, B7H1, B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1,B7-4, C3, C5, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17,CCL19, CCL20, CCL21, CCL25 CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24,CD27, CD28, CD30, CD38, CD39, CD40, CD40L, CD47, CD52, CD70, CD80, CD86,CD123, CD133, CD137, CD137L, CD160, CD272, CEACAM5, CLEC9, CLEC91,CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12, CXCL13, CXCR3,cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin, EGFR, ENTPD1, EpCAM, FCER1,FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24, GITR, GITRL, GPR5, GP100,GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1, HVEM, IDO, IFNa, IgE,IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R,IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O, IL12, IL13, IL13Ra1,IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23, IL25, IL7, IL33, IL35,ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II, MUC-1,MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L, PD-1, PD-L1,PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1, STEAP2,Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3, TLR,TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP, TSLPR,TWEAK, VEGF, VISTA, Vstm3, or WUCAM. For example, the antigen bindingpolypeptide or polypeptide comprised within the antigen binding complexmay comprise a VH2 that specifically binds to A2AR, APRIL, ATPDase,BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1, B7H2, B7H3, B7H4, B7H5,B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3, CCL4, CCLS, CCL7, CCL8,CCL11, CCL15, CCL17, CCL19, CCL20, CCL21, CCL25 CCR3, CCR4, CD3, CD16A,CD19, CD20, CD24, CD27, CD28, CD30, CD38, CD39, CD40, CD40L, CD47, CD52,CD70, CD80, CD86, CD123, CD133, CD137, CD137L, CD160, CD272, CEACAM5,CLEC9, CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12,CXCL13, CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin, EGFR,ENTPD1, EpCAM, FCER1, FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24, GITR,GITRL, GPR5, GP100, GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1, HVEM,IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2, IL4,IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O, IL12,IL13, IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23, IL25, IL7,IL33, IL35, ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II,MUC-1, MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L, PD-1,PD-L1, PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1,STEAP2, Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3,TLR, TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP,TSLPR, TWEAK, VEGF, VISTA, Vstm3, or WUCAM. For example, the antigenbinding polypeptide or polypeptide comprised within the antigen bindingcomplex may comprise a VH3 that specifically binds to A2AR, APRIL,ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1, B7H2, B7H3,B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3, CCL4, CCLS,CCL7, CCL8, CCL11, CCL15, CCL17, CCL19, CCL20, CCL21, CCL25 CCR3, CCR4,CD3, CD16A, CD19, CD20, CD24, CD27, CD28, CD30, CD38, CD39, CD40, CD40L,CD47, CD52, CD70, CD80, CD86, CD123, CD133, CD137, CD137L, CD160, CD272,CEACAM5, CLEC9, CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4,CXCL12, CXCL13, CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin,EGFR, ENTPD1, EpCAM, FCER1, FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24,GITR, GITRL, GPR5, GP100, GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1,HVEM, IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2,IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O,IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23,IL25, IL7, IL33, IL35, ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHCclass II, MUC-1, MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L,PD-1, PD-L1, PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2,STEAP1, STEAP2, Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14,TIGIT, TIM3, TLR, TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55,TREM1, TSLP, TSLPR, TWEAK, VEGF, VISTA, Vstm3, or WUCAM. For example,the antigen binding polypeptide or polypeptide comprised within theantigen binding complex may comprise a VH4 that specifically binds toA2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1,B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3,CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19, CCL20, CCL21, CCL25CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27, CD28, CD30, CD38, CD39,CD40, CD40L, CD47, CD52, CD70, CD80, CD86, CD123, CD133, CD137, CD137L,CD160, CD272, CEACAM5, CLEC9, CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1,CXCL2, CXCL4, CXCL12, CXCL13, CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1,E-cadherin, EGFR, ENTPD1, EpCAM, FCER1, FCER1A, FCER2, FGFR, FLAP,FOLH1, Gi24, GITR, GITRL, GPR5, GP100, GPRC5D, HER2, HER3, ICOSL, ICOS,HHLA2, HMGB1, HVEM, IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1, ILIA, IL1B,IL1F10, IL2, IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8, IL9, IL9R,IL10, rhIL1O, IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb, IL18,IL22, IL23, IL25, IL7, IL33, IL35, ITGB4, ITK, KIR, LAG3, LAMP1, leptin,LPFS2, MHC class II, MUC-1, MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1,OX40, OX40L, PD-1, PD-L1, PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC,SPG64, ST2, STEAP1, STEAP2, Syk kinase, STEAP1, TROP2, TACI, TDO,TGFBETA, T14, TIGIT, TIM3, TLR, TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa,TNFRSF7, Tp55, TREM1, TSLP, TSLPR, TWEAK, VEGF, VISTA, Vstm3, or WUCAM.For example, VL1 may specifically bind CD3. For example, VL1 mayspecifically bind CD19. For example, VL1 may specifically bind HER2. Forexample, VL1 may specifically bind CD20. For example, VL1 mayspecifically bind CD28. For example, VL1 may specifically bind CD38. Forexample, VL1 may specifically bind Trop2. For example, VL1 mayspecifically bind cMet. For example, VL2 may specifically bind CD3. Forexample, VL2 may specifically bind CD19. For example, VL2 mayspecifically bind HER2. For example, VL2 may specifically bind CD20. Forexample, VL2 may specifically bind CD28. For example, VL2 mayspecifically bind CD38. For example, VL2 may specifically bind Trop2.For example, VL2 may specifically bind cMet. For example, VL3 mayspecifically bind CD3. For example, VL3 may specifically bind CD19. Forexample, VL3 may specifically bind HER2. For example, VL3 mayspecifically bind CD20. For example, VL3 may specifically bind CD28. Forexample, VL3 may specifically bind CD38. For example, VL3 mayspecifically bind Trop2. For example, VL3 may specifically bind cMet.For example, VL4 may specifically bind CD3. For example, VL4 mayspecifically bind CD19. For example, VL4 may specifically bind HER2. Forexample, VL4 may specifically bind CD20. For example, VL4 mayspecifically bind CD28. For example, VL4 may specifically bind CD38. Forexample, VL4 may specifically bind Trop2. For example, VL4 mayspecifically bind cMet. For example, VH1 may specifically bind CD3. Forexample, VH1 may specifically bind CD19. For example, VH1 mayspecifically bind HER2. For example, VH1 may specifically bind CD20. Forexample, VH1 may specifically bind CD28. For example, VH1 mayspecifically bind CD38. For example, VH1 may specifically bind Trop2.For example, VH1 may specifically bind cMet. For example, VH2 mayspecifically bind CD3. For example, VH2 may specifically bind CD19. Forexample, VH2 may specifically bind HER2. For example, VH2 mayspecifically bind CD20. For example, VH2 may specifically bind CD28. Forexample, VH2 may specifically bind CD38. For example, VH2 mayspecifically bind Trop2. For example, VH2 may specifically bind cMet.For example, VH3 may specifically bind CD3. For example, VH3 mayspecifically bind CD19. For example, VH3 may specifically bind HER2. Forexample, VH3 may specifically bind CD20. For example, VH3 mayspecifically bind CD28. For example, VH3 may specifically bind CD38. Forexample, VH3 may specifically bind Trop2. For example, VH4 mayspecifically bind CD3. For example, VH4 may specifically bind CD19. Forexample, VH4 may specifically bind HER2. For example, VH4 mayspecifically bind CD20. For example, VH4 may specifically bind CD28. Forexample, VH4 may specifically bind CD38. For example, VH4 mayspecifically bind Trop2. For example, VH4 may specifically bind cMet. Insome aspects, the VH1 and VL1 of the antigen binding polypeptide orantigen binding polypeptide complex specifically binds to CD28, VH2 andVL2 specifically bind to CD3, and VH3 and VL3 specifically bind to CD38.In some aspects, the VH1 and VL1 of the antigen binding polypeptide orantigen binding polypeptide complex specifically binds to CD28, VH2 andVL2 specifically bind to CD38, and VH3 and VL3 specifically bind to CD3.In some aspects, the VH1 and VL1 of the antigen binding polypeptide orantigen binding polypeptide complex specifically binds to CD3, VH2 andVL2 specifically bind to CD38, and VH3 and VL3 specifically bind toCD28. In some aspects, the VH1 and VL1 of the antigen bindingpolypeptide or antigen binding polypeptide complex specifically binds toCD3, VH2 and VL2 specifically bind to CD28, and VH3 and VL3 specificallybind to CD38. In some aspects, the VH1 and VL1 of the antigen bindingpolypeptide or antigen binding polypeptide complex specifically binds toCD38, VH2 and VL2 specifically bind to CD28, and VH3 and VL3specifically bind to CD3. In some aspects, the VH1 and VL1 of theantigen binding polypeptide or antigen binding polypeptide complexspecifically binds to CD38, VH2 and VL2 specifically bind to CD3, andVH3 and VL3 specifically bind to CD28. In some aspects, the VH1 and VL1of the antigen binding polypeptide or antigen binding polypeptidecomplex specifically binds to CD28, VH2 and VL2 specifically bind toCD19, and VH3 and VL3 specifically bind to CD38. In some aspects, theVH1 and VL1 of the antigen binding polypeptide or antigen bindingpolypeptide complex specifically binds to CD28, VH2 and VL2 specificallybind to CD38, and VH3 and VL3 specifically bind to CD19. In someaspects, the VH1 and VL1 of the antigen binding polypeptide or antigenbinding polypeptide complex specifically binds to CD19, VH2 and VL2specifically bind to CD38, and VH3 and VL3 specifically bind to CD28. Insome aspects, the VH1 and VL1 of the antigen binding polypeptide orantigen binding polypeptide complex specifically binds to CD19, VH2 andVL2 specifically bind to CD28, and VH3 and VL3 specifically bind toCD38. In some aspects, the VH1 and VL1 of the antigen bindingpolypeptide or antigen binding polypeptide complex specifically binds toCD38, VH2 and VL2 specifically bind to CD28, and VH3 and VL3specifically bind to CD19. In some aspects, the VH1 and VL1 of theantigen binding polypeptide or antigen binding polypeptide complexspecifically binds to CD38, VH2 and VL2 specifically bind to CD19, andVH3 and VL3 specifically bind to CD28. For example, the invention isdirected to an antigen binding polypeptide or antigen bindingpolypeptide complex that specifically binds to EGFR and cMet. Forexample, the invention is directed to an antigen binding polypeptide orantigen binding polypeptide complex that specifically binds to GP100 andCD3. For example, the invention is directed to an antigen bindingpolypeptide or antigen binding polypeptide complex that specificallybinds to CD20 and CD3. For example, the invention is directed to anantigen binding polypeptide or antigen binding polypeptide complex thatspecifically binds to BCMA and CD3. For example, the invention isdirected to an antigen binding polypeptide or antigen bindingpolypeptide complex that specifically binds to PDL1 and CTLA4. Forexample, the invention is directed to an antigen binding polypeptide orantigen binding polypeptide complex that specifically binds to PD1 andLAG3. For example, the invention is directed to an antigen bindingpolypeptide or antigen binding polypeptide complex that specificallybinds to PD1 and VEGF For example, the invention is directed to anantigen binding polypeptide or antigen binding polypeptide complex thatspecifically binds to DLL4 and VEGF. For example, the invention isdirected to an antigen binding polypeptide or antigen bindingpolypeptide complex that specifically binds to EGFR and HER3. Forexample, the invention is directed to an antigen binding polypeptide orantigen binding polypeptide complex that specifically binds to HER2. Forexample, the invention is directed to an antigen binding polypeptide orantigen binding polypeptide complex that specifically binds to EpCAM andCD3. For example, the invention is directed to an antigen bindingpolypeptide or antigen binding polypeptide complex that specificallybinds to PDL1 and TGFbeta. For example, the invention is directed to anantigen binding polypeptide or antigen binding polypeptide complex thatspecifically binds to PDL1 and TGFbeta. For example, the invention isdirected to an antigen binding polypeptide or antigen bindingpolypeptide complex that specifically binds to GPRC5D and CD3. Forexample, the invention is directed to an antigen binding polypeptide orantigen binding polypeptide complex that specifically binds to CD123 andCD3. For example, the invention is directed to an antigen bindingpolypeptide or antigen binding polypeptide complex that specificallybinds to CD30 and CD16A. For example, the invention is directed to anantigen binding polypeptide or antigen binding polypeptide complex thatspecifically binds to DLL3 and CD3. For example, the antigen bindingpolypeptide or antigen binding polypeptide complex specifically binds atleast one epitope on each of EGFR and cMet. For example, the antigenbinding polypeptide or antigen binding polypeptide complex specificallybinds at least one epitope on each of GP100 and CD3. For example, theantigen binding polypeptide or antigen binding polypeptide complexspecifically binds at least one epitope on each of CD20 and CD3. Forexample, the antigen binding polypeptide or antigen binding polypeptidecomplex specifically binds at least one epitope on each of BCMA and CD3.For example, the antigen binding polypeptide or antigen bindingpolypeptide complex specifically binds at least one epitope on each ofPDL1 and CTLA4. For example, the antigen binding polypeptide or antigenbinding polypeptide complex specifically binds at least one epitope oneach of PD1 and LAG3. For example, the antigen binding polypeptide orantigen binding polypeptide complex specifically binds at least oneepitope on each of PD1 and VEGF. For example, the antigen bindingpolypeptide or antigen binding polypeptide complex specifically binds atleast one epitope on each of DLL4 and VEGF. For example, the antigenbinding polypeptide or antigen binding polypeptide complex specificallybinds at least one epitope on each of EGFR and HER3. For example, theantigen binding polypeptide or antigen binding polypeptide complexspecifically binds at least one epitope on HER2. For example, theantigen binding polypeptide or antigen binding polypeptide complexspecifically binds at least one epitope on each of EpCAM and CD3. Forexample, the antigen binding polypeptide or antigen binding polypeptidecomplex specifically binds at least one epitope on each of PDL1 andTGFbeta. For example, the antigen binding polypeptide or antigen bindingpolypeptide complex specifically binds at least one epitope on each ofPDL1 and TGFbeta. For example, the antigen binding polypeptide orantigen binding polypeptide complex specifically binds at least oneepitope on each of GPRC5D and CD3. For example, the antigen bindingpolypeptide or antigen binding polypeptide complex specifically binds atleast one epitope on each of CD123 and CD3. For example, the antigenbinding polypeptide or antigen binding polypeptide complex specificallybinds at least one epitope on each of CD30 and CD16A. For example, theantigen binding polypeptide or antigen binding polypeptide complexspecifically binds at least one epitope on each of DLL3 and CD3. Forexample, the antigen binding polypeptide or polypeptide comprised withinthe antigen binding complex may comprise a VL1, VL2, VL3, VL4, VH1, VH2,VH3, and/or VH4 that specifically binds to EGFR and a VL1, VL2, VL3,VL4, VH1, VH2, VH3, and/or VH4 that specifically binds to cMet. Forexample, the antigen binding polypeptide or polypeptide comprised withinthe antigen binding complex may comprise a VL1, VL2, VL3, VL4, VH1, VH2,VH3, and/or VH4 that specifically binds to GP100 and a VL1, VL2, VL3,VL4, VH1, VH2, VH3, and/or VH4 that specifically binds to CD3. Forexample, the antigen binding polypeptide or polypeptide comprised withinthe antigen binding complex may comprise a VL1, VL2, VL3, VL4, VH1, VH2,VH3, and/or VH4 that specifically binds to CD20 and a VL1, VL2, VL3,VL4, VH1, VH2, VH3, and/or VH4 that specifically binds to CD3. Forexample, the antigen binding polypeptide or polypeptide comprised withinthe antigen binding complex may comprise a VL1, VL2, VL3, VL4, VH1, VH2,VH3, and/or VH4 that specifically binds to BCMA and a VL1, VL2, VL3,VL4, VH1, VH2, VH3, and/or VH4 that specifically binds to CD3. Forexample, the antigen binding polypeptide or polypeptide comprised withinthe antigen binding complex may comprise a VL1, VL2, VL3, VL4, VH1, VH2,VH3, and/or VH4 that specifically binds to PDL1 and a VL1, VL2, VL3,VL4, VH1, VH2, VH3, and/or VH4 that specifically binds to CTLA4. Forexample, the antigen binding polypeptide or polypeptide comprised withinthe antigen binding complex may comprise a VL1, VL2, VL3, VL4, VH1, VH2,VH3, and/or VH4 that specifically binds to PD1 and a VL1, VL2, VL3, VL4,VH1, VH2, VH3, and/or VH4 that specifically binds to LAG3. For example,the antigen binding polypeptide or polypeptide comprised within theantigen binding complex may comprise a VL1, VL2, VL3, VL4, VH1, VH2,VH3, and/or VH4 that specifically binds to PD1 and a VL1, VL2, VL3, VL4,VH1, VH2, VH3, and/or VH4 that specifically binds to VEGF. For example,the antigen binding polypeptide or polypeptide comprised within theantigen binding complex may comprise a VL1, VL2, VL3, VL4, VH1, VH2,VH3, and/or VH4 that specifically binds to DLL4 and a VL1, VL2, VL3,VL4, VH1, VH2, VH3, and/or VH4 that specifically binds to VEGF. Forexample, the antigen binding polypeptide or polypeptide comprised withinthe antigen binding complex may comprise a VL1, VL2, VL3, VL4, VH1, VH2,VH3, and/or VH4 that specifically binds to EGFR and a VL1, VL2, VL3,VL4, VH1, VH2, VH3, and/or VH4 that specifically binds to HER3. Forexample, the antigen binding polypeptide or polypeptide comprised withinthe antigen binding complex may comprise a VL1, VL2, VL3, VH1, VH2,and/or VH3 that specifically binds to HER2 and a VL1, VL2, VL3, VL4,VH1, VH2, VH3, and/or VH4 that specifically binds to HER2. For example,the antigen binding polypeptide or polypeptide comprised within theantigen binding complex may comprise a VL1, VL2, VL3, VL4, VH1, VH2,VH3, and/or VH4 that specifically binds to EpCAM and a VL1, VL2, VL3,VL4, VH1, VH2, VH3, and/or VH4 that specifically binds to CD3. Forexample, the antigen binding polypeptide or polypeptide comprised withinthe antigen binding complex may comprise a VL1, VL2, VL3, VL4, VH1, VH2,VH3, and/or VH4 that specifically binds to PDL1 and a VL1, VL2, VL3,VL4, VH1, VH2, VH3, and/or VH4 that specifically binds to TGFbeta. Forexample, the antigen binding polypeptide or polypeptide comprised withinthe antigen binding complex may comprise a VL1, VL2, VL3, VL4, VH1, VH2,VH3, and/or VH4 that specifically binds to PDL1 and a VL1, VL2, VL3,VL4, VH1, VH2, VH3, and/or VH4 that specifically binds to TGFbeta. Forexample, the antigen binding polypeptide or polypeptide comprised withinthe antigen binding complex may comprise a VL1, VL2, VL3, VH1, VH2,and/or VH3 that specifically binds to GPRC5D and a VL1, VL2, VL3, VL4,VH1, VH2, VH3, and/or VH4 that specifically binds to CD3. For example,the antigen binding polypeptide or polypeptide comprised within theantigen binding complex may comprise a VL1, VL2, VL3, VL4, VH1, VH2,VH3, and/or VH4 that specifically binds to CD123 and a VL1, VL2, VL3,VL4, VH1, VH2, VH3, and/or VH4 that specifically binds to CD3. Forexample, the antigen binding polypeptide or polypeptide comprised withinthe antigen binding complex may comprise a VL1, VL2, VL3, VL4, VH1, VH2,VH3, and/or VH4 that specifically binds to CD30 and a VL1, VL2, VL3,VL4, VH1, VH2, VH3, and/or VH4 that specifically binds to CD16A. Forexample, the antigen binding polypeptide or polypeptide comprised withinthe antigen binding complex may comprise a VL1, VL2, VL3, VL4, VH1, VH2,VH3, and/or VH4 that specifically binds to DLL3 and a VL1, VL2, VL3,VL4, VH1, VH2, VH3, and/or VH4 that specifically binds to CD3. Any ofthe antigen binding polypeptide structures and any of the antigenbinding polypeptide complex structures described herein may be used totarget one or more of the targets described herein. Any and alldisclosure herein in relation to targets for antigen bindingpolypeptides of the invention is generally applicable, and appliesequally and without reservation to each and every antigen bindingpolypeptide and antigen binding polypeptide complex described herein.For the avoidance of doubt, the VL1, VL2, VL3, VL4, VH1, VH2, VH3,and/or VH4 of each and every antigen binding polypeptide and antigenbinding polypeptide complex described herein may independently bind toany one of said particularly preferred targets.

In other aspects, the invention is directed to an antigen bindingpolypeptide or antigen binding polypeptide complex that specificallybinds to Ang-2 and VEGF-A. For example, the antigen binding polypeptideor antigen binding polypeptide complex specifically binds at least oneepitope on each of Ang-2 and VEGF-A. For example, the antigen bindingpolypeptide or polypeptide comprised within the antigen binding complexmay comprise a VL1, VL2, VL3, VL4, VH1, VH2, VH3, and/or VH4 thatspecifically binds to Ang-2 and a VL1, VL2, VL3, VL4, VH1, VH2, VH3,and/or VH4 that specifically binds to VEGF-A.

In other aspects, the invention is directed to an antigen bindingpolypeptide or antigen binding polypeptide complex that specificallybinds to Factor IXa and Factor X. For example, the antigen bindingpolypeptide or antigen binding polypeptide complex specifically binds atleast one epitope on each of Factor IXa and Factor X. For example, theantigen binding polypeptide or polypeptide comprised within the antigenbinding complex may comprise a VL1, VL2, VL3, VL4, VH1, VH2, VH3, and/orVH4 that specifically binds to Factor IXa and a VL1, VL2, VL3, VL4, VH1,VH2, VH3, and/or VH4 that specifically binds to Factor X.

In some aspects, the antigen binding polypeptide has a structurerepresented by VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1;VL1-L1-VL2-L2-VH2-L3-VH1; or VH1-L1-VH2-L2-VL2-L3-VL1; wherein VL1 is afirst immunoglobulin light chain variable region that specifically bindsto A2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1,B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3,CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19, CCL20, CCL21, CCL25CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27, CD28, CD30, CD38, CD39,CD40, CD40L, CD47, CD52, CD70, CD80, CD86, CD123, CD133, CD137, CD137L,CD160, CD272, CEACAM5, CLEC9, CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1,CXCL2, CXCL4, CXCL12, CXCL13, CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1,E-cadherin, EGFR, ENTPD1, EpCAM, FCER1, FCER1A, FCER2, FGFR, FLAP,FOLH1, Gi24, GITR, GITRL, GPR5, GP100, GPRC5D, HER2, HER3, ICOSL, ICOS,HHLA2, HMGB1, HVEM, IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1, ILIA, IL1B,IL1F10, IL2, IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8, IL9, IL9R,IL10, rhIL1O, IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb, IL18,IL22, IL23, IL25, IL7, IL33, IL35, ITGB4, ITK, KIR, LAG3, LAMP1, leptin,LPFS2, MHC class II, MUC-1, MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1,OX40, OX40L, PD-1, PD-L1, PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC,SPG64, ST2, STEAP1, STEAP2, Syk kinase, STEAP1, TROP2, TACI, TDO,TGFBETA, T14, TIGIT, TIM3, TLR, TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa,TNFRSF7, Tp55, TREM1, TSLP, TSLPR, TWEAK, VEGF, VISTA, Vstm3, or WUCAM;VH1 is a first immunoglobulin heavy chain variable region thatspecifically binds to A2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS,BTK, BTLA, B7DC, B7H1, B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4,C3, C5, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19,CCL20, CCL21, CCL25 CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27,CD28, CD30, CD38, CD39, CD40, CD40L, CD47, CD52, CD70, CD80, CD86,CD123, CD133, CD137, CD137L, CD160, CD272, CEACAM5, CLEC9, CLEC91,CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12, CXCL13, CXCR3,cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin, EGFR, ENTPD1, EpCAM, FCER1,FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24, GITR, GITRL, GPR5, GP100,GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1, HVEM, IDO, IFNa, IgE,IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R,IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O, IL12, IL13, IL13Ra1,IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23, IL25, IL7, IL33, IL35,ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II, MUC-1,MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L, PD-1, PD-L1,PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1, STEAP2,Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3, TLR,TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP, TSLPR,TWEAK, VEGF, VISTA, Vstm3, or WUCAM; VH2 is a second immunoglobulinheavy chain variable region that specifically binds to A2AR, APRIL,ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1, B7H2, B7H3,B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3, CCL4, CCL5,CCL7, CCL8, CCL11, CCL15, CCL17, CCL19, CCL20, CCL21, CCL25 CCR3, CCR4,CD3, CD16A, CD19, CD20, CD24, CD27, CD28, CD30, CD38, CD39, CD40, CD40L,CD47, CD52, CD70, CD80, CD86, CD123, CD133, CD137, CD137L, CD160, CD272,CEACAM5, CLEC9, CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4,CXCL12, CXCL13, CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin,EGFR, ENTPD1, EpCAM, FCER1, FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24,GITR, GITRL, GPR5, GP100, GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1,HVEM, IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2,IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O,IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23,IL25, IL7, IL33, IL35, ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHCclass II, MUC-1, MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L,PD-1, PD-L1, PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2,STEAP1, STEAP2, Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14,TIGIT, TIM3, TLR, TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55,TREM1, TSLP, TSLPR, TWEAK, VEGF, VISTA, Vstm3, or WUCAM; and L1, L2 andL3 are amino acid linkers. In some aspects, the antigen bindingpolypeptide has a structure represented by VL1-VL2-VH2-VH1, wherein VL1,VL2, VH1 and/or VH2 specifically binds to A2AR, APRIL, ATPDase, BAFF,BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1, B7H2, B7H3, B7H4, B7H5, B7H6,B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL11,CCL15, CCL17, CCL19, CCL20, CCL21, CCL25 CCR3, CCR4, CD3, CD16A, CD19,CD20, CD24, CD27, CD28, CD30, CD38, CD39, CD40, CD40L, CD47, CD52, CD70,CD80, CD86, CD123, CD133, CD137, CD137L, CD160, CD272, CEACAM5, CLEC9,CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12, CXCL13,CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin, EGFR, ENTPD1, EpCAM,FCER1, FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24, GITR, GITRL, GPR5, GP100,GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1, HVEM, IDO, IFNa, IgE,IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R,IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O, IL12, IL13, IL13Ra1,IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23, IL25, IL7, IL33, IL35,ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II, MUC-1,MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L, PD-1, PD-L1,PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1, STEAP2,Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3, TLR,TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP, TSLPR,TWEAK, VEGF, VISTA, Vstm3, or WUCAM. In some aspects, the antigenbinding polypeptide has a structure represented by VH1-VH2-VL2-VL1,wherein VL1, VL2, VH1 and/or VH2 specifically binds to A2AR, APRIL,ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1, B7H2, B7H3,B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3, CCL4, CCL5,CCL7, CCL8, CCL11, CCL15, CCL17, CCL19, CCL20, CCL21, CCL25 CCR3, CCR4,CD3, CD16A, CD19, CD20, CD24, CD27, CD28, CD30, CD38, CD39, CD40, CD40L,CD47, CD52, CD70, CD80, CD86, CD123, CD133, CD137, CD137L, CD160, CD272,CEACAM5, CLEC9, CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4,CXCL12, CXCL13, CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin,EGFR, ENTPD1, EpCAM, FCER1, FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24,GITR, GITRL, GPR5, GP100, GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1,HVEM, IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2,IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O,IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23,IL25, IL7, IL33, IL35, ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHCclass II, MUC-1, MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L,PD-1, PD-L1, PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2,STEAP1, STEAP2, Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14,TIGIT, TIM3, TLR, TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55,TREM1, TSLP, TSLPR, TWEAK, VEGF, VISTA, Vstm3, or WUCAM. In someaspects, the antigen binding polypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1, wherein VL1, VL2, VH1 and/or VH2 specificallybinds to A2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC,B7H1, B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2,CCL3, CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19, CCL20, CCL21,CCL25 CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27, CD28, CD30, CD38,CD39, CD40, CD40L, CD47, CD52, CD70, CD80, CD86, CD123, CD133, CD137,CD137L, CD160, CD272, CEACAM5, CLEC9, CLEC91, CRTH2, CSF-1, CSF-2,CSF-3, CXCL1, CXCL2, CXCL4, CXCL12, CXCL13, CXCR3, cMet, CTLA4, DLL3,DLL4, DNGR-1, E-cadherin, EGFR, ENTPD1, EpCAM, FCER1, FCER1A, FCER2,FGFR, FLAP, FOLH1, Gi24, GITR, GITRL, GPR5, GP100, GPRC5D, HER2, HER3,ICOSL, ICOS, HHLA2, HMGB1, HVEM, IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1,ILIA, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8,IL9, IL9R, IL10, rhIL1O, IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17,IL17Rb, IL18, IL22, IL23, IL25, IL7, IL33, IL35, ITGB4, ITK, KIR, LAG3,LAMP1, leptin, LPFS2, MHC class II, MUC-1, MUC-16, NCR3LG1, NKG2D,NKp46, NTPDase-1, OX40, OX40L, PD-1, PD-L1, PD-L2, PROM1, S152,SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1, STEAP2, Syk kinase, STEAP1,TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3, TLR, TLR2, TLR4, TLR5,TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP, TSLPR, TWEAK, VEGF,VISTA, Vstm3, or WUCAM. In some aspects, the antigen binding polypeptidehas a structure represented by VH1-L1-VH2-L2-VL2-L3-VL1, wherein VL1,VL2, VH1 and/or VH2 specifically binds to A2AR, APRIL, ATPDase, BAFF,BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1, B7H2, B7H3, B7H4, B7H5, B7H6,B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL11,CCL15, CCL17, CCL19, CCL20, CCL21, CCL25 CCR3, CCR4, CD3, CD16A, CD19,CD20, CD24, CD27, CD28, CD30, CD38, CD39, CD40, CD40L, CD47, CD52, CD70,CD80, CD86, CD123, CD133, CD137, CD137L, CD160, CD272, CEACAM5, CLEC9,CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12, CXCL13,CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin, EGFR, ENTPD1, EpCAM,FCER1, FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24, GITR, GITRL, GPR5, GP100,GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1, HVEM, IDO, IFNa, IgE,IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R,IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O, IL12, IL13, IL13Ra1,IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23, IL25, IL7, IL33, IL35,ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II, MUC-1,MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L, PD-1, PD-L1,PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1, STEAP2,Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3, TLR,TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP, TSLPR,TWEAK, VEGF, VISTA, Vstm3, or WUCAM. Any and all disclosure herein inrelation to targets for antigen binding polypeptides of the invention isgenerally applicable, and applies equally and without reservation toeach and every antigen binding polypeptide and antigen bindingpolypeptide complex described herein. For the avoidance of doubt, theVL1, VL2, VH1, and/or VH2 of each and every antigen binding polypeptideand antigen binding polypeptide complex described herein mayindependently bind to any one of said particularly preferred targets.

In another aspect, the antigen binding polypeptide complex comprises afirst polypeptide and a second polypeptide; wherein the firstpolypeptide has a structure represented by: VL1-VL2-VH2-VH1;VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1; or VH1-L1-VH2-L2-VL2-L3-VL1;wherein the second polypeptide has a structure represented byVL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1; orVH1-L1-VH2-L2-VL2-L3-VL1; wherein VL1 is a first immunoglobulin lightchain variable region that specifically binds to A2AR, APRIL, ATPDase,BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1, B7H2, B7H3, B7H4, B7H5,B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8,CCL11, CCL15, CCL17, CCL19, CCL20, CCL21, CCL25 CCR3, CCR4, CD3, CD16A,CD19, CD20, CD24, CD27, CD28, CD30, CD38, CD39, CD40, CD40L, CD47, CD52,CD70, CD80, CD86, CD123, CD133, CD137, CD137L, CD160, CD272, CEACAM5,CLEC9, CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12,CXCL13, CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin, EGFR,ENTPD1, EpCAM, FCER1, FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24, GITR,GITRL, GPR5, GP100, GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1, HVEM,IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2, IL4,IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O, IL12,IL13, IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23, IL25, IL7,IL33, IL35, ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II,MUC-1, MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L, PD-1,PD-L1, PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1,STEAP2, Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3,TLR, TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP,TSLPR, TWEAK, VEGF, VISTA, Vstm3, or WUCAM; VL2 is a secondimmunoglobulin light chain variable region that specifically binds toA2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1,B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3,CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19, CCL20, CCL21, CCL25CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27, CD28, CD30, CD38, CD39,CD40, CD40L, CD47, CD52, CD70, CD80, CD86, CD123, CD133, CD137, CD137L,CD160, CD272, CEACAM5, CLEC9, CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1,CXCL2, CXCL4, CXCL12, CXCL13, CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1,E-cadherin, EGFR, ENTPD1, EpCAM, FCER1, FCER1A, FCER2, FGFR, FLAP,FOLH1, Gi24, GITR, GITRL, GPR5, GP100, GPRC5D, HER2, HER3, ICOSL, ICOS,HHLA2, HMGB1, HVEM, IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1, ILIA, IL1B,IL1F10, IL2, IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8, IL9, IL9R,IL10, rhIL1O, IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb, IL18,IL22, IL23, IL25, IL7, IL33, IL35, ITGB4, ITK, KIR, LAG3, LAMP1, leptin,LPFS2, MHC class II, MUC-1, MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1,OX40, OX40L, PD-1, PD-L1, PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC,SPG64, ST2, STEAP1, STEAP2, Syk kinase, STEAP1, TROP2, TACI, TDO,TGFBETA, T14, TIGIT, TIM3, TLR, TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa,TNFRSF7, Tp55, TREM1, TSLP, TSLPR, TWEAK, VEGF, VISTA, Vstm3, or WUCAM;VH1 is a first immunoglobulin heavy chain variable region thatspecifically binds to A2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS,BTK, BTLA, B7DC, B7H1, B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4,C3, C5, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19,CCL20, CCL21, CCL25 CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27,CD28, CD30, CD38, CD39, CD40, CD40L, CD47, CD52, CD70, CD80, CD86,CD123, CD133, CD137, CD137L, CD160, CD272, CEACAM5, CLEC9, CLEC91,CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12, CXCL13, CXCR3,cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin, EGFR, ENTPD1, EpCAM, FCER1,FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24, GITR, GITRL, GPR5, GP100,GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1, HVEM, IDO, IFNa, IgE,IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R,IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O, IL12, IL13, IL13Ra1,IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23, IL25, IL7, IL33, IL35,ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II, MUC-1,MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L, PD-1, PD-L1,PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1, STEAP2,Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3, TLR,TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP, TSLPR,TWEAK, VEGF, VISTA, Vstm3, or WUCAM; VH2 is a second immunoglobulinheavy chain variable region that specifically binds to A2AR, APRIL,ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1, B7H2, B7H3,B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3, CCL4, CCL5,CCL7, CCL8, CCL11, CCL15, CCL17, CCL19, CCL20, CCL21, CCL25 CCR3, CCR4,CD3, CD16A, CD19, CD20, CD24, CD27, CD28, CD30, CD38, CD39, CD40, CD40L,CD47, CD52, CD70, CD80, CD86, CD123, CD133, CD137, CD137L, CD160, CD272,CEACAM5, CLEC9, CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4,CXCL12, CXCL13, CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin,EGFR, ENTPD1, EpCAM, FCER1, FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24,GITR, GITRL, GPR5, GP100, GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1,HVEM, IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2,IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O,IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23,IL25, IL7, IL33, IL35, ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHCclass II, MUC-1, MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L,PD-1, PD-L1, PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2,STEAP1, STEAP2, Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14,TIGIT, TIM3, TLR, TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55,TREM1, TSLP, TSLPR, TWEAK, VEGF, VISTA, Vstm3, or WUCAM; and L1, L2 andL3 are amino acid linkers. In some aspects, the first polypeptide hasthe structure VL1-VL2-VH2-VH1 and the second polypeptide has thestructure VL1-VL2-VH2-VH1, and the VL1, VL2, VH1 and/or VH2 specificallybinds to A2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC,B7H1, B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2,CCL3, CCL4, CCLS, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19, CCL20, CCL21,CCL25 CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27, CD28, CD30, CD38,CD39, CD40, CD40L, CD47, CD52, CD70, CD80, CD86, CD123, CD133, CD137,CD137L, CD160, CD272, CEACAM5, CLEC9, CLEC91, CRTH2, CSF-1, CSF-2,CSF-3, CXCL1, CXCL2, CXCL4, CXCL12, CXCL13, CXCR3, cMet, CTLA4, DLL3,DLL4, DNGR-1, E-cadherin, EGFR, ENTPD1, EpCAM, FCER1, FCER1A, FCER2,FGFR, FLAP, FOLH1, Gi24, GITR, GITRL, GPR5, GP100, GPRC5D, HER2, HER3,ICOSL, ICOS, HHLA2, HMGB1, HVEM, IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1,ILIA, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8,IL9, IL9R, IL10, rhIL1O, IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17,IL17Rb, IL18, IL22, IL23, IL25, IL7, IL33, IL35, ITGB4, ITK, KIR, LAG3,LAMP1, leptin, LPFS2, MHC class II, MUC-1, MUC-16, NCR3LG1, NKG2D,NKp46, NTPDase-1, OX40, OX40L, PD-1, PD-L1, PD-L2, PROM1, S152,SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1, STEAP2, Syk kinase, STEAP1,TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3, TLR, TLR2, TLR4, TLR5,TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP, TSLPR, TWEAK, VEGF,VISTA, Vstm3, or WUCAM. In some aspects, the first polypeptide has thestructure VH1-VH2-VL2-VL1 and the second polypeptide has the structureVH1-VH2-VL2-VL1, and the VL1, VL2, VH1 and/or VH2 specifically binds toA2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1,B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3,CCL4, CCLS, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19, CCL20, CCL21, CCL25CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27, CD28, CD30, CD38, CD39,CD40, CD40L, CD47, CD52, CD70, CD80, CD86, CD123, CD133, CD137, CD137L,CD160, CD272, CEACAM5, CLEC9, CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1,CXCL2, CXCL4, CXCL12, CXCL13, CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1,E-cadherin, EGFR, ENTPD1, EpCAM, FCER1, FCER1A, FCER2, FGFR, FLAP,FOLH1, Gi24, GITR, GITRL, GPR5, GP100, GPRC5D, HER2, HER3, ICOSL, ICOS,HHLA2, HMGB1, HVEM, IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1, ILIA, IL1B,IL1F10, IL2, IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8, IL9, IL9R,IL10, rhIL1O, IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb, IL18,IL22, IL23, IL25, IL7, IL33, IL35, ITGB4, ITK, KIR, LAG3, LAMP1, leptin,LPFS2, MHC class II, MUC-1, MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1,OX40, OX40L, PD-1, PD-L1, PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC,SPG64, ST2, STEAP1, STEAP2, Syk kinase, STEAP1, TROP2, TACI, TDO,TGFBETA, T14, TIGIT, TIM3, TLR, TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa,TNFRSF7, Tp55, TREM1, TSLP, TSLPR, TWEAK, VEGF, VISTA, Vstm3, or WUCAM.In some aspects, the first polypeptide has the structure VH1-VH2-VL2-VL1and the second polypeptide has the structure VL1-VL2-VH2-VH1, and theVL1, VL2, VH1 and/or VH2 specifically binds to A2AR, APRIL, ATPDase,BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1, B7H2, B7H3, B7H4, B7H5,B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8,CCL11, CCL15, CCL17, CCL19, CCL20, CCL21, CCL25 CCR3, CCR4, CD3, CD16A,CD19, CD20, CD24, CD27, CD28, CD30, CD38, CD39, CD40, CD40L, CD47, CD52,CD70, CD80, CD86, CD123, CD133, CD137, CD137L, CD160, CD272, CEACAM5,CLEC9, CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12,CXCL13, CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin, EGFR,ENTPD1, EpCAM, FCER1, FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24, GITR,GITRL, GPR5, GP100, GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1, HVEM,IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2, IL4,IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O, IL12,IL13, IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23, IL25, IL7,IL33, IL35, ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II,MUC-1, MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L, PD-1,PD-L1, PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1,STEAP2, Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3,TLR, TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP,TSLPR, TWEAK, VEGF, VISTA, Vstm3, or WUCAM. In some aspects, the firstpolypeptide has the structure VL1-VL2-VH2-VH1 and the second polypeptidehas the structure VH1-VH2-VL2-VL1, and the VL1, VL2, VH1 and/or VH2specifically binds to A2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS,BTK, BTLA, B7DC, B7H1, B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4,C3, C5, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19,CCL20, CCL21, CCL25 CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27,CD28, CD30, CD38, CD39, CD40, CD40L, CD47, CD52, CD70, CD80, CD86,CD123, CD133, CD137, CD137L, CD160, CD272, CEACAM5, CLEC9, CLEC91,CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12, CXCL13, CXCR3,cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin, EGFR, ENTPD1, EpCAM, FCER1,FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24, GITR, GITRL, GPR5, GP100,GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1, HVEM, IDO, IFNa, IgE,IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R,IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O, IL12, IL13, IL13Ra1,IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23, IL25, IL7, IL33, IL35,ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II, MUC-1,MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L, PD-1, PD-L1,PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1, STEAP2,Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3, TLR,TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP, TSLPR,TWEAK, VEGF, VISTA, Vstm3, or WUCAM. In the above aspects of theinvention, the VL1, VL2, VH1 and VH2 may be linked by one or more aminoacid linker e.g. to form the structure VL1-L1-VL2-L2-VH2-L3-VH1 orVH1-L1-VH2-L2-VL2-L3-VL1. Any and all disclosure herein in relation totargets for antigen binding polypeptides of the invention is generallyapplicable, and applies equally and without reservation to each andevery antigen binding polypeptide and antigen binding polypeptidecomplex described herein. For the avoidance of doubt, the VL1, VL2, VH1,and/or VH2 of each and every antigen binding polypeptide and antigenbinding polypeptide complex described herein may independently bind toany one of said particularly preferred targets.

In some aspects, the antigen binding polypeptide has a structurerepresented by VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc; or VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc;wherein VL1 is a first immunoglobulin light chain variable region thatspecifically binds to A2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS,BTK, BTLA, B7DC, B7H1, B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4,C3, C5, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19,CCL20, CCL21, CCL25 CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27,CD28, CD30, CD38, CD39, CD40, CD40L, CD47, CD52, CD70, CD80, CD86,CD123, CD133, CD137, CD137L, CD160, CD272, CEACAM5, CLEC9, CLEC91,CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12, CXCL13, CXCR3,cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin, EGFR, ENTPD1, EpCAM, FCER1,FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24, GITR, GITRL, GPR5, GP100,GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1, HVEM, IDO, IFNa, IgE,IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R,IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O, IL12, IL13, IL13Ra1,IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23, IL25, IL7, IL33, IL35,ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II, MUC-1,MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L, PD-1, PD-L1,PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1, STEAP2,Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3, TLR,TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP, TSLPR,TWEAK, VEGF, VISTA, Vstm3, or WUCAM; VL2 is a second immunoglobulinlight chain variable region that specifically binds to A2AR, APRIL,ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1, B7H2, B7H3,B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3, CCL4, CCL5,CCL7, CCL8, CCL11, CCL15, CCL17, CCL19, CCL20, CCL21, CCL25 CCR3, CCR4,CD3, CD16A, CD19, CD20, CD24, CD27, CD28, CD30, CD38, CD39, CD40, CD40L,CD47, CD52, CD70, CD80, CD86, CD123, CD133, CD137, CD137L, CD160, CD272,CEACAM5, CLEC9, CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4,CXCL12, CXCL13, CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin,EGFR, ENTPD1, EpCAM, FCER1, FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24,GITR, GITRL, GPR5, GP100, GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1,HVEM, IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2,IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O,IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23,IL25, IL7, IL33, IL35, ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHCclass II, MUC-1, MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L,PD-1, PD-L1, PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2,STEAP1, STEAP2, Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14,TIGIT, TIM3, TLR, TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55,TREM1, TSLP, TSLPR, TWEAK, VEGF, VISTA, Vstm3, or WUCAM; VH1 is a firstimmunoglobulin heavy chain variable region that specifically binds toA2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1,B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3,CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19, CCL20, CCL21, CCL25CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27, CD28, CD30, CD38, CD39,CD40, CD40L, CD47, CD52, CD70, CD80, CD86, CD123, CD133, CD137, CD137L,CD160, CD272, CEACAM5, CLEC9, CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1,CXCL2, CXCL4, CXCL12, CXCL13, CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1,E-cadherin, EGFR, ENTPD1, EpCAM, FCER1, FCER1A, FCER2, FGFR, FLAP,FOLH1, Gi24, GITR, GITRL, GPR5, GP100, GPRC5D, HER2, HER3, ICOSL, ICOS,HHLA2, HMGB1, HVEM, IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1, ILIA, IL1B,IL1F10, IL2, IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8, IL9, IL9R,IL10, rhIL1O, IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb, IL18,IL22, IL23, IL25, IL7, IL33, IL35, ITGB4, ITK, KIR, LAG3, LAMP1, leptin,LPFS2, MHC class II, MUC-1, MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1,OX40, OX40L, PD-1, PD-L1, PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC,SPG64, ST2, STEAP1, STEAP2, Syk kinase, STEAP1, TROP2, TACI, TDO,TGFBETA, T14, TIGIT, TIM3, TLR, TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa,TNFRSF7, Tp55, TREM1, TSLP, TSLPR, TWEAK, VEGF, VISTA, Vstm3, or WUCAM;VH2 is a second immunoglobulin heavy chain variable region thatspecifically binds to A2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS,BTK, BTLA, B7DC, B7H1, B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4,C3, C5, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19,CCL20, CCL21, CCL25 CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27,CD28, CD30, CD38, CD39, CD40, CD40L, CD47, CD52, CD70, CD80, CD86,CD123, CD133, CD137, CD137L, CD160, CD272, CEACAM5, CLEC9, CLEC91,CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12, CXCL13, CXCR3,cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin, EGFR, ENTPD1, EpCAM, FCER1,FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24, GITR, GITRL, GPR5, GP100,GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1, HVEM, IDO, IFNa, IgE,IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R,IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O, IL12, IL13, IL13Ra1,IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23, IL25, IL7, IL33, IL35,ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II, MUC-1,MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L, PD-1, PD-L1,PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1, STEAP2,Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3, TLR,TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP, TSLPR,TWEAK, VEGF, VISTA, Vstm3, or WUCAM; Fc is a region comprising animmunoglobulin heavy chain constant region 2 (CH2), an immunoglobulinheavy chain constant region 3 (CH3), and optionally, an immunoglobulinhinge; and L1, L2, L3 and L4 are amino acid linkers. In some aspects,the antigen binding polypeptide has the structure represented byVL1-VL2-VH2-VH1-Fc, wherein VL1, VL2, VH1 and/or VH2 specifically bindsto A2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1,B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3,CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19, CCL20, CCL21, CCL25CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27, CD28, CD30, CD38, CD39,CD40, CD40L, CD47, CD52, CD70, CD80, CD86, CD123, CD133, CD137, CD137L,CD160, CD272, CEACAM5, CLEC9, CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1,CXCL2, CXCL4, CXCL12, CXCL13, CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1,E-cadherin, EGFR, ENTPD1, EpCAM, FCER1, FCER1A, FCER2, FGFR, FLAP,FOLH1, Gi24, GITR, GITRL, GPR5, GP100, GPRC5D, HER2, HER3, ICOSL, ICOS,HHLA2, HMGB1, HVEM, IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1, ILIA, IL1B,IL1F10, IL2, IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8, IL9, IL9R,IL10, rhIL1O, IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb, IL18,IL22, IL23, IL25, IL7, IL33, IL35, ITGB4, ITK, KIR, LAG3, LAMP1, leptin,LPFS2, MHC class II, MUC-1, MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1,OX40, OX40L, PD-1, PD-L1, PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC,SPG64, ST2, STEAP1, STEAP2, Syk kinase, STEAP1, TROP2, TACI, TDO,TGFBETA, T14, TIGIT, TIM3, TLR, TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa,TNFRSF7, Tp55, TREM1, TSLP, TSLPR, TWEAK, VEGF, VISTA, Vstm3, or WUCAM.In some aspects, the antigen binding polypeptide has the structurerepresented by VH1-VH2-VL2-VL1-Fc, wherein VL1, VL2, VH1 and/or VH2specifically binds to A2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS,BTK, BTLA, B7DC, B7H1, B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4,C3, C5, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19,CCL20, CCL21, CCL25 CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27,CD28, CD30, CD38, CD39, CD40, CD40L, CD47, CD52, CD70, CD80, CD86,CD123, CD133, CD137, CD137L, CD160, CD272, CEACAM5, CLEC9, CLEC91,CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12, CXCL13, CXCR3,cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin, EGFR, ENTPD1, EpCAM, FCER1,FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24, GITR, GITRL, GPR5, GP100,GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1, HVEM, IDO, IFNa, IgE,IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R,IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O, IL12, IL13, IL13Ra1,IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23, IL25, IL7, IL33, IL35,ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II, MUC-1,MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L, PD-1, PD-L1,PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1, STEAP2,Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3, TLR,TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP, TSLPR,TWEAK, VEGF, VISTA, Vstm3, or WUCAM. In some aspects, the antigenbinding polypeptide has the structure represented byVIA-L1-VL2-L2-VH2-L3-VH1-Fc, wherein VL1, VL2, VH1 and/or VH2specifically binds to A2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS,BTK, BTLA, B7DC, B7H1, B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4,C3, C5, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19,CCL20, CCL21, CCL25 CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27,CD28, CD30, CD38, CD39, CD40, CD40L, CD47, CD52, CD70, CD80, CD86,CD123, CD133, CD137, CD137L, CD160, CD272, CEACAM5, CLEC9, CLEC91,CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12, CXCL13, CXCR3,cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin, EGFR, ENTPD1, EpCAM, FCER1,FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24, GITR, GITRL, GPR5, GP100,GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1, HVEM, IDO, IFNa, IgE,IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R,IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O, IL12, IL13, IL13Ra1,IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23, IL25, IL7, IL33, IL35,ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II, MUC-1,MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L, PD-1, PD-L1,PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1, STEAP2,Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3, TLR,TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP, TSLPR,TWEAK, VEGF, VISTA, Vstm3, or WUCAM. In some aspects, the antigenbinding polypeptide has the structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-Fc, wherein VL1, VL2, VH1 and/or VH2specifically binds to A2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS,BTK, BTLA, B7DC, B7H1, B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4,C3, C5, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19,CCL20, CCL21, CCL25 CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27,CD28, CD30, CD38, CD39, CD40, CD40L, CD47, CD52, CD70, CD80, CD86,CD123, CD133, CD137, CD137L, CD160, CD272, CEACAM5, CLEC9, CLEC91,CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12, CXCL13, CXCR3,cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin, EGFR, ENTPD1, EpCAM, FCER1,FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24, GITR, GITRL, GPR5, GP100,GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1, HVEM, IDO, IFNa, IgE,IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R,IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O, IL12, IL13, IL13Ra1,IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23, IL25, IL7, IL33, IL35,ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II, MUC-1,MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L, PD-1, PD-L1,PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1, STEAP2,Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3, TLR,TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP, TSLPR,TWEAK, VEGF, VISTA, Vstm3, or WUCAM. In some aspects, the antigenbinding polypeptide has the structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc, wherein VL1, VL2, VH1 and/or VH2specifically binds to A2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS,BTK, BTLA, B7DC, B7H1, B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4,C3, C5, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19,CCL20, CCL21, CCL25 CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27,CD28, CD30, CD38, CD39, CD40, CD40L, CD47, CD52, CD70, CD80, CD86,CD123, CD133, CD137, CD137L, CD160, CD272, CEACAM5, CLEC9, CLEC91,CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12, CXCL13, CXCR3,cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin, EGFR, ENTPD1, EpCAM, FCER1,FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24, GITR, GITRL, GPR5, GP100,GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1, HVEM, IDO, IFNa, IgE,IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R,IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O, IL12, IL13, IL13Ra1,IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23, IL25, IL7, IL33, IL35,ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II, MUC-1,MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L, PD-1, PD-L1,PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1, STEAP2,Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3, TLR,TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP, TSLPR,TWEAK, VEGF, VISTA, Vstm3, or WUCAM. In some aspects, the antigenbinding polypeptide has the structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc, wherein VL1, VL2, VH1 and/or VH2specifically binds to A2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS,BTK, BTLA, B7DC, B7H1, B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4,C3, C5, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19,CCL20, CCL21, CCL25 CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27,CD28, CD30, CD38, CD39, CD40, CD40L, CD47, CD52, CD70, CD80, CD86,CD123, CD133, CD137, CD137L, CD160, CD272, CEACAM5, CLEC9, CLEC91,CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12, CXCL13, CXCR3,cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin, EGFR, ENTPD1, EpCAM, FCER1,FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24, GITR, GITRL, GPR5, GP100,GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1, HVEM, IDO, IFNa, IgE,IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R,IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O, IL12, IL13, IL13Ra1,IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23, IL25, IL7, IL33, IL35,ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II, MUC-1,MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L, PD-1, PD-L1,PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1, STEAP2,Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3, TLR,TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP, TSLPR,TWEAK, VEGF, VISTA, Vstm3, or WUCAM. Any and all disclosure herein inrelation to targets for antigen binding polypeptides of the invention isgenerally applicable, and applies equally and without reservation toeach and every antigen binding polypeptide and antigen bindingpolypeptide complex described herein. For the avoidance of doubt, theVL1, VL2, VH1, and/or VH2 of each and every antigen binding polypeptideand antigen binding polypeptide complex described herein mayindependently bind to any one of said particularly preferred targets.

In some aspects, the antigen binding polypeptide complex comprises afirst polypeptide and a second polypeptide, wherein the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-Fc;VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; wherein the second polypeptide has astructure represented by Fc; VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc; or VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc;wherein VL1 is a first immunoglobulin light chain variable region thatspecifically binds to A2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS,BTK, BTLA, B7DC, B7H1, B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4,C3, C5, CCL2, CCL3, CCL4, CCLS, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19,CCL20, CCL21, CCL25 CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27,CD28, CD30, CD38, CD39, CD40, CD40L, CD47, CD52, CD70, CD80, CD86,CD123, CD133, CD137, CD137L, CD160, CD272, CEACAM5, CLEC9, CLEC91,CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12, CXCL13, CXCR3,cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin, EGFR, ENTPD1, EpCAM, FCER1,FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24, GITR, GITRL, GPRS, GP100,GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1, HVEM, IDO, IFNa, IgE,IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R,IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O, IL12, IL13, IL13Ra1,IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23, IL25, IL7, IL33, IL35,ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II, MUC-1,MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L, PD-1, PD-L1,PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1, STEAP2,Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3, TLR,TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP, TSLPR,TWEAK, VEGF, VISTA, Vstm3, or WUCAM; VL2 is a second immunoglobulinlight chain variable region that specifically binds to A2AR, APRIL,ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1, B7H2, B7H3,B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3, CCL4, CCLS,CCL7, CCL8, CCL11, CCL15, CCL17, CCL19, CCL20, CCL21, CCL25 CCR3, CCR4,CD3, CD16A, CD19, CD20, CD24, CD27, CD28, CD30, CD38, CD39, CD40, CD40L,CD47, CD52, CD70, CD80, CD86, CD123, CD133, CD137, CD137L, CD160, CD272,CEACAM5, CLEC9, CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4,CXCL12, CXCL13, CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin,EGFR, ENTPD1, EpCAM, FCER1, FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24,GITR, GITRL, GPRS, GP100, GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1,HVEM, IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2,IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O,IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23,IL25, IL7, IL33, IL35, ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHCclass II, MUC-1, MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L,PD-1, PD-L1, PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2,STEAP1, STEAP2, Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14,TIGIT, TIM3, TLR, TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55,TREM1, TSLP, TSLPR, TWEAK, VEGF, VISTA, Vstm3, or WUCAM; VH1 is a firstimmunoglobulin heavy chain variable region that specifically binds toA2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1,B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3,CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19, CCL20, CCL21, CCL25CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27, CD28, CD30, CD38, CD39,CD40, CD40L, CD47, CD52, CD70, CD80, CD86, CD123, CD133, CD137, CD137L,CD160, CD272, CEACAM5, CLEC9, CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1,CXCL2, CXCL4, CXCL12, CXCL13, CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1,E-cadherin, EGFR, ENTPD1, EpCAM, FCER1, FCER1A, FCER2, FGFR, FLAP,FOLH1, Gi24, GITR, GITRL, GPR5, GP100, GPRC5D, HER2, HER3, ICOSL, ICOS,HHLA2, HMGB1, HVEM, IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1, ILIA, IL1B,IL1F10, IL2, IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8, IL9, IL9R,IL10, rhIL1O, IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb, IL18,IL22, IL23, IL25, IL7, IL33, IL35, ITGB4, ITK, KIR, LAG3, LAMP1, leptin,LPFS2, MHC class II, MUC-1, MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1,OX40, OX40L, PD-1, PD-L1, PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC,SPG64, ST2, STEAP1, STEAP2, Syk kinase, STEAP1, TROP2, TACI, TDO,TGFBETA, T14, TIGIT, TIM3, TLR, TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa,TNFRSF7, Tp55, TREM1, TSLP, TSLPR, TWEAK, VEGF, VISTA, Vstm3, or WUCAM;VH2 is a second immunoglobulin heavy chain variable region thatspecifically binds to A2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS,BTK, BTLA, B7DC, B7H1, B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4,C3, C5, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19,CCL20, CCL21, CCL25 CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27,CD28, CD30, CD38, CD39, CD40, CD40L, CD47, CD52, CD70, CD80, CD86,CD123, CD133, CD137, CD137L, CD160, CD272, CEACAM5, CLEC9, CLEC91,CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12, CXCL13, CXCR3,cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin, EGFR, ENTPD1, EpCAM, FCER1,FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24, GITR, GITRL, GPR5, GP100,GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1, HVEM, IDO, IFNa, IgE,IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R,IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O, IL12, IL13, IL13Ra1,IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23, IL25, IL7, IL33, IL35,ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II, MUC-1,MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L, PD-1, PD-L1,PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1, STEAP2,Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3, TLR,TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP, TSLPR,TWEAK, VEGF, VISTA, Vstm3, or WUCAM; Fc is a region comprising animmunoglobulin heavy chain constant region 2 (CH2), an immunoglobulinheavy chain constant region 3 (CH3), and optionally, an immunoglobulinhinge; and L1, L2, L3 and L4 are amino acid linkers. In some aspects,the first polypeptide has the structure VL1-VL2-VH2-VH1-Fc and thesecond polypeptide has the structure VL1-VL2-VH2-VH1-Fc. In someaspects, the first polypeptide has the structure VH1-VH2-VL2-VL1-Fc andthe second polypeptide has the structure VH1-VH2-VL2-VL1-Fc. In someaspects, the first polypeptide has the structure VH1-VH2-VL2-VL1-Fc andthe second polypeptide has the structure VL1-VL2-VH2-VH1-Fc. In someaspects, the first polypeptide has the structure VL1-VL2-VH2-VH1-Fc andthe second polypeptide has the structure VH1-VH2-VL2-VL1-Fc. In someaspects, the first polypeptide has the structure VL1-VL2-VH2-VH1-Fc andthe second polypeptide has the structure Fc. In some aspects, the firstpolypeptide has the structure VH1-VH2-VL2-VL1-Fc, and the secondpolypeptide has the structure Fc. In the above aspects of the invention,the VL1, VL2, VH1, VH2 and Fc may be linked by one or more amino acidlinker e.g. to form the structure VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc. The VL1, VL2, VH1, and/or VH2 mayspecifically bind to A2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK,BTLA, B7DC, B7H1, B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3,C5, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19,CCL20, CCL21, CCL25 CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27,CD28, CD30, CD38, CD39, CD40, CD40L, CD47, CD52, CD70, CD80, CD86,CD123, CD133, CD137, CD137L, CD160, CD272, CEACAM5, CLEC9, CLEC91,CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12, CXCL13, CXCR3,cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin, EGFR, ENTPD1, EpCAM, FCER1,FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24, GITR, GITRL, GPR5, GP100,GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1, HVEM, IDO, IFNa, IgE,IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R,IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O, IL12, IL13, IL13Ra1,IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23, IL25, IL7, IL33, IL35,ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II, MUC-1,MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L, PD-1, PD-L1,PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1, STEAP2,Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3, TLR,TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP, TSLPR,TWEAK, VEGF, VISTA, Vstm3, or WUCAM. For the avoidance of doubt, all theantigen binding polypeptide complex structures described herein can becombined with any one or more of the targets described herein. Any andall disclosure herein in relation to targets for antigen bindingpolypeptides of the invention is generally applicable, and appliesequally and without reservation to each and every antigen bindingpolypeptide and antigen binding polypeptide complex described herein.For the avoidance of doubt, the VL1, VL2, VH1, and/or VH2 of each andevery antigen binding polypeptide and antigen binding polypeptidecomplex described herein may independently bind to any one of saidparticularly preferred targets. Any and all disclosure herein inrelation to targets for antigen binding polypeptides of the invention isgenerally applicable, and applies equally and without reservation toeach and every antigen binding polypeptide and antigen bindingpolypeptide complex described herein. For the avoidance of doubt, theVL1, VL2, VH1, and/or VH2 of each and every antigen binding polypeptideand antigen binding polypeptide complex described herein mayindependently bind to any one of said particularly preferred targets. Insome aspects, the antigen binding polypeptide has a structurerepresented by VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL;VL1-VL2-VH2-VH1-CL-CH1; VH1-VH2-VL2-VL1-CL-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-CL; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; wherein VL1 is a firstimmunoglobulin light chain variable region that specifically binds toA2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1,B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3,CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19, CCL20, CCL21, CCL25CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27, CD28, CD30, CD38, CD39,CD40, CD40L, CD47, CD52, CD70, CD80, CD86, CD123, CD133, CD137, CD137L,CD160, CD272, CEACAM5, CLEC9, CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1,CXCL2, CXCL4, CXCL12, CXCL13, CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1,E-cadherin, EGFR, ENTPD1, EpCAM, FCER1, FCER1A, FCER2, FGFR, FLAP,FOLH1, Gi24, GITR, GITRL, GPR5, GP100, GPRC5D, HER2, HER3, ICOSL, ICOS,HHLA2, HMGB1, HVEM, IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1, ILIA, IL1B,IL1F10, IL2, IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8, IL9, IL9R,IL10, rhIL1O, IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb, IL18,IL22, IL23, IL25, IL7, IL33, IL35, ITGB4, ITK, KIR, LAG3, LAMP1, leptin,LPFS2, MHC class II, MUC-1, MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1,OX40, OX40L, PD-1, PD-L1, PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC,SPG64, ST2, STEAP1, STEAP2, Syk kinase, STEAP1, TROP2, TACI, TDO,TGFBETA, T14, TIGIT, TIM3, TLR, TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa,TNFRSF7, Tp55, TREM1, TSLP, TSLPR, TWEAK, VEGF, VISTA, Vstm3, or WUCAM;VL2 is a second immunoglobulin light chain variable region thatspecifically binds to A2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS,BTK, BTLA, B7DC, B7H1, B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4,C3, C5, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19,CCL20, CCL21, CCL25 CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27,CD28, CD30, CD38, CD39, CD40, CD40L, CD47, CD52, CD70, CD80, CD86,CD123, CD133, CD137, CD137L, CD160, CD272, CEACAM5, CLEC9, CLEC91,CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12, CXCL13, CXCR3,cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin, EGFR, ENTPD1, EpCAM, FCER1,FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24, GITR, GITRL, GPR5, GP100,GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1, HVEM, IDO, IFNa, IgE,IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R,IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O, IL12, IL13, IL13Ra1,IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23, IL25, IL7, IL33, IL35,ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II, MUC-1,MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L, PD-1, PD-L1,PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1, STEAP2,Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3, TLR,TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP, TSLPR,TWEAK, VEGF, VISTA, Vstm3, or WUCAM; VH1 is a first immunoglobulin heavychain variable region that specifically binds to A2AR, APRIL, ATPDase,BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1, B7H2, B7H3, B7H4, B7H5,B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8,CCL11, CCL15, CCL17, CCL19, CCL20, CCL21, CCL25 CCR3, CCR4, CD3, CD16A,CD19, CD20, CD24, CD27, CD28, CD30, CD38, CD39, CD40, CD40L, CD47, CD52,CD70, CD80, CD86, CD123, CD133, CD137, CD137L, CD160, CD272, CEACAM5,CLEC9, CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12,CXCL13, CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin, EGFR,ENTPD1, EpCAM, FCER1, FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24, GITR,GITRL, GPR5, GP100, GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1, HVEM,IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2, IL4,IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O, IL12,IL13, IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23, IL25, IL7,IL33, IL35, ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II,MUC-1, MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L, PD-1,PD-L1, PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1,STEAP2, Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3,TLR, TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP,TSLPR, TWEAK, VEGF, VISTA, Vstm3, or WUCAM; VH2 is a secondimmunoglobulin heavy chain variable region that specifically binds toA2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1,B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3,CCL4, CCLS, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19, CCL20, CCL21, CCL25CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27, CD28, CD30, CD38, CD39,CD40, CD40L, CD47, CD52, CD70, CD80, CD86, CD123, CD133, CD137, CD137L,CD160, CD272, CEACAM5, CLEC9, CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1,CXCL2, CXCL4, CXCL12, CXCL13, CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1,E-cadherin, EGFR, ENTPD1, EpCAM, FCER1, FCER1A, FCER2, FGFR, FLAP,FOLH1, Gi24, GITR, GITRL, GPRS, GP100, GPRC5D, HER2, HER3, ICOSL, ICOS,HHLA2, HMGB1, HVEM, IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1, ILIA, IL1B,IL1F10, IL2, IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8, IL9, IL9R,IL10, rhIL1O, IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb, IL18,IL22, IL23, IL25, IL7, IL33, IL35, ITGB4, ITK, KIR, LAG3, LAMP1, leptin,LPFS2, MHC class II, MUC-1, MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1,OX40, OX40L, PD-1, PD-L1, PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC,SPG64, ST2, STEAP1, STEAP2, Syk kinase, STEAP1, TROP2, TACI, TDO,TGFBETA, T14, TIGIT, TIM3, TLR, TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa,TNFRSF7, Tp55, TREM1, TSLP, TSLPR, TWEAK, VEGF, VISTA, Vstm3, or WUCAM;CH1 is an immunoglobulin heavy chain constant region 1; CL is animmunoglobulin light chain constant region; and L1, L2, L3, L4 and L5are amino acid linkers. In some aspects, the antigen binding polypeptidehas a structure represented by VL1-VL2-VH2-VH1-CH1-CL, wherein VL1, VL2,VH1 and/or VH2 specifically binds to A2AR, APRIL, ATPDase, BAFF, BAFFR,BCMA, BlyS, BTK, BTLA, B7DC, B7H1, B7H2, B7H3, B7H4, B7H5, B7H6, B7H7,B7RP1, B7-4, C3, C5, CCL2, CCL3, CCL4, CCLS, CCL7, CCL8, CCL11, CCL15,CCL17, CCL19, CCL20, CCL21, CCL25 CCR3, CCR4, CD3, CD16A, CD19, CD20,CD24, CD27, CD28, CD30, CD38, CD39, CD40, CD40L, CD47, CD52, CD70, CD80,CD86, CD123, CD133, CD137, CD137L, CD160, CD272, CEACAM5, CLEC9, CLEC91,CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12, CXCL13, CXCR3,cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin, EGFR, ENTPD1, EpCAM, FCER1,FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24, GITR, GITRL, GPRS, GP100,GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1, HVEM, IDO, IFNa, IgE,IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R,IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O, IL12, IL13, IL13Ra1,IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23, IL25, IL7, IL33, IL35,ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II, MUC-1,MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L, PD-1, PD-L1,PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1, STEAP2,Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3, TLR,TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP, TSLPR,TWEAK, VEGF, VISTA, Vstm3, or WUCAM. In some aspects, the antigenbinding polypeptide has a structure represented byVH1-VH2-VL2-VL1-CH1-CL, wherein VL1, VL2, VH1 and/or VH2 specificallybinds to A2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC,B7H1, B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2,CCL3, CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19, CCL20, CCL21,CCL25 CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27, CD28, CD30, CD38,CD39, CD40, CD40L, CD47, CD52, CD70, CD80, CD86, CD123, CD133, CD137,CD137L, CD160, CD272, CEACAM5, CLEC9, CLEC91, CRTH2, CSF-1, CSF-2,CSF-3, CXCL1, CXCL2, CXCL4, CXCL12, CXCL13, CXCR3, cMet, CTLA4, DLL3,DLL4, DNGR-1, E-cadherin, EGFR, ENTPD1, EpCAM, FCER1, FCER1A, FCER2,FGFR, FLAP, FOLH1, Gi24, GITR, GITRL, GPR5, GP100, GPRC5D, HER2, HER3,ICOSL, ICOS, HHLA2, HMGB1, HVEM, IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1,ILIA, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8,IL9, IL9R, IL10, rhIL1O, IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17,IL17Rb, IL18, IL22, IL23, IL25, IL7, IL33, IL35, ITGB4, ITK, KIR, LAG3,LAMP1, leptin, LPFS2, MHC class II, MUC-1, MUC-16, NCR3LG1, NKG2D,NKp46, NTPDase-1, OX40, OX40L, PD-1, PD-L1, PD-L2, PROM1, S152,SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1, STEAP2, Syk kinase, STEAP1,TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3, TLR, TLR2, TLR4, TLR5,TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP, TSLPR, TWEAK, VEGF,VISTA, Vstm3, or WUCAM. In some aspects, the antigen binding polypeptidehas a structure represented by VL1-VL2-VH2-VH1-CL-CH1, wherein VL1, VL2,VH1 and/or VH2 specifically binds to A2AR, APRIL, ATPDase, BAFF, BAFFR,BCMA, BlyS, BTK, BTLA, B7DC, B7H1, B7H2, B7H3, B7H4, B7H5, B7H6, B7H7,B7RP1, B7-4, C3, C5, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL11, CCL15,CCL17, CCL19, CCL20, CCL21, CCL25 CCR3, CCR4, CD3, CD16A, CD19, CD20,CD24, CD27, CD28, CD30, CD38, CD39, CD40, CD40L, CD47, CD52, CD70, CD80,CD86, CD123, CD133, CD137, CD137L, CD160, CD272, CEACAM5, CLEC9, CLEC91,CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12, CXCL13, CXCR3,cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin, EGFR, ENTPD1, EpCAM, FCER1,FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24, GITR, GITRL, GPR5, GP100,GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1, HVEM, IDO, IFNa, IgE,IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R,IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O, IL12, IL13, IL13Ra1,IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23, IL25, IL7, IL33, IL35,ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II, MUC-1,MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L, PD-1, PD-L1,PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1, STEAP2,Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3, TLR,TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP, TSLPR,TWEAK, VEGF, VISTA, Vstm3, or WUCAM. In some aspects, the antigenbinding polypeptide has a structure represented byVH1-VH2-VL2-VL1-CL-CH1, wherein VL1, VL2, VH1 and/or VH2 specificallybinds to A2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC,B7H1, B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2,CCL3, CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19, CCL20, CCL21,CCL25 CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27, CD28, CD30, CD38,CD39, CD40, CD40L, CD47, CD52, CD70, CD80, CD86, CD123, CD133, CD137,CD137L, CD160, CD272, CEACAM5, CLEC9, CLEC91, CRTH2, CSF-1, CSF-2,CSF-3, CXCL1, CXCL2, CXCL4, CXCL12, CXCL13, CXCR3, cMet, CTLA4, DLL3,DLL4, DNGR-1, E-cadherin, EGFR, ENTPD1, EpCAM, FCER1, FCER1A, FCER2,FGFR, FLAP, FOLH1, Gi24, GITR, GITRL, GPR5, GP100, GPRC5D, HER2, HER3,ICOSL, ICOS, HHLA2, HMGB1, HVEM, IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1,ILIA, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8,IL9, IL9R, IL10, rhIL1O, IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17,IL17Rb, IL18, IL22, IL23, IL25, IL7, IL33, IL35, ITGB4, ITK, KIR, LAG3,LAMP1, leptin, LPFS2, MHC class II, MUC-1, MUC-16, NCR3LG1, NKG2D,NKp46, NTPDase-1, OX40, OX40L, PD-1, PD-L1, PD-L2, PROM1, S152,SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1, STEAP2, Syk kinase, STEAP1,TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3, TLR, TLR2, TLR4, TLR5,TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP, TSLPR, TWEAK, VEGF,VISTA, Vstm3, or WUCAM. In some aspects, the antigen binding polypeptidehas a structure represented by VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-CL,wherein VL1, VL2, VH1 and/or VH2 specifically binds to A2AR, APRIL,ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1, B7H2, B7H3,B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3, CCL4, CCL5,CCL7, CCL8, CCL11, CCL15, CCL17, CCL19, CCL20, CCL21, CCL25 CCR3, CCR4,CD3, CD16A, CD19, CD20, CD24, CD27, CD28, CD30, CD38, CD39, CD40, CD40L,CD47, CD52, CD70, CD80, CD86, CD123, CD133, CD137, CD137L, CD160, CD272,CEACAM5, CLEC9, CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4,CXCL12, CXCL13, CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin,EGFR, ENTPD1, EpCAM, FCER1, FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24,GITR, GITRL, GPR5, GP100, GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1,HVEM, IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2,IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O,IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23,IL25, IL7, IL33, IL35, ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHCclass II, MUC-1, MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L,PD-1, PD-L1, PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2,STEAP1, STEAP2, Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14,TIGIT, TIM3, TLR, TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55,TREM1, TSLP, TSLPR, TWEAK, VEGF, VISTA, Vstm3, or WUCAM. In someaspects, the antigen binding polypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-CL, wherein VL1, VL2, VH1 and/or VH2specifically binds to A2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS,BTK, BTLA, B7DC, B7H1, B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4,C3, C5, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19,CCL20, CCL21, CCL25 CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27,CD28, CD30, CD38, CD39, CD40, CD40L, CD47, CD52, CD70, CD80, CD86,CD123, CD133, CD137, CD137L, CD160, CD272, CEACAM5, CLEC9, CLEC91,CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12, CXCL13, CXCR3,cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin, EGFR, ENTPD1, EpCAM, FCER1,FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24, GITR, GITRL, GPR5, GP100,GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1, HVEM, IDO, IFNa, IgE,IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R,IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O, IL12, IL13, IL13Ra1,IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23, IL25, IL7, IL33, IL35,ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II, MUC-1,MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L, PD-1, PD-L1,PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1, STEAP2,Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3, TLR,TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP, TSLPR,TWEAK, VEGF, VISTA, Vstm3, or WUCAM. In some aspects, the antigenbinding polypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-CH1, wherein VL1, VL2, VH1 and/or VH2specifically binds to A2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS,BTK, BTLA, B7DC, B7H1, B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4,C3, C5, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19,CCL20, CCL21, CCL25 CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27,CD28, CD30, CD38, CD39, CD40, CD40L, CD47, CD52, CD70, CD80, CD86,CD123, CD133, CD137, CD137L, CD160, CD272, CEACAM5, CLEC9, CLEC91,CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12, CXCL13, CXCR3,cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin, EGFR, ENTPD1, EpCAM, FCER1,FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24, GITR, GITRL, GPR5, GP100,GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1, HVEM, IDO, IFNa, IgE,IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R,IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O, IL12, IL13, IL13Ra1,IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23, IL25, IL7, IL33, IL35,ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II, MUC-1,MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L, PD-1, PD-L1,PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1, STEAP2,Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3, TLR,TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP, TSLPR,TWEAK, VEGF, VISTA, Vstm3, or WUCAM. In some aspects, the antigenbinding polypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-CH1, wherein VL1, VL2, VH1 and/or VH2specifically binds to A2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS,BTK, BTLA, B7DC, B7H1, B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4,C3, C5, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19,CCL20, CCL21, CCL25 CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27,CD28, CD30, CD38, CD39, CD40, CD40L, CD47, CD52, CD70, CD80, CD86,CD123, CD133, CD137, CD137L, CD160, CD272, CEACAM5, CLEC9, CLEC91,CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12, CXCL13, CXCR3,cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin, EGFR, ENTPD1, EpCAM, FCER1,FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24, GITR, GITRL, GPR5, GP100,GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1, HVEM, IDO, IFNa, IgE,IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R,IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O, IL12, IL13, IL13Ra1,IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23, IL25, IL7, IL33, IL35,ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II, MUC-1,MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L, PD-1, PD-L1,PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1, STEAP2,Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3, TLR,TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP, TSLPR,TWEAK, VEGF, VISTA, Vstm3, or WUCAM. In some aspects, the antigenbinding polypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL, wherein VL1, VL2, VH1 and/or VH2specifically binds to A2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS,BTK, BTLA, B7DC, B7H1, B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4,C3, C5, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19,CCL20, CCL21, CCL25 CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27,CD28, CD30, CD38, CD39, CD40, CD40L, CD47, CD52, CD70, CD80, CD86,CD123, CD133, CD137, CD137L, CD160, CD272, CEACAM5, CLEC9, CLEC91,CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12, CXCL13, CXCR3,cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin, EGFR, ENTPD1, EpCAM, FCER1,FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24, GITR, GITRL, GPR5, GP100,GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1, HVEM, IDO, IFNa, IgE,IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R,IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O, IL12, IL13, IL13Ra1,IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23, IL25, IL7, IL33, IL35,ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II, MUC-1,MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L, PD-1, PD-L1,PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1, STEAP2,Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3, TLR,TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP, TSLPR,TWEAK, VEGF, VISTA, Vstm3, or WUCAM. In some aspects, the antigenbinding polypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL, wherein VL1, VL2, VH1 and/or VH2specifically binds to A2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS,BTK, BTLA, B7DC, B7H1, B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4,C3, C5, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19,CCL20, CCL21, CCL25 CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27,CD28, CD30, CD38, CD39, CD40, CD40L, CD47, CD52, CD70, CD80, CD86,CD123, CD133, CD137, CD137L, CD160, CD272, CEACAM5, CLEC9, CLEC91,CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12, CXCL13, CXCR3,cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin, EGFR, ENTPD1, EpCAM, FCER1,FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24, GITR, GITRL, GPR5, GP100,GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1, HVEM, IDO, IFNa, IgE,IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R,IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O, IL12, IL13, IL13Ra1,IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23, IL25, IL7, IL33, IL35,ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II, MUC-1,MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L, PD-1, PD-L1,PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1, STEAP2,Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3, TLR,TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP, TSLPR,TWEAK, VEGF, VISTA, Vstm3, or WUCAM. In some aspects, the antigenbinding polypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1, wherein VL1, VL2, VH1 and/or VH2specifically binds to A2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS,BTK, BTLA, B7DC, B7H1, B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4,C3, C5, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19,CCL20, CCL21, CCL25 CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27,CD28, CD30, CD38, CD39, CD40, CD40L, CD47, CD52, CD70, CD80, CD86,CD123, CD133, CD137, CD137L, CD160, CD272, CEACAM5, CLEC9, CLEC91,CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12, CXCL13, CXCR3,cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin, EGFR, ENTPD1, EpCAM, FCER1,FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24, GITR, GITRL, GPR5, GP100,GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1, HVEM, IDO, IFNa, IgE,IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R,IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O, IL12, IL13, IL13Ra1,IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23, IL25, IL7, IL33, IL35,ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II, MUC-1,MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L, PD-1, PD-L1,PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1, STEAP2,Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3, TLR,TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP, TSLPR,TWEAK, VEGF, VISTA, Vstm3, or WUCAM. In some aspects, the antigenbinding polypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1, wherein VL1, VL2, VH1 and/or VH2specifically binds to A2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS,BTK, BTLA, B7DC, B7H1, B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4,C3, C5, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19,CCL20, CCL21, CCL25 CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27,CD28, CD30, CD38, CD39, CD40, CD40L, CD47, CD52, CD70, CD80, CD86,CD123, CD133, CD137, CD137L, CD160, CD272, CEACAM5, CLEC9, CLEC91,CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12, CXCL13, CXCR3,cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin, EGFR, ENTPD1, EpCAM, FCER1,FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24, GITR, GITRL, GPR5, GP100,GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1, HVEM, IDO, IFNa, IgE,IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R,IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O, IL12, IL13, IL13Ra1,IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23, IL25, IL7, IL33, IL35,ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II, MUC-1,MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L, PD-1, PD-L1,PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1, STEAP2,Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3, TLR,TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP, TSLPR,TWEAK, VEGF, VISTA, Vstm3, or WUCAM. Any and all disclosure herein inrelation to targets for antigen binding polypeptides of the invention isgenerally applicable, and applies equally and without reservation toeach and every antigen binding polypeptide and antigen bindingpolypeptide complex described herein. For the avoidance of doubt, theVL1, VL2, VH1, and/or VH2 of each and every antigen binding polypeptideand antigen binding polypeptide complex described herein mayindependently bind to any one of said particularly preferred targets.

In some aspects, the antigen binding polypeptide complex comprises afirst polypeptide and a second polypeptide; wherein the firstpolypeptide has a structure represented by: VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; wherein the second polypeptidehas a structure represented by VL1-VL2-VH2-VH1-CH1; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1- VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; or VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; wherein VL1is a first immunoglobulin light chain variable region that specificallybinds to A2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC,B7H1, B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2,CCL3, CCL4, CCLS, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19, CCL20, CCL21,CCL25 CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27, CD28, CD30, CD38,CD39, CD40, CD40L, CD47, CD52, CD70, CD80, CD86, CD123, CD133, CD137,CD137L, CD160, CD272, CEACAM5, CLEC9, CLEC91, CRTH2, CSF-1, CSF-2,CSF-3, CXCL1, CXCL2, CXCL4, CXCL12, CXCL13, CXCR3, cMet, CTLA4, DLL3,DLL4, DNGR-1, E-cadherin, EGFR, ENTPD1, EpCAM, FCER1, FCER1A, FCER2,FGFR, FLAP, FOLH1, Gi24, GITR, GITRL, GPR5, GP100, GPRC5D, HER2, HER3,ICOSL, ICOS, HHLA2, HMGB1, HVEM, IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1,ILIA, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8,IL9, IL9R, IL10, rhIL1O, IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17,IL17Rb, IL18, IL22, IL23, IL25, IL7, IL33, IL35, ITGB4, ITK, KIR, LAG3,LAMP1, leptin, LPFS2, MHC class II, MUC-1, MUC-16, NCR3LG1, NKG2D,NKp46, NTPDase-1, OX40, OX40L, PD-1, PD-L1, PD-L2, PROM1, S152,SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1, STEAP2, Syk kinase, STEAP1,TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3, TLR, TLR2, TLR4, TLR5,TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP, TSLPR, TWEAK, VEGF,VISTA, Vstm3, or WUCAM; VL2 is a second immunoglobulin light chainvariable region that specifically binds to A2AR, APRIL, ATPDase, BAFF,BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1, B7H2, B7H3, B7H4, B7H5, B7H6,B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL11,CCL15, CCL17, CCL19, CCL20, CCL21, CCL25 CCR3, CCR4, CD3, CD16A, CD19,CD20, CD24, CD27, CD28, CD30, CD38, CD39, CD40, CD40L, CD47, CD52, CD70,CD80, CD86, CD123, CD133, CD137, CD137L, CD160, CD272, CEACAM5, CLEC9,CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12, CXCL13,CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin, EGFR, ENTPD1, EpCAM,FCER1, FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24, GITR, GITRL, GPR5, GP100,GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1, HVEM, IDO, IFNa, IgE,IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R,IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O, IL12, IL13, IL13Ra1,IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23, IL25, IL7, IL33, IL35,ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II, MUC-1,MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L, PD-1, PD-L1,PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1, STEAP2,Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3, TLR,TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP, TSLPR,TWEAK, VEGF, VISTA, Vstm3, or WUCAM; VH1 is a first immunoglobulin heavychain variable region that specifically binds to A2AR, APRIL, ATPDase,BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1, B7H2, B7H3, B7H4, B7H5,B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8,CCL11, CCL15, CCL17, CCL19, CCL20, CCL21, CCL25 CCR3, CCR4, CD3, CD16A,CD19, CD20, CD24, CD27, CD28, CD30, CD38, CD39, CD40, CD40L, CD47, CD52,CD70, CD80, CD86, CD123, CD133, CD137, CD137L, CD160, CD272, CEACAM5,CLEC9, CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12,CXCL13, CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin, EGFR,ENTPD1, EpCAM, FCER1, FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24, GITR,GITRL, GPR5, GP100, GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1, HVEM,IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2, IL4,IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O, IL12,IL13, IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23, IL25, IL7,IL33, IL35, ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II,MUC-1, MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L, PD-1,PD-L1, PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1,STEAP2, Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3,TLR, TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP,TSLPR, TWEAK, VEGF, VISTA, Vstm3, or WUCAM; VH2 is a secondimmunoglobulin heavy chain variable region that specifically binds toA2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1,B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3,CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19, CCL20, CCL21, CCL25CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27, CD28, CD30, CD38, CD39,CD40, CD40L, CD47, CD52, CD70, CD80, CD86, CD123, CD133, CD137, CD137L,CD160, CD272, CEACAM5, CLEC9, CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1,CXCL2, CXCL4, CXCL12, CXCL13, CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1,E-cadherin, EGFR, ENTPD1, EpCAM, FCER1, FCER1A, FCER2, FGFR, FLAP,FOLH1, Gi24, GITR, GITRL, GPR5, GP100, GPRC5D, HER2, HER3, ICOSL, ICOS,HHLA2, HMGB1, HVEM, IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1, ILIA, IL1B,IL1F10, IL2, IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8, IL9, IL9R,IL10, rhIL1O, IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb, IL18,IL22, IL23, IL25, IL7, IL33, IL35, ITGB4, ITK, KIR, LAG3, LAMP1, leptin,LPFS2, MHC class II, MUC-1, MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1,OX40, OX40L, PD-1, PD-L1, PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC,SPG64, ST2, STEAP1, STEAP2, Syk kinase, STEAP1, TROP2, TACI, TDO,TGFBETA, T14, TIGIT, TIM3, TLR, TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa,TNFRSF7, Tp55, TREM1, TSLP, TSLPR, TWEAK, VEGF, VISTA, Vstm3, or WUCAM;CH1 is an immunoglobulin heavy chain constant region 1; CL is animmunoglobulin light chain constant region; and L1, L2, L3, L4 and L5are amino acid linkers. In some aspects, the first polypeptide has astructure represented by VL1-VL2-VH2-VH1-CH1 and the second polypeptidehas a structure represented by VL1-VL2-VH2-VH1-CH1; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2- L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; or VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1. In some aspects,the first polypeptide has a structure represented by VH1-VH2-VL2-VL1-CH1and the second polypeptide has a structure represented byVL1-VL2-VH2-VH1-CH1; VL1-VL2-VH2-VH1-CH1; VH1-VH2-VL2-VL1-CH1;VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL; VL1-VL2-VH2-VH1-CH1-CL;VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1; VH1-VH2-VL2-VL1-CL-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1;VL1-L1-VL2-L2- VH2-L3-VH1-L4-CL; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-CL and thesecond polypeptide has a structure represented by VL1-VL2-VH2-VH1-CH1;VL1-VL2-VH2-VH1-CH1; VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL;VH1-VH2-VL2-VL1-CL; VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL;VL1-VL2-VH2-VH1-CL-CH1; VH1-VH2-VL2-VL1-CL-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL; VH1-L1-VH2-L2- VL2-L3-VL1-L4-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1-CL and thesecond polypeptide has a structure represented by VL1-VL2-VH2-VH1-CH1;VL1-VL2-VH2-VH1-CH1; VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL;VH1-VH2-VL2-VL1-CL; VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL;VL1-VL2-VH2-VH1-CL-CH1; VH1-VH2-VL2-VL1-CL-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL;VL1-L1-VL2-L2- VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; or VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1. In some aspects,the first polypeptide has a structure represented byVL1-VL2-VH2-VH1-CH1-CL and the second polypeptide has a structurerepresented by VL1-VL2-VH2-VH1-CH1; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1- VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5- CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1-CH1-CL andthe second polypeptide has a structure represented byVL1-VL2-VH2-VH1-CH1; VL1-VL2-VH2-VH1-CH1; VH1-VH2-VL2-VL1-CH1;VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL; VL1-VL2-VH2-VH1-CH1-CL;VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1; VH1-VH2-VL2-VL1-CL-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL; VH1- L1-VH2-L2-VL2-L3-VL1-L4-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-CL-CH1 andthe second polypeptide has a structure represented byVL1-VL2-VH2-VH1-CH1; VL1-VL2-VH2-VH1-CH1; VH1-VH2-VL2-VL1-CH1;VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL; VL1-VL2-VH2-VH1-CH1-CL;VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1; VH1-VH2-VL2-VL1-CL-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; or VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1. Insome aspects, the first polypeptide has a structure represented byVH1-VH2-VL2-VL1-CL-CH1 and the second polypeptide has a structurerepresented by VL1-VL2-VH2-VH1-CH1; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1- L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1 and the second polypeptide has astructure represented by VL1-VL2-VH2-VH1-CH1; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2- VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1 and the second polypeptide has astructure represented by VL1-VL2-VH2-VH1-CH1; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1- L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CL and the second polypeptide has astructure represented by VL1-VL2-VH2-VH1-CH1; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; or VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1. Insome aspects, the first polypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL and the second polypeptide has astructure represented by VL1-VL2-VH2-VH1-CH1; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1- L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL and the second polypeptide has astructure represented by VL1-VL2-VH2-VH1-CH1; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1- VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5- CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL and the second polypeptide has astructure represented by VL1-VL2-VH2-VH1-CH1; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1 and the second polypeptide has astructure represented by VL1-VL2-VH2-VH1-CH1; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1- L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1 and the second polypeptide has astructure represented by VL1-VL2-VH2-VH1-CH1; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2- VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1. The VL1, VL2, VH1, and/or VH2 mayspecifically bind to A2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK,BTLA, B7DC, B7H1, B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3,C5, CCL2, CCL3, CCL4, CCLS, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19,CCL20, CCL21, CCL25 CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27,CD28, CD30, CD38, CD39, CD40, CD40L, CD47, CD52, CD70, CD80, CD86,CD123, CD133, CD137, CD137L, CD160, CD272, CEACAM5, CLEC9, CLEC91,CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12, CXCL13, CXCR3,cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin, EGFR, ENTPD1, EpCAM, FCER1,FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24, GITR, GITRL, GPRS, GP100,GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1, HVEM, IDO, IFNa, IgE,IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2, 114, IL4Ra, IL5, IL5R,IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O, IL12, IL13, IL13Ra1,IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23, IL25, IL7, IL33, IL35,ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II, MUC-1,MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L, PD-1, PD-L1,PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1, STEAP2,Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3, TLR,TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP, TSLPR,TWEAK, VEGF, VISTA, Vstm3, or WUCAM. For the avoidance of doubt, all theantigen binding polypeptide complex structures described herein can becombined with any one or more of the targets described herein. Any andall disclosure herein in relation to targets for antigen bindingpolypeptides of the invention is generally applicable, and appliesequally and without reservation to each and every antigen bindingpolypeptide and antigen binding polypeptide complex described herein.For the avoidance of doubt, the VL1, VL2, VH1, and/or VH2 of each andevery antigen binding polypeptide and antigen binding polypeptidecomplex described herein may independently bind to any one of saidparticularly preferred targets. Any and all disclosure herein inrelation to targets for antigen binding polypeptides of the invention isgenerally applicable, and applies equally and without reservation toeach and every antigen binding polypeptide and antigen bindingpolypeptide complex described herein. For the avoidance of doubt, theVL1, VL2, VH1, and/or VH2 of each and every antigen binding polypeptideand antigen binding polypeptide complex described herein mayindependently bind to any one of said particularly preferred targets.

In some aspects, the antigen binding polypeptide has a structurerepresented by VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc; wherein VL1 is a firstimmunoglobulin light chain variable region that specifically binds toA2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1,B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3,CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19, CCL20, CCL21, CCL25CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27, CD28, CD30, CD38, CD39,CD40, CD40L, CD47, CD52, CD70, CD80, CD86, CD123, CD133, CD137, CD137L,CD160, CD272, CEACAM5, CLEC9, CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1,CXCL2, CXCL4, CXCL12, CXCL13, CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1,E-cadherin, EGFR, ENTPD1, EpCAM, FCER1, FCER1A, FCER2, FGFR, FLAP,FOLH1, Gi24, GITR, GITRL, GPR5, GP100, GPRC5D, HER2, HER3, ICOSL, ICOS,HHLA2, HMGB1, HVEM, IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1, ILIA, IL1B,IL1F10, IL2, IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8, IL9, IL9R,IL10, rhIL1O, IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb, IL18,IL22, IL23, IL25, IL7, IL33, IL35, ITGB4, ITK, KIR, LAG3, LAMP1, leptin,LPFS2, MHC class II, MUC-1, MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1,OX40, OX40L, PD-1, PD-L1, PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC,SPG64, ST2, STEAP1, STEAP2, Syk kinase, STEAP1, TROP2, TACI, TDO,TGFBETA, T14, TIGIT, TIM3, TLR, TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa,TNFRSF7, Tp55, TREM1, TSLP, TSLPR, TWEAK, VEGF, VISTA, Vstm3, or WUCAM;VL2 is a second immunoglobulin light chain variable region thatspecifically binds to A2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS,BTK, BTLA, B7DC, B7H1, B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4,C3, C5, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19,CCL20, CCL21, CCL25 CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27,CD28, CD30, CD38, CD39, CD40, CD40L, CD47, CD52, CD70, CD80, CD86,CD123, CD133, CD137, CD137L, CD160, CD272, CEACAM5, CLEC9, CLEC91,CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12, CXCL13, CXCR3,cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin, EGFR, ENTPD1, EpCAM, FCER1,FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24, GITR, GITRL, GPR5, GP100,GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1, HVEM, IDO, IFNa, IgE,IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R,116, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O, IL12, IL13, IL13Ra1,IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23, IL25, IL7, IL33, IL35,ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II, MUC-1,MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L, PD-1, PD-L1,PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1, STEAP2,Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3, TLR,TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP, TSLPR,TWEAK, VEGF, VISTA, Vstm3, or WUCAM; VH1 is a first immunoglobulin heavychain variable region that specifically binds to A2AR, APRIL, ATPDase,BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1, B7H2, B7H3, B7H4, B7H5,B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8,CCL11, CCL15, CCL17, CCL19, CCL20, CCL21, CCL25 CCR3, CCR4, CD3, CD16A,CD19, CD20, CD24, CD27, CD28, CD30, CD38, CD39, CD40, CD40L, CD47, CD52,CD70, CD80, CD86, CD123, CD133, CD137, CD137L, CD160, CD272, CEACAM5,CLEC9, CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12,CXCL13, CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin, EGFR,ENTPD1, EpCAM, FCER1, FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24, GITR,GITRL, GPR5, GP100, GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1, HVEM,IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2, IL4,IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O, IL12,IL13, IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23, IL25, IL7,IL33, IL35, ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II,MUC-1, MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L, PD-1,PD-L1, PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1,STEAP2, Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3,TLR, TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP,TSLPR, TWEAK, VEGF, VISTA, Vstm3, or WUCAM; VH2 is a secondimmunoglobulin heavy chain variable region that specifically binds toA2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1,B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3,CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19, CCL20, CCL21, CCL25CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27, CD28, CD30, CD38, CD39,CD40, CD40L, CD47, CD52, CD70, CD80, CD86, CD123, CD133, CD137, CD137L,CD160, CD272, CEACAM5, CLEC9, CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1,CXCL2, CXCL4, CXCL12, CXCL13, CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1,E-cadherin, EGFR, ENTPD1, EpCAM, FCER1, FCER1A, FCER2, FGFR, FLAP,FOLH1, Gi24, GITR, GITRL, GPR5, GP100, GPRC5D, HER2, HER3, ICOSL, ICOS,HHLA2, HMGB1, HVEM, IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1, ILIA, IL1B,IL1F10, IL2, IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8, IL9, IL9R,IL10, rhIL1O, IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb, IL18,IL22, IL23, IL25, IL7, IL33, IL35, ITGB4, ITK, KIR, LAG3, LAMP1, leptin,LPFS2, MHC class II, MUC-1, MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1,OX40, OX40L, PD-1, PD-L1, PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC,SPG64, ST2, STEAP1, STEAP2, Syk kinase, STEAP1, TROP2, TACI, TDO,TGFBETA, T14, TIGIT, TIM3, TLR, TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa,TNFRSF7, Tp55, TREM1, TSLP, TSLPR, TWEAK, VEGF, VISTA, Vstm3, or WUCAM;Fc is a region comprising an immunoglobulin heavy chain constant region2 (CH2), an immunoglobulin heavy chain constant region 3 (CH3), andoptionally, an immunoglobulin hinge; CH1 is an immunoglobulin heavychain constant region 1; CL is an immunoglobulin light chain constantregion; and L1, L2, L3, L4 and L5 are amino acid linkers. In someaspects, the antigen binding polypeptide has a structure represented byVL1-VL2-VH2-VH1-CH1-CL-Fc; wherein VL1, VL2, VH1 and/or VH2 specificallybinds to A2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC,B7H1, B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2,CCL3, CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19, CCL20, CCL21,CCL25 CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27, CD28, CD30, CD38,CD39, CD40, CD40L, CD47, CD52, CD70, CD80, CD86, CD123, CD133, CD137,CD137L, CD160, CD272, CEACAM5, CLEC9, CLEC91, CRTH2, CSF-1, CSF-2,CSF-3, CXCL1, CXCL2, CXCL4, CXCL12, CXCL13, CXCR3, cMet, CTLA4, DLL3,DLL4, DNGR-1, E-cadherin, EGFR, ENTPD1, EpCAM, FCER1, FCER1A, FCER2,FGFR, FLAP, FOLH1, Gi24, GITR, GITRL, GPR5, GP100, GPRC5D, HER2, HER3,ICOSL, ICOS, HHLA2, HMGB1, HVEM, IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1,ILIA, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8,IL9, IL9R, IL10, rhIL1O, IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17,IL17Rb, IL18, IL22, IL23, IL25, IL7, IL33, IL35, ITGB4, ITK, KIR, LAG3,LAMP1, leptin, LPFS2, MHC class II, MUC-1, MUC-16, NCR3LG1, NKG2D,NKp46, NTPDase-1, OX40, OX40L, PD-1, PD-L1, PD-L2, PROM1, S152,SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1, STEAP2, Syk kinase, STEAP1,TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3, TLR, TLR2, TLR4, TLR5,TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP, TSLPR, TWEAK, VEGF,VISTA, Vstm3, or WUCAM. In some aspects, the antigen binding polypeptidehas a structure represented by VH1-VH2-VL2-VL1-CH1-CL-Fc; wherein VL1,VL2, VH1 and/or VH2 specifically binds to A2AR, APRIL, ATPDase, BAFF,BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1, B7H2, B7H3, B7H4, B7H5, B7H6,B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL11,CCL15, CCL17, CCL19, CCL20, CCL21, CCL25 CCR3, CCR4, CD3, CD16A, CD19,CD20, CD24, CD27, CD28, CD30, CD38, CD39, CD40, CD40L, CD47, CD52, CD70,CD80, CD86, CD123, CD133, CD137, CD137L, CD160, CD272, CEACAM5, CLEC9,CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12, CXCL13,CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin, EGFR, ENTPD1, EpCAM,FCER1, FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24, GITR, GITRL, GPR5, GP100,GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1, HVEM, IDO, IFNa, IgE,IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R,IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O, IL12, IL13, IL13Ra1,IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23, IL25, IL7, IL33, IL35,ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II, MUC-1,MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L, PD-1, PD-L1,PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1, STEAP2,Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3, TLR,TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP, TSLPR,TWEAK, VEGF, VISTA, Vstm3, or WUCAM. In some aspects, the antigenbinding polypeptide has a structure represented byVL1-VL2-VH2-VH1-CL-CH1-Fc; wherein VL1, VL2, VH1 and/or VH2 specificallybinds to A2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC,B7H1, B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2,CCL3, CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19, CCL20, CCL21,CCL25 CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27, CD28, CD30, CD38,CD39, CD40, CD40L, CD47, CD52, CD70, CD80, CD86, CD123, CD133, CD137,CD137L, CD160, CD272, CEACAM5, CLEC9, CLEC91, CRTH2, CSF-1, CSF-2,CSF-3, CXCL1, CXCL2, CXCL4, CXCL12, CXCL13, CXCR3, cMet, CTLA4, DLL3,DLL4, DNGR-1, E-cadherin, EGFR, ENTPD1, EpCAM, FCER1, FCER1A, FCER2,FGFR, FLAP, FOLH1, Gi24, GITR, GITRL, GPR5, GP100, GPRC5D, HER2, HER3,ICOSL, ICOS, HHLA2, HMGB1, HVEM, IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1,ILIA, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8,IL9, IL9R, IL10, rhIL1O, IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17,IL17Rb, IL18, IL22, IL23, IL25, IL7, IL33, IL35, ITGB4, ITK, KIR, LAG3,LAMP1, leptin, LPFS2, MHC class II, MUC-1, MUC-16, NCR3LG1, NKG2D,NKp46, NTPDase-1, OX40, OX40L, PD-1, PD-L1, PD-L2, PROM1, S152,SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1, STEAP2, Syk kinase, STEAP1,TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3, TLR, TLR2, TLR4, TLR5,TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP, TSLPR, TWEAK, VEGF,VISTA, Vstm3, or WUCAM. In some aspects, the antigen binding polypeptidehas a structure represented by VH1-VH2-VL2-VL1-CL-CH1-Fc; wherein VL1,VL2, VH1 and/or VH2 specifically binds to A2AR, APRIL, ATPDase, BAFF,BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1, B7H2, B7H3, B7H4, B7H5, B7H6,B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL11,CCL15, CCL17, CCL19, CCL20, CCL21, CCL25 CCR3, CCR4, CD3, CD16A, CD19,CD20, CD24, CD27, CD28, CD30, CD38, CD39, CD40, CD40L, CD47, CD52, CD70,CD80, CD86, CD123, CD133, CD137, CD137L, CD160, CD272, CEACAM5, CLEC9,CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12, CXCL13,CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin, EGFR, ENTPD1, EpCAM,FCER1, FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24, GITR, GITRL, GPR5, GP100,GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1, HVEM, IDO, IFNa, IgE,IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R,IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O, IL12, IL13, IL13Ra1,IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23, IL25, IL7, IL33, IL35,ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II, MUC-1,MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L, PD-1, PD-L1,PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1, STEAP2,Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3, TLR,TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP, TSLPR,TWEAK, VEGF, VISTA, Vstm3, or WUCAM. In some aspects, the antigenbinding polypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc; wherein VL1, VL2, VH1 and/orVH2 specifically binds to A2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS,BTK, BTLA, B7DC, B7H1, B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4,C3, C5, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19,CCL20, CCL21, CCL25 CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27,CD28, CD30, CD38, CD39, CD40, CD40L, CD47, CD52, CD70, CD80, CD86,CD123, CD133, CD137, CD137L, CD160, CD272, CEACAM5, CLEC9, CLEC91,CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12, CXCL13, CXCR3,cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin, EGFR, ENTPD1, EpCAM, FCER1,FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24, GITR, GITRL, GPR5, GP100,GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1, HVEM, IDO, IFNa, IgE,IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R,IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O, IL12, IL13, IL13Ra1,IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23, IL25, IL7, IL33, IL35,ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II, MUC-1,MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L, PD-1, PD-L1,PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1, STEAP2,Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3, TLR,TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP, TSLPR,TWEAK, VEGF, VISTA, Vstm3, or WUCAM. In some aspects, the antigenbinding polypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc; wherein VL1, VL2, VH1 and/orVH2 specifically binds to A2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS,BTK, BTLA, B7DC, B7H1, B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4,C3, C5, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19,CCL20, CCL21, CCL25 CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27,CD28, CD30, CD38, CD39, CD40, CD40L, CD47, CD52, CD70, CD80, CD86,CD123, CD133, CD137, CD137L, CD160, CD272, CEACAM5, CLEC9, CLEC91,CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12, CXCL13, CXCR3,cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin, EGFR, ENTPD1, EpCAM, FCER1,FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24, GITR, GITRL, GPR5, GP100,GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1, HVEM, IDO, IFNa, IgE,IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R,IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O, IL12, IL13, IL13Ra1,IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23, IL25, IL7, IL33, IL35,ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II, MUC-1,MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L, PD-1, PD-L1,PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1, STEAP2,Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3, TLR,TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP, TSLPR,TWEAK, VEGF, VISTA, Vstm3, or WUCAM. In some aspects, the antigenbinding polypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; wherein VL1, VL2, VH1 and/orVH2 specifically binds to A2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS,BTK, BTLA, B7DC, B7H1, B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4,C3, C5, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19,CCL20, CCL21, CCL25 CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27,CD28, CD30, CD38, CD39, CD40, CD40L, CD47, CD52, CD70, CD80, CD86,CD123, CD133, CD137, CD137L, CD160, CD272, CEACAM5, CLEC9, CLEC91,CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12, CXCL13, CXCR3,cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin, EGFR, ENTPD1, EpCAM, FCER1,FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24, GITR, GITRL, GPR5, GP100,GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1, HVEM, IDO, IFNa, IgE,IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R,IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O, IL12, IL13, IL13Ra1,IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23, IL25, IL7, IL33, IL35,ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II, MUC-1,MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L, PD-1, PD-L1,PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1, STEAP2,Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3, TLR,TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP, TSLPR,TWEAK, VEGF, VISTA, Vstm3, or WUCAM. In some aspects, the antigenbinding polypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc; wherein VL1, VL2, VH1 and/orVH2 specifically binds to A2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS,BTK, BTLA, B7DC, B7H1, B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4,C3, C5, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19,CCL20, CCL21, CCL25 CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27,CD28, CD30, CD38, CD39, CD40, CD40L, CD47, CD52, CD70, CD80, CD86,CD123, CD133, CD137, CD137L, CD160, CD272, CEACAM5, CLEC9, CLEC91,CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12, CXCL13, CXCR3,cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin, EGFR, ENTPD1, EpCAM, FCER1,FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24, GITR, GITRL, GPR5, GP100,GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1, HVEM, IDO, IFNa, IgE,IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R,IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O, IL12, IL13, IL13Ra1,IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23, IL25, IL7, IL33, IL35,ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II, MUC-1,MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L, PD-1, PD-L1,PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1, STEAP2,Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3, TLR,TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP, TSLPR,TWEAK, VEGF, VISTA, Vstm3, or WUCAM. Any and all disclosure herein inrelation to targets for antigen binding polypeptides of the invention isgenerally applicable, and applies equally and without reservation toeach and every antigen binding polypeptide and antigen bindingpolypeptide complex described herein. For the avoidance of doubt, theVL1, VL2, VH1, and/or VH2 of each and every antigen binding polypeptideand antigen binding polypeptide complex described herein mayindependently bind to any one of said particularly preferred targets.

In some aspects, the antigen binding polypeptide complex comprising afirst polypeptide and a second polypeptide; wherein the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fe;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fe;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc; wherein the second polypeptidehas a structure represented by Fc; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fe;VL1-L1-VL2-L2-VH2- L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fe;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fe;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fe; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fe; wherein VL1 is a firstimmunoglobulin light chain variable region that specifically binds toA2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1,B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3,CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19, CCL20, CCL21, CCL25CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27, CD28, CD30, CD38, CD39,CD40, CD40L, CD47, CD52, CD70, CD80, CD86, CD123, CD133, CD137, CD137L,CD160, CD272, CEACAM5, CLEC9, CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1,CXCL2, CXCL4, CXCL12, CXCL13, CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1,E-cadherin, EGFR, ENTPD1, EpCAM, FCER1, FCER1A, FCER2, FGFR, FLAP,FOLH1, Gi24, GITR, GITRL, GPR5, GP100, GPRC5D, HER2, HER3, ICOSL, ICOS,HHLA2, HMGB1, HVEM, IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1, ILIA, IL1B,IL1F10, IL2, IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8, IL9, IL9R,IL10, rhIL1O, IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb, IL18,IL22, IL23, IL25, IL7, IL33, IL35, ITGB4, ITK, KIR, LAG3, LAMP1, leptin,LPFS2, MHC class II, MUC-1, MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1,OX40, OX40L, PD-1, PD-L1, PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC,SPG64, ST2, STEAP2, Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14,TIGIT, TIM3, TLR, TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55,TREM1, TSLP, TSLPR, TWEAK, VEGF, VISTA, Vstm3, or WUCAM; VL2 is a secondimmunoglobulin light chain variable region that specifically binds toA2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1,B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3,CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19, CCL20, CCL21, CCL25CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27, CD28, CD30, CD38, CD39,CD40, CD40L, CD47, CD52, CD70, CD80, CD86, CD123, CD133, CD137, CD137L,CD160, CD272, CEACAM5, CLEC9, CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1,CXCL2, CXCL4, CXCL12, CXCL13, CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1,E-cadherin, EGFR, ENTPD1, EpCAM, FCER1, FCER1A, FCER2, FGFR, FLAP,FOLH1, Gi24, GITR, GITRL, GPR5, GP100, GPRC5D, HER2, HER3, ICOSL, ICOS,HHLA2, HMGB1, HVEM, IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1, ILIA, IL1B,IL1F10, IL2, IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8, IL9, IL9R,IL10, rhIL1O, IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb, IL18,IL22, IL23, IL25, IL7, IL33, IL35, ITGB4, ITK, KIR, LAG3, LAMP1, leptin,LPFS2, MHC class II, MUC-1, MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1,OX40, OX40L, PD-1, PD-L1, PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC,SPG64, ST2, STEAP1, STEAP2, Syk kinase, STEAP1, TROP2, TACI, TDO,TGFBETA, T14, TIGIT, TIM3, TLR, TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa,TNFRSF7, Tp55, TREM1, TSLP, TSLPR, TWEAK, VEGF, VISTA, Vstm3, or WUCAM;VH1 is a first immunoglobulin heavy chain variable region thatspecifically binds to A2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS,BTK, BTLA, B7DC, B7H1, B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4,C3, C5, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19,CCL20, CCL21, CCL25 CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27,CD28, CD30, CD38, CD39, CD40, CD40L, CD47, CD52, CD70, CD80, CD86,CD123, CD133, CD137, CD137L, CD160, CD272, CEACAM5, CLEC9, CLEC91,CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12, CXCL13, CXCR3,cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin, EGFR, ENTPD1, EpCAM, FCER1,FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24, GITR, GITRL, GPR5, GP100,GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1, HVEM, IDO, IFNa, IgE,IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R,116, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O, IL12, IL13, IL13Ra1,IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23, IL25, IL7, IL33, IL35,ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II, MUC-1,MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L, PD-1, PD-L1,PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1, STEAP2,Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3, TLR,TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP, TSLPR,TWEAK, VEGF, VISTA, Vstm3, or WUCAM; VH2 is a second immunoglobulinheavy chain variable region that specifically binds to A2AR, APRIL,ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1, B7H2, B7H3,B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3, CCL4, CCL5,CCL7, CCL8, CCL11, CCL15, CCL17, CCL19, CCL20, CCL21, CCL25 CCR3, CCR4,CD3, CD16A, CD19, CD20, CD24, CD27, CD28, CD30, CD38, CD39, CD40, CD40L,CD47, CD52, CD70, CD80, CD86, CD123, CD133, CD137, CD137L, CD160, CD272,CEACAM5, CLEC9, CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4,CXCL12, CXCL13, CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin,EGFR, ENTPD1, EpCAM, FCER1, FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24,GITR, GITRL, GPR5, GP100, GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1,HVEM, IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2,IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O,IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23,IL25, IL7, IL33, IL35, ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHCclass II, MUC-1, MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L,PD-1, PD-L1, PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2,STEAP1, STEAP2, Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14,TIGIT, TIM3, TLR, TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55,TREM1, TSLP, TSLPR, TWEAK, VEGF, VISTA, Vstm3, or WUCAM; Fc is a regioncomprising an immunoglobulin heavy chain constant region 2 (CH2), animmunoglobulin heavy chain constant region 3 (CH3), and optionally, animmunoglobulin hinge; CH1 is an immunoglobulin heavy chain constantregion 1; CL is an immunoglobulin light chain constant region; and L1,L2, L3, L4 and L5 are amino acid linkers. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-CH1-Fc andthe second polypeptide has a structure represented by Fc;VL1-VL2-VH2-VH1-CH1-Fc; VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc;VH1-VH2-VL2-VL1-CL-Fc; VL1-VL2-VH2-VH1-CH1-CL-Fc;VH1-VH2-VL2-VL1-CH1-CL-Fc; VL1-VL2-VH2-VH1-CL-CH1-Fc;VH1-VH2-VL2-VL1-CL-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4- CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1-CH1-Fc andthe second polypeptide has a structure represented by Fc;VL1-VL2-VH2-VH1-CH1-Fc; VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc;VH1-VH2-VL2-VL1-CL-Fc; VL1-VL2-VH2-VH1-CH1-CL-Fc;VH1-VH2-VL2-VL1-CH1-CL-Fc; VL1-VL2-VH2-VH1-CL-CH1-Fc;VH1-VH2-VL2-VL1-CL-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-CL-Fc and thesecond polypeptide has a structure represented by Fc;VL1-VL2-VH2-VH1-CH1-Fc; VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc;VH1-VH2-VL2-VL1-CL-Fc; VL1-VL2-VH2-VH1-CH1-CL-Fc;VH1-VH2-VL2-VL1-CH1-CL-Fc; VL1-VL2-VH2-VH1-CL-CH1-Fc;VH1-VH2-VL2-VL1-CL-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1-CL-Fc and thesecond polypeptide has a structure represented by Fc;VL1-VL2-VH2-VH1-CH1-Fc; VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc;VH1-VH2-VL2-VL1-CL-Fc; VL1-VL2-VH2-VH1-CH1-CL-Fc;VH1-VH2-VL2-VL1-CH1-CL-Fc; VL1-VL2-VH2-VH1-CL-CH1-Fc;VH1-VH2-VL2-VL1-CL-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-CH1-CL-Fc andthe second polypeptide has a structure represented by Fc;VL1-VL2-VH2-VH1-CH1-Fe; VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc;VH1-VH2-VL2-VL1-CL-Fc; VL1-VL2-VH2-VH1-CH1-CL-Fc;VH1-VH2-VL2-VL1-CH1-CL-Fc; VL1-VL2-VH2-VH1-CL-CH1-Fc;VH1-VH2-VL2-VL1-CL-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1-CH1-CL-Fc andthe second polypeptide has a structure represented by Fc;VL1-VL2-VH2-VH1-CH1-Fe; VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc;VH1-VH2-VL2-VL1-CL-Fc; VL1-VL2-VH2-VH1-CH1-CL-Fc;VH1-VH2-VL2-VL1-CH1-CL-Fc; VL1-VL2-VH2-VH1-CL-CH1-Fc;VH1-VH2-VL2-VL1-CL-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-CL-CH1-Fc andthe second polypeptide has a structure represented by Fc;VL1-VL2-VH2-VH1-CH1-Fe; VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc;VH1-VH2-VL2-VL1-CL-Fc; VL1-VL2-VH2-VH1-CH1-CL-Fc;VH1-VH2-VL2-VL1-CH1-CL-Fc; VL1-VL2-VH2-VH1-CL-CH1-Fc;VH1-VH2-VL2-VL1-CL-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1-CL-CH1-Fc andthe second polypeptide has a structure represented by Fc;VL1-VL2-VH2-VH1-CH1-Fe; VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc;VH1-VH2-VL2-VL1-CL-Fc; VL1-VL2-VH2-VH1-CH1-CL-Fc;VH1-VH2-VL2-VL1-CH1-CL-Fc; VL1-VL2-VH2-VH1-CL-CH1-Fc;VH1-VH2-VL2-VL1-CL-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc and the second polypeptide has astructure represented by Fc; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc and the second polypeptide has astructure represented by Fc; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4- CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc and the second polypeptide has astructure represented by Fc; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4- CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc and the second polypeptide has astructure represented by Fc; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4- CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc and the second polypeptide hasa structure represented by Fc; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3- VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc and the second polypeptide hasa structure represented by Fc; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc and the second polypeptide hasa structure represented by Fc; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL- L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc and the second polypeptide hasa structure represented by Fc; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. The VL1, VL2, VH1, and/or VH2may specifically bind to A2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS,BTK, BTLA, B7DC, B7H1, B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4,C3, C5, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19,CCL20, CCL21, CCL25 CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27,CD28, CD30, CD38, CD39, CD40, CD40L, CD47, CD52, CD70, CD80, CD86,CD123, CD133, CD137, CD137L, CD160, CD272, CEACAM5, CLEC9, CLEC91,CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12, CXCL13, CXCR3,cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin, EGFR, ENTPD1, EpCAM, FCER1,FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24, GITR, GITRL, GPR5, GP100,GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1, HVEM, IDO, IFNa, IgE,IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R,IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O, IL12, IL13, IL13Ra1,IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23, IL25, IL7, IL33, IL35,ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II, MUC-1,MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L, PD-1, PD-L1,PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1, STEAP2,Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3, TLR,TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP, TSLPR,TWEAK, VEGF, VISTA, Vstm3, or WUCAM. For the avoidance of doubt, all theantigen binding polypeptide complex structures described herein can becombined with any one or more of the targets described herein. Any andall disclosure herein in relation to targets for antigen bindingpolypeptides of the invention is generally applicable, and appliesequally and without reservation to each and every antigen bindingpolypeptide and antigen binding polypeptide complex described herein.For the avoidance of doubt, the VL1, VL2, VH1, and/or VH2 of each andevery antigen binding polypeptide and antigen binding polypeptidecomplex described herein may independently bind to any one of saidparticularly preferred targets. Any and all disclosure herein inrelation to targets for antigen binding polypeptides of the invention isgenerally applicable, and applies equally and without reservation toeach and every antigen binding polypeptide and antigen bindingpolypeptide complex described herein. For the avoidance of doubt, theVL1, VL2, VH1, and/or VH2 of each and every antigen binding polypeptideand antigen binding polypeptide complex described herein mayindependently bind to any one of said particularly preferred targets.

In some aspects, the antigen binding polypeptide complex comprising afirst polypeptide and a second polypeptide; wherein the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1;VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1;VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3- VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc; wherein the second polypeptidehas a structure represented by Fc; VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1;VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fc;VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1- L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1- L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc; wherein VL1 is a firstimmunoglobulin light chain variable region that specifically binds toA2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1,B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3,CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19, CCL20, CCL21, CCL25CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27, CD28, CD30, CD38, CD39,CD40, CD40L, CD47, CD52, CD70, CD80, CD86, CD123, CD133, CD137, CD137L,CD160, CD272, CEACAM5, CLEC9, CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1,CXCL2, CXCL4, CXCL12, CXCL13, CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1,E-cadherin, EGFR, ENTPD1, EpCAM, FCER1, FCER1A, FCER2, FGFR, FLAP,FOLH1, Gi24, GITR, GITRL, GPR5, GP100, GPRC5D, HER2, HER3, ICOSL, ICOS,HHLA2, HMGB1, HVEM, IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1, ILIA, IL1B,IL1F10, IL2, IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8, IL9, IL9R,IL10, rhIL1O, IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb, IL18,IL22, IL23, IL25, IL7, IL33, IL35, ITGB4, ITK, KIR, LAG3, LAMP1, leptin,LPFS2, MHC class II, MUC-1, MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1,OX40, OX40L, PD-1, PD-L1, PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC,SPG64, ST2, STEAP1, STEAP2, Syk kinase, STEAP1, TROP2, TACI, TDO,TGFBETA, T14, TIGIT, TIM3, TLR, TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa,TNFRSF7, Tp55, TREM1, TSLP, TSLPR, TWEAK, VEGF, VISTA, Vstm3, or WUCAM;VL2 is a second immunoglobulin light chain variable region thatspecifically binds to A2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS,BTK, BTLA, B7DC, B7H1, B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4,C3, C5, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19,CCL20, CCL21, CCL25 CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27,CD28, CD30, CD38, CD39, CD40, CD40L, CD47, CD52, CD70, CD80, CD86,CD123, CD133, CD137, CD137L, CD160, CD272, CEACAM5, CLEC9, CLEC91,CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12, CXCL13, CXCR3,cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin, EGFR, ENTPD1, EpCAM, FCER1,FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24, GITR, GITRL, GPR5, GP100,GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1, HVEM, IDO, IFNa, IgE,IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R,IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O, IL12, IL13, IL13Ra1,IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23, IL25, IL7, IL33, IL35,ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II, MUC-1,MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L, PD-1, PD-L1,PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1, STEAP2,Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3, TLR,TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP, TSLPR,TWEAK, VEGF, VISTA, Vstm3, or WUCAM; VH1 is a first immunoglobulin heavychain variable region that specifically binds to A2AR, APRIL, ATPDase,BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1, B7H2, B7H3, B7H4, B7H5,B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8,CCL11, CCL15, CCL17, CCL19, CCL20, CCL21, CCL25 CCR3, CCR4, CD3, CD16A,CD19, CD20, CD24, CD27, CD28, CD30, CD38, CD39, CD40, CD40L, CD47, CD52,CD70, CD80, CD86, CD123, CD133, CD137, CD137L, CD160, CD272, CEACAM5,CLEC9, CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12,CXCL13, CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin, EGFR,ENTPD1, EpCAM, FCER1, FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24, GITR,GITRL, GPR5, GP100, GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1, HVEM,IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2, IL4,IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O, IL12,IL13, IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23, IL25, IL7,IL33, IL35, ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II,MUC-1, MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L, PD-1,PD-L1, PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1,STEAP2, Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3,TLR, TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP,TSLPR, TWEAK, VEGF, VISTA, Vstm3, or WUCAM; VH2 is a secondimmunoglobulin heavy chain variable region that specifically binds toA2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1,B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3,CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19, CCL20, CCL21, CCL25CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27, CD28, CD30, CD38, CD39,CD40, CD40L, CD47, CD52, CD70, CD80, CD86, CD123, CD133, CD137, CD137L,CD160, CD272, CEACAM5, CLEC9, CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1,CXCL2, CXCL4, CXCL12, CXCL13, CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1,E-cadherin, EGFR, ENTPD1, EpCAM, FCER1, FCER1A, FCER2, FGFR, FLAP,FOLH1, Gi24, GITR, GITRL, GPR5, GP100, GPRC5D, HER2, HER3, ICOSL, ICOS,HHLA2, HMGB1, HVEM, IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1, ILIA, IL1B,IL1F10, IL2, IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8, IL9, IL9R,IL10, rhIL1O, IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb, IL18,IL22, IL23, IL25, IL7, IL33, IL35, ITGB4, ITK, KIR, LAG3, LAMP1, leptin,LPFS2, MHC class II, MUC-1, MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1,OX40, OX40L, PD-1, PD-L1, PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC,SPG64, ST2, STEAP1, STEAP2, Syk kinase, STEAP1, TROP2, TACI, TDO,TGFBETA, T14, TIGIT, TIM3, TLR, TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa,TNFRSF7, Tp55, TREM1, TSLP, TSLPR, TWEAK, VEGF, VISTA, Vstm3, or WUCAM;Fc is a region comprising an immunoglobulin heavy chain constant region2 (CH2), an immunoglobulin heavy chain constant region 3 (CH3), andoptionally, an immunoglobulin hinge; CH1 is an immunoglobulin heavychain constant region 1; CL is an immunoglobulin light chain constantregion; and L1, L2, L3, L4 and L5 are amino acid linkers. In otheraspects, the invention is directed to an antigen binding polypeptide orantigen binding polypeptide complex comprising a polypeptide having astructure represented by VL1-VL2-VH2-VH1-Fc-Fc; VH1-VH2-VL2-VL1-Fc-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-Fc-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-Fc-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc-L5-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc-L5-Fc; wherein VL1 is a firstimmunoglobulin light chain variable region that specifically binds toA2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1,B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3,CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19, CCL20, CCL21, CCL25CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27, CD28, CD30, CD38, CD39,CD40, CD40L, CD47, CD52, CD70, CD80, CD86, CD123, CD133, CD137, CD137L,CD160, CD272, CEACAM5, CLEC9, CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1,CXCL2, CXCL4, CXCL12, CXCL13, CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1,E-cadherin, EGFR, ENTPD1, EpCAM, FCER1, FCER1A, FCER2, FGFR, FLAP,FOLH1, Gi24, GITR, GITRL, GPR5, GP100, GPRC5D, HER2, HER3, ICOSL, ICOS,HHLA2, HMGB1, HVEM, IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1, ILIA, IL1B,IL1F10, IL2, IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8, IL9, IL9R,IL10, rhIL1O, IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb, IL18,IL22, IL23, IL25, IL7, IL33, IL35, ITGB4, ITK, KIR, LAG3, LAMP1, leptin,LPFS2, MHC class II, MUC-1, MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1,OX40, OX40L, PD-1, PD-L1, PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC,SPG64, ST2, STEAP1, STEAP2, Syk kinase, STEAP1, TROP2, TACI, TDO,TGFBETA, T14, TIGIT, TIM3, TLR, TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa,TNFRSF7, Tp55, TREM1, TSLP, TSLPR, TWEAK, VEGF, VISTA, Vstm3, or WUCAM;VL2 is a second immunoglobulin light chain variable region thatspecifically binds to A2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS,BTK, BTLA, B7DC, B7H1, B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4,C3, C5, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19,CCL20, CCL21, CCL25 CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27,CD28, CD30, CD38, CD39, CD40, CD40L, CD47, CD52, CD70, CD80, CD86,CD123, CD133, CD137, CD137L, CD160, CD272, CEACAM5, CLEC9, CLEC91,CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12, CXCL13, CXCR3,cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin, EGFR, ENTPD1, EpCAM, FCER1,FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24, GITR, GITRL, GPR5, GP100,GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1, HVEM, IDO, IFNa, IgE,IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R,IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O, IL12, IL13, IL13Ra1,IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23, IL25, IL7, IL33, IL35,ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II, MUC-1,MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L, PD-1, PD-L1,PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1, STEAP2,Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3, TLR,TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP, TSLPR,TWEAK, VEGF, VISTA, Vstm3, or WUCAM; VH1 is a first immunoglobulin heavychain variable region that specifically binds to A2AR, APRIL, ATPDase,BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1, B7H2, B7H3, B7H4, B7H5,B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8,CCL11, CCL15, CCL17, CCL19, CCL20, CCL21, CCL25 CCR3, CCR4, CD3, CD16A,CD19, CD20, CD24, CD27, CD28, CD30, CD38, CD39, CD40, CD40L, CD47, CD52,CD70, CD80, CD86, CD123, CD133, CD137, CD137L, CD160, CD272, CEACAM5,CLEC9, CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12,CXCL13, CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin, EGFR,ENTPD1, EpCAM, FCER1, FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24, GITR,GITRL, GPR5, GP100, GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1, HVEM,IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2, IL4,IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O, IL12,IL13, IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23, IL25, IL7,IL33, IL35, ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II,MUC-1, MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L, PD-1,PD-L1, PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1,STEAP2, Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3,TLR, TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP,TSLPR, TWEAK, VEGF, VISTA, Vstm3, or WUCAM; VH2 is a secondimmunoglobulin heavy chain variable region that specifically binds toA2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1,B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3,CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19, CCL20, CCL21, CCL25CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27, CD28, CD30, CD38, CD39,CD40, CD40L, CD47, CD52, CD70, CD80, CD86, CD123, CD133, CD137, CD137L,CD160, CD272, CEACAM5, CLEC9, CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1,CXCL2, CXCL4, CXCL12, CXCL13, CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1,E-cadherin, EGFR, ENTPD1, EpCAM, FCER1, FCER1A, FCER2, FGFR, FLAP,FOLH1, Gi24, GITR, GITRL, GPR5, GP100, GPRC5D, HER2, HER3, ICOSL, ICOS,HHLA2, HMGB1, HVEM, IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1, ILIA, IL1B,IL1F10, IL2, IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8, IL9, IL9R,IL10, rhIL1O, IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb, IL18,IL22, IL23, IL25, IL7, IL33, IL35, ITGB4, ITK, KIR, LAG3, LAMP1, leptin,LPFS2, MHC class II, MUC-1, MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1,OX40, OX40L, PD-1, PD-L1, PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC,SPG64, ST2, STEAP1, STEAP2, Syk kinase, STEAP1, TROP2, TACI, TDO,TGFBETA, T14, TIGIT, TIM3, TLR, TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa,TNFRSF7, Tp55, TREM1, TSLP, TSLPR, TWEAK, VEGF, VISTA, Vstm3, or WUCAM;Fc is a region comprising an immunoglobulin heavy chain constant region2 (CH2), an immunoglobulin heavy chain constant region 3 (CH3), andoptionally, an immunoglobulin hinge; and L1, L2, L3, L4 and L5 are aminoacid linkers. In some aspects, the first polypeptide has a structurerepresented by VL1-VL2-VH2-VH1 and the second polypeptide has astructure represented by Fc; VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1;VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fc;VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VIA-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2- L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1 and thesecond polypeptide has a structure represented by Fc; VL1-VL2-VH2-VH1;VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1;VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3- VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VL1-L1-VL2-L2-VH2-L3-VH1 andthe second polypeptide has a structure represented by Fc;VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1;VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc;VL1-VL2-VH2-VH1-CH1; VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL;VH1-VH2-VL2-VL1-CL; VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL;VL1-VL2-VH2-VH1-CL-CH1; VH1-VH2-VL2-VL1-CL-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL;VL1-L1-VL2-L2- VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1;VL1-VL2-VH2-VH1-CH1-Fc; VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc;VH1-VH2-VL2-VL1-CL-Fc; VL1-VL2-VH2-VH1-CH1-CL-Fc;VH1-VH2-VL2-VL1-CH1-CL-Fc; VL1-VL2-VH2-VH1-CL-CH1-Fc;VH1-VH2-VL2-VL1-CL-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VH1-L1-VH2-L2-VL2-L3-VL1 andthe second polypeptide has a structure represented by Fc;VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1;VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc;VL1-VL2-VH2-VH1-CH1; VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL;VH1-VH2-VL2-VL1-CL; VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL;VL1-VL2-VH2-VH1-CL-CH1; VH1-VH2-VL2-VL1-CL-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1;VL1-L1- VL2-L2-VH2-L3-VH1-L4-CL; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5- CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-Fc and thesecond polypeptide has a structure represented by Fc; VL1-VL2-VH2-VH1;VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1;VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1- L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL- L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1-Fc and thesecond polypeptide has a structure represented by Fc; VL1-VL2-VH2-VH1;VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1;VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3- VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VL1-L1-VL2-L2-VH2-L3-VH1-Fcand the second polypeptide has a structure represented by Fc;VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1;VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc;VL1-VL2-VH2-VH1-CH1; VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL;VH1-VH2-VL2-VL1-CL; VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL;VL1-VL2-VH2-VH1-CL-CH1; VH1-VH2-VL2-VL1-CL-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL;VL1-L1-VL2-L2- VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1;VL1-VL2-VH2-VH1-CH1-Fc; VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc;VH1-VH2-VL2-VL1-CL-Fc; VL1-VL2-VH2-VH1-CH1-CL-Fc;VH1-VH2-VL2-VL1-CH1-CL-Fc; VL1-VL2-VH2-VH1-CL-CH1-Fc;VH1-VH2-VL2-VL1-CL-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VH1-L1-VH2-L2-VL2-L3-VL1-Fcand the second polypeptide has a structure represented by Fc;VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1;VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc;VL1-VL2-VH2-VH1-CH1; VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL;VH1-VH2-VL2-VL1-CL; VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL;VL1-VL2-VH2-VH1-CL-CH1; VH1-VH2-VL2-VL1-CL-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1;VL1-L1- VL2-L2-VH2-L3-VH1-L4-CL; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5- CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc and the second polypeptide has astructure represented by Fc; VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1;VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fc;VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2- L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc and the second polypeptide has astructure represented by Fc; VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1;VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fc;VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1- L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL- L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-CH1 and thesecond polypeptide has a structure represented by Fc; VL1-VL2-VH2-VH1;VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1;VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3- VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1-CH1 and thesecond polypeptide has a structure represented by Fc; VL1-VL2-VH2-VH1;VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1;VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3- VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-CL and thesecond polypeptide has a structure represented by Fc; VL1-VL2-VH2-VH1;VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1;VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4- Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc; VH1-VH2-VL2-VL1-CH1-Fc;VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc; VL1-VL2-VH2-VH1-CH1-CL-Fc;VH1-VH2-VL2-VL1-CH1-CL-Fc; VL1-VL2-VH2-VH1-CL-CH1-Fc;VH1-VH2-VL2-VL1-CL-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1-CL and thesecond polypeptide has a structure represented by Fc; VL1-VL2-VH2-VH1;VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1;VL1-VL2-VH2-VH1-Fe; VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1- L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL- L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-CH1-CL andthe second polypeptide has a structure represented by Fc;VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1;VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc;VL1-VL2-VH2-VH1-CH1; VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL;VH1-VH2-VL2-VL1-CL; VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL;VL1-VL2-VH2-VH1-CL-CH1; VH1-VH2-VL2-VL1-CL-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL; VH1-L1-VH2-L2-VL2- L3-VL1-L4-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL- Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1-CH1-CL andthe second polypeptide has a structure represented by Fc;VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1;VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc;VL1-VL2-VH2-VH1-CH1; VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL;VH1-VH2-VL2-VL1-CL; VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL;VL1-VL2-VH2-VH1-CL-CH1; VH1-VH2-VL2-VL1-CL-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1;VL1-VL2-VH2-VH1-CH1-Fc; VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc;VH1-VH2-VL2-VL1-CL-Fc; VL1-VL2-VH2-VH1-CH1-CL-Fc;VH1-VH2-VL2-VL1-CH1-CL-Fc; VL1-VL2-VH2-VH1-CL-CH1-Fc;VH1-VH2-VL2-VL1-CL-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4- CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-CL-CH1 andthe second polypeptide has a structure represented by Fc;VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1;VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc;VL1-VL2-VH2-VH1-CH1; VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL;VH1-VH2-VL2-VL1-CL; VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL;VL1-VL2-VH2-VH1-CL-CH1; VH1-VH2-VL2-VL1-CL-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL;VL1-L1-VL2-L2-VH2-L3-VH1- L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL- Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1-CL-CH1 andthe second polypeptide has a structure represented by Fc;VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1;VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc;VL1-VL2-VH2-VH1-CH1; VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL;VH1-VH2-VL2-VL1-CL; VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL;VL1-VL2-VH2-VH1-CL-CH1; VH1-VH2-VL2-VL1-CL-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1;VL1-L1-VL2-L2- VH2-L3-VH1-L4-CL; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc; VH1-VH2-VL2-VL1-CH1-Fc;VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc; VL1-VL2-VH2-VH1-CH1-CL-Fc;VH1-VH2-VL2-VL1-CH1-CL-Fc; VL1-VL2-VH2-VH1-CL-CH1-Fc;VH1-VH2-VL2-VL1-CL-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1 and the second polypeptide has astructure represented by Fc; VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1;VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fc;VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2- L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1 and the second polypeptide has astructure represented by Fc; VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1;VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fc;VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1- L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL- L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CL and the second polypeptide has astructure represented by Fc; VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1;VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fc;VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2- L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1- L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL and the second polypeptide has astructure represented by Fc; VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1;VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fc;VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2- L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL- Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL and the second polypeptide has astructure represented by Fc; VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1;VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fc;VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3- VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL and the second polypeptide has astructure represented by Fc; VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1;VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fc;VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1;VL1-VL2-VH2-VH1-CH1-Fc; VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc;VH1-VH2-VL2-VL1-CL-Fc; VL1-VL2-VH2-VH1-CH1-CL-Fc;VH1-VH2-VL2-VL1-CH1-CL-Fc; VL1-VL2-VH2-VH1-CL-CH1-Fc;VH1-VH2-VL2-VL1-CL-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4- CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1 and the second polypeptide has astructure represented by Fc; VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1;VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fc;VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2- VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1;VL1-VL2-VH2-VH1-CH1-Fc; VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc;VH1-VH2-VL2-VL1-CL-Fc; VL1-VL2-VH2-VH1-CH1-CL-Fc;VH1-VH2-VL2-VL1-CH1-CL-Fc; VL1-VL2-VH2-VH1-CL-CH1-Fc;VH1-VH2-VL2-VL1-CL-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1 and the second polypeptide has astructure represented by Fc; VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1;VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fc;VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3- VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-CH1-Fc andthe second polypeptide has a structure represented by Fc;VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1;VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc;VL1-VL2-VH2-VH1-CH1; VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL;VH1-VH2-VL2-VL1-CL; VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL;VL1-VL2-VH2-VH1-CL-CH1; VH1-VH2-VL2-VL1-CL-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1;VL1-L1-VL2-L2- VH2-L3-VH1-L4-CL; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc; VH1-VH2-VL2-VL1-CH1-Fc;VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc; VL1-VL2-VH2-VH1-CH1-CL-Fc;VH1-VH2-VL2-VL1-CH1-CL-Fc; VL1-VL2-VH2-VH1-CL-CH1-Fc;VH1-VH2-VL2-VL1-CL-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1-CH1-Fc andthe second polypeptide has a structure represented by Fc;VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1;VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fe; VH1-VH2-VL2-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc;VL1-VL2-VH2-VH1-CH1; VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL;VH1-VH2-VL2-VL1-CL; VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL;VL1-VL2-VH2-VH1-CL-CH1; VH1-VH2-VL2-VL1-CL-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL; VH1- L1-VH2-L2-VL2-L3-VL1-L4-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL- L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-CL-Fc and thesecond polypeptide has a structure represented by Fc; VL1-VL2-VH2-VH1;VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1;VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3- VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1-CL-Fc and thesecond polypeptide has a structure represented by Fc; VL1-VL2-VH2-VH1;VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1;VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3- VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-CH1-CL-Fc andthe second polypeptide has a structure represented by Fc;VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1;VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc;VL1-VL2-VH2-VH1-CH1; VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL;VH1-VH2-VL2-VL1-CL; VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL;VL1-VL2-VH2-VH1-CL-CH1; VH1-VH2-VL2-VL1-CL-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1;VL1-L1-VL2-L2- VH2-L3-VH1-L4-CL; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc; VH1-VH2-VL2-VL1-CH1-Fc;VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc; VL1-VL2-VH2-VH1-CH1-CL-Fc;VH1-VH2-VL2-VL1-CH1-CL-Fc; VL1-VL2-VH2-VH1-CL-CH1-Fc;VH1-VH2-VL2-VL1-CL-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1-CH1-CL-Fc andthe second polypeptide has a structure represented by Fc;VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1;VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc;VL1-VL2-VH2-VH1-CH1; VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL;VH1-VH2-VL2-VL1-CL; VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL;VL1-VL2-VH2-VH1-CL-CH1; VH1-VH2-VL2-VL1-CL-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-CL-CH1-Fc andthe second polypeptide has a structure represented by Fc;VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1;VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc;VL1-VL2-VH2-VH1-CH1; VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL;VH1-VH2-VL2-VL1-CL; VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL;VL1-VL2-VH2-VH1-CL-CH1; VH1-VH2-VL2-VL1-CL-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL; VH1-L1-VH2- L2-VL2-L3-VL1-L4-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1-CL-CH1-Fc andthe second polypeptide has a structure represented by Fc;VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1;VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc;VL1-VL2-VH2-VH1-CH1; VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL;VH1-VH2-VL2-VL1-CL; VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL;VL1-VL2-VH2-VH1-CL-CH1; VH1-VH2-VL2-VL1-CL-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3- VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc and the second polypeptide has astructure represented by Fc; VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1;VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fc;VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2- L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1;VL1-VL2-VH2-VH1-CH1-Fc; VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc;VH1-VH2-VL2-VL1-CL-Fc; VL1-VL2-VH2-VH1-CH1-CL-Fc;VH1-VH2-VL2-VL1-CH1-CL-Fc; VL1-VL2-VH2-VH1-CL-CH1-Fc;VH1-VH2-VL2-VL1-CL-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc and the second polypeptide has astructure represented by Fc; VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1;VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fc;VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3- VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc and the second polypeptide has astructure represented by Fc; VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1;VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fc;VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1- VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5- CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc and the second polypeptide has astructure represented by Fc; VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1;VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fc;VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4- Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc; VH1-VH2-VL2-VL1-CH1-Fc;VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc; VL1-VL2-VH2-VH1-CH1-CL-Fc;VH1-VH2-VL2-VL1-CH1-CL-Fc; VL1-VL2-VH2-VH1-CL-CH1-Fc;VH1-VH2-VL2-VL1-CL-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc and the second polypeptide hasa structure represented by Fc; VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1;VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fc;VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2- VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc; VH1-VH2-VL2-VL1-CH1-Fc;VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc; VL1-VL2-VH2-VH1-CH1-CL-Fc;VH1-VH2-VL2-VL1-CH1-CL-Fc; VL1-VL2-VH2-VH1-CL-CH1-Fc;VH1-VH2-VL2-VL1-CL-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc and the second polypeptide hasa structure represented by Fc; VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1;VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fc;VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2- VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc; VH1-VH2-VL2-VL1-CH1-Fc;VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc; VL1-VL2-VH2-VH1-CH1-CL-Fc;VH1-VH2-VL2-VL1-CH1-CL-Fc; VL1-VL2-VH2-VH1-CL-CH1-Fc;VH1-VH2-VL2-VL1-CL-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc and the second polypeptide hasa structure represented by Fc; VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1;VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fc;VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2- VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc; VH1-VH2-VL2-VL1-CH1-Fc;VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc; VL1-VL2-VH2-VH1-CH1-CL-Fc;VH1-VH2-VL2-VL1-CH1-CL-Fc; VL1-VL2-VH2-VH1-CL-CH1-Fc;VH1-VH2-VL2-VL1-CL-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc and the second polypeptide hasa structure represented by Fc; VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1;VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fc;VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2- VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc; VH1-VH2-VL2-VL1-CH1-Fc;VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc; VL1-VL2-VH2-VH1-CH1-CL-Fc;VH1-VH2-VL2-VL1-CH1-CL-Fc; VL1-VL2-VH2-VH1-CL-CH1-Fc;VH1-VH2-VL2-VL1-CL-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc. The VL1, VL2, VH1, and/or VH2may specifically bind to A2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS,BTK, BTLA, B7DC, B7H1, B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4,C3, C5, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19,CCL20, CCL21, CCL25 CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27,CD28, CD30, CD38, CD39, CD40, CD40L, CD47, CD52, CD70, CD80, CD86,CD123, CD133, CD137, CD137L, CD160, CD272, CEACAM5, CLEC9, CLEC91,CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12, CXCL13, CXCR3,cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin, EGFR, ENTPD1, EpCAM, FCER1,FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24, GITR, GITRL, GPR5, GP100,GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1, HVEM, IDO, IFNa, IgE,IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R,IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O, IL12, IL13, IL13Ra1,IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23, IL25, IL7, IL33, IL35,ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II, MUC-1,MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L, PD-1, PD-L1,PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1, STEAP2,Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3, TLR,TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP, TSLPR,TWEAK, VEGF, VISTA, Vstm3, or WUCAM. For the avoidance of doubt, all theantigen binding polypeptide complex structures described herein can becombined with any one or more of the targets described herein. Any andall disclosure herein in relation to targets for antigen bindingpolypeptides of the invention is generally applicable, and appliesequally and without reservation to each and every antigen bindingpolypeptide and antigen binding polypeptide complex described herein.For the avoidance of doubt, the VL1, VL2, VH1, and/or VH2 of each andevery antigen binding polypeptide and antigen binding polypeptidecomplex described herein may independently bind to any one of saidparticularly preferred targets. Any and all disclosure herein inrelation to targets for antigen binding polypeptides of the invention isgenerally applicable, and applies equally and without reservation toeach and every antigen binding polypeptide and antigen bindingpolypeptide complex described herein. For the avoidance of doubt, theVL1, VL2, VH1, and/or VH2 of each and every antigen binding polypeptideand antigen binding polypeptide complex described herein mayindependently bind to any one of said particularly preferred targets.

In other aspects, the invention is directed to an antigen bindingpolypeptide or antigen binding polypeptide complex comprising apolypeptide having a structure represented by VL1-VL2-VH2-VH1-CH3;VH1-VH2-VL2-VL1-CH3; VL1-L1-VL2-L2-VH2-L3-VH1-CH3;VH1-L1-VH2-L2-VL2-L3-VL1-CH3; VL1-L1-VL2-L2- VH2-L3-VH1-L4-CH3;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH3; VL1-VL2-VH2-VH1-CH3-CH3;VH1-VH2-VL2-VL1-CH3-CH3; VL1-L1-VL2-L2-VH2-L3-VH1-CH3-CH3;VH1-L1-VH2-L2-VL2-L3-VL1-CH3-CH3; VL1-L1-VL2- L2-VH2-L3-VH1-L4-CH3-CH3;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH3-CH3;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH3-L5-CH3; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CH3-L5-CH3; wherein VL1 is a firstimmunoglobulin light chain variable region that specifically binds toA2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1,B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3,CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19, CCL20, CCL21, CCL25CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27, CD28, CD30, CD38, CD39,CD40, CD40L, CD47, CD52, CD70, CD80, CD86, CD123, CD133, CD137, CD137L,CD160, CD272, CEACAM5, CLEC9, CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1,CXCL2, CXCL4, CXCL12, CXCL13, CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1,E-cadherin, EGFR, ENTPD1, EpCAM, FCER1, FCER1A, FCER2, FGFR, FLAP,FOLH1, Gi24, GITR, GITRL, GPR5, GP100, GPRC5D, HER2, HER3, ICOSL, ICOS,HHLA2, HMGB1, HVEM, IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1, ILIA, IL1B,IL1F10, IL2, IL4, IL4Ra, IL5, IL5R, IL6, IL7Ra, IL8, IL9, IL9R, IL10,rhIL1O, IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22,IL23, IL25, IL7, IL33, IL35, ITGB4, ITK, KIR, LAG3, LAMP1, leptin,LPFS2, MHC class II, MUC-1, MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1,OX40, OX40L, PD-1, PD-L1, PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC,SPG64, ST2, STEAP1, STEAP2, Syk kinase, STEAP1, TROP2, TACI, TDO,TGFBETA, T14, TIGIT, TIM3, TLR, TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa,TNFRSF7, Tp55, TREM1, TSLP, TSLPR, TWEAK, VEGF, VISTA, Vstm3, or WUCAM;VL2 is a second immunoglobulin light chain variable region thatspecifically binds to A2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS,BTK, BTLA, B7DC, B7H1, B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4,C3, C5, CCL2, CCL3, CCL4, CCLS, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19,CCL20, CCL21, CCL25 CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27,CD28, CD30, CD38, CD39, CD40, CD40L, CD47, CD52, CD70, CD80, CD86,CD123, CD133, CD137, CD137L, CD160, CD272, CEACAM5, CLEC9, CLEC91,CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12, CXCL13, CXCR3,cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin, EGFR, ENTPD1, EpCAM, FCER1,FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24, GITR, GITRL, GPR5, GP100,GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1, HVEM, IDO, IFNa, IgE,IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R,IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O, IL12, IL13, IL13Ra1,IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23, IL25, IL7, IL33, IL35,ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II, MUC-1,MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L, PD-1, PD-L1,PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1, STEAP2,Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3, TLR,TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP, TSLPR,TWEAK, VEGF, VISTA, Vstm3, or WUCAM; VH1 is a first immunoglobulin heavychain variable region that specifically binds to A2AR, APRIL, ATPDase,BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1, B7H2, B7H3, B7H4, B7H5,B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3, CCL4, CCLS, CCL7, CCL8,CCL11, CCL15, CCL17, CCL19, CCL20, CCL21, CCL25 CCR3, CCR4, CD3, CD16A,CD19, CD20, CD24, CD27, CD28, CD30, CD38, CD39, CD40, CD40L, CD47, CD52,CD70, CD80, CD86, CD123, CD133, CD137, CD137L, CD160, CD272, CEACAM5,CLEC9, CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12,CXCL13, CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin, EGFR,ENTPD1, EpCAM, FCER1, FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24, GITR,GITRL, GPR5, GP100, GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1, HVEM,IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2, IL4,IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL9, IL9R, IL10, rhIL1O, IL12, IL13,IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23, IL25, IL7, IL33,IL35, ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II, MUC-1,MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L, PD-1, PD-L1,PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1, STEAP2,Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3, TLR,TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP, TSLPR,TWEAK, VEGF, VISTA, Vstm3, or WUCAM; VH2 is a second immunoglobulinheavy chain variable region that specifically binds to A2AR, APRIL,ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1, B7H2, B7H3,B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3, CCL4, CCL5,CCL7, CCL8, CCL11, CCL15, CCL17, CCL19, CCL20, CCL21, CCL25 CCR3, CCR4,CD3, CD16A, CD19, CD20, CD24, CD27, CD28, CD30, CD38, CD39, CD40, CD40L,CD47, CD52, CD70, CD80, CD86, CD123, CD133, CD137, CD137L, CD160, CD272,CEACAM5, CLEC9, CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4,CXCL12, CXCL13, CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin,EGFR, ENTPD1, EpCAM, FCER1, FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24,GITR, GITRL, GPR5, GP100, GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1,HVEM, IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2,IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O,IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23,IL25, IL7, IL33, IL35, ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHCclass II, MUC-1, MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L,PD-1, PD-L1, PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2,STEAP1, STEAP2, Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14,TIGIT, TIM3, TLR, TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55,TREM1, TSLP, TSLPR, TWEAK, VEGF, VISTA, Vstm3, or WUCAM; CH3 is animmunoglobulin heavy chain constant region 3; and L1, L2, L3, L4 and L5are amino acid linkers. In other aspects, the invention is directed toan antigen binding polypeptide or antigen binding polypeptide complexcomprising a polypeptide having the structure represented byVL1-VL2-VH2-VH1-CH3, wherein VL1, VL2, VH1 and/or VH2 specifically bindsto A2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1,B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3,CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19, CCL20, CCL21, CCL25CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27, CD28, CD30, CD38, CD39,CD40, CD40L, CD47, CD52, CD70, CD80, CD86, CD123, CD133, CD137, CD137L,CD160, CD272, CEACAM5, CLEC9, CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1,CXCL2, CXCL4, CXCL12, CXCL13, CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1,E-cadherin, EGFR, ENTPD1, EpCAM, FCER1, FCER1A, FCER2, FGFR, FLAP,FOLH1, Gi24, GITR, GITRL, GPR5, GP100, GPRC5D, HER2, HER3, ICOSL, ICOS,HHLA2, HMGB1, HVEM, IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1, ILIA, IL1B,IL1F10, IL2, IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8, IL9, IL9R,IL10, rhIL1O, IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb, IL18,IL22, IL23, IL25, IL7, IL33, IL35, ITGB4, ITK, KIR, LAG3, LAMP1, leptin,LPFS2, MHC class II, MUC-1, MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1,OX40, OX40L, PD-1, PD-L1, PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC,SPG64, ST2, STEAP1, STEAP2, Syk kinase, STEAP1, TROP2, TACI, TDO,TGFBETA, T14, TIGIT, TIM3, TLR, TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa,TNFRSF7, Tp55, TREM1, TSLP, TSLPR, TWEAK, VEGF, VISTA, Vstm3, or WUCAM.In other aspects, the invention is directed to an antigen bindingpolypeptide or antigen binding polypeptide complex comprising apolypeptide having the structure represented by VH1-VH2-VL2-VL1-CH3,wherein VL1, VL2, VH1 and/or VH2 specifically binds to A2AR, APRIL,ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1, B7H2, B7H3,B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3, CCL4, CCL5,CCL7, CCL8, CCL11, CCL15, CCL17, CCL19, CCL20, CCL21, CCL25 CCR3, CCR4,CD3, CD16A, CD19, CD20, CD24, CD27, CD28, CD30, CD38, CD39, CD40, CD40L,CD47, CD52, CD70, CD80, CD86, CD123, CD133, CD137, CD137L, CD160, CD272,CEACAM5, CLEC9, CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4,CXCL12, CXCL13, CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin,EGFR, ENTPD1, EpCAM, FCER1, FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24,GITR, GITRL, GPR5, GP100, GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1,HVEM, IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2,IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O,IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23,IL25, IL7, IL33, IL35, ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHCclass II, MUC-1, MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L,PD-1, PD-L1, PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2,STEAP1, STEAP2, Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14,TIGIT, TIM3, TLR, TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55,TREM1, TSLP, TSLPR, TWEAK, VEGF, VISTA, Vstm3, or WUCAM. In otheraspects, the invention is directed to an antigen binding polypeptide orantigen binding polypeptide complex comprising a polypeptide having thestructure represented by VL1-L1-VL2-L2-VH2-L3-VH1-CH3, wherein VL1, VL2,VH1 and/or VH2 specifically binds to A2AR, APRIL, ATPDase, BAFF, BAFFR,BCMA, BlyS, BTK, BTLA, B7DC, B7H1, B7H2, B7H3, B7H4, B7H5, B7H6, B7H7,B7RP1, B7-4, C3, C5, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL11, CCL15,CCL17, CCL19, CCL20, CCL21, CCL25 CCR3, CCR4, CD3, CD16A, CD19, CD20,CD24, CD27, CD28, CD30, CD38, CD39, CD40, CD40L, CD47, CD52, CD70, CD80,CD86, CD123, CD133, CD137, CD137L, CD160, CD272, CEACAM5, CLEC9, CLEC91,CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12, CXCL13, CXCR3,cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin, EGFR, ENTPD1, EpCAM, FCER1,FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24, GITR, GITRL, GPR5, GP100,GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1, HVEM, IDO, IFNa, IgE,IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R,IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O, IL12, IL13, IL13Ra1,IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23, IL25, IL7, IL33, IL35,ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II, MUC-1,MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L, PD-1, PD-L1,PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1, STEAP2,Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3, TLR,TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP, TSLPR,TWEAK, VEGF, VISTA, Vstm3, or WUCAM. In other aspects, the invention isdirected to an antigen binding polypeptide or antigen bindingpolypeptide complex comprising a polypeptide having the structurerepresented by VH1-L1-VH2-L2-VL2-L3-VL1-CH3, wherein VL1, VL2, VH1and/or VH2 specifically binds to A2AR, APRIL, ATPDase, BAFF, BAFFR,BCMA, BlyS, BTK, BTLA, B7DC, B7H1, B7H2, B7H3, B7H4, B7H5, B7H6, B7H7,B7RP1, B7-4, C3, C5, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL11, CCL15,CCL17, CCL19, CCL20, CCL21, CCL25 CCR3, CCR4, CD3, CD16A, CD19, CD20,CD24, CD27, CD28, CD30, CD38, CD39, CD40, CD40L, CD47, CD52, CD70, CD80,CD86, CD123, CD133, CD137, CD137L, CD160, CD272, CEACAM5, CLEC9, CLEC91,CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12, CXCL13, CXCR3,cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin, EGFR, ENTPD1, EpCAM, FCER1,FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24, GITR, GITRL, GPR5, GP100,GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1, HVEM, IDO, IFNa, IgE,IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R,IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O, IL12, IL13, IL13Ra1,IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23, IL25, IL7, IL33, IL35,ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II, MUC-1,MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L, PD-1, PD-L1,PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1, STEAP2,Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3, TLR,TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP, TSLPR,TWEAK, VEGF, VISTA, Vstm3, or WUCAM. In other aspects, the invention isdirected to an antigen binding polypeptide or antigen bindingpolypeptide complex comprising a polypeptide having the structurerepresented by VII-L1-VL2-L2-VH2-L3-VH1-L4-CH3, wherein VL1, VL2, VH1and/or VH2 specifically binds to A2AR, APRIL, ATPDase, BAFF, BAFFR,BCMA, BlyS, BTK, BTLA, B7DC, B7H1, B7H2, B7H3, B7H4, B7H5, B7H6, B7H7,B7RP1, B7-4, C3, C5, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL11, CCL15,CCL17, CCL19, CCL20, CCL21, CCL25 CCR3, CCR4, CD3, CD16A, CD19, CD20,CD24, CD27, CD28, CD30, CD38, CD39, CD40, CD40L, CD47, CD52, CD70, CD80,CD86, CD123, CD133, CD137, CD137L, CD160, CD272, CEACAM5, CLEC9, CLEC91,CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12, CXCL13, CXCR3,cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin, EGFR, ENTPD1, EpCAM, FCER1,FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24, GITR, GITRL, GPR5, GP100,GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1, HVEM, IDO, IFNa, IgE,IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R,IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O, IL12, IL13, IL13Ra1,IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23, IL25, IL7, IL33, IL35,ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II, MUC-1,MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L, PD-1, PD-L1,PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1, STEAP2,Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3, TLR,TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP, TSLPR,TWEAK, VEGF, VISTA, Vstm3, or WUCAM. In other aspects, the invention isdirected to an antigen binding polypeptide or antigen bindingpolypeptide complex comprising a polypeptide having the structurerepresented by VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH3, wherein VL1, VL2, VH1and/or VH2 specifically binds to A2AR, APRIL, ATPDase, BAFF, BAFFR,BCMA, BlyS, BTK, BTLA, B7DC, B7H1, B7H2, B7H3, B7H4, B7H5, B7H6, B7H7,B7RP1, B7-4, C3, C5, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL11, CCL15,CCL17, CCL19, CCL20, CCL21, CCL25 CCR3, CCR4, CD3, CD16A, CD19, CD20,CD24, CD27, CD28, CD30, CD38, CD39, CD40, CD40L, CD47, CD52, CD70, CD80,CD86, CD123, CD133, CD137, CD137L, CD160, CD272, CEACAM5, CLEC9, CLEC91,CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12, CXCL13, CXCR3,cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin, EGFR, ENTPD1, EpCAM, FCER1,FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24, GITR, GITRL, GPR5, GP100,GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1, HVEM, IDO, IFNa, IgE,IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R,IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O, IL12, IL13, IL13Ra1,IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23, IL25, IL7, IL33, IL35,ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II, MUC-1,MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L, PD-1, PD-L1,PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1, STEAP2,Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3, TLR,TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP, TSLPR,TWEAK, VEGF, VISTA, Vstm3, or WUCAM. In other aspects, the invention isdirected to an antigen binding polypeptide or antigen bindingpolypeptide complex comprising a polypeptide having the structurerepresented by VL1-VL2-VH2-VH1-CH3-CH3, wherein VL1, VL2, VH1 and/or VH2specifically binds to A2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS,BTK, BTLA, B7DC, B7H1, B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4,C3, C5, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19,CCL20, CCL21, CCL25 CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27,CD28, CD30, CD38, CD39, CD40, CD40L, CD47, CD52, CD70, CD80, CD86,CD123, CD133, CD137, CD137L, CD160, CD272, CEACAM5, CLEC9, CLEC91,CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12, CXCL13, CXCR3,cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin, EGFR, ENTPD1, EpCAM, FCER1,FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24, GITR, GITRL, GPR5, GP100,GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1, HVEM, IDO, IFNa, IgE,IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R,IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O, IL12, IL13, IL13Ra1,IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23, IL25, IL7, IL33, IL35,ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II, MUC-1,MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L, PD-1, PD-L1,PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1, STEAP2,Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3, TLR,TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP, TSLPR,TWEAK, VEGF, VISTA, Vstm3, or WUCAM. In other aspects, the invention isdirected to an antigen binding polypeptide or antigen bindingpolypeptide complex comprising a polypeptide having the structurerepresented by VH1-VH2-VL2-VL1-CH3-CH3, wherein VL1, VL2, VH1 and/or VH2specifically binds to A2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS,BTK, BTLA, B7DC, B7H1, B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4,C3, C5, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19,CCL20, CCL21, CCL25 CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27,CD28, CD30, CD38, CD39, CD40, CD40L, CD47, CD52, CD70, CD80, CD86,CD123, CD133, CD137, CD137L, CD160, CD272, CEACAM5, CLEC9, CLEC91,CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12, CXCL13, CXCR3,cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin, EGFR, ENTPD1, EpCAM, FCER1,FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24, GITR, GITRL, GPR5, GP100,GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1, HVEM, IDO, IFNa, IgE,IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R,IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O, IL12, IL13, IL13Ra1,IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23, IL25, IL7, IL33, IL35,ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II, MUC-1,MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L, PD-1, PD-L1,PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1, STEAP2,Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3, TLR,TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP, TSLPR,TWEAK, VEGF, VISTA, Vstm3, or WUCAM. In other aspects, the invention isdirected to an antigen binding polypeptide or antigen bindingpolypeptide complex comprising a polypeptide having the structurerepresented by VL1-L1-VL2-L2-VH2-L3-VH1-CH3-CH3, wherein VL1, VL2, VH1and/or VH2 specifically binds to A2AR, APRIL, ATPDase, BAFF, BAFFR,BCMA, BlyS, BTK, BTLA, B7DC, B7H1, B7H2, B7H3, B7H4, B7H5, B7H6, B7H7,B7RP1, B7-4, C3, C5, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL11, CCL15,CCL17, CCL19, CCL20, CCL21, CCL25 CCR3, CCR4, CD3, CD16A, CD19, CD20,CD24, CD27, CD28, CD30, CD38, CD39, CD40, CD40L, CD47, CD52, CD70, CD80,CD86, CD123, CD133, CD137, CD137L, CD160, CD272, CEACAM5, CLEC9, CLEC91,CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12, CXCL13, CXCR3,cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin, EGFR, ENTPD1, EpCAM, FCER1,FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24, GITR, GITRL, GPR5, GP100,GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1, HVEM, IDO, IFNa, IgE,IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R,IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O, IL12, IL13, IL13Ra1,IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23, IL25, IL7, IL33, IL35,ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II, MUC-1,MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L, PD-1, PD-L1,PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1, STEAP2,Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3, TLR,TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP, TSLPR,TWEAK, VEGF, VISTA, Vstm3, or WUCAM. In other aspects, the invention isdirected to an antigen binding polypeptide or antigen bindingpolypeptide complex comprising a polypeptide having the structurerepresented by VH1-L1-VH2-L2-VL2-L3-VL1-CH3-CH3, wherein VL1, VL2, VH1and/or VH2 specifically binds to A2AR, APRIL, ATPDase, BAFF, BAFFR,BCMA, BlyS, BTK, BTLA, B7DC, B7H1, B7H2, B7H3, B7H4, B7H5, B7H6, B7H7,B7RP1, B7-4, C3, C5, CCL2, CCL3, CCL4, CCLS, CCL7, CCL8, CCL11, CCL15,CCL17, CCL19, CCL20, CCL21, CCL25 CCR3, CCR4, CD3, CD16A, CD19, CD20,CD24, CD27, CD28, CD30, CD38, CD39, CD40, CD40L, CD47, CD52, CD70, CD80,CD86, CD123, CD133, CD137, CD137L, CD160, CD272, CEACAM5, CLEC9, CLEC91,CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12, CXCL13, CXCR3,cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin, EGFR, ENTPD1, EpCAM, FCER1,FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24, GITR, GITRL, GPR5, GP100,GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1, HVEM, IDO, IFNa, IgE,IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R,IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O, IL12, IL13, IL13Ra1,IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23, IL25, IL7, IL33, IL35,ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II, MUC-1,MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L, PD-1, PD-L1,PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1, STEAP2,Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3, TLR,TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP, TSLPR,TWEAK, VEGF, VISTA, Vstm3, or WUCAM. In other aspects, the invention isdirected to an antigen binding polypeptide or antigen bindingpolypeptide complex comprising a polypeptide having the structurerepresented by VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH3-CH3, wherein VL1, VL2,VH1 and/or VH2 specifically binds to A2AR, APRIL, ATPDase, BAFF, BAFFR,BCMA, BlyS, BTK, BTLA, B7DC, B7H1, B7H2, B7H3, B7H4, B7H5, B7H6, B7H7,B7RP1, B7-4, C3, C5, CCL2, CCL3, CCL4, CCLS, CCL7, CCL8, CCL11, CCL15,CCL17, CCL19, CCL20, CCL21, CCL25 CCR3, CCR4, CD3, CD16A, CD19, CD20,CD24, CD27, CD28, CD30, CD38, CD39, CD40, CD40L, CD47, CD52, CD70, CD80,CD86, CD123, CD133, CD137, CD137L, CD160, CD272, CEACAM5, CLEC9, CLEC91,CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12, CXCL13, CXCR3,cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin, EGFR, ENTPD1, EpCAM, FCER1,FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24, GITR, GITRL, GPR5, GP100,GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1, HVEM, IDO, IFNa, IgE,IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R,IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O, IL12, IL13, IL13Ra1,IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23, IL25, IL7, IL33, IL35,ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II, MUC-1,MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L, PD-1, PD-L1,PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1, STEAP2,Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3, TLR,TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP, TSLPR,TWEAK, VEGF, VISTA, Vstm3, or WUCAM. In other aspects, the invention isdirected to an antigen binding polypeptide or antigen bindingpolypeptide complex comprising a polypeptide having the structurerepresented by VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH3-CH3, wherein VL1, VL2,VH1 and/or VH2 specifically binds to A2AR, APRIL, ATPDase, BAFF, BAFFR,BCMA, BlyS, BTK, BTLA, B7DC, B7H1, B7H2, B7H3, B7H4, B7H5, B7H6, B7H7,B7RP1, B7-4, C3, C5, CCL2, CCL3, CCL4, CCLS, CCL7, CCL8, CCL11, CCL15,CCL17, CCL19, CCL20, CCL21, CCL25 CCR3, CCR4, CD3, CD16A, CD19, CD20,CD24, CD27, CD28, CD30, CD38, CD39, CD40, CD40L, CD47, CD52, CD70, CD80,CD86, CD123, CD133, CD137, CD137L, CD160, CD272, CEACAM5, CLEC9, CLEC91,CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12, CXCL13, CXCR3,cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin, EGFR, ENTPD1, EpCAM, FCER1,FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24, GITR, GITRL, GPRS, GP100,GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1, HVEM, IDO, IFNa, IgE,IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R,IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O, IL12, IL13, IL13Ra1,IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23, IL25, IL7, IL33, IL35,ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II, MUC-1,MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L, PD-1, PD-L1,PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1, STEAP2,Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3, TLR,TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP, TSLPR,TWEAK, VEGF, VISTA, Vstm3, or WUCAM. In other aspects, the invention isdirected to an antigen binding polypeptide or antigen bindingpolypeptide complex comprising a polypeptide having the structurerepresented by VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH3-L5-CH3, wherein VL1, VL2,VH1 and/or VH2 specifically binds to A2AR, APRIL, ATPDase, BAFF, BAFFR,BCMA, BlyS, BTK, BTLA, B7DC, B7H1, B7H2, B7H3, B7H4, B7H5, B7H6, B7H7,B7RP1, B7-4, C3, C5, CCL2, CCL3, CCL4, CCLS, CCL7, CCL8, CCL11, CCL15,CCL17, CCL19, CCL20, CCL21, CCL25 CCR3, CCR4, CD3, CD16A, CD19, CD20,CD24, CD27, CD28, CD30, CD38, CD39, CD40, CD40L, CD47, CD52, CD70, CD80,CD86, CD123, CD133, CD137, CD137L, CD160, CD272, CEACAM5, CLEC9, CLEC91,CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12, CXCL13, CXCR3,cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin, EGFR, ENTPD1, EpCAM, FCER1,FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24, GITR, GITRL, GPRS, GP100,GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1, HVEM, IDO, IFNa, IgE,IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R,IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O, IL12, IL13, IL13Ra1,IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23, IL25, IL7, IL33, IL35,ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II, MUC-1,MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L, PD-1, PD-L1,PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1, STEAP2,Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3, TLR,TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP, TSLPR,TWEAK, VEGF, VISTA, Vstm3, or WUCAM. In other aspects, the invention isdirected to an antigen binding polypeptide or antigen bindingpolypeptide complex comprising a polypeptide having the structurerepresented by VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH3-L5-CH3, wherein VL1, VL2,VH1 and/or VH2 specifically binds to A2AR, APRIL, ATPDase, BAFF, BAFFR,BCMA, BlyS, BTK, BTLA, B7DC, B7H1, B7H2, B7H3, B7H4, B7H5, B7H6, B7H7,B7RP1, B7-4, C3, C5, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL11, CCL15,CCL17, CCL19, CCL20, CCL21, CCL25 CCR3, CCR4, CD3, CD16A, CD19, CD20,CD24, CD27, CD28, CD30, CD38, CD39, CD40, CD40L, CD47, CD52, CD70, CD80,CD86, CD123, CD133, CD137, CD137L, CD160, CD272, CEACAM5, CLEC9, CLEC91,CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12, CXCL13, CXCR3,cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin, EGFR, ENTPD1, EpCAM, FCER1,FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24, GITR, GITRL, GPR5, GP100,GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1, HVEM, IDO, IFNa, IgE,IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R,IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O, IL12, IL13, IL13Ra1,IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23, IL25, IL7, IL33, IL35,ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II, MUC-1,MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L, PD-1, PD-L1,PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1, STEAP2,Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3, TLR,TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP, TSLPR,TWEAK, VEGF, VISTA, Vstm3, or WUCAM.

All the disclosures relating to the antigen binding polypeptidestructures described herein and the antigen binding polypeptide complexstructures described herein apply to and can be combined with all the VHand VL regions described herein including all the target antigensdescribed herein and all the VH and VL sequences and CDR sequencesdescribed herein.

In some aspects, the VH1 and VL1 of the antigen binding polypeptide orantigen binding polypeptide complex specifically bind to human CD28, andVH2 and VL2 specifically bind to human CD3. In another aspect, the VH1and VL1 of the antigen binding polypeptide or antigen bindingpolypeptide complex specifically bind to human CD3, and VH2 and VL2specifically bind to human CD28.

In some aspects, the VH1 and VL1 of the antigen binding polypeptide orantigen binding polypeptide complex specifically bind to human CD19, andVH2 and VL2 specifically bind to human CD38. In another aspect, the VH1and VL1 of the antigen binding polypeptide or antigen bindingpolypeptide complex specifically bind to human CD38, and VH2 and VL2specifically bind to human CD19.

In some aspects, the VH1 and VL1 of the antigen binding polypeptide orantigen binding polypeptide complex specifically bind to human CD3, andVH2 and VL2 specifically bind to human CD19. In another aspect, the VH1and VL1 of the antigen binding polypeptide or antigen bindingpolypeptide complex specifically bind to human CD19, and VH2 and VL2specifically bind to human CD3.

In some aspects, the VH1 and VL1 of the antigen binding polypeptide orantigen binding polypeptide complex specifically bind to human CD3, andVH2 and VL2 specifically bind to human CD38. In another aspect, the VH1and VL1 of the antigen binding polypeptide or antigen bindingpolypeptide complex specifically bind to human CD38, and VH2 and VL2specifically bind to human CD3.

In some aspects, the VH1 and VL1 of the antigen binding polypeptide orantigen binding polypeptide complex specifically bind to human CD19, andVH2 and VL2 specifically bind to human CD28. In another aspect, the VH1and VL1 of the antigen binding polypeptide or antigen bindingpolypeptide complex specifically bind to human CD28, and VH2 and VL2specifically bind to human CD19.

In some aspects, the VH1 and VL1 of the antigen binding polypeptide orantigen binding polypeptide complex specifically bind to human CD28, andVH2 and VL2 specifically bind to human CD38. In another aspect, the VH1and VL1 of the antigen binding polypeptide or antigen bindingpolypeptide complex specifically bind to human CD38, and VH2 and VL2specifically bind to human CD28.

In some aspects, the VH1 and VL1 of the antigen binding polypeptide orantigen binding polypeptide complex specifically bind to human CD3, andVH2 and VL2 specifically bind to human Her2. In another aspect, the VH1and VL1 of the antigen binding polypeptide or antigen bindingpolypeptide complex specifically bind to human Her2, and VH2 and VL2specifically bind to human CD3.

In some aspects, the VH1 and VL1 of the antigen binding polypeptide orantigen binding polypeptide complex specifically bind to human CD19, andVH2 and VL2 specifically bind to human CD20. In some aspects, the VH1and VL1 of the antigen binding polypeptide or antigen bindingpolypeptide complex specifically bind to human CD20, and VH2 and VL2specifically bind to human CD19.

In some aspects, the VH1 and VL1 of the antigen binding polypeptide orantigen binding polypeptide complex specifically bind to human Trop2,and VH2 and VL2 specifically bind to human cMet. In some aspects, theVH1 and VL1 of the antigen binding polypeptide or antigen bindingpolypeptide complex specifically bind to human cMet, and VH2 and VL2specifically bind to human Trop2.

Antigen binding sequences (e.g., CDR, VH, VL, heavy chain and lightchain sequences from antibodies) for A2AR, APRIL, ATPDase, BAFF, BAFFR,BCMA, BlyS, BTK, BTLA, B7DC, B7H1, B7H2, B7H3, B7H4, B7H5, B7H6, B7H7,B7RP1, B7-4, C3, C5, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL11, CCL15,CCL17, CCL19, CCL20, CCL21, CCL25 CCR3, CCR4, CD3, CD16A, CD19, CD20,CD24, CD27, CD28, CD30, CD38, CD39, CD40, CD40L, CD47, CD52, CD70, CD80,CD86, CD123, CD133, CD137, CD137L, CD160, CD272, CEACAM5, CLEC9, CLEC91,CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12, CXCL13, CXCR3,cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin, EGFR, ENTPD1, EpCAM, FCER1,FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24, GITR, GITRL, GPR5, GP100,GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1, HVEM, IDO, IFNa, IgE,IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R,IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O, IL12, IL13, IL13Ra1,IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23, IL25, IL7, IL33, IL35,ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II, MUC-1,MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L, PD-1, PD-L1,PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1, STEAP2,Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3, TLR,TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP, TSLPR,TWEAK, VEGF, VISTA, Vstm3, and WUCAM are well known. Such sequencesinclude, but are not limited to, GenBank Accession Nos. AAA39272.1,AAA39159.1, ABN79462.1, AVW80143.1, AVW80142.1, AVW80141.1, AAB34430.1,AAB34429.1, CAD45042.1, 4CMH_C and 4CMH_B, and UniProt IdentifiersP04626-1, P04626-2, P04626-3, P04626-4, P04626-4, P04626-5 andP-04626-6. Such sequences are also described, for example, in Wernly etal., Cells, 9(2):295, 2020; Arakawa et al., Journal of Biochemistry,120(3):657-662, 1996; Cole et al., Transplantation, 68(4):563-571, 1999;L1 et al., International Immunopharmacology, 62:299-308, 2018; Castellaet al., Methods & Clinical Development, 12:134-144, 2019; Sun et al.,Molecular Immunology, 41(9):929-938, 2004; Iwaszkiewicz-Grzes et al.,Cytotherapy, 22(11):629-641, 2020, Rosinski et al., Transplant Direct,1(2):e7, 2015; Ellis et al., J Immunology, 155(2):925-937, 1995;Stevenson et al., Blood, 77(5):1071-1079, 1991; Chillemi et al.,Molecular Medicine, 19:99-108, 2013, and Int'l Pub. No. WO 2020/076853.

In addition, molecular biology and recombinant DNA methods for making,screening and engineering antigen binding complexes and antibodiescontaining such sequences are well known and described, for example, inAdair et al. Human Antibodies, 5(1-2):41-47, 1994; Kostelny et al., JImmunol, 148(5):1547-1553 (1992), Shiraiwa et al., Methods, 154:10-20,2019; and Zola, “Monoclonal Antibodies: A Manual of Techniques,” 1987,1^(st) Ed., CRC Press; and Steinitz, Human Antibodies, 18(1-2):1-10,2009.

In some aspects, VH1 of the antigen binding polypeptide or antigenbinding polypeptide complex comprises an amino acid sequence having atleast 90% identity, at least 95% identity, or 100% identity to any oneof SEQ ID NOs:20-25 and 122; VH2 comprises an amino acid sequence havingat least 90% identity, at least 95% identity, or 100% identity to anyone of SEQ ID NOs:20-25 and 122; VL1 comprises an amino acid sequencehaving at least 90% identity, at least 95% identity, or 100% identity toany one of SEQ ID NOs:26-31 and 123; and/or VL2 comprises an amino acidsequence having at least 90% identity, at least 95% identity, or 100%identity to any one of SEQ ID NOs:26-31 and 123. For example, the VH1may comprise an amino acid sequence having at least 90% identity to anyone of SEQ ID NOs:20-25 and 122; VH2 may comprise an amino acid sequencehaving at least 90% identity to any one of SEQ ID NOs:20-25 and 122; VL1may comprise an amino acid sequence having at least 90% identity to anyone of SEQ ID NOs:26-31 and 123; and/or VL2 may comprise an amino acidsequence having at least 90% identity to any one of SEQ ID NOs:26-31 and123. At least 90% identity may include at least 91%, 92%, 93%, 94%, 95%,96%, 97%, 98%, 99% or 100% identity to the reference polypeptidesequence. For example, the VH1 may comprise the amino acid sequence ofany one of SEQ ID NOs:20-25 and 122; VH2 may comprise the amino acidsequence of any one of SEQ ID NOs:20-25 and 122; VL1 may comprise theamino acid sequence of any one of SEQ ID NOs:26-31 and 123; and/or VL2may comprise the amino acid sequence of any one of SEQ ID NOs:26-31 and123.

In some aspects, VH1 comprises a CDR1 comprising SEQ ID NO:98 or asequence having at least 90% identity or at least 95% identity to SEQ IDNO:98; a CDR2 comprising SEQ ID NO:99 or a sequence having at least 90%identity or at least 95% identity to SEQ ID NO:99; and a CDR3 comprisingSEQ ID NO:100 or a sequence having at least 90% identity or at least 95%identity to SEQ ID NO:100; and VL1 comprises a CDR1 comprising SEQ IDNO:101 or a sequence having at least 90% identity or at least 95%identity to SEQ ID NO:101, a CDR2 comprising SEQ ID NO:102 or a sequencehaving at least 90% identity or 95% identity to SEQ ID NO:102, and aCDR3 comprising SEQ ID NO:103 or a sequence having at least 90% identityor at least 95% identity to SEQ ID NO:103. For example, the VH1 maycomprise a CDR1 comprising a sequence having at least 90% identity toSEQ ID NO: 98, a CDR2 comprising a sequence having at least 90% identityto SEQ ID NO: 99, and a CDR3 comprising a sequence having at least 90%identity to SEQ ID NO: 100; and the VL1 may comprise a CDR1 comprising asequence having at least 90% identity to SEQ ID NO: 101, a CDR2comprising a sequence having at least 90% identity to SEQ ID NO: 102 anda CDR3 comprising a sequence having at least 90% identity to SEQ ID NO:103. At least 90% identity may include at least 91%, 92%, 93%, 94%, 95%,96%, 97%, 98%, 99% or 100% identity to the reference polypeptidesequence. For example, the VH1 may comprise a CDR1 comprising SEQ ID NO:98, a CDR2 comprising SEQ ID NO: 99, and a CDR3 comprising SEQ ID NO:100; and the VL1 may comprise a CDR1 comprising SEQ ID NO: 101, a CDR2comprising SEQ ID NO: 102 and a CDR3 comprising SEQ ID NO: 103.

In some aspects, VH2 comprises a CDR1 comprising SEQ ID NO:98 or asequence having at least 90% or at least 95% identity to SEQ ID NO:98; aCDR2 comprising SEQ ID NO:99 or a sequence having at least 90% identityor at least 95% identity to SEQ ID NO:99; and a CDR3 comprising SEQ IDNO:100 or a sequence having at least 90% identity or at least 95%identity to SEQ ID NO:100; and VL2 comprises a CDR1 comprising SEQ IDNO:101 or a sequence having at least 90% identity or at least 95%identity to SEQ ID NO:101, a CDR2 comprising SEQ ID NO:102 or a sequencehaving at least 90% identity or 95% identity to SEQ ID NO:102, and aCDR3 comprising SEQ ID NO:103 or a sequence having at least 90% identityor at least 95% identity to SEQ ID NO:103. For example, the VH2 maycomprise a CDR1 comprising a sequence having at least 90% identity toSEQ ID NO: 98, a CDR2 comprising a sequence having at least 90% identityto SEQ ID NO: 99, and a CDR3 comprising a sequence having at least 90%identity to SEQ ID NO: 100; and the VL2 may comprise a CDR1 comprising asequence having at least 90% identity to SEQ ID NO: 101, a CDR2comprising a sequence having at least 90% identity to SEQ ID NO: 102 anda CDR3 comprising a sequence having at least 90% identity to SEQ ID NO:103. At least 90% identity may include at least 91%, 92%, 93%, 94%, 95%,96%, 97%, 98%, 99% or 100% identity to the reference polypeptidesequence. For example, the VH2 may comprise a CDR1 comprising SEQ ID NO:98, a CDR2 comprising SEQ ID NO: 99, and a CDR3 comprising SEQ ID NO:100; and the VL2 may comprise a CDR1 comprising SEQ ID NO: 101, a CDR2comprising SEQ ID NO: 102 and a CDR3 comprising SEQ ID NO: 103.

In some aspects, VH1 comprises a CDR1 comprising SEQ ID NO:104 or asequence having at least 90% identity or at least 95% identity to SEQ IDNO:104; a CDR2 comprising SEQ ID NO:105 or a sequence having at least90% identity or at least 95% identity to SEQ ID NO:105; and a CDR3comprising SEQ ID NO:106 or a sequence having at least 90% identity orat least 95% identity to SEQ ID NO:106; and VL1 comprises a CDR1comprising SEQ ID NO:107 or a sequence having at least 90% identity orat least 95% identity to SEQ ID NO:107, a CDR2 comprising SEQ ID NO:108or a sequence having at least 90% identity or 95% identity to SEQ IDNO:108, and a CDR3 comprising SEQ ID NO:109 or a sequence having atleast 90% identity or at least 95% identity to SEQ ID NO:109. Forexample, the VH1 may comprise a CDR1 comprising a sequence having atleast 90% identity to SEQ ID NO: 104, a CDR2 comprising a sequencehaving at least 90% identity to SEQ ID NO: 105, and a CDR3 comprising asequence having at least 90% identity to SEQ ID NO: 106; and the VL1 maycomprise a CDR1 comprising a sequence having at least 90% identity toSEQ ID NO: 107, a CDR2 comprising a sequence having at least 90%identity to SEQ ID NO: 108 and a CDR3 comprising a sequence having atleast 90% identity to SEQ ID NO: 109. At least 90% identity may includeat least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity tothe reference polypeptide sequence. For example, the VH1 may comprise aCDR1 comprising SEQ ID NO: 104, a CDR2 comprising SEQ ID NO: 105, and aCDR3 comprising SEQ ID NO: 106; and the VL1 may comprise a CDR1comprising SEQ ID NO: 107, a CDR2 comprising SEQ ID NO: 108 and a CDR3comprising SEQ ID NO: 109.

In some aspects, VH2 comprises a CDR1 comprising SEQ ID NO:104 or asequence having at least 90% or at least 95% identity to SEQ ID NO:104;a CDR2 comprising SEQ ID NO:105 or a sequence having at least 90%identity or at least 95% identity to SEQ ID NO:105; and a CDR3comprising SEQ ID NO:106 or a sequence having at least 90% identity orat least 95% identity to SEQ ID NO:106; and VL2 comprises a CDR1comprising SEQ ID NO:107 or a sequence having at least 90% identity orat least 95% identity to SEQ ID NO:107, a CDR2 comprising SEQ ID NO:108or a sequence having at least 90% identity or 95% identity to SEQ IDNO:108, and a CDR3 comprising SEQ ID NO:109 or a sequence having atleast 90% identity or at least 95% identity to SEQ ID NO:109. Forexample, the VH2 may comprise a CDR1 comprising a sequence having atleast 90% identity to SEQ ID NO: 104, a CDR2 comprising a sequencehaving at least 90% identity to SEQ ID NO: 105, and a CDR3 comprising asequence having at least 90% identity to SEQ ID NO: 106; and the VL2 maycomprise a CDR1 comprising a sequence having at least 90% identity toSEQ ID NO: 107, a CDR2 comprising a sequence having at least 90%identity to SEQ ID NO: 108 and a CDR3 comprising a sequence having atleast 90% identity to SEQ ID NO: 109. At least 90% identity may includeat least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity tothe reference polypeptide sequence. For example, the VH2 may comprise aCDR1 comprising SEQ ID NO: 104, a CDR2 comprising SEQ ID NO: 105, and aCDR3 comprising SEQ ID NO: 106; and the VL2 may comprise a CDR1comprising SEQ ID NO: 107, a CDR2 comprising SEQ ID NO: 108 and a CDR3comprising SEQ ID NO: 109.

In some aspects, VH1 comprises a CDR1 comprising SEQ ID NO:56 or asequence having at least 90% identity or at least 95% identity to SEQ IDNO:56; a CDR2 comprising SEQ ID NO:57 or a sequence having at least 90%identity or at least 95% identity to SEQ ID NO:57; and a CDR3 comprisingSEQ ID NO:58 or a sequence having at least 90% identity or at least 95%identity to SEQ ID NO:58; and VL1 comprises a CDR1 comprising SEQ IDNO:59 or a sequence having at least 90% identity or at least 95%identity to SEQ ID NO:59, a CDR2 comprising SEQ ID NO:60 or a sequencehaving at least 90% identity or 95% identity to SEQ ID NO:60, and a CDR3comprising SEQ ID NO:61 or a sequence having at least 90% identity or atleast 95% identity to SEQ ID NO:61. For example, the VH1 may comprise aCDR1 comprising a sequence having at least 90% identity to SEQ ID NO:56, a CDR2 comprising a sequence having at least 90% identity to SEQ IDNO: 57, and a CDR3 comprising a sequence having at least 90% identity toSEQ ID NO: 58; and the VL1 may comprise a CDR1 comprising a sequencehaving at least 90% identity to SEQ ID NO: 59, a CDR2 comprising asequence having at least 90% identity to SEQ ID NO: 60 and a CDR3comprising a sequence having at least 90% identity to SEQ ID NO: 61. Atleast 90% identity may include at least 91%, 92%, 93%, 94%, 95%, 96%,97%, 98%, 99% or 100% identity to the reference polypeptide sequence.For example, the VH1 may comprise a CDR1 comprising SEQ ID NO: 56, aCDR2 comprising SEQ ID NO: 57, and a CDR3 comprising SEQ ID NO: 58; andthe VL1 may comprise a CDR1 comprising SEQ ID NO: 59, a CDR2 comprisingSEQ ID NO: 60 and a CDR3 comprising SEQ ID NO: 61.

In some aspects, VH2 comprises a CDR1 comprising SEQ ID NO:56 or asequence having at least 90% or at least 95% identity to SEQ ID NO:56; aCDR2 comprising SEQ ID NO:57 or a sequence having at least 90% identityor at least 95% identity to SEQ ID NO:57; and a CDR3 comprising SEQ IDNO:58 or a sequence having at least 90% identity or at least 95%identity to SEQ ID NO:58; and VL2 comprises a CDR1 comprising SEQ IDNO:59 or a sequence having at least 90% identity or at least 95%identity to SEQ ID NO:59, a CDR2 comprising SEQ ID NO:60 or a sequencehaving at least 90% identity or 95% identity to SEQ ID NO:60, and a CDR3comprising SEQ ID NO:61 or a sequence having at least 90% identity or atleast 95% identity to SEQ ID NO:61. For example, the VH2 may comprise aCDR1 comprising a sequence having at least 90% identity to SEQ ID NO:56, a CDR2 comprising a sequence having at least 90% identity to SEQ IDNO: 57, and a CDR3 comprising a sequence having at least 90% identity toSEQ ID NO: 58; and the VL2 may comprise a CDR1 comprising a sequencehaving at least 90% identity to SEQ ID NO: 59, a CDR2 comprising asequence having at least 90% identity to SEQ ID NO: 60 and a CDR3comprising a sequence having at least 90% identity to SEQ ID NO: 61. Atleast 90% identity may include at least 91%, 92%, 93%, 94%, 95%, 96%,97%, 98%, 99% or 100% identity to the reference polypeptide sequence.For example, the VH2 may comprise a CDR1 comprising SEQ ID NO: 56, aCDR2 comprising SEQ ID NO: 57, and a CDR3 comprising SEQ ID NO: 58; andthe VL2 may comprise a CDR1 comprising SEQ ID NO: 59, a CDR2 comprisingSEQ ID NO: 60 and a CDR3 comprising SEQ ID NO: 61.

In some aspects, VH1 comprises a CDR1 comprising SEQ ID NO:110 or asequence having at least 90% identity or at least 95% identity to SEQ IDNO:110; a CDR2 comprising SEQ ID NO:111 or a sequence having at least90% identity or at least 95% identity to SEQ ID NO:111; and a CDR3comprising SEQ ID NO:112 or a sequence having at least 90% identity orat least 95% identity to SEQ ID NO:112; and VL1 comprises a CDR1comprising SEQ ID NO:113 or a sequence having at least 90% identity orat least 95% identity to SEQ ID NO:113, a CDR2 comprising SEQ ID NO:114or a sequence having at least 90% identity or 95% identity to SEQ IDNO:114, and a CDR3 comprising SEQ ID NO:115 or a sequence having atleast 90% identity or at least 95% identity to SEQ ID NO:115. Forexample, the VH1 may comprise a CDR1 comprising a sequence having atleast 90% identity to SEQ ID NO: 110, a CDR2 comprising a sequencehaving at least 90% identity to SEQ ID NO: 111, and a CDR3 comprising asequence having at least 90% identity to SEQ ID NO: 112; and the VL1 maycomprise a CDR1 comprising a sequence having at least 90% identity toSEQ ID NO: 113, a CDR2 comprising a sequence having at least 90%identity to SEQ ID NO: 114 and a CDR3 comprising a sequence having atleast 90% identity to SEQ ID NO: 115. At least 90% identity may includeat least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity tothe reference polypeptide sequence. For example, the VH1 may comprise aCDR1 comprising SEQ ID NO: 110, a CDR2 comprising SEQ ID NO: 111, and aCDR3 comprising SEQ ID NO: 112; and the VL1 may comprise a CDR1comprising SEQ ID NO: 113, a CDR2 comprising SEQ ID NO: 114 and a CDR3comprising SEQ ID NO: 115.

In some aspects, VH2 comprises a CDR1 comprising SEQ ID NO:110 or asequence having at least 90% or at least 95% identity to SEQ ID NO:110;a CDR2 comprising SEQ ID NO:111 or a sequence having at least 90%identity or at least 95% identity to SEQ ID NO:111; and a CDR3comprising SEQ ID NO:112 or a sequence having at least 90% identity orat least 95% identity to SEQ ID NO:112; and VL2 comprises a CDR1comprising SEQ ID NO:113 or a sequence having at least 90% identity orat least 95% identity to SEQ ID NO:113, a CDR2 comprising SEQ ID NO:114or a sequence having at least 90% identity or 95% identity to SEQ IDNO:114, and a CDR3 comprising SEQ ID NO:115 or a sequence having atleast 90% identity or at least 95% identity to SEQ ID NO:115. Forexample, the VH2 may comprise a CDR1 comprising a sequence having atleast 90% identity to SEQ ID NO: 110, a CDR2 comprising a sequencehaving at least 90% identity to SEQ ID NO: 111, and a CDR3 comprising asequence having at least 90% identity to SEQ ID NO: 112; and the VL2 maycomprise a CDR1 comprising a sequence having at least 90% identity toSEQ ID NO: 113, a CDR2 comprising a sequence having at least 90%identity to SEQ ID NO: 114 and a CDR3 comprising a sequence having atleast 90% identity to SEQ ID NO: 115. At least 90% identity may includeat least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity tothe reference polypeptide sequence. For example, the VH2 may comprise aCDR1 comprising SEQ ID NO: 110, a CDR2 comprising SEQ ID NO: 111, and aCDR3 comprising SEQ ID NO: 112; and the VL2 may comprise a CDR1comprising SEQ ID NO: 113, a CDR2 comprising SEQ ID NO: 114 and a CDR3comprising SEQ ID NO: 115.

In some aspects, VH1 comprises a CDR1 comprising SEQ ID NO:116 or asequence having at least 90% identity or at least 95% identity to SEQ IDNO:116; a CDR2 comprising SEQ ID NO:117 or a sequence having at least90% identity or at least 95% identity to SEQ ID NO:117; and a CDR3comprising SEQ ID NO:118 or a sequence having at least 90% identity orat least 95% identity to SEQ ID NO:118; and VL1 comprises a CDR1comprising SEQ ID NO:119 or a sequence having at least 90% identity orat least 95% identity to SEQ ID NO:119, a CDR2 comprising SEQ ID NO:120or a sequence having at least 90% identity or 95% identity to SEQ IDNO:120, and a CDR3 comprising SEQ ID NO:121 or a sequence having atleast 90% identity or at least 95% identity to SEQ ID NO:121. Forexample, the VH1 may comprise a CDR1 comprising a sequence having atleast 90% identity to SEQ ID NO: 116, a CDR2 comprising a sequencehaving at least 90% identity to SEQ ID NO: 117, and a CDR3 comprising asequence having at least 90% identity to SEQ ID NO: 118; and the VL1 maycomprise a CDR1 comprising a sequence having at least 90% identity toSEQ ID NO: 119, a CDR2 comprising a sequence having at least 90%identity to SEQ ID NO: 120 and a CDR3 comprising a sequence having atleast 90% identity to SEQ ID NO: 121. At least 90% identity may includeat least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity tothe reference polypeptide sequence. For example, the VH1 may comprise aCDR1 comprising SEQ ID NO: 116, a CDR2 comprising SEQ ID NO: 117, and aCDR3 comprising SEQ ID NO: 118; and the VL1 may comprise a CDR1comprising SEQ ID NO: 119, a CDR2 comprising SEQ ID NO: 120 and a CDR3comprising SEQ ID NO: 121.

In some aspects, VH2 comprises a CDR1 comprising SEQ ID NO:116 or asequence having at least 90% or at least 95% identity to SEQ ID NO:116;a CDR2 comprising SEQ ID NO:117 or a sequence having at least 90%identity or at least 95% identity to SEQ ID NO:117; and a CDR3comprising SEQ ID NO:118 or a sequence having at least 90% identity orat least 95% identity to SEQ ID NO:118; and VL2 comprises a CDR1comprising SEQ ID NO:119 or a sequence having at least 90% identity orat least 95% identity to SEQ ID NO:119, a CDR2 comprising SEQ ID NO:120or a sequence having at least 90% identity or 95% identity to SEQ IDNO:120, and a CDR3 comprising SEQ ID NO:121 or a sequence having atleast 90% identity or at least 95% identity to SEQ ID NO:121. Forexample, the VH2 may comprise a CDR1 comprising a sequence having atleast 90% identity to SEQ ID NO: 116, a CDR2 comprising a sequencehaving at least 90% identity to SEQ ID NO: 117, and a CDR3 comprising asequence having at least 90% identity to SEQ ID NO: 118; and the VL2 maycomprise a CDR1 comprising a sequence having at least 90% identity toSEQ ID NO: 119, a CDR2 comprising a sequence having at least 90%identity to SEQ ID NO: 120 and a CDR3 comprising a sequence having atleast 90% identity to SEQ ID NO: 121. At least 90% identity may includeat least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity tothe reference polypeptide sequence. For example, the VH2 may comprise aCDR1 comprising SEQ ID NO: 116, a CDR2 comprising SEQ ID NO: 117, and aCDR3 comprising SEQ ID NO: 118; and the VL2 may comprise a CDR1comprising SEQ ID NO: 119, a CDR2 comprising SEQ ID NO: 120 and a CDR3comprising SEQ ID NO: 121.

In some aspects, VH1 comprises a CDR1 comprising SEQ ID NO:124 or asequence having at least 90% identity or at least 95% identity to SEQ IDNO:124; a CDR2 comprising SEQ ID NO:125 or a sequence having at least90% identity or at least 95% identity to SEQ ID NO:125; and a CDR3comprising SEQ ID NO:126 or a sequence having at least 90% identity orat least 95% identity to SEQ ID NO:126; and VL1 comprises a CDR1comprising SEQ ID NO:127 or a sequence having at least 90% identity orat least 95% identity to SEQ ID NO:127, a CDR2 comprising SEQ ID NO:128or a sequence having at least 90% identity or 95% identity to SEQ IDNO:128, and a CDR3 comprising SEQ ID NO:129 or a sequence having atleast 90% identity or at least 95% identity to SEQ ID NO:129. Forexample, the VH1 may comprise a CDR1 comprising a sequence having atleast 90% identity to SEQ ID NO: 124, a CDR2 comprising a sequencehaving at least 90% identity to SEQ ID NO: 125, and a CDR3 comprising asequence having at least 90% identity to SEQ ID NO: 126; and the VL1 maycomprise a CDR1 comprising a sequence having at least 90% identity toSEQ ID NO: 127, a CDR2 comprising a sequence having at least 90%identity to SEQ ID NO: 128 and a CDR3 comprising a sequence having atleast 90% identity to SEQ ID NO: 129. At least 90% identity may includeat least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity tothe reference polypeptide sequence. For example, the VH1 may comprise aCDR1 comprising SEQ ID NO: 124, a CDR2 comprising SEQ ID NO: 125, and aCDR3 comprising SEQ ID NO: 126; and the VL1 may comprise a CDR1comprising SEQ ID NO: 127, a CDR2 comprising SEQ ID NO: 128 and a CDR3comprising SEQ ID NO: 129.

In some aspects, VH2 comprises a CDR1 comprising SEQ ID NO:124 or asequence having at least 90% or at least 95% identity to SEQ ID NO:124;a CDR2 comprising SEQ ID NO:125 or a sequence having at least 90%identity or at least 95% identity to SEQ ID NO:125; and a CDR3comprising SEQ ID NO:126 or a sequence having at least 90% identity orat least 95% identity to SEQ ID NO:126; and VL2 comprises a CDR1comprising SEQ ID NO:127 or a sequence having at least 90% identity orat least 95% identity to SEQ ID NO:127, a CDR2 comprising SEQ ID NO:128or a sequence having at least 90% identity or 95% identity to SEQ IDNO:128, and a CDR3 comprising SEQ ID NO:129 or a sequence having atleast 90% identity or at least 95% identity to SEQ ID NO:129. Forexample, the VH2 may comprise a CDR1 comprising a sequence having atleast 90% identity to SEQ ID NO: 124, a CDR2 comprising a sequencehaving at least 90% identity to SEQ ID NO: 125, and a CDR3 comprising asequence having at least 90% identity to SEQ ID NO: 126; and the VL2 maycomprise a CDR1 comprising a sequence having at least 90% identity toSEQ ID NO: 127, a CDR2 comprising a sequence having at least 90%identity to SEQ ID NO: 128 and a CDR3 comprising a sequence having atleast 90% identity to SEQ ID NO: 129. At least 90% identity may includeat least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity tothe reference polypeptide sequence. For example, the VH2 may comprise aCDR1 comprising SEQ ID NO: 124, a CDR2 comprising SEQ ID NO: 125, and aCDR3 comprising SEQ ID NO: 126; and the VL2 may comprise a CDR1comprising SEQ ID NO: 127, a CDR2 comprising SEQ ID NO: 128 and a CDR3comprising SEQ ID NO: 129.

In some aspects, VH1 comprises an amino acid sequence having at least90% identity, at least 95% identity, or 100% identity to SEQ ID NO:21;VH2 comprises an amino acid sequence having at least 90% identity, atleast 95% identity, or 100% identity to SEQ ID NO:20; VL1 comprises anamino acid sequence having at least 90% identity, at least 95% identity,or 100% identity to SEQ ID NO:27; and VL2 comprises an amino acidsequence having at least 90% identity, at least 95% identity, or 100%identity to SEQ ID NO:26. For example, VH1 may comprise an amino acidsequence having at least 90% identity to SEQ ID NO:21; VH2 may comprisean amino acid sequence having at least 90% identity to SEQ ID NO:20; VL1may comprise an amino acid sequence having at least 90% identity to SEQID NO:27; and VL2 may comprises an amino acid sequence having at least90% identity to SEQ ID NO:26. At least 90% identity may include at least91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to thereference polypeptide sequence. For example, VH1 may comprise the aminoacid sequence of SEQ ID NO:21; VH2 may comprise the amino acid sequenceof SEQ ID NO:20; VL1 may comprise the amino acid sequence of SEQ IDNO:27; and VL2 may comprises the amino acid sequence of SEQ ID NO:26. Insome aspects, VH1 comprises an amino acid sequence having at least 90%identity, at least 95% identity, or 100% identity to SEQ ID NO:23; VH2comprises an amino acid sequence having at least 90% identity, at least95% identity, or 100% identity to SEQ ID NO:22; VL1 comprises an aminoacid sequence having at least 90% identity, at least 95% identity, or100% identity to SEQ ID NO:28; and VL2 comprises an amino acid sequencehaving at least 90% identity, at least 95% identity, or 100% identity toSEQ ID NO:29. For example, VH1 may comprise an amino acid sequencehaving at least 90% identity to SEQ ID NO:23; VH2 may comprise an aminoacid sequence having at least 90% identity to SEQ ID NO:22; VL1 maycomprise an amino acid sequence having at least 90% identity to SEQ IDNO:28; and VL2 may comprises an amino acid sequence having at least 90%identity to SEQ ID NO:29. At least 90% identity may include at least91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to thereference polypeptide sequence. For example, VH1 may comprise the aminoacid sequence of SEQ ID NO:23; VH2 may comprise the amino acid sequenceof SEQ ID NO:22; VL1 may comprise the amino acid sequence of SEQ IDNO:28; and VL2 may comprises the amino acid sequence of SEQ ID NO:29.

In some aspects, VH1 comprises an amino acid sequence having at least90% identity, at least 95% identity, or 100% identity to SEQ ID NO:22;VH2 comprises an amino acid sequence having at least 90% identity, atleast 95% identity, or 100% identity to SEQ ID NO:23; VL1 comprises anamino acid sequence having at least 90% identity, at least 95% identity,or 100% identity to SEQ ID NO:29; and VL2 comprises an amino acidsequence having at least 90% identity, at least 95% identity, or 100%identity to SEQ ID NO:28. For example, VH1 may comprise an amino acidsequence having at least 90% identity to SEQ ID NO:22; VH2 may comprisean amino acid sequence having at least 90% identity to SEQ ID NO:23; VL1may comprise an amino acid sequence having at least 90% identity to SEQID NO:29; and VL2 may comprises an amino acid sequence having at least90% identity to SEQ ID NO:28. At least 90% identity may include at least91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to thereference polypeptide sequence. For example, VH1 may comprise the aminoacid sequence of SEQ ID NO:22; VH2 may comprise the amino acid sequenceof SEQ ID NO:23; VL1 may comprise the amino acid sequence of SEQ IDNO:29; and VL2 may comprises the amino acid sequence of SEQ ID NO:28.

In some aspects, VH1 comprises an amino acid sequence having at least90% identity, at least 95% identity, or 100% identity to SEQ ID NO:24;VH2 comprises an amino acid sequence having at least 90% identity, atleast 95% identity, or 100% identity to SEQ ID NO:25; VL1 comprises anamino acid sequence having at least 90% identity, at least 95% identity,or 100% identity to SEQ ID NO:30; and VL2 comprises an amino acidsequence having at least 90% identity, at least 95% identity, or 100%identity to SEQ ID NO:31. For example, VH1 may comprise an amino acidsequence having at least 90% identity to SEQ ID NO:24; VH2 may comprisean amino acid sequence having at least 90% identity to SEQ ID NO:25; VL1may comprise an amino acid sequence having at least 90% identity to SEQID NO:30; and VL2 may comprises an amino acid sequence having at least90% identity to SEQ ID NO:31. At least 90% identity may include at least91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to thereference polypeptide sequence. For example, VH1 may comprise the aminoacid sequence of SEQ ID NO:24; VH2 may comprise the amino acid sequenceof SEQ ID NO:25; VL1 may comprise the amino acid sequence of SEQ IDNO:30; and VL2 may comprises the amino acid sequence of SEQ ID NO:31.

In some aspects, VH1 comprises an amino acid sequence having at least90% identity, at least 95% identity, or 100% identity to SEQ ID NO:25;VH2 comprises an amino acid sequence having at least 90% identity, atleast 95% identity, or 100% identity to SEQ ID NO:24; VL1 comprises anamino acid sequence having at least 90% identity, at least 95% identity,or 100% identity to SEQ ID NO:31; and VL2 comprises an amino acidsequence having at least 90% identity, at least 95% identity, or 100%identity to SEQ ID NO:30. For example, VH1 may comprise an amino acidsequence having at least 90% identity to SEQ ID NO:25; VH2 may comprisean amino acid sequence having at least 90% identity to SEQ ID NO:24; VL1may comprise an amino acid sequence having at least 90% identity to SEQID NO:31; and VL2 may comprises an amino acid sequence having at least90% identity to SEQ ID NO:30. At least 90% identity may include at least91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to thereference polypeptide sequence. For example, VH1 may comprise the aminoacid sequence of SEQ ID NO:25; VH2 may comprise the amino acid sequenceof SEQ ID NO:24; VL1 may comprise the amino acid sequence of SEQ IDNO:31; and VL2 may comprises the amino acid sequence of SEQ ID NO:30.

In some aspects, VH1 comprises an amino acid sequence having at least90% identity, at least 95% identity, or 100% identity to SEQ ID NO:20;VH2 comprises an amino acid sequence having at least 90% identity, atleast 95% identity, or 100% identity to SEQ ID NO:21; VL1 comprises anamino acid sequence having at least 90% identity, at least 95% identity,or 100% identity to SEQ ID NO:26; and VL2 comprises an amino acidsequence having at least 90% identity, at least 95% identity, or 100%identity to SEQ ID NO:27. For example, VH1 may comprise an amino acidsequence having at least 90% identity to SEQ ID NO:20; VH2 may comprisean amino acid sequence having at least 90% identity to SEQ ID NO:21; VL1may comprise an amino acid sequence having at least 90% identity to SEQID NO:26; and VL2 may comprises an amino acid sequence having at least90% identity to SEQ ID NO:27. At least 90% identity may include at least91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to thereference polypeptide sequence. For example, VH1 may comprise the aminoacid sequence of SEQ ID NO:20; VH2 may comprise the amino acid sequenceof SEQ ID NO:21; VL1 may comprise the amino acid sequence of SEQ IDNO:26; and VL2 may comprises the amino acid sequence of SEQ ID NO:27.

In some aspects, the VH1 comprises an amino acid sequence having atleast 90% identity, at least 95% identity, or 100% identity to SEQ IDNO:20 or 25; VH2 comprises an amino acid sequence having at least 90%identity, at least 95% identity, or 100% identity to SEQ ID NO:122; VL1an amino acid sequence having at least 90% identity, at least 95%identity, or 100% identity to SEQ ID NO:26 or 31; and VL2 comprises anamino acid sequence having at least 90% identity, at least 95% identity,or 100% identity to SEQ ID NO:123. For example, VH1 may comprise anamino acid sequence having at least 90% identity to SEQ ID NO:20 or 25;VH2 may comprise an amino acid sequence having at least 90% identity toSEQ ID NO:122; VL1 may comprise an amino acid sequence having at least90% identity to SEQ ID NO:26 or 31; and VL2 may comprises an amino acidsequence having at least 90% identity to SEQ ID NO:123. At least 90%identity may include at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%,99% or 100% identity to the reference polypeptide sequence. For example,VH1 may comprise the amino acid sequence of SEQ ID NO:20 or 25; VH2 maycomprise the amino acid sequence of SEQ ID NO:122; VL1 may comprise theamino acid sequence of SEQ ID NO:26 or 31; and VL2 may comprises theamino acid sequence of SEQ ID NO:123. For example, VH1 may comprise theamino acid sequence of SEQ ID NO:20; VH2 may comprise the amino acidsequence of SEQ ID NO:122; VL1 may comprise the amino acid sequence ofSEQ ID NO:26; and VL2 may comprises the amino acid sequence of SEQ IDNO:123. For example, VH1 may comprise the amino acid sequence of SEQ IDNO:20; VH2 may comprise the amino acid sequence of SEQ ID NO:122; VL1may comprise the amino acid sequence of SEQ ID NO: 31, and VL2 maycomprises the amino acid sequence of SEQ ID NO:123. For example, VH1 maycomprise the amino acid sequence of SEQ ID NO:25; VH2 may comprise theamino acid sequence of SEQ ID NO:122; VL1 may comprise the amino acidsequence of SEQ ID NO:26; and VL2 may comprises the amino acid sequenceof SEQ ID NO:123. For example, VH1 may comprise the amino acid sequenceof SEQ ID NO:25; VH2 may comprise the amino acid sequence of SEQ IDNO:122; VL1 may comprise the amino acid sequence of SEQ ID NO:31; andVL2 may comprises the amino acid sequence of SEQ ID NO:123.

In some aspects, the VH1 comprises an amino acid sequence having atleast 90% identity, at least 95% identity, or 100% identity to SEQ IDNO:122; VH2 comprises an amino acid sequence having at least 90%identity, at least 95% identity, or 100% identity to SEQ ID NO:20 or 25;VL1 comprises an amino acid sequence having at least 90% identity, atleast 95% identity, or 100% identity to SEQ ID NO:123; and VL2 comprisesan amino acid sequence having at least 90% identity, at least 95%identity, or 100% identity to SEQ ID NO:26 or 31. For example, VH1 maycomprise an amino acid sequence having at least 90% identity to SEQ IDNO: 122; VH2 may comprise an amino acid sequence having at least 90%identity to SEQ ID NO:20 or 25; VL1 may comprise an amino acid sequencehaving at least 90% identity to SEQ ID NO: 123; and VL2 may comprises anamino acid sequence having at least 90% identity to SEQ ID NO:26 or 31.At least 90% identity may include at least 91%, 92%, 93%, 94%, 95%, 96%,97%, 98%, 99% or 100% identity to the reference polypeptide sequence.For example, VH1 may comprise the amino acid sequence of SEQ ID NO:122;VH2 may comprise the amino acid sequence of SEQ ID NO:20 or 25; VL1 maycomprise the amino acid sequence of SEQ ID NO:123; and VL2 may comprisesthe amino acid sequence of SEQ ID NO: 26 or 31. For example, VH1 maycomprise the amino acid sequence of SEQ ID NO: 122; VH2 may comprise theamino acid sequence of SEQ ID NO:20; VL1 may comprise the amino acidsequence of SEQ ID NO:123; and VL2 may comprises the amino acid sequenceof SEQ ID NO:26. For example, VH1 may comprise the amino acid sequenceof SEQ ID NO:122; VH2 may comprise the amino acid sequence of SEQ IDNO:20; VL1 may comprise the amino acid sequence of SEQ ID NO: 123, andVL2 may comprises the amino acid sequence of SEQ ID NO:31. For example,VH1 may comprise the amino acid sequence of SEQ ID NO:122; VH2 maycomprise the amino acid sequence of SEQ ID NO:25; VL1 may comprise theamino acid sequence of SEQ ID NO:123; and VL2 may comprises the aminoacid sequence of SEQ ID NO:26. For example, VH1 may comprise the aminoacid sequence of SEQ ID NO:122; VH2 may comprise the amino acid sequenceof SEQ ID NO:25; VL1 may comprise the amino acid sequence of SEQ IDNO:123; and VL2 may comprises the amino acid sequence of SEQ ID NO:31.

In some aspects, the invention is directed to an antigen bindingpolypeptide or antigen binding polypeptide complex (e.g., antibody orantigen binding fragment thereof) comprising an amino acid sequencehaving at least 90% identity, at least 95% identity, or 100% identity toany one of SEQ ID NOs:32-43, 62-79, 130-138, 633, 635, 637, 639, 641,643, 645, 647, 649, 651, 653, 655, 657, 659, 661, 663, 665, 667, 669,671, 673, 675, 677, and 679. For example, the antigen bindingpolypeptide or antigen binding polypeptide complex (e.g., antibody orantigen binding fragment thereof) may comprise an amino acid sequencehaving at least 90% (such as at least 91%, 92%, 93%, 94%, 95%, 96%, 97%,98%, or 99%) identity to any one of SEQ ID NOs:32-43, 62-79, 130-138,633, 635, 637, 639, 641, 643, 645, 647, 649, 651, 653, 655, 657, 659,661, 663, 665, 667, 669, 671, 673, 675, 677, and 679. For example, theantigen binding polypeptide or antigen binding polypeptide complex(e.g., antibody or antigen binding fragment thereof) may comprise theamino acid sequence of SEQ ID NOs:32-43, 62-79, 130-138, 633, 635, 637,639, 641, 643, 645, 647, 649, 651, 653, 655, 657, 659, 661, 663, 665,667, 669, 671, 673, 675, 677, and 679. In other aspects, the inventionis directed to an antigen binding polypeptide or antigen bindingpolypeptide complex (e.g., antibody or antigen binding fragment thereof)comprising an amino acid sequence having at least 90% identity, at least95% identity, or 100% identity to the amino acid sequence of SEQ IDNOs:32 or 33 that does not contain the eight histidine residues at theC-terminus. For example, the antigen binding polypeptide or antigenbinding polypeptide complex (e.g., antibody or antigen binding fragmentthereof) may comprise an amino acid sequence having at least 90%identity to SEQ ID Nos: 32 or 33 that does not contain the eighthistidine residues at the C-terminus. At least 90% identity may includeat least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity tothe reference polypeptide sequence. For example, the antigen bindingpolypeptide or antigen binding polypeptide complex (e.g., antibody orantigen binding fragment thereof) may comprise the amino acid sequenceof SEQ ID NOs: 32 or 33 that does not contain the eight histidineresidues at the C-terminus.

In other aspects, the invention is directed to an antigen bindingpolypeptide or antigen binding polypeptide complex (e.g., antibody orantigen binding fragment thereof) comprising an amino acid sequenceencoded by a polynucleotide of any one of SEQ ID NOs:44-55, 80-97,139-147, 634, 636, 638, 640, 642, 644, 646, 648, 650, 652, 654, 656,658, 660, 662, 664, 666, 668, 670, 672, 674, 676, 678, and 680, or apolynucleotide having at least 90% identity or at least 95% identity toany one of SEQ ID NOs:44-55, 80-97, 139-147, 634, 636, 638, 640, 642,644, 646, 648, 650, 652, 654, 656, 658, 660, 662, 664, 666, 668, 670,672, 674, 676, 678, and 680. For example, the antigen bindingpolypeptide or antigen binding polypeptide complex (e.g., antibody orantigen binding fragment thereof) may comprise an amino acid sequenceencoded by a polynucleotide having at least 90% (such as at least 91%,92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity to any one of SEQ IDNOs: 44-55, 80-97, 139-147, 634, 636, 638, 640, 642, 644, 646, 648, 650,652, 654, 656, 658, 660, 662, 664, 666, 668, 670, 672, 674, 676, 678,and 680. For example, the antigen binding polypeptide or antigen bindingpolypeptide complex (e.g., antibody or antigen binding fragment thereof)may comprise an amino acid sequence encoded by the polynucleotide of SEQID NOs: 44-55, 80-97, 139-147, 634, 636, 638, 640, 642, 644, 646, 648,650, 652, 654, 656, 658, 660, 662, 664, 666, 668, 670, 672, 674, 676,678, and 680.

In some aspects, the invention is directed to an antigen bindingpolypeptide complex comprising a first polypeptide and a secondpolypeptide; wherein the first polypeptide has a structure representedby VL1-VL2-VH2-VH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc; orVL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc; wherein the second polypeptide has astructure represented by Fc; VL1-VL2-VH2-VH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-Fc; or VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc; whereinVL1 is a first immunoglobulin light chain variable region; VL2 is asecond immunoglobulin light chain variable region; VH1 is a firstimmunoglobulin heavy chain variable region; VH2 is a secondimmunoglobulin heavy chain variable region; Fc is a region comprising animmunoglobulin heavy chain constant region 2 (CH2), an immunoglobulinheavy chain constant region 3 (CH3), and optionally, an immunoglobulinhinge; L1, L2, L3 and L4 are amino acid linkers; VH1 comprises an aminoacid sequence having at least 90% identity, at least 95% identity, or100% identity to any one of SEQ ID NOs:20-25; VH2 comprises an aminoacid sequence having at least 90% identity, at least 95% identity, or100% identity to any one of SEQ ID NOs:20-25; VL1 comprises an aminoacid sequence having at least 90% identity, at least 95% identity, or100% identity to any one of SEQ ID NOs:26-31; and VL2 comprises an aminoacid sequence having at least 90% identity, at least 95% identity, or100% identity to any one of SEQ ID NOs:26-31. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-Fc and thesecond polypeptide has a structure represented by Fc. In some aspects,the first polypeptide has a structure represented by VL1-VL2-VH2-VH1-Fcand the second polypeptide has a structure represented byVL1-VL2-VH2-VH1-Fc. In some aspects, the first polypeptide has astructure represented by VL1-VL2-VH2-VH1-Fc and the second polypeptidehas a structure represented by VL1-L1-VL2-L2-VH2-L3-VH1-Fc. In someaspects, the first polypeptide has a structure represented byVL1-VL2-VH2-VH1-Fc and the second polypeptide has a structurerepresented by VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc. In some aspects, thefirst polypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-Fc and the second polypeptide has a structurerepresented by Fc. In some aspects, the first polypeptide has astructure represented by VL1-L1-VL2-L2-VH2-L3-VH1-Fc and the secondpolypeptide has a structure represented by VL1-VL2-VH2-VH1-Fc. In someaspects, the first polypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-Fc and the second polypeptide has a structurerepresented by VL1-L1-VL2-L2-VH2-L3-VH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VL1-L1-VL2-L2-VH2-L3-VH1-Fcand the second polypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc. In some aspects, the first polypeptidehas a structure represented by VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc and thesecond polypeptide has a structure represented by Fc. In some aspects,the first polypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc and the second polypeptide has astructure represented by VL1-VL2-VH2-VH1-Fc. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc and the second polypeptide has astructure represented by VL1-L1-VL2-L2-VH2-L3-VH1-Fc. In some aspects,the first polypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc and the second polypeptide has astructure represented by VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc. In someaspects, the VH1 may comprise an amino acid sequence having at least 90%identity to any one of SEQ ID NOs:20-25; VH2 may comprise an amino acidsequence having at least 90% identity to any one of SEQ ID NOs:20-25;VL1 may comprise an amino acid sequence having at least 90% identity toany one of SEQ ID NOs:26-31; and/or VL2 may comprise an amino acidsequence having at least 90% identity to any one of SEQ ID NOs:26-31. Atleast 90% identity may include at least 91%, 92%, 93%, 94%, 95%, 96%,97%, 98%, 99% or 100% identity to the reference polypeptide sequence.For example, the VH1 may comprise the amino acid sequence of any one ofSEQ ID NOs:20-25; VH2 may comprise the amino acid sequence of any one ofSEQ ID NOs:20-25; VL1 may comprise the amino acid sequence of any one ofSEQ ID NOs:26-31; and/or VL2 may comprise the amino acid sequence of anyone of SEQ ID NOs:26-31.

In other aspects, the invention is directed to an antigen bindingpolypeptide complex comprising a first polypeptide and a secondpolypeptide; wherein the first polypeptide has a structure representedby VL1-VL2-VH2-VH1-CL-CH1-Fc; VL1-VL2-VH2-VH1-CH1-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-CL-L4-CH1-Fc orVL1-L1-VL2-L2-VH2-L3-VH1-CH1-L4-CH1-Fc; wherein the second polypeptidehas a structure represented by Fc; wherein VL1 is a first immunoglobulinlight chain variable region; VL2 is a second immunoglobulin light chainvariable region; VH1 is a first immunoglobulin heavy chain variableregion; VH2 is a second immunoglobulin heavy chain variable region; Fcis a region comprising an immunoglobulin heavy chain constant region 2(CH2), an immunoglobulin heavy chain constant region 3 (CH3), andoptionally, an immunoglobulin hinge; CH1 is an immunoglobulin heavychain constant region 1; CL is an immunoglobulin light chain constantregion; L1, L2, L3 and L4 are amino acid linkers; VH1 comprises an aminoacid sequence having at least 90% identity, at least 95% identity, or100% identity to any one of SEQ ID NOs:20-25; VH2 comprises an aminoacid sequence having at least 90% identity, at least 95% identity, or100% identity to any one of SEQ ID NOs:20-25; VL1 comprises an aminoacid sequence having at least 90% identity, at least 95% identity, or100% identity to any one of SEQ ID NOs:26-31; and VL2 comprises an aminoacid sequence having at least 90% identity, at least 95% identity, or100% identity to any one of SEQ ID NOs:26-31. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-CL-CH1-Fc andthe second polypeptide has a structure represented by Fc. In someaspects, the first polypeptide has a structure represented byVL1-VL2-VH2-VH1-CH1-CL-Fc and the second polypeptide has a structurerepresented by Fc. In some aspects, the first polypeptide has astructure represented by VL1-L1-VL2-L2-VH2-L3-VH1-CL-L4-CH1-Fc and thesecond polypeptide has a structure represented by Fc. In some aspects,the first polypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-CH1-L4-CH1-Fc and the second polypeptide has astructure represented by Fc. In some aspects, the VH1 may comprise anamino acid sequence having at least 90% identity to any one of SEQ IDNOs:20-25; VH2 may comprise an amino acid sequence having at least 90%identity to any one of SEQ ID NOs:20-25; VL1 may comprise an amino acidsequence having at least 90% identity to any one of SEQ ID NOs:26-31;and/or VL2 may comprise an amino acid sequence having at least 90%identity to any one of SEQ ID NOs:26-31. At least 90% identity mayinclude at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%identity to the reference polypeptide sequence. For example, the VH1 maycomprise the amino acid sequence of any one of SEQ ID NOs:20-25; VH2 maycomprise the amino acid sequence of any one of SEQ ID NOs:20-25; VL1 maycomprise the amino acid sequence of any one of SEQ ID NOs:26-31; and/orVL2 may comprise the amino acid sequence of any one of SEQ ID NOs:26-31.

In other aspects, the invention is directed to an antigen bindingpolypeptide complex comprising a first polypeptide and a secondpolypeptide; wherein the first polypeptide has a structure representedby VL1-VL2-VH2-VH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc; orVL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc; wherein the second polypeptide has astructure represented by Fc; VL1-VL2-VH2-VH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-Fc; or VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc; whereinVL1 is a first immunoglobulin light chain variable region; VL2 is asecond immunoglobulin light chain variable region; VH1 is a firstimmunoglobulin heavy chain variable region; VH2 is a secondimmunoglobulin heavy chain variable region; Fc is a region comprising animmunoglobulin heavy chain constant region 2 (CH2), an immunoglobulinheavy chain constant region 3 (CH3), and optionally, an immunoglobulinhinge; L1, L2, L3 and L4 are amino acid linkers; VH1 comprises an aminoacid sequence having at least 90% identity, at least 95% identity, or100% identity to any one of SEQ ID NO:25; VH2 comprises an amino acidsequence having at least 90% identity, at least 95% identity, or 100%identity to any one of SEQ ID NO:24; VL1 comprises an amino acidsequence having at least 90% identity, at least 95% identity, or 100%identity to any one of SEQ ID NO:31; and VL2 comprises an amino acidsequence having at least 90% identity, at least 95% identity, or 100%identity to any one of SEQ ID NO:30. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-Fc and thesecond polypeptide has a structure represented by Fc. In some aspects,the first polypeptide has a structure represented by VL1-VL2-VH2-VH1-Fcand the second polypeptide has a structure represented byVL1-VL2-VH2-VH1-Fc. In some aspects, the first polypeptide has astructure represented by VL1-VL2-VH2-VH1-Fc and the second polypeptidehas a structure represented by VL1-L1-VL2-L2-VH2-L3-VH1-Fc. In someaspects, the first polypeptide has a structure represented byVL1-VL2-VH2-VH1-Fc and the second polypeptide has a structurerepresented by VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc. In some aspects, thefirst polypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-Fc and the second polypeptide has a structurerepresented by Fc. In some aspects, the first polypeptide has astructure represented by VL1-L1-VL2-L2-VH2-L3-VH1-Fc and the secondpolypeptide has a structure represented by VL1-VL2-VH2-VH1-Fc. In someaspects, the first polypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-Fc and the second polypeptide has a structurerepresented by VL1-L1-VL2-L2-VH2-L3-VH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VL1-L1-VL2-L2-VH2-L3-VH1-Fcand the second polypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc. In some aspects, the first polypeptidehas a structure represented by VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc and thesecond polypeptide has a structure represented by Fc. In some aspects,the first polypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc and the second polypeptide has astructure represented by VL1-VL2-VH2-VH1-Fc. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc and the second polypeptide has astructure represented by VL1-L1-VL2-L2-VH2-L3-VH1-Fc. In some aspects,the first polypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc and the second polypeptide has astructure represented by VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc. In someaspects, VH1 may comprise an amino acid sequence having at least 90%identity to SEQ ID NO: 25; VH2 may comprise an amino acid sequencehaving at least 90% identity to SEQ ID NO:24; VL1 may comprise an aminoacid sequence having at least 90% identity to SEQ ID NO: 31; and VL2 maycomprises an amino acid sequence having at least 90% identity to SEQ IDNO:30. At least 90% identity may include at least 91%, 92%, 93%, 94%,95%, 96%, 97%, 98%, 99% or 100% identity to the reference polypeptidesequence. For example, VH1 may comprise the amino acid sequence of SEQID NO:25; VH2 may comprise the amino acid sequence of SEQ ID NO:24; VL1may comprise the amino acid sequence of SEQ ID NO:31; and VL2 maycomprises the amino acid sequence of SEQ ID NO: 30. In some aspects, thefirst polypeptide and the second polypeptide comprise an amino acidsequence having at least 90% identity, at least 95% identity, or 100%identity to SEQ ID NO:36 or 37. In some aspects, the first polypeptideand the second polypeptide may comprise an amino acid sequence having atleast 90% identity (such as at least 91%, 92%, 93%, 94%, 95%, 96%, 97%,98%, or 99%) to SEQ ID NO:36 or 37. In some aspects, the firstpolypeptide and the second polypeptide may comprise the amino acidsequence of SEQ ID NO:36 or 37. For example, the first polypeptide andsecond polypeptide may both comprise the amino acid sequence of SEQ IDNO: 36. For example, the first polypeptide and second polypeptide mayboth comprise the amino acid sequence of SEQ ID NO: 37. For example, thefirst polypeptide may comprise the amino acid sequence of SEQ ID NO: 36,and the second polypeptide may comprise the amino acid sequence of SEQID NO: 37. For example, the first polypeptide may comprise the aminoacid sequence of SEQ ID NO: 37, and the second polypeptide may comprisethe amino acid sequence of SEQ ID NO: 36.

In other aspects, the invention is directed to an antigen bindingpolypeptide complex comprising a first polypeptide and a secondpolypeptide; wherein the first polypeptide has a structure representedby VL1-VL2-VH2-VH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc; orVL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc; wherein the second polypeptide has astructure represented by Fc; VL1-VL2-VH2-VH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-Fc; or VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc; whereinVL1 is a first immunoglobulin light chain variable region; VL2 is asecond immunoglobulin light chain variable region; VH1 is a firstimmunoglobulin heavy chain variable region; VH2 is a secondimmunoglobulin heavy chain variable region; Fc is a region comprising animmunoglobulin heavy chain constant region 2 (CH2), an immunoglobulinheavy chain constant region 3 (CH3), and optionally, an immunoglobulinhinge; L1, L2, L3 and L4 are amino acid linkers; VH1 comprises an aminoacid sequence having at least 90% identity, at least 95% identity, or100% identity to any one of SEQ ID NO:24; VH2 comprises an amino acidsequence having at least 90% identity, at least 95% identity, or 100%identity to any one of SEQ ID NO:25; VL1 comprises an amino acidsequence having at least 90% identity, at least 95% identity, or 100%identity to any one of SEQ ID NO:30; and VL2 comprises an amino acidsequence having at least 90% identity, at least 95% identity, or 100%identity to any one of SEQ ID NO:31. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-Fc and thesecond polypeptide has a structure represented by Fc. In some aspects,the first polypeptide has a structure represented by VL1-VL2-VH2-VH1-Fcand the second polypeptide has a structure represented byVL1-VL2-VH2-VH1-Fc. In some aspects, the first polypeptide has astructure represented by VL1-VL2-VH2-VH1-Fc and the second polypeptidehas a structure represented by VL1-L1-VL2-L2-VH2-L3-VH1-Fc. In someaspects, the first polypeptide has a structure represented byVL1-VL2-VH2-VH1-Fc and the second polypeptide has a structurerepresented by VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc. In some aspects, thefirst polypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-Fc and the second polypeptide has a structurerepresented by Fc. In some aspects, the first polypeptide has astructure represented by VL1-L1-VL2-L2-VH2-L3-VH1-Fc and the secondpolypeptide has a structure represented by VL1-VL2-VH2-VH1-Fc. In someaspects, the first polypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-Fc and the second polypeptide has a structurerepresented by VL1-L1-VL2-L2-VH2-L3-VH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VL1-L1-VL2-L2-VH2-L3-VH1-Fcand the second polypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc. In some aspects, the first polypeptidehas a structure represented by VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc and thesecond polypeptide has a structure represented by Fc. In some aspects,the first polypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc and the second polypeptide has astructure represented by VL1-VL2-VH2-VH1-Fc. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc and the second polypeptide has astructure represented by VL1-L1-VL2-L2-VH2-L3-VH1-Fc. In some aspects,the first polypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc and the second polypeptide has astructure represented by VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc. In someaspects, VH1 may comprise an amino acid sequence having at least 90%identity to SEQ ID NO: 24; VH2 may comprise an amino acid sequencehaving at least 90% identity to SEQ ID NO:25; VL1 may comprise an aminoacid sequence having at least 90% identity to SEQ ID NO: 30; and VL2 maycomprises an amino acid sequence having at least 90% identity to SEQ IDNO:31. At least 90% identity may include at least 91%, 92%, 93%, 94%,95%, 96%, 97%, 98%, 99% or 100% identity to the reference polypeptidesequence. For example, VH1 may comprise the amino acid sequence of SEQID NO:24; VH2 may comprise the amino acid sequence of SEQ ID NO:25; VL1may comprise the amino acid sequence of SEQ ID NO:30; and VL2 maycomprises the amino acid sequence of SEQ ID NO: 31. In some aspects, thefirst polypeptide and the second polypeptide comprise an amino acidsequence having at least 90% identity, at least 95% identity, or 100%identity to SEQ ID NO:34 or 35. In some aspects, the first polypeptideand the second polypeptide may comprise an amino acid sequence having atleast 90% (such as at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or99%) identity to SEQ ID NO:34 or 35. In some aspects, the firstpolypeptide and the second polypeptide may comprise the amino acidsequence of SEQ ID NO:34 or 35. For example, the first polypeptide andsecond polypeptide may both comprise the amino acid sequence of SEQ IDNO: 34. For example, the first polypeptide and second polypeptide mayboth comprise the amino acid sequence of SEQ ID NO: 35. For example, thefirst polypeptide may comprise the amino acid sequence of SEQ ID NO: 34,and the second polypeptide may comprise the amino acid sequence of SEQID NO: 35. For example, the first polypeptide may comprise the aminoacid sequence of SEQ ID NO: 35, and the second polypeptide may comprisethe amino acid sequence of SEQ ID NO: 34.

In other aspects, the invention is directed to an antigen bindingpolypeptide complex comprising a first polypeptide and a secondpolypeptide; wherein the first polypeptide has a structure representedby VL1-VL2-VH2-VH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc; orVL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc; wherein the second polypeptide has astructure represented by Fc; VL1-VL2-VH2-VH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-Fc; or VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc; whereinVL1 is a first immunoglobulin light chain variable region; VL2 is asecond immunoglobulin light chain variable region; VH1 is a firstimmunoglobulin heavy chain variable region; VH2 is a secondimmunoglobulin heavy chain variable region; Fc is a region comprising animmunoglobulin heavy chain constant region 2 (CH2), an immunoglobulinheavy chain constant region 3 (CH3), and optionally, an immunoglobulinhinge; L1, L2, L3 and L4 are amino acid linkers; VH1 of the firstpolypeptide comprises an amino acid sequence having at least 90%identity, at least 95% identity, or 100% identity to any one of SEQ IDNO:25; VH2 of the first polypeptide comprises an amino acid sequencehaving at least 90% identity, at least 95% identity, or 100% identity toany one of SEQ ID NO:24; VL1 of the first polypeptide comprises an aminoacid sequence having at least 90% identity, at least 95% identity, or100% identity to any one of SEQ ID NO:31; VL2 of the first polypeptidecomprises an amino acid sequence having at least 90% identity, at least95% identity, or 100% identity to any one of SEQ ID NO:30; VH1 of thesecond polypeptide comprises an amino acid sequence having at least 90%identity, at least 95% identity, or 100% identity to any one of SEQ IDNO:24; VH2 of the second polypeptide comprises an amino acid sequencehaving at least 90% identity, at least 95% identity, or 100% identity toany one of SEQ ID NO:25; VL1 of the second polypeptide comprises anamino acid sequence having at least 90% identity, at least 95% identity,or 100% identity to any one of SEQ ID NO:30; and VL2 of the secondpolypeptide comprises an amino acid sequence having at least 90%identity, at least 95% identity, or 100% identity to any one of SEQ IDNO:31. In some aspects, the first polypeptide has a structurerepresented by VL1-VL2-VH2-VH1-Fc and the second polypeptide has astructure represented by Fc. In some aspects, the first polypeptide hasa structure represented by VL1-VL2-VH2-VH1-Fc and the second polypeptidehas a structure represented by VL1-VL2-VH2-VH1-Fc. In some aspects, thefirst polypeptide has a structure represented by VL1-VL2-VH2-VH1-Fc andthe second polypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-Fc. In some aspects, the first polypeptide hasa structure represented by VL1-VL2-VH2-VH1-Fc and the second polypeptidehas a structure represented by VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc. In someaspects, the first polypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-Fc and the second polypeptide has a structurerepresented by Fc. In some aspects, the first polypeptide has astructure represented by VL1-L1-VL2-L2-VH2-L3-VH1-Fc and the secondpolypeptide has a structure represented by VL1-VL2-VH2-VH1-Fc. In someaspects, the first polypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-Fc and the second polypeptide has a structurerepresented by VL1-L1-VL2-L2-VH2-L3-VH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VL1-L1-VL2-L2-VH2-L3-VH1-Fcand the second polypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc. In some aspects, the first polypeptidehas a structure represented by VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc and thesecond polypeptide has a structure represented by Fc. In some aspects,the first polypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc and the second polypeptide has astructure represented by VL1-VL2-VH2-VH1-Fc. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc and the second polypeptide has astructure represented by VL1-L1-VL2-L2-VH2-L3-VH1-Fc. In some aspects,the first polypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc and the second polypeptide has astructure represented by VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc. In someaspects, the first polypeptide comprises a VH1 comprising an amino acidsequence having at least 90% identity to SEQ ID NO: 25; a VH2 comprisingan amino acid sequence having at least 90% identity to SEQ ID NO:24; aVL1 comprising an amino acid sequence having at least 90% identity toSEQ ID NO: 31; and a VL2 comprising an amino acid sequence having atleast 90% identity to SEQ ID NO:30; and the second polypeptide comprisesa VH1 comprising an amino acid sequence having at least 90% identity toSEQ ID NO: 24; a VH2 comprising an amino acid sequence having at least90% identity to SEQ ID NO:25; a VL1 comprising an amino acid sequencehaving at least 90% identity to SEQ ID NO: 30; and a VL2 comprising anamino acid sequence having at least 90% identity to SEQ ID NO:31. Atleast 90% identity may include at least 91%, 92%, 93%, 94%, 95%, 96%,97%, 98%, 99% or 100% identity to the reference polypeptide sequence.For example, the first polypeptide may comprise a VH1 comprising theamino acid sequence of SEQ ID NO:25; a VH2 comprising the amino acidsequence of SEQ ID NO:24; a VL1 comprising the amino acid sequence ofSEQ ID NO:31; and a VL2 comprising the amino acid sequence of SEQ ID NO:30, and the second polypeptide may comprise a VH1 comprising the aminoacid sequence of SEQ ID NO:24; a VH2 comprising the amino acid sequenceof SEQ ID NO:25; a VL1 comprising the amino acid sequence of SEQ IDNO:30; and a VL2 comprising the amino acid sequence of SEQ ID NO: 31. Insome aspects, the first polypeptide comprises an amino acid sequencehaving at least 90% identity, at least 95% identity, or 100% identity toSEQ ID NO:36 or 37, and the second polypeptide comprises an amino acidsequence having at least 90% identity, at least 95% identity, or 100%identity to SEQ ID NO:34 or 35. In some aspects, the first polypeptidemay comprise an amino acid sequence having at least 90% identity to SEQID NO:36 or 37 and the second polypeptide may comprise an amino acidsequence having at least 90% identity to SEQ ID NO: 34 or 35. At least90% identity may include at least 91%, 92%, 93%, 94%, 95%, 96%, 97%,98%, 99% or 100% identity to the reference polypeptide sequence. In someaspects, the first polypeptide may comprise the amino acid sequence ofSEQ ID NO:36 or 37; and the second polypeptide may comprise the aminoacid sequence of SEQ ID NO: 34 or 35. For example, the first polypeptidemay comprise the amino acid sequence of SEQ ID NO: 36 and the secondpolypeptide may comprise the amino acid sequence of SEQ ID NO: 34. Forexample, the first polypeptide may comprise the amino acid sequence ofSEQ ID NO: 36 and the second polypeptide may comprise the amino acidsequence of SEQ ID NO: 35. For example, the first polypeptide maycomprise the amino acid sequence of SEQ ID NO: 37 and the secondpolypeptide may comprise the amino acid sequence of SEQ ID NO: 34. Forexample, the first polypeptide may comprise the amino acid sequence ofSEQ ID NO: 37 and the second polypeptide may comprise the amino acidsequence of SEQ ID NO: 35.

In other aspects, the invention is directed to an antigen bindingpolypeptide complex comprising a first polypeptide and a secondpolypeptide; wherein the first polypeptide has a structure representedby VL1-VL2-VH2-VH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc; orVL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc; wherein the second polypeptide has astructure represented by Fc; VL1-VL2-VH2-VH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-Fc; or VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc; whereinVL1 is a first immunoglobulin light chain variable region; VL2 is asecond immunoglobulin light chain variable region; VH1 is a firstimmunoglobulin heavy chain variable region; VH2 is a secondimmunoglobulin heavy chain variable region; Fc is a region comprising animmunoglobulin heavy chain constant region 2 (CH2), an immunoglobulinheavy chain constant region 3 (CH3), and optionally, an immunoglobulinhinge; L1, L2, L3 and L4 are amino acid linkers; VH1 of the firstpolypeptide comprises an amino acid sequence having at least 90%identity, at least 95% identity, or 100% identity to any one of SEQ IDNO:25; VH2 of the first polypeptide comprises an amino acid sequencehaving at least 90% identity, at least 95% identity, or 100% identity toany one of SEQ ID NO:24; VL1 of the first polypeptide comprises an aminoacid sequence having at least 90% identity, at least 95% identity, or100% identity to any one of SEQ ID NO:31; VL2 of the first polypeptidecomprises an amino acid sequence having at least 90% identity, at least95% identity, or 100% identity to any one of SEQ ID NO:30; VH1 of thesecond polypeptide comprises an amino acid sequence having at least 90%identity, at least 95% identity, or 100% identity to any one of SEQ IDNO:24; VH2 of the second polypeptide comprises an amino acid sequencehaving at least 90% identity, at least 95% identity, or 100% identity toany one of SEQ ID NO:25; VL1 of the second polypeptide comprises anamino acid sequence having at least 90% identity, at least 95% identity,or 100% identity to any one of SEQ ID NO:30; and VL2 of the secondpolypeptide comprises an amino acid sequence having at least 90%identity, at least 95% identity, or 100% identity to any one of SEQ IDNO:31. In some aspects, the first polypeptide has a structurerepresented by VL1-VL2-VH2-VH1-Fc and the second polypeptide has astructure represented by Fc. In some aspects, the first polypeptide hasa structure represented by VL1-VL2-VH2-VH1-Fc and the second polypeptidehas a structure represented by VL1-VL2-VH2-VH1-Fc. In some aspects, thefirst polypeptide has a structure represented by VL1-VL2-VH2-VH1-Fc andthe second polypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-Fc. In some aspects, the first polypeptide hasa structure represented by VL1-VL2-VH2-VH1-Fc and the second polypeptidehas a structure represented by VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc. In someaspects, the first polypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-Fc and the second polypeptide has a structurerepresented by Fc. In some aspects, the first polypeptide has astructure represented by VL1-L1-VL2-L2-VH2-L3-VH1-Fc and the secondpolypeptide has a structure represented by VL1-VL2-VH2-VH1-Fc. In someaspects, the first polypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-Fc and the second polypeptide has a structurerepresented by VL1-L1-VL2-L2-VH2-L3-VH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VL1-L1-VL2-L2-VH2-L3-VH1-Fcand the second polypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc. In some aspects, the first polypeptidehas a structure represented by VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc and thesecond polypeptide has a structure represented by Fc. In some aspects,the first polypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc and the second polypeptide has astructure represented by VL1-VL2-VH2-VH1-Fc. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc and the second polypeptide has astructure represented by VL1-L1-VL2-L2-VH2-L3-VH1-Fc. In some aspects,the first polypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc and the second polypeptide has astructure represented by VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc. In someaspects, the first polypeptide comprises a VH1 comprising an amino acidsequence having at least 90% identity to SEQ ID NO: 25; a VH2 comprisingan amino acid sequence having at least 90% identity to SEQ ID NO:24; aVL1 comprising an amino acid sequence having at least 90% identity toSEQ ID NO: 31; and a VL2 comprising an amino acid sequence having atleast 90% identity to SEQ ID NO:30; and the second polypeptide comprisesa VH1 comprising an amino acid sequence having at least 90% identity toSEQ ID NO: 24; a VH2 comprising an amino acid sequence having at least90% identity to SEQ ID NO:25; a VL1 comprising an amino acid sequencehaving at least 90% identity to SEQ ID NO: 30; and a VL2 comprising anamino acid sequence having at least 90% identity to SEQ ID NO:31. Atleast 90% identity may include at least 91%, 92%, 93%, 94%, 95%, 96%,97%, 98%, 99% or 100% identity to the reference polypeptide sequence.For example, the first polypeptide may comprise a VH1 comprising theamino acid sequence of SEQ ID NO:25; a VH2 comprising the amino acidsequence of SEQ ID NO:24; a VL1 comprising the amino acid sequence ofSEQ ID NO:31; and a VL2 comprising the amino acid sequence of SEQ ID NO:30, and the second polypeptide may comprise a VH1 comprising the aminoacid sequence of SEQ ID NO:24; a VH2 comprising the amino acid sequenceof SEQ ID NO:25; a VL1 comprising the amino acid sequence of SEQ IDNO:30; and a VL2 comprising the amino acid sequence of SEQ ID NO: 31. Insome aspects, the first polypeptide comprises an amino acid sequencehaving at least 90% identity, at least 95% identity, or 100% identity toSEQ ID NO:36 or 37, and the second polypeptide comprises an amino acidsequence having at least 90% identity, at least 95% identity, or 100%identity to SEQ ID NO:34 or 35. In some aspects, the first polypeptidemay comprise an amino acid sequence having at least 90% identity to SEQID NO:36 or 37 and the second polypeptide may comprise an amino acidsequence having at least 90% identity to SEQ ID NO: 34 or 35. At least90% identity may include at least 91%, 92%, 93%, 94%, 95%, 96%, 97%,98%, 99% or 100% identity to the reference polypeptide sequence. In someaspects, the first polypeptide may comprise the amino acid sequence ofSEQ ID NO:36 or 37; and the second polypeptide may comprise the aminoacid sequence of SEQ ID NO: 34 or 35. For example, the first polypeptidemay comprise the amino acid sequence of SEQ ID NO: 36 and the secondpolypeptide may comprise the amino acid sequence of SEQ ID NO: 34. Forexample, the first polypeptide may comprise the amino acid sequence ofSEQ ID NO: 36 and the second polypeptide may comprise the amino acidsequence of SEQ ID NO: 35. For example, the first polypeptide maycomprise the amino acid sequence of SEQ ID NO: 37 and the secondpolypeptide may comprise the amino acid sequence of SEQ ID NO: 34. Forexample, the first polypeptide may comprise the amino acid sequence ofSEQ ID NO: 37 and the second polypeptide may comprise the amino acidsequence of SEQ ID NO: 35.

In yet other aspects, the invention is directed to antigen bindingpolypeptide complexes having a first polypeptide and a secondpolypeptide, wherein the first polypeptide has a structure representedby VL1-VL2-VH2-VH1 or VH1-VH2-VL2-VL1, and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3 or VH3-VH4-VL4-VL3. In someaspects, the first polypeptide has a structure represented byVL1-VL2-VH2-VH1 and the second polypeptide has a structure representedby VL3-VL4-VH4-VH3. In some aspects, the first polypeptide has astructure represented by VL1-VL2-VH2-VH1 and the second polypeptide hasa structure represented by VH3-VH4-VL4-VL3. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1 and thesecond polypeptide has a structure represented by VL3-VL4-VH4-VH3. Insome aspects, the first polypeptide has a structure represented byVH1-VH2-VL2-VL1 and the second polypeptide has a structure representedby VH3-VH4-VL4-VL3. In some aspects, the antigen binding polypeptidecomplex contains an amino acid linker between any two regions denoted ina structure described herein. In some aspects, the antigen bindingpolypeptide complex can contain an Fc region, CH1 region, CL region,and/or CH3 or any combination thereof. In some aspects, the Fc region,CH1 region, CL region and/or CH3 is located at the carboxy terminus ofthe antigen binding polypeptide, and is optionally linked to polypeptideby at least one amino acid linker. In some aspects, the Fc regioncomprises an amino acid sequence of any one of SEQ ID NOs:391-404, or anamino acid sequence having at least 80%, at least 85%, at least 90%, atleast 95%, at least 96%, at least 97%, at least 98%, or at least 99%identity to any one of SEQ ID NOs:391-404. In some aspects, the CH1region comprises an amino acid sequence of any one of SEQ ID NOs:405-409or an amino acid sequence having at least 80%, at least 85%, at least90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least99% identity to any one of SEQ ID NOs:405-409. In some aspects, the CLregion comprises an amino acid sequence of SEQ ID NO:420 or 421, or anamino acid sequence having at least 80%, at least 85%, at least 90%, atleast 95%, at least 96%, at least 97%, at least 98% or at least 99%identity to SEQ ID NO:420 or 421. In some aspects, the antigen bindingpolypeptide complex is an antibody or antigen binding fragment thereof.

In some aspects, the antigen binding polypeptide and antigen bindingpolypeptide complex of the invention specifically bind to an HIVprotein. The HIV protein specifically bound by the antigen bindingpolypeptide and antigen binding polypeptide complex of the invention maybe selected from: Env, gp160, gp120, gp41, p17, p24, p7, p55, p66, p31,Nef, Tat, Rev, Vif, Vpr and Vpu. In some aspects, the antigen bindingpolypeptide or antigen binding polypeptide complex specifically binds atleast one epitope on at least HIV protein selected from: Env, gp160,gp120, gp41, p17, p24, p7, p55, p66, p31, Nef, Tat, Rev, Vif, Vpr andVpu. In some aspects, the antigen binding polypeptide or polypeptidecomprised within the antigen binding complex may comprise a VL1, VL2,VL3, VL4, VH1, VH2, VH3, and/or VH4 that specifically binds to one ormore of: Env, gp160, gp120, gp41, p17, p24, p7, p55, p66, p31, Nef, Tat,Rev, Vif, Vpr and Vpu. For example, the antigen binding polypeptide orpolypeptide comprised within the antigen binding complex may comprise aVL1 that specifically binds to Env, gp160, gp120, gp41, p17, p24, p7,p55, p66, p31, Nef, Tat, Rev, Vif, Vpr and Vpu. For example, the VL1 mayspecifically bind to Env. For example, the VL1 may specifically bind togp160. For example, the VL1 may specifically bind to gp120. For example,the VL1 may specifically bind to gp41. For example, the VL1 mayspecifically bind to p17. For example, the VL1 may specifically bind top24. For example, the VL1 may specifically bind to p7. For example, theVL1 may specifically bind to p55. For example, the VL1 may specificallybind to p66. For example, the VL1 may specifically bind to p31. Forexample, the VL1 may specifically bind to Nef. For example, the VL1 mayspecifically bind to Tat. For example, the VL1 may specifically bind toRev. For example, the VL1 may specifically bind to Vif. For example, theVL1 may specifically bind to Vpr. or example, the VL1 may specificallybind to Vpu. For example, the antigen binding polypeptide or polypeptidecomprised within the antigen binding complex may comprise a VL2 thatspecifically binds to Env, gp160, gp120, gp41, p17, p24, p7, p55, p66,p31, Nef, Tat, Rev, Vif, Vpr and Vpu. For example, the VL2 mayspecifically bind to Env. For example, the VL2 may specifically bind togp160. For example, the VL2 may specifically bind to gp120. For example,the VL2 may specifically bind to gp41. For example, the VL2 mayspecifically bind to p17. For example, the VL2 may specifically bind top24. For example, the VL2 may specifically bind to p7. For example, theVL2 may specifically bind to p55. For example, the VL2 may specificallybind to p66. For example, the VL2 may specifically bind to p31. Forexample, the VL2 may specifically bind to Nef. For example, the VL2 mayspecifically bind to Tat. For example, the VL2 may specifically bind toRev. For example, the VL2 may specifically bind to Vif. For example, theVL2 may specifically bind to Vpr. or example, the VL2 may specificallybind to Vpu. For example, the antigen binding polypeptide or polypeptidecomprised within the antigen binding complex may comprise a VL3 thatspecifically binds to Env, gp160, gp120, gp41, p17, p24, p7, p55, p66,p31, Nef, Tat, Rev, Vif, Vpr and Vpu. For example, the VL3 mayspecifically bind to Env. For example, the VL3 may specifically bind togp160. For example, the VL3 may specifically bind to gp120. For example,the VL3 may specifically bind to gp41. For example, the VL3 mayspecifically bind to p17. For example, the VL3 may specifically bind top24. For example, the VL3 may specifically bind to p7. For example, theVL3 may specifically bind to p55. For example, the VL3 may specificallybind to p66. For example, the VL3 may specifically bind to p31. Forexample, the VL3 may specifically bind to Nef. For example, the VL3 mayspecifically bind to Tat. For example, the VL3 may specifically bind toRev. For example, the VL3 may specifically bind to Vif. For example, theVL3 may specifically bind to Vpr. or example, the VL3 may specificallybind to Vpu. For example, the antigen binding polypeptide or polypeptidecomprised within the antigen binding complex may comprise a VL4 thatspecifically binds to Env, gp160, gp120, gp41, p17, p24, p7, p55, p66,p31, Nef, Tat, Rev, Vif, Vpr and Vpu. For example, the VL4 mayspecifically bind to Env. For example, the VL4 may specifically bind togp160. For example, the VL4 may specifically bind to gp120. For example,the VL4 may specifically bind to gp41. For example, the VL4 mayspecifically bind to p17. For example, the VL4 may specifically bind top24. For example, the VL4 may specifically bind to p7. For example, theVL4 may specifically bind to p55. For example, the VL4 may specificallybind to p66. For example, the VL4 may specifically bind to p31. Forexample, the VL4 may specifically bind to Nef. For example, the VL4 mayspecifically bind to Tat. For example, the VL4 may specifically bind toRev. For example, the VL4 may specifically bind to Vif. For example, theVL4 may specifically bind to Vpr. or example, the VL4 may specificallybind to Vpu. For example, the antigen binding polypeptide or polypeptidecomprised within the antigen binding complex may comprise a VH1 thatspecifically binds to Env, gp160, gp120, gp41, p17, p24, p7, p55, p66,p31, Nef, Tat, Rev, Vif, Vpr and Vpu. For example, the VH1 mayspecifically bind to Env. For example, the VH1 may specifically bind togp160. For example, the VH1 may specifically bind to gp120. For example,the VH1 may specifically bind to gp41. For example, the VH1 mayspecifically bind to p17. For example, the VH1 may specifically bind top24. For example, the VH1 may specifically bind to p7. For example, theVH1 may specifically bind to p55. For example, the VH1 may specificallybind to p66. For example, the VH1 may specifically bind to p31. Forexample, the VH1 may specifically bind to Nef. For example, the VH1 mayspecifically bind to Tat. For example, the VH1 may specifically bind toRev. For example, the VH1 may specifically bind to Vif. For example, theVH1 may specifically bind to Vpr. or example, the VH1 may specificallybind to Vpu. For example, the antigen binding polypeptide or polypeptidecomprised within the antigen binding complex may comprise a VH2 thatspecifically binds to Env, gp160, gp120, gp41, p17, p24, p7, p55, p66,p31, Nef, Tat, Rev, Vif, Vpr and Vpu. For example, the VH2 mayspecifically bind to Env. For example, the VH2 may specifically bind togp160. For example, the VH2 may specifically bind to gp120. For example,the VH2 may specifically bind to gp41. For example, the VH2 mayspecifically bind to p17. For example, the VH2 may specifically bind top24. For example, the VH2 may specifically bind to p7. For example, theVH2 may specifically bind to p55. For example, the VH2 may specificallybind to p66. For example, the VH2 may specifically bind to p31. Forexample, the VH2 may specifically bind to Nef. For example, the VH2 mayspecifically bind to Tat. For example, the VH2 may specifically bind toRev. For example, the VH2 may specifically bind to Vif. For example, theVH2 may specifically bind to Vpr. or example, the VH2 may specificallybind to Vpu. For example, the antigen binding polypeptide or polypeptidecomprised within the antigen binding complex may comprise a VH3 thatspecifically binds to Env, gp160, gp120, gp41, p17, p24, p7, p55, p66,p31, Nef, Tat, Rev, Vif, Vpr and Vpu. For example, the VH3 mayspecifically bind to Env. For example, the VH3 may specifically bind togp160. For example, the VH3 may specifically bind to gp120. For example,the VH3 may specifically bind to gp41. For example, the VH3 mayspecifically bind to p17. For example, the VH3 may specifically bind top24. For example, the VH3 may specifically bind to p7. For example, theVH3 may specifically bind to p55. For example, the VH3 may specificallybind to p66. For example, the VH3 may specifically bind to p31. Forexample, the VH3 may specifically bind to Nef. For example, the VH3 mayspecifically bind to Tat. For example, the VH3 may specifically bind toRev. For example, the VH3 may specifically bind to Vif. For example, theVH3 may specifically bind to Vpr. or example, the VH3 may specificallybind to Vpu. For example, the antigen binding polypeptide or polypeptidecomprised within the antigen binding complex may comprise a VH4 thatspecifically binds to Env, gp160, gp120, gp41, p17, p24, p7, p55, p66,p31, Nef, Tat, Rev, Vif, Vpr and Vpu. For example, the VH4 mayspecifically bind to Env. For example, the VH4 may specifically bind togp160. For example, the VH4 may specifically bind to gp120. For example,the VH4 may specifically bind to gp41. For example, the VH4 mayspecifically bind to p17. For example, the VH4 may specifically bind top24. For example, the VH4 may specifically bind to p7. For example, theVH4 may specifically bind to p55. For example, the VH4 may specificallybind to p66. For example, the VH4 may specifically bind to p31. Forexample, the VH4 may specifically bind to Nef. For example, the VH4 mayspecifically bind to Tat. For example, the VH4 may specifically bind toRev. For example, the VH4 may specifically bind to Vif. For example, theVH4 may specifically bind to Vpr. or example, the VH4 may specificallybind to Vpu. Any of the antigen binding polypeptide structures and anyof the antigen binding polypeptide complex structures described hereinmay be used to target one or more of the HIV proteins described herein.

In some aspects, the invention is directed to an antigen bindingpolypeptide complex comprising a first polypeptide and a secondpolypeptide; wherein the first polypeptide has a structure representedby VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1; orVH1-L1-VH2-L2-VL2-L3-VL1; wherein the second polypeptide has a structurerepresented by VL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3;VL3-L4-VL4-L5-VH4-L6-VH3; or VH3-L4-VH4-L5-VL4-L6-VL3; wherein VL1 is afirst immunoglobulin light chain variable region; VL2 is a secondimmunoglobulin light chain variable region; VL3 is a thirdimmunoglobulin light chain variable region; VL4 is a fourthimmunoglobulin light chain variable region; VH1 is a firstimmunoglobulin heavy chain variable region; VH2 is a secondimmunoglobulin heavy chain variable region; VH3 is a thirdimmunoglobulin heavy chain variable region; VH4 is a fourthimmunoglobulin heavy chain variable region; and L1, L2, L3, L4, L5 andL6 are amino acid linkers. In some aspects, the first polypeptide has astructure represented by VL1-VL2-VH2-VH1, and the second polypeptide hasa structure represented by VL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3;VL3-L4-VL4-L5-VH4-L6-VH3; or VH3-L4-VH4-L5-VL4-L6-VL3. In some aspects,the first polypeptide has a structure represented by VH1-VH2-VL2-VL1,and the second polypeptide has a structure represented byVL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3; VL3-L4-VL4-L5-VH4-L6-VH3; orVH3-L4-VH4-L5-VL4-L6-VL3. In some aspects, the first polypeptide has astructure represented by VL1-L1-VL2-L2-VH2-L3-VH1, and the secondpolypeptide has a structure represented by VL3-VL4-VH4-VH3;VH3-VH4-VL4-VL3; VL3-L4-VL4-L5-VH4-L6-VH3; or VH3-L4-VH4-L5-VL4-L6-VL3.In some aspects, the first polypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1, and the second polypeptide has a structurerepresented by VL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3;VL3-L4-VL4-L5-VH4-L6-VH3; or VH3-L4-VH4-L5-VL4-L6-VL3.

In other aspects, the invention is directed to an antigen bindingpolypeptide complex comprising a first polypeptide and a secondpolypeptide; wherein the first polypeptide has a structure representedby VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; wherein the second polypeptide has astructure represented by VL3-VL4-VH4-VH3-Fe; VH3-VH4-VL4-VL3-Fc;VL3-L5-VL4-L6-VH4-L7-VH3-Fc; VH3-L5-VH4-L6-VL4-L7-VL3-Fc;VL3-L5-VL4-L6-VH4-L7-VH3-L8-Fc; or VH3-L5-VH4-L6-VL4-L7-VL3-L8-Fc;wherein VL1 is a first immunoglobulin light chain variable region; VL2is a second immunoglobulin light chain variable region; VL3 is a thirdimmunoglobulin light chain variable region; VL4 is a fourthimmunoglobulin light chain variable region; VH1 is a firstimmunoglobulin heavy chain variable region; VH2 is a secondimmunoglobulin heavy chain variable region; VH3 is a thirdimmunoglobulin heavy chain variable region; VH4 is a fourthimmunoglobulin heavy chain variable region; Fc is a region comprising animmunoglobulin heavy chain constant region 2 (CH2), an immunoglobulinheavy chain constant region 3 (CH3), and optionally, an immunoglobulinhinge; and L1, L2, L3, L4, L5, L6, L7 and L8 are amino acid linkers. Insome aspects, the first polypeptide has a structure represented byVL1-VL2-VH2-VH1-Fc and the second polypeptide has a structurerepresented by VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc;VL3-L5-VL4-L6-VH4-L7-VH3-Fc; VH3-L5-VH4-L6-VL4-L7-VL3-Fc;VL3-L5-VL4-L6-VH4-L7-VH3-L8-Fc; or VH3-L5-VH4-L6-VL4-L7-VL3-L8-Fe. Insome aspects, the first polypeptide has a structure represented byVH1-VH2-VL2-VL1-Fc and the second polypeptide has a structurerepresented by VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc;VL3-L5-VL4-L6-VH4-L7-VH3-Fc; VH3-L5-VH4-L6-VL4-L7-VL3-Fc;VL3-L5-VL4-L6-VH4-L7-VH3-L8-Fc; or VH3-L5-VH4-L6-VL4-L7-VL3-L8-Fc. Insome aspects, the first polypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-Fe and the second polypeptide has a structurerepresented by VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc;VL3-L5-VL4-L6-VH4-L7-VH3-Fc; VH3-L5-VH4-L6-VL4-L7-VL3-Fc;VL3-L5-VL4-L6-VH4-L7-VH3-L8-Fc; or VH3-L5-VH4-L6-VL4-L7-VL3-L8-Fe. Insome aspects, the first polypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-Fc and the second polypeptide has a structurerepresented by VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc;VL3-L5-VL4-L6-VH4-L7-VH3-Fc; VH3-L5-VH4-L6-VL4-L7-VL3-Fc;VL3-L5-VL4-L6-VH4-L7-VH3-L8-Fc; or VH3-L5-VH4-L6-VL4-L7-VL3-L8-Fc. Insome aspects, the first polypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fe;VL3-L5-VL4-L6-VH4-L7-VH3-Fc; VH3-L5-VH4-L6-VL4-L7-VL3-Fc;VL3-L5-VL4-L6-VH4-L7-VH3-L8-Fe; or VH3-L5-VH4-L6-VL4-L7-VL3-L8-Fc. Insome aspects, the first polypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc;VL3-L5-VL4-L6-VH4-L7-VH3-Fc; VH3-L5-VH4-L6-VL4-L7-VL3-Fc;VL3-L5-VL4-L6-VH4-L7-VH3-L8-Fc; or VH3-L5-VH4-L6-VL4-L7-VL3-L8-Fe.

In other aspects, the invention is directed to an antigen bindingpolypeptide complex comprising a first polypeptide and a secondpolypeptide; wherein the first polypeptide has a structure representedby VL1-VL2-VH2-VH1-CH1; VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL;VH1-VH2-VL2-VL1-CL; VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL;VL1-VL2-VH2-VH1-CL-CH1; VH1-VH2-VL2-VL1-CL-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL; VH1-L1- VH2-L2-VL2-L3-VL1-L4-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; wherein the second polypeptidehas a structure represented by VL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1;VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL;VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL;VL3-L6-VL4- L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1; wherein VL1 is a firstimmunoglobulin light chain variable region; VL2 is a secondimmunoglobulin light chain variable region; VL3 is a thirdimmunoglobulin light chain variable region; VL4 is a fourthimmunoglobulin light chain variable region; VH1 is a firstimmunoglobulin heavy chain variable region; VH2 is a secondimmunoglobulin heavy chain variable region; VH3 is a thirdimmunoglobulin heavy chain variable region; VH4 is a fourthimmunoglobulin heavy chain variable region; CH1 is an immunoglobulinheavy chain constant region 1; CL is an immunoglobulin light chainconstant region; and L1, L2, L3, L4, L5, L6, L7, L8, L9 and L10 areamino acid linkers. In some aspects, the first polypeptide has astructure represented by VL1-VL2-VH2-VH1-CH1 and the second polypeptidehas a structure represented by VL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1;VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL;VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1; or VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1. Insome aspects, the first polypeptide has a structure represented byVH1-VH2-VL2-VL1-CH1 and the second polypeptide has a structurerepresented by VL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1;VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL;VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-CL and thesecond polypeptide has a structure represented by VL3-VL4-VH4-VH3-CH1;VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL;VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1;VH3-VH4-VL4-VL3-CL-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4- L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1-CL and thesecond polypeptide has a structure represented by VL3-VL4-VH4-VH3-CH1;VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL;VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1;VH3-VH4-VL4-VL3-CL-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3- L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-CH1-CL andthe second polypeptide has a structure represented byVL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL;VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL;VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL;VL3-L6-VL4-L7-VH4- L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1-CH1-CL andthe second polypeptide has a structure represented byVL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL;VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL;VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-CL-CH1 andthe second polypeptide has a structure represented byVL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL;VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL;VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL;VL3-L6-VL4-L7-VH4- L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1-CL-CH1 andthe second polypeptide has a structure represented byVL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL;VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL;VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1 and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1;VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL;VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL;VL3-L6-VL4- L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1 and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1;VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL;VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1;VL3-L6-VL4-L7-VH4- L8-VH3-L9-CL; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CL and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1;VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL;VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1;VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL;VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1- L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1;VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL;VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL; VH3-L6- VH4-L7-VL4-L8-VL3-L9-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1;VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL;VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL;VL3-L6-VL4- L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1 and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1;VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL;VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1;VL3-L6-VL4- L7-VH4-L8-VH3-L9-CL; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1 and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1;VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL;VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL; VH3-L6-VH4- L7-VL4-L8-VL3-L9-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1.

In other aspects, the invention is directed to an antigen bindingpolypeptide complex comprising a first polypeptide and a secondpolypeptide; wherein the first polypeptide has a structure representedby VL1-VL2-VH2-VH1-CH1-Fc; VH1-VH2-VL2-VL1-CH1-Fc;VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc; VL1-VL2-VH2-VH1-CH1-CL-Fc;VH1-VH2-VL2-VL1-CH1-CL-Fe; VL1-VL2-VH2-VH1-CL-CH1-Fc;VH1-VH2-VL2-VL1-CL-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fe; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL- Fe;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fe;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fe; wherein the second polypeptidehas a structure represented by VL3-VL4-VH4-VH3-CH1-Fc;VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc;VL3-VL4-VH4-VH3-CH1-CL-Fc; VH3-VH4-VL4-VL3-CH1-CL-Fc;VL3-VL4-VH4-VH3-CL-CH1-Fc; VH3-VH4-VL4-VL3-CL-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fe;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fe; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fe; wherein VL1 is a firstimmunoglobulin light chain variable region; VL2 is a secondimmunoglobulin light chain variable region; VL3 is a thirdimmunoglobulin light chain variable region; VL4 is a fourthimmunoglobulin light chain variable region; VH1 is a firstimmunoglobulin heavy chain variable region; VH2 is a secondimmunoglobulin heavy chain variable region; VH3 is a thirdimmunoglobulin heavy chain variable region; VH4 is a fourthimmunoglobulin heavy chain variable region; Fc is a region comprising animmunoglobulin heavy chain constant region 2 (CH2), an immunoglobulinheavy chain constant region 3 (CH3), and optionally, an immunoglobulinhinge; CH1 is an immunoglobulin heavy chain constant region 1; CL is animmunoglobulin light chain constant region; and L1, L2, L3, L4, L5, L6,L7, L8, L9 and L10 are amino acid linkers. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-CH1-Fc; andthe second polypeptide has a structure represented byVL3-VL4-VH4-VH3-CH1-F c; VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc;VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fc;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fe;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fe; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fe. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1-CH1-Fc; andthe second polypeptide has a structure represented byVL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc;VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fc;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fe;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fe; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fe. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-CL-Fc; andthe second polypeptide has a structure represented byVL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc;VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fc;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fe;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fe; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fe. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1-CL-Fc; andthe second polypeptide has a structure represented byVL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc;VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fc;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fe;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fe; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fe. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-CH1-CL-Fc;and the second polypeptide has a structure represented byVL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc;VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fc;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fe;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fe; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fe. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1-CH1-CL-Fc;and the second polypeptide has a structure represented byVL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc;VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fc;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fe;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fe; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fe. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-CL-CH1-Fc;and the second polypeptide has a structure represented byVL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc;VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fc;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fe;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1-CL-CH1-Fc;and the second polypeptide has a structure represented byVL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc;VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fc;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fe;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc;VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fc;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc; and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc;VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fc;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc;VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fc;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc; and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc;VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fc;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fe;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fe; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fe. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc; and the second polypeptide hasa structure represented by VL3-VL4-VH4-VH3-CH1-Fc;VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc;VL3-VL4-VH4-VH3-CH1-CL-Fc; VH3-VH4-VL4-VL3-CH1-CL-Fc;VL3-VL4-VH4-VH3-CL-CH1-Fc; VH3-VH4-VL4-VL3-CL-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fe. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fe; and the second polypeptide hasa structure represented by VL3-VL4-VH4-VH3-CH1-Fe;VH3-VH4-VL4-VL3-CH1-Fe; VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc;VL3-VL4-VH4-VH3-CH1-CL-Fc; VH3-VH4-VL4-VL3-CH1-CL-Fc;VL3-VL4-VH4-VH3-CL-CH1-Fc; VH3-VH4-VL4-VL3-CL-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fe;VL3-L6-VL4-L7-VH4- L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fe;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fe; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fe. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fe; and the second polypeptide hasa structure represented by VL3-VL4-VH4-VH3-CH1-Fe;VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc;VL3-VL4-VH4-VH3-CH1-CL-Fc; VH3-VH4-VL4-VL3-CH1-CL-Fc;VL3-VL4-VH4-VH3-CL-CH1-Fc; VH3-VH4-VL4-VL3-CL-CH1-Fe;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fe; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fe. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fe; and the second polypeptide hasa structure represented by VL3-VL4-VH4-VH3-CH1-Fc;VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc;VL3-VL4-VH4-VH3-CH1-CL-Fe; VH3-VH4-VL4-VL3-CH1-CL-Fc;VL3-VL4-VH4-VH3-CL-CH1-Fc; VH3-VH4-VL4-VL3-CL-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fe; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fe.

In other aspects, the invention is directed to an antigen bindingpolypeptide complex comprising a first polypeptide and a secondpolypeptide; wherein the first polypeptide has a structure representedby VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1; VL1-VL2-VH2-VH1-Fc;VH1-VH2-VL2-VL1-Fe; VL1-VL2-VH2-VH1-CH1; VH1-VH2-VL2-VL1-CH1;VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL; VL1-VL2-VH2-VH1-CH1-CL;VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1; VH1-VH2-VL2-VL1-CL-CH1;VL1-VL2-VH2-VH1-CH1-Fc; VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc;VH1-VH2-VL2-VL1-CL-Fc; VL1-VL2-VH2-VH1-CH1-CL-Fc;VH1-VH2-VL2-VL1-CH1-CL-Fc; VL1-VL2-VH2-VH1-CL-CH1-Fc;VH1-VH2-VL2-VL1-CL-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1;VH1-L1-VH2-L2-VL2-L3-VL1; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2- L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2- L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1- L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4- CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc; wherein the second polypeptidehas a structure represented by VL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3;VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc; VL3-VL4-VH4-VH3-CH1;VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL;VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1;VH3-VH4-VL4-VL3-CL-CH1; VL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc;VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fc;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3;VH3-L6-VH4-L7-VL4-L8-VL3; VL3-L6-VL4-L7-VH4-L8-VH3-Fc;VH3-L6-VH4-L7-VL4-L8- VL3-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7-VL4- L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc; wherein VL1 is a firstimmunoglobulin light chain variable region; VL2 is a secondimmunoglobulin light chain variable region; VL3 is a thirdimmunoglobulin light chain variable region; VL4 is a fourthimmunoglobulin light chain variable region; VH1 is a firstimmunoglobulin heavy chain variable region; VH2 is a secondimmunoglobulin heavy chain variable region; VH3 is a thirdimmunoglobulin heavy chain variable region; VH4 is a fourthimmunoglobulin heavy chain variable region; Fc is a region comprising animmunoglobulin heavy chain constant region 2 (CH2), an immunoglobulinheavy chain constant region 3 (CH3), and optionally, an immunoglobulinhinge; CH1 is an immunoglobulin heavy chain constant region 1; CL is animmunoglobulin light chain constant region; and L1, L2, L3, L4, L5, L6,L7, L8, L9 and L10 are amino acid linkers. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1, and thesecond polypeptide has a structure represented by VL3-VL4-VH4-VH3;VH3-VH4-VL4-VL3; VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc;VL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL;VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL;VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1; VL3-VL4-VH4-VH3-CH1-Fc;VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc;VL3-VL4-VH4-VH3-CH1-CL-Fc; VH3-VH4-VL4-VL3-CH1-CL-Fc;VL3-VL4-VH4-VH3-CL-CH1-Fc; VH3-VH4-VL4-VL3-CL-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3; VH3-L6-VH4-L7-VL4-L8-VL3;VL3-L6-VL4-L7-VH4-L8-VH3-Fc; VH3-L6-VH4- L7-VL4-L8-VL3-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL; VH3- L6-VH4-L7-VL4-L8-VL3-L9-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fe;VL3-L6-VL4-L7-VH4- L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1, and thesecond polypeptide has a structure represented by VL3-VL4-VH4-VH3;VH3-VH4-VL4-VL3; VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc;VL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL;VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL;VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1; VL3-VL4-VH4-VH3-CH1-Fc;VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc;VL3-VL4-VH4-VH3-CH1-CL-Fc; VH3-VH4-VL4-VL3-CH1-CL-Fc;VL3-VL4-VH4-VH3-CL-CH1-Fc; VH3-VH4-VL4-VL3-CL-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3; VH3-L6-VH4-L7-VL4-L8-VL3;VL3-L6-VL4-L7-VH4-L8-VH3-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9- CH1; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-Fc, and thesecond polypeptide has a structure represented by VL3-VL4-VH4-VH3;VH3-VH4-VL4-VL3; VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc;VL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL;VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL;VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1; VL3-VL4-VH4-VH3-CH1-Fe;VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc;VL3-VL4-VH4-VH3-CH1-CL-Fc; VH3-VH4-VL4-VL3-CH1-CL-Fc;VL3-VL4-VH4-VH3-CL-CH1-Fc; VH3-VH4-VL4-VL3-CL-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3; VH3-L6-VH4-L7-VL4-L8-VL3;VL3-L6-VL4-L7-VH4-L8-VH3-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1; VH3-L6-VH4-L7- VL4-L8-VL3-L9-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL;VL3-L6-VL4- L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1-Fc, and thesecond polypeptide has a structure represented by VL3-VL4-VH4-VH3;VH3-VH4-VL4-VL3; VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc;VL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL;VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL;VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1; VL3-VL4-VH4-VH3-CH1-Fc;VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc;VL3-VL4-VH4-VH3-CH1-CL-Fc; VH3-VH4-VL4-VL3-CH1-CL-Fc;VL3-VL4-VH4-VH3-CL-CH1-Fc; VH3-VH4-VL4-VL3-CL-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3; VH3-L6-VH4-L7-VL4-L8-VL3;VL3-L6-VL4-L7-VH4-L8-VH3-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1;VL3-L6- VL4-L7-VH4-L8-VH3-L9-CL; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3- L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-CH1, and thesecond polypeptide has a structure represented by VL3-VL4-VH4-VH3;VH3-VH4-VL4-VL3; VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc;VL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL;VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL;VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1; VL3-VL4-VH4-VH3-CH1-Fc;VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc;VL3-VL4-VH4-VH3-CH1-CL-Fc; VH3-VH4-VL4-VL3-CH1-CL-Fc;VL3-VL4-VH4-VH3-CL-CH1-Fc; VH3-VH4-VL4-VL3-CL-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3; VH3-L6-VH4-L7-VL4-L8-VL3;VL3-L6-VL4-L7-VH4-L8-VH3-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1;VL3-L6-VL4-L7- VH4-L8-VH3-L9-CL; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1-CH1, and thesecond polypeptide has a structure represented by VL3-VL4-VH4-VH3;VH3-VH4-VL4-VL3; VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc;VL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL;VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL;VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1; VL3-VL4-VH4-VH3-CH1-Fc;VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc;VL3-VL4-VH4-VH3-CH1-CL-Fc; VH3-VH4-VL4-VL3-CH1-CL-Fc;VL3-VL4-VH4-VH3-CL-CH1-Fc; VH3-VH4-VL4-VL3-CL-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3; VH3-L6-VH4-L7-VL4-L8-VL3;VL3-L6-VL4-L7-VH4-L8-VH3-Fc; VH3-L6-VH4-L7-VL4- L8-VL3-Fe;VL3-L6-VL4-L7-VH4-L8-VH3-L9-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL; VH3-L6-VH4- L7-VL4-L8-VL3-L9-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3- L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-CL, and thesecond polypeptide has a structure represented by VL3-VL4-VH4-VH3;VH3-VH4-VL4-VL3; VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc;VL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL;VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL;VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1; VL3-VL4-VH4-VH3-CH1-Fc;VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc;VL3-VL4-VH4-VH3-CH1-CL-Fc; VH3-VH4-VL4-VL3-CH1-CL-Fc;VL3-VL4-VH4-VH3-CL-CH1-Fc; VH3-VH4-VL4-VL3-CL-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3; VH3-L6-VH4-L7-VL4-L8-VL3;VL3-L6-VL4-L7-VH4-L8-VH3-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-Fe; VH3-L6-VH4-L7-VL4-L8-VL3-L9-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fe;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1-CL, and thesecond polypeptide has a structure represented by VL3-VL4-VH4-VH3;VH3-VH4-VL4-VL3; VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc;VL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL;VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL;VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1; VL3-VL4-VH4-VH3-CH1-Fc;VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc;VL3-VL4-VH4-VH3-CH1-CL-Fc; VH3-VH4-VL4-VL3-CH1-CL-Fc;VL3-VL4-VH4-VH3-CL-CH1-Fc; VH3-VH4-VL4-VL3-CL-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3; VH3-L6-VH4-L7-VL4-L8-VL3;VL3-L6-VL4-L7-VH4-L8-VH3-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL;VL3-L6-VL4-L7-VH4-L8-VH3- L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-CH1-CL, andthe second polypeptide has a structure represented by VL3-VL4-VH4-VH3;VH3-VH4-VL4-VL3; VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc;VL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL;VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL;VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1; VL3-VL4-VH4-VH3-CH1-Fc;VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc;VL3-VL4-VH4-VH3-CH1-CL-Fc; VH3-VH4-VL4-VL3-CH1-CL-Fc;VL3-VL4-VH4-VH3-CL-CH1-Fc; VH3-VH4-VL4-VL3-CL-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3; VH3-L6-VH4-L7-VL4-L8-VL3;VL3-L6-VL4-L7-VH4-L8-VH3-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1;VL3-L6-VL4- L7-VH4-L8-VH3-L9-CL; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3- L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1-CH1-CL, andthe second polypeptide has a structure represented by VL3-VL4-VH4-VH3;VH3-VH4-VL4-VL3; VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc;VL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL;VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL;VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1; VL3-VL4-VH4-VH3-CH1-Fc;VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc;VL3-VL4-VH4-VH3-CH1-CL-Fc; VH3-VH4-VL4-VL3-CH1-CL-Fc;VL3-VL4-VH4-VH3-CL-CH1-Fc; VH3-VH4-VL4-VL3-CL-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3; VH3-L6-VH4-L7-VL4-L8-VL3;VL3-L6-VL4-L7-VH4-L8-VH3-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1;VL3-L6-VL4-L7- VH4-L8-VH3-L9-CL; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-CL-CH1, andthe second polypeptide has a structure represented by VL3-VL4-VH4-VH3;VH3-VH4-VL4-VL3; VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc;VL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL;VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL;VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1; VL3-VL4-VH4-VH3-CH1-Fc;VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc;VL3-VL4-VH4-VH3-CH1-CL-Fc; VH3-VH4-VL4-VL3-CH1-CL-Fc;VL3-VL4-VH4-VH3-CL-CH1-Fc; VH3-VH4-VL4-VL3-CL-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3; VH3-L6-VH4-L7-VL4-L8-VL3;VL3-L6-VL4-L7-VH4-L8-VH3-Fc; VH3-L6-VH4- L7-VL4-L8-VL3-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL; VH3- L6-VH4-L7-VL4-L8-VL3-L9-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fe;VL3-L6-VL4-L7-VH4- L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1-CL-CH1, andthe second polypeptide has a structure represented by VL3-VL4-VH4-VH3;VH3-VH4-VL4-VL3; VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc;VL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL;VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL;VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1; VL3-VL4-VH4-VH3-CH1-Fc;VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc;VL3-VL4-VH4-VH3-CH1-CL-Fc; VH3-VH4-VL4-VL3-CH1-CL-Fc;VL3-VL4-VH4-VH3-CL-CH1-Fc; VH3-VH4-VL4-VL3-CL-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3; VH3-L6-VH4-L7-VL4-L8-VL3;VL3-L6-VL4-L7-VH4-L8-VH3-Fc; VH3-L6-VH4-L7-VL4-L8- VL3-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL; VH3-L6-VH4-L7-VL4- L8-VL3-L9-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-CH1-Fc, andthe second polypeptide has a structure represented by VL3-VL4-VH4-VH3;VH3-VH4-VL4-VL3; VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc;VL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL;VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL;VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1; VL3-VL4-VH4-VH3-CH1-Fc;VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc;VL3-VL4-VH4-VH3-CH1-CL-Fc; VH3-VH4-VL4-VL3-CH1-CL-Fc;VL3-VL4-VH4-VH3-CL-CH1-Fc; VH3-VH4-VL4-VL3-CL-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3; VH3-L6-VH4-L7-VL4-L8-VL3;VL3-L6-VL4-L7-VH4-L8-VH3-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1; VH3-L6- VH4-L7-VL4-L8-VL3-L9-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1-CH1-Fc, andthe second polypeptide has a structure represented by VL3-VL4-VH4-VH3;VH3-VH4-VL4-VL3; VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc;VL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL;VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL;VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1; VL3-VL4-VH4-VH3-CH1-Fc;VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc;VL3-VL4-VH4-VH3-CH1-CL-Fc; VH3-VH4-VL4-VL3-CH1-CL-Fc;VL3-VL4-VH4-VH3-CL-CH1-Fc; VH3-VH4-VL4-VL3-CL-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3; VH3-L6-VH4-L7-VL4-L8-VL3;VL3-L6-VL4-L7-VH4-L8-VH3-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL;VL3-L6-VL4-L7-VH4-L8-VH3- L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-CL-Fc, andthe second polypeptide has a structure represented by VL3-VL4-VH4-VH3;VH3-VH4-VL4-VL3; VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc;VL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL;VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL;VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1; VL3-VL4-VH4-VH3-CH1-Fc;VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc;VL3-VL4-VH4-VH3-CH1-CL-Fc; VH3-VH4-VL4-VL3-CH1-CL-Fc;VL3-VL4-VH4-VH3-CL-CH1-Fc; VH3-VH4-VL4-VL3-CL-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3; VH3-L6-VH4-L7-VL4-L8-VL3;VL3-L6-VL4-L7-VH4-L8-VH3-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-Fe;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1;VL3-L6-VL4- L7-VH4-L8-VH3-L9-CL; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3- L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1-CL-Fc, andthe second polypeptide has a structure represented by VL3-VL4-VH4-VH3;VH3-VH4-VL4-VL3; VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc;VL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL;VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL;VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1; VL3-VL4-VH4-VH3-CH1-Fc;VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc;VL3-VL4-VH4-VH3-CH1-CL-Fc; VH3-VH4-VL4-VL3-CH1-CL-Fc;VL3-VL4-VH4-VH3-CL-CH1-Fc; VH3-VH4-VL4-VL3-CL-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3; VH3-L6-VH4-L7-VL4-L8-VL3;VL3-L6-VL4-L7-VH4-L8-VH3-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1;VL3-L6-VL4-L7- VH4-L8-VH3-L9-CL; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-CH1-CL-Fc,and the second polypeptide has a structure represented byVL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3; VL3-VL4-VH4-VH3-Fc;VH3-VH4-VL4-VL3-Fc; VL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1;VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL;VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1;VL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc;VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fc;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3;VH3-L6-VH4-L7-VL4-L8-VL3; VL3-L6-VL4-L7-VH4-L8-VH3-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3- L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fe;VL3-L6-VL4-L7-VH4- L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1-CH1-CL-Fc,and the second polypeptide has a structure represented byVL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3; VL3-VL4-VH4-VH3-Fc;VH3-VH4-VL4-VL3-Fc; VL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1;VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL;VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1;VL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc;VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fc;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3;VH3-L6-VH4-L7-VL4-L8-VL3; VL3-L6-VL4-L7-VH4-L8-VH3-Fc;VH3-L6-VH4-L7-VL4- L8-VL3-Fe; VL3-L6-VL4-L7-VH4-L8-VH3-L9-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4- L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1- L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3- L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-CL-CH1-Fc,and the second polypeptide has a structure represented byVL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3; VL3-VL4-VH4-VH3-Fc;VH3-VH4-VL4-VL3-Fc; VL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1;VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL;VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1;VL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc;VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fc;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3;VH3-L6-VH4-L7-VL4-L8-VL3; VL3-L6-VL4-L7-VH4-L8-VH3-Fc;VH3-L6-VH4-L7-VL4-L8-VL3- Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-Fc; VL3-L6-VL4-L7-VH4-L8-VH3- L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7-VL4- L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1-CL-CH1-Fc,and the second polypeptide has a structure represented byVL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3; VL3-VL4-VH4-VH3-Fc;VH3-VH4-VL4-VL3-Fc; VL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1;VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL;VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1;VL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc;VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fc;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3;VH3-L6-VH4-L7-VL4-L8-VL3; VL3-L6-VL4-L7-VH4-L8-VH3-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-Fe;VH3-L6-VH4-L7-VL4-L8-VL3-L9-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fe;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VL1-L1-VL2-L2-VH2-L3-VH1, andthe second polypeptide has a structure represented by VL3-VL4-VH4-VH3;VH3-VH4-VL4-VL3; VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc;VL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL;VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL;VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1; VL3-VL4-VH4-VH3-CH1-Fc;VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc;VL3-VL4-VH4-VH3-CH1-CL-Fc; VH3-VH4-VL4-VL3-CH1-CL-Fc;VL3-VL4-VH4-VH3-CL-CH1-Fc; VH3-VH4-VL4-VL3-CL-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3; VH3-L6-VH4-L7-VL4-L8-VL3;VL3-L6-VL4-L7-VH4-L8-VH3-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL;VL3-L6-VL4-L7-VH4-L8-VH3- L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VH1-L1-VH2-L2-VL2-L3-VL1, andthe second polypeptide has a structure represented by VL3-VL4-VH4-VH3;VH3-VH4-VL4-VL3; VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc;VL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL;VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL;VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1; VL3-VL4-VH4-VH3-CH1-Fc;VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc;VL3-VL4-VH4-VH3-CH1-CL-Fc; VH3-VH4-VL4-VL3-CH1-CL-Fc;VL3-VL4-VH4-VH3-CL-CH1-Fc; VH3-VH4-VL4-VL3-CL-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3; VH3-L6-VH4-L7-VL4-L8-VL3;VL3-L6-VL4-L7-VH4-L8-VH3-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-Fe;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1;VL3-L6-VL4- L7-VH4-L8-VH3-L9-CL; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3- L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VL1-L1-VL2-L2-VH2-L3-VH1-Fc,and the second polypeptide has a structure represented byVL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3; VL3-VL4-VH4-VH3-Fc;VH3-VH4-VL4-VL3-Fc; VL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1;VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL;VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1;VL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc;VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fc;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3;VH3-L6-VH4-L7-VL4-L8-VL3; VL3-L6-VL4-L7-VH4-L8-VH3-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-Fe; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4- L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3- L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VH1-L1-VH2-L2-VL2-L3-VL1-Fc,and the second polypeptide has a structure represented byVL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3; VL3-VL4-VH4-VH3-Fc;VH3-VH4-VL4-VL3-Fc; VL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1;VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL;VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1;VL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc;VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fc;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3;VH3-L6-VH4-L7-VL4-L8-VL3; VL3-L6-VL4-L7-VH4-L8-VH3-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-Fe; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4- L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3- L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc, and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3;VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc; VL3-VL4-VH4-VH3-CH1;VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL;VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1;VH3-VH4-VL4-VL3-CL-CH1; VL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc;VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fc;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3;VH3-L6-VH4-L7-VL4-L8-VL3; VL3-L6-VL4-L7-VH4-L8-VH3-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4- L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3- L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc, and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3;VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc; VL3-VL4-VH4-VH3-CH1;VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL;VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1;VH3-VH4-VL4-VL3-CL-CH1; VL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc;VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fc;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3;VH3-L6-VH4-L7-VL4-L8-VL3; VL3-L6-VL4-L7-VH4-L8-VH3-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4- L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3- L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1, and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3;VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc; VL3-VL4-VH4-VH3-CH1;VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL;VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1;VH3-VH4-VL4-VL3-CL-CH1; VL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc;VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fc;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3;VH3-L6-VH4-L7-VL4-L8-VL3; VL3-L6-VL4-L7-VH4-L8-VH3-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4- L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3- L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1, and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3;VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc; VL3-VL4-VH4-VH3-CH1;VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL;VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1;VH3-VH4-VL4-VL3-CL-CH1; VL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc;VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fc;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3;VH3-L6-VH4-L7-VL4-L8-VL3; VL3-L6-VL4-L7-VH4-L8-VH3-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4- L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3- L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CL, and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3;VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc; VL3-VL4-VH4-VH3-CH1;VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL;VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1;VH3-VH4-VL4-VL3-CL-CH1; VL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc;VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fc;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3;VH3-L6-VH4-L7-VL4-L8-VL3; VL3-L6-VL4-L7-VH4-L8-VH3-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4- L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3- L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fe. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL, and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3;VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc; VL3-VL4-VH4-VH3-CH1;VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL;VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1;VH3-VH4-VL4-VL3-CL-CH1; VL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc;VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fc;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3;VH3-L6-VH4-L7-VL4-L8-VL3; VL3-L6-VL4-L7-VH4-L8-VH3-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4- L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3- L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL, and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3;VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc; VL3-VL4-VH4-VH3-CH1;VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL;VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1;VH3-VH4-VL4-VL3-CL-CH1; VL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc;VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fc;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3;VH3-L6-VH4-L7-VL4-L8-VL3; VL3-L6-VL4-L7-VH4-L8-VH3-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6- VL4-L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3- L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL, and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3;VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc; VL3-VL4-VH4-VH3-CH1;VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL;VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1;VH3-VH4-VL4-VL3-CL-CH1; VL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc;VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fc;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3;VH3-L6-VH4-L7-VL4-L8-VL3; VL3-L6-VL4-L7-VH4-L8-VH3-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6- VL4-L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3- L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1, and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3;VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc; VL3-VL4-VH4-VH3-CH1;VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL;VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1;VH3-VH4-VL4-VL3-CL-CH1; VL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc;VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fc;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3;VH3-L6-VH4-L7-VL4-L8-VL3; VL3-L6-VL4-L7-VH4-L8-VH3-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6- VL4-L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3- L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1, and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3;VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc; VL3-VL4-VH4-VH3-CH1;VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL;VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1;VH3-VH4-VL4-VL3-CL-CH1; VL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc;VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fc;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3;VH3-L6-VH4-L7-VL4-L8-VL3; VL3-L6-VL4-L7-VH4-L8-VH3-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6- VL4-L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3- L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fe. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc, and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3;VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc; VL3-VL4-VH4-VH3-CH1;VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL;VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1;VH3-VH4-VL4-VL3-CL-CH1; VL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc;VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fc;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3;VH3-L6-VH4-L7-VL4-L8-VL3; VL3-L6-VL4-L7-VH4-L8-VH3-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6- VL4-L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3- L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc, and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3;VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc; VL3-VL4-VH4-VH3-CH1;VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL;VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1;VH3-VH4-VL4-VL3-CL-CH1; VL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc;VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fc;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3;VH3-L6-VH4-L7-VL4-L8-VL3; VL3-L6-VL4-L7-VH4-L8-VH3-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6- VL4-L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3- L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc, and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3;VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc; VL3-VL4-VH4-VH3-CH1;VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL;VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1;VH3-VH4-VL4-VL3-CL-CH1; VL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc;VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fc;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3;VH3-L6-VH4-L7-VL4-L8-VL3; VL3-L6-VL4-L7-VH4-L8-VH3-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4- L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3- L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc, and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3;VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc; VL3-VL4-VH4-VH3-CH1;VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL;VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1;VH3-VH4-VL4-VL3-CL-CH1; VL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc;VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fc;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3;VH3-L6-VH4-L7-VL4-L8-VL3; VL3-L6-VL4-L7-VH4-L8-VH3-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4- L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3- L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc, and the second polypeptide hasa structure represented by VL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3;VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc; VL3-VL4-VH4-VH3-CH1;VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL;VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1;VH3-VH4-VL4-VL3-CL-CH1; VL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc;VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fc;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3;VH3-L6-VH4-L7-VL4-L8-VL3; VL3-L6-VL4-L7-VH4-L8-VH3-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3- L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc, and the second polypeptide hasa structure represented by VL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3;VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc; VL3-VL4-VH4-VH3-CH1;VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL;VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1;VH3-VH4-VL4-VL3-CL-CH1; VL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc;VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fc;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3;VH3-L6-VH4-L7-VL4-L8-VL3; VL3-L6-VL4-L7-VH4-L8-VH3-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3- L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc, and the second polypeptide hasa structure represented by VL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3;VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc; VL3-VL4-VH4-VH3-CH1;VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL;VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1;VH3-VH4-VL4-VL3-CL-CH1; VL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc;VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fc;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3;VH3-L6-VH4-L7-VL4-L8-VL3; VL3-L6-VL4-L7-VH4-L8-VH3-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3- L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc, and the second polypeptide hasa structure represented by VL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3;VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc; VL3-VL4-VH4-VH3-CH1;VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL;VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1;VH3-VH4-VL4-VL3-CL-CH1; VL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc;VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fc;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3;VH3-L6-VH4-L7-VL4-L8-VL3; VL3-L6-VL4-L7-VH4-L8-VH3-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3- L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc.

In some aspects, an antigen binding polypeptide or antigen bindingpolypeptide complex of the invention does not specifically bind to anantigen associated with human immunodeficiency virus (HIV) (e.g., an HIVenvelope protein) and/or an antigen associated with severe acuterespiratory syndrome (SARS).

In other aspects, the invention is directed to an antigen bindingpolypeptide complex comprising a first polypeptide and a secondpolypeptide; wherein the first polypeptide has a structure representedby VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1; orVH1-L1-VH2-L2-VL2-L3-VL1; wherein the second polypeptide has a structurerepresented by VL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3;VL3-L4-VL4-L5-VH4-L6-VH3; or VH3-L4-VH4-L5-VL4-L6-VL3; wherein VL1 is afirst immunoglobulin light chain variable region that specifically bindsto A2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1,B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3,CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19, CCL20, CCL21, CCL25CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27, CD28, CD30, CD38, CD39,CD40, CD40L, CD47, CD52, CD70, CD80, CD86, CD123, CD133, CD137, CD137L,CD160, CD272, CEACAM5, CLEC9, CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1,CXCL2, CXCL4, CXCL12, CXCL13, CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1,E-cadherin, EGFR, ENTPD1, EpCAM, FCER1, FCER1A, FCER2, FGFR, FLAP,FOLH1, Gi24, GITR, GITRL, GPR5, GP100, GPRC5D, HER2, HER3, ICOSL, ICOS,HHLA2, HMGB1, HVEM, IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1, ILIA, IL1B,IL1F10, IL2, IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8, IL9, IL9R,IL10, rhIL1O, IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb, IL18,IL22, IL23, IL25, IL7, IL33, IL35, ITGB4, ITK, KIR, LAG3, LAMP1, leptin,LPFS2, MHC class II, MUC-1, MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1,OX40, OX40L, PD-1, PD-L1, PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC,SPG64, ST2, STEAP1, STEAP2, Syk kinase, STEAP1, TROP2, TACI, TDO,TGFBETA, T14, TIGIT, TIM3, TLR, TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa,TNFRSF7, Tp55, TREM1, TSLP, TSLPR, TWEAK, VEGF, VISTA, Vstm3, or WUCAM;VL2 is a second immunoglobulin light chain variable region thatspecifically binds to A2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS,BTK, BTLA, B7DC, B7H1, B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4,C3, C5, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19,CCL20, CCL21, CCL25 CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27,CD28, CD30, CD38, CD39, CD40, CD40L, CD47, CD52, CD70, CD80, CD86,CD123, CD133, CD137, CD137L, CD160, CD272, CEACAM5, CLEC9, CLEC91,CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12, CXCL13, CXCR3,cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin, EGFR, ENTPD1, EpCAM, FCER1,FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24, GITR, GITRL, GPR5, GP100,GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1, HVEM, IDO, IFNa, IgE,IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R,IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O, IL12, IL13, IL13Ra1,IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23, IL25, IL7, IL33, IL35,ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II, MUC-1,MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L, PD-1, PD-L1,PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1, STEAP2,Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3, TLR,TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP, TSLPR,TWEAK, VEGF, VISTA, Vstm3, or WUCAM; VL3 is a third immunoglobulin lightchain variable region that specifically binds to A2AR, APRIL, ATPDase,BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1, B7H2, B7H3, B7H4, B7H5,B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8,CCL11, CCL15, CCL17, CCL19, CCL20, CCL21, CCL25 CCR3, CCR4, CD3, CD16A,CD19, CD20, CD24, CD27, CD28, CD30, CD38, CD39, CD40, CD40L, CD47, CD52,CD70, CD80, CD86, CD123, CD133, CD137, CD137L, CD160, CD272, CEACAM5,CLEC9, CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12,CXCL13, CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin, EGFR,ENTPD1, EpCAM, FCER1, FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24, GITR,GITRL, GPR5, GP100, GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1, HVEM,IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2, IL4,IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O, IL12,IL13, IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23, IL25, IL7,IL33, IL35, ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II,MUC-1, MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L, PD-1,PD-L1, PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1,STEAP2, Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3,TLR, TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP,TSLPR, TWEAK, VEGF, VISTA, Vstm3, or WUCAM; VL4 is a fourthimmunoglobulin light chain variable region that specifically binds toA2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1,B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3,CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19, CCL20, CCL21, CCL25CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27, CD28, CD30, CD38, CD39,CD40, CD40L, CD47, CD52, CD70, CD80, CD86, CD123, CD133, CD137, CD137L,CD160, CD272, CEACAM5, CLEC9, CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1,CXCL2, CXCL4, CXCL12, CXCL13, CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1,E-cadherin, EGFR, ENTPD1, EpCAM, FCER1, FCER1A, FCER2, FGFR, FLAP,FOLH1, Gi24, GITR, GITRL, GPR5, GP100, GPRC5D, HER2, HER3, ICOSL, ICOS,HHLA2, HMGB1, HVEM, IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1, ILIA, IL1B,IL1F10, IL2, IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8, IL9, IL9R,IL10, rhIL1O, IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb, IL18,IL22, IL23, IL25, IL7, IL33, IL35, ITGB4, ITK, KIR, LAG3, LAMP1, leptin,LPFS2, MHC class II, MUC-1, MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1,OX40, OX40L, PD-1, PD-L1, PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC,SPG64, ST2, STEAP1, STEAP2, Syk kinase, STEAP1, TROP2, TACI, TDO,TGFBETA, T14, TIGIT, TIM3, TLR, TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa,TNFRSF7, Tp55, TREM1, TSLP, TSLPR, TWEAK, VEGF, VISTA, Vstm3, or WUCAM;VH1 is a first immunoglobulin heavy chain variable region thatspecifically binds to A2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS,BTK, BTLA, B7DC, B7H1, B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4,C3, C5, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19,CCL20, CCL21, CCL25 CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27,CD28, CD30, CD38, CD39, CD40, CD40L, CD47, CD52, CD70, CD80, CD86,CD123, CD133, CD137, CD137L, CD160, CD272, CEACAM5, CLEC9, CLEC91,CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12, CXCL13, CXCR3,cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin, EGFR, ENTPD1, EpCAM, FCER1,FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24, GITR, GITRL, GPR5, GP100,GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1, HVEM, IDO, IFNa, IgE,IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R,IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O, IL12, IL13, IL13Ra1,IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23, IL25, IL7, IL33, IL35,ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II, MUC-1,MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L, PD-1, PD-L1,PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1, STEAP2,Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3, TLR,TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP, TSLPR,TWEAK, VEGF, VISTA, Vstm3, or WUCAM; VH2 is a second immunoglobulinheavy chain variable region that specifically binds to A2AR, APRIL,ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1, B7H2, B7H3,B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3, CCL4, CCL5,CCL7, CCL8, CCL11, CCL15, CCL17, CCL19, CCL20, CCL21, CCL25 CCR3, CCR4,CD3, CD16A, CD19, CD20, CD24, CD27, CD28, CD30, CD38, CD39, CD40, CD40L,CD47, CD52, CD70, CD80, CD86, CD123, CD133, CD137, CD137L, CD160, CD272,CEACAM5, CLEC9, CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4,CXCL12, CXCL13, CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin,EGFR, ENTPD1, EpCAM, FCER1, FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24,GITR, GITRL, GPR5, GP100, GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1,HVEM, IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2,IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O,IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23,IL25, IL7, IL33, IL35, ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHCclass II, MUC-1, MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L,PD-1, PD-L1, PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2,STEAP1, STEAP2, Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14,TIGIT, TIM3, TLR, TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55,TREM1, TSLP, TSLPR, TWEAK, VEGF, VISTA, Vstm3, or WUCAM; VH3 is a thirdimmunoglobulin heavy chain variable region that specifically binds toA2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1,B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3,CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19, CCL20, CCL21, CCL25CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27, CD28, CD30, CD38, CD39,CD40, CD40L, CD47, CD52, CD70, CD80, CD86, CD123, CD133, CD137, CD137L,CD160, CD272, CEACAM5, CLEC9, CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1,CXCL2, CXCL4, CXCL12, CXCL13, CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1,E-cadherin, EGFR, ENTPD1, EpCAM, FCER1, FCER1A, FCER2, FGFR, FLAP,FOLH1, Gi24, GITR, GITRL, GPR5, GP100, GPRC5D, HER2, HER3, ICOSL, ICOS,HHLA2, HMGB1, HVEM, IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1, ILIA, IL1B,IL1F10, IL2, IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8, IL9, IL9R,IL10, rhIL1O, IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb, IL18,IL22, IL23, IL25, IL7, IL33, IL35, ITGB4, ITK, KIR, LAG3, LAMP1, leptin,LPFS2, MHC class II, MUC-1, MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1,OX40, OX40L, PD-1, PD-L1, PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC,SPG64, ST2, STEAP1, STEAP2, Syk kinase, STEAP1, TROP2, TACI, TDO,TGFBETA, T14, TIGIT, TIM3, TLR, TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa,TNFRSF7, Tp55, TREM1, TSLP, TSLPR, TWEAK, VEGF, VISTA, Vstm3, or WUCAM;VH4 is a fourth immunoglobulin heavy chain variable region thatspecifically binds to A2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS,BTK, BTLA, B7DC, B7H1, B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4,C3, C5, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19,CCL20, CCL21, CCL25 CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27,CD28, CD30, CD38, CD39, CD40, CD40L, CD47, CD52, CD70, CD80, CD86,CD123, CD133, CD137, CD137L, CD160, CD272, CEACAM5, CLEC9, CLEC91,CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12, CXCL13, CXCR3,cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin, EGFR, ENTPD1, EpCAM, FCER1,FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24, GITR, GITRL, GPR5, GP100,GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1, HVEM, IDO, IFNa, IgE,IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R,IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O, IL12, IL13, IL13Ra1,IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23, IL25, IL7, IL33, IL35,ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II, MUC-1,MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L, PD-1, PD-L1,PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1, STEAP2,Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3, TLR,TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP, TSLPR,TWEAK, VEGF, VISTA, Vstm3, or WUCAM; and L1, L2, L3, L4, L5 and L6 areamino acid linkers. In some aspects, the first polypeptide has astructure represented by VL1-VL2-VH2-VH1 and the second polypeptide hasa structure represented by VL3-VL4-VH4-VH3. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1 and thesecond polypeptide has a structure represented by VH3-VH4-VL4-VL3. Insome aspects, the first polypeptide has a structure represented byVL1-VL2-VH2-VH1 and the second polypeptide has a structure representedby VL3-L4-VL4-L5-VH4-L6-VH3. In some aspects, the first polypeptide hasa structure represented by VL1-VL2-VH2-VH1 and the second polypeptidehas a structure represented by VH3-L4-VH4-L5-VL4-L6-VL3. In someaspects, the first polypeptide has a structure represented byVH1-VH2-VL2-VL1 and the second polypeptide has a structure representedby VL3-VL4-VH4-VH3. In some aspects, the first polypeptide has astructure represented by VH1-VH2-VL2-VL1 and the second polypeptide hasa structure represented by VH3-VH4-VL4-VL3. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1 and thesecond polypeptide has a structure represented byVL3-L4-VL4-L5-VH4-L6-VH3. In some aspects, the first polypeptide has astructure represented by VH1-VH2-VL2-VL1 and the second polypeptide hasa structure represented by VH3-L4-VH4-L5-VL4-L6-VL3. In some aspects,the first polypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1 and the second polypeptide has a structurerepresented by VL3-VL4-VH4-VH3. In some aspects, the first polypeptidehas a structure represented by VL1-L1-VL2-L2-VH2-L3-VH1 and the secondpolypeptide has a structure represented by VH3-VH4-VL4-VL3. In someaspects, the first polypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1 and the second polypeptide has a structurerepresented by VL3-L4-VL4-L5-VH4-L6-VH3. In some aspects, the firstpolypeptide has a structure represented by VL1-L1-VL2-L2-VH2-L3-VH1 andthe second polypeptide has a structure represented byVH3-L4-VH4-L5-VL4-L6-VL3. In some aspects, the first polypeptide has astructure represented by VH1-L1-VH2-L2-VL2-L3-VL1 and the secondpolypeptide has a structure represented by VL3-VL4-VH4-VH3. In someaspects, the first polypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1 and the second polypeptide has a structurerepresented by VH3-VH4-VL4-VL3. In some aspects, the first polypeptidehas a structure represented by VH1-L1-VH2-L2-VL2-L3-VL1 and the secondpolypeptide has a structure represented by VL3-L4-VL4-L5-VH4-L6-VH3. Insome aspects, the first polypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1 and the second polypeptide has a structurerepresented by VH3-L4-VH4-L5-VL4-L6-VL3. In some aspects, the VL1, VL2,VL3, VL4, VH1, VH2, VH3 and/or VH4 specifically binds to A2AR, APRIL,ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1, B7H2, B7H3,B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3, CCL4, CCL5,CCL7, CCL8, CCL11, CCL15, CCL17, CCL19, CCL20, CCL21, CCL25 CCR3, CCR4,CD3, CD16A, CD19, CD20, CD24, CD27, CD28, CD30, CD38, CD39, CD40, CD40L,CD47, CD52, CD70, CD80, CD86, CD123, CD133, CD137, CD137L, CD160, CD272,CEACAM5, CLEC9, CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4,CXCL12, CXCL13, CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin,EGFR, ENTPD1, EpCAM, FCER1, FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24,GITR, GITRL, GPR5, GP100, GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1,HVEM, IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2,IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O,IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23,IL25, IL7, IL33, IL35, ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHCclass II, MUC-1, MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L,PD-1, PD-L1, PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2,STEAP1, STEAP2, Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14,TIGIT, TIM3, TLR, TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55,TREM1, TSLP, TSLPR, TWEAK, VEGF, VISTA, Vstm3, or WUCAM. Any and alldisclosure herein in relation to targets for antigen bindingpolypeptides of the invention is generally applicable, and appliesequally and without reservation to each and every antigen bindingpolypeptide and antigen binding polypeptide complex described herein.For the avoidance of doubt, the VL1, VL2, VL3, VL4, VH1, VH2, VH3 and/orVH4 of each and every antigen binding polypeptide and antigen bindingpolypeptide complex described herein may independently bind to any oneof said particularly preferred targets.

In other aspects, the invention is directed to an antigen bindingpolypeptide complex comprising a first polypeptide and a secondpolypeptide; wherein the first polypeptide has a structure representedby VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; wherein the second polypeptide has astructure represented by VL3-VL4-VH4-VH3-Fe; VH3-VH4-VL4-VL3-Fc;VL3-L5-VL4-L6-VH4-L7-VH3-Fc; VH3-L5-VH4-L6-VL4-L7-VL3-Fc;VL3-L5-VL4-L6-VH4-L7-VH3-L8-Fc; or VH3-L5-VH4-L6-VL4-L7-VL3-L8-Fc;wherein VL1 is a first immunoglobulin light chain variable region thatspecifically binds to A2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS,BTK, BTLA, B7DC, B7H1, B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4,C3, C5, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19,CCL20, CCL21, CCL25 CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27,CD28, CD30, CD38, CD39, CD40, CD40L, CD47, CD52, CD70, CD80, CD86,CD123, CD133, CD137, CD137L, CD160, CD272, CEACAM5, CLEC9, CLEC91,CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12, CXCL13, CXCR3,cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin, EGFR, ENTPD1, EpCAM, FCER1,FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24, GITR, GITRL, GPR5, GP100,GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1, HVEM, IDO, IFNa, IgE,IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R,IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O, IL12, IL13, IL13Ra1,IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23, IL25, IL7, IL33, IL35,ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II, MUC-1,MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L, PD-1, PD-L1,PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1, STEAP2,Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3, TLR,TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP, TSLPR,TWEAK, VEGF, VISTA, Vstm3, or WUCAM; VL2 is a second immunoglobulinlight chain variable region that specifically binds to A2AR, APRIL,ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1, B7H2, B7H3,B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3, CCL4, CCL5,CCL7, CCL8, CCL11, CCL15, CCL17, CCL19, CCL20, CCL21, CCL25 CCR3, CCR4,CD3, CD16A, CD19, CD20, CD24, CD27, CD28, CD30, CD38, CD39, CD40, CD40L,CD47, CD52, CD70, CD80, CD86, CD123, CD133, CD137, CD137L, CD160, CD272,CEACAM5, CLEC9, CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4,CXCL12, CXCL13, CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin,EGFR, ENTPD1, EpCAM, FCER1, FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24,GITR, GITRL, GPR5, GP100, GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1,HVEM, IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2,IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O,IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23,IL25, IL7, IL33, IL35, ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHCclass II, MUC-1, MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L,PD-1, PD-L1, PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2,STEAP1, STEAP2, Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14,TIGIT, TIM3, TLR, TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55,TREM1, TSLP, TSLPR, TWEAK, VEGF, VISTA, Vstm3, or WUCAM; VL3 is a thirdimmunoglobulin light chain variable region that specifically binds toA2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1,B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3,CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19, CCL20, CCL21, CCL25CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27, CD28, CD30, CD38, CD39,CD40, CD40L, CD47, CD52, CD70, CD80, CD86, CD123, CD133, CD137, CD137L,CD160, CD272, CEACAM5, CLEC9, CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1,CXCL2, CXCL4, CXCL12, CXCL13, CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1,E-cadherin, EGFR, ENTPD1, EpCAM, FCER1, FCER1A, FCER2, FGFR, FLAP,FOLH1, Gi24, GITR, GITRL, GPR5, GP100, GPRC5D, HER2, HER3, ICOSL, ICOS,HHLA2, HMGB1, HVEM, IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1, ILIA, IL1B,IL1F10, IL2, IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8, IL9, IL9R,IL10, rhIL1O, IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb, IL18,IL22, IL23, IL25, IL7, IL33, IL35, ITGB4, ITK, KIR, LAG3, LAMP1, leptin,LPFS2, MHC class II, MUC-1, MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1,OX40, OX40L, PD-1, PD-L1, PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC,SPG64, ST2, STEAP1, STEAP2, Syk kinase, STEAP1, TROP2, TACI, TDO,TGFBETA, T14, TIGIT, TIM3, TLR, TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa,TNFRSF7, Tp55, TREM1, TSLP, TSLPR, TWEAK, VEGF, VISTA, Vstm3, or WUCAM;VL4 is a fourth immunoglobulin light chain variable region thatspecifically binds to A2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS,BTK, BTLA, B7DC, B7H1, B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4,C3, C5, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19,CCL20, CCL21, CCL25 CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27,CD28, CD30, CD38, CD39, CD40, CD40L, CD47, CD52, CD70, CD80, CD86,CD123, CD133, CD137, CD137L, CD160, CD272, CEACAM5, CLEC9, CLEC91,CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12, CXCL13, CXCR3,cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin, EGFR, ENTPD1, EpCAM, FCER1,FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24, GITR, GITRL, GPR5, GP100,GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1, HVEM, IDO, IFNa, IgE,IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R,IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O, IL12, IL13, IL13Ra1,IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23, IL25, IL7, IL33, IL35,ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II, MUC-1,MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L, PD-1, PD-L1,PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1, STEAP2,Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3, TLR,TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP, TSLPR,TWEAK, VEGF, VISTA, Vstm3, or WUCAM; VH1 is a first immunoglobulin heavychain variable region that specifically binds to A2AR, APRIL, ATPDase,BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1, B7H2, B7H3, B7H4, B7H5,B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8,CCL11, CCL15, CCL17, CCL19, CCL20, CCL21, CCL25 CCR3, CCR4, CD3, CD16A,CD19, CD20, CD24, CD27, CD28, CD30, CD38, CD39, CD40, CD40L, CD47, CD52,CD70, CD80, CD86, CD123, CD133, CD137, CD137L, CD160, CD272, CEACAM5,CLEC9, CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12,CXCL13, CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin, EGFR,ENTPD1, EpCAM, FCER1, FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24, GITR,GITRL, GPR5, GP100, GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1, HVEM,IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2, IL4,IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O, IL12,IL13, IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23, IL25, IL7,IL33, IL35, ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II,MUC-1, MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L, PD-1,PD-L1, PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1,STEAP2, Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3,TLR, TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP,TSLPR, TWEAK, VEGF, VISTA, Vstm3, or WUCAM; VH2 is a secondimmunoglobulin heavy chain variable region that specifically binds toA2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1,B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3,CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19, CCL20, CCL21, CCL25CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27, CD28, CD30, CD38, CD39,CD40, CD40L, CD47, CD52, CD70, CD80, CD86, CD123, CD133, CD137, CD137L,CD160, CD272, CEACAM5, CLEC9, CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1,CXCL2, CXCL4, CXCL12, CXCL13, CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1,E-cadherin, EGFR, ENTPD1, EpCAM, FCER1, FCER1A, FCER2, FGFR, FLAP,FOLH1, Gi24, GITR, GITRL, GPR5, GP100, GPRC5D, HER2, HER3, ICOSL, ICOS,HHLA2, HMGB1, HVEM, IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1, ILIA, IL1B,IL1F10, IL2, IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8, IL9, IL9R,IL10, rhIL1O, IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb, IL18,IL22, IL23, IL25, IL7, IL33, IL35, ITGB4, ITK, KIR, LAG3, LAMP1, leptin,LPFS2, MHC class II, MUC-1, MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1,OX40, OX40L, PD-1, PD-L1, PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC,SPG64, ST2, STEAP1, STEAP2, Syk kinase, STEAP1, TROP2, TACI, TDO,TGFBETA, T14, TIGIT, TIM3, TLR, TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa,TNFRSF7, Tp55, TREM1, TSLP, TSLPR, TWEAK, VEGF, VISTA, Vstm3, or WUCAM;VH3 is a third immunoglobulin heavy chain variable region thatspecifically binds to A2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS,BTK, BTLA, B7DC, B7H1, B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4,C3, C5, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19,CCL20, CCL21, CCL25 CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27,CD28, CD30, CD38, CD39, CD40, CD40L, CD47, CD52, CD70, CD80, CD86,CD123, CD133, CD137, CD137L, CD160, CD272, CEACAM5, CLEC9, CLEC91,CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12, CXCL13, CXCR3,cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin, EGFR, ENTPD1, EpCAM, FCER1,FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24, GITR, GITRL, GPR5, GP100,GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1, HVEM, IDO, IFNa, IgE,IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R,IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O, IL12, IL13, IL13Ra1,IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23, IL25, IL7, IL33, IL35,ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II, MUC-1,MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L, PD-1, PD-L1,PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1, STEAP2,Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3, TLR,TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP, TSLPR,TWEAK, VEGF, VISTA, Vstm3, or WUCAM; VH4 is a fourth immunoglobulinheavy chain variable region that specifically binds to A2AR, APRIL,ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1, B7H2, B7H3,B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3, CCL4, CCL5,CCL7, CCL8, CCL11, CCL15, CCL17, CCL19, CCL20, CCL21, CCL25 CCR3, CCR4,CD3, CD16A, CD19, CD20, CD24, CD27, CD28, CD30, CD38, CD39, CD40, CD40L,CD47, CD52, CD70, CD80, CD86, CD123, CD133, CD137, CD137L, CD160, CD272,CEACAM5, CLEC9, CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4,CXCL12, CXCL13, CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin,EGFR, ENTPD1, EpCAM, FCER1, FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24,GITR, GITRL, GPR5, GP100, GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1,HVEM, IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2,IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O,IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23,IL25, IL7, IL33, IL35, ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHCclass II, MUC-1, MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L,PD-1, PD-L1, PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2,STEAP1, STEAP2, Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14,TIGIT, TIM3, TLR, TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55,TREM1, TSLP, TSLPR, TWEAK, VEGF, VISTA, Vstm3, or WUCAM; Fc is a regioncomprising an immunoglobulin heavy chain constant region 2 (CH2), animmunoglobulin heavy chain constant region 3 (CH3), and optionally, animmunoglobulin hinge; and L1, L2, L3, L4, L5, L6, L7 and L8 are aminoacid linkers. In some aspects, the first polypeptide has a structurerepresented by VL1-VL2-VH2-VH1-Fc and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3-Fc. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-Fc and thesecond polypeptide has a structure represented by VH3-VH4-VL4-VL3-Fc. Insome aspects, the first polypeptide has a structure represented byVL1-VL2-VH2-VH1-Fc and the second polypeptide has a structurerepresented by VL3-L5-VL4-L6-VH4-L7-VH3-Fc. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-Fc and thesecond polypeptide has a structure represented byVH3-L5-VH4-L6-VL4-L7-VL3-Fc. In some aspects, the first polypeptide hasa structure represented by VL1-VL2-VH2-VH1-Fc and the second polypeptidehas a structure represented by VL3-L5-VL4-L6-VH4-L7-VH3-L8-Fc. In someaspects, the first polypeptide has a structure represented byVL1-VL2-VH2-VH1-Fc and the second polypeptide has a structurerepresented by VH3-L5-VH4-L6-VL4-L7-VL3-L8-Fc. In some aspects, thefirst polypeptide has a structure represented by VH1-VH2-VL2-VL1-Fc andthe second polypeptide has a structure represented byVL3-VL4-VH4-VH3-Fc. In some aspects, the first polypeptide has astructure represented by VH1-VH2-VL2-VL1-Fc and the second polypeptidehas a structure represented by VH3-VH4-VL4-VL3-Fc. In some aspects, thefirst polypeptide has a structure represented by VH1-VH2-VL2-VL1-Fc andthe second polypeptide has a structure represented byVL3-L5-VL4-L6-VH4-L7-VH3-Fc. In some aspects, the first polypeptide hasa structure represented by VH1-VH2-VL2-VL1-Fc and the second polypeptidehas a structure represented by VH3-L5-VH4-L6-VL4-L7-VL3-Fc. In someaspects, the first polypeptide has a structure represented byVH1-VH2-VL2-VL1-Fc and the second polypeptide has a structurerepresented by VL3-L5-VL4-L6-VH4-L7-VH3-L8-Fc. In some aspects, thefirst polypeptide has a structure represented by VH1-VH2-VL2-VL1-Fc andthe second polypeptide has a structure represented byVH3-L5-VH4-L6-VL4-L7-VL3-L8-Fc. In some aspects, the first polypeptidehas a structure represented by VL1-L1-VL2-L2-VH2-L3-VH1-Fc and thesecond polypeptide has a structure represented by VL3-VL4-VH4-VH3-Fc. Insome aspects, the first polypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-Fc and the second polypeptide has a structurerepresented by VH3-VH4-VL4-VL3-Fc. In some aspects, the firstpolypeptide has a structure represented by VL1-L1-VL2-L2-VH2-L3-VH1-Fcand the second polypeptide has a structure represented byVL3-L5-VL4-L6-VH4-L7-VH3-Fc. In some aspects, the first polypeptide hasa structure represented by VL1-L1-VL2-L2-VH2-L3-VH1-Fc and the secondpolypeptide has a structure represented by VH3-L5-VH4-L6-VL4-L7-VL3-Fc.In some aspects, the first polypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-Fc and the second polypeptide has a structurerepresented by VL3-L5-VL4-L6-VH4-L7-VH3-L8-Fc. In some aspects, thefirst polypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-Fc and the second polypeptide has a structurerepresented by VH3-L5-VH4-L6-VL4-L7-VL3-L8-Fc. In some aspects, thefirst polypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-Fc and the second polypeptide has a structurerepresented by VL3-VL4-VH4-VH3-Fc. In some aspects, the firstpolypeptide has a structure represented by VH1-L1-VH2-L2-VL2-L3-VL1-Fcand the second polypeptide has a structure represented byVH3-VH4-VL4-VL3-Fc. In some aspects, the first polypeptide has astructure represented by VH1-L1-VH2-L2-VL2-L3-VL1-Fc and the secondpolypeptide has a structure represented by VL3-L5-VL4-L6-VH4-L7-VH3-Fc.In some aspects, the first polypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-Fc and the second polypeptide has a structurerepresented by VH3-L5-VH4-L6-VL4-L7-VL3-Fc. In some aspects, the firstpolypeptide has a structure represented by VH1-L1-VH2-L2-VL2-L3-VL1-Fcand the second polypeptide has a structure represented byVL3-L5-VL4-L6-VH4-L7-VH3-L8-Fc. In some aspects, the first polypeptidehas a structure represented by VH1-L1-VH2-L2-VL2-L3-VL1-Fc and thesecond polypeptide has a structure represented byVH3-L5-VH4-L6-VL4-L7-VL3-L8-Fc. In some aspects, the first polypeptidehas a structure represented by VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc and thesecond polypeptide has a structure represented by VL3-VL4-VH4-VH3-Fc. Insome aspects, the first polypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc and the second polypeptide has astructure represented by VH3-VH4-VL4-VL3-Fc. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc and the second polypeptide has astructure represented by VL3-L5-VL4-L6-VH4-L7-VH3-Fc. In some aspects,the first polypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc and the second polypeptide has astructure represented by VH3-L5-VH4-L6-VL4-L7-VL3-Fc. In some aspects,the first polypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc and the second polypeptide has astructure represented by VL3-L5-VL4-L6-VH4-L7-VH3-L8-Fc. In someaspects, the first polypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc and the second polypeptide has astructure represented by VH3-L5-VH4-L6-VL4-L7-VL3-L8-Fc. In someaspects, the first polypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3-Fc. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc and the second polypeptide has astructure represented by VH3-VH4-VL4-VL3-Fc. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc and the second polypeptide has astructure represented by VL3-L5-VL4-L6-VH4-L7-VH3-Fc. In some aspects,the first polypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc and the second polypeptide has astructure represented by VH3-L5-VH4-L6-VL4-L7-VL3-Fc. In some aspects,the first polypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc and the second polypeptide has astructure represented by VL3-L5-VL4-L6-VH4-L7-VH3-L8-Fc. In someaspects, the first polypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc and the second polypeptide has astructure represented by VH3-L5-VH4-L6-VL4-L7-VL3-L8-Fc. In someaspects, the VL1, VL2, VL3, VL4, VH1, VH2, VH3 and/or VH4 specificallybinds to A2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC,B7H1, B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2,CCL3, CCL4, CCLS, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19, CCL20, CCL21,CCL25 CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27, CD28, CD30, CD38,CD39, CD40, CD40L, CD47, CD52, CD70, CD80, CD86, CD123, CD133, CD137,CD137L, CD160, CD272, CEACAM5, CLEC9, CLEC91, CRTH2, CSF-1, CSF-2,CSF-3, CXCL1, CXCL2, CXCL4, CXCL12, CXCL13, CXCR3, cMet, CTLA4, DLL3,DLL4, DNGR-1, E-cadherin, EGFR, ENTPD1, EpCAM, FCER1, FCER1A, FCER2,FGFR, FLAP, FOLH1, Gi24, GITR, GITRL, GPRS, GP100, GPRC5D, HER2, HER3,ICOSL, ICOS, HHLA2, HMGB1, HVEM, IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1,ILIA, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R, 116, IL7, IL7Ra, IL8,IL9, IL9R, IL10, rhIL1O, IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17,IL17Rb, IL18, IL22, IL23, IL25, IL7, IL33, IL35, ITGB4, ITK, KIR, LAG3,LAMP1, leptin, LPFS2, MHC class II, MUC-1, MUC-16, NCR3LG1, NKG2D,NKp46, NTPDase-1, OX40, OX40L, PD-1, PD-L1, PD-L2, PROM1, S152,SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1, STEAP2, Syk kinase, STEAP1,TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3, TLR, TLR2, TLR4, TLR5,TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP, TSLPR, TWEAK, VEGF,VISTA, Vstm3, or WUCAM. Any and all disclosure herein in relation totargets for antigen binding polypeptides of the invention is generallyapplicable, and applies equally and without reservation to each andevery antigen binding polypeptide and antigen binding polypeptidecomplex described herein. For the avoidance of doubt, the VL1, VL2, VL3,VL4, VH1, VH2, VH3 and/or VH4 of each and every antigen bindingpolypeptide and antigen binding polypeptide complex described herein mayindependently bind to any one of said particularly preferred targets.

In other aspects, the invention is directed to an antigen bindingpolypeptide complex comprising a first polypeptide and a secondpolypeptide; wherein the first polypeptide has a structure representedby VL1-VL2-VH2-VH1-CH1; VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL;VH1-VH2-VL2-VL1-CL; VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL;VL1-VL2-VH2-VH1-CL-CH1; VH1-VH2-VL2-VL1-CL-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL; VH1-L1- VH2-L2-VL2-L3-VL1-L4-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; wherein the second polypeptidehas a structure represented by VL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1;VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL;VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL;VL3-L6-VL4- L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1; wherein VL1 is a firstimmunoglobulin light chain variable region that specifically binds toA2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1,B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3,CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19, CCL20, CCL21, CCL25CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27, CD28, CD30, CD38, CD39,CD40, CD40L, CD47, CD52, CD70, CD80, CD86, CD123, CD133, CD137, CD137L,CD160, CD272, CEACAM5, CLEC9, CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1,CXCL2, CXCL4, CXCL12, CXCL13, CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1,E-cadherin, EGFR, ENTPD1, EpCAM, FCER1, FCER1A, FCER2, FGFR, FLAP,FOLH1, Gi24, GITR, GITRL, GPR5, GP100, GPRC5D, HER2, HER3, ICOSL, ICOS,HHLA2, HMGB1, HVEM, IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1, ILIA, IL1B,IL1F10, IL2, IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8, IL9, IL9R,IL10, rhIL1O, IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb, IL18,IL22, IL23, IL25, IL7, IL33, IL35, ITGB4, ITK, KIR, LAG3, LAMP1, leptin,LPFS2, MHC class II, MUC-1, MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1,OX40, OX40L, PD-1, PD-L1, PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC,SPG64, ST2, STEAP1, STEAP2, Syk kinase, STEAP1, TROP2, TACI, TDO,TGFBETA, T14, TIGIT, TIM3, TLR, TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa,TNFRSF7, Tp55, TREM1, TSLP, TSLPR, TWEAK, VEGF, VISTA, Vstm3, or WUCAM;VL2 is a second immunoglobulin light chain variable region thatspecifically binds to A2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS,BTK, BTLA, B7DC, B7H1, B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4,C3, C5, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19,CCL20, CCL21, CCL25 CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27,CD28, CD30, CD38, CD39, CD40, CD40L, CD47, CD52, CD70, CD80, CD86,CD123, CD133, CD137, CD137L, CD160, CD272, CEACAM5, CLEC9, CLEC91,CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12, CXCL13, CXCR3,cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin, EGFR, ENTPD1, EpCAM, FCER1,FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24, GITR, GITRL, GPR5, GP100,GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1, HVEM, IDO, IFNa, IgE,IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R,IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O, IL12, IL13, IL13Ra1,IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23, IL25, IL7, IL33, IL35,ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II, MUC-1,MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L, PD-1, PD-L1,PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1, STEAP2,Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3, TLR,TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP, TSLPR,TWEAK, VEGF, VISTA, Vstm3, or WUCAM; VL3 is a third immunoglobulin lightchain variable region that specifically binds to A2AR, APRIL, ATPDase,BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1, B7H2, B7H3, B7H4, B7H5,B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8,CCL11, CCL15, CCL17, CCL19, CCL20, CCL21, CCL25 CCR3, CCR4, CD3, CD16A,CD19, CD20, CD24, CD27, CD28, CD30, CD38, CD39, CD40, CD40L, CD47, CD52,CD70, CD80, CD86, CD123, CD133, CD137, CD137L, CD160, CD272, CEACAM5,CLEC9, CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12,CXCL13, CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin, EGFR,ENTPD1, EpCAM, FCER1, FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24, GITR,GITRL, GPR5, GP100, GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1, HVEM,IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2, IL4,IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O, IL12,IL13, IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23, IL25, IL7,IL33, IL35, ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II,MUC-1, MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L, PD-1,PD-L1, PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1,STEAP2, Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3,TLR, TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP,TSLPR, TWEAK, VEGF, VISTA, Vstm3, or WUCAM; VL4 is a fourthimmunoglobulin light chain variable region that specifically binds toA2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1,B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3,CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19, CCL20, CCL21, CCL25CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27, CD28, CD30, CD38, CD39,CD40, CD40L, CD47, CD52, CD70, CD80, CD86, CD123, CD133, CD137, CD137L,CD160, CD272, CEACAM5, CLEC9, CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1,CXCL2, CXCL4, CXCL12, CXCL13, CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1,E-cadherin, EGFR, ENTPD1, EpCAM, FCER1, FCER1A, FCER2, FGFR, FLAP,FOLH1, Gi24, GITR, GITRL, GPR5, GP100, GPRC5D, HER2, HER3, ICOSL, ICOS,HHLA2, HMGB1, HVEM, IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1, ILIA, IL1B,IL1F10, IL2, IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8, IL9, IL9R,IL10, rhIL1O, IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb, IL18,IL22, IL23, IL25, IL7, IL33, IL35, ITGB4, ITK, KIR, LAG3, LAMP1, leptin,LPFS2, MHC class II, MUC-1, MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1,OX40, OX40L, PD-1, PD-L1, PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC,SPG64, ST2, STEAP1, STEAP2, Syk kinase, STEAP1, TROP2, TACI, TDO,TGFBETA, T14, TIGIT, TIM3, TLR, TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa,TNFRSF7, Tp55, TREM1, TSLP, TSLPR, TWEAK, VEGF, VISTA, Vstm3, or WUCAM;VH1 is a first immunoglobulin heavy chain variable region thatspecifically binds to A2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS,BTK, BTLA, B7DC, B7H1, B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4,C3, C5, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19,CCL20, CCL21, CCL25 CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27,CD28, CD30, CD38, CD39, CD40, CD40L, CD47, CD52, CD70, CD80, CD86,CD123, CD133, CD137, CD137L, CD160, CD272, CEACAM5, CLEC9, CLEC91,CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12, CXCL13, CXCR3,cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin, EGFR, ENTPD1, EpCAM, FCER1,FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24, GITR, GITRL, GPR5, GP100,GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1, HVEM, IDO, IFNa, IgE,IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R,IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O, IL12, IL13, IL13Ra1,IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23, IL25, IL7, IL33, IL35,ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II, MUC-1,MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L, PD-1, PD-L1,PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1, STEAP2,Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3, TLR,TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP, TSLPR,TWEAK, VEGF, VISTA, Vstm3, or WUCAM; VH2 is a second immunoglobulinheavy chain variable region that specifically binds to A2AR, APRIL,ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1, B7H2, B7H3,B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3, CCL4, CCL5,CCL7, CCL8, CCL11, CCL15, CCL17, CCL19, CCL20, CCL21, CCL25 CCR3, CCR4,CD3, CD16A, CD19, CD20, CD24, CD27, CD28, CD30, CD38, CD39, CD40, CD40L,CD47, CD52, CD70, CD80, CD86, CD123, CD133, CD137, CD137L, CD160, CD272,CEACAM5, CLEC9, CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4,CXCL12, CXCL13, CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin,EGFR, ENTPD1, EpCAM, FCER1, FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24,GITR, GITRL, GPR5, GP100, GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1,HVEM, IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2,IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O,IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23,IL25, IL7, IL33, IL35, ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHCclass II, MUC-1, MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L,PD-1, PD-L1, PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2,STEAP1, STEAP2, Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14,TIGIT, TIM3, TLR, TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55,TREM1, TSLP, TSLPR, TWEAK, VEGF, VISTA, Vstm3, or WUCAM; VH3 is a thirdimmunoglobulin heavy chain variable region that specifically binds toA2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1,B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3,CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19, CCL20, CCL21, CCL25CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27, CD28, CD30, CD38, CD39,CD40, CD40L, CD47, CD52, CD70, CD80, CD86, CD123, CD133, CD137, CD137L,CD160, CD272, CEACAM5, CLEC9, CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1,CXCL2, CXCL4, CXCL12, CXCL13, CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1,E-cadherin, EGFR, ENTPD1, EpCAM, FCER1, FCER1A, FCER2, FGFR, FLAP,FOLH1, Gi24, GITR, GITRL, GPR5, GP100, GPRC5D, HER2, HER3, ICOSL, ICOS,HHLA2, HMGB1, HVEM, IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1, ILIA, IL1B,IL1F10, IL2, IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8, IL9, IL9R,IL10, rhIL1O, IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb, IL18,IL22, IL23, IL25, IL7, IL33, IL35, ITGB4, ITK, KIR, LAG3, LAMP1, leptin,LPFS2, MHC class II, MUC-1, MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1,OX40, OX40L, PD-1, PD-L1, PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC,SPG64, ST2, STEAP1, STEAP2, Syk kinase, STEAP1, TROP2, TACI, TDO,TGFBETA, T14, TIGIT, TIM3, TLR, TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa,TNFRSF7, Tp55, TREM1, TSLP, TSLPR, TWEAK, VEGF, VISTA, Vstm3, or WUCAM;VH4 is a fourth immunoglobulin heavy chain variable region thatspecifically binds to A2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS,BTK, BTLA, B7DC, B7H1, B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4,C3, C5, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19,CCL20, CCL21, CCL25 CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27,CD28, CD30, CD38, CD39, CD40, CD40L, CD47, CD52, CD70, CD80, CD86,CD123, CD133, CD137, CD137L, CD160, CD272, CEACAM5, CLEC9, CLEC91,CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12, CXCL13, CXCR3,cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin, EGFR, ENTPD1, EpCAM, FCER1,FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24, GITR, GITRL, GPR5, GP100,GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1, HVEM, IDO, IFNa, IgE,IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R,IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O, IL12, IL13, IL13Ra1,IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23, IL25, IL7, IL33, IL35,ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II, MUC-1,MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L, PD-1, PD-L1,PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1, STEAP2,Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3, TLR,TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP, TSLPR,TWEAK, VEGF, VISTA, Vstm3, or WUCAM; CH1 is an immunoglobulin heavychain constant region 1; CL is an immunoglobulin light chain constantregion; and L1, L2, L3, L4, L5, L6, L7, L8, L9 and L10 are amino acidlinkers. In some aspects, the first polypeptide has a structurerepresented by VL1-VL2-VH2-VH1-CH1, and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1;VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL;VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1-CH1, and thesecond polypeptide has a structure represented by VL3-VL4-VH4-VH3-CH1;VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL;VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1;VH3-VH4-VL4-VL3-CL-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4- L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-CL, and thesecond polypeptide has a structure represented by VL3-VL4-VH4-VH3-CH1;VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL;VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1;VH3-VH4-VL4-VL3-CL-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4- L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1-CL, and thesecond polypeptide has a structure represented by VL3-VL4-VH4-VH3-CH1;VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL;VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1;VH3-VH4-VL4-VL3-CL-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3- L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-CH1-CL, andthe second polypeptide has a structure represented byVL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL;VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL;VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL;VL3-L6-VL4-L7-VH4- L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1-CH1-CL, andthe second polypeptide has a structure represented byVL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL;VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL;VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-CL-CH1, andthe second polypeptide has a structure represented byVL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL;VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL;VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL;VL3-L6-VL4-L7-VH4- L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1-CL-CH1, andthe second polypeptide has a structure represented byVL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL;VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL;VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1, and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1;VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL;VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL;VL3-L6-VL4- L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1, and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1;VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL;VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1;VL3-L6-VL4- L7-VH4-L8-VH3-L9-CL; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CL, and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1;VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL;VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL; VH3-L6-VH4-L7- VL4-L8-VL3-L9-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL, and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1;VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL;VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL;VL3-L6-VL4-L7-VH4- L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL, and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1;VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL;VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1;VL3-L6-VL4-L7-VH4- L8-VH3-L9-CL; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL, and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1;VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL;VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL; VH3-L6-VH4-L7- VL4-L8-VL3-L9-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1, and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1;VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL;VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL;VL3-L6-VL4- L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1, and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1;VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL;VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1;VL3-L6-VL4- L7-VH4-L8-VH3-L9-CL; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1. In some aspects, the VL1, VL2,VL3, VL4, VH1, VH2, VH3 and/or VH4 specifically binds to A2AR, APRIL,ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1, B7H2, B7H3,B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3, CCL4, CCL5,CCL7, CCL8, CCL11, CCL15, CCL17, CCL19, CCL20, CCL21, CCL25 CCR3, CCR4,CD3, CD16A, CD19, CD20, CD24, CD27, CD28, CD30, CD38, CD39, CD40, CD40L,CD47, CD52, CD70, CD80, CD86, CD123, CD133, CD137, CD137L, CD160, CD272,CEACAM5, CLEC9, CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4,CXCL12, CXCL13, CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin,EGFR, ENTPD1, EpCAM, FCER1, FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24,GITR, GITRL, GPR5, GP100, GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1,HVEM, IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2,IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O,IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23,IL25, IL7, IL33, IL35, ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHCclass II, MUC-1, MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L,PD-1, PD-L1, PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2,STEAP1, STEAP2, Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14,TIGIT, TIM3, TLR, TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55,TREM1, TSLP, TSLPR, TWEAK, VEGF, VISTA, Vstm3, or WUCAM. Any and alldisclosure herein in relation to targets for antigen bindingpolypeptides of the invention is generally applicable, and appliesequally and without reservation to each and every antigen bindingpolypeptide and antigen binding polypeptide complex described herein.For the avoidance of doubt, the VL1, VL2, VL3, VL4, VH1, VH2, VH3 and/orVH4 of each and every antigen binding polypeptide and antigen bindingpolypeptide complex described herein may independently bind to any oneof said particularly preferred targets.

In other aspects, the invention is directed to an antigen bindingpolypeptide complex comprising a first polypeptide and a secondpolypeptide; wherein the first polypeptide has a structure representedby VL1-VL2-VH2-VH1-CH1-Fc; VH1-VH2-VL2-VL1-CH1-Fc;VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc; VL1-VL2-VH2-VH1-CH1-CL-Fc;VH1-VH2-VL2-VL1-CH1-CL-Fc; VL1-VL2-VH2-VH1-CL-CH1-Fc;VH1-VH2-VL2-VL1-CL-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL- Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc; wherein the second polypeptidehas a structure represented by VL3-VL4-VH4-VH3-CH1-Fc;VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc;VL3-VL4-VH4-VH3-CH1-CL-Fc; VH3-VH4-VL4-VL3-CH1-CL-Fc;VL3-VL4-VH4-VH3-CL-CH1-Fc; VH3-VH4-VL4-VL3-CL-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc; wherein VL1 is a firstimmunoglobulin light chain variable region that specifically binds toA2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1,B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3,CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19, CCL20, CCL21, CCL25CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27, CD28, CD30, CD38, CD39,CD40, CD40L, CD47, CD52, CD70, CD80, CD86, CD123, CD133, CD137, CD137L,CD160, CD272, CEACAM5, CLEC9, CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1,CXCL2, CXCL4, CXCL12, CXCL13, CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1,E-cadherin, EGFR, ENTPD1, EpCAM, FCER1, FCER1A, FCER2, FGFR, FLAP,FOLH1, Gi24, GITR, GITRL, GPR5, GP100, GPRC5D, HER2, HER3, ICOSL, ICOS,HHLA2, HMGB1, HVEM, IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1, ILIA, IL1B,IL1F10, IL2, IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8, IL9, IL9R,IL10, rhIL1O, IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb, IL18,IL22, IL23, IL25, IL7, IL33, IL35, ITGB4, ITK, KIR, LAG3, LAMP1, leptin,LPFS2, MHC class II, MUC-1, MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1,OX40, OX40L, PD-1, PD-L1, PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC,SPG64, ST2, STEAP1, STEAP2, Syk kinase, STEAP1, TROP2, TACI, TDO,TGFBETA, T14, TIGIT, TIM3, TLR, TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa,TNFRSF7, Tp55, TREM1, TSLP, TSLPR, TWEAK, VEGF, VISTA, Vstm3, or WUCAM;VL2 is a second immunoglobulin light chain variable region thatspecifically binds to A2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS,BTK, BTLA, B7DC, B7H1, B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4,C3, C5, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19,CCL20, CCL21, CCL25 CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27,CD28, CD30, CD38, CD39, CD40, CD40L, CD47, CD52, CD70, CD80, CD86,CD123, CD133, CD137, CD137L, CD160, CD272, CEACAM5, CLEC9, CLEC91,CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12, CXCL13, CXCR3,cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin, EGFR, ENTPD1, EpCAM, FCER1,FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24, GITR, GITRL, GPR5, GP100,GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1, HVEM, IDO, IFNa, IgE,IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R,IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O, IL12, IL13, IL13Ra1,IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23, IL25, IL7, IL33, IL35,ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II, MUC-1,MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L, PD-1, PD-L1,PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1, STEAP2,Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3, TLR,TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP, TSLPR,TWEAK, VEGF, VISTA, Vstm3, or WUCAM; VL3 is a third immunoglobulin lightchain variable region that specifically binds to A2AR, APRIL, ATPDase,BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1, B7H2, B7H3, B7H4, B7H5,B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8,CCL11, CCL15, CCL17, CCL19, CCL20, CCL21, CCL25 CCR3, CCR4, CD3, CD16A,CD19, CD20, CD24, CD27, CD28, CD30, CD38, CD39, CD40, CD40L, CD47, CD52,CD70, CD80, CD86, CD123, CD133, CD137, CD137L, CD160, CD272, CEACAM5,CLEC9, CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12,CXCL13, CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin, EGFR,ENTPD1, EpCAM, FCER1, FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24, GITR,GITRL, GPR5, GP100, GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1, HVEM,IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2, IL4,IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL9, IL9R, IL10, rhIL1O, IL12, IL13,IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23, IL25, IL7, IL33,IL35, ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II, MUC-1,MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L, PD-1, PD-L1,PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1, STEAP2,Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3, TLR,TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP, TSLPR,TWEAK, VEGF, VISTA, Vstm3, or WUCAM; VL4 is a fourth immunoglobulinlight chain variable region that specifically binds to A2AR, APRIL,ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1, B7H2, B7H3,B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3, CCL4, CCL5,CCL7, CCL8, CCL11, CCL15, CCL17, CCL19, CCL20, CCL21, CCL25 CCR3, CCR4,CD3, CD16A, CD19, CD20, CD24, CD27, CD28, CD30, CD38, CD39, CD40, CD40L,CD47, CD52, CD70, CD80, CD86, CD123, CD133, CD137, CD137L, CD160, CD272,CEACAM5, CLEC9, CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4,CXCL12, CXCL13, CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin,EGFR, ENTPD1, EpCAM, FCER1, FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24,GITR, GITRL, GPR5, GP100, GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1,HVEM, IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2,IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O,IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23,IL25, IL7, IL33, IL35, ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHCclass II, MUC-1, MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L,PD-1, PD-L1, PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2,STEAP1, STEAP2, Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14,TIGIT, TIM3, TLR, TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55,TREM1, TSLP, TSLPR, TWEAK, VEGF, VISTA, Vstm3, or WUCAM; VH1 is a firstimmunoglobulin heavy chain variable region that specifically binds toA2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1,B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3,CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19, CCL20, CCL21, CCL25CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27, CD28, CD30, CD38, CD39,CD40, CD40L, CD47, CD52, CD70, CD80, CD86, CD123, CD133, CD137, CD137L,CD160, CD272, CEACAM5, CLEC9, CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1,CXCL2, CXCL4, CXCL12, CXCL13, CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1,E-cadherin, EGFR, ENTPD1, EpCAM, FCER1, FCER1A, FCER2, FGFR, FLAP,FOLH1, Gi24, GITR, GITRL, GPRS, GP100, GPRC5D, HER2, HER3, ICOSL, ICOS,HHLA2, HMGB1, HVEM, IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1, ILIA, IL1B,IL1F10, IL2, IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8, IL9, IL9R,IL10, rhIL1O, IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb, IL18,IL22, IL23, IL25, IL7, IL33, IL35, ITGB4, ITK, KIR, LAG3, LAMP1, leptin,LPFS2, MHC class II, MUC-1, MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1,OX40, OX40L, PD-1, PD-L1, PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC,SPG64, ST2, STEAP1, STEAP2, Syk kinase, STEAP1, TROP2, TACI, TDO,TGFBETA, T14, TIGIT, TIM3, TLR, TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa,TNFRSF7, Tp55, TREM1, TSLP, TSLPR, TWEAK, VEGF, VISTA, Vstm3, or WUCAM;VH2 is a second immunoglobulin heavy chain variable region thatspecifically binds to A2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS,BTK, BTLA, B7DC, B7H1, B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4,C3, C5, CCL2, CCL3, CCL4, CCLS, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19,CCL20, CCL21, CCL25 CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27,CD28, CD30, CD38, CD39, CD40, CD40L, CD47, CD52, CD70, CD80, CD86,CD123, CD133, CD137, CD137L, CD160, CD272, CEACAM5, CLEC9, CLEC91,CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12, CXCL13, CXCR3,cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin, EGFR, ENTPD1, EpCAM, FCER1,FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24, GITR, GITRL, GPRS, GP100,GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1, HVEM, IDO, IFNa, IgE,IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R,IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O, IL12, IL13, IL13Ra1,IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23, IL25, IL7, IL33, IL35,ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II, MUC-1,MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L, PD-1, PD-L1,PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1, STEAP2,Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3, TLR,TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP, TSLPR,TWEAK, VEGF, VISTA, Vstm3, or WUCAM; VH3 is a third immunoglobulin heavychain variable region that specifically binds to A2AR, APRIL, ATPDase,BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1, B7H2, B7H3, B7H4, B7H5,B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3, CCL4, CCLS, CCL7, CCL8,CCL11, CCL15, CCL17, CCL19, CCL20, CCL21, CCL25 CCR3, CCR4, CD3, CD16A,CD19, CD20, CD24, CD27, CD28, CD30, CD38, CD39, CD40, CD40L, CD47, CD52,CD70, CD80, CD86, CD123, CD133, CD137, CD137L, CD160, CD272, CEACAM5,CLEC9, CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12,CXCL13, CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin, EGFR,ENTPD1, EpCAM, FCER1, FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24, GITR,GITRL, GPRS, GP100, GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1, HVEM,IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2, IL4,IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O, IL12,IL13, IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23, IL25, IL7,IL33, IL35, ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II,MUC-1, MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L, PD-1,PD-L1, PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1,STEAP2, Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3,TLR, TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP,TSLPR, TWEAK, VEGF, VISTA, Vstm3, or WUCAM; VH4 is a fourthimmunoglobulin heavy chain variable region that specifically binds toA2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1,B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3,CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19, CCL20, CCL21, CCL25CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27, CD28, CD30, CD38, CD39,CD40, CD40L, CD47, CD52, CD70, CD80, CD86, CD123, CD133, CD137, CD137L,CD160, CD272, CEACAM5, CLEC9, CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1,CXCL2, CXCL4, CXCL12, CXCL13, CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1,E-cadherin, EGFR, ENTPD1, EpCAM, FCER1, FCER1A, FCER2, FGFR, FLAP,FOLH1, Gi24, GITR, GITRL, GPR5, GP100, GPRC5D, HER2, HER3, ICOSL, ICOS,HHLA2, HMGB1, HVEM, IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1, ILIA, IL1B,IL1F10, IL2, IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8, IL9, IL9R,IL10, rhIL1O, IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb, IL18,IL22, IL23, IL25, IL7, IL33, IL35, ITGB4, ITK, KIR, LAG3, LAMP1, leptin,LPFS2, MHC class II, MUC-1, MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1,OX40, OX40L, PD-1, PD-L1, PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC,SPG64, ST2, STEAP1, STEAP2, Syk kinase, STEAP1, TROP2, TACI, TDO,TGFBETA, T14, TIGIT, TIM3, TLR, TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa,TNFRSF7, Tp55, TREM1, TSLP, TSLPR, TWEAK, VEGF, VISTA, Vstm3, or WUCAM;Fc is a region comprising an immunoglobulin heavy chain constant region2 (CH2), an immunoglobulin heavy chain constant region 3 (CH3), andoptionally, an immunoglobulin hinge; CH1 is an immunoglobulin heavychain constant region 1; CL is an immunoglobulin light chain constantregion; and L1, L2, L3, L4, L5, L6, L7, L8, L9 and L10 are amino acidlinkers. In some aspects, the first polypeptide has a structurerepresented by VL1-VL2-VH2-VH1-CH1-Fc, and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc;VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fe;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-F c. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1-CH1-Fc, andthe second polypeptide has a structure represented byVL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc;VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fe;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-F c. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-CL-Fc, andthe second polypeptide has a structure represented byVL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc;VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fe;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-F c. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1-CL-Fc, andthe second polypeptide has a structure represented byVL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc;VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fe;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-F c. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-CH1-CL-Fc,and the second polypeptide has a structure represented byVL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc;VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fe;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-F c. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1-CH1-CL-Fc,and the second polypeptide has a structure represented byVL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc;VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fe;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-F c. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-CL-CH1-Fc,and the second polypeptide has a structure represented byVL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc;VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fe;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-F c. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1-CL-CH1-Fc,and the second polypeptide has a structure represented byVL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc;VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fe;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-F c. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fe, and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc;VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fc;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fe, and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc;VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fc;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fe; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fe. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fe, and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc;VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fc;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fe;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fe; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fe. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fe, and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc;VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fc;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fe;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fe; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fe. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fe, and the second polypeptide hasa structure represented by VL3-VL4-VH4-VH3-CH1-Fc;VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc;VL3-VL4-VH4-VH3-CH1-CL-Fc; VH3-VH4-VL4-VL3-CH1-CL-Fc;VL3-VL4-VH4-VH3-CL-CH1-Fc; VH3-VH4-VL4-VL3-CL-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fe. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fe, and the second polypeptide hasa structure represented by VL3-VL4-VH4-VH3-CH1-Fc;VH3-VH4-VL4-VL3-CH1-Fe; VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc;VL3-VL4-VH4-VH3-CH1-CL-Fc; VH3-VH4-VL4-VL3-CH1-CL-Fc;VL3-VL4-VH4-VH3-CL-CH1-Fc; VH3-VH4-VL4-VL3-CL-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fe;VL3-L6-VL4-L7-VH4- L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fe;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fe; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fe. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc, and the second polypeptide hasa structure represented by VL3-VL4-VH4-VH3-CH1-Fc;VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc;VL3-VL4-VH4-VH3-CH1-CL-Fc; VH3-VH4-VL4-VL3-CH1-CL-Fc;VL3-VL4-VH4-VH3-CL-CH1-Fc; VH3-VH4-VL4-VL3-CL-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fe; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fe. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc, and the second polypeptide hasa structure represented by VL3-VL4-VH4-VH3-CH1-Fc;VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc;VL3-VL4-VH4-VH3-CH1-CL-Fe; VH3-VH4-VL4-VL3-CH1-CL-Fc;VL3-VL4-VH4-VH3-CL-CH1-Fc; VH3-VH4-VL4-VL3-CL-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc. In some aspects, the VL1,VL2, VL3, VL4, VH1, VH2, VH3 and/or VH4 specifically binds to A2AR,APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1, B7H2,B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3, CCL4,CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19, CCL20, CCL21, CCL25 CCR3,CCR4, CD3, CD16A, CD19, CD20, CD24, CD27, CD28, CD30, CD38, CD39, CD40,CD40L, CD47, CD52, CD70, CD80, CD86, CD123, CD133, CD137, CD137L, CD160,CD272, CEACAM5, CLEC9, CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2,CXCL4, CXCL12, CXCL13, CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1,E-cadherin, EGFR, ENTPD1, EpCAM, FCER1, FCER1A, FCER2, FGFR, FLAP,FOLH1, Gi24, GITR, GITRL, GPR5, GP100, GPRC5D, HER2, HER3, ICOSL, ICOS,HHLA2, HMGB1, HVEM, IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1, ILIA, IL1B,IL1F10, IL2, IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8, IL9, IL9R,IL10, rhIL1O, IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb, IL18,IL22, IL23, IL25, IL7, IL33, IL35, ITGB4, ITK, KIR, LAG3, LAMP1, leptin,LPFS2, MHC class II, MUC-1, MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1,OX40, OX40L, PD-1, PD-L1, PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC,SPG64, ST2, STEAP1, STEAP2, Syk kinase, STEAP1, TROP2, TACI, TDO,TGFBETA, T14, TIGIT, TIM3, TLR, TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa,TNFRSF7, Tp55, TREM1, TSLP, TSLPR, TWEAK, VEGF, VISTA, Vstm3, or WUCAM.Any and all disclosure herein in relation to targets for antigen bindingpolypeptides of the invention is generally applicable, and appliesequally and without reservation to each and every antigen bindingpolypeptide and antigen binding polypeptide complex described herein.For the avoidance of doubt, the VL1, VL2, VL3, VL4, VH1, VH2, VH3 and/orVH4 of each and every antigen binding polypeptide and antigen bindingpolypeptide complex described herein may independently bind to any oneof said particularly preferred targets.

In other aspects, the invention is directed to an antigen bindingpolypeptide complex comprising a first polypeptide and a secondpolypeptide; wherein the first polypeptide has a structure representedby VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1;VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc;VL1-VL2-VH2-VH1-CH1; VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL;VH1-VH2-VL2-VL1-CL; VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL;VL1-VL2-VH2-VH1-CL-CH1; VH1-VH2-VL2-VL1-CL-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL;VL1-L1-VL2- L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1;VL1-VL2-VH2-VH1-CH1-Fc; VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc;VH1-VH2-VL2-VL1-CL-Fc; VL1-VL2-VH2-VH1-CH1-CL-Fc;VH1-VH2-VL2-VL1-CH1-CL-Fc; VL1-VL2-VH2-VH1-CL-CH1-Fc;VH1-VH2-VL2-VL1-CL-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fe;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fe;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fe; wherein the second polypeptidehas a structure represented by VL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3;VL3-L4-VL4-L5-VH4-L6-VH3; VH3-L4-VH4-L5-VL4-L6-VL3; VL3-VL4-VH4-VH3-Fc;VH3-VH4-VL4-VL3-Fc; VL3-L5-VL4-L6-VH4-L7-VH3-Fc;VH3-L5-VH4-L6-VL4-L7-VL3-Fc; VL3-L5-VL4-L6-VH4-L7-VH3-L8-Fc;VH3-L5-VH4-L6-VL4-L7-VL3-L8-Fc; VL3-VL4-VH4-VH3-CH1;VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL;VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1;VH3-VH4-VL4-VL3-CL-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4- L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1; VL3-VL4-VH4-VH3-CH1-Fc;VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc;VL3-VL4-VH4-VH3-CH1-CL-Fc; VH3-VH4-VL4-VL3-CH1-CL-Fc;VL3-VL4-VH4-VH3-CL-CH1-Fc; VH3-VH4-VL4-VL3-CL-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fe;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fe; wherein VL1 is a firstimmunoglobulin light chain variable region that specifically binds tohuman CD3, CD19, CD28, CD38 or Her2; VL2 is a second immunoglobulinlight chain variable region that specifically binds to human CD3, CD19,CD28, CD38 or Her2; VL3 is a third immunoglobulin light chain variableregion that specifically binds to human CD3, CD19, CD28, CD38 or Her2;VL4 is a fourth immunoglobulin light chain variable region thatspecifically binds to human CD3, CD19, CD28, CD38 or Her2; VH1 is afirst immunoglobulin heavy chain variable region that specifically bindsto A2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1,B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3,CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19, CCL20, CCL21, CCL25CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27, CD28, CD30, CD38, CD39,CD40, CD40L, CD47, CD52, CD70, CD80, CD86, CD123, CD133, CD137, CD137L,CD160, CD272, CEACAM5, CLEC9, CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1,CXCL2, CXCL4, CXCL12, CXCL13, CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1,E-cadherin, EGFR, ENTPD1, EpCAM, FCER1, FCER1A, FCER2, FGFR, FLAP,FOLH1, Gi24, GITR, GITRL, GPR5, GP100, GPRC5D, HER2, HER3, ICOSL, ICOS,HHLA2, HMGB1, HVEM, IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1, ILIA, IL1B,IL1F10, IL2, IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL9, IL9R, IL10,rhIL1O, IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22,IL23, IL25, IL7, IL33, IL35, ITGB4, ITK, KIR, LAG3, LAMP1, leptin,LPFS2, MHC class II, MUC-1, MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1,OX40, OX40L, PD-1, PD-L1, PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC,SPG64, ST2, STEAP1, STEAP2, Syk kinase, STEAP1, TROP2, TACI, TDO,TGFBETA, T14, TIGIT, TIM3, TLR, TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa,TNFRSF7, Tp55, TREM1, TSLP, TSLPR, TWEAK, VEGF, VISTA, Vstm3, or WUCAM;VH2 is a second immunoglobulin heavy chain variable region thatspecifically binds to A2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS,BTK, BTLA, B7DC, B7H1, B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4,C3, C5, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19,CCL20, CCL21, CCL25 CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27,CD28, CD30, CD38, CD39, CD40, CD40L, CD47, CD52, CD70, CD80, CD86,CD123, CD133, CD137, CD137L, CD160, CD272, CEACAM5, CLEC9, CLEC91,CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12, CXCL13, CXCR3,cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin, EGFR, ENTPD1, EpCAM, FCER1,FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24, GITR, GITRL, GPR5, GP100,GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1, HVEM, IDO, IFNa, IgE,IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R,IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O, IL12, IL13, IL13Ra1,IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23, IL25, IL7, IL33, IL35,ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II, MUC-1,MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L, PD-1, PD-L1,PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1, STEAP2,Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3, TLR,TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP, TSLPR,TWEAK, VEGF, VISTA, Vstm3, or WUCAM; VH3 is a third immunoglobulin heavychain variable region that specifically binds to A2AR, APRIL, ATPDase,BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1, B7H2, B7H3, B7H4, B7H5,B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8,CCL11, CCL15, CCL17, CCL19, CCL20, CCL21, CCL25 CCR3, CCR4, CD3, CD16A,CD19, CD20, CD24, CD27, CD28, CD30, CD38, CD39, CD40, CD40L, CD47, CD52,CD70, CD80, CD86, CD123, CD133, CD137, CD137L, CD160, CD272, CEACAM5,CLEC9, CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12,CXCL13, CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin, EGFR,ENTPD1, EpCAM, FCER1, FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24, GITR,GITRL, GPR5, GP100, GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1, HVEM,IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2, IL4,IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL9, IL9R, IL10, rhIL1O, IL12, IL13,IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23, IL25, IL7, IL33,IL35, ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II, MUC-1,MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L, PD-1, PD-L1,PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1, STEAP2,Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3, TLR,TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP, TSLPR,TWEAK, VEGF, VISTA, Vstm3, or WUCAM; VH4 is a fourth immunoglobulinheavy chain variable region that specifically binds to A2AR, APRIL,ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1, B7H2, B7H3,B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3, CCL4, CCL5,CCL7, CCL8, CCL11, CCL15, CCL17, CCL19, CCL20, CCL21, CCL25 CCR3, CCR4,CD3, CD16A, CD19, CD20, CD24, CD27, CD28, CD30, CD38, CD39, CD40, CD40L,CD47, CD52, CD70, CD80, CD86, CD123, CD133, CD137, CD137L, CD160, CD272,CEACAM5, CLEC9, CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4,CXCL12, CXCL13, CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin,EGFR, ENTPD1, EpCAM, FCER1, FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24,GITR, GITRL, GPR5, GP100, GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1,HVEM, IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2,IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O,IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23,IL25, IL7, IL33, IL35, ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHCclass II, MUC-1, MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L,PD-1, PD-L1, PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2,STEAP1, STEAP2, Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14,TIGIT, TIM3, TLR, TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55,TREM1, TSLP, TSLPR, TWEAK, VEGF, VISTA, Vstm3, or WUCAM; Fc is a regioncomprising an immunoglobulin heavy chain constant region 2 (CH2), animmunoglobulin heavy chain constant region 3 (CH3), and optionally, animmunoglobulin hinge; CH1 is an immunoglobulin heavy chain constantregion 1; CL is an immunoglobulin light chain constant region; and L1,L2, L3, L4, L5, L6, L7, L8, L9 and L10 are amino acid linkers. In someaspects, the first polypeptide has a structure represented byVL1-VL2-VH2-VH1, and the second polypeptide has a structure representedby VL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3; VL3-L4-VL4-L5-VH4-L6-VH3;VH3-L4-VH4-L5-VL4-L6-VL3; VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc;VL3-L5-VL4-L6-VH4-L7-VH3-Fc; VH3-L5-VH4-L6-VL4-L7-VL3-Fc;VL3-L5-VL4-L6-VH4-L7-VH3-L8-Fc; VH3-L5-VH4-L6-VL4-L7-VL3-L8-Fc;VL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL;VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL;VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL; VH3-L6-VH4-L7-VL4- L8-VL3-L9-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1; VL3-VL4-VH4-VH3-CH1-Fc;VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc;VL3-VL4-VH4-VH3-CH1-CL-Fc; VH3-VH4-VL4-VL3-CH1-CL-Fc;VL3-VL4-VH4-VH3-CL-CH1-Fc; VH3-VH4-VL4-VL3-CL-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1, and thesecond polypeptide has a structure represented by VL3-VL4-VH4-VH3;VH3-VH4-VL4-VL3; VL3-L4-VL4-L5-VH4-L6-VH3; VH3-L4-VH4-L5-VL4-L6-VL3;VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fe; VL3-L5-VL4-L6-VH4-L7-VH3-Fc;VH3-L5-VH4-L6-VL4-L7-VL3-Fc; VL3-L5-VL4-L6-VH4-L7-VH3-L8-Fc;VH3-L5-VH4-L6-VL4-L7-VL3-L8-Fc; VL3-VL4-VH4-VH3-CH1;VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL;VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1;VH3-VH4-VL4-VL3-CL-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4- L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1; VL3-VL4-VH4-VH3-CH1-Fe;VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc;VL3-VL4-VH4-VH3-CH1-CL-Fc; VH3-VH4-VL4-VL3-CH1-CL-Fc;VL3-VL4-VH4-VH3-CL-CH1-Fc; VH3-VH4-VL4-VL3-CL-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VL1-L1-VL2-L2-VH2-L3-VH1, andthe second polypeptide has a structure represented by VL3-VL4-VH4-VH3;VH3-VH4-VL4-VL3; VL3-L4-VL4-L5-VH4-L6-VH3; VH3-L4-VH4-L5-VL4-L6-VL3;VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc; VL3-L5-VL4-L6-VH4-L7-VH3-Fc;VH3-L5-VH4-L6-VL4-L7-VL3-Fc; VL3-L5-VL4-L6-VH4-L7-VH3-L8-Fc;VH3-L5-VH4-L6-VL4-L7-VL3-L8-Fc; VL3-VL4-VH4-VH3-CH1;VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL;VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1;VH3-VH4-VL4-VL3-CL-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8- VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1; VL3-VL4-VH4-VH3-CH1-Fc;VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc;VL3-VL4-VH4-VH3-CH1-CL-Fc; VH3-VH4-VL4-VL3-CH1-CL-Fc;VL3-VL4-VH4-VH3-CL-CH1-Fc; VH3-VH4-VL4-VL3-CL-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VH1-L1-VH2-L2-VL2-L3-VL1, andthe second polypeptide has a structure represented by VL3-VL4-VH4-VH3;VH3-VH4-VL4-VL3; VL3-L4-VL4-L5-VH4-L6-VH3; VH3-L4-VH4-L5-VL4-L6-VL3;VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc; VL3-L5-VL4-L6-VH4-L7-VH3-Fc;VH3-L5-VH4-L6-VL4-L7-VL3-Fc; VL3-L5-VL4-L6-VH4-L7-VH3-L8-Fc;VH3-L5-VH4-L6-VL4-L7-VL3-L8-Fc; VL3-VL4-VH4-VH3-CH1;VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL;VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1;VH3-VH4-VL4-VL3-CL-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1; VL3-VL4-VH4-VH3-CH1-Fc;VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc;VL3-VL4-VH4-VH3-CH1-CL-Fc; VH3-VH4-VL4-VL3-CH1-CL-Fc;VL3-VL4-VH4-VH3-CL-CH1-Fc; VH3-VH4-VL4-VL3-CL-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-F c. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-Fc, and thesecond polypeptide has a structure represented by VL3-VL4-VH4-VH3;VH3-VH4-VL4-VL3; VL3-L4-VL4-L5-VH4-L6-VH3; VH3-L4-VH4-L5-VL4-L6-VL3;VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc; VL3-L5-VL4-L6-VH4-L7-VH3-Fc;VH3-L5-VH4-L6-VL4-L7-VL3-Fc; VL3-L5-VL4-L6-VH4-L7-VH3-L8-Fc;VH3-L5-VH4-L6-VL4-L7-VL3-L8-Fc; VL3-VL4-VH4-VH3-CH1;VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL;VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1;VH3-VH4-VL4-VL3-CL-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1- L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1; VL3-VL4-VH4-VH3-CH1-Fc;VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc;VL3-VL4-VH4-VH3-CH1-CL-Fc; VH3-VH4-VL4-VL3-CH1-CL-Fc;VL3-VL4-VH4-VH3-CL-CH1-Fc; VH3-VH4-VL4-VL3-CL-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1-Fc, and thesecond polypeptide has a structure represented by VL3-VL4-VH4-VH3;VH3-VH4-VL4-VL3; VL3-L4-VL4-L5-VH4-L6-VH3; VH3-L4-VH4-L5-VL4-L6-VL3;VL3-VL4-VH4-VH3- Fc; VH3-VH4-VL4-VL3-Fc; VL3-L5-VL4-L6-VH4-L7-VH3-Fc;VH3-L5-VH4-L6-VL4-L7-VL3-Fc; VL3-L5-VL4-L6-VH4-L7-VH3-L8-Fc;VH3-L5-VH4-L6-VL4-L7-VL3-L8-Fc; VL3-VL4-VH4-VH3-CH1;VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL;VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1;VH3-VH4-VL4-VL3-CL-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1;VL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc;VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fc;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9- CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VL1-L1-VL2-L2-VH2-L3-VH1-Fc,and the second polypeptide has a structure represented byVL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3; VL3-L4-VL4-L5-VH4-L6-VH3;VH3-L4-VH4-L5-VL4-L6-VL3; VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc;VL3-L5-VL4-L6-VH4-L7-VH3-Fc; VH3-L5-VH4-L6-VL4-L7-VL3-Fc;VL3-L5-VL4-L6-VH4-L7-VH3-L8-Fc; VH3-L5-VH4-L6-VL4-L7-VL3-L8-Fc;VL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL;VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL;VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL;VL3-L6-VL4-L7-VH4- L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1; VL3-VL4-VH4-VH3-CH1-Fc;VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc;VL3-VL4-VH4-VH3-CH1-CL-Fc; VH3-VH4-VL4-VL3-CH1-CL-Fc;VL3-VL4-VH4-VH3-CL-CH1-Fc; VH3-VH4-VL4-VL3-CL-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VH1-L1-VH2-L2-VL2-L3-VL1-Fc,and the second polypeptide has a structure represented byVL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3; VL3-L4-VL4-L5-VH4-L6-VH3;VH3-L4-VH4-L5-VL4-L6-VL3; VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc;VL3-L5-VL4-L6-VH4-L7-VH3-Fc; VH3-L5-VH4-L6-VL4-L7-VL3-Fc;VL3-L5-VL4-L6-VH4-L7-VH3-L8-Fc; VH3-L5-VH4-L6-VL4-L7-VL3-L8-Fc;VL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL;VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL;VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1;VL3-L6- VL4-L7-VH4-L8-VH3-L9-CL; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10- CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1; VL3-VL4-VH4-VH3-CH1-Fc;VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc;VL3-VL4-VH4-VH3-CH1-CL-Fc; VH3-VH4-VL4-VL3-CH1-CL-Fc;VL3-VL4-VH4-VH3-CL-CH1-Fc; VH3-VH4-VL4-VL3-CL-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc, and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3;VL3-L4-VL4-L5-VH4-L6-VH3; VH3-L4-VH4-L5-VL4-L6-VL3; VL3-VL4-VH4-VH3-Fc;VH3-VH4-VL4-VL3-Fc; VL3-L5-VL4-L6-VH4-L7-VH3-Fc;VH3-L5-VH4-L6-VL4-L7-VL3-Fc; VL3-L5-VL4-L6-VH4-L7-VH3-L8-Fc;VH3-L5-VH4-L6-VL4-L7-VL3-L8-Fc; VL3-VL4-VH4-VH3-CH1;VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL;VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1;VH3-VH4-VL4-VL3-CL-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1; VL3-VL4-VH4-VH3-CH1-Fc;VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc;VL3-VL4-VH4-VH3-CH1-CL-Fc; VH3-VH4-VL4-VL3-CH1-CL-Fc;VL3-VL4-VH4-VH3-CL-CH1-Fc; VH3-VH4-VL4-VL3-CL-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-F c. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc, and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3;VL3-L4-VL4-L5-VH4-L6-VH3; VH3-L4-VH4-L5-VL4-L6-VL3; VL3-VL4-VH4-VH3-Fc;VH3-VH4-VL4-VL3-Fc; VL3-L5-VL4-L6-VH4-L7-VH3-Fc;VH3-L5-VH4-L6-VL4-L7-VL3-Fc; VL3-L5-VL4-L6-VH4-L7-VH3-L8-Fc;VH3-L5-VH4-L6-VL4-L7-VL3-L8-Fc; VL3-VL4-VH4-VH3-CH1;VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL;VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1;VH3-VH4-VL4-VL3-CL-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3- L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1; VL3-VL4-VH4-VH3-CH1-Fc;VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc;VL3-VL4-VH4-VH3-CH1-CL-Fc; VH3-VH4-VL4-VL3-CH1-CL-Fc;VL3-VL4-VH4-VH3-CL-CH1-Fc; VH3-VH4-VL4-VL3-CL-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-CH1, and thesecond polypeptide has a structure represented by VL3-VL4-VH4-VH3;VH3-VH4-VL4-VL3; VL3-L4-VL4-L5-VH4-L6-VH3; VH3-L4-VH4-L5-VL4-L6-VL3;VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc; VL3-L5-VL4-L6-VH4-L7-VH3-Fc;VH3-L5-VH4-L6-VL4-L7-VL3-Fc; VL3-L5-VL4-L6-VH4-L7-VH3-L8-Fc;VH3-L5-VH4-L6-VL4-L7-VL3-L8-Fc; VL3-VL4-VH4-VH3-CH1;VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL;VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1;VH3-VH4-VL4-VL3-CL-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1; VL3-VL4-VH4-VH3-CH1-Fc;VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc;VL3-VL4-VH4-VH3-CH1-CL-Fc; VH3-VH4-VL4-VL3-CH1-CL-Fc;VL3-VL4-VH4-VH3-CL-CH1-Fc; VH3-VH4-VL4-VL3-CL-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fe;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1-CH1, and thesecond polypeptide has a structure represented by VL3-VL4-VH4-VH3;VH3-VH4-VL4-VL3; VL3-L4-VL4-L5-VH4-L6-VH3; VH3-L4-VH4-L5-VL4-L6-VL3;VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc; VL3-L5-VL4-L6-VH4-L7-VH3-Fc;VH3-L5-VH4-L6-VL4-L7-VL3-Fc; VL3-L5-VL4-L6-VH4-L7-VH3-L8-Fc;VH3-L5-VH4-L6-VL4-L7-VL3-L8-Fc; VL3-VL4-VH4-VH3-CH1;VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL;VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1;VH3-VH4-VL4-VL3-CL-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7- VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1;VL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc;VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fc;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-CL, and thesecond polypeptide has a structure represented by VL3-VL4-VH4-VH3;VH3-VH4-VL4-VL3; VL3-L4-VL4-L5-VH4-L6-VH3; VH3-L4-VH4-L5-VL4-L6-VL3;VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc; VL3-L5-VL4-L6-VH4-L7-VH3-Fc;VH3-L5-VH4-L6-VL4-L7-VL3-Fc; VL3-L5-VL4-L6-VH4-L7-VH3-L8-Fc;VH3-L5-VH4-L6-VL4-L7-VL3-L8-Fc; VL3-VL4-VH4-VH3-CH1;VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL;VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1;VH3-VH4-VL4-VL3-CL-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6- VL4-L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10- CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1; VL3-VL4-VH4-VH3-CH1-Fc;VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc;VL3-VL4-VH4-VH3-CH1-CL-Fc; VH3-VH4-VL4-VL3-CH1-CL-Fc;VL3-VL4-VH4-VH3-CL-CH1-Fc; VH3-VH4-VL4-VL3-CL-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1-CL, and thesecond polypeptide has a structure represented by VL3-VL4-VH4-VH3;VH3-VH4-VL4-VL3; VL3-L4-VL4-L5-VH4-L6-VH3; VH3-L4-VH4-L5-VL4-L6-VL3;VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc; VL3-L5-VL4-L6-VH4-L7-VH3-Fc;VH3-L5-VH4-L6-VL4-L7-VL3-Fc; VL3-L5-VL4-L6-VH4-L7-VH3-L8-Fc;VH3-L5-VH4-L6-VL4-L7-VL3-L8-Fc; VL3-VL4-VH4-VH3-CH1;VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL;VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1;VH3-VH4-VL4-VL3-CL-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3- L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1; VL3-VL4-VH4-VH3-CH1-Fc;VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc;VL3-VL4-VH4-VH3-CH1-CL-Fc; VH3-VH4-VL4-VL3-CH1-CL-Fc;VL3-VL4-VH4-VH3-CL-CH1-Fc; VH3-VH4-VL4-VL3-CL-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-CH1-CL, andthe second polypeptide has a structure represented by VL3-VL4-VH4-VH3;VH3-VH4-VL4-VL3; VL3-L4-VL4-L5-VH4-L6-VH3; VH3-L4-VH4-L5-VL4-L6-VL3;VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc; VL3-L5-VL4-L6-VH4-L7-VH3-Fc;VH3-L5-VH4-L6-VL4-L7-VL3-Fc; VL3-L5-VL4-L6-VH4-L7-VH3-L8-Fc;VH3-L5-VH4-L6-VL4-L7-VL3-L8-Fc; VL3-VL4-VH4-VH3-CH1;VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL;VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1;VH3-VH4-VL4-VL3-CL-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1; VL3-VL4-VH4-VH3-CH1-Fc;VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc;VL3-VL4-VH4-VH3-CH1-CL-Fc; VH3-VH4-VL4-VL3-CH1-CL-Fc;VL3-VL4-VH4-VH3-CL-CH1-Fc; VH3-VH4-VL4-VL3-CL-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1-CH1-CL, andthe second polypeptide has a structure represented by VL3-VL4-VH4-VH3;VH3-VH4-VL4-VL3; VL3-L4-VL4-L5-VH4-L6-VH3; VH3-L4-VH4-L5-VL4-L6-VL3;VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fe; VL3-L5-VL4-L6-VH4-L7-VH3-Fc;VH3-L5-VH4-L6-VL4-L7-VL3-Fc; VL3-L5-VL4-L6-VH4-L7-VH3-L8-Fc;VH3-L5-VH4-L6-VL4-L7-VL3-L8-Fc; VL3-VL4-VH4-VH3-CH1;VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL;VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1;VH3-VH4-VL4-VL3-CL-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4- L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1; VL3-VL4-VH4-VH3-CH1-Fc;VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc;VL3-VL4-VH4-VH3-CH1-CL-Fc; VH3-VH4-VL4-VL3-CH1-CL-Fc;VL3-VL4-VH4-VH3-CL-CH1-Fc; VH3-VH4-VL4-VL3-CL-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-CL-CH1, andthe second polypeptide has a structure represented by VL3-VL4-VH4-VH3;VH3-VH4-VL4-VL3; VL3-L4-VL4-L5-VH4-L6-VH3; VH3-L4-VH4-L5-VL4-L6-VL3;VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc; VL3-L5-VL4-L6-VH4-L7-VH3-Fc;VH3-L5-VH4-L6-VL4-L7-VL3-Fc; VL3-L5-VL4-L6-VH4-L7-VH3-L8-Fc;VH3-L5-VH4-L6-VL4-L7-VL3-L8-Fc; VL3-VL4-VH4-VH3-CH1;VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL;VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1;VH3-VH4-VL4-VL3-CL-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3- L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1; VL3-VL4-VH4-VH3-CH1-Fc;VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc;VL3-VL4-VH4-VH3-CH1-CL-Fc; VH3-VH4-VL4-VL3-CH1-CL-Fc;VL3-VL4-VH4-VH3-CL-CH1-Fc; VH3-VH4-VL4-VL3-CL-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1-CL-CH1, andthe second polypeptide has a structure represented by VL3-VL4-VH4-VH3;VH3-VH4-VL4-VL3; VL3-L4-VL4-L5-VH4-L6-VH3; VH3-L4-VH4-L5-VL4-L6-VL3;VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc; VL3-L5-VL4-L6-VH4-L7-VH3-Fc;VH3-L5-VH4-L6-VL4-L7-VL3-Fc; VL3-L5-VL4-L6-VH4-L7-VH3-L8-Fc;VH3-L5-VH4-L6-VL4-L7-VL3-L8-Fc; VL3-VL4-VH4-VH3-CH1;VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL;VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1;VH3-VH4-VL4-VL3-CL-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1; VL3-VL4-VH4-VH3-CH1-Fc;VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc;VL3-VL4-VH4-VH3-CH1-CL-Fc; VH3-VH4-VL4-VL3-CH1-CL-Fc;VL3-VL4-VH4-VH3-CL-CH1-Fc; VH3-VH4-VL4-VL3-CL-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-F c. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1, and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3;VL3-L4-VL4-L5-VH4-L6-VH3; VH3-L4-VH4-L5-VL4-L6-VL3; VL3-VL4-VH4-VH3-Fc;VH3-VH4-VL4-VL3-Fc; VL3-L5-VL4-L6-VH4-L7-VH3-Fc;VH3-L5-VH4-L6-VL4-L7-VL3-Fc; VL3-L5-VL4-L6-VH4-L7-VH3-L8-Fc;VH3-L5-VH4-L6-VL4-L7-VL3-L8-Fc; VL3-VL4-VH4-VH3-CH1;VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL;VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1;VH3-VH4-VL4-VL3-CL-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3- L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1; VL3-VL4-VH4-VH3-CH1-Fc;VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc;VL3-VL4-VH4-VH3-CH1-CL-Fc; VH3-VH4-VL4-VL3-CH1-CL-Fc;VL3-VL4-VH4-VH3-CL-CH1-Fc; VH3-VH4-VL4-VL3-CL-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1, and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3;VL3-L4-VL4-L5-VH4-L6-VH3; VH3-L4-VH4-L5-VL4-L6-VL3; VL3-VL4-VH4-VH3-Fc;VH3-VH4-VL4-VL3-Fc; VL3-L5-VL4-L6-VH4-L7-VH3-Fc;VH3-L5-VH4-L6-VL4-L7-VL3-Fc; VL3-L5-VL4-L6-VH4-L7-VH3-L8-Fc;VH3-L5-VH4-L6-VL4-L7-VL3-L8-Fc; VL3-VL4-VH4-VH3-CH1;VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL;VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1;VH3-VH4-VL4-VL3-CL-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1- L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1; VL3-VL4-VH4-VH3-CH1-Fc;VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc;VL3-VL4-VH4-VH3-CH1-CL-Fc; VH3-VH4-VL4-VL3-CH1-CL-Fc;VL3-VL4-VH4-VH3-CL-CH1-Fc; VH3-VH4-VL4-VL3-CL-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CL, and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3;VL3-L4-VL4-L5-VH4-L6-VH3; VH3-L4-VH4-L5-VL4-L6-VL3; VL3-VL4-VH4-VH3-Fc;VH3-VH4-VL4-VL3-Fc; VL3-L5-VL4-L6-VH4-L7-VH3-Fc;VH3-L5-VH4-L6-VL4-L7-VL3-Fc; VL3-L5-VL4-L6-VH4-L7-VH3-L8-Fc;VH3-L5-VH4-L6-VL4-L7-VL3-L8-Fc; VL3-VL4-VH4-VH3-CH1;VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL;VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1;VH3-VH4-VL4-VL3-CL-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1; VL3-VL4-VH4-VH3-CH1-Fc;VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc;VL3-VL4-VH4-VH3-CH1-CL-Fc; VH3-VH4-VL4-VL3-CH1-CL-Fc;VL3-VL4-VH4-VH3-CL-CH1-Fc; VH3-VH4-VL4-VL3-CL-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL, and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3;VL3-L4-VL4-L5-VH4-L6-VH3; VH3-L4-VH4-L5-VL4-L6-VL3; VL3-VL4-VH4-VH3- Fc;VH3-VH4-VL4-VL3-Fc; VL3-L5-VL4-L6-VH4-L7-VH3-Fc;VH3-L5-VH4-L6-VL4-L7-VL3-Fc; VL3-L5-VL4-L6-VH4-L7-VH3-L8-Fc;VH3-L5-VH4-L6-VL4-L7-VL3-L8-Fc; VL3-VL4-VH4-VH3-CH1;VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL;VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1;VH3-VH4-VL4-VL3-CL-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1;VL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc;VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fc;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9- CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL, and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3;VL3-L4-VL4-L5-VH4-L6-VH3; VH3-L4-VH4-L5-VL4-L6-VL3; VL3-VL4-VH4-VH3-Fc;VH3-VH4-VL4-VL3-Fc; VL3-L5-VL4-L6-VH4-L7-VH3-Fc;VH3-L5-VH4-L6-VL4-L7-VL3-Fc; VL3-L5-VL4-L6-VH4-L7-VH3-L8-Fc;VH3-L5-VH4-L6-VL4-L7-VL3-L8-Fc; VL3-VL4-VH4-VH3-CH1;VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL;VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1;VH3-VH4-VL4-VL3-CL-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7- VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1;VL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc;VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fc;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL, and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3;VL3-L4-VL4-L5-VH4-L6-VH3; VH3-L4-VH4-L5-VL4-L6-VL3; VL3-VL4-VH4-VH3-Fc;VH3-VH4-VL4-VL3-Fc; VL3-L5-VL4-L6-VH4-L7-VH3-Fc;VH3-L5-VH4-L6-VL4-L7-VL3-Fc; VL3-L5-VL4-L6-VH4-L7-VH3-L8-Fc;VH3-L5-VH4-L6-VL4-L7-VL3-L8-Fc; VL3-VL4-VH4-VH3-CH1;VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL;VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1;VH3-VH4-VL4-VL3-CL-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4- L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1; VL3-VL4-VH4-VH3-CH1-Fc;VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc;VL3-VL4-VH4-VH3-CH1-CL-Fc; VH3-VH4-VL4-VL3-CH1-CL-Fc;VL3-VL4-VH4-VH3-CL-CH1-Fc; VH3-VH4-VL4-VL3-CL-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1, and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3;VL3-L4-VL4-L5-VH4-L6-VH3; VH3-L4-VH4-L5-VL4-L6-VL3; VL3-VL4-VH4-VH3-Fc;VH3-VH4-VL4-VL3-Fc; VL3-L5-VL4-L6-VH4-L7-VH3-Fc;VH3-L5-VH4-L6-VL4-L7-VL3-Fc; VL3-L5-VL4-L6-VH4-L7-VH3-L8-Fc;VH3-L5-VH4-L6-VL4-L7-VL3-L8-Fc; VL3-VL4-VH4-VH3-CH1;VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL;VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1;VH3-VH4-VL4-VL3-CL-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3- L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1; VL3-VL4-VH4-VH3-CH1-Fc;VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc;VL3-VL4-VH4-VH3-CH1-CL-Fc; VH3-VH4-VL4-VL3-CH1-CL-Fc;VL3-VL4-VH4-VH3-CL-CH1-Fc; VH3-VH4-VL4-VL3-CL-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1, and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3;VL3-L4-VL4-L5-VH4-L6-VH3; VH3-L4-VH4-L5-VL4-L6-VL3; VL3-VL4-VH4-VH3-Fc;VH3-VH4-VL4-VL3-Fc; VL3-L5-VL4-L6-VH4-L7-VH3-Fc;VH3-L5-VH4-L6-VL4-L7-VL3-Fc; VL3-L5-VL4-L6-VH4-L7-VH3-L8-Fc;VH3-L5-VH4-L6-VL4-L7-VL3-L8-Fc; VL3-VL4-VH4-VH3-CH1;VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL;VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1;VH3-VH4-VL4-VL3-CL-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3- L6-VL4-L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1- L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1; VL3-VL4-VH4-VH3-CH1-Fc;VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc;VL3-VL4-VH4-VH3-CH1-CL-Fc; VH3-VH4-VL4-VL3-CH1-CL-Fc;VL3-VL4-VH4-VH3-CL-CH1-Fc; VH3-VH4-VL4-VL3-CL-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fe; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-CH1-Fc, andthe second polypeptide has a structure represented by VL3-VL4-VH4-VH3;VH3-VH4-VL4-VL3; VL3-L4-VL4-L5-VH4-L6-VH3; VH3-L4-VH4-L5-VL4-L6-VL3;VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc; VL3-L5-VL4-L6-VH4-L7-VH3-Fc;VH3-L5-VH4-L6-VL4-L7-VL3-Fc; VL3-L5-VL4-L6-VH4-L7-VH3-L8-Fc;VH3-L5-VH4-L6-VL4-L7-VL3-L8-Fc; VL3-VL4-VH4-VH3-CH1;VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL;VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1;VH3-VH4-VL4-VL3-CL-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1; VL3-VL4-VH4-VH3-CH1-Fc;VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc;VL3-VL4-VH4-VH3-CH1-CL-Fc; VH3-VH4-VL4-VL3-CH1-CL-Fc;VL3-VL4-VH4-VH3-CL-CH1-Fc; VH3-VH4-VL4-VL3-CL-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-F c. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1-CH1-Fc, andthe second polypeptide has a structure represented by VL3-VL4-VH4-VH3;VH3-VH4-VL4-VL3; VL3-L4-VL4-L5-VH4-L6-VH3; VH3-L4-VH4-L5-VL4-L6-VL3;VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc; VL3-L5-VL4-L6-VH4-L7-VH3-Fc;VH3-L5-VH4-L6-VL4-L7-VL3-Fc; VL3-L5-VL4-L6-VH4-L7-VH3-L8-Fc;VH3-L5-VH4-L6-VL4-L7-VL3-L8-Fc; VL3-VL4-VH4-VH3-CH1;VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL;VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1;VH3-VH4-VL4-VL3-CL-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1- L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1; VL3-VL4-VH4-VH3-CH1-Fc;VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc;VL3-VL4-VH4-VH3-CH1-CL-Fc; VH3-VH4-VL4-VL3-CH1-CL-Fc;VL3-VL4-VH4-VH3-CL-CH1-Fc; VH3-VH4-VL4-VL3-CL-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-CL-Fc, andthe second polypeptide has a structure represented by VL3-VL4-VH4-VH3;VH3-VH4-VL4-VL3; VL3-L4-VL4-L5-VH4-L6-VH3; VH3-L4-VH4-L5-VL4-L6-VL3;VL3-VL4-VH4-VH3- Fc; VH3-VH4-VL4-VL3-Fc; VL3-L5-VL4-L6-VH4-L7-VH3-Fc;VH3-L5-VH4-L6-VL4-L7-VL3-Fc; VL3-L5-VL4-L6-VH4-L7-VH3-L8-Fc;VH3-L5-VH4-L6-VL4-L7-VL3-L8-Fc; VL3-VL4-VH4-VH3-CH1;VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL;VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1;VH3-VH4-VL4-VL3-CL-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1;VL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc;VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fc;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9- CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1-CL-Fc, andthe second polypeptide has a structure represented by VL3-VL4-VH4-VH3;VH3-VH4-VL4-VL3; VL3-L4-VL4-L5-VH4-L6-VH3; VH3-L4-VH4-L5-VL4-L6-VL3;VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc; VL3-L5-VL4-L6-VH4-L7-VH3-Fc;VH3-L5-VH4-L6-VL4-L7-VL3-Fc; VL3-L5-VL4-L6-VH4-L7-VH3-L8-Fc;VH3-L5-VH4-L6-VL4-L7-VL3-L8-Fc; VL3-VL4-VH4-VH3-CH1;VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL;VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1;VH3-VH4-VL4-VL3-CL-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3- L6-VL4-L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1- L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1; VL3-VL4-VH4-VH3-CH1-Fc;VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc;VL3-VL4-VH4-VH3-CH1-CL-Fc; VH3-VH4-VL4-VL3-CH1-CL-Fc;VL3-VL4-VH4-VH3-CL-CH1-Fc; VH3-VH4-VL4-VL3-CL-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-CH1-CL-Fc,and the second polypeptide has a structure represented byVL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3; VL3-L4-VL4-L5-VH4-L6-VH3;VH3-L4-VH4-L5-VL4-L6-VL3; VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc;VL3-L5-VL4-L6-VH4-L7-VH3-Fc; VH3-L5-VH4-L6-VL4-L7-VL3-Fc;VL3-L5-VL4-L6-VH4-L7-VH3-L8-Fc; VH3-L5-VH4-L6-VL4-L7-VL3-L8-Fc;VL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL;VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL;VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1; VL3-VL4-VH4-VH3-CH1-Fc;VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc;VL3-VL4-VH4-VH3-CH1-CL-Fc; VH3-VH4-VL4-VL3-CH1-CL-Fc;VL3-VL4-VH4-VH3-CL-CH1-Fc; VH3-VH4-VL4-VL3-CL-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-F c. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1-CH1-CL-Fc,and the second polypeptide has a structure represented byVL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3; VL3-L4-VL4-L5-VH4-L6-VH3;VH3-L4-VH4-L5-VL4-L6-VL3; VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc;VL3-L5-VL4-L6-VH4-L7-VH3-Fc; VH3-L5-VH4-L6-VL4-L7-VL3-Fc;VL3-L5-VL4-L6-VH4-L7-VH3-L8-Fc; VH3-L5-VH4-L6-VL4-L7-VL3-L8-Fc;VL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL;VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL;VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL; VH3-L6- VH4-L7-VL4-L8-VL3-L9-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1; VL3-VL4-VH4-VH3-CH1-Fc;VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc;VL3-VL4-VH4-VH3-CH1-CL-Fc; VH3-VH4-VL4-VL3-CH1-CL-Fc;VL3-VL4-VH4-VH3-CL-CH1-Fc; VH3-VH4-VL4-VL3-CL-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-CL-CH1-Fc,and the second polypeptide has a structure represented byVL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3; VL3-L4-VL4-L5-VH4-L6-VH3;VH3-L4-VH4-L5-VL4-L6-VL3; VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc;VL3-L5-VL4-L6-VH4-L7-VH3-Fc; VH3-L5-VH4-L6-VL4-L7-VL3-Fc;VL3-L5-VL4-L6-VH4-L7-VH3-L8-Fe; VH3-L5-VH4-L6-VL4-L7-VL3-L8-Fc;VL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL;VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL;VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1; VL3-VL4-VH4-VH3-CH1-Fc;VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc;VL3-VL4-VH4-VH3-CH1-CL-Fc; VH3-VH4-VL4-VL3-CH1-CL-Fc;VL3-VL4-VH4-VH3-CL-CH1-Fc; VH3-VH4-VL4-VL3-CL-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1-CL-CH1-Fc,and the second polypeptide has a structure represented byVL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3; VL3-L4-VL4-L5-VH4-L6-VH3;VH3-L4-VH4-L5-VL4-L6-VL3; VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fe;VL3-L5-VL4-L6-VH4-L7-VH3-Fc; VH3-L5-VH4-L6-VL4-L7-VL3-Fc;VL3-L5-VL4-L6-VH4-L7-VH3-L8-Fc; VH3-L5-VH4-L6-VL4-L7-VL3-L8-Fc;VL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL;VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL;VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL;VL3-L6-VL4- L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1; VL3-VL4-VH4-VH3-CH1-Fc;VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc;VL3-VL4-VH4-VH3-CH1-CL-Fc; VH3-VH4-VL4-VL3-CH1-CL-Fc;VL3-VL4-VH4-VH3-CL-CH1-Fc; VH3-VH4-VL4-VL3-CL-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc, and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3;VL3-L4-VL4-L5-VH4-L6-VH3; VH3-L4-VH4-L5-VL4-L6-VL3; VL3-VL4-VH4-VH3-Fc;VH3-VH4-VL4-VL3-Fc; VL3-L5-VL4-L6-VH4-L7-VH3-Fc;VH3-L5-VH4-L6-VL4-L7-VL3-Fc; VL3-L5-VL4-L6-VH4-L7-VH3-L8-Fc;VH3-L5-VH4-L6-VL4-L7-VL3-L8-Fc; VL3-VL4-VH4-VH3-CH1;VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL;VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1;VH3-VH4-VL4-VL3-CL-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7- VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1;VL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc;VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fc;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc, and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3;VL3-L4-VL4-L5-VH4-L6-VH3; VH3-L4-VH4-L5-VL4-L6-VL3; VL3-VL4-VH4-VH3-Fc;VH3-VH4-VL4-VL3-Fc; VL3-L5-VL4-L6-VH4-L7-VH3-Fc;VH3-L5-VH4-L6-VL4-L7-VL3-Fc; VL3-L5-VL4-L6-VH4-L7-VH3-L8-Fc;VH3-L5-VH4-L6-VL4-L7-VL3-L8-Fc; VL3-VL4-VH4-VH3-CH1;VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL;VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1;VH3-VH4-VL4-VL3-CL-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8- VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1; VL3-VL4-VH4-VH3-CH1-Fc;VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc;VL3-VL4-VH4-VH3-CH1-CL-Fc; VH3-VH4-VL4-VL3-CH1-CL-Fc;VL3-VL4-VH4-VH3-CL-CH1-Fc; VH3-VH4-VL4-VL3-CL-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc, and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3;VL3-L4-VL4-L5-VH4-L6-VH3; VH3-L4-VH4-L5-VL4-L6-VL3; VL3-VL4-VH4-VH3-Fc;VH3-VH4-VL4-VL3-Fc; VL3-L5-VL4-L6-VH4-L7-VH3-Fc;VH3-L5-VH4-L6-VL4-L7-VL3-Fc; VL3-L5-VL4-L6-VH4-L7-VH3-L8-Fc;VH3-L5-VH4-L6-VL4-L7-VL3-L8-Fc; VL3-VL4-VH4-VH3-CH1;VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL;VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1;VH3-VH4-VL4-VL3-CL-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6- VL4-L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10- CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1; VL3-VL4-VH4-VH3-CH1-Fc;VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc;VL3-VL4-VH4-VH3-CH1-CL-Fc; VH3-VH4-VL4-VL3-CH1-CL-Fc;VL3-VL4-VH4-VH3-CL-CH1-Fc; VH3-VH4-VL4-VL3-CL-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc, and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3;VL3-L4-VL4-L5-VH4-L6-VH3; VH3-L4-VH4-L5-VL4-L6-VL3; VL3-VL4-VH4-VH3-Fc;VH3-VH4-VL4-VL3-Fc; VL3-L5-VL4-L6-VH4-L7-VH3-Fc;VH3-L5-VH4-L6-VL4-L7-VL3-Fc; VL3-L5-VL4-L6-VH4-L7-VH3-L8-Fc;VH3-L5-VH4-L6-VL4-L7-VL3-L8-Fc; VL3-VL4-VH4-VH3-CH1;VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL;VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1;VH3-VH4-VL4-VL3-CL-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1; VL3-VL4-VH4-VH3-CH1-Fc;VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc;VL3-VL4-VH4-VH3-CH1-CL-Fc; VH3-VH4-VL4-VL3-CH1-CL-Fc;VL3-VL4-VH4-VH3-CL-CH1-Fc; VH3-VH4-VL4-VL3-CL-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-F c. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc, and the second polypeptide hasa structure represented by VL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3;VL3-L4-VL4-L5-VH4-L6-VH3; VH3-L4-VH4-L5-VL4-L6-VL3; VL3-VL4-VH4-VH3-Fc;VH3-VH4-VL4-VL3-Fc; VL3-L5-VL4-L6-VH4-L7-VH3-Fc;VH3-L5-VH4-L6-VL4-L7-VL3-Fc; VL3-L5-VL4-L6-VH4-L7-VH3-L8-Fc;VH3-L5-VH4-L6-VL4-L7-VL3-L8-Fc; VL3-VL4-VH4-VH3-CH1;VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL;VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1;VH3-VH4-VL4-VL3-CL-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1; VL3-VL4-VH4-VH3-CH1-Fc;VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc;VL3-VL4-VH4-VH3-CH1-CL-Fc; VH3-VH4-VL4-VL3-CH1-CL-Fc;VL3-VL4-VH4-VH3-CL-CH1-Fc; VH3-VH4-VL4-VL3-CL-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-F c. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc, and the second polypeptide hasa structure represented by VL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3;VL3-L4-VL4-L5-VH4-L6-VH3; VH3-L4-VH4-L5-VL4-L6-VL3; VL3-VL4-VH4-VH3-Fc;VH3-VH4-VL4-VL3-Fc; VL3-L5-VL4-L6-VH4-L7-VH3-Fc;VH3-L5-VH4-L6-VL4-L7-VL3-Fc; VL3-L5-VL4-L6-VH4-L7-VH3-L8-Fc;VH3-L5-VH4-L6-VL4-L7-VL3-L8-Fc; VL3-VL4-VH4-VH3-CH1;VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL;VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1;VH3-VH4-VL4-VL3-CL-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1; VL3-VL4-VH4-VH3-CH1-Fc;VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc;VL3-VL4-VH4-VH3-CH1-CL-Fc; VH3-VH4-VL4-VL3-CH1-CL-Fc;VL3-VL4-VH4-VH3-CL-CH1-Fc; VH3-VH4-VL4-VL3-CL-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-F c. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc, and the second polypeptide hasa structure represented by VL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3;VL3-L4-VL4-L5-VH4-L6-VH3; VH3-L4-VH4-L5-VL4-L6-VL3; VL3-VL4-VH4-VH3-Fc;VH3-VH4-VL4-VL3-Fc; VL3-L5-VL4-L6-VH4-L7-VH3-Fc;VH3-L5-VH4-L6-VL4-L7-VL3-Fc; VL3-L5-VL4-L6-VH4-L7-VH3-L8-Fc;VH3-L5-VH4-L6-VL4-L7-VL3-L8-Fc; VL3-VL4-VH4-VH3-CH1;VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL;VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1;VH3-VH4-VL4-VL3-CL-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1; VL3-VL4-VH4-VH3-CH1-Fc;VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc;VL3-VL4-VH4-VH3-CH1-CL-Fc; VH3-VH4-VL4-VL3-CH1-CL-Fc;VL3-VL4-VH4-VH3-CL-CH1-Fc; VH3-VH4-VL4-VL3-CL-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-F c. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc, and the second polypeptide hasa structure represented by VL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3;VL3-L4-VL4-L5-VH4-L6-VH3; VH3-L4-VH4-L5-VL4-L6-VL3; VL3-VL4-VH4-VH3-Fc;VH3-VH4-VL4-VL3-Fc; VL3-L5-VL4-L6-VH4-L7-VH3-Fc;VH3-L5-VH4-L6-VL4-L7-VL3-Fc; VL3-L5-VL4-L6-VH4-L7-VH3-L8-Fc;VH3-L5-VH4-L6-VL4-L7-VL3-L8-Fc; VL3-VL4-VH4-VH3-CH1;VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL;VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1;VH3-VH4-VL4-VL3-CL-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1; VL3-VL4-VH4-VH3-CH1-Fc;VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc;VL3-VL4-VH4-VH3-CH1-CL-Fc; VH3-VH4-VL4-VL3-CH1-CL-Fc;VL3-VL4-VH4-VH3-CL-CH1-Fc; VH3-VH4-VL4-VL3-CL-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc. In some aspects, the VL1,VL2, VL3, and/or VL4, specifically binds to human CD3, CD19, CD28, CD38or Her2. In some aspects, the VH1, VH2, VH3 and/or VH4 specificallybinds to A2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC,B7H1, B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2,CCL3, CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19, CCL20, CCL21,CCL25 CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27, CD28, CD30, CD38,CD39, CD40, CD40L, CD47, CD52, CD70, CD80, CD86, CD123, CD133, CD137,CD137L, CD160, CD272, CEACAM5, CLEC9, CLEC91, CRTH2, CSF-1, CSF-2,CSF-3, CXCL1, CXCL2, CXCL4, CXCL12, CXCL13, CXCR3, cMet, CTLA4, DLL3,DLL4, DNGR-1, E-cadherin, EGFR, ENTPD1, EpCAM, FCER1, FCER1A, FCER2,FGFR, FLAP, FOLH1, Gi24, GITR, GITRL, GPR5, GP100, GPRC5D, HER2, HER3,ICOSL, ICOS, HHLA2, HMGB1, HVEM, IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1,ILIA, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8,IL9, IL9R, IL10, rhIL1O, IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17,IL17Rb, IL18, IL22, IL23, IL25, IL7, IL33, IL35, ITGB4, ITK, KIR, LAG3,LAMP1, leptin, LPFS2, MHC class II, MUC-1, MUC-16, NCR3LG1, NKG2D,NKp46, NTPDase-1, OX40, OX40L, PD-1, PD-L1, PD-L2, PROM1, S152,SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1, STEAP2, Syk kinase, STEAP1,TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3, TLR, TLR2, TLR4, TLR5,TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP, TSLPR, TWEAK, VEGF,VISTA, Vstm3, or WUCAM. In some aspects, the VL1, VL2, VL3, VL4, VH1,VH2, VH3 and/or VH4 specifically binds to A2AR, APRIL, ATPDase, BAFF,BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1, B7H2, B7H3, B7H4, B7H5, B7H6,B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL11,CCL15, CCL17, CCL19, CCL20, CCL21, CCL25 CCR3, CCR4, CD3, CD16A, CD19,CD20, CD24, CD27, CD28, CD30, CD38, CD39, CD40, CD40L, CD47, CD52, CD70,CD80, CD86, CD123, CD133, CD137, CD137L, CD160, CD272, CEACAM5, CLEC9,CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12, CXCL13,CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin, EGFR, ENTPD1, EpCAM,FCER1, FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24, GITR, GITRL, GPR5, GP100,GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1, HVEM, IDO, IFNa, IgE,IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R,IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O, IL12, IL13, IL13Ra1,IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23, IL25, IL7, IL33, IL35,ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II, MUC-1,MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L, PD-1, PD-L1,PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1, STEAP2,Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3, TLR,TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP, TSLPR,TWEAK, VEGF, VISTA, Vstm3, or WUCAM. Any and all disclosure herein inrelation to targets for antigen binding polypeptides of the invention isgenerally applicable, and applies equally and without reservation toeach and every antigen binding polypeptide and antigen bindingpolypeptide complex described herein. For the avoidance of doubt, theVL1, VL2, VL3, VL4, VH1, VH2, VH3 and/or VH4 of each and every antigenbinding polypeptide and antigen binding polypeptide complex describedherein may independently bind to any one of said particularly preferredtargets.

In some aspects, VH1 and VL1 specifically bind to human CD3; VH2 and VL2specifically bind to human CD28; VH3 and VL3 specifically bind to humanCD19; and VH4 and VL4 specifically bind to human CD38.

In some aspects, VH1 and VL1 specifically bind to human CD3; VH2 and VL2specifically bind to human CD28; VH3 and VL3 specifically bind to humanCD38; and VH4 and VL4 specifically bind to human CD19.

In some aspects, VH1 and VL1 specifically bind to human CD28; VH2 andVL2 specifically bind to human CD3; VH3 and VL3 specifically bind tohuman CD19; and VH4 and VL4 specifically bind to human CD38.

In some aspects, VH1 and VL1 specifically bind to human CD28; VH2 andVL2 specifically bind to human CD3; VH3 and VL3 specifically bind tohuman CD38; and VH4 and VL4 specifically bind to human CD19.

In some aspects, VH1 and VL1 specifically bind to human CD28; VH2 andVL2 specifically bind to human CD3; VH3 and VL3 specifically bind tohuman Trop2; and VH4 and VL4 specifically bind to human cMet.

In some aspects, VH1 and VL1 specifically bind to human CD28; VH2 andVL2 specifically bind to human CD3; VH3 and VL3 specifically bind tohuman cMet; and VH4 and VL4 specifically bind to human Trop2.

In some aspects, VH1 and VL1 specifically bind to human CD3; VH2 and VL2specifically bind to human CD28; VH3 and VL3 specifically bind to humanTrop2; and VH4 and VL4 specifically bind to human cMet.

In some aspects, VH1 and VL1 specifically bind to human CD3; VH2 and VL2specifically bind to human CD28; VH3 and VL3 specifically bind to humancMet; and VH4 and VL4 specifically bind to human Trop2.

In some aspects, VH1 and VL1 specifically bind to human CD28; VH2 andVL2 specifically bind to human CD3; VH3 and VL3 specifically bind tohuman CD19; and VH4 and VL4 specifically bind to human CD20.

In some aspects, VH1 and VL1 specifically bind to human CD28; VH2 andVL2 specifically bind to human CD3; VH3 and VL3 specifically bind tohuman CD20; and VH4 and VL4 specifically bind to human CD19.

In some aspects, VH1 and VL1 specifically bind to human CD3; VH2 and VL2specifically bind to human CD28; VH3 and VL3 specifically bind to humanCD19; and VH4 and VL4 specifically bind to human CD20.

In some aspects, VH1 and VL1 specifically bind to human CD3; VH2 and VL2specifically bind to human CD28; VH3 and VL3 specifically bind to humanCD20; and VH4 and VL4 specifically bind to human CD19.

In other aspects, VH1 VH2, VH3 and VH4 each comprise an amino acidsequence having at least 90% identity, at least 95% identity, or 100%identity to any one of SEQ ID NOs:20-25 and 122; and VL1, VL2, VL3 andVL4 each comprise an amino acid sequence having at least 90% identity,at least 95% identity, or 100% identity to any one of SEQ ID NOs:26-31and 123. For example, VH1 VH2, VH3 and VH4 may each comprise an aminoacid sequence having at least 90% (such as at least 91%, 92%, 93%, 94%,95%, 96%, 97%, 98%, or 99%) identity to any one of SEQ ID NOs:20-25 and122; and VL1, VL2, VL3 and VL4 may each comprise an amino acid sequencehaving at least 90% (such as at least 91%, 92%, 93%, 94%, 95%, 96%, 97%,98%, or 99%) identity to any one of SEQ ID NOs:26-31 and 123. Forexample, VH1 VH2, VH3 and VH4 may each comprise the amino acid sequenceof any one of SEQ ID NOs:20-25 and 122; and VL1, VL2, VL3 and VL4 mayeach comprise the amino acid sequence of any one of SEQ ID NOs:26-31 and123. In other aspects, VH1 VH2, VH3 and VH4 each comprise an amino acidsequence having at least 90% (such as at least 91%, 92%, 93%, 94%, 95%,96%, 97%, 98%, or 99%) identity to any one of SEQ ID NOs:20-25; and VL1,VL2, VL3 and VL4 each comprise an amino acid sequence having at least90% (such as at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%)identity to any one of SEQ ID NOs:26-31. For example, VH1 VH2, VH3 andVH4 may each comprise the amino acid sequence of any one of SEQ IDNOs:20-25; and VL1, VL2, VL3 and VL4 may each comprise the amino acidsequence of any one of SEQ ID NOs:26-31.

In other aspects, VH1 comprises an amino acid sequence having at least90% identity, at least 95% identity, or 100% identity SEQ ID NO:20; VH2comprises an amino acid sequence having at least 90% identity, at least95% identity, or 100% identity to SEQ ID NO:21; VH3 comprises an aminoacid sequence having at least 90% identity, at least 95% identity, or100% identity to SEQ ID NO:22; and VH4 comprises an amino acid sequencehaving at least 90% identity, at least 95% identity, or 100% identity toSEQ ID NO:23. For example, VH1 may comprise an amino acid sequencehaving at least 90% identity to SEQ ID NO:20; VH2 may comprise an aminoacid sequence having at least 90% identity to SEQ ID NO:21; VH3 maycomprise an amino acid sequence having at least 90% identity to SEQ IDNO:22; and VH4 may comprise an amino acid sequence having at least 90%identity to SEQ ID NO:23. At least 90% identity may include at least91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to thereference polypeptide sequence. For example, VH1 may comprise the aminoacid sequence of SEQ ID NO:20; VH2 may comprise the amino acid sequenceof SEQ ID NO:21; VH3 may comprise the amino acid sequence of SEQ IDNO:22; and VH4 may comprise the amino acid sequence of SEQ ID NO:23.

In other aspects, VH1 comprises an amino acid sequence having at least90% identity, at least 95% identity, or 100% identity SEQ ID NO:20; VH2comprises an amino acid sequence having at least 90% identity, at least95% identity, or 100% identity to SEQ ID NO:21; VH3 comprises an aminoacid sequence having at least 90% identity, at least 95% identity, or100% identity to SEQ ID NO:23; and VH4 comprises an amino acid sequencehaving at least 90% identity, at least 95% identity, or 100% identity toSEQ ID NO:22. For example, VH1 may comprise an amino acid sequencehaving at least 90% identity to SEQ ID NO:20; VH2 may comprise an aminoacid sequence having at least 90% identity to SEQ ID NO:21; VH3 maycomprise an amino acid sequence having at least 90% identity to SEQ IDNO:23; and VH4 may comprise an amino acid sequence having at least 90%identity to SEQ ID NO:22. At least 90% identity may include at least91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to thereference polypeptide sequence. For example, VH1 may comprise the aminoacid sequence of SEQ ID NO:20; VH2 may comprise the amino acid sequenceof SEQ ID NO:21; VH3 may comprise the amino acid sequence of SEQ IDNO:23; and VH4 may comprise the amino acid sequence of SEQ ID NO:22.

In other aspects, VH1 comprises an amino acid sequence having at least90% identity, at least 95% identity, or 100% identity SEQ ID NO:21; VH2comprises an amino acid sequence having at least 90% identity, at least95% identity, or 100% identity to SEQ ID NO:20; VH3 comprises an aminoacid sequence having at least 90% identity, at least 95% identity, or100% identity to SEQ ID NO:22; and VH4 comprises an amino acid sequencehaving at least 90% identity, at least 95% identity, or 100% identity toSEQ ID NO:23. For example, VH1 may comprise an amino acid sequencehaving at least 90% identity to SEQ ID NO:21; VH2 may comprise an aminoacid sequence having at least 90% identity to SEQ ID NO:20; VH3 maycomprise an amino acid sequence having at least 90% identity to SEQ IDNO:22; and VH4 may comprise an amino acid sequence having at least 90%identity to SEQ ID NO:23. At least 90% identity may include at least91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to thereference polypeptide sequence. For example, VH1 may comprise the aminoacid sequence of SEQ ID NO:21; VH2 may comprise the amino acid sequenceof SEQ ID NO:20; VH3 may comprise the amino acid sequence of SEQ IDNO:22; and VH4 may comprise the amino acid sequence of SEQ ID NO:23.

In other aspects, VH1 comprises an amino acid sequence having at least90% identity, at least 95% identity, or 100% identity SEQ ID NO:21; VH2comprises an amino acid sequence having at least 90% identity, at least95% identity, or 100% identity to SEQ ID NO:20; VH3 comprises an aminoacid sequence having at least 90% identity, at least 95% identity, or100% identity to SEQ ID NO:23; and VH4 comprises an amino acid sequencehaving at least 90% identity, at least 95% identity, or 100% identity toSEQ ID NO:22. For example, VH1 may comprise an amino acid sequencehaving at least 90% identity to SEQ ID NO:21; VH2 may comprise an aminoacid sequence having at least 90% identity to SEQ ID NO:20; VH3 maycomprise an amino acid sequence having at least 90% identity to SEQ IDNO:23; and VH4 may comprise an amino acid sequence having at least 90%identity to SEQ ID NO:22. At least 90% identity may include at least91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to thereference polypeptide sequence. For example, VH1 may comprise the aminoacid sequence of SEQ ID NO:21; VH2 may comprise the amino acid sequenceof SEQ ID NO:20; VH3 may comprise the amino acid sequence of SEQ IDNO:23; and VH4 may comprise the amino acid sequence of SEQ ID NO:22.

In other aspects, VL1 comprises an amino acid sequence having at least90% identity, at least 95% identity, or 100% identity SEQ ID NO:26; VL2comprises an amino acid sequence having at least 90% identity, at least95% identity, or 100% identity to SEQ ID NO:27; VL3 comprises an aminoacid sequence having at least 90% identity, at least 95% identity, or100% identity to SEQ ID NO:28; and VL4 comprises an amino acid sequencehaving at least 90% identity, at least 95% identity, or 100% identity toSEQ ID NO:29. For example, VL1 may comprise an amino acid sequencehaving at least 90% identity to SEQ ID NO:26; VL2 may comprise an aminoacid sequence having at least 90% identity to SEQ ID NO:27; VL3 maycomprise an amino acid sequence having at least 90% identity to SEQ IDNO:28; and VL4 may comprise an amino acid sequence having at least 90%identity to SEQ ID NO:29. At least 90% identity may include at least91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to thereference polypeptide sequence. For example, VL1 may comprise the aminoacid sequence of SEQ ID NO:26; VL2 may comprise the amino acid sequenceof SEQ ID NO:27; VL3 may comprise the amino acid sequence of SEQ IDNO:28; and VL4 may comprise the amino acid sequence of SEQ ID NO:29.

In other aspects, VL1 comprises an amino acid sequence having at least90% identity, at least 95% identity, or 100% identity SEQ ID NO:26; VL2comprises an amino acid sequence having at least 90% identity, at least95% identity, or 100% identity to SEQ ID NO:27; VL3 comprises an aminoacid sequence having at least 90% identity, at least 95% identity, or100% identity to SEQ ID NO:29; and VL4 comprises an amino acid sequencehaving at least 90% identity, at least 95% identity, or 100% identity toSEQ ID NO:28. For example, VL1 may comprise an amino acid sequencehaving at least 90% identity to SEQ ID NO:26; VL2 may comprise an aminoacid sequence having at least 90% identity to SEQ ID NO:27; VL3 maycomprise an amino acid sequence having at least 90% identity to SEQ IDNO:29; and VL4 may comprise an amino acid sequence having at least 90%identity to SEQ ID NO:28. At least 90% identity may include at least91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to thereference polypeptide sequence. For example, VL1 may comprise the aminoacid sequence of SEQ ID NO:26; VL2 may comprise the amino acid sequenceof SEQ ID NO:27; VL3 may comprise the amino acid sequence of SEQ IDNO:29; and VL4 may comprise the amino acid sequence of SEQ ID NO:28.

In other aspects, VL1 comprises an amino acid sequence having at least90% identity, at least 95% identity, or 100% identity SEQ ID NO:27; VL2comprises an amino acid sequence having at least 90% identity, at least95% identity, or 100% identity to SEQ ID NO:26; VL3 comprises an aminoacid sequence having at least 90% identity, at least 95% identity, or100% identity to SEQ ID NO:28; and VL4 comprises an amino acid sequencehaving at least 90% identity, at least 95% identity, or 100% identity toSEQ ID NO:29. For example, VL1 may comprise an amino acid sequencehaving at least 90% identity to SEQ ID NO:27; VL2 may comprise an aminoacid sequence having at least 90% identity to SEQ ID NO:26; VL3 maycomprise an amino acid sequence having at least 90% identity to SEQ IDNO:28; and VL4 may comprise an amino acid sequence having at least 90%identity to SEQ ID NO:29. At least 90% identity may include at least91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to thereference polypeptide sequence. For example, VL1 may comprise the aminoacid sequence of SEQ ID NO:27; VL2 may comprise the amino acid sequenceof SEQ ID NO:26; VL3 may comprise the amino acid sequence of SEQ IDNO:28; and VL4 may comprise the amino acid sequence of SEQ ID NO:29.

In other aspects, VL1 comprises an amino acid sequence having at least90% identity, at least 95% identity, or 100% identity SEQ ID NO:27; VL2comprises an amino acid sequence having at least 90% identity, at least95% identity or 100% identity to SEQ ID NO:26; VL3 comprises an aminoacid sequence having at least 90% identity, at least 95% identity or100% identity to SEQ ID NO:29; and VL4 comprises an amino acid sequencehaving at least 90% identity, at least 95% identity or 100% identity toSEQ ID NO:28. For example, VL1 may comprise an amino acid sequencehaving at least 90% identity to SEQ ID NO:27; VL2 may comprise an aminoacid sequence having at least 90% identity to SEQ ID NO:26; VL3 maycomprise an amino acid sequence having at least 90% identity to SEQ IDNO:29; and VL4 may comprise an amino acid sequence having at least 90%identity to SEQ ID NO:28. At least 90% identity may include at least91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to thereference polypeptide sequence. For example, VL1 may comprise the aminoacid sequence of SEQ ID NO:27; VL2 may comprise the amino acid sequenceof SEQ ID NO:26; VL3 may comprise the amino acid sequence of SEQ IDNO:29; and VL4 may comprise the amino acid sequence of SEQ ID NO:28.

In some aspects, the invention is directed to an antigen bindingpolypeptide complex comprising a first polypeptide and a secondpolypeptide; wherein the first polypeptide has a structure representedby VL1-VL2-VH2-VH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc; orVL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc; wherein the second polypeptide has astructure represented by VL3-VL4-VH4-VH3-Fc;VL3-L1-VL4-L2-VH4-L3-VH3-Fc; or VL3-L1-VL4-L2-VH4-L3-VH3-L4-Fc; whereinVL1 is a first immunoglobulin light chain variable region; VL2 is asecond immunoglobulin light chain variable region; VL3 is a thirdimmunoglobulin light chain variable region; VL4 is a fourthimmunoglobulin light chain variable region; VH1 is a firstimmunoglobulin heavy chain variable region; VH2 is a secondimmunoglobulin heavy chain variable region; VH3 is a thirdimmunoglobulin heavy chain variable region; VH4 is a fourthimmunoglobulin heavy chain variable region; Fc is a region comprising animmunoglobulin heavy chain constant region 2 (CH2), an immunoglobulinheavy chain constant region 3 (CH3), and optionally, an immunoglobulinhinge; L1, L2, L3 and L4 are amino acid linkers; VH1 comprises an aminoacid sequence having at least 90% identity, at least 95% identity, or100% identity to any one of SEQ ID NOs:20-25; VH2 comprises an aminoacid sequence having at least 90% identity, at least 95% identity, or100% identity to any one of SEQ ID NOs:20-25; VH3 comprises an aminoacid sequence having at least 90% identity, at least 95% identity, or100% identity to any one of SEQ ID NOs:20-25; VH4 comprises an aminoacid sequence having at least 90% identity, at least 95% identity, or100% identity to any one of SEQ ID NOs:20-25; VL1 comprises an aminoacid sequence having at least 90% identity, at least 95% identity, or100% identity to any one of SEQ ID NOs:26-31; VL2 comprises an aminoacid sequence having at least 90% identity, at least 95% identity, or100% identity to any one of SEQ ID NOs:26-31; VL3 comprises an aminoacid sequence having at least 90% identity, at least 95% identity, or100% identity to any one of SEQ ID NOs:26-31; and VL4 comprises an aminoacid sequence having at least 90% identity, at least 95% identity, or100% identity to any one of SEQ ID NOs:26-31. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-Fc and thesecond polypeptide has a structure represented by VL3-VL4-VH4-VH3-Fc. Insome aspects, the first polypeptide has a structure represented byVL1-VL2-VH2-VH1-Fc and the second polypeptide has a structurerepresented by VL3-L1-VL4-L2-VH4-L3-VH3-Fc. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-Fc and thesecond polypeptide has a structure represented byVL3-L1-VL4-L2-VH4-L3-VH3-L4-Fc. In some aspects, the first polypeptidehas a structure represented by VL1-L1-VL2-L2-VH2-L3-VH1-Fc and thesecond polypeptide has a structure represented by VL3-VL4-VH4-VH3-Fc. Insome aspects, the first polypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-Fc and the second polypeptide has a structurerepresented by VL3-L1-VL4-L2-VH4-L3-VH3-Fc. In some aspects, the firstpolypeptide has a structure represented by VL1-L1-VL2-L2-VH2-L3-VH1-Fcand the second polypeptide has a structure represented byVL3-L1-VL4-L2-VH4-L3-VH3-L4-Fc. In some aspects, the first polypeptidehas a structure represented by VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc and thesecond polypeptide has a structure represented by VL3-VL4-VH4-VH3-Fc. Insome aspects, the first polypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc and the second polypeptide has astructure represented by VL3-L1-VL4-L2-VH4-L3-VH3-Fc. In some aspects,the first polypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc and the second polypeptide has astructure represented by VL3-L1-VL4-L2-VH4-L3-VH3-L4-Fc. In someaspects, VH1 comprises an amino acid sequence having at least 90%identity to any one of SEQ ID NOs:20-25; VH2 comprises an amino acidsequence having at least 90% identity to any one of SEQ ID NOs:20-25;VH3 comprises an amino acid sequence having at least 90% identity to anyone of SEQ ID NOs:20-25; VH4 comprises an amino acid sequence having atleast 90% identity to any one of SEQ ID NOs:20-25; VL1 comprises anamino acid sequence having at least 90% identity to any one of SEQ IDNOs:26-31; VL2 comprises an amino acid sequence having at least 90%identity to any one of SEQ ID NOs:26-31; VL3 comprises an amino acidsequence having at least 90% identity to any one of SEQ ID NOs:26-31;and VL4 comprises an amino acid sequence having at least 90% identity toany one of SEQ ID NOs:26-31. At least 90% identity may include at least91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to thereference polypeptide sequence. For example, VH1, VH2, VH3 and/or VH4may comprise the amino acid sequence of any one of SEQ ID NOs:20-25. Forexample, VL1, VL2, VL3 and/or VL4 may comprise the amino acid sequenceof any one of SEQ ID Nos: 26-31.

In some aspects, L1 comprises the amino acid sequence of g, ggssg (SEQID NO:1), or sggsgssggs (SEQ ID NO:8), L2 comprises the amino acidsequence of ggggsggsgsggggsasgsg (SEQ ID NO:12); L3 comprises the aminoacid sequence of g, ggssg (SEQ ID NO:1), or ggsggssgss (SEQ ID NO:7);and L4 comprises the amino acid sequence of asggsg (SEQ ID NO:6).

In other aspects, the invention is directed to an antigen bindingpolypeptide complex comprising a first polypeptide and a secondpolypeptide; wherein the first polypeptide has a structure representedby VL1-VL2-VH2-VH1-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-CL-Fc; or VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc;wherein the second polypeptide has a structure represented byVL3-VL4-VH4-VH3-CH1-Fc; VL3-L1-VL4-L2-VH4-L3-VH3-CH1-Fc;VL3-L1-VL4-L2-VH4-L3-VH3-L4-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc;VL3-L1-VL4-L2-VH4-L3-VH3-CL-Fc; or VL3-L1-VL4-L2-VH4-L3-VH3-L4-CL-Fc;wherein VL1 is a first immunoglobulin light chain variable region; VL2is a second immunoglobulin light chain variable region; VL3 is a thirdimmunoglobulin light chain variable region; VL4 is a fourthimmunoglobulin light chain variable region; VH1 is a firstimmunoglobulin heavy chain variable region; VH2 is a secondimmunoglobulin heavy chain variable region; VH3 is a thirdimmunoglobulin heavy chain variable region; VH4 is a fourthimmunoglobulin heavy chain variable region; Fc is a region comprising animmunoglobulin heavy chain constant region 2 (CH2), an immunoglobulinheavy chain constant region 3 (CH3), and optionally, an immunoglobulinhinge; CH1 is an immunoglobulin heavy chain constant region 1; CL is animmunoglobulin light chain constant region; L1, L2, L3 and L4 are aminoacid linkers; VH1 comprises an amino acid sequence having at least 90%identity, at least 95% identity, or 100% identity to any one of SEQ IDNOs:20-25; VH2 comprises an amino acid sequence having at least 90%identity, at least 95% identity, or 100% identity to any one of SEQ IDNOs:20-25; VH3 comprises an amino acid sequence having at least 90%identity, at least 95% identity, or 100% identity to any one of SEQ IDNOs:20-25; VH4 comprises an amino acid sequence having at least 90%identity, at least 95% identity, or 100% identity to any one of SEQ IDNOs:20-25; VL1 comprises an amino acid sequence having at least 90%identity, at least 95% identity, or 100% identity to any one of SEQ IDNOs:26-31; VL2 comprises an amino acid sequence having at least 90%identity, at least 95% identity, or 100% identity to any one of SEQ IDNOs:26-31; VL3 comprises an amino acid sequence having at least 90%identity, at least 95% identity, or 100% identity to any one of SEQ IDNOs:26-31; and VL4 comprises an amino acid sequence having at least 90%identity, at least 95% identity, or 100% identity to any one of SEQ IDNOs:26-31. In some aspects, the first polypeptide has a structurerepresented by VL1-VL2-VH2-VH1-CH1-Fc and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3-CH1-Fc. In some aspects, thefirst polypeptide has a structure represented by VL1-VL2-VH2-VH1-CH1-Fcand the second polypeptide has a structure represented byVL3-L1-VL4-L2-VH4-L3-VH3-CH1-Fc. In some aspects, the first polypeptidehas a structure represented by VL1-VL2-VH2-VH1-CH1-Fc and the secondpolypeptide has a structure represented byVL3-L1-VL4-L2-VH4-L3-VH3-L4-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-CH1-Fc andthe second polypeptide has a structure represented byVL3-VL4-VH4-VH3-CL-Fc. In some aspects, the first polypeptide has astructure represented by VL1-VL2-VH2-VH1-CH1-Fc and the secondpolypeptide has a structure represented byVL3-L1-VL4-L2-VH4-L3-VH3-CL-Fc. In some aspects, the first polypeptidehas a structure represented by VL1-VL2-VH2-VH1-CH1-Fc and the secondpolypeptide has a structure represented byVL3-L1-VL4-L2-VH4-L3-VH3-L4-CL-Fc. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-CH1-Fc and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3-CH1-Fc. In some aspects, thefirst polypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-CH1-Fc and the second polypeptide has astructure represented by VL3-L1-VL4-L2-VH4-L3-VH3-CH1-Fc. In someaspects, the first polypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-CH1-Fc and the second polypeptide has astructure represented by VL3-L1-VL4-L2-VH4-L3-VH3-L4-CH1-Fc. In someaspects, the first polypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-CH1-Fc and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3-CL-Fc. In some aspects, thefirst polypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-CH1-Fc and the second polypeptide has astructure represented by VL3-L1-VL4-L2-VH4-L3-VH3-CL-Fc. In someaspects, the first polypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-CH1-Fc and the second polypeptide has astructure represented by VL3-L1-VL4-L2-VH4-L3-VH3-L4-CL-Fc. In someaspects, the first polypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3-CH1-Fc. In some aspects, thefirst polypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc and the second polypeptide has astructure represented by VL3-L1-VL4-L2-VH4-L3-VH3-CH1-Fc. In someaspects, the first polypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc and the second polypeptide has astructure represented by VL3-L1-VL4-L2-VH4-L3-VH3-L4-CH1-Fc. In someaspects, the first polypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3-CL-Fc. In some aspects, thefirst polypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc and the second polypeptide has astructure represented by VL3-L1-VL4-L2-VH4-L3-VH3-CL-Fc. In someaspects, the first polypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc and the second polypeptide has astructure represented by VL3-L1-VL4-L2-VH4-L3-VH3-L4-CL-Fc. In someaspects, the first polypeptide has a structure represented byVL1-VL2-VH2-VH1-CL-Fc and the second polypeptide has a structurerepresented by VL3-VL4-VH4-VH3-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-CL-Fc and thesecond polypeptide has a structure represented byVL3-L1-VL4-L2-VH4-L3-VH3-CH1-Fc. In some aspects, the first polypeptidehas a structure represented by VL1-VL2-VH2-VH1-CL-Fc and the secondpolypeptide has a structure represented byVL3-L1-VL4-L2-VH4-L3-VH3-L4-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-CL-Fc and thesecond polypeptide has a structure represented by VL3-VL4-VH4-VH3-CL-Fc.In some aspects, the first polypeptide has a structure represented byVL1-VL2-VH2-VH1-CL-Fc and the second polypeptide has a structurerepresented by VL3-L1-VL4-L2-VH4-L3-VH3-CL-Fc. In some aspects, thefirst polypeptide has a structure represented by VL1-VL2-VH2-VH1-CL-Fcand the second polypeptide has a structure represented byVL3-L1-VL4-L2-VH4-L3-VH3-L4-CL-Fc. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-CL-Fc and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3-CH1-Fc. In some aspects, thefirst polypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-CL-Fc and the second polypeptide has astructure represented by VL3-L1-VL4-L2-VH4-L3-VH3-CH1-Fc. In someaspects, the first polypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-CL-Fc and the second polypeptide has astructure represented by VL3-L1-VL4-L2-VH4-L3-VH3-L4-CH1-Fc. In someaspects, the first polypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-CL-Fc and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3-CL-Fc. In some aspects, thefirst polypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-CL-Fc and the second polypeptide has astructure represented by VL3-L1-VL4-L2-VH4-L3-VH3-CL-Fc. In someaspects, the first polypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-CL-Fc and the second polypeptide has astructure represented by VL3-L1-VL4-L2-VH4-L3-VH3-L4-CL-Fc. In someaspects, the first polypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3-CH1-Fc. In some aspects, thefirst polypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc and the second polypeptide has astructure represented by VL3-L1-VL4-L2-VH4-L3-VH3-CH1-Fc. In someaspects, the first polypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc and the second polypeptide has astructure represented by VL3-L1-VL4-L2-VH4-L3-VH3-L4-CH1-Fc. In someaspects, the first polypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3-CL-Fc. In some aspects, thefirst polypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc and the second polypeptide has astructure represented by VL3-L1-VL4-L2-VH4-L3-VH3-CL-Fc. In someaspects, the first polypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc and the second polypeptide has astructure represented by VL3-L1-VL4-L2-VH4-L3-VH3-L4-CL-Fc. In someaspects, VH1 comprises an amino acid sequence having at least 90%identity to any one of SEQ ID NOs:20-25; VH2 comprises an amino acidsequence having at least 90% identity to any one of SEQ ID NOs:20-25;VH3 comprises an amino acid sequence having at least 90% identity to anyone of SEQ ID NOs:20-25; VH4 comprises an amino acid sequence having atleast 90% identity to any one of SEQ ID NOs:20-25; VL1 comprises anamino acid sequence having at least 90% identity to any one of SEQ IDNOs:26-31; VL2 comprises an amino acid sequence having at least 90%identity to any one of SEQ ID NOs:26-31; VL3 comprises an amino acidsequence having at least 90% identity to any one of SEQ ID NOs:26-31;and VL4 comprises an amino acid sequence having at least 90% identity toany one of SEQ ID NOs:26-31. At least 90% identity may include at least91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to thereference polypeptide sequence. For example, VH1, VH2, VH3 and/or VH4may comprise the amino acid sequence of any one of SEQ ID NOs:20-25. Forexample, VL1, VL2, VL3 and/or VL4 may comprise the amino acid sequenceof any one of SEQ ID Nos: 26-31.

In some aspects, L1 comprises the amino acid sequence of ggssg (SEQ IDNO:1), L2 comprises the amino acid sequence of ggggsggsgsggggsasgsg (SEQID NO:12); L3 comprises the amino acid sequence of ggssg (SEQ ID NO:1);and L4 comprises the amino acid sequence of a, gss, asg or asggs (SEQ IDNO:4).

In other aspects, the invention is directed to an antigen bindingpolypeptide complex comprising a first polypeptide and a secondpolypeptide; wherein the first polypeptide has a structure representedby VL1-VL2-VH2-VH1-CH1-CL-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; or VL1-L1-VL2-L2-VH2-L3-VH1-CL-CH1-Fc;wherein the second polypeptide has a structure represented byVL3-VL4-VH4-VH3-Fc; VL3-L1-VL4-L2-VH4-L3-VH3-Fc; orVL3-L1-VL4-L2-VH4-L3-VH3-L4-Fc; wherein VL1 is a first immuno globulinlight chain variable region; VL2 is a second immunoglobulin light chainvariable region; VL3 is a third immunoglobulin light chain variableregion; VL4 is a fourth immunoglobulin light chain variable region; VH1is a first immunoglobulin heavy chain variable region; VH2 is a secondimmunoglobulin heavy chain variable region; VH3 is a thirdimmunoglobulin heavy chain variable region; VH4 is a fourthimmunoglobulin heavy chain variable region; Fc is a region comprising animmunoglobulin heavy chain constant region 2 (CH2), an immunoglobulinheavy chain constant region 3 (CH3), and optionally, an immunoglobulinhinge; CH1 is an immunoglobulin heavy chain constant region 1; CL is animmunoglobulin light chain constant region; L1, L2 and L3 are amino acidlinkers; VH1 comprises an amino acid sequence having at least 90%identity, at least 95% identity, or 100% identity to any one of SEQ IDNOs:20-25; VH2 comprises an amino acid sequence having at least 90%identity, at least 95% identity, or 100% identity to any one of SEQ IDNOs:20-25; VH3 comprises an amino acid sequence having at least 90%identity, at least 95% identity, or 100% identity to any one of SEQ IDNOs:20-25; VH4 comprises an amino acid sequence having at least 90%identity, at least 95% identity, or 100% identity to any one of SEQ IDNOs:20-25; VL1 comprises an amino acid sequence having at least 90%identity, at least 95% identity, or 100% identity to any one of SEQ IDNOs:26-31; VL2 comprises an amino acid sequence having at least 90%identity, at least 95% identity, or 100% identity to any one of SEQ IDNOs:26-31; VL3 comprises an amino acid sequence having at least 90%identity, at least 95% identity, or 100% identity to any one of SEQ IDNOs:26-31; and VL4 comprises an amino acid sequence having at least 90%identity, at least 95% identity, or 100% identity to any one of SEQ IDNOs:26-31. In some aspects, the first polypeptide has a structurerepresented by VL1-VL2-VH2-VH1-CH1-CL-Fc and the second polypeptide hasa structure represented by VL3-VL4-VH4-VH3-Fc. In some aspects, thefirst polypeptide has a structure represented byVL1-VL2-VH2-VH1-CH1-CL-Fc and the second polypeptide has a structurerepresented by VL3-L1-VL4-L2-VH4-L3-VH3-Fc. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-CH1-CL-Fc andthe second polypeptide has a structure represented byVL3-L1-VL4-L2-VH4-L3-VH3-L4-Fc. In some aspects, the first polypeptidehas a structure represented by VL1-L1-VL2-L2-VH2-L3-VH1-CH1-CL-Fc andthe second polypeptide has a structure represented byVL3-VL4-VH4-VH3-Fc. In some aspects, the first polypeptide has astructure represented by VL1-L1-VL2-L2-VH2-L3-VH1-CH1-CL-Fc and thesecond polypeptide has a structure represented byVL3-L1-VL4-L2-VH4-L3-VH3-Fc. In some aspects, the first polypeptide hasa structure represented by VL1-L1-VL2-L2-VH2-L3-VH1-CH1-CL-Fc and thesecond polypeptide has a structure represented byVL3-L1-VL4-L2-VH4-L3-VH3-L4-Fc. In some aspects, the first polypeptidehas a structure represented by VL1-VL2-VH2-VH1-CL-CH1-Fc and the secondpolypeptide has a structure represented by VL3-VL4-VH4-VH3-Fc. In someaspects, the first polypeptide has a structure represented byVL1-VL2-VH2-VH1-CL-CH1-Fc and the second polypeptide has a structurerepresented by VL3-L1-VL4-L2-VH4-L3-VH3-Fc. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-CL-CH1-Fc andthe second polypeptide has a structure represented byVL3-L1-VL4-L2-VH4-L3-VH3-L4-Fc. In some aspects, the first polypeptidehas a structure represented by VL1-L1-VL2-L2-VH2-L3-VH1-CL-CH1-Fc andthe second polypeptide has a structure represented byVL3-VL4-VH4-VH3-Fc. In some aspects, the first polypeptide has astructure represented by VL1-L1-VL2-L2-VH2-L3-VH1-CL-CH1-Fc and thesecond polypeptide has a structure represented byVL3-L1-VL4-L2-VH4-L3-VH3-Fc. In some aspects, the first polypeptide hasa structure represented by VL1-L1-VL2-L2-VH2-L3-VH1-CL-CH1-Fc and thesecond polypeptide has a structure represented byVL3-L1-VL4-L2-VH4-L3-VH3-L4-Fc. In some aspects, VH1 comprises an aminoacid sequence having at least 90% identity to any one of SEQ IDNOs:20-25; VH2 comprises an amino acid sequence having at least 90%identity to any one of SEQ ID NOs:20-25; VH3 comprises an amino acidsequence having at least 90% identity to any one of SEQ ID NOs:20-25;VH4 comprises an amino acid sequence having at least 90% identity to anyone of SEQ ID NOs:20-25; VL1 comprises an amino acid sequence having atleast 90% identity to any one of SEQ ID NOs:26-31; VL2 comprises anamino acid sequence having at least 90% identity to any one of SEQ IDNOs:26-31; VL3 comprises an amino acid sequence having at least 90%identity to any one of SEQ ID NOs:26-31; and VL4 comprises an amino acidsequence having at least 90% identity to any one of SEQ ID NOs:26-31. Atleast 90% identity may include at least 91%, 92%, 93%, 94%, 95%, 96%,97%, 98%, 99% or 100% identity to the reference polypeptide sequence.For example, VH1, VH2, VH3 and/or VH4 may comprise the amino acidsequence of any one of SEQ ID NOs:20-25. For example, VL1, VL2, VL3and/or VL4 may comprise the amino acid sequence of any one of SEQ IDNos: 26-31.

In other aspects, the invention is directed to an antigen bindingpolypeptide complex comprising a first polypeptide and a secondpolypeptide; wherein the first polypeptide has a structure representedby VH1-VH2-VL2-VL1-Fc; or VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; wherein thesecond polypeptide has a structure represented by VH3-VH4-VL4-VL3-Fc; orVH3-L1-VH4-L2-VL4-L3-VL3-L4-Fc; wherein VL1 is a first immunoglobulinlight chain variable region; VL2 is a second immunoglobulin light chainvariable region; VL3 is a third immunoglobulin light chain variableregion; VL4 is a fourth immunoglobulin light chain variable region; VH1is a first immunoglobulin heavy chain variable region; VH2 is a secondimmunoglobulin heavy chain variable region; VH3 is a thirdimmunoglobulin heavy chain variable region; VH4 is a fourthimmunoglobulin heavy chain variable region; Fc is a region comprising animmunoglobulin heavy chain constant region 2 (CH2), an immunoglobulinheavy chain constant region 3 (CH3), and optionally, an immunoglobulinhinge; L1, L2, L3 and L4 are amino acid linkers; VH1 comprises an aminoacid sequence having at least 90% identity, at least 95% identity, or100% identity to any one of SEQ ID NOs:20-25; VH2 comprises an aminoacid sequence having at least 90% identity, at least 95% identity, or100% identity to any one of SEQ ID NOs:20-25; VH3 comprises an aminoacid sequence having at least 90% identity, at least 95% identity, or100% identity to any one of SEQ ID NOs:20-25; VH4 comprises an aminoacid sequence having at least 90% identity, at least 95% identity, or100% identity to any one of SEQ ID NOs:20-25; VL1 comprises an aminoacid sequence having at least 90% identity, at least 95% identity, or100% identity to any one of SEQ ID NOs:26-31; VL2 comprises an aminoacid sequence having at least 90% identity, at least 95% identity, or100% identity to any one of SEQ ID NOs:26-31; VL3 comprises an aminoacid sequence having at least 90% identity, at least 95% identity, or100% identity to any one of SEQ ID NOs:26-31; and VL4 comprises an aminoacid sequence having at least 90% identity, at least 95% identity, or100% identity to any one of SEQ ID NOs:26-31. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1-Fc and thesecond polypeptide has a structure represented by VH3-VH4-VL4-VL3-Fc. Insome aspects, the first polypeptide has a structure represented byVH1-VH2-VL2-VL1-Fc and the second polypeptide has a structurerepresented by VH3-L1-VH4-L2-VL4-L3-VL3-L4-Fc. In some aspects, thefirst polypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc and the second polypeptide has astructure represented by VH3-VH4-VL4-VL3-Fc. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc and the second polypeptide has astructure represented by VH3-L1-VH4-L2-VL4-L3-VL3-L4-Fc. In someaspects, VH1 comprises an amino acid sequence having at least 90%identity to any one of SEQ ID NOs:20-25; VH2 comprises an amino acidsequence having at least 90% identity to any one of SEQ ID NOs:20-25;VH3 comprises an amino acid sequence having at least 90% identity to anyone of SEQ ID NOs:20-25; VH4 comprises an amino acid sequence having atleast 90% identity to any one of SEQ ID NOs:20-25; VL1 comprises anamino acid sequence having at least 90% identity to any one of SEQ IDNOs:26-31; VL2 comprises an amino acid sequence having at least 90%identity to any one of SEQ ID NOs:26-31; VL3 comprises an amino acidsequence having at least 90% identity to any one of SEQ ID NOs:26-31;and VL4 comprises an amino acid sequence having at least 90% identity toany one of SEQ ID NOs:26-31. At least 90% identity may include at least91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to thereference polypeptide sequence. For example, VH1, VH2, VH3 and/or VH4may comprise the amino acid sequence of any one of SEQ ID NOs:20-25. Forexample, VL1, VL2, VL3 and/or VL4 may comprise the amino acid sequenceof any one of SEQ ID Nos: 26-31.

In some aspects, L1 comprises the amino acid sequence of ggssg (SEQ IDNO:1), L2 comprises the amino acid sequence of ggggsggsgsggggsasgsg (SEQID NO:12); L3 comprises the amino acid sequence of ggssg (SEQ ID NO:1);and L4 comprises the amino acid sequence of asggsg (SEQ ID NO:6).

In some aspects, one or more of VH1, VH2, VH3 and VH4 comprises a CDR1comprising the amino acid sequence of SEQ ID NO:98 or an amino acidsequence having at least 90% identity or at least 95% identity to SEQ IDNO:98; a CDR2 comprising the amino acid sequence of SEQ ID NO:99 or anamino acid sequence having at least 90% identity or at least 95%identity to SEQ ID NO:99; and a CDR3 comprising the amino acid sequenceof SEQ ID NO:100 or an amino acid sequence having at least 90% identityor at least 95% identity to SEQ ID NO:100; and one or more of VL1, VL2,VL3 and VL4 comprises a CDR1 comprising the amino acid sequence of SEQID NO:101 or an amino acid sequence having at least 90% identity or atleast 95% identity to SEQ ID NO:101, a CDR2 comprising an amino acidsequence of SEQ ID NO:102 or an amino acid sequence having at least 90%identity or 95% identity to SEQ ID NO:102, and a CDR3 comprising theamino acid sequence of SEQ ID NO:103 or an amino acid sequence having atleast 90% identity or at least 95% identity to SEQ ID NO:103. In someaspects, one or more of VH1, VH2, VH3 and VH4 comprises a CDR1comprising an amino acid sequence having at least 90% identity to SEQ IDNO:98; a CDR2 comprising an amino acid sequence having at least 90%identity to SEQ ID NO:99; and a CDR3 comprising an amino acid sequencehaving at least 90% identity to SEQ ID NO:100; and one or more of VL1,VL2, VL3 and VL4 comprises a CDR1 comprising an amino acid sequencehaving at least 90% identity to SEQ ID NO:101, a CDR2 comprising anamino acid sequence having at least 90% identity to SEQ ID NO:102, and aCDR3 comprising an amino acid sequence having at least 90% identity toSEQ ID NO:103. At least 90% identity may include at least 91%, 92%, 93%,94%, 95%, 96%, 97%, 98%, 99% or 100% identity to the referencepolypeptide sequence. For example, one or more of VH1, VH2, VH3 and VH4may comprise a CDR1 comprising the amino acid sequence of SEQ ID NO:98;a CDR2 comprising the amino acid sequence of SEQ ID NO:99; and a CDR3comprising the amino acid sequence of SEQ ID NO:100; and one or more ofVL1, VL2, VL3 and VL4 comprises a CDR1 comprising the amino acidsequence of SEQ ID NO:101, a CDR2 comprising the amino acid sequence ofSEQ ID NO:102, and a CDR3 comprising the amino acid sequence of SEQ IDNO:103.

In some aspects, one or more of VH1, VH2, VH3 and VH4 comprises a CDR1comprising the amino acid sequence of SEQ ID NO:104 or an amino acidsequence having at least 90% identity or at least 95% identity to SEQ IDNO:104; a CDR2 comprising the amino acid sequence of SEQ ID NO:105 or anamino acid sequence having at least 90% identity or at least 95%identity to SEQ ID NO:105; and a CDR3 comprising the amino acid sequenceof SEQ ID NO:106 or an amino acid sequence having at least 90% identityor at least 95% identity to SEQ ID NO:106; and one or more of VL1, VL2,VL3 and VL4 comprises a CDR1 comprising the amino acid sequence of SEQID NO:107 or an amino acid sequence having at least 90% identity or atleast 95% identity to SEQ ID NO:107, a CDR2 comprising an amino acidsequence of SEQ ID NO:108 or an amino acid sequence having at least 90%identity or 95% identity to SEQ ID NO:108, and a CDR3 comprising theamino acid sequence of SEQ ID NO:109 or an amino acid sequence having atleast 90% identity or at least 95% identity to SEQ ID NO:109. In someaspects, one or more of VH1, VH2, VH3 and VH4 comprises a CDR1comprising an amino acid sequence having at least 90% identity to SEQ IDNO:104; a CDR2 comprising an amino acid sequence having at least 90%identity to SEQ ID NO:105; and a CDR3 comprising an amino acid sequencehaving at least 90% identity to SEQ ID NO:106; and one or more of VL1,VL2, VL3 and VL4 comprises a CDR1 comprising an amino acid sequencehaving at least 90% identity to SEQ ID NO:107, a CDR2 comprising anamino acid sequence having at least 90% identity to SEQ ID NO:108, and aCDR3 comprising an amino acid sequence having at least 90% identity toSEQ ID NO:109. At least 90% identity may include at least 91%, 92%, 93%,94%, 95%, 96%, 97%, 98%, 99% or 100% identity to the referencepolypeptide sequence. For example, one or more of VH1, VH2, VH3 and VH4may comprise a CDR1 comprising the amino acid sequence of SEQ ID NO:104;a CDR2 comprising the amino acid sequence of SEQ ID NO:105; and a CDR3comprising the amino acid sequence of SEQ ID NO:106; and one or more ofVL1, VL2, VL3 and VL4 comprises a CDR1 comprising the amino acidsequence of SEQ ID NO:107, a CDR2 comprising the amino acid sequence ofSEQ ID NO:108, and a CDR3 comprising the amino acid sequence of SEQ IDNO:109.

In some aspects, one or more of VH1, VH2, VH3 and VH4 comprises a CDR1comprising the amino acid sequence of SEQ ID NO:56 or an amino acidsequence having at least 90% identity or at least 95% identity to SEQ IDNO:56; a CDR2 comprising the amino acid sequence of SEQ ID NO:57 or anamino acid sequence having at least 90% identity or at least 95%identity to SEQ ID NO:57; and a CDR3 comprising the amino acid sequenceof SEQ ID NO:58 or an amino acid sequence having at least 90% identityor at least 95% identity to SEQ ID NO:58; and one or more of VL1, VL2,VL3 and VL4 comprises a CDR1 comprising the amino acid sequence of SEQID NO:59 or an amino acid sequence having at least 90% identity or atleast 95% identity to SEQ ID NO:59, a CDR2 comprising an amino acidsequence of SEQ ID NO:60 or an amino acid sequence having at least 90%identity or 95% identity to SEQ ID NO:60, and a CDR3 comprising theamino acid sequence of SEQ ID NO:61 or an amino acid sequence having atleast 90% identity or at least 95% identity to SEQ ID NO:61. In someaspects, one or more of VH1, VH2, VH3 and VH4 comprises a CDR1comprising an amino acid sequence having at least 90% identity to SEQ IDNO:56; a CDR2 comprising an amino acid sequence having at least 90%identity to SEQ ID NO:57; and a CDR3 comprising an amino acid sequencehaving at least 90% identity to SEQ ID NO:58; and one or more of VL1,VL2, VL3 and VL4 comprises a CDR1 comprising an amino acid sequencehaving at least 90% identity to SEQ ID NO:59, a CDR2 comprising an aminoacid sequence having at least 90% identity to SEQ ID NO:60, and a CDR3comprising an amino acid sequence having at least 90% identity to SEQ IDNO:61. At least 90% identity may include at least 91%, 92%, 93%, 94%,95%, 96%, 97%, 98%, 99% or 100% identity to the reference polypeptidesequence. For example, one or more of VH1, VH2, VH3 and VH4 may comprisea CDR1 comprising the amino acid sequence of SEQ ID NO:56; a CDR2comprising the amino acid sequence of SEQ ID NO:57; and a CDR3comprising the amino acid sequence of SEQ ID NO:58; and one or more ofVL1, VL2, VL3 and VL4 comprises a CDR1 comprising the amino acidsequence of SEQ ID NO:59, a CDR2 comprising the amino acid sequence ofSEQ ID NO:60, and a CDR3 comprising the amino acid sequence of SEQ IDNO:61.

In some aspects, one or more of VH1, VH2, VH3 and VH4 comprises a CDR1comprising the amino acid sequence of SEQ ID NO:110 or an amino acidsequence having at least 90% identity or at least 95% identity to SEQ IDNO:110; a CDR2 comprising the amino acid sequence of SEQ ID NO:111 or anamino acid sequence having at least 90% identity or at least 95%identity to SEQ ID NO:111; and a CDR3 comprising the amino acid sequenceof SEQ ID NO:112 or an amino acid sequence having at least 90% identityor at least 95% identity to SEQ ID NO:112; and one or more of VL1, VL2,VL3 and VL4 comprises a CDR1 comprising the amino acid sequence of SEQID NO:113 or an amino acid sequence having at least 90% identity or atleast 95% identity to SEQ ID NO:113, a CDR2 comprising an amino acidsequence of SEQ ID NO:114 or an amino acid sequence having at least 90%identity or 95% identity to SEQ ID NO:114, and a CDR3 comprising theamino acid sequence of SEQ ID NO:115 or an amino acid sequence having atleast 90% identity or at least 95% identity to SEQ ID NO:115. In someaspects, one or more of VH1, VH2, VH3 and VH4 comprises a CDR1comprising an amino acid sequence having at least 90% identity to SEQ IDNO:110; a CDR2 comprising an amino acid sequence having at least 90%identity to SEQ ID NO:111; and a CDR3 comprising an amino acid sequencehaving at least 90% identity to SEQ ID NO:112; and one or more of VL1,VL2, VL3 and VL4 comprises a CDR1 comprising an amino acid sequencehaving at least 90% identity to SEQ ID NO:113, a CDR2 comprising anamino acid sequence having at least 90% identity to SEQ ID NO:114, and aCDR3 comprising an amino acid sequence having at least 90% identity toSEQ ID NO:115. At least 90% identity may include at least 91%, 92%, 93%,94%, 95%, 96%, 97%, 98%, 99% or 100% identity to the referencepolypeptide sequence. For example, one or more of VH1, VH2, VH3 and VH4may comprise a CDR1 comprising the amino acid sequence of SEQ ID NO:110;a CDR2 comprising the amino acid sequence of SEQ ID NO:111; and a CDR3comprising the amino acid sequence of SEQ ID NO:112; and one or more ofVL1, VL2, VL3 and VL4 comprises a CDR1 comprising the amino acidsequence of SEQ ID NO:113, a CDR2 comprising the amino acid sequence ofSEQ ID NO:114, and a CDR3 comprising the amino acid sequence of SEQ IDNO:115.

In some aspects, one or more of VH1, VH2, VH3 and VH4 comprises a CDR1comprising the amino acid sequence of SEQ ID NO:116 or an amino acidsequence having at least 90% identity or at least 95% identity to SEQ IDNO:116; a CDR2 comprising the amino acid sequence of SEQ ID NO:117 or anamino acid sequence having at least 90% identity or at least 95%identity to SEQ ID NO:117; and a CDR3 comprising the amino acid sequenceof SEQ ID NO:118 or an amino acid sequence having at least 90% identityor at least 95% identity to SEQ ID NO:118; and one or more of VL1, VL2,VL3 and VL4 comprises a CDR1 comprising the amino acid sequence of SEQID NO:119 or an amino acid sequence having at least 90% identity or atleast 95% identity to SEQ ID NO:119, a CDR2 comprising an amino acidsequence of SEQ ID NO:120 or an amino acid sequence having at least 90%identity or 95% identity to SEQ ID NO:120, and a CDR3 comprising theamino acid sequence of SEQ ID NO:121 or an amino acid sequence having atleast 90% identity or at least 95% identity to SEQ ID NO:121. In someaspects, one or more of VH1, VH2, VH3 and VH4 comprises a CDR1comprising an amino acid sequence having at least 90% identity to SEQ IDNO:116; a CDR2 comprising an amino acid sequence having at least 90%identity to SEQ ID NO:117; and a CDR3 comprising an amino acid sequencehaving at least 90% identity to SEQ ID NO:118; and one or more of VL1,VL2, VL3 and VL4 comprises a CDR1 comprising an amino acid sequencehaving at least 90% identity to SEQ ID NO:119, a CDR2 comprising anamino acid sequence having at least 90% identity to SEQ ID NO:120, and aCDR3 comprising an amino acid sequence having at least 90% identity toSEQ ID NO:21 At least 90% identity may include at least 91%, 92%, 93%,94%, 95%, 96%, 97%, 98%, 99% or 100% identity to the referencepolypeptide sequence. For example, one or more of VH1, VH2, VH3 and VH4may comprise a CDR1 comprising the amino acid sequence of SEQ ID NO:116;a CDR2 comprising the amino acid sequence of SEQ ID NO:117; and a CDR3comprising the amino acid sequence of SEQ ID NO:118; and one or more ofVL1, VL2, VL3 and VL4 comprises a CDR1 comprising the amino acidsequence of SEQ ID NO:119, a CDR2 comprising the amino acid sequence ofSEQ ID NO:120, and a CDR3 comprising the amino acid sequence of SEQ IDNO:121.

In some aspects, one or more of VH1, VH2, VH3 and VH4 comprises a CDR1comprising the amino acid sequence of SEQ ID NO:124 or an amino acidsequence having at least 90% identity or at least 95% identity to SEQ IDNO:124; a CDR2 comprising the amino acid sequence of SEQ ID NO:125 or anamino acid sequence having at least 90% identity or at least 95%identity to SEQ ID NO:125; and a CDR3 comprising the amino acid sequenceof SEQ ID NO:126 or an amino acid sequence having at least 90% identityor at least 95% identity to SEQ ID NO:126; and one or more of VL1, VL2,VL3 and VL4 comprises a CDR1 comprising the amino acid sequence of SEQID NO:127 or an amino acid sequence having at least 90% identity or atleast 95% identity to SEQ ID NO:127, a CDR2 comprising an amino acidsequence of SEQ ID NO:128 or an amino acid sequence having at least 90%identity or 95% identity to SEQ ID NO:128, and a CDR3 comprising theamino acid sequence of SEQ ID NO:129 or an amino acid sequence having atleast 90% identity or at least 95% identity to SEQ ID NO:129. In someaspects, one or more of VH1, VH2, VH3 and VH4 comprises a CDR1comprising an amino acid sequence having at least 90% identity to SEQ IDNO:124; a CDR2 comprising an amino acid sequence having at least 90%identity to SEQ ID NO:125; and a CDR3 comprising an amino acid sequencehaving at least 90% identity to SEQ ID NO:126; and one or more of VL1,VL2, VL3 and VL4 comprises a CDR1 comprising an amino acid sequencehaving at least 90% identity to SEQ ID NO:127, a CDR2 comprising anamino acid sequence having at least 90% identity to SEQ ID NO:128, and aCDR3 comprising an amino acid sequence having at least 90% identity toSEQ ID NO:129. At least 90% identity may include at least 91%, 92%, 93%,94%, 95%, 96%, 97%, 98%, 99% or 100% identity to the referencepolypeptide sequence. For example, one or more of VH1, VH2, VH3 and VH4may comprise a CDR1 comprising the amino acid sequence of SEQ ID NO:124;a CDR2 comprising the amino acid sequence of SEQ ID NO:125; and a CDR3comprising the amino acid sequence of SEQ ID NO:126; and one or more ofVL1, VL2, VL3 and VL4 comprises a CDR1 comprising the amino acidsequence of SEQ ID NO:127, a CDR2 comprising the amino acid sequence ofSEQ ID NO:128, and a CDR3 comprising the amino acid sequence of SEQ IDNO:129.

In other aspects, the invention is directed to an antigen bindingpolypeptide complex comprising one, two, three or four antigen bindingpolypeptides described herein. In some aspects, the antigen bindingpolypeptide complex comprises a polypeptide having an amino acidsequence having at least 90% identity, at least 95% identity, or 100%identity to one or more of SEQ ID NOs:32-43, 62-79, 130-138, 633, 635,637, 639, 641, 643, 645, 647, 649, 651, 653, 655, 657, 659, 661, 663,665, 667, 669, 671, 673, 675, 677, and 679. In some aspects, the antigenbinding polypeptide complex comprises a polypeptide having an amino acidsequence having at least 90% identity (such as at least 91%, 92%, 93%,94%, 95%, 96%, 97%, 98%, or 99%) to one or more of SEQ ID NOs:32-43,62-79, 130-138, 633, 635, 637, 639, 641, 643, 645, 647, 649, 651, 653,655, 657, 659, 661, 663, 665, 667, 669, 671, 673, 675, 677, and 679. Forexample, the antigen binding polypeptide complex may comprise apolypeptide having the amino acid sequence of any one or more of SEQ IDNOs:32-43, 62-79 130-138, 633, 635, 637, 639, 641, 643, 645, 647, 649,651, 653, 655, 657, 659, 661, 663, 665, 667, 669, 671, 673, 675, 677,and 679. In some aspects, the invention is directed to an antigenbinding polypeptide or antigen binding polypeptide complex (e.g.,antibody or antigen binding fragment thereof) comprising an amino acidsequence having at least 90% identity, at least 95% identity, or 100%identity to the amino acid sequence of SEQ ID NOs:32 or 33 that does notcontain the eight histidine residues at the C-terminus. In some aspects,the antigen binding polypeptide complex comprises a polypeptide havingan amino acid sequence having at least 90% (such as at least 91%, 92%,93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity to the amino acidsequence of SEQ ID NOs:32 or 33 that does not contain the eighthistidine residues at the C-terminus. For example, the antigen bindingpolypeptide complex may comprise a polypeptide having the amino acidsequence of the amino acid sequence of SEQ ID NOs:32 or 33 that does notcontain the eight histidine residues at the C-terminus. In some aspects,the antigen binding polypeptide complex comprises a first polypeptideand a second polypeptide each having an amino acid sequence having atleast 90% identity, at least 95% identity, or 100% identity to one ormore of SEQ ID NOs:32-43, 62-79, 130-138, 633, 635, 637, 639, 641, 643,645, 647, 649, 651, 653, 655, 657, 659, 661, 663, 665, 667, 669, 671,673, 675, 677, and 679. For example, the antigen binding polypeptidecomplex may comprise a first polypeptide and a second polypeptide eachhaving an amino acid sequence having at least 90% (such as at least 91%,92%, 93%, 94%, 95% identity, 96%, 97%, 98% or 99%) identity to one ormore of SEQ ID NOs:32-43, 62-79, 130-138, 633, 635, 637, 639, 641, 643,645, 647, 649, 651, 653, 655, 657, 659, 661, 663, 665, 667, 669, 671,673, 675, 677, and 679. For example, the antigen binding polypeptidecomplex may comprise a first polypeptide and a second polypeptide eachhaving the amino acid sequence of any one or more of SEQ ID NOs:32-43,62-79, 130-138, 633, 635, 637, 639, 641, 643, 645, 647, 649, 651, 653,655, 657, 659, 661, 663, 665, 667, 669, 671, 673, 675, 677, and 679. Insome aspects, the antigen binding polypeptide complex comprises a firstpolypeptide and a second polypeptide each having an amino acid sequencehaving at least 90% identity, at least 95% identity, or 100% identity tothe amino acid sequence of SEQ ID NOs:32 or 33 that does not contain theeight histidine residues at the C-terminus. For example, the antigenbinding polypeptide complex may comprise a first polypeptide and asecond polypeptide each having an amino acid sequence having at least90% (such as at least 91%, 92%, 93%, 94%, 95% identity, 96%, 97%, 98% or99%) identity to SEQ ID NOs: 32 or 33 that does not contain the eighthistidine residues at the C-terminus. For example, the antigen bindingpolypeptide complex may comprise a first polypeptide and a secondpolypeptide each having the amino acid sequence of SEQ ID NOs: 32 or 33that does not contain the eight histidine residues at the C-terminus. Insome aspects, the antigen binding polypeptide complex comprises apolypeptide having an amino acid sequence encoded by a polynucleotidehaving at least 90% identity, at least 95% identity, or 100% identity toone or more of SEQ ID NOs:44-55, 80-97, 139-147, 634, 636, 638, 640,642, 644, 646, 648, 650, 652, 654, 656, 658, 660, 662, 664, 666, 668,670, 672, 674, 676, 678, and 680. For example, the antigen bindingpolypeptide complex may comprise a polypeptide having an amino acidsequence encoded by a polynucleotide having at least 90% (such as atleast 91%, 92%, 93%, 94%, 95% identity, 96%, 97%, 98% or 99%) identityto one or more of SEQ ID NOs:44-55, 80-97, 139-147, 634, 636, 638, 640,642, 644, 646, 648, 650, 652, 654, 656, 658, 660, 662, 664, 666, 668,670, 672, 674, 676, 678, and 680. For example, the antigen bindingpolypeptide complex may comprise a polypeptide having an amino acidsequence encoded by a polynucleotide having any one of SEQ ID NOs:44-55,80-97, 139-147, 634, 636, 638, 640, 642, 644, 646, 648, 650, 652, 654,656, 658, 660, 662, 664, 666, 668, 670, 672, 674, 676, 678, and 680. Insome aspects, the antigen binding polypeptide complex comprises a firstpolypeptide and a second polypeptide each having an amino acid sequenceencoded by a polynucleotide having at least 90% identity, at least 95%identity, or 100% identity to one or more of SEQ ID NOs:44-55, 80-97,139-147, 634, 636, 638, 640, 642, 644, 646, 648, 650, 652, 654, 656,658, 660, 662, 664, 666, 668, 670, 672, 674, 676, 678, and 680. Forexample, the antigen binding polypeptide complex may comprise a firstpolypeptide and a second polypeptide each having an amino acid sequenceencoded by a polynucleotide having at least 90% (such as at least 91%,92%, 93%, 94%, 95% identity, 96%, 97%, 98% or 99%) identity to one ormore of SEQ ID NOs:44-55, 80-97, 139-147, 634, 636, 638, 640, 642, 644,646, 648, 650, 652, 654, 656, 658, 660, 662, 664, 666, 668, 670, 672,674, 676, 678, and 680. For example, the antigen binding polypeptidecomplex may comprise a first polypeptide and a second polypeptide eachhaving an amino acid sequence encoded by a polynucleotide as shown inany one of SEQ ID NOs:44-55, 80-97, 139-147, 634, 636, 638, 640, 642,644, 646, 648, 650, 652, 654, 656, 658, 660, 662, 664, 666, 668, 670,672, 674, 676, 678, and 680. In some aspects, the antigen bindingpolypeptide complex comprises a first polypeptide and a secondpolypeptide, wherein the first polypeptide comprises an amino acidsequence having at least 90% identity, at least 95% identity, or 100%identity to any one of SEQ ID NOs:32-43, 62-79, 130-138, 633, 635, 637,639, 641, 643, 645, 647, 649, 651, 653, 655, 657, 659, 661, 663, 665,667, 669, 671, 673, 675, 677, and 679, or an amino acid sequence havingat least 90% identity, at least 95% identity, or 100% identity to theamino acid sequence of SEQ ID NOs:32 or 33 that does not contain theeight histidine residues at the C-terminus, wherein the secondpolypeptide has a structure represented by: Fc, and wherein Fc is aregion comprising an immunoglobulin heavy chain constant region 2 (CH2),an immunoglobulin heavy chain constant region 3 (CH3), and optionally,an immunoglobulin hinge. For example, the antigen binding polypeptidecomplex may comprise a first polypeptide and a second polypeptide,wherein the first polypeptide comprises an amino acid sequence having atleast 90% (such as at least 91%, 92%, 93%, 94%, 95% identity, 96%, 97%,98% or 99%) identity to any one of SEQ ID NOs:32-43, 62-79, 130-138,633, 635, 637, 639, 641, 643, 645, 647, 649, 651, 653, 655, 657, 659,661, 663, 665, 667, 669, 671, 673, 675, 677, and 679; and the secondpolypeptide comprises an Fc. For example, the antigen bindingpolypeptide complex may comprise a first polypeptide and a secondpolypeptide, wherein the first polypeptide comprises the amino acidsequence of any one of SEQ ID NOs:32-43, 62-79, 130-138, 633, 635, 637,639, 641, 643, 645, 647, 649, 651, 653, 655, 657, 659, 661, 663, 665,667, 669, 671, 673, 675, 677, and 679; and the second polypeptidecomprises an Fc. For example, the antigen binding polypeptide complexmay comprise a first polypeptide and a second polypeptide, wherein thefirst polypeptide comprises an amino acid sequence having at least 90%(such as at least 91%, 92%, 93%, 94%, 95% identity, 96%, 97%, 98% or99%) identity to SEQ ID NOs:32 or 33 that does not contain the eighthistidine residues at the C-terminus; and the second polypeptidecomprises an Fc. For example, the antigen binding polypeptide complexmay comprise a first polypeptide and a second polypeptide, wherein thefirst polypeptide comprises the amino acid sequence of SEQ ID NOs:32 or33 that does not contain the eight histidine residues at the C-terminus;and the second polypeptide comprises an Fc.

In some aspects of an antigen binding polypeptide or antigen bindingpolypeptide complex of the invention, VL1 is a first immunoglobulinlight chain variable region that specifically binds to at least oneepitope on at least one antigen selected from the group consisting ofA2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1,B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3,CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19, CCL20, CCL21, CCL25CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27, CD28, CD30, CD38, CD39,CD40, CD40L, CD47, CD52, CD70, CD80, CD86, CD123, CD133, CD137, CD137L,CD160, CD272, CEACAM5, CLEC9, CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1,CXCL2, CXCL4, CXCL12, CXCL13, CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1,E-cadherin, EGFR, ENTPD1, EpCAM, FCER1, FCER1A, FCER2, FGFR, FLAP,FOLH1, Gi24, GITR, GITRL, GPR5, GP100, GPRC5D, HER2, HER3, ICOSL, ICOS,HHLA2, HMGB1, HVEM, IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1, ILIA, IL1B,IL1F10, IL2, IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8, IL9, IL9R,IL10, rhIL1O, IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb, IL18,IL22, IL23, IL25, IL7, IL33, IL35, ITGB4, ITK, KIR, LAG3, LAMP1, leptin,LPFS2, MHC class II, MUC-1, MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1,OX40, OX40L, PD-1, PD-L1, PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC,SPG64, ST2, STEAP1, STEAP2, Syk kinase, STEAP1, TROP2, TACI, TDO,TGFBETA, T14, TIGIT, TIM3, TLR, TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa,TNFRSF7, Tp55, TREM1, TSLP, TSLPR, TWEAK, VEGF, VISTA, Vstm3, or WUCAM.For example, VL1 may specifically bind to at least one epitope on A2AR.For example, VL1 may specifically bind to at least one epitope on APRIL.For example, VL1 may specifically bind to at least one epitope onATPDase. For example, VL1 may specifically bind to at least one epitopeon BAFF. For example, VL1 may specifically bind to at least one epitopeon BAFFR. For example, VL1 may specifically bind to at least one epitopeon BCMA. For example, VL1 may specifically bind to at least one epitopeon BlyS. For example, VL1 may specifically bind to at least one epitopeon BTK. For example, VL1 may specifically bind to at least one epitopeon BTLA. For example, VL1 may specifically bind to at least one epitopeon B7DC. For example, VL1 may specifically bind to at least one epitopeon B7H1. For example, VL1 may specifically bind to at least one epitopeon B7H2. For example, VL1 may specifically bind to at least one epitopeon B7H3. For example, VL1 may specifically bind to at least one epitopeon B7H4. For example, VL1 may specifically bind to at least one epitopeon B7H5. For example, VL1 may specifically bind to at least one epitopeon B7H6. For example, VL1 may specifically bind to at least one epitopeon B7H7. For example, VL1 may specifically bind to at least one epitopeon B7RP1. For example, VL1 may specifically bind to at least one epitopeon B7-4. For example, VL1 may specifically bind to at least one epitopeon C3. For example, VL1 may specifically bind to at least one epitope onC5. For example, VL1 may specifically bind to at least one epitope onCCL2. For example, VL1 may specifically bind to at least one epitope onCCL3. For example, VL1 may specifically bind to at least one epitope onCCL4. For example, VL1 may specifically bind to at least one epitope onCCL5. For example, VL1 may specifically bind to at least one epitope onCCL7. For example, VL1 may specifically bind to at least one epitope onCCL8. For example, VL1 may specifically bind to at least one epitope onCCL11. For example, VL1 may specifically bind to at least one epitope onCCL15. For example, VL1 may specifically bind to at least one epitope onCCL17. For example, VL1 may specifically bind to at least one epitope onCCL19. For example, VL1 may specifically bind to at least one epitope onCCL20. For example, VL1 may specifically bind to at least one epitope onCCL21. For example, VL1 may specifically bind to at least one epitope onCCL25. For example, VL1 may specifically bind to at least one epitope onCCR3. For example, VL1 may specifically bind to at least one epitope onCCR4. For example, VL1 may specifically bind to at least one epitope onCD3. For example, VL1 may specifically bind to at least one epitope onCD19. For example, VL1 may specifically bind to at least one epitope onCD20. For example, VL1 may specifically bind to at least one epitope onCD24. For example, VL1 may specifically bind to at least one epitope onCD27. For example, VL1 may specifically bind to at least one epitope onCD28. For example, VL1 may specifically bind to at least one epitope onCD38. For example, VL1 may specifically bind to at least one epitope onCD39. For example, VL1 may specifically bind to at least one epitope onCD40. For example, VL1 may specifically bind to at least one epitope onCD40L. For example, VL1 may specifically bind to at least one epitope onCD47. For example, VL1 may specifically bind to at least one epitope onCD52. For example, VL1 may specifically bind to at least one epitope onCD70. For example, VL1 may specifically bind to at least one epitope onCD80. For example, VL1 may specifically bind to at least one epitope onCD86. For example, VL1 may specifically bind to at least one epitope onCD123. For example, VL1 may specifically bind to at least one epitope onCD133. For example, VL1 may specifically bind to at least one epitope onCD137. For example, VL1 may specifically bind to at least one epitope onCD137L. For example, VL1 may specifically bind to at least one epitopeon CD160. For example, VL1 may specifically bind to at least one epitopeon CD272. For example, VL1 may specifically bind to at least one epitopeon CEACAM5. For example, VL1 may specifically bind to at least oneepitope on CLEC9. For example, VL1 may specifically bind to at least oneepitope on CLEC91. For example, VL1 may specifically bind to at leastone epitope on CRTH2. For example, VL1 may specifically bind to at leastone epitope on CSF-1. For example, VL1 may specifically bind to at leastone epitope on CSF-2. For example, VL1 may specifically bind to at leastone epitope on CSF-3. For example, VL1 may specifically bind to at leastone epitope on CXCL1. For example, VL1 may specifically bind to at leastone epitope on CXCL2. For example, VL1 may specifically bind to at leastone epitope on CXCL4. For example, VL1 may specifically bind to at leastone epitope on CXCL12. For example, VL1 may specifically bind to atleast one epitope on CXCL13. For example, VL1 may specifically bind toat least one epitope on CXCR3. For example, VL1 may specifically bind toat least one epitope on cMet. For example, VL1 may specifically bind toat least one epitope on CTLA4. For example, VL1 may specifically bind toat least one epitope on DLL3. For example, VL1 may specifically bind toat least one epitope on DNGR-1. For example, VL1 may specifically bindto at least one epitope on E-cadherin. For example, VL1 may specificallybind to at least one epitope on EGFR. For example, VL1 may specificallybind to at least one epitope on ENTPD1. For example, VL1 mayspecifically bind to at least one epitope on EpCAM. For example, VL1 mayspecifically bind to at least one epitope on FCER1. For example, VL1 mayspecifically bind to at least one epitope on FCER1A. For example, VL1may specifically bind to at least one epitope on FCER2. For example, VL1may specifically bind to at least one epitope on FGFR. For example, VL1may specifically bind to at least one epitope on FLAP. For example, VL1may specifically bind to at least one epitope on FOLH1. For example, VL1may specifically bind to at least one epitope on Gi24. For example, VL1may specifically bind to at least one epitope on GITR. For example, VL1may specifically bind to at least one epitope on GITRL. For example, VL1may specifically bind to at least one epitope on GPR5. For example, VL1may specifically bind to at least one epitope on HER2. For example, VL1may specifically bind to at least one epitope on HER3. For example, VL1may specifically bind to at least one epitope on ICOSL. For example, VL1may specifically bind to at least one epitope on ICOS. For example, VL1may specifically bind to at least one epitope on HHLA2. For example, VL1may specifically bind to at least one epitope on HMGB1. For example, VL1may specifically bind to at least one epitope on HVEM. For example, VL1may specifically bind to at least one epitope on IDO. For example, VL1may specifically bind to at least one epitope on IFNa. For example, VL1may specifically bind to at least one epitope on IgE. For example, VL1may specifically bind to at least one epitope on IGF1R. For example, VL1may specifically bind to at least one epitope on IL2Rbeta. For example,VL1 may specifically bind to at least one epitope on ILL For example,VL1 may specifically bind to at least one epitope on ILIA. For example,VL1 may specifically bind to at least one epitope on IL1B. For example,VL1 may specifically bind to at least one epitope on IL1F10. Forexample, VL1 may specifically bind to at least one epitope on IL2. Forexample, VL1 may specifically bind to at least one epitope on IL4. Forexample, VL1 may specifically bind to at least one epitope on IL4Ra. Forexample, VL1 may specifically bind to at least one epitope on IL5. Forexample, VL1 may specifically bind to at least one epitope on IL5R. Forexample, VL1 may specifically bind to at least one epitope on IL6. Forexample, VL1 may specifically bind to at least one epitope on IL7. Forexample, VL1 may specifically bind to at least one epitope on IL7Ra. Forexample, VL1 may specifically bind to at least one epitope on IL8. Forexample, VL1 may specifically bind to at least one epitope on IL9. Forexample, VL1 may specifically bind to at least one epitope on IL9R. Forexample, VL1 may specifically bind to at least one epitope on IL10. Forexample, VL1 may specifically bind to at least one epitope on rhIL10.For example, VL1 may specifically bind to at least one epitope on IL12.For example, VL1 may specifically bind to at least one epitope on IL13.For example, VL1 may specifically bind to at least one epitope onIL13Ra1. For example, VL1 may specifically bind to at least one epitopeon IL13Ra2. For example, VL1 may specifically bind to at least oneepitope on IL15. For example, VL1 may specifically bind to at least oneepitope on IL17. For example, VL1 may specifically bind to at least oneepitope on IL17Rb. For example, VL1 may specifically bind to at leastone epitope on IL18. For example, VL1 may specifically bind to at leastone epitope on IL22. For example, VL1 may specifically bind to at leastone epitope on IL23. For example, VL1 may specifically bind to at leastone epitope on IL25. For example, VL1 may specifically bind to at leastone epitope on IL7. For example, VL1 may specifically bind to at leastone epitope on IL33. For example, VL1 may specifically bind to at leastone epitope on IL35. For example, VL1 may specifically bind to at leastone epitope on ITGB4. For example, VL1 may specifically bind to at leastone epitope on ITK. For example, VL1 may specifically bind to at leastone epitope on KIR. For example, VL1 may specifically bind to at leastone epitope on LAG3. For example, VL1 may specifically bind to at leastone epitope on LAMP 1. For example, VL1 may specifically bind to atleast one epitope on leptin. For example, VL1 may specifically bind toat least one epitope on LPFS2. For example, VL1 may specifically bind toat least one epitope on MHC class II. For example, VL1 may specificallybind to at least one epitope on MUC-1. For example, VL1 may specificallybind to at least one epitope on MUC-16. For example, VL1 mayspecifically bind to at least one epitope on NCR3LG1. For example, VL1may specifically bind to at least one epitope on NKG2D. For example, VL1may specifically bind to at least one epitope on NKp46. For example, VL1may specifically bind to at least one epitope on NTPDase-1. For example,VL1 may specifically bind to at least one epitope on OX40. For example,VL1 may specifically bind to at least one epitope on OX40L. For example,VL1 may specifically bind to at least one epitope on PD-1. For example,VL1 may specifically bind to at least one epitope on PD-L1. For example,VL1 may specifically bind to at least one epitope on PD-L2. For example,VL1 may specifically bind to at least one epitope on PROM1. For example,VL1 may specifically bind to at least one epitope on S152. For example,VL1 may specifically bind to at least one epitope on SIRPalpha. Forexample, VL1 may specifically bind to at least one epitope on SISP1. Forexample, VL1 may specifically bind to at least one epitope on SLC. Forexample, VL1 may specifically bind to at least one epitope on SPG64. Forexample, VL1 may specifically bind to at least one epitope on ST2. Forexample, VL1 may specifically bind to at least one epitope on STEAP1.For example, VL1 may specifically bind to at least one epitope onSTEAP2. For example, VL1 may specifically bind to at least one epitopeon Syk kinase. For example, VL1 may specifically bind to at least oneepitope on STEAP1. For example, VL1 may specifically bind to at leastone epitope on TROP2. For example, VL1 may specifically bind to at leastone epitope on TACI. For example, VL1 may specifically bind to at leastone epitope on TDO. For example, VL1 may specifically bind to at leastone epitope on T14. For example, VL1 may specifically bind to at leastone epitope on TIGIT. For example, VL1 may specifically bind to at leastone epitope on TIM3. For example, VL1 may specifically bind to at leastone epitope on TLR. For example, VL1 may specifically bind to at leastone epitope on TLR2. For example, VL1 may specifically bind to at leastone epitope on TLR4. For example, VL1 may specifically bind to at leastone epitope on TLR5. For example, VL1 may specifically bind to at leastone epitope on TLR9. For example, VL1 may specifically bind to at leastone epitope on TMEF1. For example, VL1 may specifically bind to at leastone epitope on TNFa. For example, VL1 may specifically bind to at leastone epitope on TNFRSF7. For example, VL1 may specifically bind to atleast one epitope on Tp55. For example, VL1 may specifically bind to atleast one epitope on TREM1. For example, VL1 may specifically bind to atleast one epitope on TSLP. For example, VL1 may specifically bind to atleast one epitope on TSLPR. For example, VL1 may specifically bind to atleast one epitope on TWEAK. For example, VL1 may specifically bind to atleast one epitope on VEGF. For example, VL1 may specifically bind to atleast one epitope on VISTA. For example, VL1 may specifically bind to atleast one epitope on Vstm3. For example, VL1 may specifically bind to atleast one epitope on WUCAM. For example, VL1 may specifically bind to atleast one epitope on CD16A. For example, VL1 may specifically bind to atleast one epitope on CD30. For example, VL1 may specifically bind to atleast one epitope on DLL4. For example, VL1 may specifically bind to atleast one epitope on GP100. For example, VL1 may specifically bind to atleast one epitope on GPRC5D. For example, VL1 may specifically bind toat least one epitope on TGFbeta.

In some aspects of an antigen binding polypeptide or antigen bindingpolypeptide complex of the invention, VL2 is a second immunoglobulinlight chain variable region that specifically binds to at least oneepitope on at least one antigen selected from the group consisting ofA2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1,B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3,CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19, CCL20, CCL21, CCL25CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27, CD28, CD30, CD38, CD39,CD40, CD40L, CD47, CD52, CD70, CD80, CD86, CD123, CD133, CD137, CD137L,CD160, CD272, CEACAM5, CLEC9, CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1,CXCL2, CXCL4, CXCL12, CXCL13, CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1,E-cadherin, EGFR, ENTPD1, EpCAM, FCER1, FCER1A, FCER2, FGFR, FLAP,FOLH1, Gi24, GITR, GITRL, GPR5, GP100, GPRC5D, HER2, HER3, ICOSL, ICOS,HHLA2, HMGB1, HVEM, IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1, ILIA, IL1B,IL1F10, IL2, IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8, IL9, IL9R,IL10, rhIL1O, IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb, IL18,IL22, IL23, IL25, IL7, IL33, IL35, ITGB4, ITK, KIR, LAG3, LAMP1, leptin,LPFS2, MHC class II, MUC-1, MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1,OX40, OX40L, PD-1, PD-L1, PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC,SPG64, ST2, STEAP1, STEAP2, Syk kinase, STEAP1, TROP2, TACI, TDO,TGFBETA, T14, TIGIT, TIM3, TLR, TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa,TNFRSF7, Tp55, TREM1, TSLP, TSLPR, TWEAK, VEGF, VISTA, Vstm3, or WUCAM.For example, VL2 may specifically bind to at least one epitope on A2AR.For example, VL2 may specifically bind to at least one epitope on APRIL.For example, VL2 may specifically bind to at least one epitope onATPDase. For example, VL2 may specifically bind to at least one epitopeon BAFF. For example, VL2 may specifically bind to at least one epitopeon BAFFR. For example, VL2 may specifically bind to at least one epitopeon BCMA. For example, VL2 may specifically bind to at least one epitopeon BlyS. For example, VL2 may specifically bind to at least one epitopeon BTK. For example, VL2 may specifically bind to at least one epitopeon BTLA. For example, VL2 may specifically bind to at least one epitopeon B7DC. For example, VL2 may specifically bind to at least one epitopeon B7H1. For example, VL2 may specifically bind to at least one epitopeon B7H2. For example, VL2 may specifically bind to at least one epitopeon B7H3. For example, VL2 may specifically bind to at least one epitopeon B7H4. For example, VL2 may specifically bind to at least one epitopeon B7H5. For example, VL2 may specifically bind to at least one epitopeon B7H6. For example, VL2 may specifically bind to at least one epitopeon B7H7. For example, VL2 may specifically bind to at least one epitopeon B7RP1. For example, VL2 may specifically bind to at least one epitopeon B7-4. For example, VL2 may specifically bind to at least one epitopeon C3. For example, VL2 may specifically bind to at least one epitope onC5. For example, VL2 may specifically bind to at least one epitope onCCL2. For example, VL2 may specifically bind to at least one epitope onCCL3. For example, VL2 may specifically bind to at least one epitope onCCL4. For example, VL2 may specifically bind to at least one epitope onCCL5. For example, VL2 may specifically bind to at least one epitope onCCL7. For example, VL2 may specifically bind to at least one epitope onCCL8. For example, VL2 may specifically bind to at least one epitope onCCL11. For example, VL2 may specifically bind to at least one epitope onCCL15. For example, VL2 may specifically bind to at least one epitope onCCL17. For example, VL2 may specifically bind to at least one epitope onCCL19. For example, VL2 may specifically bind to at least one epitope onCCL20. For example, VL2 may specifically bind to at least one epitope onCCL21. For example, VL2 may specifically bind to at least one epitope onCCL25. For example, VL2 may specifically bind to at least one epitope onCCR3. For example, VL2 may specifically bind to at least one epitope onCCR4. For example, VL2 may specifically bind to at least one epitope onCD3. For example, VL2 may specifically bind to at least one epitope onCD19. For example, VL2 may specifically bind to at least one epitope onCD20. For example, VL2 may specifically bind to at least one epitope onCD24. For example, VL2 may specifically bind to at least one epitope onCD27. For example, VL2 may specifically bind to at least one epitope onCD28. For example, VL2 may specifically bind to at least one epitope onCD38. For example, VL2 may specifically bind to at least one epitope onCD39. For example, VL2 may specifically bind to at least one epitope onCD40. For example, VL2 may specifically bind to at least one epitope onCD40L. For example, VL2 may specifically bind to at least one epitope onCD47. For example, VL2 may specifically bind to at least one epitope onCD52. For example, VL2 may specifically bind to at least one epitope onCD70. For example, VL2 may specifically bind to at least one epitope onCD80. For example, VL2 may specifically bind to at least one epitope onCD86. For example, VL2 may specifically bind to at least one epitope onCD123. For example, VL2 may specifically bind to at least one epitope onCD133. For example, VL2 may specifically bind to at least one epitope onCD137. For example, VL2 may specifically bind to at least one epitope onCD137L. For example, VL2 may specifically bind to at least one epitopeon CD160. For example, VL2 may specifically bind to at least one epitopeon CD272. For example, VL2 may specifically bind to at least one epitopeon CEACAM5. For example, VL2 may specifically bind to at least oneepitope on CLEC9. For example, VL2 may specifically bind to at least oneepitope on CLEC91. For example, VL2 may specifically bind to at leastone epitope on CRTH2. For example, VL2 may specifically bind to at leastone epitope on CSF-1. For example, VL2 may specifically bind to at leastone epitope on CSF-2. For example, VL2 may specifically bind to at leastone epitope on CSF-3. For example, VL2 may specifically bind to at leastone epitope on CXCL1. For example, VL2 may specifically bind to at leastone epitope on CXCL2. For example, VL2 may specifically bind to at leastone epitope on CXCL4. For example, VL2 may specifically bind to at leastone epitope on CXCL12. For example, VL2 may specifically bind to atleast one epitope on CXCL13. For example, VL2 may specifically bind toat least one epitope on CXCR3. For example, VL2 may specifically bind toat least one epitope on cMet. For example, VL2 may specifically bind toat least one epitope on CTLA4. For example, VL2 may specifically bind toat least one epitope on DLL3. For example, VL2 may specifically bind toat least one epitope on DNGR-1. For example, VL2 may specifically bindto at least one epitope on E-cadherin. For example, VL2 may specificallybind to at least one epitope on EGFR. For example, VL2 may specificallybind to at least one epitope on ENTPD1. For example, VL2 mayspecifically bind to at least one epitope on EpCAM. For example, VL2 mayspecifically bind to at least one epitope on FCER1. For example, VL2 mayspecifically bind to at least one epitope on FCER1A. For example, VL2may specifically bind to at least one epitope on FCER2. For example, VL2may specifically bind to at least one epitope on FGFR. For example, VL2may specifically bind to at least one epitope on FLAP. For example, VL2may specifically bind to at least one epitope on FOLH1. For example, VL2may specifically bind to at least one epitope on Gi24. For example, VL2may specifically bind to at least one epitope on GITR. For example, VL2may specifically bind to at least one epitope on GITRL. For example, VL2may specifically bind to at least one epitope on GPR5. For example, VL2may specifically bind to at least one epitope on HER2. For example, VL2may specifically bind to at least one epitope on HER3. For example, VL2may specifically bind to at least one epitope on ICOSL. For example, VL2may specifically bind to at least one epitope on ICOS. For example, VL2may specifically bind to at least one epitope on HHLA2. For example, VL2may specifically bind to at least one epitope on HMGB1. For example, VL2may specifically bind to at least one epitope on HVEM. For example, VL2may specifically bind to at least one epitope on IDO. For example, VL2may specifically bind to at least one epitope on IFNa. For example, VL2may specifically bind to at least one epitope on IgE. For example, VL2may specifically bind to at least one epitope on IGF1R. For example, VL2may specifically bind to at least one epitope on IL2Rbeta. For example,VL2 may specifically bind to at least one epitope on ILL For example,VL2 may specifically bind to at least one epitope on ILIA. For example,VL2 may specifically bind to at least one epitope on IL1B. For example,VL2 may specifically bind to at least one epitope on IL1F10. Forexample, VL2 may specifically bind to at least one epitope on IL2. Forexample, VL2 may specifically bind to at least one epitope on IL4. Forexample, VL2 may specifically bind to at least one epitope on IL4Ra. Forexample, VL2 may specifically bind to at least one epitope on IL5. Forexample, VL2 may specifically bind to at least one epitope on IL5R. Forexample, VL2 may specifically bind to at least one epitope on IL6. Forexample, VL2 may specifically bind to at least one epitope on IL7. Forexample, VL2 may specifically bind to at least one epitope on IL7Ra. Forexample, VL2 may specifically bind to at least one epitope on IL8. Forexample, VL2 may specifically bind to at least one epitope on IL9. Forexample, VL2 may specifically bind to at least one epitope on IL9R. Forexample, VL2 may specifically bind to at least one epitope on IL10. Forexample, VL2 may specifically bind to at least one epitope on rhIL10.For example, VL2 may specifically bind to at least one epitope on IL12.For example, VL2 may specifically bind to at least one epitope on IL13.For example, VL2 may specifically bind to at least one epitope onIL13Ra1. For example, VL2 may specifically bind to at least one epitopeon IL13Ra2. For example, VL2 may specifically bind to at least oneepitope on IL15. For example, VL2 may specifically bind to at least oneepitope on IL17. For example, VL2 may specifically bind to at least oneepitope on IL17Rb. For example, VL2 may specifically bind to at leastone epitope on IL18. For example, VL2 may specifically bind to at leastone epitope on IL22. For example, VL2 may specifically bind to at leastone epitope on IL23. For example, VL2 may specifically bind to at leastone epitope on IL25. For example, VL2 may specifically bind to at leastone epitope on IL7. For example, VL2 may specifically bind to at leastone epitope on IL33. For example, VL2 may specifically bind to at leastone epitope on IL35. For example, VL2 may specifically bind to at leastone epitope on ITGB4. For example, VL2 may specifically bind to at leastone epitope on ITK. For example, VL2 may specifically bind to at leastone epitope on KIR. For example, VL2 may specifically bind to at leastone epitope on LAG3. For example, VL2 may specifically bind to at leastone epitope on LAMP1. For example, VL2 may specifically bind to at leastone epitope on leptin. For example, VL2 may specifically bind to atleast one epitope on LPFS2. For example, VL2 may specifically bind to atleast one epitope on MHC class II. For example, VL2 may specificallybind to at least one epitope on MUC-1. For example, VL2 may specificallybind to at least one epitope on MUC-16. For example, VL2 mayspecifically bind to at least one epitope on NCR3LG1. For example, VL2may specifically bind to at least one epitope on NKG2D. For example, VL2may specifically bind to at least one epitope on NKp46. For example, VL2may specifically bind to at least one epitope on NTPDase-1. For example,VL2 may specifically bind to at least one epitope on OX40. For example,VL2 may specifically bind to at least one epitope on OX40L. For example,VL2 may specifically bind to at least one epitope on PD-1. For example,VL2 may specifically bind to at least one epitope on PD-L1. For example,VL2 may specifically bind to at least one epitope on PD-L2. For example,VL2 may specifically bind to at least one epitope on PROM1. For example,VL2 may specifically bind to at least one epitope on S152. For example,VL2 may specifically bind to at least one epitope on SIRPalpha. Forexample, VL2 may specifically bind to at least one epitope on SISP1. Forexample, VL2 may specifically bind to at least one epitope on SLC. Forexample, VL2 may specifically bind to at least one epitope on SPG64. Forexample, VL2 may specifically bind to at least one epitope on ST2. Forexample, VL2 may specifically bind to at least one epitope on STEAP1.For example, VL2 may specifically bind to at least one epitope onSTEAP2. For example, VL2 may specifically bind to at least one epitopeon Syk kinase. For example, VL2 may specifically bind to at least oneepitope on STEAP1. For example, VL2 may specifically bind to at leastone epitope on TROP2. For example, VL2 may specifically bind to at leastone epitope on TACI. For example, VL2 may specifically bind to at leastone epitope on TDO. For example, VL2 may specifically bind to at leastone epitope on T14. For example, VL2 may specifically bind to at leastone epitope on TIGIT. For example, VL2 may specifically bind to at leastone epitope on TIM3. For example, VL2 may specifically bind to at leastone epitope on TLR. For example, VL2 may specifically bind to at leastone epitope on TLR2. For example, VL2 may specifically bind to at leastone epitope on TLR4. For example, VL2 may specifically bind to at leastone epitope on TLR5. For example, VL2 may specifically bind to at leastone epitope on TLR9. For example, VL2 may specifically bind to at leastone epitope on TMEF1. For example, VL2 may specifically bind to at leastone epitope on TNFa. For example, VL2 may specifically bind to at leastone epitope on TNFRSF7. For example, VL2 may specifically bind to atleast one epitope on Tp55. For example, VL2 may specifically bind to atleast one epitope on TREM1. For example, VL2 may specifically bind to atleast one epitope on TSLP. For example, VL2 may specifically bind to atleast one epitope on TSLPR. For example, VL2 may specifically bind to atleast one epitope on TWEAK. For example, VL2 may specifically bind to atleast one epitope on VEGF. For example, VL2 may specifically bind to atleast one epitope on VISTA. For example, VL2 may specifically bind to atleast one epitope on Vstm3. For example, VL2 may specifically bind to atleast one epitope on WUCAM. For example, VL2 may specifically bind to atleast one epitope on CD16A. For example, VL2 may specifically bind to atleast one epitope on CD30. For example, VL2 may specifically bind to atleast one epitope on DLL4. For example, VL2 may specifically bind to atleast one epitope on GP100. For example, VL2 may specifically bind to atleast one epitope on GPRC5D. For example, VL2 may specifically bind toat least one epitope on TGFbeta.

In some aspects of an antigen binding polypeptide or antigen bindingpolypeptide complex of the invention, VL3 is a third immunoglobulinlight chain variable region that specifically binds to at least oneepitope on at least one antigen selected from the group consisting ofA2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1,B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3,CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19, CCL20, CCL21, CCL25CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27, CD28, CD30, CD38, CD39,CD40, CD40L, CD47, CD52, CD70, CD80, CD86, CD123, CD133, CD137, CD137L,CD160, CD272, CEACAM5, CLEC9, CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1,CXCL2, CXCL4, CXCL12, CXCL13, CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1,E-cadherin, EGFR, ENTPD1, EpCAM, FCER1, FCER1A, FCER2, FGFR, FLAP,FOLH1, Gi24, GITR, GITRL, GPR5, GP100, GPRC5D, HER2, HER3, ICOSL, ICOS,HHLA2, HMGB1, HVEM, IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1, ILIA, IL1B,IL1F10, IL2, IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8, IL9, IL9R,IL10, rhIL1O, IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb, IL18,IL22, IL23, IL25, IL7, IL33, IL35, ITGB4, ITK, KIR, LAG3, LAMP1, leptin,LPFS2, MHC class II, MUC-1, MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1,OX40, OX40L, PD-1, PD-L1, PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC,SPG64, ST2, STEAP1, STEAP2, Syk kinase, STEAP1, TROP2, TACI, TDO,TGFBETA, T14, TIGIT, TIM3, TLR, TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa,TNFRSF7, Tp55, TREM1, TSLP, TSLPR, TWEAK, VEGF, VISTA, Vstm3, and WUCAM.For example, VL3 may specifically bind to at least one epitope on A2AR.For example, VL3 may specifically bind to at least one epitope on APRIL.For example, VL3 may specifically bind to at least one epitope onATPDase. For example, VL3 may specifically bind to at least one epitopeon BAFF. For example, VL3 may specifically bind to at least one epitopeon BAFFR. For example, VL3 may specifically bind to at least one epitopeon BCMA. For example, VL3 may specifically bind to at least one epitopeon BlyS. For example, VL3 may specifically bind to at least one epitopeon BTK. For example, VL3 may specifically bind to at least one epitopeon BTLA. For example, VL3 may specifically bind to at least one epitopeon B7DC. For example, VL3 may specifically bind to at least one epitopeon B7H1. For example, VL3 may specifically bind to at least one epitopeon B7H2. For example, VL3 may specifically bind to at least one epitopeon B7H3. For example, VL3 may specifically bind to at least one epitopeon B7H4. For example, VL3 may specifically bind to at least one epitopeon B7H5. For example, VL3 may specifically bind to at least one epitopeon B7H6. For example, VL3 may specifically bind to at least one epitopeon B7H7. For example, VL3 may specifically bind to at least one epitopeon B7RP1. For example, VL3 may specifically bind to at least one epitopeon B7-4. For example, VL3 may specifically bind to at least one epitopeon C3. For example, VL3 may specifically bind to at least one epitope onC5. For example, VL3 may specifically bind to at least one epitope onCCL2. For example, VL3 may specifically bind to at least one epitope onCCL3. For example, VL3 may specifically bind to at least one epitope onCCL4. For example, VL3 may specifically bind to at least one epitope onCCL5. For example, VL3 may specifically bind to at least one epitope onCCL7. For example, VL3 may specifically bind to at least one epitope onCCL8. For example, VL3 may specifically bind to at least one epitope onCCL11. For example, VL3 may specifically bind to at least one epitope onCCL15. For example, VL3 may specifically bind to at least one epitope onCCL17. For example, VL3 may specifically bind to at least one epitope onCCL19. For example, VL3 may specifically bind to at least one epitope onCCL20. For example, VL3 may specifically bind to at least one epitope onCCL21. For example, VL3 may specifically bind to at least one epitope onCCL25. For example, VL3 may specifically bind to at least one epitope onCCR3. For example, VL3 may specifically bind to at least one epitope onCCR4. For example, VL3 may specifically bind to at least one epitope onCD3. For example, VL3 may specifically bind to at least one epitope onCD19. For example, VL3 may specifically bind to at least one epitope onCD20. For example, VL3 may specifically bind to at least one epitope onCD24. For example, VL3 may specifically bind to at least one epitope onCD27. For example, VL3 may specifically bind to at least one epitope onCD28. For example, VL3 may specifically bind to at least one epitope onCD38. For example, VL3 may specifically bind to at least one epitope onCD39. For example, VL3 may specifically bind to at least one epitope onCD40. For example, VL3 may specifically bind to at least one epitope onCD40L. For example, VL3 may specifically bind to at least one epitope onCD47. For example, VL3 may specifically bind to at least one epitope onCD52. For example, VL3 may specifically bind to at least one epitope onCD70. For example, VL3 may specifically bind to at least one epitope onCD80. For example, VL3 may specifically bind to at least one epitope onCD86. For example, VL3 may specifically bind to at least one epitope onCD123. For example, VL3 may specifically bind to at least one epitope onCD133. For example, VL3 may specifically bind to at least one epitope onCD137. For example, VL3 may specifically bind to at least one epitope onCD137L. For example, VL3 may specifically bind to at least one epitopeon CD160. For example, VL3 may specifically bind to at least one epitopeon CD272. For example, VL3 may specifically bind to at least one epitopeon CEACAM5. For example, VL3 may specifically bind to at least oneepitope on CLEC9. For example, VL3 may specifically bind to at least oneepitope on CLEC91. For example, VL3 may specifically bind to at leastone epitope on CRTH2. For example, VL3 may specifically bind to at leastone epitope on CSF-1. For example, VL3 may specifically bind to at leastone epitope on CSF-2. For example, VL3 may specifically bind to at leastone epitope on CSF-3. For example, VL3 may specifically bind to at leastone epitope on CXCL1. For example, VL3 may specifically bind to at leastone epitope on CXCL2. For example, VL3 may specifically bind to at leastone epitope on CXCL4. For example, VL3 may specifically bind to at leastone epitope on CXCL12. For example, VL3 may specifically bind to atleast one epitope on CXCL13. For example, VL3 may specifically bind toat least one epitope on CXCR3. For example, VL3 may specifically bind toat least one epitope on cMet. For example, VL3 may specifically bind toat least one epitope on CTLA4. For example, VL3 may specifically bind toat least one epitope on DLL3. For example, VL3 may specifically bind toat least one epitope on DNGR-1. For example, VL3 may specifically bindto at least one epitope on E-cadherin. For example, VL3 may specificallybind to at least one epitope on EGFR. For example, VL3 may specificallybind to at least one epitope on ENTPD1. For example, VL3 mayspecifically bind to at least one epitope on EpCAM. For example, VL3 mayspecifically bind to at least one epitope on FCER1. For example, VL3 mayspecifically bind to at least one epitope on FCER1A. For example, VL3may specifically bind to at least one epitope on FCER2. For example, VL3may specifically bind to at least one epitope on FGFR. For example, VL3may specifically bind to at least one epitope on FLAP. For example, VL3may specifically bind to at least one epitope on FOLH1. For example, VL3may specifically bind to at least one epitope on Gi24. For example, VL3may specifically bind to at least one epitope on GITR. For example, VL3may specifically bind to at least one epitope on GITRL. For example, VL3may specifically bind to at least one epitope on GPR5. For example, VL3may specifically bind to at least one epitope on HER2. For example, VL3may specifically bind to at least one epitope on HER3. For example, VL3may specifically bind to at least one epitope on ICOSL. For example, VL3may specifically bind to at least one epitope on ICOS. For example, VL3may specifically bind to at least one epitope on HHLA2. For example, VL3may specifically bind to at least one epitope on HMGB1. For example, VL3may specifically bind to at least one epitope on HVEM. For example, VL3may specifically bind to at least one epitope on IDO. For example, VL3may specifically bind to at least one epitope on IFNa. For example, VL3may specifically bind to at least one epitope on IgE. For example, VL3may specifically bind to at least one epitope on IGF1R. For example, VL3may specifically bind to at least one epitope on IL2Rbeta. For example,VL3 may specifically bind to at least one epitope on ILL For example,VL3 may specifically bind to at least one epitope on ILIA. For example,VL3 may specifically bind to at least one epitope on IL1B. For example,VL3 may specifically bind to at least one epitope on IL1F10. Forexample, VL3 may specifically bind to at least one epitope on IL2. Forexample, VL3 may specifically bind to at least one epitope on IL4. Forexample, VL3 may specifically bind to at least one epitope on IL4Ra. Forexample, VL3 may specifically bind to at least one epitope on IL5. Forexample, VL3 may specifically bind to at least one epitope on IL5R. Forexample, VL3 may specifically bind to at least one epitope on IL6. Forexample, VL3 may specifically bind to at least one epitope on IL7. Forexample, VL3 may specifically bind to at least one epitope on IL7Ra. Forexample, VL3 may specifically bind to at least one epitope on IL8. Forexample, VL3 may specifically bind to at least one epitope on IL9. Forexample, VL3 may specifically bind to at least one epitope on IL9R. Forexample, VL3 may specifically bind to at least one epitope on IL10. Forexample, VL3 may specifically bind to at least one epitope on rhIL10.For example, VL3 may specifically bind to at least one epitope on IL12.For example, VL3 may specifically bind to at least one epitope on IL13.For example, VL3 may specifically bind to at least one epitope onIL13Ra1. For example, VL3 may specifically bind to at least one epitopeon IL13Ra2. For example, VL3 may specifically bind to at least oneepitope on IL15. For example, VL3 may specifically bind to at least oneepitope on IL17. For example, VL3 may specifically bind to at least oneepitope on IL17Rb. For example, VL3 may specifically bind to at leastone epitope on IL18. For example, VL3 may specifically bind to at leastone epitope on IL22. For example, VL3 may specifically bind to at leastone epitope on IL23. For example, VL3 may specifically bind to at leastone epitope on IL25. For example, VL3 may specifically bind to at leastone epitope on IL7. For example, VL3 may specifically bind to at leastone epitope on IL33. For example, VL3 may specifically bind to at leastone epitope on IL35. For example, VL3 may specifically bind to at leastone epitope on ITGB4. For example, VL3 may specifically bind to at leastone epitope on ITK. For example, VL3 may specifically bind to at leastone epitope on KIR. For example, VL3 may specifically bind to at leastone epitope on LAG3. For example, VL3 may specifically bind to at leastone epitope on LAMP 1. For example, VL3 may specifically bind to atleast one epitope on leptin. For example, VL3 may specifically bind toat least one epitope on LPFS2. For example, VL3 may specifically bind toat least one epitope on MHC class II. For example, VL3 may specificallybind to at least one epitope on MUC-1. For example, VL3 may specificallybind to at least one epitope on MUC-16. For example, VL3 mayspecifically bind to at least one epitope on NCR3LG1. For example, VL3may specifically bind to at least one epitope on NKG2D. For example, VL3may specifically bind to at least one epitope on NKp46. For example, VL3may specifically bind to at least one epitope on NTPDase-1. For example,VL3 may specifically bind to at least one epitope on OX40. For example,VL3 may specifically bind to at least one epitope on OX40L. For example,VL3 may specifically bind to at least one epitope on PD-1. For example,VL3 may specifically bind to at least one epitope on PD-L1. For example,VL3 may specifically bind to at least one epitope on PD-L2. For example,VL3 may specifically bind to at least one epitope on PROM1. For example,VL3 may specifically bind to at least one epitope on S152. For example,VL3 may specifically bind to at least one epitope on SIRPalpha. Forexample, VL3 may specifically bind to at least one epitope on SISP1. Forexample, VL3 may specifically bind to at least one epitope on SLC. Forexample, VL3 may specifically bind to at least one epitope on SPG64. Forexample, VL3 may specifically bind to at least one epitope on ST2. Forexample, VL3 may specifically bind to at least one epitope on STEAP1.For example, VL3 may specifically bind to at least one epitope onSTEAP2. For example, VL3 may specifically bind to at least one epitopeon Syk kinase. For example, VL3 may specifically bind to at least oneepitope on STEAP1. For example, VL3 may specifically bind to at leastone epitope on TROP2. For example, VL3 may specifically bind to at leastone epitope on TACI. For example, VL3 may specifically bind to at leastone epitope on TDO. For example, VL3 may specifically bind to at leastone epitope on T14. For example, VL3 may specifically bind to at leastone epitope on TIGIT. For example, VL3 may specifically bind to at leastone epitope on TIM3. For example, VL3 may specifically bind to at leastone epitope on TLR. For example, VL3 may specifically bind to at leastone epitope on TLR2. For example, VL3 may specifically bind to at leastone epitope on TLR4. For example, VL3 may specifically bind to at leastone epitope on TLR5. For example, VL3 may specifically bind to at leastone epitope on TLR9. For example, VL3 may specifically bind to at leastone epitope on TMEF1. For example, VL3 may specifically bind to at leastone epitope on TNFa. For example, VL3 may specifically bind to at leastone epitope on TNFRSF7. For example, VL3 may specifically bind to atleast one epitope on Tp55. For example, VL3 may specifically bind to atleast one epitope on TREM1. For example, VL3 may specifically bind to atleast one epitope on TSLP. For example, VL3 may specifically bind to atleast one epitope on TSLPR. For example, VL3 may specifically bind to atleast one epitope on TWEAK. For example, VL3 may specifically bind to atleast one epitope on VEGF. For example, VL3 may specifically bind to atleast one epitope on VISTA. For example, VL3 may specifically bind to atleast one epitope on Vstm3. For example, VL3 may specifically bind to atleast one epitope on WUCAM. For example, VL3 may specifically bind to atleast one epitope on CD16A. For example, VL3 may specifically bind to atleast one epitope on CD30. For example, VL3 may specifically bind to atleast one epitope on DLL4. For example, VL3 may specifically bind to atleast one epitope on GP100. For example, VL3 may specifically bind to atleast one epitope on GPRC5D. For example, VL3 may specifically bind toat least one epitope on TGFbeta.

In some aspects of an antigen binding polypeptide or antigen bindingpolypeptide complex of the invention, VL4 is a fourth immunoglobulinlight chain variable region that specifically binds to at least oneepitope on at least one antigen selected from the group consisting ofA2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1,B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3,CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19, CCL20, CCL21, CCL25CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27, CD28, CD30, CD38, CD39,CD40, CD40L, CD47, CD52, CD70, CD80, CD86, CD123, CD133, CD137, CD137L,CD160, CD272, CEACAM5, CLEC9, CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1,CXCL2, CXCL4, CXCL12, CXCL13, CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1,E-cadherin, EGFR, ENTPD1, EpCAM, FCER1, FCER1A, FCER2, FGFR, FLAP,FOLH1, Gi24, GITR, GITRL, GPR5, GP100, GPRC5D, HER2, HER3, ICOSL, ICOS,HHLA2, HMGB1, HVEM, IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1, ILIA, IL1B,IL1F10, IL2, IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8, IL9, IL9R,IL10, rhIL1O, IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb, IL18,IL22, IL23, IL25, IL7, IL33, IL35, ITGB4, ITK, KIR, LAG3, LAMP1, leptin,LPFS2, MHC class II, MUC-1, MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1,OX40, OX40L, PD-1, PD-L1, PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC,SPG64, ST2, STEAP1, STEAP2, Syk kinase, STEAP1, TROP2, TACI, TDO,TGFBETA, T14, TIGIT, TIM3, TLR, TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa,TNFRSF7, Tp55, TREM1, TSLP, TSLPR, TWEAK, VEGF, VISTA, Vstm3, and WUCAM.For example, VL4 may specifically bind to at least one epitope on A2AR.For example, VL4 may specifically bind to at least one epitope on APRIL.For example, VL4 may specifically bind to at least one epitope onATPDase. For example, VL4 may specifically bind to at least one epitopeon BAFF. For example, VL4 may specifically bind to at least one epitopeon BAFFR. For example, VL4 may specifically bind to at least one epitopeon BCMA. For example, VL4 may specifically bind to at least one epitopeon BlyS. For example, VL4 may specifically bind to at least one epitopeon BTK. For example, VL4 may specifically bind to at least one epitopeon BTLA. For example, VL4 may specifically bind to at least one epitopeon B7DC. For example, VL4 may specifically bind to at least one epitopeon B7H1. For example, VL4 may specifically bind to at least one epitopeon B7H2. For example, VL4 may specifically bind to at least one epitopeon B7H3. For example, VL4 may specifically bind to at least one epitopeon B7H4. For example, VL4 may specifically bind to at least one epitopeon B7H5. For example, VL4 may specifically bind to at least one epitopeon B7H6. For example, VL4 may specifically bind to at least one epitopeon B7H7. For example, VL4 may specifically bind to at least one epitopeon B7RP1. For example, VL4 may specifically bind to at least one epitopeon B7-4. For example, VL4 may specifically bind to at least one epitopeon C3. For example, VL4 may specifically bind to at least one epitope onC5. For example, VL4 may specifically bind to at least one epitope onCCL2. For example, VL4 may specifically bind to at least one epitope onCCL3. For example, VL4 may specifically bind to at least one epitope onCCL4. For example, VL4 may specifically bind to at least one epitope onCCL5. For example, VL4 may specifically bind to at least one epitope onCCL7. For example, VL4 may specifically bind to at least one epitope onCCL8. For example, VL4 may specifically bind to at least one epitope onCCL11. For example, VL4 may specifically bind to at least one epitope onCCL15. For example, VL4 may specifically bind to at least one epitope onCCL17. For example, VL4 may specifically bind to at least one epitope onCCL19. For example, VL4 may specifically bind to at least one epitope onCCL20. For example, VL4 may specifically bind to at least one epitope onCCL21. For example, VL4 may specifically bind to at least one epitope onCCL25. For example, VL4 may specifically bind to at least one epitope onCCR3. For example, VL4 may specifically bind to at least one epitope onCCR4. For example, VL4 may specifically bind to at least one epitope onCD3. For example, VL4 may specifically bind to at least one epitope onCD19. For example, VL4 may specifically bind to at least one epitope onCD20. For example, VL4 may specifically bind to at least one epitope onCD24. For example, VL4 may specifically bind to at least one epitope onCD27. For example, VL4 may specifically bind to at least one epitope onCD28. For example, VL4 may specifically bind to at least one epitope onCD38. For example, VL4 may specifically bind to at least one epitope onCD39. For example, VL4 may specifically bind to at least one epitope onCD40. For example, VL4 may specifically bind to at least one epitope onCD40L. For example, VL4 may specifically bind to at least one epitope onCD47. For example, VL4 may specifically bind to at least one epitope onCD52. For example, VL4 may specifically bind to at least one epitope onCD70. For example, VL4 may specifically bind to at least one epitope onCD80. For example, VL4 may specifically bind to at least one epitope onCD86. For example, VL4 may specifically bind to at least one epitope onCD123. For example, VL4 may specifically bind to at least one epitope onCD133. For example, VL4 may specifically bind to at least one epitope onCD137. For example, VL4 may specifically bind to at least one epitope onCD137L. For example, VL4 may specifically bind to at least one epitopeon CD160. For example, VL4 may specifically bind to at least one epitopeon CD272. For example, VL4 may specifically bind to at least one epitopeon CEACAM5. For example, VL4 may specifically bind to at least oneepitope on CLEC9. For example, VL4 may specifically bind to at least oneepitope on CLEC91. For example, VL4 may specifically bind to at leastone epitope on CRTH2. For example, VL4 may specifically bind to at leastone epitope on CSF-1. For example, VL4 may specifically bind to at leastone epitope on CSF-2. For example, VL4 may specifically bind to at leastone epitope on CSF-3. For example, VL4 may specifically bind to at leastone epitope on CXCL1. For example, VL4 may specifically bind to at leastone epitope on CXCL2. For example, VL4 may specifically bind to at leastone epitope on CXCL4. For example, VL4 may specifically bind to at leastone epitope on CXCL12. For example, VL4 may specifically bind to atleast one epitope on CXCL13. For example, VL4 may specifically bind toat least one epitope on CXCR3. For example, VL4 may specifically bind toat least one epitope on cMet. For example, VL4 may specifically bind toat least one epitope on CTLA4. For example, VL4 may specifically bind toat least one epitope on DLL3. For example, VL4 may specifically bind toat least one epitope on DNGR-1. For example, VL4 may specifically bindto at least one epitope on E-cadherin. For example, VL4 may specificallybind to at least one epitope on EGFR. For example, VL4 may specificallybind to at least one epitope on ENTPD1. For example, VL4 mayspecifically bind to at least one epitope on EpCAM. For example, VL4 mayspecifically bind to at least one epitope on FCER1. For example, VL4 mayspecifically bind to at least one epitope on FCER1A. For example, VL4may specifically bind to at least one epitope on FCER2. For example, VL4may specifically bind to at least one epitope on FGFR. For example, VL4may specifically bind to at least one epitope on FLAP. For example, VL4may specifically bind to at least one epitope on FOLH1. For example, VL4may specifically bind to at least one epitope on Gi24. For example, VL4may specifically bind to at least one epitope on GITR. For example, VL4may specifically bind to at least one epitope on GITRL. For example, VL4may specifically bind to at least one epitope on GPR5. For example, VL4may specifically bind to at least one epitope on HER2. For example, VL4may specifically bind to at least one epitope on HER3. For example, VL4may specifically bind to at least one epitope on ICOSL. For example, VL4may specifically bind to at least one epitope on ICOS. For example, VL4may specifically bind to at least one epitope on HHLA2. For example, VL4may specifically bind to at least one epitope on HMGB1. For example, VL4may specifically bind to at least one epitope on HVEM. For example, VL4may specifically bind to at least one epitope on IDO. For example, VL4may specifically bind to at least one epitope on IFNa. For example, VL4may specifically bind to at least one epitope on IgE. For example, VL4may specifically bind to at least one epitope on IGF1R. For example, VL4may specifically bind to at least one epitope on IL2Rbeta. For example,VL4 may specifically bind to at least one epitope on ILL For example,VL4 may specifically bind to at least one epitope on ILIA. For example,VL4 may specifically bind to at least one epitope on IL1B. For example,VL4 may specifically bind to at least one epitope on IL1F10. Forexample, VL4 may specifically bind to at least one epitope on IL2. Forexample, VL4 may specifically bind to at least one epitope on IL4. Forexample, VL4 may specifically bind to at least one epitope on IL4Ra. Forexample, VL4 may specifically bind to at least one epitope on IL5. Forexample, VL4 may specifically bind to at least one epitope on IL5R. Forexample, VL4 may specifically bind to at least one epitope on IL6. Forexample, VL4 may specifically bind to at least one epitope on IL7. Forexample, VL4 may specifically bind to at least one epitope on IL7Ra. Forexample, VL4 may specifically bind to at least one epitope on IL8. Forexample, VL4 may specifically bind to at least one epitope on IL9. Forexample, VL4 may specifically bind to at least one epitope on IL9R. Forexample, VL4 may specifically bind to at least one epitope on IL10. Forexample, VL4 may specifically bind to at least one epitope on rhIL10.For example, VL4 may specifically bind to at least one epitope on IL12.For example, VL4 may specifically bind to at least one epitope on IL13.For example, VL4 may specifically bind to at least one epitope onIL13Ra1. For example, VL4 may specifically bind to at least one epitopeon IL13Ra2. For example, VL4 may specifically bind to at least oneepitope on IL15. For example, VL4 may specifically bind to at least oneepitope on IL17. For example, VL4 may specifically bind to at least oneepitope on IL17Rb. For example, VL4 may specifically bind to at leastone epitope on IL18. For example, VL4 may specifically bind to at leastone epitope on IL22. For example, VL4 may specifically bind to at leastone epitope on IL23. For example, VL4 may specifically bind to at leastone epitope on IL25. For example, VL4 may specifically bind to at leastone epitope on IL7. For example, VL4 may specifically bind to at leastone epitope on IL33. For example, VL4 may specifically bind to at leastone epitope on IL35. For example, VL4 may specifically bind to at leastone epitope on ITGB4. For example, VL4 may specifically bind to at leastone epitope on ITK. For example, VL4 may specifically bind to at leastone epitope on KIR. For example, VL4 may specifically bind to at leastone epitope on LAG3. For example, VL4 may specifically bind to at leastone epitope on LAMP 1. For example, VL4 may specifically bind to atleast one epitope on leptin. For example, VL4 may specifically bind toat least one epitope on LPFS2. For example, VL4 may specifically bind toat least one epitope on MHC class II. For example, VL4 may specificallybind to at least one epitope on MUC-1. For example, VL4 may specificallybind to at least one epitope on MUC-16. For example, VL4 mayspecifically bind to at least one epitope on NCR3LG1. For example, VL4may specifically bind to at least one epitope on NKG2D. For example, VL4may specifically bind to at least one epitope on NKp46. For example, VL4may specifically bind to at least one epitope on NTPDase-1. For example,VL4 may specifically bind to at least one epitope on OX40. For example,VL4 may specifically bind to at least one epitope on OX40L. For example,VL4 may specifically bind to at least one epitope on PD-1. For example,VL4 may specifically bind to at least one epitope on PD-L1. For example,VL4 may specifically bind to at least one epitope on PD-L2. For example,VL4 may specifically bind to at least one epitope on PROM1. For example,VL4 may specifically bind to at least one epitope on S152. For example,VL4 may specifically bind to at least one epitope on SIRPalpha. Forexample, VL4 may specifically bind to at least one epitope on SISP1. Forexample, VL4 may specifically bind to at least one epitope on SLC. Forexample, VL4 may specifically bind to at least one epitope on SPG64. Forexample, VL4 may specifically bind to at least one epitope on ST2. Forexample, VL4 may specifically bind to at least one epitope on STEAP1.For example, VL4 may specifically bind to at least one epitope onSTEAP2. For example, VL4 may specifically bind to at least one epitopeon Syk kinase. For example, VL4 may specifically bind to at least oneepitope on STEAP1. For example, VL4 may specifically bind to at leastone epitope on TROP2. For example, VL4 may specifically bind to at leastone epitope on TACI. For example, VL4 may specifically bind to at leastone epitope on TDO. For example, VL4 may specifically bind to at leastone epitope on T14. For example, VL4 may specifically bind to at leastone epitope on TIGIT. For example, VL4 may specifically bind to at leastone epitope on TIM3. For example, VL4 may specifically bind to at leastone epitope on TLR. For example, VL4 may specifically bind to at leastone epitope on TLR2. For example, VL4 may specifically bind to at leastone epitope on TLR4. For example, VL4 may specifically bind to at leastone epitope on TLR5. For example, VL4 may specifically bind to at leastone epitope on TLR9. For example, VL4 may specifically bind to at leastone epitope on TMEF1. For example, VL4 may specifically bind to at leastone epitope on TNFa. For example, VL4 may specifically bind to at leastone epitope on TNFRSF7. For example, VL4 may specifically bind to atleast one epitope on Tp55. For example, VL4 may specifically bind to atleast one epitope on TREM1. For example, VL4 may specifically bind to atleast one epitope on TSLP. For example, VL4 may specifically bind to atleast one epitope on TSLPR. For example, VL4 may specifically bind to atleast one epitope on TWEAK. For example, VL4 may specifically bind to atleast one epitope on VEGF. For example, VL4 may specifically bind to atleast one epitope on VISTA. For example, VL4 may specifically bind to atleast one epitope on Vstm3. For example, VL4 may specifically bind to atleast one epitope on WUCAM. For example, VL4 may specifically bind to atleast one epitope on CD16A. For example, VL4 may specifically bind to atleast one epitope on CD30. For example, VL4 may specifically bind to atleast one epitope on DLL4. For example, VL4 may specifically bind to atleast one epitope on GP100. For example, VL4 may specifically bind to atleast one epitope on GPRC5D. For example, VL4 may specifically bind toat least one epitope on TGFbeta.

In some aspects of an antigen binding polypeptide or antigen bindingpolypeptide complex of the invention, VH1 is a first immunoglobulinheavy chain variable region that specifically binds to at least oneepitope on at least one antigen selected from the group consisting ofA2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1,B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3,CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19, CCL20, CCL21, CCL25CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27, CD28, CD30, CD38, CD39,CD40, CD40L, CD47, CD52, CD70, CD80, CD86, CD123, CD133, CD137, CD137L,CD160, CD272, CEACAM5, CLEC9, CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1,CXCL2, CXCL4, CXCL12, CXCL13, CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1,E-cadherin, EGFR, ENTPD1, EpCAM, FCER1, FCER1A, FCER2, FGFR, FLAP,FOLH1, Gi24, GITR, GITRL, GPR5, GP100, GPRC5D, HER2, HER3, ICOSL, ICOS,HHLA2, HMGB1, HVEM, IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1, ILIA, IL1B,IL1F10, IL2, IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8, IL9, IL9R,IL10, rhIL1O, IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb, IL18,IL22, IL23, IL25, IL7, IL33, IL35, ITGB4, ITK, KIR, LAG3, LAMP1, leptin,LPFS2, MHC class II, MUC-1, MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1,OX40, OX40L, PD-1, PD-L1, PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC,SPG64, ST2, STEAP1, STEAP2, Syk kinase, STEAP1, TROP2, TACI, TDO,TGFBETA, T14, TIGIT, TIM3, TLR, TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa,TNFRSF7, Tp55, TREM1, TSLP, TSLPR, TWEAK, VEGF, VISTA, Vstm3, and WUCAM.For example, VH1 may specifically bind to at least one epitope on A2AR.For example, VH1 may specifically bind to at least one epitope on APRIL.For example, VH1 may specifically bind to at least one epitope onATPDase. For example, VH1 may specifically bind to at least one epitopeon BAFF. For example, VH1 may specifically bind to at least one epitopeon BAFFR. For example, VH1 may specifically bind to at least one epitopeon BCMA. For example, VH1 may specifically bind to at least one epitopeon BlyS. For example, VH1 may specifically bind to at least one epitopeon BTK. For example, VH1 may specifically bind to at least one epitopeon BTLA. For example, VH1 may specifically bind to at least one epitopeon B7DC. For example, VH1 may specifically bind to at least one epitopeon B7H1. For example, VH1 may specifically bind to at least one epitopeon B7H2. For example, VH1 may specifically bind to at least one epitopeon B7H3. For example, VH1 may specifically bind to at least one epitopeon B7H4. For example, VH1 may specifically bind to at least one epitopeon B7H5. For example, VH1 may specifically bind to at least one epitopeon B7H6. For example, VH1 may specifically bind to at least one epitopeon B7H7. For example, VH1 may specifically bind to at least one epitopeon B7RP1. For example, VH1 may specifically bind to at least one epitopeon B7-4. For example, VH1 may specifically bind to at least one epitopeon C3. For example, VH1 may specifically bind to at least one epitope onC5. For example, VH1 may specifically bind to at least one epitope onCCL2. For example, VH1 may specifically bind to at least one epitope onCCL3. For example, VH1 may specifically bind to at least one epitope onCCL4. For example, VH1 may specifically bind to at least one epitope onCCL5. For example, VH1 may specifically bind to at least one epitope onCCL7. For example, VH1 may specifically bind to at least one epitope onCCL8. For example, VH1 may specifically bind to at least one epitope onCCL11. For example, VH1 may specifically bind to at least one epitope onCCL15. For example, VH1 may specifically bind to at least one epitope onCCL17. For example, VH1 may specifically bind to at least one epitope onCCL19. For example, VH1 may specifically bind to at least one epitope onCCL20. For example, VH1 may specifically bind to at least one epitope onCCL21. For example, VH1 may specifically bind to at least one epitope onCCL25. For example, VH1 may specifically bind to at least one epitope onCCR3. For example, VH1 may specifically bind to at least one epitope onCCR4. For example, VH1 may specifically bind to at least one epitope onCD3. For example, VH1 may specifically bind to at least one epitope onCD19. For example, VH1 may specifically bind to at least one epitope onCD20. For example, VH1 may specifically bind to at least one epitope onCD24. For example, VH1 may specifically bind to at least one epitope onCD27. For example, VH1 may specifically bind to at least one epitope onCD28. For example, VH1 may specifically bind to at least one epitope onCD38. For example, VH1 may specifically bind to at least one epitope onCD39. For example, VH1 may specifically bind to at least one epitope onCD40. For example, VH1 may specifically bind to at least one epitope onCD40L. For example, VH1 may specifically bind to at least one epitope onCD47. For example, VH1 may specifically bind to at least one epitope onCD52. For example, VH1 may specifically bind to at least one epitope onCD70. For example, VH1 may specifically bind to at least one epitope onCD80. For example, VH1 may specifically bind to at least one epitope onCD86. For example, VH1 may specifically bind to at least one epitope onCD123. For example, VH1 may specifically bind to at least one epitope onCD133. For example, VH1 may specifically bind to at least one epitope onCD137. For example, VH1 may specifically bind to at least one epitope onCD137L. For example, VH1 may specifically bind to at least one epitopeon CD160. For example, VH1 may specifically bind to at least one epitopeon CD272. For example, VH1 may specifically bind to at least one epitopeon CEACAM5. For example, VH1 may specifically bind to at least oneepitope on CLEC9. For example, VH1 may specifically bind to at least oneepitope on CLEC91. For example, VH1 may specifically bind to at leastone epitope on CRTH2. For example, VH1 may specifically bind to at leastone epitope on CSF-1. For example, VH1 may specifically bind to at leastone epitope on CSF-2. For example, VH1 may specifically bind to at leastone epitope on CSF-3. For example, VH1 may specifically bind to at leastone epitope on CXCL1. For example, VH1 may specifically bind to at leastone epitope on CXCL2. For example, VH1 may specifically bind to at leastone epitope on CXCL4. For example, VH1 may specifically bind to at leastone epitope on CXCL12. For example, VH1 may specifically bind to atleast one epitope on CXCL13. For example, VH1 may specifically bind toat least one epitope on CXCR3. For example, VH1 may specifically bind toat least one epitope on cMet. For example, VH1 may specifically bind toat least one epitope on CTLA4. For example, VH1 may specifically bind toat least one epitope on DLL3. For example, VH1 may specifically bind toat least one epitope on DNGR-1. For example, VH1 may specifically bindto at least one epitope on E-cadherin. For example, VH1 may specificallybind to at least one epitope on EGFR. For example, VH1 may specificallybind to at least one epitope on ENTPD1. For example, VH1 mayspecifically bind to at least one epitope on EpCAM. For example, VH1 mayspecifically bind to at least one epitope on FCER1. For example, VH1 mayspecifically bind to at least one epitope on FCER1A. For example, VH1may specifically bind to at least one epitope on FCER2. For example, VH1may specifically bind to at least one epitope on FGFR. For example, VH1may specifically bind to at least one epitope on FLAP. For example, VH1may specifically bind to at least one epitope on FOLH1. For example, VH1may specifically bind to at least one epitope on Gi24. For example, VH1may specifically bind to at least one epitope on GITR. For example, VH1may specifically bind to at least one epitope on GITRL. For example, VH1may specifically bind to at least one epitope on GPR5. For example, VH1may specifically bind to at least one epitope on HER2. For example, VH1may specifically bind to at least one epitope on HER3. For example, VH1may specifically bind to at least one epitope on ICOSL. For example, VH1may specifically bind to at least one epitope on ICOS. For example, VH1may specifically bind to at least one epitope on HHLA2. For example, VH1may specifically bind to at least one epitope on HMGB1. For example, VH1may specifically bind to at least one epitope on HVEM. For example, VH1may specifically bind to at least one epitope on IDO. For example, VH1may specifically bind to at least one epitope on IFNa. For example, VH1may specifically bind to at least one epitope on IgE. For example, VH1may specifically bind to at least one epitope on IGF1R. For example, VH1may specifically bind to at least one epitope on IL2Rbeta. For example,VH1 may specifically bind to at least one epitope on ILL For example,VH1 may specifically bind to at least one epitope on ILIA. For example,VH1 may specifically bind to at least one epitope on IL1B. For example,VH1 may specifically bind to at least one epitope on IL1F10. Forexample, VH1 may specifically bind to at least one epitope on IL2. Forexample, VH1 may specifically bind to at least one epitope on IL4. Forexample, VH1 may specifically bind to at least one epitope on IL4Ra. Forexample, VH1 may specifically bind to at least one epitope on IL5. Forexample, VH1 may specifically bind to at least one epitope on IL5R. Forexample, VH1 may specifically bind to at least one epitope on IL6. Forexample, VH1 may specifically bind to at least one epitope on IL7. Forexample, VH1 may specifically bind to at least one epitope on IL7Ra. Forexample, VH1 may specifically bind to at least one epitope on IL8. Forexample, VH1 may specifically bind to at least one epitope on IL9. Forexample, VH1 may specifically bind to at least one epitope on IL9R. Forexample, VH1 may specifically bind to at least one epitope on IL10. Forexample, VH1 may specifically bind to at least one epitope on rhIL10.For example, VH1 may specifically bind to at least one epitope on IL12.For example, VH1 may specifically bind to at least one epitope on IL13.For example, VH1 may specifically bind to at least one epitope onIL13Ra1. For example, VH1 may specifically bind to at least one epitopeon IL13Ra2. For example, VH1 may specifically bind to at least oneepitope on IL15. For example, VH1 may specifically bind to at least oneepitope on IL17. For example, VH1 may specifically bind to at least oneepitope on IL17Rb. For example, VH1 may specifically bind to at leastone epitope on IL18. For example, VH1 may specifically bind to at leastone epitope on IL22. For example, VH1 may specifically bind to at leastone epitope on IL23. For example, VH1 may specifically bind to at leastone epitope on IL25. For example, VH1 may specifically bind to at leastone epitope on IL7. For example, VH1 may specifically bind to at leastone epitope on IL33. For example, VH1 may specifically bind to at leastone epitope on IL35. For example, VH1 may specifically bind to at leastone epitope on ITGB4. For example, VH1 may specifically bind to at leastone epitope on ITK. For example, VH1 may specifically bind to at leastone epitope on KIR. For example, VH1 may specifically bind to at leastone epitope on LAG3. For example, VH1 may specifically bind to at leastone epitope on LAMP1. For example, VH1 may specifically bind to at leastone epitope on leptin. For example, VH1 may specifically bind to atleast one epitope on LPFS2. For example, VH1 may specifically bind to atleast one epitope on MHC class II. For example, VH1 may specificallybind to at least one epitope on MUC-1. For example, VH1 may specificallybind to at least one epitope on MUC-16. For example, VH1 mayspecifically bind to at least one epitope on NCR3LG1. For example, VH1may specifically bind to at least one epitope on NKG2D. For example, VH1may specifically bind to at least one epitope on NKp46. For example, VH1may specifically bind to at least one epitope on NTPDase-1. For example,VH1 may specifically bind to at least one epitope on OX40. For example,VH1 may specifically bind to at least one epitope on OX40L. For example,VH1 may specifically bind to at least one epitope on PD-1. For example,VH1 may specifically bind to at least one epitope on PD-L1. For example,VH1 may specifically bind to at least one epitope on PD-L2. For example,VH1 may specifically bind to at least one epitope on PROM1. For example,VH1 may specifically bind to at least one epitope on S152. For example,VH1 may specifically bind to at least one epitope on SIRPalpha. Forexample, VH1 may specifically bind to at least one epitope on SISP1. Forexample, VH1 may specifically bind to at least one epitope on SLC. Forexample, VH1 may specifically bind to at least one epitope on SPG64. Forexample, VH1 may specifically bind to at least one epitope on ST2. Forexample, VH1 may specifically bind to at least one epitope on STEAP1.For example, VH1 may specifically bind to at least one epitope onSTEAP2. For example, VH1 may specifically bind to at least one epitopeon Syk kinase. For example, VH1 may specifically bind to at least oneepitope on STEAP1. For example, VH1 may specifically bind to at leastone epitope on TROP2. For example, VH1 may specifically bind to at leastone epitope on TACI. For example, VH1 may specifically bind to at leastone epitope on TDO. For example, VH1 may specifically bind to at leastone epitope on T14. For example, VH1 may specifically bind to at leastone epitope on TIGIT. For example, VH1 may specifically bind to at leastone epitope on TIM3. For example, VH1 may specifically bind to at leastone epitope on TLR. For example, VH1 may specifically bind to at leastone epitope on TLR2. For example, VH1 may specifically bind to at leastone epitope on TLR4. For example, VH1 may specifically bind to at leastone epitope on TLR5. For example, VH1 may specifically bind to at leastone epitope on TLR9. For example, VH1 may specifically bind to at leastone epitope on TMEF1. For example, VH1 may specifically bind to at leastone epitope on TNFa. For example, VH1 may specifically bind to at leastone epitope on TNFRSF7. For example, VH1 may specifically bind to atleast one epitope on Tp55. For example, VH1 may specifically bind to atleast one epitope on TREM1. For example, VH1 may specifically bind to atleast one epitope on TSLP. For example, VH1 may specifically bind to atleast one epitope on TSLPR. For example, VH1 may specifically bind to atleast one epitope on TWEAK. For example, VH1 may specifically bind to atleast one epitope on VEGF. For example, VH1 may specifically bind to atleast one epitope on VISTA. For example, VH1 may specifically bind to atleast one epitope on Vstm3. For example, VH1 may specifically bind to atleast one epitope on WUCAM. For example, VH1 may specifically bind to atleast one epitope on CD16A. For example, VH1 may specifically bind to atleast one epitope on CD30. For example, VH1 may specifically bind to atleast one epitope on DLL4. For example, VH1 may specifically bind to atleast one epitope on GP100. For example, VH1 may specifically bind to atleast one epitope on GPRC5D. For example, VH1 may specifically bind toat least one epitope on TGFbeta.

In some aspects of an antigen binding polypeptide or antigen bindingpolypeptide complex of the invention, VH2 is a second immunoglobulinheavy chain variable region that specifically binds to at least oneepitope on at least one antigen selected from the group consisting ofA2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1,B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3,CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19, CCL20, CCL21, CCL25CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27, CD28, CD30, CD38, CD39,CD40, CD40L, CD47, CD52, CD70, CD80, CD86, CD123, CD133, CD137, CD137L,CD160, CD272, CEACAM5, CLEC9, CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1,CXCL2, CXCL4, CXCL12, CXCL13, CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1,E-cadherin, EGFR, ENTPD1, EpCAM, FCER1, FCER1A, FCER2, FGFR, FLAP,FOLH1, Gi24, GITR, GITRL, GPR5, GP100, GPRC5D, HER2, HER3, ICOSL, ICOS,HHLA2, HMGB1, HVEM, IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1, ILIA, IL1B,IL1F10, IL2, IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8, IL9, IL9R,IL10, rhIL1O, IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb, IL18,IL22, IL23, IL25, IL7, IL33, IL35, ITGB4, ITK, KIR, LAG3, LAMP1, leptin,LPFS2, MHC class II, MUC-1, MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1,OX40, OX40L, PD-1, PD-L1, PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC,SPG64, ST2, STEAP1, STEAP2, Syk kinase, STEAP1, TROP2, TACI, TDO,TGFBETA, T14, TIGIT, TIM3, TLR, TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa,TNFRSF7, Tp55, TREM1, TSLP, TSLPR, TWEAK, VEGF, VISTA, Vstm3, and WUCAM.For example, VH2 may specifically bind to at least one epitope on A2AR.For example, VH2 may specifically bind to at least one epitope on APRIL.For example, VH2 may specifically bind to at least one epitope onATPDase. For example, VH2 may specifically bind to at least one epitopeon BAFF. For example, VH2 may specifically bind to at least one epitopeon BAFFR. For example, VH2 may specifically bind to at least one epitopeon BCMA. For example, VH2 may specifically bind to at least one epitopeon BlyS. For example, VH2 may specifically bind to at least one epitopeon BTK. For example, VH2 may specifically bind to at least one epitopeon BTLA. For example, VH2 may specifically bind to at least one epitopeon B7DC. For example, VH2 may specifically bind to at least one epitopeon B7H1. For example, VH2 may specifically bind to at least one epitopeon B7H2. For example, VH2 may specifically bind to at least one epitopeon B7H3. For example, VH2 may specifically bind to at least one epitopeon B7H4. For example, VH2 may specifically bind to at least one epitopeon B7H5. For example, VH2 may specifically bind to at least one epitopeon B7H6. For example, VH2 may specifically bind to at least one epitopeon B7H7. For example, VH2 may specifically bind to at least one epitopeon B7RP1. For example, VH2 may specifically bind to at least one epitopeon B7-4. For example, VH2 may specifically bind to at least one epitopeon C3. For example, VH2 may specifically bind to at least one epitope onC5. For example, VH2 may specifically bind to at least one epitope onCCL2. For example, VH2 may specifically bind to at least one epitope onCCL3. For example, VH2 may specifically bind to at least one epitope onCCL4. For example, VH2 may specifically bind to at least one epitope onCCL5. For example, VH2 may specifically bind to at least one epitope onCCL7. For example, VH2 may specifically bind to at least one epitope onCCL8. For example, VH2 may specifically bind to at least one epitope onCCL11. For example, VH2 may specifically bind to at least one epitope onCCL15. For example, VH2 may specifically bind to at least one epitope onCCL17. For example, VH2 may specifically bind to at least one epitope onCCL19. For example, VH2 may specifically bind to at least one epitope onCCL20. For example, VH2 may specifically bind to at least one epitope onCCL21. For example, VH2 may specifically bind to at least one epitope onCCL25. For example, VH2 may specifically bind to at least one epitope onCCR3. For example, VH2 may specifically bind to at least one epitope onCCR4. For example, VH2 may specifically bind to at least one epitope onCD3. For example, VH2 may specifically bind to at least one epitope onCD19. For example, VH2 may specifically bind to at least one epitope onCD20. For example, VH2 may specifically bind to at least one epitope onCD24. For example, VH2 may specifically bind to at least one epitope onCD27. For example, VH2 may specifically bind to at least one epitope onCD28. For example, VH2 may specifically bind to at least one epitope onCD38. For example, VH2 may specifically bind to at least one epitope onCD39. For example, VH2 may specifically bind to at least one epitope onCD40. For example, VH2 may specifically bind to at least one epitope onCD40L. For example, VH2 may specifically bind to at least one epitope onCD47. For example, VH2 may specifically bind to at least one epitope onCD52. For example, VH2 may specifically bind to at least one epitope onCD70. For example, VH2 may specifically bind to at least one epitope onCD80. For example, VH2 may specifically bind to at least one epitope onCD86. For example, VH2 may specifically bind to at least one epitope onCD123. For example, VH2 may specifically bind to at least one epitope onCD133. For example, VH2 may specifically bind to at least one epitope onCD137. For example, VH2 may specifically bind to at least one epitope onCD137L. For example, VH2 may specifically bind to at least one epitopeon CD160. For example, VH2 may specifically bind to at least one epitopeon CD272. For example, VH2 may specifically bind to at least one epitopeon CEACAM5. For example, VH2 may specifically bind to at least oneepitope on CLEC9. For example, VH2 may specifically bind to at least oneepitope on CLEC91. For example, VH2 may specifically bind to at leastone epitope on CRTH2. For example, VH2 may specifically bind to at leastone epitope on CSF-1. For example, VH2 may specifically bind to at leastone epitope on CSF-2. For example, VH2 may specifically bind to at leastone epitope on CSF-3. For example, VH2 may specifically bind to at leastone epitope on CXCL1. For example, VH2 may specifically bind to at leastone epitope on CXCL2. For example, VH2 may specifically bind to at leastone epitope on CXCL4. For example, VH2 may specifically bind to at leastone epitope on CXCL12. For example, VH2 may specifically bind to atleast one epitope on CXCL13. For example, VH2 may specifically bind toat least one epitope on CXCR3. For example, VH2 may specifically bind toat least one epitope on cMet. For example, VH2 may specifically bind toat least one epitope on CTLA4. For example, VH2 may specifically bind toat least one epitope on DLL3. For example, VH2 may specifically bind toat least one epitope on DNGR-1. For example, VH2 may specifically bindto at least one epitope on E-cadherin. For example, VH2 may specificallybind to at least one epitope on EGFR. For example, VH2 may specificallybind to at least one epitope on ENTPD1. For example, VH2 mayspecifically bind to at least one epitope on EpCAM. For example, VH2 mayspecifically bind to at least one epitope on FCER1. For example, VH2 mayspecifically bind to at least one epitope on FCER1A. For example, VH2may specifically bind to at least one epitope on FCER2. For example, VH2may specifically bind to at least one epitope on FGFR. For example, VH2may specifically bind to at least one epitope on FLAP. For example, VH2may specifically bind to at least one epitope on FOLH1. For example, VH2may specifically bind to at least one epitope on Gi24. For example, VH2may specifically bind to at least one epitope on GITR. For example, VH2may specifically bind to at least one epitope on GITRL. For example, VH2may specifically bind to at least one epitope on GPR5. For example, VH2may specifically bind to at least one epitope on HER2. For example, VH2may specifically bind to at least one epitope on HER3. For example, VH2may specifically bind to at least one epitope on ICOSL. For example, VH2may specifically bind to at least one epitope on ICOS. For example, VH2may specifically bind to at least one epitope on HHLA2. For example, VH2may specifically bind to at least one epitope on HMGB1. For example, VH2may specifically bind to at least one epitope on HVEM. For example, VH2may specifically bind to at least one epitope on IDO. For example, VH2may specifically bind to at least one epitope on IFNa. For example, VH2may specifically bind to at least one epitope on IgE. For example, VH2may specifically bind to at least one epitope on IGF1R. For example, VH2may specifically bind to at least one epitope on IL2Rbeta. For example,VH2 may specifically bind to at least one epitope on ILL For example,VH2 may specifically bind to at least one epitope on ILIA. For example,VH2 may specifically bind to at least one epitope on IL1B. For example,VH2 may specifically bind to at least one epitope on IL1F10. Forexample, VH2 may specifically bind to at least one epitope on IL2. Forexample, VH2 may specifically bind to at least one epitope on IL4. Forexample, VH2 may specifically bind to at least one epitope on IL4Ra. Forexample, VH2 may specifically bind to at least one epitope on IL5. Forexample, VH2 may specifically bind to at least one epitope on IL5R. Forexample, VH2 may specifically bind to at least one epitope on IL6. Forexample, VH2 may specifically bind to at least one epitope on IL7. Forexample, VH2 may specifically bind to at least one epitope on IL7Ra. Forexample, VH2 may specifically bind to at least one epitope on IL8. Forexample, VH2 may specifically bind to at least one epitope on IL9. Forexample, VH2 may specifically bind to at least one epitope on IL9R. Forexample, VH2 may specifically bind to at least one epitope on IL10. Forexample, VH2 may specifically bind to at least one epitope on rhIL10.For example, VH2 may specifically bind to at least one epitope on IL12.For example, VH2 may specifically bind to at least one epitope on IL13.For example, VH2 may specifically bind to at least one epitope onIL13Ra1. For example, VH2 may specifically bind to at least one epitopeon IL13Ra2. For example, VH2 may specifically bind to at least oneepitope on IL15. For example, VH2 may specifically bind to at least oneepitope on IL17. For example, VH2 may specifically bind to at least oneepitope on IL17Rb. For example, VH2 may specifically bind to at leastone epitope on IL18. For example, VH2 may specifically bind to at leastone epitope on IL22. For example, VH2 may specifically bind to at leastone epitope on IL23. For example, VH2 may specifically bind to at leastone epitope on IL25. For example, VH2 may specifically bind to at leastone epitope on IL7. For example, VH2 may specifically bind to at leastone epitope on IL33. For example, VH2 may specifically bind to at leastone epitope on IL35. For example, VH2 may specifically bind to at leastone epitope on ITGB4. For example, VH2 may specifically bind to at leastone epitope on ITK. For example, VH2 may specifically bind to at leastone epitope on KIR. For example, VH2 may specifically bind to at leastone epitope on LAG3. For example, VH2 may specifically bind to at leastone epitope on LAMP1. For example, VH2 may specifically bind to at leastone epitope on leptin. For example, VH2 may specifically bind to atleast one epitope on LPFS2. For example, VH2 may specifically bind to atleast one epitope on MHC class II. For example, VH2 may specificallybind to at least one epitope on MUC-1. For example, VH2 may specificallybind to at least one epitope on MUC-16. For example, VH2 mayspecifically bind to at least one epitope on NCR3LG1. For example, VH2may specifically bind to at least one epitope on NKG2D. For example, VH2may specifically bind to at least one epitope on NKp46. For example, VH2may specifically bind to at least one epitope on NTPDase-1. For example,VH2 may specifically bind to at least one epitope on OX40. For example,VH2 may specifically bind to at least one epitope on OX40L. For example,VH2 may specifically bind to at least one epitope on PD-1. For example,VH2 may specifically bind to at least one epitope on PD-L1. For example,VH2 may specifically bind to at least one epitope on PD-L2. For example,VH2 may specifically bind to at least one epitope on PROM1. For example,VH2 may specifically bind to at least one epitope on S152. For example,VH2 may specifically bind to at least one epitope on SIRPalpha. Forexample, VH2 may specifically bind to at least one epitope on SISP1. Forexample, VH2 may specifically bind to at least one epitope on SLC. Forexample, VH2 may specifically bind to at least one epitope on SPG64. Forexample, VH2 may specifically bind to at least one epitope on ST2. Forexample, VH2 may specifically bind to at least one epitope on STEAP1.For example, VH2 may specifically bind to at least one epitope onSTEAP2. For example, VH2 may specifically bind to at least one epitopeon Syk kinase. For example, VH2 may specifically bind to at least oneepitope on STEAP1. For example, VH2 may specifically bind to at leastone epitope on TROP2. For example, VH2 may specifically bind to at leastone epitope on TACI. For example, VH2 may specifically bind to at leastone epitope on TDO. For example, VH2 may specifically bind to at leastone epitope on T14. For example, VH2 may specifically bind to at leastone epitope on TIGIT. For example, VH2 may specifically bind to at leastone epitope on TIM3. For example, VH2 may specifically bind to at leastone epitope on TLR. For example, VH2 may specifically bind to at leastone epitope on TLR2. For example, VH2 may specifically bind to at leastone epitope on TLR4. For example, VH2 may specifically bind to at leastone epitope on TLR5. For example, VH2 may specifically bind to at leastone epitope on TLR9. For example, VH2 may specifically bind to at leastone epitope on TMEF1. For example, VH2 may specifically bind to at leastone epitope on TNFa. For example, VH2 may specifically bind to at leastone epitope on TNFRSF7. For example, VH2 may specifically bind to atleast one epitope on Tp55. For example, VH2 may specifically bind to atleast one epitope on TREM1. For example, VH2 may specifically bind to atleast one epitope on TSLP. For example, VH2 may specifically bind to atleast one epitope on TSLPR. For example, VH2 may specifically bind to atleast one epitope on TWEAK. For example, VH2 may specifically bind to atleast one epitope on VEGF. For example, VH2 may specifically bind to atleast one epitope on VISTA. For example, VH2 may specifically bind to atleast one epitope on Vstm3. For example, VH2 may specifically bind to atleast one epitope on WUCAM. For example, VH2 may specifically bind to atleast one epitope on CD16A. For example, VH2 may specifically bind to atleast one epitope on CD30. For example, VH2 may specifically bind to atleast one epitope on DLL4. For example, VH2 may specifically bind to atleast one epitope on GP100. For example, VH2 may specifically bind to atleast one epitope on GPRC5D. For example, VH2 may specifically bind toat least one epitope on TGFbeta.

In some aspects of an antigen binding polypeptide or antigen bindingpolypeptide complex of the invention, VH3 is a third immunoglobulinheavy chain variable region that specifically binds to at least oneepitope on at least one antigen selected from the group consisting ofA2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1,B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3,CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19, CCL20, CCL21, CCL25CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27, CD28, CD30, CD38, CD39,CD40, CD40L, CD47, CD52, CD70, CD80, CD86, CD123, CD133, CD137, CD137L,CD160, CD272, CEACAM5, CLEC9, CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1,CXCL2, CXCL4, CXCL12, CXCL13, CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1,E-cadherin, EGFR, ENTPD1, EpCAM, FCER1, FCER1A, FCER2, FGFR, FLAP,FOLH1, Gi24, GITR, GITRL, GPR5, GP100, GPRC5D, HER2, HER3, ICOSL, ICOS,HHLA2, HMGB1, HVEM, IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1, ILIA, IL1B,IL1F10, IL2, IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8, IL9, IL9R,IL10, rhIL1O, IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb, IL18,IL22, IL23, IL25, IL7, IL33, IL35, ITGB4, ITK, KIR, LAG3, LAMP1, leptin,LPFS2, MHC class II, MUC-1, MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1,OX40, OX40L, PD-1, PD-L1, PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC,SPG64, ST2, STEAP1, STEAP2, Syk kinase, STEAP1, TROP2, TACI, TDO,TGFBETA, T14, TIGIT, TIM3, TLR, TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa,TNFRSF7, Tp55, TREM1, TSLP, TSLPR, TWEAK, VEGF, VISTA, Vstm3, and WUCAM.For example, VH3 may specifically bind to at least one epitope on A2AR.For example, VH3 may specifically bind to at least one epitope on APRIL.For example, VH3 may specifically bind to at least one epitope onATPDase. For example, VH3 may specifically bind to at least one epitopeon BAFF. For example, VH3 may specifically bind to at least one epitopeon BAFFR. For example, VH3 may specifically bind to at least one epitopeon BCMA. For example, VH3 may specifically bind to at least one epitopeon BlyS. For example, VH3 may specifically bind to at least one epitopeon BTK. For example, VH3 may specifically bind to at least one epitopeon BTLA. For example, VH3 may specifically bind to at least one epitopeon B7DC. For example, VH3 may specifically bind to at least one epitopeon B7H1. For example, VH3 may specifically bind to at least one epitopeon B7H2. For example, VH3 may specifically bind to at least one epitopeon B7H3. For example, VH3 may specifically bind to at least one epitopeon B7H4. For example, VH3 may specifically bind to at least one epitopeon B7H5. For example, VH3 may specifically bind to at least one epitopeon B7H6. For example, VH3 may specifically bind to at least one epitopeon B7H7. For example, VH3 may specifically bind to at least one epitopeon B7RP1. For example, VH3 may specifically bind to at least one epitopeon B7-4. For example, VH3 may specifically bind to at least one epitopeon C3. For example, VH3 may specifically bind to at least one epitope onC5. For example, VH3 may specifically bind to at least one epitope onCCL2. For example, VH3 may specifically bind to at least one epitope onCCL3. For example, VH3 may specifically bind to at least one epitope onCCL4. For example, VH3 may specifically bind to at least one epitope onCCL5. For example, VH3 may specifically bind to at least one epitope onCCL7. For example, VH3 may specifically bind to at least one epitope onCCL8. For example, VH3 may specifically bind to at least one epitope onCCL11. For example, VH3 may specifically bind to at least one epitope onCCL15. For example, VH3 may specifically bind to at least one epitope onCCL17. For example, VH3 may specifically bind to at least one epitope onCCL19. For example, VH3 may specifically bind to at least one epitope onCCL20. For example, VH3 may specifically bind to at least one epitope onCCL21. For example, VH3 may specifically bind to at least one epitope onCCL25. For example, VH3 may specifically bind to at least one epitope onCCR3. For example, VH3 may specifically bind to at least one epitope onCCR4. For example, VH3 may specifically bind to at least one epitope onCD3. For example, VH3 may specifically bind to at least one epitope onCD19. For example, VH3 may specifically bind to at least one epitope onCD20. For example, VH3 may specifically bind to at least one epitope onCD24. For example, VH3 may specifically bind to at least one epitope onCD27. For example, VH3 may specifically bind to at least one epitope onCD28. For example, VH3 may specifically bind to at least one epitope onCD38. For example, VH3 may specifically bind to at least one epitope onCD39. For example, VH3 may specifically bind to at least one epitope onCD40. For example, VH3 may specifically bind to at least one epitope onCD40L. For example, VH3 may specifically bind to at least one epitope onCD47. For example, VH3 may specifically bind to at least one epitope onCD52. For example, VH3 may specifically bind to at least one epitope onCD70. For example, VH3 may specifically bind to at least one epitope onCD80. For example, VH3 may specifically bind to at least one epitope onCD86. For example, VH3 may specifically bind to at least one epitope onCD123. For example, VH3 may specifically bind to at least one epitope onCD133. For example, VH3 may specifically bind to at least one epitope onCD137. For example, VH3 may specifically bind to at least one epitope onCD137L. For example, VH3 may specifically bind to at least one epitopeon CD160. For example, VH3 may specifically bind to at least one epitopeon CD272. For example, VH3 may specifically bind to at least one epitopeon CEACAM5. For example, VH3 may specifically bind to at least oneepitope on CLEC9. For example, VH3 may specifically bind to at least oneepitope on CLEC91. For example, VH3 may specifically bind to at leastone epitope on CRTH2. For example, VH3 may specifically bind to at leastone epitope on CSF-1. For example, VH3 may specifically bind to at leastone epitope on CSF-2. For example, VH3 may specifically bind to at leastone epitope on CSF-3. For example, VH3 may specifically bind to at leastone epitope on CXCL1. For example, VH3 may specifically bind to at leastone epitope on CXCL2. For example, VH3 may specifically bind to at leastone epitope on CXCL4. For example, VH3 may specifically bind to at leastone epitope on CXCL12. For example, VH3 may specifically bind to atleast one epitope on CXCL13. For example, VH3 may specifically bind toat least one epitope on CXCR3. For example, VH3 may specifically bind toat least one epitope on cMet. For example, VH3 may specifically bind toat least one epitope on CTLA4. For example, VH3 may specifically bind toat least one epitope on DLL3. For example, VH3 may specifically bind toat least one epitope on DNGR-1. For example, VH3 may specifically bindto at least one epitope on E-cadherin. For example, VH3 may specificallybind to at least one epitope on EGFR. For example, VH3 may specificallybind to at least one epitope on ENTPD1. For example, VH3 mayspecifically bind to at least one epitope on EpCAM. For example, VH3 mayspecifically bind to at least one epitope on FCER1. For example, VH3 mayspecifically bind to at least one epitope on FCER1A. For example, VH3may specifically bind to at least one epitope on FCER2. For example, VH3may specifically bind to at least one epitope on FGFR. For example, VH3may specifically bind to at least one epitope on FLAP. For example, VH3may specifically bind to at least one epitope on FOLH1. For example, VH3may specifically bind to at least one epitope on Gi24. For example, VH3may specifically bind to at least one epitope on GITR. For example, VH3may specifically bind to at least one epitope on GITRL. For example, VH3may specifically bind to at least one epitope on GPR5. For example, VH3may specifically bind to at least one epitope on HER2. For example, VH3may specifically bind to at least one epitope on HER3. For example, VH3may specifically bind to at least one epitope on ICOSL. For example, VH3may specifically bind to at least one epitope on ICOS. For example, VH3may specifically bind to at least one epitope on HHLA2. For example, VH3may specifically bind to at least one epitope on HMGB1. For example, VH3may specifically bind to at least one epitope on HVEM. For example, VH3may specifically bind to at least one epitope on IDO. For example, VH3may specifically bind to at least one epitope on IFNa. For example, VH3may specifically bind to at least one epitope on IgE. For example, VH3may specifically bind to at least one epitope on IGF1R. For example, VH3may specifically bind to at least one epitope on IL2Rbeta. For example,VH3 may specifically bind to at least one epitope on ILL For example,VH3 may specifically bind to at least one epitope on ILIA. For example,VH3 may specifically bind to at least one epitope on IL1B. For example,VH3 may specifically bind to at least one epitope on IL1F10. Forexample, VH3 may specifically bind to at least one epitope on IL2. Forexample, VH3 may specifically bind to at least one epitope on IL4. Forexample, VH3 may specifically bind to at least one epitope on IL4Ra. Forexample, VH3 may specifically bind to at least one epitope on IL5. Forexample, VH3 may specifically bind to at least one epitope on IL5R. Forexample, VH3 may specifically bind to at least one epitope on IL6. Forexample, VH3 may specifically bind to at least one epitope on IL7. Forexample, VH3 may specifically bind to at least one epitope on IL7Ra. Forexample, VH3 may specifically bind to at least one epitope on IL8. Forexample, VH3 may specifically bind to at least one epitope on IL9. Forexample, VH3 may specifically bind to at least one epitope on IL9R. Forexample, VH3 may specifically bind to at least one epitope on IL10. Forexample, VH3 may specifically bind to at least one epitope on rhIL10.For example, VH3 may specifically bind to at least one epitope on IL12.For example, VH3 may specifically bind to at least one epitope on IL13.For example, VH3 may specifically bind to at least one epitope onIL13Ra1. For example, VH3 may specifically bind to at least one epitopeon IL13Ra2. For example, VH3 may specifically bind to at least oneepitope on IL15. For example, VH3 may specifically bind to at least oneepitope on IL17. For example, VH3 may specifically bind to at least oneepitope on IL17Rb. For example, VH3 may specifically bind to at leastone epitope on IL18. For example, VH3 may specifically bind to at leastone epitope on IL22. For example, VH3 may specifically bind to at leastone epitope on IL23. For example, VH3 may specifically bind to at leastone epitope on IL25. For example, VH3 may specifically bind to at leastone epitope on IL7. For example, VH3 may specifically bind to at leastone epitope on IL33. For example, VH3 may specifically bind to at leastone epitope on IL35. For example, VH3 may specifically bind to at leastone epitope on ITGB4. For example, VH3 may specifically bind to at leastone epitope on ITK. For example, VH3 may specifically bind to at leastone epitope on KIR. For example, VH3 may specifically bind to at leastone epitope on LAG3. For example, VH3 may specifically bind to at leastone epitope on LAMP1. For example, VH3 may specifically bind to at leastone epitope on leptin. For example, VH3 may specifically bind to atleast one epitope on LPFS2. For example, VH3 may specifically bind to atleast one epitope on MHC class II. For example, VH3 may specificallybind to at least one epitope on MUC-1. For example, VH3 may specificallybind to at least one epitope on MUC-16. For example, VH3 mayspecifically bind to at least one epitope on NCR3LG1. For example, VH3may specifically bind to at least one epitope on NKG2D. For example, VH3may specifically bind to at least one epitope on NKp46. For example, VH3may specifically bind to at least one epitope on NTPDase-1. For example,VH3 may specifically bind to at least one epitope on OX40. For example,VH3 may specifically bind to at least one epitope on OX40L. For example,VH3 may specifically bind to at least one epitope on PD-1. For example,VH3 may specifically bind to at least one epitope on PD-L1. For example,VH3 may specifically bind to at least one epitope on PD-L2. For example,VH3 may specifically bind to at least one epitope on PROM1. For example,VH3 may specifically bind to at least one epitope on S152. For example,VH3 may specifically bind to at least one epitope on SIRPalpha. Forexample, VH3 may specifically bind to at least one epitope on SISP1. Forexample, VH3 may specifically bind to at least one epitope on SLC. Forexample, VH3 may specifically bind to at least one epitope on SPG64. Forexample, VH3 may specifically bind to at least one epitope on ST2. Forexample, VH3 may specifically bind to at least one epitope on STEAP1.For example, VH3 may specifically bind to at least one epitope onSTEAP2. For example, VH3 may specifically bind to at least one epitopeon Syk kinase. For example, VH3 may specifically bind to at least oneepitope on STEAP1. For example, VH3 may specifically bind to at leastone epitope on TROP2. For example, VH3 may specifically bind to at leastone epitope on TACI. For example, VH3 may specifically bind to at leastone epitope on TDO. For example, VH3 may specifically bind to at leastone epitope on T14. For example, VH3 may specifically bind to at leastone epitope on TIGIT. For example, VH3 may specifically bind to at leastone epitope on TIM3. For example, VH3 may specifically bind to at leastone epitope on TLR. For example, VH3 may specifically bind to at leastone epitope on TLR2. For example, VH3 may specifically bind to at leastone epitope on TLR4. For example, VH3 may specifically bind to at leastone epitope on TLR5. For example, VH3 may specifically bind to at leastone epitope on TLR9. For example, VH3 may specifically bind to at leastone epitope on TMEF1. For example, VH3 may specifically bind to at leastone epitope on TNFa. For example, VH3 may specifically bind to at leastone epitope on TNFRSF7. For example, VH3 may specifically bind to atleast one epitope on Tp55. For example, VH3 may specifically bind to atleast one epitope on TREM1. For example, VH3 may specifically bind to atleast one epitope on TSLP. For example, VH3 may specifically bind to atleast one epitope on TSLPR. For example, VH3 may specifically bind to atleast one epitope on TWEAK. For example, VH3 may specifically bind to atleast one epitope on VEGF. For example, VH3 may specifically bind to atleast one epitope on VISTA. For example, VH3 may specifically bind to atleast one epitope on Vstm3. For example, VH3 may specifically bind to atleast one epitope on WUCAM. For example, VH3 may specifically bind to atleast one epitope on CD16A. For example, VH3 may specifically bind to atleast one epitope on CD30. For example, VH3 may specifically bind to atleast one epitope on DLL4. For example, VH3 may specifically bind to atleast one epitope on GP100. For example, VH3 may specifically bind to atleast one epitope on GPRC5D. For example, VH3 may specifically bind toat least one epitope on TGFbeta.

In some aspects of an antigen binding polypeptide or antigen bindingpolypeptide complex of the invention, VH4 is a fourth immunoglobulinheavy chain variable region that specifically binds to at least oneepitope on at least one antigen selected from the group consisting ofA2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1,B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3,CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19, CCL20, CCL21, CCL25CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27, CD28, CD30, CD38, CD39,CD40, CD40L, CD47, CD52, CD70, CD80, CD86, CD123, CD133, CD137, CD137L,CD160, CD272, CEACAM5, CLEC9, CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1,CXCL2, CXCL4, CXCL12, CXCL13, CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1,E-cadherin, EGFR, ENTPD1, EpCAM, FCER1, FCER1A, FCER2, FGFR, FLAP,FOLH1, Gi24, GITR, GITRL, GPR5, GP100, GPRC5D, HER2, HER3, ICOSL, ICOS,HHLA2, HMGB1, HVEM, IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1, ILIA, IL1B,IL1F10, IL2, IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8, IL9, IL9R,IL10, rhIL1O, IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb, IL18,IL22, IL23, IL25, IL7, IL33, IL35, ITGB4, ITK, KIR, LAG3, LAMP1, leptin,LPFS2, MHC class II, MUC-1, MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1,OX40, OX40L, PD-1, PD-L1, PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC,SPG64, ST2, STEAP1, STEAP2, Syk kinase, STEAP1, TROP2, TACI, TDO,TGFBETA, T14, TIGIT, TIM3, TLR, TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa,TNFRSF7, Tp55, TREM1, TSLP, TSLPR, TWEAK, VEGF, VISTA, Vstm3, and WUCAM.For example, VH4 may specifically bind to at least one epitope on A2AR.For example, VH4 may specifically bind to at least one epitope on APRIL.For example, VH4 may specifically bind to at least one epitope onATPDase. For example, VH4 may specifically bind to at least one epitopeon BAFF. For example, VH4 may specifically bind to at least one epitopeon BAFFR. For example, VH4 may specifically bind to at least one epitopeon BCMA. For example, VH4 may specifically bind to at least one epitopeon BlyS. For example, VH4 may specifically bind to at least one epitopeon BTK. For example, VH4 may specifically bind to at least one epitopeon BTLA. For example, VH4 may specifically bind to at least one epitopeon B7DC. For example, VH4 may specifically bind to at least one epitopeon B7H1. For example, VH4 may specifically bind to at least one epitopeon B7H2. For example, VH4 may specifically bind to at least one epitopeon B7H3. For example, VH4 may specifically bind to at least one epitopeon B7H4. For example, VH4 may specifically bind to at least one epitopeon B7H5. For example, VH4 may specifically bind to at least one epitopeon B7H6. For example, VH4 may specifically bind to at least one epitopeon B7H7. For example, VH4 may specifically bind to at least one epitopeon B7RP1. For example, VH4 may specifically bind to at least one epitopeon B7-4. For example, VH4 may specifically bind to at least one epitopeon C3. For example, VH4 may specifically bind to at least one epitope onC5. For example, VH4 may specifically bind to at least one epitope onCCL2. For example, VH4 may specifically bind to at least one epitope onCCL3. For example, VH4 may specifically bind to at least one epitope onCCL4. For example, VH4 may specifically bind to at least one epitope onCCL5. For example, VH4 may specifically bind to at least one epitope onCCL7. For example, VH4 may specifically bind to at least one epitope onCCL8. For example, VH4 may specifically bind to at least one epitope onCCL11. For example, VH4 may specifically bind to at least one epitope onCCL15. For example, VH4 may specifically bind to at least one epitope onCCL17. For example, VH4 may specifically bind to at least one epitope onCCL19. For example, VH4 may specifically bind to at least one epitope onCCL20. For example, VH4 may specifically bind to at least one epitope onCCL21. For example, VH4 may specifically bind to at least one epitope onCCL25. For example, VH4 may specifically bind to at least one epitope onCCR3. For example, VH4 may specifically bind to at least one epitope onCCR4. For example, VH4 may specifically bind to at least one epitope onCD3. For example, VH4 may specifically bind to at least one epitope onCD19. For example, VH4 may specifically bind to at least one epitope onCD20. For example, VH4 may specifically bind to at least one epitope onCD24. For example, VH4 may specifically bind to at least one epitope onCD27. For example, VH4 may specifically bind to at least one epitope onCD28. For example, VH4 may specifically bind to at least one epitope onCD38. For example, VH4 may specifically bind to at least one epitope onCD39. For example, VH4 may specifically bind to at least one epitope onCD40. For example, VH4 may specifically bind to at least one epitope onCD40L. For example, VH4 may specifically bind to at least one epitope onCD47. For example, VH4 may specifically bind to at least one epitope onCD52. For example, VH4 may specifically bind to at least one epitope onCD70. For example, VH4 may specifically bind to at least one epitope onCD80. For example, VH4 may specifically bind to at least one epitope onCD86. For example, VH4 may specifically bind to at least one epitope onCD123. For example, VH4 may specifically bind to at least one epitope onCD133. For example, VH4 may specifically bind to at least one epitope onCD137. For example, VH4 may specifically bind to at least one epitope onCD137L. For example, VH4 may specifically bind to at least one epitopeon CD160. For example, VH4 may specifically bind to at least one epitopeon CD272. For example, VH4 may specifically bind to at least one epitopeon CEACAM5. For example, VH4 may specifically bind to at least oneepitope on CLEC9. For example, VH4 may specifically bind to at least oneepitope on CLEC91. For example, VH4 may specifically bind to at leastone epitope on CRTH2. For example, VH4 may specifically bind to at leastone epitope on CSF-1. For example, VH4 may specifically bind to at leastone epitope on CSF-2. For example, VH4 may specifically bind to at leastone epitope on CSF-3. For example, VH4 may specifically bind to at leastone epitope on CXCL1. For example, VH4 may specifically bind to at leastone epitope on CXCL2. For example, VH4 may specifically bind to at leastone epitope on CXCL4. For example, VH4 may specifically bind to at leastone epitope on CXCL12. For example, VH4 may specifically bind to atleast one epitope on CXCL13. For example, VH4 may specifically bind toat least one epitope on CXCR3. For example, VH4 may specifically bind toat least one epitope on cMet. For example, VH4 may specifically bind toat least one epitope on CTLA4. For example, VH4 may specifically bind toat least one epitope on DLL3. For example, VH4 may specifically bind toat least one epitope on DNGR-1. For example, VH4 may specifically bindto at least one epitope on E-cadherin. For example, VH4 may specificallybind to at least one epitope on EGFR. For example, VH4 may specificallybind to at least one epitope on ENTPD1. For example, VH4 mayspecifically bind to at least one epitope on EpCAM. For example, VH4 mayspecifically bind to at least one epitope on FCER1. For example, VH4 mayspecifically bind to at least one epitope on FCER1A. For example, VH4may specifically bind to at least one epitope on FCER2. For example, VH4may specifically bind to at least one epitope on FGFR. For example, VH4may specifically bind to at least one epitope on FLAP. For example, VH4may specifically bind to at least one epitope on FOLH1. For example, VH4may specifically bind to at least one epitope on Gi24. For example, VH4may specifically bind to at least one epitope on GITR. For example, VH4may specifically bind to at least one epitope on GITRL. For example, VH4may specifically bind to at least one epitope on GPR5. For example, VH4may specifically bind to at least one epitope on HER2. For example, VH4may specifically bind to at least one epitope on HER3. For example, VH4may specifically bind to at least one epitope on ICOSL. For example, VH4may specifically bind to at least one epitope on ICOS. For example, VH4may specifically bind to at least one epitope on HHLA2. For example, VH4may specifically bind to at least one epitope on HMGB1. For example, VH4may specifically bind to at least one epitope on HVEM. For example, VH4may specifically bind to at least one epitope on IDO. For example, VH4may specifically bind to at least one epitope on IFNa. For example, VH4may specifically bind to at least one epitope on IgE. For example, VH4may specifically bind to at least one epitope on IGF1R. For example, VH4may specifically bind to at least one epitope on IL2Rbeta. For example,VH4 may specifically bind to at least one epitope on ILL For example,VH4 may specifically bind to at least one epitope on ILIA. For example,VH4 may specifically bind to at least one epitope on IL1B. For example,VH4 may specifically bind to at least one epitope on IL1F10. Forexample, VH4 may specifically bind to at least one epitope on IL2. Forexample, VH4 may specifically bind to at least one epitope on IL4. Forexample, VH4 may specifically bind to at least one epitope on IL4Ra. Forexample, VH4 may specifically bind to at least one epitope on IL5. Forexample, VH4 may specifically bind to at least one epitope on IL5R. Forexample, VH4 may specifically bind to at least one epitope on IL6. Forexample, VH4 may specifically bind to at least one epitope on IL7. Forexample, VH4 may specifically bind to at least one epitope on IL7Ra. Forexample, VH4 may specifically bind to at least one epitope on IL8. Forexample, VH4 may specifically bind to at least one epitope on IL9. Forexample, VH4 may specifically bind to at least one epitope on IL9R. Forexample, VH4 may specifically bind to at least one epitope on IL10. Forexample, VH4 may specifically bind to at least one epitope on rhIL10.For example, VH4 may specifically bind to at least one epitope on IL12.For example, VH4 may specifically bind to at least one epitope on IL13.For example, VH4 may specifically bind to at least one epitope onIL13Ra1. For example, VH4 may specifically bind to at least one epitopeon IL13Ra2. For example, VH4 may specifically bind to at least oneepitope on IL15. For example, VH4 may specifically bind to at least oneepitope on IL17. For example, VH4 may specifically bind to at least oneepitope on IL17Rb. For example, VH4 may specifically bind to at leastone epitope on IL18. For example, VH4 may specifically bind to at leastone epitope on IL22. For example, VH4 may specifically bind to at leastone epitope on IL23. For example, VH4 may specifically bind to at leastone epitope on IL25. For example, VH4 may specifically bind to at leastone epitope on IL7. For example, VH4 may specifically bind to at leastone epitope on IL33. For example, VH4 may specifically bind to at leastone epitope on IL35. For example, VH4 may specifically bind to at leastone epitope on ITGB4. For example, VH4 may specifically bind to at leastone epitope on ITK. For example, VH4 may specifically bind to at leastone epitope on KIR. For example, VH4 may specifically bind to at leastone epitope on LAG3. For example, VH4 may specifically bind to at leastone epitope on LAMP1. For example, VH4 may specifically bind to at leastone epitope on leptin. For example, VH4 may specifically bind to atleast one epitope on LPFS2. For example, VH4 may specifically bind to atleast one epitope on MHC class II. For example, VH4 may specificallybind to at least one epitope on MUC-1. For example, VH4 may specificallybind to at least one epitope on MUC-16. For example, VH4 mayspecifically bind to at least one epitope on NCR3LG1. For example, VH4may specifically bind to at least one epitope on NKG2D. For example, VH4may specifically bind to at least one epitope on NKp46. For example, VH4may specifically bind to at least one epitope on NTPDase-1. For example,VH4 may specifically bind to at least one epitope on OX40. For example,VH4 may specifically bind to at least one epitope on OX40L. For example,VH4 may specifically bind to at least one epitope on PD-1. For example,VH4 may specifically bind to at least one epitope on PD-L1. For example,VH4 may specifically bind to at least one epitope on PD-L2. For example,VH4 may specifically bind to at least one epitope on PROM1. For example,VH4 may specifically bind to at least one epitope on S152. For example,VH4 may specifically bind to at least one epitope on SIRPalpha. Forexample, VH4 may specifically bind to at least one epitope on SISP1. Forexample, VH4 may specifically bind to at least one epitope on SLC. Forexample, VH4 may specifically bind to at least one epitope on SPG64. Forexample, VH4 may specifically bind to at least one epitope on ST2. Forexample, VH4 may specifically bind to at least one epitope on STEAP1.For example, VH4 may specifically bind to at least one epitope onSTEAP2. For example, VH4 may specifically bind to at least one epitopeon Syk kinase. For example, VH4 may specifically bind to at least oneepitope on STEAP1. For example, VH4 may specifically bind to at leastone epitope on TROP2. For example, VH4 may specifically bind to at leastone epitope on TACI. For example, VH4 may specifically bind to at leastone epitope on TDO. For example, VH4 may specifically bind to at leastone epitope on T14. For example, VH4 may specifically bind to at leastone epitope on TIGIT. For example, VH4 may specifically bind to at leastone epitope on TIM3. For example, VH4 may specifically bind to at leastone epitope on TLR. For example, VH4 may specifically bind to at leastone epitope on TLR2. For example, VH4 may specifically bind to at leastone epitope on TLR4. For example, VH4 may specifically bind to at leastone epitope on TLR5. For example, VH4 may specifically bind to at leastone epitope on TLR9. For example, VH4 may specifically bind to at leastone epitope on TMEF1. For example, VH4 may specifically bind to at leastone epitope on TNFa. For example, VH4 may specifically bind to at leastone epitope on TNFRSF7. For example, VH4 may specifically bind to atleast one epitope on Tp55. For example, VH4 may specifically bind to atleast one epitope on TREM1. For example, VH4 may specifically bind to atleast one epitope on TSLP. For example, VH4 may specifically bind to atleast one epitope on TSLPR. For example, VH4 may specifically bind to atleast one epitope on TWEAK. For example, VH4 may specifically bind to atleast one epitope on VEGF. For example, VH4 may specifically bind to atleast one epitope on VISTA. For example, VH4 may specifically bind to atleast one epitope on Vstm3. For example, VH4 may specifically bind to atleast one epitope on WUCAM. For example, VH4 may specifically bind to atleast one epitope on CD16A. For example, VH4 may specifically bind to atleast one epitope on CD30. For example, VH4 may specifically bind to atleast one epitope on DLL4. For example, VH4 may specifically bind to atleast one epitope on GP100. For example, VH4 may specifically bind to atleast one epitope on GPRC5D. For example, VH4 may specifically bind toat least one epitope on TGFbeta.

In other aspects of an antigen binding polypeptide or antigen bindingpolypeptide complex of the invention, VL1 is a first immunoglobulinlight chain variable region that specifically binds to at least oneepitope on at least one antigen selected from the group consisting ofhuman A2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC,B7H1, B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2,CCL3, CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19, CCL20, CCL21,CCL25 CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27, CD28, CD30, CD38,CD39, CD40, CD40L, CD47, CD52, CD70, CD80, CD86, CD123, CD133, CD137,CD137L, CD160, CD272, CEACAM5, CLEC9, CLEC91, CRTH2, CSF-1, CSF-2,CSF-3, CXCL1, CXCL2, CXCL4, CXCL12, CXCL13, CXCR3, cMet, CTLA4, DLL3,DLL4, DNGR-1, E-cadherin, EGFR, ENTPD1, EpCAM, FCER1, FCER1A, FCER2,FGFR, FLAP, FOLH1, Gi24, GITR, GITRL, GPR5, GP100, GPRC5D, HER2, HER3,ICOSL, ICOS, HHLA2, HMGB1, HVEM, IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1,ILIA, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8,IL9, IL9R, IL10, rhIL1O, IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17,IL17Rb, IL18, IL22, IL23, IL25, IL7, IL33, IL35, ITGB4, ITK, KIR, LAG3,LAMP1, leptin, LPFS2, MHC class II, MUC-1, MUC-16, NCR3LG1, NKG2D,NKp46, NTPDase-1, OX40, OX40L, PD-1, PD-L1, PD-L2, PROM1, S152,SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1, STEAP2, Syk kinase, STEAP1,TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3, TLR, TLR2, TLR4, TLR5,TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP, TSLPR, TWEAK, VEGF,VISTA, Vstm3, and WUCAM; VL2 is a second immunoglobulin light chainvariable region that specifically binds to at least one epitope on atleast one antigen selected from the group consisting of A2AR, APRIL,ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1, B7H2, B7H3,B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3, CCL4, CCL5,CCL7, CCL8, CCL11, CCL15, CCL17, CCL19, CCL20, CCL21, CCL25 CCR3, CCR4,CD3, CD16A, CD19, CD20, CD24, CD27, CD28, CD30, CD38, CD39, CD40, CD40L,CD47, CD52, CD70, CD80, CD86, CD123, CD133, CD137, CD137L, CD160, CD272,CEACAM5, CLEC9, CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4,CXCL12, CXCL13, CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin,EGFR, ENTPD1, EpCAM, FCER1, FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24,GITR, GITRL, GPR5, GP100, GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1,HVEM, IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2,IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O,IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23,IL25, IL7, IL33, IL35, ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHCclass II, MUC-1, MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L,PD-1, PD-L1, PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2,STEAP1, STEAP2, Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14,TIGIT, TIM3, TLR, TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55,TREM1, TSLP, TSLPR, TWEAK, VEGF, VISTA, Vstm3, and WUCAM; VL3 is a thirdimmunoglobulin light chain variable region that specifically binds to atleast one epitope on at least one antigen selected from the groupconsisting of A2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA,B7DC, B7H1, B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5,CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19, CCL20,CCL21, CCL25 CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27, CD28, CD30,CD38, CD39, CD40, CD40L, CD47, CD52, CD70, CD80, CD86, CD123, CD133,CD137, CD137L, CD160, CD272, CEACAM5, CLEC9, CLEC91, CRTH2, CSF-1,CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12, CXCL13, CXCR3, cMet, CTLA4,DLL3, DLL4, DNGR-1, E-cadherin, EGFR, ENTPD1, EpCAM, FCER1, FCER1A,FCER2, FGFR, FLAP, FOLH1, Gi24, GITR, GITRL, GPR5, GP100, GPRC5D, HER2,HER3, ICOSL, ICOS, HHLA2, HMGB1, HVEM, IDO, IFNa, IgE, IGF1R, IL2Rbeta,IL1, ILIA, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra,IL8, IL9, IL9R, IL10, rhIL1O, IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17,IL17Rb, IL18, IL22, IL23, IL25, IL7, IL33, IL35, ITGB4, ITK, KIR, LAG3,LAMP1, leptin, LPFS2, MHC class II, MUC-1, MUC-16, NCR3LG1, NKG2D,NKp46, NTPDase-1, OX40, OX40L, PD-1, PD-L1, PD-L2, PROM1, S152,SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1, STEAP2, Syk kinase, STEAP1,TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3, TLR, TLR2, TLR4, TLR5,TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP, TSLPR, TWEAK, VEGF,VISTA, Vstm3, and WUCAM; VL4 is a fourth immunoglobulin light chainvariable region that specifically binds to at least one epitope on atleast one antigen selected from the group consisting of A2AR, APRIL,ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1, B7H2, B7H3,B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3, CCL4, CCL5,CCL7, CCL8, CCL11, CCL15, CCL17, CCL19, CCL20, CCL21, CCL25 CCR3, CCR4,CD3, CD16A, CD19, CD20, CD24, CD27, CD28, CD30, CD38, CD39, CD40, CD40L,CD47, CD52, CD70, CD80, CD86, CD123, CD133, CD137, CD137L, CD160, CD272,CEACAM5, CLEC9, CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4,CXCL12, CXCL13, CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin,EGFR, ENTPD1, EpCAM, FCER1, FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24,GITR, GITRL, GPR5, GP100, GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1,HVEM, IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2,IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O,IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23,IL25, IL7, IL33, IL35, ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHCclass II, MUC-1, MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L,PD-1, PD-L1, PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2,STEAP1, STEAP2, Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14,TIGIT, TIM3, TLR, TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55,TREM1, TSLP, TSLPR, TWEAK, VEGF, VISTA, Vstm3, and WUCAM; VH1 is a firstimmunoglobulin heavy chain variable region that specifically binds to atleast one epitope on at least one antigen selected from the groupconsisting of A2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA,B7DC, B7H1, B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5,CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19, CCL20,CCL21, CCL25 CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27, CD28, CD30,CD38, CD39, CD40, CD40L, CD47, CD52, CD70, CD80, CD86, CD123, CD133,CD137, CD137L, CD160, CD272, CEACAM5, CLEC9, CLEC91, CRTH2, CSF-1,CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12, CXCL13, CXCR3, cMet, CTLA4,DLL3, DLL4, DNGR-1, E-cadherin, EGFR, ENTPD1, EpCAM, FCER1, FCER1A,FCER2, FGFR, FLAP, FOLH1, Gi24, GITR, GITRL, GPR5, GP100, GPRC5D, HER2,HER3, ICOSL, ICOS, HHLA2, HMGB1, HVEM, IDO, IFNa, IgE, IGF1R, IL2Rbeta,IL1, ILIA, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra,IL8, IL9, IL9R, IL10, rhIL1O, IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17,IL17Rb, IL18, IL22, IL23, IL25, IL7, IL33, IL35, ITGB4, ITK, KIR, LAG3,LAMP1, leptin, LPFS2, MHC class II, MUC-1, MUC-16, NCR3LG1, NKG2D,NKp46, NTPDase-1, OX40, OX40L, PD-1, PD-L1, PD-L2, PROM1, S152,SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1, STEAP2, Syk kinase, STEAP1,TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3, TLR, TLR2, TLR4, TLR5,TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP, TSLPR, TWEAK, VEGF,VISTA, Vstm3, and WUCAM; VH2 is a second immunoglobulin heavy chainvariable region that specifically binds to at least one epitope on atleast one antigen selected from the group consisting of A2AR, APRIL,ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1, B7H2, B7H3,B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3, CCL4, CCL5,CCL7, CCL8, CCL11, CCL15, CCL17, CCL19, CCL20, CCL21, CCL25 CCR3, CCR4,CD3, CD16A, CD19, CD20, CD24, CD27, CD28, CD30, CD38, CD39, CD40, CD40L,CD47, CD52, CD70, CD80, CD86, CD123, CD133, CD137, CD137L, CD160, CD272,CEACAM5, CLEC9, CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4,CXCL12, CXCL13, CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin,EGFR, ENTPD1, EpCAM, FCER1, FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24,GITR, GITRL, GPR5, GP100, GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1,HVEM, IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2,IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O,IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23,IL25, IL7, IL33, IL35, ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHCclass II, MUC-1, MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L,PD-1, PD-L1, PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2,STEAP1, STEAP2, Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14,TIGIT, TIM3, TLR, TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55,TREM1, TSLP, TSLPR, TWEAK, VEGF, VISTA, Vstm3, and WUCAM; VH3 is a thirdimmunoglobulin heavy chain variable region that specifically binds to atleast one epitope on at least one antigen selected from the groupconsisting of A2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA,B7DC, B7H1, B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5,CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19, CCL20,CCL21, CCL25 CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27, CD28, CD30,CD38, CD39, CD40, CD40L, CD47, CD52, CD70, CD80, CD86, CD123, CD133,CD137, CD137L, CD160, CD272, CEACAM5, CLEC9, CLEC91, CRTH2, CSF-1,CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12, CXCL13, CXCR3, cMet, CTLA4,DLL3, DLL4, DNGR-1, E-cadherin, EGFR, ENTPD1, EpCAM, FCER1, FCER1A,FCER2, FGFR, FLAP, FOLH1, Gi24, GITR, GITRL, GPR5, GP100, GPRC5D, HER2,HER3, ICOSL, ICOS, HHLA2, HMGB1, HVEM, IDO, IFNa, IgE, IGF1R, IL2Rbeta,IL1, ILIA, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra,IL8, IL9, IL9R, IL10, rhIL1O, IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17,IL17Rb, IL18, IL22, IL23, IL25, IL7, IL33, IL35, ITGB4, ITK, KIR, LAG3,LAMP1, leptin, LPFS2, MHC class II, MUC-1, MUC-16, NCR3LG1, NKG2D,NKp46, NTPDase-1, OX40, OX40L, PD-1, PD-L1, PD-L2, PROM1, S152,SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1, STEAP2, Syk kinase, STEAP1,TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3, TLR, TLR2, TLR4, TLR5,TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP, TSLPR, TWEAK, VEGF,VISTA, Vstm3, and WUCAM; and VH4 is a fourth immunoglobulin heavy chainvariable region that specifically binds to at least one epitope on atleast one antigen selected from the group consisting of A2AR, APRIL,ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1, B7H2, B7H3,B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3, CCL4, CCL5,CCL7, CCL8, CCL11, CCL15, CCL17, CCL19, CCL20, CCL21, CCL25 CCR3, CCR4,CD3, CD16A, CD19, CD20, CD24, CD27, CD28, CD30, CD38, CD39, CD40, CD40L,CD47, CD52, CD70, CD80, CD86, CD123, CD133, CD137, CD137L, CD160, CD272,CEACAM5, CLEC9, CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4,CXCL12, CXCL13, CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin,EGFR, ENTPD1, EpCAM, FCER1, FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24,GITR, GITRL, GPR5, GP100, GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1,HVEM, IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2,IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O,IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23,IL25, IL7, IL33, IL35, ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHCclass II, MUC-1, MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L,PD-1, PD-L1, PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2,STEAP1, STEAP2, Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14,TIGIT, TIM3, TLR, TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55,TREM1, TSLP, TSLPR, TWEAK, VEGF, VISTA, Vstm3, and WUCAM.

In some aspects, provided herein is an antigen binding polypeptidehaving a structure represented by VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1;VL1-L1-VL2-L2-VH2-L3-VH1; or VH1-L1-VH2-L2-VL2-L3-VL1; wherein VL1 is afirst immunoglobulin light chain variable region that specifically bindsto at least one epitope on at least one antigen selected from the groupconsisting of A2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA,B7DC, B7H1, B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5,CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19, CCL20,CCL21, CCL25 CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27, CD28, CD30,CD38, CD39, CD40, CD40L, CD47, CD52, CD70, CD80, CD86, CD123, CD133,CD137, CD137L, CD160, CD272, CEACAM5, CLEC9, CLEC91, CRTH2, CSF-1,CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12, CXCL13, CXCR3, cMet, CTLA4,DLL3, DLL4, DNGR-1, E-cadherin, EGFR, ENTPD1, EpCAM, FCER1, FCER1A,FCER2, FGFR, FLAP, FOLH1, Gi24, GITR, GITRL, GPR5, GP100, GPRC5D, HER2,HER3, ICOSL, ICOS, HHLA2, HMGB1, HVEM, IDO, IFNa, IgE, IGF1R, IL2Rbeta,IL1, ILIA, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra,IL8, IL9, IL9R, IL10, rhIL1O, IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17,IL17Rb, IL18, IL22, IL23, IL25, IL7, IL33, IL35, ITGB4, ITK, KIR, LAG3,LAMP1, leptin, LPFS2, MHC class II, MUC-1, MUC-16, NCR3LG1, NKG2D,NKp46, NTPDase-1, OX40, OX40L, PD-1, PD-L1, PD-L2, PROM1, S152,SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1, STEAP2, Syk kinase, STEAP1,TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3, TLR, TLR2, TLR4, TLR5,TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP, TSLPR, TWEAK, VEGF,VISTA, Vstm3, and WUCAM; VL2 is a second immunoglobulin light chainvariable region that specifically binds to at least one epitope on atleast one antigen selected from the group consisting of A2AR, APRIL,ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1, B7H2, B7H3,B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3, CCL4, CCL5,CCL7, CCL8, CCL11, CCL15, CCL17, CCL19, CCL20, CCL21, CCL25 CCR3, CCR4,CD3, CD16A, CD19, CD20, CD24, CD27, CD28, CD30, CD38, CD39, CD40, CD40L,CD47, CD52, CD70, CD80, CD86, CD123, CD133, CD137, CD137L, CD160, CD272,CEACAM5, CLEC9, CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4,CXCL12, CXCL13, CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin,EGFR, ENTPD1, EpCAM, FCER1, FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24,GITR, GITRL, GPR5, GP100, GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1,HVEM, IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2,IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O,IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23,IL25, IL7, IL33, IL35, ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHCclass II, MUC-1, MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L,PD-1, PD-L1, PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2,STEAP1, STEAP2, Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14,TIGIT, TIM3, TLR, TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55,TREM1, TSLP, TSLPR, TWEAK, VEGF, VISTA, Vstm3, and WUCAM; VH1 is a firstimmunoglobulin heavy chain variable region that specifically binds to atleast one epitope on at least one antigen selected from the groupconsisting of A2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA,B7DC, B7H1, B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5,CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19, CCL20,CCL21, CCL25 CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27, CD28, CD30,CD38, CD39, CD40, CD40L, CD47, CD52, CD70, CD80, CD86, CD123, CD133,CD137, CD137L, CD160, CD272, CEACAM5, CLEC9, CLEC91, CRTH2, CSF-1,CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12, CXCL13, CXCR3, cMet, CTLA4,DLL3, DLL4, DNGR-1, E-cadherin, EGFR, ENTPD1, EpCAM, FCER1, FCER1A,FCER2, FGFR, FLAP, FOLH1, Gi24, GITR, GITRL, GPR5, GP100, GPRC5D, HER2,HER3, ICOSL, ICOS, HHLA2, HMGB1, HVEM, IDO, IFNa, IgE, IGF1R, IL2Rbeta,IL1, ILIA, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra,IL8, IL9, IL9R, IL10, rhIL1O, IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17,IL17Rb, IL18, IL22, IL23, IL25, IL7, IL33, IL35, ITGB4, ITK, KIR, LAG3,LAMP1, leptin, LPFS2, MHC class II, MUC-1, MUC-16, NCR3LG1, NKG2D,NKp46, NTPDase-1, OX40, OX40L, PD-1, PD-L1, PD-L2, PROM1, S152,SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1, STEAP2, Syk kinase, STEAP1,TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3, TLR, TLR2, TLR4, TLR5,TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP, TSLPR, TWEAK, VEGF,VISTA, Vstm3, and WUCAM; VH2 is a second immunoglobulin heavy chainvariable region that specifically binds to at least one epitope on atleast one antigen selected from the group consisting of A2AR, APRIL,ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1, B7H2, B7H3,B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3, CCL4, CCL5,CCL7, CCL8, CCL11, CCL15, CCL17, CCL19, CCL20, CCL21, CCL25 CCR3, CCR4,CD3, CD16A, CD19, CD20, CD24, CD27, CD28, CD30, CD38, CD39, CD40, CD40L,CD47, CD52, CD70, CD80, CD86, CD123, CD133, CD137, CD137L, CD160, CD272,CEACAM5, CLEC9, CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4,CXCL12, CXCL13, CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin,EGFR, ENTPD1, EpCAM, FCER1, FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24,GITR, GITRL, GPR5, GP100, GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1,HVEM, IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2,IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O,IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23,IL25, IL7, IL33, IL35, ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHCclass II, MUC-1, MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L,PD-1, PD-L1, PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2,STEAP1, STEAP2, Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14,TIGIT, TIM3, TLR, TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55,TREM1, TSLP, TSLPR, TWEAK, VEGF, VISTA, Vstm3, and WUCAM; L1, L2 and L3are amino acid linkers; and wherein said antigen binding polypeptidefurther comprises at least one of the following (i)-(xxi); (i) an Fcregion having an optional immunoglobulin hinge, wherein theimmunoglobulin hinge comprises an upper hinge region, a middle hingeregion, a lower hinge region, or a combination thereof; (ii) a linkerselected from the group consisting of L1, L2 or L3 having a length offrom about 1 amino acid to about 50 amino acids; (iii) a linker selectedfrom the group consisting of L1, L2 or L3 selected from the groupconsisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4,SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9,SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO:14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ IDNO: 19, SEQ ID NO: 681, SEQ ID NO: 682, SEQ ID NO: 683, SEQ ID NO: 684,SEQ ID NO: 685, SEQ ID NO: 686, SEQ ID NO: 687 or SEQ ID NO: 688, or asequence having at least 50%, at least 60%, at least 70%, at least 80%,at least 90%, or at least 95% identity to any one of SEQ ID NOs:1-19 or681-688; (iv) a linker selected from L1, L2 or L3 which isnon-immunogenic; (v) a linker selected from L1, L2 or L3 wherein saidlinker does not contain a consensus T cell epitope; (vi) an Fc regioncomprising at least one knob-into-hole modification; (vii) a detectablelabel; (viii) a detectable label selected from the group consisting of aradioactive label, chemiluminescent label, fluorescent label, enzyme, orpeptide tag, or a combination thereof; (ix) a peptide tag; (x) a peptidetag selected from a polyhistidine tag consisting of from about 4 toabout 10 histidine residues; (xi) a peptide tag having about 8 histidineresidues; (xii) the polypeptide is conjugated to an agent to form anantibody-agent conjugate; (xiii) an antibody-agent conjugate wherein theagent is selected from the group consisting of a cytotoxic agent, animmunomodulating agent, an imaging agent, a therapeutic protein, or acombination thereof; (xiv) an antigen binding polypeptide having anequilibrium dissociation constant (KD) of from about 10 μM to about 1 pMwhen bound to an epitope on a target antigen or when complexed withanother antigen binding polypeptide to form an antigen bindingpolypeptide complex having at least two antigen binding polypeptides;(xv) an antibody or antigen binding fragment thereof; (xvi) an antibodyor antigen binding fragment thereof selected from the group consistingof IgG, IgM, IgE, IgA or IgD; (xvii) an antibody or antigen bindingfragment thereof selected from an IgG antibody selected from the groupconsisting of IgG1, IgG2, IgG3 or IgG4; (xviii) an antibody or antigenbinding fragment selected from the group consisting of Fab, scFab, Fab′,F(ab′)₂, Fv or scFv; (xix) an antigen binding polypeptide having aneffector function mutation; (xx) an antigen bind polypeptide which, whenformed into an antigen binding polypeptide complex, is an IgG1 or IgG4antibody and the knob-into-hole modification comprises (i) knobsubstitutions of S354C and T366W and hole substitutions of Y349C, T366S,L368A and Y407V; (ii) hole substitutions of L234A, L235A and P239A;(iii) hole substitutions of L234A and L235A; (iv) hole substitutions ofM428L and N433S; (v) hole substitutions of M252Y, S254T and T256E; or(vi) a combination thereof, based on the EU numbering scheme; and (xxi)an antigen binding polypeptide as part of a chimeric receptor antigen.

In some aspects, provided herein is an antigen binding polypeptidecomplex comprising a first polypeptide and a second polypeptide; whereinthe first polypeptide has a structure represented by VL1-VL2-VH2-VH1;VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1; or VH1-L1-VH2-L2-VL2-L3-VL1;wherein the second polypeptide has a structure represented byVL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1; orVH1-L1-VH2-L2-VL2-L3-VL1; wherein VL1 is a first immunoglobulin lightchain variable region that specifically binds to at least one epitope onat least one antigen selected from the group consisting of A2AR, APRIL,ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1, B7H2, B7H3,B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3, CCL4, CCL5,CCL7, CCL8, CCL11, CCL15, CCL17, CCL19, CCL20, CCL21, CCL25 CCR3, CCR4,CD3, CD16A, CD19, CD20, CD24, CD27, CD28, CD30, CD38, CD39, CD40, CD40L,CD47, CD52, CD70, CD80, CD86, CD123, CD133, CD137, CD137L, CD160, CD272,CEACAM5, CLEC9, CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4,CXCL12, CXCL13, CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin,EGFR, ENTPD1, EpCAM, FCER1, FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24,GITR, GITRL, GPR5, GP100, GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1,HVEM, IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2,IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O,IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23,IL25, IL7, IL33, IL35, ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHCclass II, MUC-1, MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L,PD-1, PD-L1, PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2,STEAP1, STEAP2, Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14,TIGIT, TIM3, TLR, TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55,TREM1, TSLP, TSLPR, TWEAK, VEGF, VISTA, Vstm3, and WUCAM; VL2 is asecond immunoglobulin light chain variable region that specificallybinds to at least one epitope on at least one antigen selected from thegroup consisting of A2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK,BTLA, B7DC, B7H1, B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3,C5, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19,CCL20, CCL21, CCL25 CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27,CD28, CD30, CD38, CD39, CD40, CD40L, CD47, CD52, CD70, CD80, CD86,CD123, CD133, CD137, CD137L, CD160, CD272, CEACAM5, CLEC9, CLEC91,CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12, CXCL13, CXCR3,cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin, EGFR, ENTPD1, EpCAM, FCER1,FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24, GITR, GITRL, GPR5, GP100,GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1, HVEM, IDO, IFNa, IgE,IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R,IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O, IL12, IL13, IL13Ra1,IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23, IL25, IL7, IL33, IL35,ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II, MUC-1,MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L, PD-1, PD-L1,PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1, STEAP2,Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3, TLR,TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP, TSLPR,TWEAK, VEGF, VISTA, Vstm3, and WUCAM; VH1 is a first immunoglobulinheavy chain variable region that specifically binds to at least oneepitope on at least one antigen selected from the group consisting ofA2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1,B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3,CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19, CCL20, CCL21, CCL25CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24, CD27, CD28, CD30, CD38, CD39,CD40, CD40L, CD47, CD52, CD70, CD80, CD86, CD123, CD133, CD137, CD137L,CD160, CD272, CEACAM5, CLEC9, CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1,CXCL2, CXCL4, CXCL12, CXCL13, CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1,E-cadherin, EGFR, ENTPD1, EpCAM, FCER1, FCER1A, FCER2, FGFR, FLAP,FOLH1, Gi24, GITR, GITRL, GPR5, GP100, GPRC5D, HER2, HER3, ICOSL, ICOS,HHLA2, HMGB1, HVEM, IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1, ILIA, IL1B,IL1F10, IL2, IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8, IL9, IL9R,IL10, rhIL1O, IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb, IL18,IL22, IL23, IL25, IL7, IL33, IL35, ITGB4, ITK, KIR, LAG3, LAMP1, leptin,LPFS2, MHC class II, MUC-1, MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1,OX40, OX40L, PD-1, PD-L1, PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC,SPG64, ST2, STEAP1, STEAP2, Syk kinase, STEAP1, TROP2, TACI, TDO,TGFBETA, T14, TIGIT, TIM3, TLR, TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa,TNFRSF7, Tp55, TREM1, TSLP, TSLPR, TWEAK, VEGF, VISTA, Vstm3, and WUCAM;VH2 is a second immunoglobulin heavy chain variable region thatspecifically binds to at least one epitope on at least one antigenselected from the group consisting of A2AR, APRIL, ATPDase, BAFF, BAFFR,BCMA, BlyS, BTK, BTLA, B7DC, B7H1, B7H2, B7H3, B7H4, B7H5, B7H6, B7H7,B7RP1, B7-4, C3, C5, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL11, CCL15,CCL17, CCL19, CCL20, CCL21, CCL25 CCR3, CCR4, CD3, CD16A, CD19, CD20,CD24, CD27, CD28, CD30, CD38, CD39, CD40, CD40L, CD47, CD52, CD70, CD80,CD86, CD123, CD133, CD137, CD137L, CD160, CD272, CEACAM5, CLEC9, CLEC91,CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12, CXCL13, CXCR3,cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin, EGFR, ENTPD1, EpCAM, FCER1,FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24, GITR, GITRL, GPR5, GP100,GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1, HVEM, IDO, IFNa, IgE,IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R,IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O, IL12, IL13, IL13Ra1,IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23, IL25, IL7, IL33, IL35,ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II, MUC-1,MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L, PD-1, PD-L1,PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1, STEAP2,Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14, TIGIT, TIM3, TLR,TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP, TSLPR,TWEAK, VEGF, VISTA, Vstm3, and WUCAM; L1, L2 and L3 are amino acidlinkers; and wherein said antigen binding polypeptide complex furthercomprises at least one of the following (i)-(xxi); (i) an Fc regionhaving an optional immunoglobulin hinge, wherein the immunoglobulinhinge comprises an upper hinge region, a middle hinge region, a lowerhinge region, or a combination thereof; (ii) a linker selected from thegroup consisting of L1, L2 or L3 having a length of from about 1 aminoacid to about 50 amino acids; (iii) a linker selected from the groupconsisting of L1, L2 or L3 selected from the group consisting of SEQ IDNO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ IDNO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ IDNO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 681,SEQ ID NO: 682, SEQ ID NO: 683, SEQ ID NO: 684, SEQ ID NO: 685, SEQ IDNO: 686, SEQ ID NO: 687, or SEQ ID NO: 688, or a sequence having atleast 50%, at least 60%, at least 70%, at least 80%, at least 90%, or atleast 95% identity to any one of SEQ ID NOs:1-19 or 681-688; (iv) alinker selected from L1, L2 or L3 which is non-immunogenic; (v) a linkerselected from L1, L2 or L3 wherein said linker does not contain aconsensus T cell epitope; (vi) an Fc region comprising at least oneknob-into-hole modification; (vii) a detectable label; (viii) adetectable label selected from the group consisting of a radioactivelabel, chemiluminescent label, fluorescent label, enzyme, or peptidetag, or a combination thereof; (ix) a peptide tag; (x) a peptide tagselected from a polyhistidine tag consisting of from about 4 to about 10histidine residues; (xi) a peptide tag having about 8 histidineresidues; (xii) the polypeptide is conjugated to an agent to form anantibody-agent conjugate; (xiii) an antibody-agent conjugate wherein theagent is selected from the group consisting of a cytotoxic agent, animmunomodulating agent, an imaging agent, a therapeutic protein, or acombination thereof; (xiv) an antigen binding polypeptide having anequilibrium dissociation constant (KD) of from about 10 μM to about 1 pMwhen bound to an epitope on a target antigen or when complexed withanother antigen binding polypeptide to form an antigen bindingpolypeptide complex having at least two antigen binding polypeptides;(xv) an antibody or antigen binding fragment thereof; (xvi) an antibodyor antigen binding fragment thereof selected from the group consistingof IgG, IgM, IgE, IgA or IgD; (xvii) an antibody or antigen bindingfragment thereof selected from an IgG antibody selected from the groupconsisting of IgG1, IgG2, IgG3 or IgG4; (xviii) an antibody or antigenbinding fragment selected from the group consisting of Fab, scFab, Fab′,F(ab′)₂, Fv or scFv; (xix) an antigen binding polypeptide having aneffector function mutation; (xx) an antigen bind polypeptide which, whenformed into an antigen binding polypeptide complex, is an IgG1 or IgG4antibody and the knob-into-hole modification comprises (i) knobsubstitutions of S354C and T366W and hole substitutions of Y349C, T366S,L368A and Y407V; (ii) hole substitutions of L234A, L235A and P239A;(iii) hole substitutions of L234A and L235A; (iv) hole substitutions ofM428L and N433S; (v) hole substitutions of M252Y, S254T and T256E; or(vi) a combination thereof, based on the EU numbering scheme; and (xxi)an antigen binding polypeptide as part of a chimeric receptor antigen.

In some aspects, the invention is directed to antigen bindingpolypeptides and antigen binding polypeptide complexes having astructure represented by VL1-VL2-VH2-VH1 or VH1-VH2-VL2-VL1 thatspecifically binds to an HIV protein. In some aspects, the antigenbinding polypeptide or antigen binding polypeptide complex contains anamino acid linker between any two regions denoted in a structuredescribed herein. In some aspects, the antigen binding polypeptide orantigen binding polypeptide complex can contain one or more Fc region,CH1 region, or CL region, CH3 region or any combination thereof. In someaspects, the Fc region, CH1 region, CL region and/or CH3 is located atthe carboxy terminus of the antigen binding polypeptide, and isoptionally linked to polypeptide by at least one amino acid linker. Insome aspects, the Fc region comprises an amino acid sequence of any oneof SEQ ID NOs:391-404 or an amino acid sequence having at least 80%, atleast 85%, at least 90%, at least 95%, at least 96%, at least 97%, atleast 98%, or at least 99% identity to any one of SEQ ID NOs:391-404. Insome aspects, the CH1 region comprises an amino acid sequence of any oneof SEQ ID NOs:405-409 or an amino acid sequence having at least 80%, atleast 85%, at least 90%, at least 95%, at least 96%, at least 97%, atleast 98%, or at least 99% identity to any one of SEQ ID NOs:405-409. Insome aspects, the CL region comprises an amino acid sequence of SEQ IDNO:420 or 421 or an amino acid sequence having at least 80%, at least85%, at least 90%, at least 95%, at least 96%, at least 97%, at least98% or at least 99% identity to SEQ ID NO:420 or 421. In some aspects,the antigen binding polypeptide complex is an antibody or antigenbinding fragment thereof.

Specific binding to an HIV protein includes, but is not limited to,specific binding to one or more HIV proteins and specific binding to oneor more epitopes on the same HIV protein. In some aspects, the HIVprotein is selected from the group consisting of an HIV envelopeprotein, an HIV structural protein, an HIV functional protein, or an HIVaccessory protein. In some aspects, the HIV envelope protein is HIVenvelope glycoprotein (Env), HIV envelope glycoprotein gp160, HIVenvelope surface glycoprotein gp120, or HIV transmembrane envelopeprotein gp41. In some aspects, the HIV structural protein is p17, p24,p7 or p55. In some aspects, the HIV functional protein is p66, HIV-1protease (PR) or p31. In some aspects, the HIV accessory protein is Nef,Tat, Rev, Vif, Vpr or Vpu.

In some aspects of an antigen binding polypeptide or antigen bindingpolypeptide complex provided herein, VH1 is a first immunoglobulin heavychain variable region that specifically binds to at least one epitope onat least one antigen selected from the group consisting of Env, gp160,gp120, gp41, p17, p24, p7, p55, p66, p31, Nef, Tat, Rev, Vif, Vpr andVpu. In some aspects, VH1 specifically binds to at least one epitope onEnv. In some aspects, VH1 specifically binds to at least one epitope ongp160. In some aspects, VH1 specifically binds to at least one epitopeon gp120. In some aspects, VH1 specifically binds to at least oneepitope on gp41. In some aspects, VH1 specifically binds to at least oneepitope on p17. In some aspects, VH1 specifically binds to at least oneepitope on p24. In some aspects, VH1 specifically binds to at least oneepitope on p7. In some aspects, VH1 specifically binds to at least oneepitope on p55. In some aspects, VH1 specifically binds to at least oneepitope on p66. In some aspects, VH1 specifically binds to at least oneepitope on p31. In some aspects, VH1 specifically binds to at least oneepitope on Nef. In some aspects, VH1 specifically binds to at least oneepitope on Tat. In some aspects, VH1 specifically binds to at least oneepitope on Rev. In some aspects, VH1 specifically binds to at least oneepitope on Vif. In some aspects, VH1 specifically binds to at least oneepitope on Vpr. In some aspects, VH1 specifically binds to at least oneepitope on Vpu.

In some aspects of an antigen binding polypeptide or antigen bindingpolypeptide complex provided herein, VH2 is a second immunoglobulinheavy chain variable region that specifically binds to at least oneepitope on at least one antigen selected from the group consisting ofEnv, gp160, gp120, gp41, p17, p24, p7, p55, p66, p31, Nef, Tat, Rev,Vif, Vpr and Vpu. In some aspects, VH2 specifically binds to at leastone epitope on Env. In some aspects, VH2 specifically binds to at leastone epitope on gp160. In some aspects, VH2 specifically binds to atleast one epitope on gp120. In some aspects, VH2 specifically binds toat least one epitope on gp41. In some aspects, VH2 specifically binds toat least one epitope on p17. In some aspects, VH2 specifically binds toat least one epitope on p24. In some aspects, VH2 specifically binds toat least one epitope on p7. In some aspects, VH2 specifically binds toat least one epitope on p55. In some aspects, VH2 specifically binds toat least one epitope on p66. In some aspects, VH2 specifically binds toat least one epitope on p31. In some aspects, VH2 specifically binds toat least one epitope on Nef. In some aspects, VH2 specifically binds toat least one epitope on Tat. In some aspects, VH2 specifically binds toat least one epitope on Rev. In some aspects, VH2 specifically binds toat least one epitope on Vif. In some aspects, VH2 specifically binds toat least one epitope on Vpr. In some aspects, VH2 specifically binds toat least one epitope on Vpu.

In some aspects of an antigen binding polypeptide or antigen bindingpolypeptide complex provided herein, VH3 is a third immunoglobulin heavychain variable region that specifically binds to at least one epitope onat least one antigen selected from the group consisting of Env, gp160,gp120, gp41, p17, p24, p7, p55, p66, p31, Nef, Tat, Rev, Vif, Vpr andVpu. In some aspects, VH3 specifically binds to at least one epitope onEnv. In some aspects, VH3 specifically binds to at least one epitope ongp160. In some aspects, VH3 specifically binds to at least one epitopeon gp120. In some aspects, VH3 specifically binds to at least oneepitope on gp41. In some aspects, VH3 specifically binds to at least oneepitope on p17. In some aspects, VH3 specifically binds to at least oneepitope on p24. In some aspects, VH3 specifically binds to at least oneepitope on p7. In some aspects, VH3 specifically binds to at least oneepitope on p55. In some aspects, VH3 specifically binds to at least oneepitope on p66. In some aspects, VH3 specifically binds to at least oneepitope on p31. In some aspects, VH3 specifically binds to at least oneepitope on Nef. In some aspects, VH3 specifically binds to at least oneepitope on Tat. In some aspects, VH3 specifically binds to at least oneepitope on Rev. In some aspects, VH3 specifically binds to at least oneepitope on Vif. In some aspects, VH3 specifically binds to at least oneepitope on Vpr. In some aspects, VH3 specifically binds to at least oneepitope on Vpu.

In some aspects of an antigen binding polypeptide or antigen bindingpolypeptide complex provided herein, VH4 is a fourth immunoglobulinheavy chain variable region that specifically binds to at least oneepitope on at least one antigen selected from the group consisting ofEnv, gp160, gp120, gp41, p17, p24, p7, p55, p66, p31, Nef, Tat, Rev,Vif, Vpr and Vpu. In some aspects, VH4 specifically binds to at leastone epitope on Env. In some aspects, VH4 specifically binds to at leastone epitope on gp160. In some aspects, VH4 specifically binds to atleast one epitope on gp120. In some aspects, VH4 specifically binds toat least one epitope on gp41. In some aspects, VH4 specifically binds toat least one epitope on p17. In some aspects, VH4 specifically binds toat least one epitope on p24. In some aspects, VH4 specifically binds toat least one epitope on p7. In some aspects, VH4 specifically binds toat least one epitope on p55. In some aspects, VH4 specifically binds toat least one epitope on p66. In some aspects, VH4 specifically binds toat least one epitope on p31. In some aspects, VH4 specifically binds toat least one epitope on Nef. In some aspects, VH4 specifically binds toat least one epitope on Tat. In some aspects, VH4 specifically binds toat least one epitope on Rev. In some aspects, VH4 specifically binds toat least one epitope on Vif. In some aspects, VH4 specifically binds toat least one epitope on Vpr. In some aspects, VH4 specifically binds toat least one epitope on Vpu.

In some aspects of an antigen binding polypeptide or antigen bindingpolypeptide complex provided herein, VL1 is a first immunoglobulin lightchain variable region that specifically binds to at least one epitope onat least one antigen selected from the group consisting of Env, gp160,gp120, gp41, p17, p24, p7, p55, p66, p31, Nef, Tat, Rev, Vif, Vpr andVpu. In some aspects, VL1 specifically binds to at least one epitope onEnv. In some aspects, VL1 specifically binds to at least one epitope ongp160. In some aspects, VL1 specifically binds to at least one epitopeon gp120. In some aspects, VL1 specifically binds to at least oneepitope on gp41. In some aspects, VL1 specifically binds to at least oneepitope on p17. In some aspects, VL1 specifically binds to at least oneepitope on p24. In some aspects, VL1 specifically binds to at least oneepitope on p7. In some aspects, VL1 specifically binds to at least oneepitope on p55. In some aspects, VL1 specifically binds to at least oneepitope on p66. In some aspects, VL1 specifically binds to at least oneepitope on p31. In some aspects, VL1 specifically binds to at least oneepitope on Nef. In some aspects, VL1 specifically binds to at least oneepitope on Tat. In some aspects, VL1 specifically binds to at least oneepitope on Rev. In some aspects, VL1 specifically binds to at least oneepitope on Vif. In some aspects, VL1 specifically binds to at least oneepitope on Vpr. In some aspects, VL1 specifically binds to at least oneepitope on Vpu.

In some aspects of an antigen binding polypeptide or antigen bindingpolypeptide complex provided herein, VL2 is a second immunoglobulinlight chain variable region that specifically binds to at least oneepitope on at least one antigen selected from the group consisting ofEnv, gp160, gp120, gp41, p17, p24, p7, p55, p66, p31, Nef, Tat, Rev,Vif, Vpr and Vpu. In some aspects, VL2 specifically binds to at leastone epitope on Env. In some aspects, VL2 specifically binds to at leastone epitope on gp160. In some aspects, VL2 specifically binds to atleast one epitope on gp120. In some aspects, VL2 specifically binds toat least one epitope on gp41. In some aspects, VL2 specifically binds toat least one epitope on p17. In some aspects, VL2 specifically binds toat least one epitope on p24. In some aspects, VL2 specifically binds toat least one epitope on p7. In some aspects, VL2 specifically binds toat least one epitope on p55. In some aspects, VL2 specifically binds toat least one epitope on p66. In some aspects, VL2 specifically binds toat least one epitope on p31. In some aspects, VL2 specifically binds toat least one epitope on Nef. In some aspects, VL2 specifically binds toat least one epitope on Tat. In some aspects, VL2 specifically binds toat least one epitope on Rev. In some aspects, VL2 specifically binds toat least one epitope on Vif. In some aspects, VL2 specifically binds toat least one epitope on Vpr. In some aspects, VL2 specifically binds toat least one epitope on Vpu.

In some aspects of an antigen binding polypeptide or antigen bindingpolypeptide complex provided herein, VL3 is a third immunoglobulin lightchain variable region that specifically binds to at least one epitope onat least one antigen selected from the group consisting of Env, gp160,gp120, gp41, p17, p24, p7, p55, p66, p31, Nef, Tat, Rev, Vif, Vpr andVpu. In some aspects, VL3 specifically binds to at least one epitope onEnv. In some aspects, VL3 specifically binds to at least one epitope ongp160. In some aspects, VL3 specifically binds to at least one epitopeon gp120. In some aspects, VL3 specifically binds to at least oneepitope on gp41. In some aspects, VL3 specifically binds to at least oneepitope on p17. In some aspects, VL3 specifically binds to at least oneepitope on p24. In some aspects, VL3 specifically binds to at least oneepitope on p7. In some aspects, VL3 specifically binds to at least oneepitope on p55. In some aspects, VL3 specifically binds to at least oneepitope on p66. In some aspects, VL3 specifically binds to at least oneepitope on p31. In some aspects, VL3 specifically binds to at least oneepitope on Nef. In some aspects, VL3 specifically binds to at least oneepitope on Tat. In some aspects, VL3 specifically binds to at least oneepitope on Rev. In some aspects, VL3 specifically binds to at least oneepitope on Vif. In some aspects, VL3 specifically binds to at least oneepitope on Vpr. In some aspects, VL3 specifically binds to at least oneepitope on Vpu.

In some aspects of an antigen binding polypeptide or antigen bindingpolypeptide complex provided herein, VL4 is a fourth immunoglobulinlight chain variable region that specifically binds to at least oneepitope on at least one antigen selected from the group consisting ofEnv, gp160, gp120, gp41, p17, p24, p7, p55, p66, p31, Nef, Tat, Rev,Vif, Vpr and Vpu. In some aspects, VL4 specifically binds to at leastone epitope on Env. In some aspects, VL4 specifically binds to at leastone epitope on gp160. In some aspects, VL4 specifically binds to atleast one epitope on gp120. In some aspects, VL4 specifically binds toat least one epitope on gp41. In some aspects, VL4 specifically binds toat least one epitope on p17. In some aspects, VL4 specifically binds toat least one epitope on p24. In some aspects, VL4 specifically binds toat least one epitope on p7. In some aspects, VL4 specifically binds toat least one epitope on p55. In some aspects, VL4 specifically binds toat least one epitope on p66. In some aspects, VL4 specifically binds toat least one epitope on p31. In some aspects, VL4 specifically binds toat least one epitope on Nef. In some aspects, VL4 specifically binds toat least one epitope on Tat. In some aspects, VL4 specifically binds toat least one epitope on Rev. In some aspects, VL4 specifically binds toat least one epitope on Vif. In some aspects, VL4 specifically binds toat least one epitope on Vpr. In some aspects, VL4 specifically binds toat least one epitope on Vpu.

In some aspects of an antigen binding polypeptide or antigen bindingpolypeptide complex provided herein, VH1 is a first immunoglobulin heavychain variable region that specifically binds to at least one epitope onat least one antigen selected from the group consisting of Env, gp160,gp120, gp41, p17, p24, p7, p55, p66, p31, Nef, Tat, Rev, Vif, Vpr andVpu; VH2 is a second immunoglobulin heavy chain variable region thatspecifically binds to at least one epitope on at least one antigenselected from the group consisting of Env, gp160, gp120, gp41, p17, p24,p7, p55, p66, p31, Nef, Tat, Rev, Vif, Vpr and Vpu; VH3 is a thirdimmunoglobulin heavy chain variable region that specifically binds to atleast one epitope on at least one antigen selected from the groupconsisting of Env, gp160, gp120, gp41, p17, p24, p7, p55, p66, p31, Nef,Tat, Rev, Vif, Vpr and Vpu; VH4 is a fourth immunoglobulin heavy chainvariable region that specifically binds to at least one epitope on atleast one antigen selected from the group consisting of Env, gp160,gp120, gp41, p17, p24, p7, p55, p66, p31, Nef, Tat, Rev, Vif, Vpr andVpu; VL1 is a first immunoglobulin light chain variable region thatspecifically binds to at least one epitope on at least one antigenselected from the group consisting of Env, gp160, gp120, gp41, p17, p24,p7, p55, p66, p31, Nef, Tat, Rev, Vif, Vpr and Vpu; VL2 is a secondimmunoglobulin light chain variable region that specifically binds to atleast one epitope on at least one antigen selected from the groupconsisting of Env, gp160, gp120, gp41, p17, p24, p7, p55, p66, p31, Nef,Tat, Rev, Vif, Vpr and Vpu; VL3 is a third immunoglobulin light chainvariable region that specifically binds to at least one epitope on atleast one antigen selected from the group consisting of Env, gp160,gp120, gp41, p17, p24, p7, p55, p66, p31, Nef, Tat, Rev, Vif, Vpr andVpu; and VL4 is a fourth immunoglobulin light chain variable region thatspecifically binds to at least one epitope on at least one antigenselected from the group consisting of Env, gp160, gp120, gp41, p17, p24,p7, p55, p66, p31, Nef, Tat, Rev, Vif, Vpr and Vpu.

In some aspects, an antigen binding polypeptide provided has a structurerepresented by VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1;VL1-L1-VL2-L2-VH2-L3-VH1; or VH1-L1-VH2-L2-VL2-L3-VL1; wherein VL1 is afirst immunoglobulin light chain variable region that specifically bindsto at least one epitope on at least one antigen selected from the groupconsisting of Env, gp160, gp120, gp41, p17, p24, p7, p55, p66, p31, Nef,Tat, Rev, Vif, Vpr and Vpu; VL2 is a second immunoglobulin light chainvariable region that specifically binds to at least one epitope on atleast one antigen selected from the group consisting of Env, gp160,gp120, gp41, p17, p24, p7, p55, p66, p31, Nef, Tat, Rev, Vif, Vpr andVpu; VH1 is a first immunoglobulin heavy chain variable region thatspecifically binds to at least one epitope on at least one antigenselected from the group consisting of Env, gp160, gp120, gp41, p17, p24,p7, p55, p66, p31, Nef, Tat, Rev, Vif, Vpr and Vpu; VH2 is a secondimmunoglobulin heavy chain variable region that specifically binds to atleast one epitope on at least one antigen selected from the groupconsisting of Env, gp160, gp120, gp41, p17, p24, p7, p55, p66, p31, Nef,Tat, Rev, Vif, Vpr and Vpu; L1, L2 and L3 are amino acid linkers;wherein said antigen binding polypeptide further comprises at least oneof the following (i)-(xxi): (i) an Fc region having an optionalimmunoglobulin hinge, wherein the immunoglobulin hinge comprises anupper hinge region, a middle hinge region, a lower hinge region, or acombination thereof; (ii) a linker selected from the group consisting ofL1, L2 or L3 having a length of from about 1 amino acid to about 50amino acids; (iii) a linker selected from the group consisting of L1, L2or L3 selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2,SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7,SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12,SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO:17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 681, SEQ ID NO: 682, SEQ IDNO: 683, SEQ ID NO: 684, SEQ ID NO: 685, SEQ ID NO: 686, SEQ ID NO: 687,or SEQ ID NO: 688, or a sequence having at least 50%, at least 60%, atleast 70%, at least 80%, at least 90%, or at least 95% identity to anyone of SEQ ID NOs:1-19 and 681-688; (iv) a linker selected from L1, L2or L3 which is non-immunogenic; (v) a linker selected from L1, L2 or L3wherein said linker does not contain a consensus T cell epitope; (vi) anFc region comprising at least one knob-into-hole modification; (vii) adetectable label; (viii) a detectable label selected from the groupconsisting of a radioactive label, chemiluminescent label, fluorescentlabel, enzyme, or peptide tag, or a combination thereof; (ix) a peptidetag; (x) a peptide tag selected from a polyhistidine tag consisting offrom about 4 to about 10 histidine residues; (xi) a peptide tag havingabout 8 histidine residues; (xii) the polypeptide is conjugated to anagent to form an antibody-agent conjugate; (xiii) an antibody-agentconjugate wherein the agent is selected from the group consisting of acytotoxic agent, an immunomodulating agent, an imaging agent, atherapeutic protein, or a combination thereof; (xiv) an antigen bindingpolypeptide having an equilibrium dissociation constant (KD) of fromabout 10 μM to about 1 pM when bound to an epitope on a target antigenor when complexed with another antigen binding polypeptide to form anantigen binding polypeptide complex having at least two antigen bindingpolypeptides; (xv) an antibody or antigen binding fragment thereof;(xvi) an antibody or antigen binding fragment thereof selected from thegroup consisting of IgG, IgM, IgE, IgA or IgD; (xvii) an antibody orantigen binding fragment thereof selected from an IgG antibody selectedfrom the group consisting of IgG1, IgG2, IgG3 or IgG4; (xviii) anantibody or antigen binding fragment selected from the group consistingof Fab, scFab, Fab′, F(ab′)₂, Fv or scFv; (xix) an antigen bindingpolypeptide having an effector function mutation; (xx) an antigen bindpolypeptide which, when formed into an antigen binding polypeptidecomplex, is an IgG1 or IgG4 antibody and the knob-into-hole modificationcomprises: (i) knob substitutions of S354C and T366W and holesubstitutions of Y349C, T366S, L368A and Y407V; (ii) hole substitutionsof L234A, L235A and P239A; (iii) hole substitutions of L234A and L235A;(iv) hole substitutions of M428L and N433S; (v) hole substitutions ofM252Y, S254T and T256E; or (vi) a combination thereof, based on the EUnumbering scheme; and (xxi) an antigen binding polypeptide as part of achimeric receptor antigen.

In some aspects, an antigen binding polypeptide complex provided hereincomprises a first polypeptide and a second polypeptide; wherein thefirst polypeptide has a structure represented by VL1-VL-VH2-VH1;VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1; or VH1-L1-VH2-L2-VL2-L3-VL1;wherein the second polypeptide has a structure represented byVL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1; orVH1-L1-VH2-L2-VL2-L3-VL1; wherein VL1 is a first immunoglobulin lightchain variable region that specifically binds to at least one epitope onat least one antigen selected from the group consisting of Env, gp160,gp120, gp41, p17, p24, p7, p55, p66, p31, Nef, Tat, Rev, Vif, Vpr andVpu; VL2 is a second immunoglobulin light chain variable region thatspecifically binds to at least one epitope on at least one antigenselected from the group consisting of Env, gp160, gp120, gp41, p17, p24,p7, p55, p66, p31, Nef, Tat, Rev, Vif, Vpr and Vpu; VH1 is a firstimmunoglobulin heavy chain variable region that specifically binds to atleast one epitope on at least one antigen selected from the groupconsisting of Env, gp160, gp120, gp41, p17, p24, p7, p55, p66, p31, Nef,Tat, Rev, Vif, Vpr and Vpu; VH2 is a second immunoglobulin heavy chainvariable region that specifically binds to at least one epitope on atleast one antigen selected from the group consisting of Env, gp160,gp120, gp41, p17, p24, p7, p55, p66, p31, Nef, Tat, Rev, Vif, Vpr andVpu; L1, L2 and L3 are amino acid linkers; wherein said antigen bindingpolypeptide complex further comprises at least one of the following(i)-(xxi): (i) an Fc region having an optional immunoglobulin hinge,wherein the immunoglobulin hinge comprises an upper hinge region, amiddle hinge region, a lower hinge region, or a combination thereof;(ii) a linker selected from the group consisting of L1, L2 or L3 havinga length of from about 1 amino acid to about 50 amino acids; (iii) alinker selected from the group consisting of L1, L2 or L3 selected fromthe group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ IDNO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ IDNO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18,SEQ ID NO: 19, SEQ ID NO: 681, SEQ ID NO: 682, SEQ ID NO: 683, SEQ IDNO: 684, SEQ ID NO: 685, SEQ ID NO: 686, SEQ ID NO: 687, or SEQ ID NO:688, or a sequence having at least 50%, at least 60%, at least 70%, atleast 80%, at least 90%, or at least 95% identity to any one of SEQ IDNOs:1-19 or 681-688; (iv) a linker selected from L1, L2 or L3 which isnon-immunogenic; (v) a linker selected from L1, L2 or L3 wherein saidlinker does not contain a consensus T cell epitope; (vi) an Fc regioncomprising at least one knob-into-hole modification; (vii) a detectablelabel; (viii) a detectable label selected from the group consisting of aradioactive label, chemiluminescent label, fluorescent label, enzyme, orpeptide tag, or a combination thereof; (ix) a peptide tag; (x) a peptidetag selected from a polyhistidine tag consisting of from about 4 toabout 10 histidine residues; (xi) a peptide tag having about 8 histidineresidues; (xii) the polypeptide is conjugated to an agent to form anantibody-agent conjugate; (xiii) an antibody-agent conjugate wherein theagent is selected from the group consisting of a cytotoxic agent, animmunomodulating agent, an imaging agent, a therapeutic protein, or acombination thereof; (xiv) an antigen binding polypeptide having anequilibrium dissociation constant (KD) of from about 10 μM to about 1 pMwhen bound to an epitope on a target antigen or when complexed withanother antigen binding polypeptide to form an antigen bindingpolypeptide complex having at least two antigen binding polypeptides;(xv) an antibody or antigen binding fragment thereof; (xvi) an antibodyor antigen binding fragment thereof selected from the group consistingof IgG, IgM, IgE, IgA or IgD; (xvii) an antibody or antigen bindingfragment thereof selected from an IgG antibody selected from the groupconsisting of IgG1, IgG2, IgG3 or IgG4; (xviii) an antibody or antigenbinding fragment selected from the group consisting of Fab, scFab, Fab′,F(ab′)₂, Fv or scFv; (xix) an antigen binding polypeptide having aneffector function mutation; (xx) an antigen binding polypeptide which,when formed into an antigen binding polypeptide complex, is an IgG1 orIgG4 antibody and the knob-into-hole modification comprises (i) knobsubstitutions of S354C and T366W and hole substitutions of Y349C, T366S,L368A and Y407V; (ii) hole substitutions of L234A, L235A and P239A;(iii) hole substitutions of L234A and L235A; (iv) hole substitutions ofM428L and N433S; (v) hole substitutions of M252Y, S254T and T256E; or(vi) a combination thereof, based on the EU numbering scheme; and (xxi)an antigen binding polypeptide as part of a chimeric receptor antigen.

In some aspects, an antigen binding polypeptide of the invention has astructure represented by VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1;VL1-L1-VL2-L2-VH2-L3-VH1; or VH1-L1-VH2-L2-VL2-L3-VL1; wherein VL1 is afirst immunoglobulin light chain variable region that specifically bindsto an HIV protein; VL2 is a second immunoglobulin light chain variableregion that specifically binds to an HIV protein; VH1 is a firstimmunoglobulin heavy chain variable region that specifically binds to anHIV protein; VH2 is a second immunoglobulin heavy chain variable regionthat specifically binds to an HIV protein; and L1, L2 and L3 are aminoacid linkers.

In some aspects, an antigen binding polypeptide complex of the inventioncomprises a first polypeptide and a second polypeptide; wherein thefirst polypeptide has a structure represented by VL1-VL2-VH2-VH1;VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1; or VH1-L1-VH2-L2-VL2-L3-VL1;wherein the second polypeptide has a structure represented byVL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1; orVH1-L1-VH2-L2-VL2-L3-VL1; wherein VL1 is a first immunoglobulin lightchain variable region that specifically binds to an HIV protein; VL2 isa second immunoglobulin light chain variable region that specificallybinds to an HIV protein; VH1 is a first immunoglobulin heavy chainvariable region that specifically binds to an HIV protein; VH2 is asecond immunoglobulin heavy chain variable region that specificallybinds to an HIV protein; and L1, L2 and L3 are amino acid linkers. Insome aspects, the first polypeptide has a structure represented byVL1-VL2-VH2-VH1 and the second polypeptide has a structure representedby VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1; orVH1-L1-VH2-L2-VL2-L3-VL1. In some aspects, the first polypeptide has astructure represented by VH1-VH2-VL2-VL1 and the second polypeptide hasa structure represented by VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1;VL1-L1-VL2-L2-VH2-L3-VH1; or VH1-L1-VH2-L2-VL2-L3-VL1. In some aspects,the first polypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1 and the second polypeptide has a structurerepresented by VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1;VL1-L1-VL2-L2-VH2-L3-VH1; or VH1-L1-VH2-L2-VL2-L3-VL1. In some aspects,the first polypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1 and the second polypeptide has a structurerepresented by VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1;VL1-L1-VL2-L2-VH2-L3-VH1; or VH1-L1-VH2-L2-VL2-L3-VL1.

In some aspects, an antigen binding polypeptide of the invention has astructure represented by VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fe; or VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fe;wherein VL1 is a first immunoglobulin light chain variable region thatspecifically binds to an HIV protein; VL2 is a second immunoglobulinlight chain variable region that specifically binds to an HIV protein;VH1 is a first immunoglobulin heavy chain variable region thatspecifically binds to an HIV protein; VH2 is a second immunoglobulinheavy chain variable region that specifically binds to an HIV protein;Fc is a region comprising an immunoglobulin heavy chain constant region2 (CH2), an immunoglobulin heavy chain constant region 3 (CH3), andoptionally, an immunoglobulin hinge; and L1, L2, L3 and L4 are aminoacid linkers.

In some aspects, an antigen binding polypeptide complex of the inventioncomprises a first polypeptide and a second polypeptide; wherein thefirst polypeptide has a structure represented by VL1-VL2-VH2-VH1-Fc;VH1-VH2-VL2-VL1-Fe; VL1-L1-VL2-L2-VH2-L3-VH1-Fe;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fe; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-Fe; wherein the second polypeptide has astructure represented by Fc; VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-Fe;VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fe; or VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fe;wherein VL1 is a first immunoglobulin light chain variable region thatspecifically binds to an HIV protein; VL2 is a second immunoglobulinlight chain variable region that specifically binds to an HIV protein;VH1 is a first immunoglobulin heavy chain variable region thatspecifically binds to an HIV protein; VH2 is a second immunoglobulinheavy chain variable region that specifically binds to an HIV protein;Fc is a region comprising an immunoglobulin heavy chain constant region2 (CH2), an immunoglobulin heavy chain constant region 3 (CH3), andoptionally, an immunoglobulin hinge; and L1, L2, L3 and L4 are aminoacid linkers. In some aspects, the first polypeptide has a structurerepresented by VL1-VL2-VH2-VH1-Fc and the second polypeptide has astructure represented by Fc; VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-Fe; VH1-L1-VH2-L2-VL2-L3-VL1-Fe;VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fe; or VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fe. Insome aspects, the first polypeptide has a structure represented byVH1-VH2-VL2-VL1-Fc and the second polypeptide has a structurerepresented by Fc; VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fe;VL1-L1-VL2-L2-VH2-L3-VH1-Fe; VH1-L1-VH2-L2-VL2-L3-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc; or VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fe. Insome aspects, the first polypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-Fc and the second polypeptide has a structurerepresented by Fc; VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fe;VL1-L1-VL2-L2-VH2-L3-VH1-Fe; VH1-L1-VH2-L2-VL2-L3-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc; or VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fe. Insome aspects, the first polypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-Fc and the second polypeptide has a structurerepresented by Fc; VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fe; or VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fe. Insome aspects, the first polypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc and the second polypeptide has astructure represented by Fc; VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-F c; VH1-L1-VH2-L2-VL2-L3-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc; or VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc. Insome aspects, the first polypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc and the second polypeptide has astructure represented by Fc; VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fe;VL1-L1-VL2-L2-VH2-L3-VH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc; or VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fe.

In some aspects, an antigen binding polypeptide of the invention has astructure represented by VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL;VL1-VL2-VH2-VH1-CL-CH1; VH1-VH2-VL2-VL1-CL-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; wherein VL1 is a firstimmunoglobulin light chain variable region that specifically binds to anHIV protein; VL2 is a second immunoglobulin light chain variable regionthat specifically binds to an HIV protein; VH1 is a first immunoglobulinheavy chain variable region that specifically binds to an HIV protein;VH2 is a second immunoglobulin heavy chain variable region thatspecifically binds to an HIV protein; CH1 is an immunoglobulin heavychain constant region 1; CL is an immunoglobulin light chain constantregion; and L1, L2, L3, L4 and L5 are amino acid linkers.

In some aspects, an antigen binding polypeptide complex of the inventioncomprises a first polypeptide and a second polypeptide; wherein thefirst polypeptide has a structure represented by VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2- VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; wherein the second polypeptidehas a structure represented by VL1-VL2-VH2-VH1-CH1; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; or VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1;wherein VL1 is a first immunoglobulin light chain variable region thatspecifically binds to an HIV protein; VL2 is a second immunoglobulinlight chain variable region that specifically binds to an HIV protein;VH1 is a first immunoglobulin heavy chain variable region thatspecifically binds to an HIV protein; VH2 is a second immunoglobulinheavy chain variable region that specifically binds to an HIV protein;CH1 is an immunoglobulin heavy chain constant region 1; CL is animmunoglobulin light chain constant region; and L1, L2, L3, L4 and L5are amino acid linkers. In some aspects, the first polypeptide has astructure represented by VL1-VL2-VH2-VH1-CH1 and the second polypeptidehas a structure represented by VL1-VL2-VH2-VH1-CH1; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2- VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1-CH1 and thesecond polypeptide has a structure represented by VL1-VL2-VH2-VH1-CH1;VL1-VL2-VH2-VH1-CH1; VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL;VH1-VH2-VL2-VL1-CL; VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL;VL1-VL2-VH2-VH1-CL-CH1; VH1-VH2-VL2-VL1-CL-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL; VH1-L1-VH2-L2- VL2-L3-VL1-L4-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-CL and thesecond polypeptide has a structure represented by VL1-VL2-VH2-VH1-CH1;VL1-VL2-VH2-VH1-CH1; VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL;VH1-VH2-VL2-VL1-CL; VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL;VL1-VL2-VH2-VH1-CL-CH1; VH1-VH2-VL2-VL1-CL-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL;VL1-L1-VL2-L2- VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; or VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1. In some aspects,the first polypeptide has a structure represented by VH1-VH2-VL2-VL1-CLand the second polypeptide has a structure represented byVL1-VL2-VH2-VH1-CH1; VL1-VL2-VH2-VH1-CH1; VH1-VH2-VL2-VL1-CH1;VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL; VL1-VL2-VH2-VH1-CH1-CL;VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1; VH1-VH2-VL2-VL1-CL-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1;VL1-L1-VL2-L2- VH2-L3-VH1-L4-CL; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-CH1-CL andthe second polypeptide has a structure represented byVL1-VL2-VH2-VH1-CH1; VL1-VL2-VH2-VH1-CH1; VH1-VH2-VL2-VL1-CH1;VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL; VL1-VL2-VH2-VH1-CH1-CL;VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1; VH1-VH2-VL2-VL1-CL-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL; VH1-L1- VH2-L2-VL2-L3-VL1-L4-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1-CH1-CL andthe second polypeptide has a structure represented byVL1-VL2-VH2-VH1-CH1; VL1-VL2-VH2-VH1-CH1; VH1-VH2-VL2-VL1-CH1;VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL; VL1-VL2-VH2-VH1-CH1-CL;VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1; VH1-VH2-VL2-VL1-CL-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3- VH1-L4-CL-L5-CH1; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-CL-CH1 andthe second polypeptide has a structure represented byVL1-VL2-VH2-VH1-CH1; VL1-VL2-VH2-VH1-CH1; VH1-VH2-VL2-VL1-CH1;VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL; VL1-VL2-VH2-VH1-CH1-CL;VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1; VH1-VH2-VL2-VL1-CL-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1- L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1-CL-CH1 andthe second polypeptide has a structure represented byVL1-VL2-VH2-VH1-CH1; VL1-VL2-VH2-VH1-CH1; VH1-VH2-VL2-VL1-CH1;VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL; VL1-VL2-VH2-VH1-CH1-CL;VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1; VH1-VH2-VL2-VL1-CL-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1 and the second polypeptide has astructure represented by VL1-VL2-VH2-VH1-CH1; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2- L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1 and the second polypeptide has astructure represented by VL1-VL2-VH2-VH1-CH1; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1- VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; or VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1. In someaspects, the first polypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CL and the second polypeptide has astructure represented by VL1-VL2-VH2-VH1-CH1; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1- L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL and the second polypeptide has astructure represented by VL1-VL2-VH2-VH1-CH1; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2- L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL and the second polypeptide has astructure represented by VL1-VL2-VH2-VH1-CH1; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1- L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL and the second polypeptide has astructure represented by VL1-VL2-VH2-VH1-CH1; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2- VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1 and the second polypeptide has astructure represented by VL1-VL2-VH2-VH1-CH1; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; or VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1. Insome aspects, the first polypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1 and the second polypeptide has astructure represented by VL1-VL2-VH2-VH1-CH1; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2- VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; or VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1.

In some aspects, an antigen binding polypeptide of the invention has astructure represented by VL1-VL2-VH2-VH1-CH1-CL-Fc;VH1-VH2-VL2-VL1-CH1-CL-Fc; VL1-VL2-VH2-VH1-CL-CH1-Fc;VH1-VH2-VL2-VL1-CL-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc; wherein VL1 is a firstimmunoglobulin light chain variable region that specifically binds to anHIV protein; VL2 is a second immunoglobulin light chain variable regionthat specifically binds to an HIV protein; VH1 is a first immunoglobulinheavy chain variable region that specifically binds to an HIV protein;VH2 is a second immunoglobulin heavy chain variable region thatspecifically binds to an HIV protein; CH1 is an immunoglobulin heavychain constant region 1; CL is an immunoglobulin light chain constantregion; Fc is a region comprising an immunoglobulin heavy chain constantregion 2 (CH2), an immunoglobulin heavy chain constant region 3 (CH3),and optionally, an immunoglobulin hinge; and L1, L2, L3, L4, L5 and L6are amino acid linkers.

In some aspects, an antigen binding polypeptide complex of the inventioncomprises a first polypeptide and a second polypeptide; wherein thefirst polypeptide has a structure represented by VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3- VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc; wherein the secondpolypeptide has a structure represented by Fc; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc; wherein VL1 is a firstimmunoglobulin light chain variable region that specifically binds to anHIV protein; VL2 is a second immunoglobulin light chain variable regionthat specifically binds to an HIV protein; VH1 is a first immunoglobulinheavy chain variable region that specifically binds to an HIV protein;VH2 is a second immunoglobulin heavy chain variable region thatspecifically binds to an HIV protein; CH1 is an immunoglobulin heavychain constant region 1; CL is an immunoglobulin light chain constantregion; Fc is a region comprising an immunoglobulin heavy chain constantregion 2 (CH2), an immunoglobulin heavy chain constant region 3 (CH3),and optionally, an immunoglobulin hinge; and L1, L2, L3, L4, L5 and L6are amino acid linkers. In some aspects, the first polypeptide has astructure represented by VL1-VL2-VH2-VH1-CH1-Fc and the secondpolypeptide has a structure represented by Fc; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL- L5-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1-CH1-Fc andthe second polypeptide has a structure represented by Fc;VL1-VL2-VH2-VH1-CH1-Fc; VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc;VH1-VH2-VL2-VL1-CL-Fc; VL1-VL2-VH2-VH1-CH1-CL-Fc;VH1-VH2-VL2-VL1-CH1-CL-Fc; VL1-VL2-VH2-VH1-CL-CH1-Fc;VH1-VH2-VL2-VL1-CL-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL- L5-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-CL-Fc and thesecond polypeptide has a structure represented by Fc;VL1-VL2-VH2-VH1-CH1-Fc; VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc;VH1-VH2-VL2-VL1-CL-Fc; VL1-VL2-VH2-VH1-CH1-CL-Fc;VH1-VH2-VL2-VL1-CH1-CL-Fc; VL1-VL2-VH2-VH1-CL-CH1-Fc;VH1-VH2-VL2-VL1-CL-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL- L5-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1-CL-Fc and thesecond polypeptide has a structure represented by Fc;VL1-VL2-VH2-VH1-CH1-Fc; VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc;VH1-VH2-VL2-VL1-CL-Fc; VL1-VL2-VH2-VH1-CH1-CL-Fc;VH1-VH2-VL2-VL1-CH1-CL-Fc; VL1-VL2-VH2-VH1-CL-CH1-Fc;VH1-VH2-VL2-VL1-CL-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL- L5-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-CH1-CL-Fc andthe second polypeptide has a structure represented by Fc;VL1-VL2-VH2-VH1-CH1-Fc; VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc;VH1-VH2-VL2-VL1-CL-Fc; VL1-VL2-VH2-VH1-CH1-CL-Fc;VH1-VH2-VL2-VL1-CH1-CL-Fc; VL1-VL2-VH2-VH1-CL-CH1-Fc;VH1-VH2-VL2-VL1-CL-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL- L5-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1-CH1-CL-Fc andthe second polypeptide has a structure represented by Fc;VL1-VL2-VH2-VH1-CH1-Fc; VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc;VH1-VH2-VL2-VL1-CL-Fc; VL1-VL2-VH2-VH1-CH1-CL-Fc;VH1-VH2-VL2-VL1-CH1-CL-Fc; VL1-VL2-VH2-VH1-CL-CH1-Fc;VH1-VH2-VL2-VL1-CL-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-CL-CH1-Fc andthe second polypeptide has a structure represented by Fc;VL1-VL2-VH2-VH1-CH1-Fc; VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc;VH1-VH2-VL2-VL1-CL-Fc; VL1-VL2-VH2-VH1-CH1-CL-Fc;VH1-VH2-VL2-VL1-CH1-CL-Fc; VL1-VL2-VH2-VH1-CL-CH1-Fc;VH1-VH2-VL2-VL1-CL-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4- CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1-CL-CH1-Fc andthe second polypeptide has a structure represented by Fc;VL1-VL2-VH2-VH1-CH1-Fc; VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc;VH1-VH2-VL2-VL1-CL-Fc; VL1-VL2-VH2-VH1-CH1-CL-Fc;VH1-VH2-VL2-VL1-CH1-CL-Fc; VL1-VL2-VH2-VH1-CL-CH1-Fc;VH1-VH2-VL2-VL1-CL-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc and the second polypeptide has astructure represented by Fc; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fe;VL1-L1-VL2-L2-VH2- L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc and the second polypeptide has astructure represented by Fc; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL- Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6- Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc and the second polypeptide has astructure represented by Fc; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL- L5-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc and the second polypeptide has astructure represented by Fc; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4- CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc and the second polypeptide hasa structure represented by Fc; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL- Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6- Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc and the second polypeptide hasa structure represented by Fc; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc and the second polypeptide hasa structure represented by Fc; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6- Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc and the second polypeptide hasa structure represented by Fc; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL- L5-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-Fc and the second polypeptide has astructure represented by Fc; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-Fc and the second polypeptide has astructure represented by Fc; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-Fc and the second polypeptide has astructure represented by Fc; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3- VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-Fc and the second polypeptide has astructure represented by Fc; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL- Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6- Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fc and the second polypeptidehas a structure represented by Fc; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6-Fc and the second polypeptidehas a structure represented by Fc; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6-Fc and the second polypeptidehas a structure represented by Fc; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4- CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc and the second polypeptidehas a structure represented by Fc; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL- Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6- Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc.

In some aspects, an antigen binding polypeptide complex of the inventioncomprises a first polypeptide and a second polypeptide; wherein thefirst polypeptide has a structure represented by: VL1-VL2-VH2-VH1;VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1;VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2- VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1;VL1-VL2-VH2-VH1-CH1-Fc; VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc;VH1-VH2-VL2-VL1-CL-Fc; VL1-VL2-VH2-VH1-CH1-CL-Fc;VH1-VH2-VL2-VL1-CH1-CL-Fc; VL1-VL2-VH2-VH1-CL-CH1-Fc;VH1-VH2-VL2-VL1-CL-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc; wherein the secondpolypeptide has a structure represented by VL1-VL2-VH2-VH1;VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1;VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1- L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc; wherein VL1 is a firstimmunoglobulin light chain variable region that specifically binds to anHIV protein; VL2 is a second immunoglobulin light chain variable regionthat specifically binds to an HIV protein; VH1 is a first immunoglobulinheavy chain variable region that specifically binds to an HIV protein;VH2 is a second immunoglobulin heavy chain variable region thatspecifically binds to an HIV protein; CH1 is an immunoglobulin heavychain constant region 1; CL is an immunoglobulin light chain constantregion; Fc is a region comprising an immunoglobulin heavy chain constantregion 2 (CH2), an immunoglobulin heavy chain constant region 3 (CH3),and optionally, an immunoglobulin hinge; and L1, L2, L3, L4, L5 and L6are amino acid linkers. In some aspects, the first polypeptide has astructure represented by VL1-VL2-VH2-VH1 and the second polypeptide hasa structure represented by VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1;VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fc;VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3- VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1 and thesecond polypeptide has a structure represented by VL1-VL2-VH2-VH1;VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1;VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1- L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc. In some aspects, the firstpolypeptide has a structure represented by VL1-L1-VL2-L2-VH2-L3-VH1 andthe second polypeptide has a structure represented by VL1-VL2-VH2-VH1;VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1;VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2- L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc; VH1-VH2-VL2-VL1-CH1-Fc;VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc; VL1-VL2-VH2-VH1-CH1-CL-Fc;VH1-VH2-VL2-VL1-CH1-CL-Fc; VL1-VL2-VH2-VH1-CL-CH1-Fc;VH1-VH2-VL2-VL1-CL-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc. In some aspects, the firstpolypeptide has a structure represented by VH1-L1-VH2-L2-VL2-L3-VL1 andthe second polypeptide has a structure represented by VL1-VL2-VH2-VH1;VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1;VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3- VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-Fc and thesecond polypeptide has a structure represented by VL1-VL2-VH2-VH1;VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1;VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1- L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1-Fc and thesecond polypeptide has a structure represented by VL1-VL2-VH2-VH1;VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1;VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc; VH1-VH2-VL2-VL1-CH1-Fc;VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc; VL1-VL2-VH2-VH1-CH1-CL-Fc;VH1-VH2-VL2-VL1-CH1-CL-Fc; VL1-VL2-VH2-VH1-CL-CH1-Fc;VH1-VH2-VL2-VL1-CL-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc. In some aspects, the firstpolypeptide has a structure represented by VL1-L1-VL2-L2-VH2-L3-VH1-Fcand the second polypeptide has a structure represented byVL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1;VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc;VL1-VL2-VH2-VH1-CH1; VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL;VH1-VH2-VL2-VL1-CL; VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL;VL1-VL2-VH2-VH1-CL-CH1; VH1-VH2-VL2-VL1-CL-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL;VL1-L1-VL2-L2-VH2- L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc. In some aspects, the firstpolypeptide has a structure represented by VH1-L1-VH2-L2-VL2-L3-VL1-Fcand the second polypeptide has a structure represented byVL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1;VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc;VL1-VL2-VH2-VH1-CH1; VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL;VH1-VH2-VL2-VL1-CL; VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL;VL1-VL2-VH2-VH1-CL-CH1; VH1-VH2-VL2-VL1-CL-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL; VH1-L1-VH2-L2-VL2- L3-VL1-L4-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL- Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc and the second polypeptide has astructure represented by VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1;VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fc;VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc; VH1-VH2-VL2-VL1-CH1-Fc;VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc; VL1-VL2-VH2-VH1-CH1-CL-Fc;VH1-VH2-VL2-VL1-CH1-CL-Fc; VL1-VL2-VH2-VH1-CL-CH1-Fc;VH1-VH2-VL2-VL1-CL-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc and the second polypeptide has astructure represented by VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1;VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fc;VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2- VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1;VL1-VL2-VH2-VH1-CH1-Fc; VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc;VH1-VH2-VL2-VL1-CL-Fc; VL1-VL2-VH2-VH1-CH1-CL-Fc;VH1-VH2-VL2-VL1-CH1-CL-Fc; VL1-VL2-VH2-VH1-CL-CH1-Fc;VH1-VH2-VL2-VL1-CL-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-CH1 and thesecond polypeptide has a structure represented by VL1-VL2-VH2-VH1;VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1;VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3- VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1-CH1 and thesecond polypeptide has a structure represented by VL1-VL2-VH2-VH1;VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1;VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1- L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-CL and thesecond polypeptide has a structure represented by VL1-VL2-VH2-VH1;VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1;VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc; VH1-VH2-VL2-VL1-CH1-Fc;VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc; VL1-VL2-VH2-VH1-CH1-CL-Fc;VH1-VH2-VL2-VL1-CH1-CL-Fc; VL1-VL2-VH2-VH1-CL-CH1-Fc;VH1-VH2-VL2-VL1-CL-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1-CL and thesecond polypeptide has a structure represented by VL1-VL2-VH2-VH1;VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1;VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3- VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6- Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-CH1-CL andthe second polypeptide has a structure represented by VL1-VL2-VH2-VH1;VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1;VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3- VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1-CH1-CL andthe second polypeptide has a structure represented by VL1-VL2-VH2-VH1;VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1;VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1- L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL- L5-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-CL-CH1 andthe second polypeptide has a structure represented by VL1-VL2-VH2-VH1;VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1;VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1- L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1- L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1-CL-CH1 andthe second polypeptide has a structure represented by VL1-VL2-VH2-VH1;VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1;VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3- VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1 and the second polypeptide has astructure represented by VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1;VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fc;VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2- L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1 and the second polypeptide has astructure represented by VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1;VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fc;VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2- L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CL and the second polypeptide has astructure represented by VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1;VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fc;VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2- L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL- Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL and the second polypeptide has astructure represented by VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1;VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fc;VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc; VH1-VH2-VL2-VL1-CH1-Fc;VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc; VL1-VL2-VH2-VH1-CH1-CL-Fc;VH1-VH2-VL2-VL1-CH1-CL-Fc; VL1-VL2-VH2-VH1-CL-CH1-Fc;VH1-VH2-VL2-VL1-CL-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL and the second polypeptide has astructure represented by VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1;VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fc;VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2- L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1;VL1-VL2-VH2-VH1-CH1-Fc; VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc;VH1-VH2-VL2-VL1-CL-Fc; VL1-VL2-VH2-VH1-CH1-CL-Fc;VH1-VH2-VL2-VL1-CH1-CL-Fc; VL1-VL2-VH2-VH1-CL-CH1-Fc;VH1-VH2-VL2-VL1-CL-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL- L5-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL and the second polypeptide has astructure represented by VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1;VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fc;VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1- L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL- L5-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1 and the second polypeptide has astructure represented by VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1;VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fc;VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2- L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1 and the second polypeptide has astructure represented by VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1;VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fc;VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1- L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-CH1-Fc andthe second polypeptide has a structure represented by VL1-VL2-VH2-VH1;VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1;VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc; VH1-VH2-VL2-VL1-CH1-Fc;VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc; VL1-VL2-VH2-VH1-CH1-CL-Fc;VH1-VH2-VL2-VL1-CH1-CL-Fc; VL1-VL2-VH2-VH1-CL-CH1-Fc;VH1-VH2-VL2-VL1-CL-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1-CH1-Fc andthe second polypeptide has a structure represented by VL1-VL2-VH2-VH1;VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1;VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2- L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-CL-Fc and thesecond polypeptide has a structure represented by VL1-VL2-VH2-VH1;VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1;VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3- VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1-CL-Fc and thesecond polypeptide has a structure represented by VL1-VL2-VH2-VH1;VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1;VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1- L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL- L5-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-CH1-CL-Fc andthe second polypeptide has a structure represented by VL1-VL2-VH2-VH1;VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1;VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1- L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1- L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1-CH1-CL-Fc andthe second polypeptide has a structure represented by VL1-VL2-VH2-VH1;VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1;VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3- VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-CL-CH1-Fc andthe second polypeptide has a structure represented by VL1-VL2-VH2-VH1;VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1;VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1- L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL- L5-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1-CL-CH1-Fc andthe second polypeptide has a structure represented by VL1-VL2-VH2-VH1;VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1;VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1- L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1- L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc and the second polypeptide has astructure represented by VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1;VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fc;VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2- L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL- Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc and the second polypeptide has astructure represented by VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1;VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fc;VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc; VH1-VH2-VL2-VL1-CH1-Fc;VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc; VL1-VL2-VH2-VH1-CH1-CL-Fc;VH1-VH2-VL2-VL1-CH1-CL-Fc; VL1-VL2-VH2-VH1-CL-CH1-Fc;VH1-VH2-VL2-VL1-CL-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc and the second polypeptide has astructure represented by VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1;VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fc;VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2- VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1;VL1-VL2-VH2-VH1-CH1-Fc; VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc;VH1-VH2-VL2-VL1-CL-Fc; VL1-VL2-VH2-VH1-CH1-CL-Fc;VH1-VH2-VL2-VL1-CH1-CL-Fc; VL1-VL2-VH2-VH1-CL-CH1-Fc;VH1-VH2-VL2-VL1-CL-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc and the second polypeptide has astructure represented by VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1;VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fc;VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1- L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc and the second polypeptide hasa structure represented by VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1;VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fc;VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1- L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1- L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc and the second polypeptide hasa structure represented by VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1;VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fc;VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1- L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc and the second polypeptide hasa structure represented by VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1;VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fc;VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1- L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1- L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc and the second polypeptide hasa structure represented by VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1;VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fc;VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1- L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-Fc and the second polypeptide has astructure represented by VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1;VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fc;VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1- L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1- L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-Fc and the second polypeptide has astructure represented by VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1;VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fc;VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2- L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL- Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-Fc and the second polypeptide has astructure represented by VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1;VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fc;VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2- L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc; VH1-VH2-VL2-VL1-CH1-Fc;VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc; VL1-VL2-VH2-VH1-CH1-CL-Fc;VH1-VH2-VL2-VL1-CH1-CL-Fc; VL1-VL2-VH2-VH1-CL-CH1-Fc;VH1-VH2-VL2-VL1-CL-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-Fc and the second polypeptide has astructure represented by VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1;VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fc;VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2- L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL- Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fc and the second polypeptidehas a structure represented by VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1;VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fc;VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1- VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5- CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6-Fc and the second polypeptidehas a structure represented by VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1;VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fc;VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1- L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6-Fc and the second polypeptidehas a structure represented by VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1;VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fc;VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1- L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL- Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6- Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc and the second polypeptidehas a structure represented by VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1;VL1-L1-VL2-L2-VH2-L3-VH1; VH1-L1-VH2-L2-VL2-L3-VL1; VL1-VL2-VH2-VH1-Fc;VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-VL2-VH2-VH1-CH1;VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL;VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1;VH1-VH2-VL2-VL1-CL-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1- L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fe;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fe; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fe;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fe;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-Fe;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-Fe;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-Fe;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fe;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc.

In other aspects, the invention is directed to an antigen bindingpolypeptide or antigen binding polypeptide complex comprising apolypeptide having a structure represented by VL1-VL2-VH2-VH1 orVH1-VH2-VL2-VL1 which has two Fc regions. In some aspects, one or bothFc regions comprise an amino acid sequence of any one of SEQ IDNOs:391-404 or an amino acid sequence having at least 80%, at least 85%,at least 90%, at least 95%, at least 96%, at least 97%, at least 98% orat least 99% identity to any one of SEQ ID NOs:391-404. In some aspects,an antigen binding polypeptide or antigen binding polypeptide complexcomprises a polypeptide having a structure represented byVL1-VL2-VH2-VH1-Fc-Fc; VH1-VH2-VL2-VL1-Fc-F c;VL1-L1-VL2-L2-VH2-L3-VH1-Fc-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-Fc-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc- Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc-L5-Fe; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-Fe-L5-Fe; wherein VL1 is a firstimmunoglobulin light chain variable region that specifically binds to anHIV protein; VL2 is a second immunoglobulin light chain variable regionthat specifically binds to an HIV protein; VH1 is a first immunoglobulinheavy chain variable region that specifically binds to an HIV protein;VH2 is a second immunoglobulin heavy chain variable region thatspecifically binds to an HIV protein; Fc is a region comprising animmunoglobulin heavy chain constant region 2 (CH2), an immunoglobulinheavy chain constant region 3 (CH3), and optionally, an immunoglobulinhinge; and L1, L2, L3, L4 and L5 are amino acid linkers.

In other aspects, the invention is directed to an antigen bindingpolypeptide or antigen binding polypeptide complex comprising apolypeptide having a structure represented by VL1-VL2-VH2-VH1 orVH1-VH2-VL2-VL1 which has one or two CH3 regions. In some aspects, oneor both CH3 regions comprise an amino acid sequence of any one of SEQ IDNOs:416-419 or an amino acid sequence having at least 80%, at least 85%,at least 90%, at least 95%, at least 96%, at least 97%, at least 98% orat least 99% identity to any one of SEQ ID NOs:416-419. In some aspects,the antigen binding polypeptide or antigen binding polypeptide complexcomprises a polypeptide having a structure represented byVL1-VL2-VH2-VH1-CH3; VH1-VH2-VL2-VL1-CH3; VL1-L1-VL2-L2-VH2-L3-VH1-CH3;VH1-L1-VH2-L2-VL2-L3-VL1-CH3; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH3;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH3; VL1-VL2-VH2-VH1-CH3-CH3;VH1-VH2-VL2-VL1-CH3-CH3; VL1-L1-VL2-L2-VH2-L3-VH1-CH3-CH3;VH1-L1-VH2-L2-VL2-L3-VL1-CH3-CH3; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH3-CH3;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH3-CH3;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH3-L5-CH3; or VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH3-L5-CH3; wherein VL1 is a first immunoglobulin light chain variableregion that specifically binds to an HIV protein; VL2 is a secondimmunoglobulin light chain variable region that specifically binds to anHIV protein; VH1 is a first immunoglobulin heavy chain variable regionthat specifically binds to an HIV protein; VH2 is a secondimmunoglobulin heavy chain variable region that specifically binds to anHIV protein; CH3 is an immunoglobulin heavy chain constant region 3; andL1, L2, L3, L4 and L5 are amino acid linkers.

In some aspects of an antigen binding polypeptide or antigen bindingpolypeptide complex of the invention, VH1 and VH2 each comprise a heavychain variable region from the PGT121, VRC01, 10E8v4 or PG16 antibody ora variant thereof. In another aspect, VL1 and VL2 each comprise a lightchain variable region from the PGT121, VRC01, 10E8v4 or PG16 antibody ora variant thereof. In some aspects, VH1 and VH2 each comprise a heavychain variable region from the PGT121, VRC01, 10E8v4 or PG16 antibody ora variant thereof, and VL1 and VL2 each comprise a light chain variableregion from the PGT121, VRC01, 10E8v4 or PG16 antibody or a variantthereof.

In some aspects, antigen binding polypeptides or antigen bindingpolypeptide complexes comprise VH and VL sequences from broadlyneutralizing antibodies that target CD4bs inclusive of VRC01, VRC03,3BNC117, N6, N49P7, 3BNC60, VRC-PG04, VRC-PG20, NIH45-46, VRC-CH31,12A12, CH103, 8ANC131, VRC13 and VRC16.

In some aspects, VH1 and VH2 of an antigen binding polypeptide orantigen binding polypeptide complex of the invention each comprise anamino acid sequence having at least 90% identity, at least 95% identityor 100% identity to any one of SEQ ID NOs:20-23. For example, the VH1and VH2 of an antigen binding polypeptide or antigen binding polypeptidecomplex may each comprise an amino acid sequence having at least 90%identity (such as at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%identity) to any one of SEQ ID NOs:20-23. For example, the VH1 and VH2of an antigen binding polypeptide or antigen binding polypeptide complexmay each comprise the amino acid sequence of any one of SEQ IDNOs:20-23. In some aspects, VL1 and VL2 each comprise an amino acidsequence having at least 90% identity, at least 95% identity or 100%identity to any one of SEQ ID NOs:24-27. For example, the VL1 and VL2 ofan antigen binding polypeptide or antigen binding polypeptide complexmay each comprise an amino acid sequence having at least 90% identity(such as at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%identity) to any one of SEQ ID NOs: 24-27. For example, the VL1 and VL2of an antigen binding polypeptide or antigen binding polypeptide complexmay each comprise the amino acid sequence of any one of SEQ ID NOs:24-27. In some aspects, VH1 and VH2 of an antigen binding polypeptide orantigen binding polypeptide complex of the invention each comprise anamino acid sequence having at least 90% identity, at least 95% identityor 100% identity to any one of SEQ ID NOs:20-23, and VL1 and VL2 eachcomprise an amino acid sequence having at least 90% identity, at least95% identity or 100% identity to any one of SEQ ID NOs:24-27. Forexample, the VH1 and VH2 of an antigen binding polypeptide or antigenbinding polypeptide complex of the invention may each comprise an aminoacid sequence having at least 90% identity (such as at least 91%, 92%,93%, 94%, 95%, 96%, 97%, 98% or 99% identity) to any one of SEQ IDNOs:20-23, and VL1 and VL2 each comprise an amino acid sequence havingat least 90% identity (such as at least 91%, 92%, 93%, 94%, 95%, 96%,97%, 98% or 99% identity) to any one of SEQ ID NOs:24-27.

In some aspects, VH1 and VH2 of an antigen binding polypeptide orantigen binding polypeptide complex of the invention each comprise aCDR1 having an amino acid sequence with at least 90% identity, at least95% identity or 100% identity to any one of SEQ ID NOs:60, 63, 66 and69; a CDR2 having an amino acid sequence with at least 90% identity, atleast 95% identity or 100% identity to any one of SEQ ID NOs:61, 64, 67and 70; and a CDR3 having an amino acid sequence with at least 90%identity, at least 95% identity or 100% identity to any one of SEQ IDNOs:62, 65, 68 and 71; and/or VL1 and VL2 each comprise a CDR1 having anamino acid sequence with at least 90% identity, at least 95% identity or100% identity to any one of SEQ ID NOs:72, 75, 78 and 81; a CDR2 havingan amino acid sequence with at least 90% identity, at least 95% identityor 100% identity to any one of SEQ ID NOs:73, 76, 79 and 82; and a CDR3having an amino acid sequence with at least 90% identity, at least 95%identity or 100% identity to any one of SEQ ID NOs:74, 77, 80 and 83.For example, the VH1 and VH2 of an antigen binding polypeptide orantigen binding polypeptide complex may each comprise a CDR1 having anamino acid sequence with at least 90% identity (such as at least 91%,92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity) to any one of SEQ IDNOs:60, 63, 66 and 69; a CDR2 having an amino acid sequence with atleast 90% identity (such as at least 91%, 92%, 93%, 94%, 95%, 96%, 97%,98% or 99% identity) to any one of SEQ ID NOs:61, 64, 67 and 70; and aCDR3 having an amino acid sequence with at least 90% identity (such asat least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity) to anyone of SEQ ID NOs:62, 65, 68 and 71; and/or the VL1 and VL2 may eachcomprise a CDR1 having an amino acid sequence with at least 90% identity(such as at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%identity) to any one of SEQ ID NOs:72, 75, 78 and 81; a CDR2 having anamino acid sequence with at least 90% identity (such as at least 91%,92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity) to any one of SEQ IDNOs:73, 76, 79 and 82; and a CDR3 having an amino acid sequence with atleast 90% identity (such as at least 91%, 92%, 93%, 94%, 95%, 96%, 97%,98% or 99% identity) to any one of SEQ ID NOs:74, 77, 80 and 83. Forexample, the VH1 and VH2 of an antigen binding polypeptide or antigenbinding polypeptide complex may each comprise a CDR1 having the aminoacid sequence of any one of SEQ ID NOs:60, 63, 66 and 69; a CDR2 havingthe amino acid sequence of any one of SEQ ID NOs:61, 64, 67 and 70; anda CDR3 having the amino acid sequence of any one of SEQ ID NOs:62, 65,68 and 71; and/or the VL1 and VL2 may each comprise a CDR1 having theamino acid sequence of any one of SEQ ID NOs:72, 75, 78 and 81; a CDR2having the amino acid sequence of any one of SEQ ID NOs:73, 76, 79 and82; and a CDR3 having the amino acid sequence of any one of SEQ IDNOs:74, 77, 80 and 83.

In another example, the VH1 and VH2 of an antigen binding polypeptide orantigen binding polypeptide complex may each comprise a CDR1 having anamino acid sequence with at least 90% identity (such as at least 91%,92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity) to SEQ ID NO:60; aCDR2 having an amino acid sequence with at least 90% identity (such asat least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity) to SEQID NO:61; and a CDR3 having an amino acid sequence with at least 90%identity (such as at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%identity) to SEQ ID NO:62; and the VL1 and VL2 may each comprise a CDR1having an amino acid sequence with at least 90% identity (such as atleast 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity) to SEQ IDNO:72; a CDR2 having an amino acid sequence with at least 90% identity(such as at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%identity) to SEQ ID NO:73; and a CDR3 having an amino acid sequence withat least 90% identity (such as at least 91%, 92%, 93%, 94%, 95%, 96%,97%, 98% or 99% identity) to SEQ ID NO:74. For example, the VH1 and VH2of an antigen binding polypeptide or antigen binding polypeptide complexmay each comprise a CDR1 having the amino acid sequence of SEQ ID NO:60;a CDR2 having the amino acid sequence of any one of SEQ ID NO:61; and aCDR3 having the amino acid sequence of SEQ ID NO:62; and the VL1 and VL2may each comprise a CDR1 having the amino acid sequence of SEQ ID NO:72;a CDR2 having the amino acid sequence of SEQ ID NO:73; and a CDR3 havingthe amino acid sequence of SEQ ID NO:74.

In another example, the VH1 and VH2 of an antigen binding polypeptide orantigen binding polypeptide complex may each comprise a CDR1 having anamino acid sequence with at least 90% identity (such as at least 91%,92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity) to SEQ ID NO:63; aCDR2 having an amino acid sequence with at least 90% identity (such asat least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity) to SEQID NO:64; and a CDR3 having an amino acid sequence with at least 90%identity (such as at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%identity) to SEQ ID NO:65; and the VL1 and VL2 may each comprise a CDR1having an amino acid sequence with at least 90% identity (such as atleast 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity) to SEQ IDNO:75; a CDR2 having an amino acid sequence with at least 90% identity(such as at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%identity) to SEQ ID NO:76; and a CDR3 having an amino acid sequence withat least 90% identity (such as at least 91%, 92%, 93%, 94%, 95%, 96%,97%, 98% or 99% identity) to SEQ ID NO:77. For example, the VH1 and VH2of an antigen binding polypeptide or antigen binding polypeptide complexmay each comprise a CDR1 having the amino acid sequence of SEQ ID NO:63a CDR2 having the amino acid sequence of any one of SEQ ID NO:64; and aCDR3 having the amino acid sequence of SEQ ID NO:65; and the VL1 and VL2may each comprise a CDR1 having the amino acid sequence of SEQ ID NO:75;a CDR2 having the amino acid sequence of SEQ ID NO:76; and a CDR3 havingthe amino acid sequence of SEQ ID NO:77.

In another example, the VH1 and VH2 of an antigen binding polypeptide orantigen binding polypeptide complex may each comprise a CDR1 having anamino acid sequence with at least 90% identity (such as at least 91%,92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity) to SEQ ID NO:66; aCDR2 having an amino acid sequence with at least 90% identity (such asat least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity) to SEQID NO:67; and a CDR3 having an amino acid sequence with at least 90%identity (such as at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%identity) to SEQ ID NO:68; and the VL1 and VL2 may each comprise a CDR1having an amino acid sequence with at least 90% identity (such as atleast 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity) to SEQ IDNO:78; a CDR2 having an amino acid sequence with at least 90% identity(such as at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%identity) to SEQ ID NO:79; and a CDR3 having an amino acid sequence withat least 90% identity (such as at least 91%, 92%, 93%, 94%, 95%, 96%,97%, 98% or 99% identity) to SEQ ID NO:80. For example, the VH1 and VH2of an antigen binding polypeptide or antigen binding polypeptide complexmay each comprise a CDR1 having the amino acid sequence of SEQ ID NO:66;a CDR2 having the amino acid sequence of any one of SEQ ID NO:67; and aCDR3 having the amino acid sequence of SEQ ID NO:68; and the VL1 and VL2may each comprise a CDR1 having the amino acid sequence of SEQ ID NO:78;a CDR2 having the amino acid sequence of SEQ ID NO:79; and a CDR3 havingthe amino acid sequence of SEQ ID NO:80.

In another example, the VH1 and VH2 of an antigen binding polypeptide orantigen binding polypeptide complex may each comprise a CDR1 having anamino acid sequence with at least 90% identity (such as at least 91%,92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity) to SEQ ID NO:69; aCDR2 having an amino acid sequence with at least 90% identity (such asat least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity) to SEQID NO:70; and a CDR3 having an amino acid sequence with at least 90%identity (such as at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%identity) to SEQ ID NO:71; and the VL1 and VL2 may each comprise a CDR1having an amino acid sequence with at least 90% identity (such as atleast 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity) to SEQ IDNO:81; a CDR2 having an amino acid sequence with at least 90% identity(such as at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%identity) to SEQ ID NO:82; and a CDR3 having an amino acid sequence withat least 90% identity (such as at least 91%, 92%, 93%, 94%, 95%, 96%,97%, 98% or 99% identity) to SEQ ID NO:83. For example, the VH1 and VH2of an antigen binding polypeptide or antigen binding polypeptide complexmay each comprise a CDR1 having the amino acid sequence of SEQ ID NO:69;a CDR2 having the amino acid sequence of any one of SEQ ID NO:70; and aCDR3 having the amino acid sequence of SEQ ID NO:71; and the VL1 and VL2may each comprise a CDR1 having the amino acid sequence of SEQ ID NO:81;a CDR2 having the amino acid sequence of SEQ ID NO:82; and a CDR3 havingthe amino acid sequence of SEQ ID NO:83.

In yet other aspects, the invention is directed to antigen bindingpolypeptide complexes having a first polypeptide and a secondpolypeptide, wherein the first polypeptide has a structure representedby VL1-VL2-VH2-VH1 or VH1-VH2-VL2-VL1, and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3 or VH3-VH4-VL4-VL3, wherein theantigen binding polypeptide complexes specifically bind to an HIVprotein. In some aspects, the first polypeptide has a structurerepresented by VL1-VL2-VH2-VH1 and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1 and thesecond polypeptide has a structure represented by VH3-VH4-VL4-VL3. Insome aspects, the first polypeptide has a structure represented byVH1-VH2-VL2-VL1 and the second polypeptide has a structure representedby VL3-VL4-VH4-VH3. In some aspects, the first polypeptide has astructure represented by VH1-VH2-VL2-VL1 and the second polypeptide hasa structure represented by VH3-VH4-VL4-VL3. In some aspects, the antigenbinding polypeptide complex contains an amino acid linker between anytwo regions denoted in a structure described herein. In some aspects,the antigen binding polypeptide complex can contain an Fc region, CH1region, CL region, CH3 region or any combination thereof. In someaspects, the Fc region, CH1 region, CL region and/or CH3 is located atthe carboxy terminus of the first polypeptide and/or second polypeptide,and is optionally linked to polypeptide by at least one amino acidlinker. In some aspects, the Fc region, CH1 region, CL region and/or CH3is located at the carboxy terminus of the first polypeptide, and isoptionally linked to polypeptide by at least one amino acid linker. Insome aspects, the Fc region, CH1 region, CL region and/or CH3 is locatedat the carboxy terminus of the second polypeptide, and is optionallylinked to polypeptide by at least one amino acid linker. In someaspects, the Fc region, CH1 region, CL region and/or CH3 is located atthe carboxy terminus of the first polypeptide and second polypeptide,and is optionally linked to polypeptide by at least one amino acidlinker. In some aspects, the Fc region comprises an amino acid sequenceof any one of SEQ ID NOs:391-404 or an amino acid sequence having atleast 80%, at least 85%, at least 90%, at least 95%, at least 96%, atleast 97%, at least 98%, or at least 99% identity to any one of SEQ IDNOs:391-404. In some aspects, the CH1 region comprises an amino acidsequence of any one of SEQ ID NOs:405-409 or an amino acid sequencehaving at least 80%, at least 85%, at least 90%, at least 95%, at least96%, at least 97%, at least 98%, or at least 99% identity to any one ofSEQ ID NOs:405-409. In some aspects, the CL region comprises an aminoacid sequence of SEQ ID NO:420 or 421 or an amino acid sequence havingat least 80%, at least 85%, at least 90%, at least 95%, at least 96%, atleast 97%, at least 98% or at least 99% identity to SEQ ID NO:420 or421. In some aspects, the antigen binding polypeptide complex is anantibody or antigen binding fragment thereof.

Specific binding to an HIV protein includes, but is not limited to,specific binding to one or more HIV proteins and specific binding to oneor more epitopes on the same HIV protein. In some aspects, the HIVprotein is selected from the group consisting of an HIV envelopeprotein, an HIV structural protein, an HIV functional protein, or an HIVaccessory protein. In some aspects, the HIV envelope protein is HIVenvelope glycoprotein (Env), HIV envelope glycoprotein gp160, HIVenvelope surface glycoprotein gp120, or HIV transmembrane envelopeprotein gp41. In some aspects, the HIV structural protein is p17, p24,p7 or p55. In some aspects, the HIV functional protein is p66, HIV-1protease (PR) or p31. In some aspects, the HIV accessory protein is Nef,Tat, Rev, Vif, Vpr or Vpu.

In some aspects, the invention is directed to an antigen bindingpolypeptide complex comprising a first polypeptide and a secondpolypeptide; wherein the first polypeptide has a structure representedby VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1; orVH1-L1-VH2-L2-VL2-L3-VL1; wherein the second polypeptide has a structurerepresented by VL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3;VL3-L4-VL4-L5-VH4-L6-VH3; or VH3-L4-VH4-L5-VL4-L6-VL3; wherein VL1 is afirst immunoglobulin light chain variable region that specifically bindsto an HIV protein; VL2 is a second immunoglobulin light chain variableregion that specifically binds to an HIV protein; VL3 is a thirdimmunoglobulin light chain variable region that specifically binds to anHIV protein; VL4 is a fourth immunoglobulin light chain variable regionthat specifically binds to an HIV protein; VH1 is a first immunoglobulinheavy chain variable region that specifically binds to an HIV protein;VH2 is a second immunoglobulin heavy chain variable region thatspecifically binds to an HIV protein; VH3 is a third immunoglobulinheavy chain variable region that specifically binds to an HIV protein;VH4 is a fourth immunoglobulin heavy chain variable region thatspecifically binds to an HIV protein; and L1, L2, L3, L4, L5 and L6 areamino acid linkers. In some aspects, the first polypeptide has astructure represented by VL1-VL2-VH2-VH1, and the second polypeptide hasa structure represented by VL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3;VL3-L4-VL4-L5-VH4-L6-VH3; or VH3-L4-VH4-L5-VL4-L6-VL3. In some aspects,the first polypeptide has a structure represented by VH1-VH2-VL2-VL1,and the second polypeptide has a structure represented byVL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3; VL3-L4-VL4-L5-VH4-L6-VH3; orVH3-L4-VH4-L5-VL4-L6-VL3. In some aspects, the first polypeptide has astructure represented by VL1-L1-VL2-L2-VH2-L3-VH1, and the secondpolypeptide has a structure represented by VL3-VL4-VH4-VH3;VH3-VH4-VL4-VL3; VL3-L4-VL4-L5-VH4-L6-VH3; or VH3-L4-VH4-L5-VL4-L6-VL3.In some aspects, the first polypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1, and the second polypeptide has a structurerepresented by VL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3;VL3-L4-VL4-L5-VH4-L6-VH3; or VH3-L4-VH4-L5-VL4-L6-VL3.

In other aspects, the invention is directed to an antigen bindingpolypeptide complex comprising a first polypeptide and a secondpolypeptide; wherein the first polypeptide has a structure representedby VL1-VL2-VH2-VH1-Fe; VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; wherein the second polypeptide has astructure represented by VL3-VL4-VH4-VH3-Fe; VH3-VH4-VL4-VL3-Fc;VL3-L5-VL4-L6-VH4-L7-VH3-Fc; VH3-L5-VH4-L6-VL4-L7-VL3-Fc;VL3-L5-VL4-L6-VH4-L7-VH3-L8-Fc; or VH3-L5-VH4-L6-VL4-L7-VL3-L8-Fc;wherein VL1 is a first immunoglobulin light chain variable region thatspecifically binds to an HIV protein; VL2 is a second immunoglobulinlight chain variable region that specifically binds to an HIV protein;VL3 is a third immunoglobulin light chain variable region thatspecifically binds to an HIV protein; VL4 is a fourth immunoglobulinlight chain variable region that specifically binds to an HIV protein;VH1 is a first immunoglobulin heavy chain variable region thatspecifically binds to an HIV protein; VH2 is a second immunoglobulinheavy chain variable region that specifically binds to an HIV protein;VH3 is a third immunoglobulin heavy chain variable region thatspecifically binds to an HIV protein; VH4 is a fourth immunoglobulinheavy chain variable region that specifically binds to an HIV protein;Fc is a region comprising an immunoglobulin heavy chain constant region2 (CH2), an immunoglobulin heavy chain constant region 3 (CH3), andoptionally, an immunoglobulin hinge; and L1, L2, L3, L4, L5, L6, L7 andL8 are amino acid linkers. In some aspects, the first polypeptide has astructure represented by VL1-VL2-VH2-VH1-Fc and the second polypeptidehas a structure represented by VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc;VL3-L5-VL4-L6-VH4-L7-VH3-Fc; VH3-L5-VH4-L6-VL4-L7-VL3-Fc;VL3-L5-VL4-L6-VH4-L7-VH3-L8-Fc; or VH3-L5-VH4-L6-VL4-L7-VL3-L8-Fe. Insome aspects, the first polypeptide has a structure represented byVH1-VH2-VL2-VL1-Fc and the second polypeptide has a structurerepresented by VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc;VL3-L5-VL4-L6-VH4-L7-VH3-Fc; VH3-L5-VH4-L6-VL4-L7-VL3-Fc;VL3-L5-VL4-L6-VH4-L7-VH3-L8-Fc; or VH3-L5-VH4-L6-VL4-L7-VL3-L8-Fc. Insome aspects, the first polypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-Fe and the second polypeptide has a structurerepresented by VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc;VL3-L5-VL4-L6-VH4-L7-VH3-Fc; VH3-L5-VH4-L6-VL4-L7-VL3-Fc;VL3-L5-VL4-L6-VH4-L7-VH3-L8-Fc; or VH3-L5-VH4-L6-VL4-L7-VL3-L8-Fe. Insome aspects, the first polypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-Fc and the second polypeptide has a structurerepresented by VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc;VL3-L5-VL4-L6-VH4-L7-VH3-Fc; VH3-L5-VH4-L6-VL4-L7-VL3-Fc;VL3-L5-VL4-L6-VH4-L7-VH3-L8-Fc; or VH3-L5-VH4-L6-VL4-L7-VL3-L8-Fc. Insome aspects, the first polypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fe;VL3-L5-VL4-L6-VH4-L7-VH3-Fc; VH3-L5-VH4-L6-VL4-L7-VL3-Fc;VL3-L5-VL4-L6-VH4-L7-VH3-L8-Fc; or VH3-L5-VH4-L6-VL4-L7-VL3-L8-Fc. Insome aspects, the first polypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc;VL3-L5-VL4-L6-VH4-L7-VH3-Fc; VH3-L5-VH4-L6-VL4-L7-VL3-Fc;VL3-L5-VL4-L6-VH4-L7-VH3-L8-Fc; or VH3-L5-VH4-L6-VL4-L7-VL3-L8-Fe.

In other aspects, the invention is directed to an antigen bindingpolypeptide complex comprising a first polypeptide and a secondpolypeptide; wherein the first polypeptide has a structure representedby VL1-VL2-VH2-VH1-CH1; VH1-VH2-VL2-VL1-CH1; VL1-VL2-VH2-VH1-CL;VH1-VH2-VL2-VL1-CL; VL1-VL2-VH2-VH1-CH1-CL; VH1-VH2-VL2-VL1-CH1-CL;VL1-VL2-VH2-VH1-CL-CH1; VH1-VH2-VL2-VL1-CL-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL; VH1-L1- VH2-L2-VL2-L3-VL1-L4-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; wherein the second polypeptidehas a structure represented by VL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1;VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL;VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL;VL3-L6-VL4- L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1; wherein VL1 is a firstimmunoglobulin light chain variable region that specifically binds to anHIV protein; VL2 is a second immunoglobulin light chain variable regionthat specifically binds to an HIV protein; VL3 is a third immunoglobulinlight chain variable region that specifically binds to an HIV protein;VL4 is a fourth immunoglobulin light chain variable region thatspecifically binds to an HIV protein; VH1 is a first immunoglobulinheavy chain variable region that specifically binds to an HIV protein;VH2 is a second immunoglobulin heavy chain variable region thatspecifically binds to an HIV protein; VH3 is a third immunoglobulinheavy chain variable region that specifically binds to an HIV protein;VH4 is a fourth immunoglobulin heavy chain variable region thatspecifically binds to an HIV protein; CH1 is an immunoglobulin heavychain constant region 1; CL is an immunoglobulin light chain constantregion; and L1, L2, L3, L4, L5, L6, L7, L8, L9 and L10 are amino acidlinkers. In some aspects, the first polypeptide has a structurerepresented by VL1-VL2-VH2-VH1-CH1 and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1;VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL;VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL;VL3-L6-VL4- L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1-CH1 and thesecond polypeptide has a structure represented by VL3-VL4-VH4-VH3-CH1;VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL;VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1;VH3-VH4-VL4-VL3-CL-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3- L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-CL and thesecond polypeptide has a structure represented by VL3-VL4-VH4-VH3-CH1;VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL;VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1;VH3-VH4-VL4-VL3-CL-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3- L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1-CL and thesecond polypeptide has a structure represented by VL3-VL4-VH4-VH3-CH1;VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL;VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1;VH3-VH4-VL4-VL3-CL-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7- VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-CH1-CL andthe second polypeptide has a structure represented byVL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL;VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL;VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL;VL3-L6-VL4-L7-VH4-L8-VH3- L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1-CH1-CL andthe second polypeptide has a structure represented byVL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL;VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL;VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL; VH3-L6-VH4- L7-VL4-L8-VL3-L9-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-CL-CH1 andthe second polypeptide has a structure represented byVL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL;VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL;VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL;VL3-L6-VL4-L7-VH4-L8-VH3- L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1-CL-CH1 andthe second polypeptide has a structure represented byVL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL;VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL;VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL; VH3-L6-VH4- L7-VL4-L8-VL3-L9-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1 and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1;VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL;VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL;VL3-L6-VL4-L7-VH4- L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1 and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1;VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL;VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CL and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1;VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL;VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1;VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL;VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1;VL3-L6-VL4-L7-VH4- L8-VH3-L9-CL; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1;VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL;VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL; VH3-L6-VH4-L7- VL4-L8-VL3-L9-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1;VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL;VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL;VL3-L6-VL4- L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1 and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1;VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL;VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1;VL3-L6-VL4- L7-VH4-L8-VH3-L9-CL; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1 and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1;VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL;VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL; VH3-L6-VH4- L7-VL4-L8-VL3-L9-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1.

In other aspects, the invention is directed to an antigen bindingpolypeptide complex comprising a first polypeptide and a secondpolypeptide; wherein the first polypeptide has a structure representedby VL1-VL2-VH2-VH1-CH1-Fc; VH1-VH2-VL2-VL1-CH1-Fe;VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc; VL1-VL2-VH2-VH1-CH1-CL-Fc;VH1-VH2-VL2-VL1-CH1-CL-Fe; VL1-VL2-VH2-VH1-CL-CH1-Fc;VH1-VH2-VL2-VL1-CL-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fe; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL- Fe;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fe;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fe; wherein the second polypeptidehas a structure represented by VL3-VL4-VH4-VH3-CH1-Fc;VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc;VL3-VL4-VH4-VH3-CH1-CL-Fc; VH3-VH4-VL4-VL3-CH1-CL-Fc;VL3-VL4-VH4-VH3-CL-CH1-Fc; VH3-VH4-VL4-VL3-CL-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fe;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fe;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc; wherein VL1 is a firstimmunoglobulin light chain variable region that specifically binds to anHIV protein; VL2 is a second immunoglobulin light chain variable regionthat specifically binds to an HIV protein; VL3 is a third immunoglobulinlight chain variable region that specifically binds to an HIV protein;VL4 is a fourth immunoglobulin light chain variable region thatspecifically binds to an HIV protein; VH1 is a first immunoglobulinheavy chain variable region that specifically binds to an HIV protein;VH2 is a second immunoglobulin heavy chain variable region thatspecifically binds to an HIV protein; VH3 is a third immunoglobulinheavy chain variable region that specifically binds to an HIV protein;VH4 is a fourth immunoglobulin heavy chain variable region thatspecifically binds to an HIV protein; Fc is a region comprising animmunoglobulin heavy chain constant region 2 (CH2), an immunoglobulinheavy chain constant region 3 (CH3), and optionally, an immunoglobulinhinge; CH1 is an immunoglobulin heavy chain constant region 1; CL is animmunoglobulin light chain constant region; and L1, L2, L3, L4, L5, L6,L7, L8, L9, L10, L11 and L12 are amino acid linkers. In some aspects,the first polypeptide has a structure represented byVL1-VL2-VH2-VH1-CH1-Fc, and the second polypeptide has a structurerepresented by VL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc;VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fe;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-F c. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1-CH1-Fc, andthe second polypeptide has a structure represented byVL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc;VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fe;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-F c. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-CL-Fc, andthe second polypeptide has a structure represented byVL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc;VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fe;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-F c. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1-CL-Fc, andthe second polypeptide has a structure represented byVL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc;VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fe;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-F c. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-CH1-CL-Fc,and the second polypeptide has a structure represented byVL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc;VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fe;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-F c. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1-CH1-CL-Fc,and the second polypeptide has a structure represented byVL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc;VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fe;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-F c. In some aspects, the firstpolypeptide has a structure represented by VL1-VL2-VH2-VH1-CL-CH1-Fc,and the second polypeptide has a structure represented byVL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc;VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fe;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-F c. In some aspects, the firstpolypeptide has a structure represented by VH1-VH2-VL2-VL1-CL-CH1-Fc,and the second polypeptide has a structure represented byVL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc;VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fe;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-F c. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fe, and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc;VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fc;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fe, and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc;VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fc;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc, and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc;VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fc;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc, and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc;VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fc;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc, and the second polypeptide hasa structure represented by VL3-VL4-VH4-VH3-CH1-Fc;VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc;VL3-VL4-VH4-VH3-CH1-CL-Fc; VH3-VH4-VL4-VL3-CH1-CL-Fc;VL3-VL4-VH4-VH3-CL-CH1-Fc; VH3-VH4-VL4-VL3-CL-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc, and the second polypeptide hasa structure represented by VL3-VL4-VH4-VH3-CH1-Fc;VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc;VL3-VL4-VH4-VH3-CH1-CL-Fc; VH3-VH4-VL4-VL3-CH1-CL-Fc;VL3-VL4-VH4-VH3-CL-CH1-Fc; VH3-VH4-VL4-VL3-CL-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4- L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc, and the second polypeptide hasa structure represented by VL3-VL4-VH4-VH3-CH1-Fc;VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc;VL3-VL4-VH4-VH3-CH1-CL-Fc; VH3-VH4-VL4-VL3-CH1-CL-Fc;VL3-VL4-VH4-VH3-CL-CH1-Fc; VH3-VH4-VL4-VL3-CL-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc. In some aspects, the firstpolypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc, and the second polypeptide hasa structure represented by VL3-VL4-VH4-VH3-CH1-Fc;VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc;VL3-VL4-VH4-VH3-CH1-CL-Fc; VH3-VH4-VL4-VL3-CH1-CL-Fc;VL3-VL4-VH4-VH3-CL-CH1-Fc; VH3-VH4-VL4-VL3-CL-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc.

In other aspects, the invention is directed to an antigen bindingpolypeptide complex comprising a first polypeptide and a secondpolypeptide; wherein the first polypeptide has a structure representedby VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1; VL1-VL2-VH2-VH1-Fc;VH1-VH2-VL2-VL1-Fc; VL1-VL2-VH2-VH1-CH1; VH1-VH2-VL2-VL1-CH1;VL1-VL2-VH2-VH1-CL; VH1-VH2-VL2-VL1-CL; VL1-VL2-VH2-VH1-CH1-CL;VH1-VH2-VL2-VL1-CH1-CL; VL1-VL2-VH2-VH1-CL-CH1; VH1-VH2-VL2-VL1-CL-CH1;VL1-VL2-VH2-VH1-CH1-Fc; VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc;VH1-VH2-VL2-VL1-CL-Fc; VL1-VL2-VH2-VH1-CH1-CL-Fc;VH1-VH2-VL2-VL1-CH1-CL-Fc; VL1-VL2-VH2-VH1-CL-CH1-Fc;VH1-VH2-VL2-VL1-CL-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1;VH1-L1-VH2-L2-VL2-L3-VL1; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2- L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;VH1-L1-VH2- L2-VL2-L3-VL1-L4-CL; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1- L5-CL;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4- CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc; wherein the second polypeptidehas a structure represented by VL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3;VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc; VL3-VL4-VH4-VH3-CH1;VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL;VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1;VH3-VH4-VL4-VL3-CL-CH1; VL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc;VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fc;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3;VH3-L6-VH4-L7-VL4-L8-VL3; VL3-L6-VL4-L7-VH4-L8-VH3-Fc;VH3-L6-VH4-L7-VL4-L8- VL3-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7-VL4- L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-L11-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-L11-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-L11-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-L11-Fc; wherein VL1 is a firstimmunoglobulin light chain variable region that specifically binds to anHIV protein; VL2 is a second immunoglobulin light chain variable regionthat specifically binds to an HIV protein; VL3 is a third immunoglobulinlight chain variable region that specifically binds to an HIV protein;VL4 is a fourth immunoglobulin light chain variable region thatspecifically binds to an HIV protein; VH1 is a first immunoglobulinheavy chain variable region that specifically binds to an HIV protein;VH2 is a second immunoglobulin heavy chain variable region thatspecifically binds to an HIV protein; VH3 is a third immunoglobulinheavy chain variable region that specifically binds to an HIV protein;VH4 is a fourth immunoglobulin heavy chain variable region thatspecifically binds to an HIV protein; Fc is a region comprising animmunoglobulin heavy chain constant region 2 (CH2), an immunoglobulinheavy chain constant region 3 (CH3), and optionally, an immunoglobulinhinge; CH1 is an immunoglobulin heavy chain constant region 1; CL is animmunoglobulin light chain constant region; and L1, L2, L3, L4, L5, L6,L7, L8, L9, L10 or L11 are amino acid linkers. In some aspects, thefirst polypeptide has a structure represented by VL1-VL2-VH2-VH1, andthe second polypeptide has a structure represented by VL3-VL4-VH4-VH3;VH3-VH4-VL4-VL3; VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc;VL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL;VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL;VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1; VL3-VL4-VH4-VH3-CH1-Fc;VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc;VL3-VL4-VH4-VH3-CH1-CL-Fc; VH3-VH4-VL4-VL3-CH1-CL-Fc;VL3-VL4-VH4-VH3-CL-CH1-Fc; VH3-VH4-VL4-VL3-CL-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3; VH3-L6-VH4-L7-VL4-L8-VL3;VL3-L6-VL4-L7-VH4-L8-VH3-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL;VL3-L6-VL4-L7-VH4-L8-VH3- L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-L11-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-L11-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-L11-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-L11-Fc. In some aspects, thefirst polypeptide has a structure represented by VH1-VH2-VL2-VL1, andthe second polypeptide has a structure represented by VL3-VL4-VH4-VH3;VH3-VH4-VL4-VL3; VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc;VL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL;VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL;VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1; VL3-VL4-VH4-VH3-CH1-Fc;VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc;VL3-VL4-VH4-VH3-CH1-CL-Fc; VH3-VH4-VL4-VL3-CH1-CL-Fc;VL3-VL4-VH4-VH3-CL-CH1-Fc; VH3-VH4-VL4-VL3-CL-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3; VH3-L6-VH4-L7-VL4-L8-VL3;VL3-L6-VL4-L7-VH4-L8-VH3-Fc; VH3-L6-VH4-L7-VL4- L8-VL3-Fe;VL3-L6-VL4-L7-VH4-L8-VH3-L9-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL; VH3-L6-VH4- L7-VL4-L8-VL3-L9-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3- L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-L11-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-L11-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-L11-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-L11-Fc. In some aspects, thefirst polypeptide has a structure represented by VL1-VL2-VH2-VH1-Fc, andthe second polypeptide has a structure represented by VL3-VL4-VH4-VH3;VH3-VH4-VL4-VL3; VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc;VL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL;VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL;VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1; VL3-VL4-VH4-VH3-CH1-Fc;VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc;VL3-VL4-VH4-VH3-CH1-CL-Fc; VH3-VH4-VL4-VL3-CH1-CL-Fc;VL3-VL4-VH4-VH3-CL-CH1-Fc; VH3-VH4-VL4-VL3-CL-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3; VH3-L6-VH4-L7-VL4-L8-VL3;VL3-L6-VL4-L7-VH4-L8-VH3-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL;VL3-L6-VL4-L7-VH4-L8-VH3- L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-L11-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-L11-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-L11-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-L11-Fc. In some aspects, thefirst polypeptide has a structure represented by VH1-VH2-VL2-VL1-Fc, andthe second polypeptide has a structure represented by VL3-VL4-VH4-VH3;VH3-VH4-VL4-VL3; VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc;VL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL;VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL;VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1; VL3-VL4-VH4-VH3-CH1-Fc;VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc;VL3-VL4-VH4-VH3-CH1-CL-Fc; VH3-VH4-VL4-VL3-CH1-CL-Fc;VL3-VL4-VH4-VH3-CL-CH1-Fc; VH3-VH4-VL4-VL3-CL-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3; VH3-L6-VH4-L7-VL4-L8-VL3;VL3-L6-VL4-L7-VH4-L8-VH3-Fc; VH3-L6-VH4-L7-VL4- L8-VL3-Fe;VL3-L6-VL4-L7-VH4-L8-VH3-L9-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL; VH3-L6-VH4- L7-VL4-L8-VL3-L9-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3- L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-L11-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-L11-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-L11-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-L11-Fc. In some aspects, thefirst polypeptide has a structure represented by VL1-VL2-VH2-VH1-CH1,and the second polypeptide has a structure represented byVL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3; VL3-VL4-VH4-VH3-Fc;VH3-VH4-VL4-VL3-Fc; VL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1;VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL;VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1;VL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc;VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fc;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3;VH3-L6-VH4-L7-VL4-L8-VL3; VL3-L6-VL4-L7-VH4-L8-VH3-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3- L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-L11-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-L11-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-L11-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-L11-Fc. In some aspects, thefirst polypeptide has a structure represented by VH1-VH2-VL2-VL1-CH1,and the second polypeptide has a structure represented byVL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3; VL3-VL4-VH4-VH3-Fc;VH3-VH4-VL4-VL3-Fc; VL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1;VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL;VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1;VL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc;VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fc;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3;VH3-L6-VH4-L7-VL4-L8-VL3; VL3-L6-VL4-L7-VH4-L8-VH3-Fc;VH3-L6-VH4-L7-VL4- L8-VL3-Fe; VL3-L6-VL4-L7-VH4-L8-VH3-L9-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4- L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1- L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3- L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-L11-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-L11-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-L11-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-L11-Fc. In some aspects, thefirst polypeptide has a structure represented by VL1-VL2-VH2-VH1-CL, andthe second polypeptide has a structure represented by VL3-VL4-VH4-VH3;VH3-VH4-VL4-VL3; VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc;VL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL;VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL;VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1; VL3-VL4-VH4-VH3-CH1-Fc;VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc;VL3-VL4-VH4-VH3-CH1-CL-Fc; VH3-VH4-VL4-VL3-CH1-CL-Fc;VL3-VL4-VH4-VH3-CL-CH1-Fc; VH3-VH4-VL4-VL3-CL-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3; VH3-L6-VH4-L7-VL4-L8-VL3;VL3-L6-VL4-L7-VH4-L8-VH3-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL;VL3-L6-VL4-L7-VH4-L8-VH3- L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-L11-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-L11-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-L11-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-L11-Fc. In some aspects, thefirst polypeptide has a structure represented by VH1-VH2-VL2-VL1-CL, andthe second polypeptide has a structure represented by VL3-VL4-VH4-VH3;VH3-VH4-VL4-VL3; VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc;VL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL;VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL;VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1; VL3-VL4-VH4-VH3-CH1-Fc;VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc;VL3-VL4-VH4-VH3-CH1-CL-Fc; VH3-VH4-VL4-VL3-CH1-CL-Fc;VL3-VL4-VH4-VH3-CL-CH1-Fc; VH3-VH4-VL4-VL3-CL-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3; VH3-L6-VH4-L7-VL4-L8-VL3;VL3-L6-VL4-L7-VH4-L8-VH3-Fc; VH3-L6-VH4-L7-VL4- L8-VL3-Fe;VL3-L6-VL4-L7-VH4-L8-VH3-L9-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL; VH3-L6-VH4- L7-VL4-L8-VL3-L9-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3- L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-L11-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-L11-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-L11-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-L11-Fc. In some aspects, thefirst polypeptide has a structure represented by VL1-VL2-VH2-VH1-CH1-CL,and the second polypeptide has a structure represented byVL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3; VL3-VL4-VH4-VH3-Fc;VH3-VH4-VL4-VL3-Fc; VL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1;VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL;VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1;VL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc;VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fc;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3;VH3-L6-VH4-L7-VL4-L8-VL3; VL3-L6-VL4-L7-VH4-L8-VH3-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3- L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-L11-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-L11-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-L11-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-L11-Fc. In some aspects, thefirst polypeptide has a structure represented by VH1-VH2-VL2-VL1-CH1-CL,and the second polypeptide has a structure represented byVL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3; VL3-VL4-VH4-VH3-Fc;VH3-VH4-VL4-VL3-Fc; VL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1;VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL;VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1;VL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc;VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fc;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3;VH3-L6-VH4-L7-VL4-L8-VL3; VL3-L6-VL4-L7-VH4-L8-VH3-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3- L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fe;VL3-L6-VL4-L7-VH4- L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fe;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-L11-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-L11-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-L11-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-L11-Fc. In some aspects, thefirst polypeptide has a structure represented by VL1-VL2-VH2-VH1-CL-CH1,and the second polypeptide has a structure represented byVL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3; VL3-VL4-VH4-VH3-Fc;VH3-VH4-VL4-VL3-Fc; VL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1;VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL;VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1;VL3-VL4-VH4-VH3-CH1-Fe; VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc;VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fc;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3;VH3-L6-VH4-L7-VL4-L8-VL3; VL3-L6-VL4-L7-VH4-L8-VH3-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7- VL4-L8-VL3-L9-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4- L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-L11-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-L11-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-L11-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-L11-Fc. In some aspects, thefirst polypeptide has a structure represented by VH1-VH2-VL2-VL1-CL-CH1,and the second polypeptide has a structure represented byVL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3; VL3-VL4-VH4-VH3-Fc;VH3-VH4-VL4-VL3-Fc; VL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1;VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL;VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1;VL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc;VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fc;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3;VH3-L6-VH4-L7-VL4-L8-VL3; VL3-L6-VL4-L7-VH4-L8-VH3-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4-L7- VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-L11-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-L11-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-L11-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-L11-Fc. In some aspects, thefirst polypeptide has a structure represented by VL1-VL2-VH2-VH1-CH1-Fc,and the second polypeptide has a structure represented byVL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3; VL3-VL4-VH4-VH3-Fc;VH3-VH4-VL4-VL3-Fc; VL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1;VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL;VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1;VL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc;VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fc;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3;VH3-L6-VH4-L7-VL4-L8-VL3; VL3-L6-VL4-L7-VH4-L8-VH3-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-Fe;VH3-L6-VH4-L7-VL4-L8-VL3-L9-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-L11-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-L11-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-L11-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-L11-Fc. In some aspects, thefirst polypeptide has a structure represented by VH1-VH2-VL2-VL1-CH1-Fc,and the second polypeptide has a structure represented byVL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3; VL3-VL4-VH4-VH3-Fc;VH3-VH4-VL4-VL3-Fc; VL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1;VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL;VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1;VL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc;VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fc;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3;VH3-L6-VH4-L7-VL4-L8-VL3; VL3-L6-VL4-L7-VH4-L8-VH3-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4-L7- VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fe;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-L11-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-L11-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-L11-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-L11-Fc. In some aspects, thefirst polypeptide has a structure represented by VL1-VL2-VH2-VH1-CL-Fc,and the second polypeptide has a structure represented byVL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3; VL3-VL4-VH4-VH3-Fc;VH3-VH4-VL4-VL3-Fc; VL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1;VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL;VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1;VL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc;VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fc;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3;VH3-L6-VH4-L7-VL4-L8-VL3; VL3-L6-VL4-L7-VH4-L8-VH3-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-Fe;VH3-L6-VH4-L7-VL4-L8-VL3-L9-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fe;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-L11-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-L11-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-L11-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-L11-Fc. In some aspects, thefirst polypeptide has a structure represented by VH1-VH2-VL2-VL1-CL-Fc,and the second polypeptide has a structure represented byVL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3; VL3-VL4-VH4-VH3-Fc;VH3-VH4-VL4-VL3-Fc; VL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1;VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL;VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1;VL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc;VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fc;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3;VH3-L6-VH4-L7-VL4-L8-VL3; VL3-L6-VL4-L7-VH4-L8-VH3-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4-L7- VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fe;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-L11-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-L11-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-L11-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-L11-Fc. In some aspects, thefirst polypeptide has a structure represented byVL1-VL2-VH2-VH1-CH1-CL-Fc, and the second polypeptide has a structurerepresented by VL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3; VL3-VL4-VH4-VH3-Fc;VH3-VH4-VL4-VL3-Fc; VL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1;VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL;VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1;VL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc;VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fc;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3;VH3-L6-VH4-L7-VL4-L8-VL3; VL3-L6-VL4-L7-VH4-L8-VH3-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9- CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-L11-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-L11-Fe;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-L11-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-L11-Fc. In some aspects, thefirst polypeptide has a structure represented byVH1-VH2-VL2-VL1-CH1-CL-Fc, and the second polypeptide has a structurerepresented by VL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3; VL3-VL4-VH4-VH3-Fc;VH3-VH4-VL4-VL3-Fc; VL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1;VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL;VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1;VL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc;VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fc;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3;VH3-L6-VH4-L7-VL4-L8-VL3; VL3-L6-VL4-L7-VH4-L8-VH3-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-Fe; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4- L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3- L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-L11-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-L11-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-L11-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-L11-Fc. In some aspects, thefirst polypeptide has a structure represented byVL1-VL2-VH2-VH1-CL-CH1-Fc, and the second polypeptide has a structurerepresented by VL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3; VL3-VL4-VH4-VH3-Fc;VH3-VH4-VL4-VL3-Fc; VL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1;VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL;VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1;VL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc;VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fc;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3;VH3-L6-VH4-L7-VL4-L8-VL3; VL3-L6-VL4-L7-VH4-L8-VH3-Fc;VH3-L6-VH4-L7-VL4- L8-VL3-Fe; VL3-L6-VL4-L7-VH4-L8-VH3-L9-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4- L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1- L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3- L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-L11-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-L11-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-L11-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-L11-Fc. In some aspects, thefirst polypeptide has a structure represented byVH1-VH2-VL2-VL1-CL-CH1-Fc, and the second polypeptide has a structurerepresented by VL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3; VL3-VL4-VH4-VH3-Fc;VH3-VH4-VL4-VL3-Fc; VL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1;VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL;VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1;VL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc;VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fc;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3;VH3-L6-VH4-L7-VL4-L8-VL3; VL3-L6-VL4-L7-VH4-L8-VH3-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3- L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-L11-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-L11-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-L11-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-L11-Fc. In some aspects, thefirst polypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1, and the second polypeptide has a structurerepresented by VL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3; VL3-VL4-VH4-VH3-Fc;VH3-VH4-VL4-VL3-Fc; VL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1;VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL;VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1;VL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc;VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fc;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3;VH3-L6-VH4-L7-VL4-L8-VL3; VL3-L6-VL4-L7-VH4-L8-VH3-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3- L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fe;VL3-L6-VL4-L7-VH4- L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fe;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-L11-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-L11-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-L11-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-L11-Fc. In some aspects, thefirst polypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1, and the second polypeptide has a structurerepresented by VL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3; VL3-VL4-VH4-VH3-Fc;VH3-VH4-VL4-VL3-Fc; VL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1;VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL;VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1;VL3-VL4-VH4-VH3-CH1-Fe; VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc;VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fc;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3;VH3-L6-VH4-L7-VL4-L8-VL3; VL3-L6-VL4-L7-VH4-L8-VH3-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7- VL4-L8-VL3-L9-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4- L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-L11-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-L11-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-L11-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-L11-F c. In some aspects, thefirst polypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-Fc, and the second polypeptide has a structurerepresented by VL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3; VL3-VL4-VH4-VH3-Fc;VH3-VH4-VL4-VL3-Fc; VL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1;VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL;VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1;VL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc;VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fc;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3;VH3-L6-VH4-L7-VL4-L8-VL3; VL3-L6-VL4-L7-VH4-L8-VH3-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-Fe; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4- L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3- L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-L11-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-L11-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-L11-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-L11-Fc. In some aspects, thefirst polypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-Fc, and the second polypeptide has a structurerepresented by VL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3; VL3-VL4-VH4-VH3-Fc;VH3-VH4-VL4-VL3-Fc; VL3-VL4-VH4-VH3-CH1; VH3-VH4-VL4-VL3-CH1;VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL; VL3-VL4-VH4-VH3-CH1-CL;VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1; VH3-VH4-VL4-VL3-CL-CH1;VL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc; VL3-VL4-VH4-VH3-CL-Fc;VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fc;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3;VH3-L6-VH4-L7-VL4-L8-VL3; VL3-L6-VL4-L7-VH4-L8-VH3-Fc;VH3-L6-VH4-L7-VL4- L8-VL3-Fe; VL3-L6-VL4-L7-VH4-L8-VH3-L9-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4- L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1- L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3- L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-L11-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-L11-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-L11-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-L11-Fc. In some aspects, thefirst polypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc, and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3;VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc; VL3-VL4-VH4-VH3-CH1;VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL;VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1;VH3-VH4-VL4-VL3-CL-CH1; VL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc;VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fc;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3;VH3-L6-VH4-L7-VL4-L8-VL3; VL3-L6-VL4-L7-VH4-L8-VH3-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3- L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-L11-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-L11-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-L11-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-L11-Fc. In some aspects, thefirst polypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc, and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3;VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fe; VL3-VL4-VH4-VH3-CH1;VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL;VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1;VH3-VH4-VL4-VL3-CL-CH1; VL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc;VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fc;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3;VH3-L6-VH4-L7-VL4-L8-VL3; VL3-L6-VL4-L7-VH4-L8-VH3-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3- L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fe;VL3-L6-VL4-L7-VH4- L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fe;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-L11-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-L11-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-L11-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-L11-Fc. In some aspects, thefirst polypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1, and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3;VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc; VL3-VL4-VH4-VH3-CH1;VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL;VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1;VH3-VH4-VL4-VL3-CL-CH1; VL3-VL4-VH4-VH3-CH1-Fe; VH3-VH4-VL4-VL3-CH1-Fc;VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fc;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3;VH3-L6-VH4-L7-VL4-L8-VL3; VL3-L6-VL4-L7-VH4-L8-VH3-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7- VL4-L8-VL3-L9-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4- L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-L11-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-L11-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-L11-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-L11-Fc. In some aspects, thefirst polypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1, and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3;VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc; VL3-VL4-VH4-VH3-CH1;VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL;VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1;VH3-VH4-VL4-VL3-CL-CH1; VL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc;VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fc;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3;VH3-L6-VH4-L7-VL4-L8-VL3; VL3-L6-VL4-L7-VH4-L8-VH3-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-Fe; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4- L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3- L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-L11-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-L11-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-L11-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-L11-Fc. In some aspects, thefirst polypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CL, and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3;VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc; VL3-VL4-VH4-VH3-CH1;VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL;VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1;VH3-VH4-VL4-VL3-CL-CH1; VL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc;VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fc;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3;VH3-L6-VH4-L7-VL4-L8-VL3; VL3-L6-VL4-L7-VH4-L8-VH3-Fc;VH3-L6-VH4-L7-VL4- L8-VL3-Fe; VL3-L6-VL4-L7-VH4-L8-VH3-L9-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4- L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1- L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3- L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-L11-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-L11-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-L11-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-L11-Fc. In some aspects, thefirst polypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL, and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3;VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc; VL3-VL4-VH4-VH3-CH1;VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL;VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1;VH3-VH4-VL4-VL3-CL-CH1; VL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc;VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fc;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3;VH3-L6-VH4-L7-VL4-L8-VL3; VL3-L6-VL4-L7-VH4-L8-VH3-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3- L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-L11-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-L11-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-L11-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-L11-Fc. In some aspects, thefirst polypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL, and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3;VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc; VL3-VL4-VH4-VH3-CH1;VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL;VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1;VH3-VH4-VL4-VL3-CL-CH1; VL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc;VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fc;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3;VH3-L6-VH4-L7-VL4-L8-VL3; VL3-L6-VL4-L7-VH4-L8-VH3-Fe;VH3-L6-VH4-L7-VL4-L8-VL3-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9- Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-L11-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-L11-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-L11-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-L11-Fc. In some aspects, thefirst polypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL, and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3;VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc; VL3-VL4-VH4-VH3-CH1;VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL;VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1;VH3-VH4-VL4-VL3-CL-CH1; VL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc;VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fc;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3;VH3-L6-VH4-L7-VL4-L8-VL3; VL3-L6-VL4-L7-VH4-L8-VH3-Fc;VH3-L6-VH4-L7-VL4-L8-VL3- Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-Fc; VL3-L6-VL4-L7-VH4-L8-VH3- L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7-VL4- L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-L11-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-L11-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-L11-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-L11-Fc. In some aspects, thefirst polypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1, and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3;VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc; VL3-VL4-VH4-VH3-CH1;VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL;VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1;VH3-VH4-VL4-VL3-CL-CH1; VL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc;VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fc;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3;VH3-L6-VH4-L7-VL4-L8-VL3; VL3-L6-VL4-L7-VH4-L8-VH3-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3- L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-L11-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-L11-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-L11-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-L11-Fc. In some aspects, thefirst polypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1, and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3;VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc; VL3-VL4-VH4-VH3-CH1;VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL;VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1;VH3-VH4-VL4-VL3-CL-CH1; VL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc;VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fc;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3;VH3-L6-VH4-L7-VL4-L8-VL3; VL3-L6-VL4-L7-VH4-L8-VH3-Fe;VH3-L6-VH4-L7-VL4-L8-VL3-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9- Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-L11-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-L11-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-L11-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-L11-Fc. In some aspects, thefirst polypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc, and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3;VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc; VL3-VL4-VH4-VH3-CH1;VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL;VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1;VH3-VH4-VL4-VL3-CL-CH1; VL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc;VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fc;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3;VH3-L6-VH4-L7-VL4-L8-VL3; VL3-L6-VL4-L7-VH4-L8-VH3-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9- CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-L11-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-L11-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-L11-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-L11-Fc. In some aspects, thefirst polypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc, and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3;VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc; VL3-VL4-VH4-VH3-CH1;VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL;VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1;VH3-VH4-VL4-VL3-CL-CH1; VL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc;VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fc;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3;VH3-L6-VH4-L7-VL4-L8-VL3; VL3-L6-VL4-L7-VH4-L8-VH3-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3- L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-L11-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-L11-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-L11-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-L11-Fc. In some aspects, thefirst polypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc, and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3;VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc; VL3-VL4-VH4-VH3-CH1;VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL;VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1;VH3-VH4-VL4-VL3-CL-CH1; VL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc;VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fc;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3;VH3-L6-VH4-L7-VL4-L8-VL3; VL3-L6-VL4-L7-VH4-L8-VH3-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4- L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-L11-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-L11-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-L11-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-L11-Fc. In some aspects, thefirst polypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc, and the second polypeptide has astructure represented by VL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3;VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc; VL3-VL4-VH4-VH3-CH1;VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL;VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1;VH3-VH4-VL4-VL3-CL-CH1; VL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc;VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fc;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3;VH3-L6-VH4-L7-VL4-L8-VL3; VL3-L6-VL4-L7-VH4-L8-VH3-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3- L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-L11-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-L11-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-L11-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-L11-Fc. In some aspects, thefirst polypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc, and the second polypeptide hasa structure represented by VL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3;VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc; VL3-VL4-VH4-VH3-CH1;VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL;VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1;VH3-VH4-VL4-VL3-CL-CH1; VL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc;VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fc;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3;VH3-L6-VH4-L7-VL4-L8-VL3; VL3-L6-VL4-L7-VH4-L8-VH3-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3- L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-L11-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-L11-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-L11-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-L11-Fc. In some aspects, thefirst polypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc, and the second polypeptide hasa structure represented by VL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3;VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc; VL3-VL4-VH4-VH3-CH1;VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL;VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1;VH3-VH4-VL4-VL3-CL-CH1; VL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc;VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fc;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3;VH3-L6-VH4-L7-VL4-L8-VL3; VL3-L6-VL4-L7-VH4-L8-VH3-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4-L7- VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-L11-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-L11-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-L11-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-L11-Fc. In some aspects, thefirst polypeptide has a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc, and the second polypeptide hasa structure represented by VL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3;VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc; VL3-VL4-VH4-VH3-CH1;VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL;VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1;VH3-VH4-VL4-VL3-CL-CH1; VL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc;VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fc;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3;VH3-L6-VH4-L7-VL4-L8-VL3; VL3-L6-VL4-L7-VH4-L8-VH3-Fc;VH3-L6-VH4-L7-VL4- L8-VL3-Fe; VL3-L6-VL4-L7-VH4-L8-VH3-L9-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4- L7-VL4-L8-VL3-L9-CL; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1- L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3- L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-L11-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-L11-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-L11-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-L11-Fc. In some aspects, thefirst polypeptide has a structure represented byVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc, and the second polypeptide hasa structure represented by VL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3;VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc; VL3-VL4-VH4-VH3-CH1;VH3-VH4-VL4-VL3-CH1; VL3-VL4-VH4-VH3-CL; VH3-VH4-VL4-VL3-CL;VL3-VL4-VH4-VH3-CH1-CL; VH3-VH4-VL4-VL3-CH1-CL; VL3-VL4-VH4-VH3-CL-CH1;VH3-VH4-VL4-VL3-CL-CH1; VL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-Fc;VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-Fc; VL3-VL4-VH4-VH3-CH1-CL-Fc;VH3-VH4-VL4-VL3-CH1-CL-Fc; VL3-VL4-VH4-VH3-CL-CH1-Fc;VH3-VH4-VL4-VL3-CL-CH1-Fc; VL3-L6-VL4-L7-VH4-L8-VH3;VH3-L6-VH4-L7-VL4-L8-VL3; VL3-L6-VL4-L7-VH4-L8-VH3-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL; VL3- L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-Fc; VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-Fc; VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL-L11-Fc;VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL-L11-Fc;VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1-L11-Fc; orVH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1-L11-Fc.

In some aspects of an antigen binding polypeptide or antigen bindingpolypeptide complex of the invention, VH1, VH2, VH3 and VH4 eachcomprise a heavy chain variable region from the PGT121, VRC01, 10E8v4 orPG16 antibody or a variant thereof; and/or VL1, VL2, VL3 and VL4 eachcomprise a light chain variable region from the PGT121, VRC01, 10E8v4 orPG16 antibody or a variant thereof.

In some aspects, VH1, VH2, VH3 and VH4 of an antigen binding polypeptideor antigen binding polypeptide complex of the invention each comprise anamino acid sequence having at least 90% identity, at least 95% identityor 100% identity to any one of SEQ ID NOs:338-341; and/or VL1, VL2, VL3and VL4 each comprise an amino acid sequence having at least 90%identity, at least 95% identity or 100% identity to any one of SEQ IDNOs:342-345. For example, the VH1, VH2, VH3 and VH4 of an antigenbinding polypeptide or antigen binding polypeptide complex of theinvention may each comprise an amino acid sequence having at least 90%identity (such as at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or99% identity) to any one of SEQ ID NOs:338-341; and/or VL1, VL2, VL3 andVL4 may each comprise an amino acid sequence having at least 90%identity (such as at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or99% identity) to any one of SEQ ID NOs:342-345. For example, the VH1,VH2, VH3 and VH4 of an antigen binding polypeptide or antigen bindingpolypeptide complex of the invention may each comprise the amino acidsequence of any one of SEQ ID NOs:338-341; and/or VL1, VL2, VL3 and VL4may each comprise the amino acid sequence of any one of SEQ IDNOs:342-345. For example, the VH1, VH2, VH3 and VH4 of an antigenbinding polypeptide or antigen binding polypeptide complex of theinvention may each comprise the amino acid sequence of any one of SEQ IDNOs:338-341. For example, the VL1, VL2, VL3 and VL4 may each comprisethe amino acid sequence of any one of SEQ ID NOs:342-345. For example,the VH1, VH2, VH3 and VH4 of an antigen binding polypeptide or antigenbinding polypeptide complex of the invention may each comprise the aminoacid sequence of any one of SEQ ID NOs:338-341; and the VL1, VL2, VL3and VL4 may each comprise the amino acid sequence of any one of SEQ IDNOs:342-345. In some aspects, the heavy chain CDR1 of an antigen bindingpolypeptide or antigen binding polypeptide complex of the inventioncomprises an amino acid sequence having at least 90% identity, at least95% identity or 100% identity to any one of SEQ ID NOs:362, 365, 368 and371; the heavy chain CDR2 of an antigen binding polypeptide or antigenbinding polypeptide complex of the invention comprises an amino acidsequence having at least 90% identity, at least 95% identity or 100%identity to any one of SEQ ID NOs:363, 366, 369 and 372; the heavy chainCDR3 of an antigen binding polypeptide or antigen binding polypeptidecomplex of the invention comprises an amino acid sequence having atleast 90% identity, at least 95% identity or 100% identity to any one ofSEQ ID NOs:364, 367, 370 and 373; the light chain CDR1 of an antigenbinding polypeptide or antigen binding polypeptide complex of theinvention comprises an amino acid sequence having at least 90% identity,at least 95% identity or 100% identity to any one of SEQ ID NOs:374,378, 381 and 384; the light chain CDR2 of an antigen binding polypeptideor antigen binding polypeptide complex of the invention comprises anamino acid sequence having at least 90% identity, at least 95% identityor 100% identity to any one of SEQ ID NOs:375, 379, 382 and 385; and/orthe light chain CDR3 of an antigen binding polypeptide or antigenbinding polypeptide complex of the invention comprises an amino acidsequence having at least 90% identity, at least 95% identity or 100%identity to any one of SEQ ID NOs:376, 380, 383 and 386. For example,the heavy chain CDR1 of an antigen binding polypeptide or antigenbinding polypeptide complex of the invention comprises an amino acidsequence having at least 90% identity (such as at least 91%, 92%, 93%,94%, 95%, 96%, 97%, 98%, or 99% identity) to any one of SEQ ID NOs:362,365, 368 and 371; the heavy chain CDR2 of an antigen binding polypeptideor antigen binding polypeptide complex of the invention comprises anamino acid sequence having at least 90% identity (such as at least 91%,92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity) to any one of SEQ IDNOs:363, 366, 369 and 372; the heavy chain CDR3 of an antigen bindingpolypeptide or antigen binding polypeptide complex of the inventioncomprises an amino acid sequence having at least 90% identity (such asat least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity) to anyone of SEQ ID NOs:364, 367, 370 and 373; the light chain CDR1 of anantigen binding polypeptide or antigen binding polypeptide complex ofthe invention comprises an amino acid sequence having at least 90%identity (such as at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or99% identity) to any one of SEQ ID NOs:374, 378, 381 and 384; the lightchain CDR2 of an antigen binding polypeptide or antigen bindingpolypeptide complex of the invention comprises an amino acid sequencehaving at least 90% identity (such as at least 91%, 92%, 93%, 94%, 95%,96%, 97%, 98%, or 99% identity) to any one of SEQ ID NOs:375, 379, 382and 385; and/or the light chain CDR3 of an antigen binding polypeptideor antigen binding polypeptide complex of the invention comprises anamino acid sequence having at least 90% identity (such as at least 91%,92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity) to any one of SEQ IDNOs:376, 380, 383 and 386. For example, the heavy chain CDR1 of anantigen binding polypeptide or antigen binding polypeptide complex ofthe invention comprises the amino acid sequence of any one of SEQ IDNOs:362, 365, 368 and 371; the heavy chain CDR2 of an antigen bindingpolypeptide or antigen binding polypeptide complex of the inventioncomprises the amino acid sequence of any one of SEQ ID NOs:363, 366, 369and 372; the heavy chain CDR3 of an antigen binding polypeptide orantigen binding polypeptide complex of the invention comprises the aminoacid sequence of any one of SEQ ID NOs:364, 367, 370 and 373; the lightchain CDR1 of an antigen binding polypeptide or antigen bindingpolypeptide complex of the invention comprises the amino acid sequenceof any one of SEQ ID NOs:374, 378, 381 and 384; the light chain CDR2 ofan antigen binding polypeptide or antigen binding polypeptide complex ofthe invention comprises the amino acid sequence of any one of SEQ IDNOs:375, 379, 382 and 385; and/or the light chain CDR3 of an antigenbinding polypeptide or antigen binding polypeptide complex of theinvention comprises the amino acid sequence of any one of SEQ IDNOs:376, 380, 383 and 386. For example, the heavy chain CDR1 of anantigen binding polypeptide or antigen binding polypeptide complex ofthe invention comprises the amino acid sequence of any one of SEQ IDNOs:362, 365, 368 and 371; the heavy chain CDR2 of an antigen bindingpolypeptide or antigen binding polypeptide complex of the inventioncomprises the amino acid sequence of any one of SEQ ID NOs:363, 366, 369and 372; and the heavy chain CDR3 of an antigen binding polypeptide orantigen binding polypeptide complex of the invention comprises the aminoacid sequence of any one of SEQ ID NOs:364, 367, 370 and 373. Forexample, the light chain CDR1 of an antigen binding polypeptide orantigen binding polypeptide complex of the invention comprises the aminoacid sequence of any one of SEQ ID NOs:374, 378, 381 and 384; the lightchain CDR2 of an antigen binding polypeptide or antigen bindingpolypeptide complex of the invention comprises the amino acid sequenceof any one of SEQ ID NOs:375, 379, 382 and 385; and the light chain CDR3of an antigen binding polypeptide or antigen binding polypeptide complexof the invention comprises the amino acid sequence of any one of SEQ IDNOs:376, 380, 383 and 386. For example, the heavy chain CDR1 of anantigen binding polypeptide or antigen binding polypeptide complex ofthe invention comprises the amino acid sequence of any one of SEQ IDNOs:362, 365, 368 and 371; the heavy chain CDR2 of an antigen bindingpolypeptide or antigen binding polypeptide complex of the inventioncomprises the amino acid sequence of any one of SEQ ID NOs:363, 366, 369and 372; the heavy chain CDR3 of an antigen binding polypeptide orantigen binding polypeptide complex of the invention comprises the aminoacid sequence of any one of SEQ ID NOs:364, 367, 370 and 373; the lightchain CDR1 of an antigen binding polypeptide or antigen bindingpolypeptide complex of the invention comprises the amino acid sequenceof any one of SEQ ID NOs:374, 378, 381 and 384; the light chain CDR2 ofan antigen binding polypeptide or antigen binding polypeptide complex ofthe invention comprises the amino acid sequence of any one of SEQ IDNOs:375, 379, 382 and 385; and the light chain CDR3 of an antigenbinding polypeptide or antigen binding polypeptide complex of theinvention comprises the amino acid sequence of any one of SEQ IDNOs:376, 380, 383 and 386. For example, the heavy chain CDR1 of anantigen binding polypeptide or antigen binding polypeptide complex ofthe invention comprises the amino acid sequence of SEQ ID NO:362; theheavy chain CDR2 of an antigen binding polypeptide or antigen bindingpolypeptide complex of the invention comprises the amino acid sequenceof SEQ ID NO:363; the heavy chain CDR3 of an antigen binding polypeptideor antigen binding polypeptide complex of the invention comprises theamino acid sequence of SEQ ID NO:364; the light chain CDR1 of an antigenbinding polypeptide or antigen binding polypeptide complex of theinvention comprises the amino acid sequence of SEQ ID NO:378; the lightchain CDR2 of an antigen binding polypeptide or antigen bindingpolypeptide complex of the invention comprises the amino acid sequenceof SEQ ID NO:379; and the light chain CDR3 of an antigen bindingpolypeptide or antigen binding polypeptide complex of the inventioncomprises the amino acid sequence of SEQ ID NO:380. For example, theheavy chain CDR1 of an antigen binding polypeptide or antigen bindingpolypeptide complex of the invention comprises the amino acid sequenceof SEQ ID NO:365; the heavy chain CDR2 of an antigen binding polypeptideor antigen binding polypeptide complex of the invention comprises theamino acid sequence of SEQ ID NO:366; the heavy chain CDR3 of an antigenbinding polypeptide or antigen binding polypeptide complex of theinvention comprises the amino acid sequence of SEQ ID NO:367; the lightchain CDR1 of an antigen binding polypeptide or antigen bindingpolypeptide complex of the invention comprises the amino acid sequenceof SEQ ID NO:381; the light chain CDR2 of an antigen binding polypeptideor antigen binding polypeptide complex of the invention comprises theamino acid sequence of SEQ ID NO:382; and the light chain CDR3 of anantigen binding polypeptide or antigen binding polypeptide complex ofthe invention comprises the amino acid sequence of SEQ ID NO:383. Forexample, the heavy chain CDR1 of an antigen binding polypeptide orantigen binding polypeptide complex of the invention comprises the aminoacid sequence of SEQ ID NO:368; the heavy chain CDR2 of an antigenbinding polypeptide or antigen binding polypeptide complex of theinvention comprises the amino acid sequence of SEQ ID NO:369; the heavychain CDR3 of an antigen binding polypeptide or antigen bindingpolypeptide complex of the invention comprises the amino acid sequenceof SEQ ID NO:370; the light chain CDR1 of an antigen binding polypeptideor antigen binding polypeptide complex of the invention comprises theamino acid sequence of SEQ ID NO:384; the light chain CDR2 of an antigenbinding polypeptide or antigen binding polypeptide complex of theinvention comprises the amino acid sequence of SEQ ID NO:385; and thelight chain CDR3 of an antigen binding polypeptide or antigen bindingpolypeptide complex of the invention comprises the amino acid sequenceof SEQ ID NO:386. For example, the heavy chain CDR1 of an antigenbinding polypeptide or antigen binding polypeptide complex of theinvention comprises the amino acid sequence of SEQ ID NO:371; the heavychain CDR2 of an antigen binding polypeptide or antigen bindingpolypeptide complex of the invention comprises the amino acid sequenceof SEQ ID NO:372; the heavy chain CDR3 of an antigen binding polypeptideor antigen binding polypeptide complex of the invention comprises theamino acid sequence of SEQ ID NO:373; the light chain CDR1 of an antigenbinding polypeptide or antigen binding polypeptide complex of theinvention comprises the amino acid sequence of SEQ ID NO:374; the lightchain CDR2 of an antigen binding polypeptide or antigen bindingpolypeptide complex of the invention comprises the amino acid sequenceof SEQ ID NO:375; and the light chain CDR3 of an antigen bindingpolypeptide or antigen binding polypeptide complex of the inventioncomprises the amino acid sequence of SEQ ID NO:376.

In some aspects, VH1, VH2, VH3 and VH4 of an antigen binding polypeptideor antigen binding polypeptide complex of the invention each comprise aCDR1 having an amino acid sequence with at least 90% identity, at least95% identity or 100% identity to any one of SEQ ID NOs:362, 365, 368 and371; a CDR2 having an amino acid sequence with at least 90% identity, atleast 95% identity or 100% identity to any one of SEQ ID NOs:363, 366,369 and 372; and a CDR3 having an amino acid sequence with at least 90%identity, at least 95% identity or 100% identity to any one of SEQ IDNOs:364, 367, 370 and 373; and VL1, VL2, VL3 and VL4 each comprise aCDR1 having an amino acid sequence with at least 90% identity, at least95% identity or 100% identity to any one of SEQ ID NOs:374, 378, 381 and384; a CDR2 having an amino acid sequence with at least 90% identity, atleast 95% identity or 100% identity to any one of SEQ ID NOs:375, 379,382 and 385; and a CDR3 having an amino acid sequence with at least 90%identity, at least 95% identity or 100% identity to any one of SEQ IDNOs:376, 380, 383 and 386. For example, the VH1, VH2, VH3 and VH4 of anantigen binding polypeptide or antigen binding polypeptide complex ofthe invention may each comprise a CDR1 having an amino acid sequencewith at least 90% identity (such as at least 91%, 92%, 93%, 94%, 95%,96%, 97%, 98%, or 99% identity) to any one of SEQ ID NOs:362, 365, 368and 371; a CDR2 having an amino acid sequence with at least 90% identity(such as at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%identity) to any one of SEQ ID NOs:363, 366, 369 and 372; and a CDR3having an amino acid sequence with at least 90% identity (such as atleast 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity) to anyone of SEQ ID NOs:364, 367, 370 and 373; and the VL1, VL2, VL3 and VL4may each comprise a CDR1 having an amino acid sequence with at least 90%identity (such as at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or99% identity) to any one of SEQ ID NOs:374, 378, 381 and 384; a CDR2having an amino acid sequence with at least 90% identity (such as atleast 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity) to anyone of SEQ ID NOs:375, 379, 382 and 385; and a CDR3 having an amino acidsequence with at least 90% identity (such as at least 91%, 92%, 93%,94%, 95%, 96%, 97%, 98%, or 99% identity) to any one of SEQ ID NOs:376,380, 383 and 386. For example, the VH1, VH2, VH3 and VH4 of an antigenbinding polypeptide or antigen binding polypeptide complex of theinvention may each comprise a CDR1 having the amino acid sequence of anyone of SEQ ID NOs:362, 365, 368 and 371; a CDR2 having the amino acidsequence of any one of SEQ ID NOs:363, 366, 369 and 372; and a CDR3having the amino acid sequence of any one of SEQ ID NOs:364, 367, 370and 373; and the VL1, VL2, VL3 and VL4 may each comprise a CDR1 havingthe amino acid sequence of any one of SEQ ID NOs:374, 378, 381 and 384;a CDR2 having the amino acid sequence of any one of SEQ ID NOs:375, 379,382 and 385; and a CDR3 having the amino acid sequence of any one of SEQID NOs:376, 380, 383 and 386.

In some aspects, the antigen binding polypeptides and antigen bindingpolypeptide complexes described herein specifically bind to an HIVprotein. This includes specific binding to one or more HIV proteins andspecific binding to one or more epitopes on the same HIV protein. Insome aspects, the HIV protein is selected from the group consisting ofan HIV envelope protein, an HIV structural protein, an HIV functionalprotein, or an HIV accessory protein. In some aspects, the HIV envelopeprotein is HIV envelope glycoprotein (Env), HIV envelope glycoproteingp160, HIV envelope surface glycoprotein gp120, or HIV transmembraneenvelope protein gp41. In some aspects, the HIV structural protein isp17, p24, p7 or p55. In some aspects, the HIV functional protein is p66,HIV-1 protease (PR) or p31. In some aspects, the HIV accessory proteinis Nef, Tat, Rev, Vif, Vpr or Vpu.

Antigen binding sequences (e.g., CDR, VH, VL, heavy chain and lightchain sequences from antibodies) for HIV proteins are well known. Suchantibodies include, but are not limited to PGT145, PG9, PG16, PGT128,PGT121, 10-1074, 3BNC117, VRC01, PGT151, 4E10, 10E8, or a variantthereof (e.g., 10E8v4). In addition, molecular biology and recombinantDNA methods for making, screening and engineering antigen bindingcomplexes and antibodies containing such sequences are well known anddescribed, for example, in Adair et al Human Antibodies, 5(1-2):41-47,1994; Kostelny et al., J. Immunol., 148(5):1547-1553 (1992), Shiraiwa etal., Methods, 154:10-20, 2019; and Zola, “Monoclonal Antibodies: AManual of Techniques,” 1987, 1^(st) Ed., CRC Press; and Steinitz, HumanAntibodies, 18(1-2):1-10, 2009.

In some aspects, an antigen binding polypeptide or antigen bindingpolypeptide complex of the invention does not specifically bind to anantigen associated with severe acute respiratory syndrome (SARS).

In some aspects, one or more of VH1, VH2, VH3 and VH4 of an antigenbinding polypeptide or antigen binding polypeptide complex of theinvention comprises an amino acid sequence encoded by a polynucleotidehaving at least 90% identity, at least 95% identity or 100% identity toSEQ ID NO:387 or 388; and/or one or more of VL1, VL2, VL3 and VL4 of anantigen binding polypeptide or antigen binding polypeptide complex ofthe invention comprises an amino acid sequence encoded by apolynucleotide having at least 90% identity, at least 95% identity or100% identity to SEQ ID NO:389 or 390. For example, one or more of VH1,VH2, VH3 and VH4 of an antigen binding polypeptide or antigen bindingpolypeptide complex of the invention may comprise an amino acid sequenceencoded by a polynucleotide having at least 90% identity to SEQ IDNO:387 or 388; and/or one or more of VL1, VL2, VL3 and VL4 of an antigenbinding polypeptide or antigen binding polypeptide complex of theinvention may comprise an amino acid sequence encoded by apolynucleotide having at least 90% identity to SEQ ID NO:389 or 390. Atleast 90% identity may include at least 91%, 92%, 93%, 94%, 95%, 96%,97%, 98%, 99% or 100% identity to the reference polynucleotide sequence.For example, one or more of VH1, VH2, VH3 and VH4 of an antigen bindingpolypeptide or antigen binding polypeptide complex of the invention maycomprise an amino acid sequence encoded by the polynucleotide shown inSEQ ID NO:387 or 388; and/or one or more of VL1, VL2, VL3 and VL4 of anantigen binding polypeptide or antigen binding polypeptide complex ofthe invention may comprise an amino acid sequence encoded by thepolynucleotide shown in SEQ ID NO:389 or 390.

In some aspects, the invention is directed to an antigen bindingpolypeptide or antigen binding polypeptide complex (e.g., antibody orantigen binding fragment thereof) comprising one or more amino acidsequences having at least 90% identity, at least 95% identity, or 100%identity to any one of SEQ ID NOs:198-209, 346 and 348. For example, theantigen binding polypeptide or antigen binding polypeptide complex(e.g., antibody or antigen binding fragment thereof) may comprise one ormore amino acid sequences having at least 90% (such as at least 91%,92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity to any one of SEQ IDNOs:198-209, 346 and 348. For example, the antigen binding polypeptideor antigen binding polypeptide complex (e.g., antibody or antigenbinding fragment thereof) may comprise one or more amino acid sequencesas shown in SEQ ID NOs:198-209, 346 and 348.

In other aspects, the invention is directed to an antigen bindingpolypeptide or antigen binding polypeptide complex (e.g., antibody orantigen binding fragment thereof) comprising one or more amino acidsequences encoded by a polynucleotide having at least 90% identity, atleast 95% identity, or 100% identity to any one of SEQ ID NOs:347 and349-361. For example, the antigen binding polypeptide or antigen bindingpolypeptide complex (e.g., antibody or antigen binding fragment thereof)may comprise one or more amino acid sequences encoded by apolynucleotide having at least 90% (such as at least 91%, 92%, 93%, 94%,95%, 96%, 97%, 98%, or 99%) identity to any one of SEQ ID NOs:347 and349-361. For example, the antigen binding polypeptide or antigen bindingpolypeptide complex (e.g., antibody or antigen binding fragment thereof)may comprise one or more amino acid sequences encoded by thepolynucleotide shown in any one of SEQ ID NOs:347 and 349-361.

As used herein, an antigen binding polypeptide, antigen bindingpolypeptide complex (e.g., an antibody or antigen binding fragmentthereof), or region or domain thereof that “specifically binds” refersto its association with an epitope by its antigen binding domain, andthat the binding entails some complementarity between the antigenbinding domain and the epitope. Specific binding to an epitope occurswhere there is binding to that epitope via its antigen binding domainmore readily than there would be binding to a random, unrelated epitope.

As used herein, an “epitope” refers to a localized region of an antigento which an antigen binding polypeptide or antigen binding polypeptidecomplex (e.g., antibody or antigen binding fragment thereof) canspecifically bind. An epitope can be, for example, contiguous aminoacids of a polypeptide (linear or contiguous epitope) or an epitope can,for example, come together from two or more non-contiguous regions of apolypeptide or polypeptides (conformational, non-linear, discontinuous,or non-contiguous epitope). In some aspects, the epitope to which anantibody or antigen-binding fragment thereof binds can be determined by,e.g., NMR spectroscopy, X-ray diffraction crystallography studies, ELISAassays, hydrogen/deuterium exchange coupled with mass spectrometry(e.g., liquid chromatography electrospray mass spectrometry),array-based oligo-peptide scanning assays, and/or mutagenesis mapping(e.g., site-directed mutagenesis mapping). See, e.g., Giegé R et al.,(1994) Acta Crystallogr D Biol Crystallogr 50(Pt 4): 339-350; McPhersonA (1990) Eur J Biochem 189: 1-23; Chayen N E (1997) Structure 5:1269-1274; McPherson A (1976) J Biol Chem 251: 6300-6303; Meth Enzymol(1985) volumes 114 & 115, eds Wyckoff H W et al., U.S. Pub. No.2004/0014194), Bricogne G (1993) Acta Crystallogr D Biol Crystallogr49(Pt 1): 37-60, Bricogne G (1997) Meth Enzymol 276A: 361-423, ed CarterC W, and Roversi et al., (2000) Acta Crystallogr D Biol Crystallogr56(Pt 10): 1316-1323 (X-ray diffraction crystallography studies); andChampe et al., (1995) J Biol Chem 270: 1388-1394 and Cunningham B C &Wells J A (1989) Science 244: 1081-1085 (mutagenesis mapping).

Specific binding can be represented by a “binding affinity.” Bindingaffinity refers to an intrinsic binding affinity which reflects a 1:1interaction between members of a binding pair (e.g., an antigen bindingpolypeptide or antigen binding polypeptide complex and an antigen).Binding affinity can be measured and/or expressed in several ways knownin the art, including, but not limited to, equilibrium dissociationconstant (K_(D)). K_(D) is calculated from the quotient ofk_(off)/k_(on), where k_(on) refers to the association rate constant of,e.g., an antigen binding polypeptide or antigen binding polypeptidecomplex to an antigen, and k_(off) refers to the dissociation of, e.g.,an antigen binding polypeptide or antigen binding polypeptide complexfrom an antigen. The k_(on) and k_(off) can be determined by techniquesknown to one of ordinary skill in the art, such as Octet BLI, BIAcore®or KinExA.

Accordingly, in some aspects, an antigen binding polypeptide complex ofthe invention is an antibody or antigen binding fragment thereof. Insome aspects, the antibody or antigen binding fragment thereof comprisesone, two, three or four antigen binding polypeptides described herein.

In some aspects, the antibody or antigen binding fragment thereofspecifically binds to an antigen with an equilibrium dissociationconstant (K_(D)) of from about 10 μM to about 1 pM. In another aspect,the antibody is IgG, IgM, IgE, IgA or IgD. For example, the antibody maybe IgG. For example, the antibody may be IgM. For example, the antibodymay be IgE. For example, the antibody may be IgA. For example, theantibody may be IgD. In some aspects, the IgG is IgG1, IgG2, IgG3 orIgG4. For example, the antibody may be IgG1. For example, the antibodymay be IgG2. For example, the antibody may be IgG3. For example, theantibody may be IgG4. In some aspects, the antigen binding fragment is aFab, scFab, Fab′, F(ab′)₂, Fv or scFv. For example, the antigen bindingfragment may be a Fab. For example, the antigen binding fragment may bea scFab. For example, the antigen binding fragment may be a Fab′. Forexample, the antigen binding fragment may be a F(ab′)₂. For example, theantigen binding fragment may be a Fv. For example, the antigen bindingfragment may be a scFv. In some aspects, the antibody is human orhumanized. For example, the antibody may be human. For the example, theantibody may be humanized

Amino Acid Linkers

In some aspects, an antigen binding polypeptide or antigen bindingpolypeptide complex (e.g., an antibody or antigen binding fragmentthereof) of the invention comprises one or more amino acid linkersbetween one or more regions of the antigen binding polypeptide orantigen binding polypeptide complex.

As used herein, an “amino acid linker” refers to a single amino acid orshort amino acid sequence that is capable of joining two polypeptideregions of the invention described herein in a stable manner thatmaintains or promotes a function associated with the polypeptideregions. In some aspects, an amino acid linker is represented herein ina structure of an antigen binding polypeptide or antigen bindingpolypeptide complex by the abbreviation “1” or “L” and a number (e.g.,L1 to denote a first linker, L2 to denote a second linker, L3 to denotea third linker, L4 to denote a fourth linker, L5 to denote a fifthlinker, L6 to denote a sixth linker, L7 to denote a seventh linker, L8to denote an eighth linker, L9 to denote a ninth linker, L10 to denote atenth linker, L11 to denote an eleventh linker, L12 to denote a twelfthlinker). In some aspects, such enumerated amino acid linkers (e.g., L1)can have the same or different sequence as any other enumerated aminoacid linker (e.g., L2, etc.). Furthermore, in other aspects, anenumerated amino acid linker present in one polypeptide (e.g., L1 on afirst polypeptide of an antigen binding polypeptide and/or antigenbinding polypeptide complex structure described herein) can have thesame or different sequence as the same enumerated amino acid linkerpresent in another polypeptide (e.g., L1 on a second polypeptide, thirdpolypeptide, etc. of an antigen binding polypeptide and/or antigenbinding polypeptide complex structure described herein).

In some aspects, an amino acid linker has a length of from about 1 aminoacid to about 50 amino acids (e.g., one or more of L1, L2, L3, L4, L5,L6, L7, L8, L9, L10, L11, L12 etc. of an antigen binding polypeptide ora first, second, third, etc. polypeptide of an antigen bindingpolypeptide complex structure described herein). In some aspects, theamino acid linker has a length of from about 1 amino acid to about 45amino acids, about 1 amino acid to about 40 amino acids, about 1 aminoacid to about 35 amino acids, about 1 amino acid to about 30 aminoacids, about 1 amino acid to about 25 amino acids, about 1 amino acid toabout 20 amino acids, 1 amino acid to about 15 amino acids, about 1amino acid to about 10 amino acids, about 1 amino acid to about 5 aminoacids, about 5 amino acids to about 50 amino acids, about 5 amino acidsto about 45 amino acids, about 5 amino acids to about 40 amino acids,about 5 amino acids to about 35 amino acids, about 5 amino acids toabout 30 amino acids, about 5 amino acids to about 25 amino acids, about5 amino acids to about 20 amino acids, about 5 amino acids to about 15amino acids, about 5 amino acids to about 10 amino acids, about 10 aminoacids to about 50 amino acids, about 10 amino acids to about 45 aminoacids, about 10 amino acids to about 40 amino acids, about 10 aminoacids to about 35 amino acids, about 10 amino acids to about 30 aminoacids, about 10 amino acids to about 25 amino acids, about 10 aminoacids to about 20 amino acids, about 10 amino acids to about 15 aminoacids, about 15 amino acids to about 50 amino acids, about 15 aminoacids to about 45 amino acids, about 15 amino acids to about 40 aminoacids, about 15 amino acids to about 35 amino acids, about 15 aminoacids to about 30 amino acids, about 15 amino acids to about 25 aminoacids, about 15 amino acids to about 20 amino acids, about 20 aminoacids to about 50 amino acids, about 20 amino acids to about 45 aminoacids, about 20 amino acids to about 40 amino acids, about 20 aminoacids to about 35 amino acids, about 20 amino acids to about 30 aminoacids, about 20 amino acids to about 25 amino acids, about 25 aminoacids to about 50 amino acids, about 25 amino acids to about 45 aminoacids, about 25 amino acids to about 40 amino acids, about 25 aminoacids to about 35 amino acids, about 25 amino acids to about 30 aminoacids, about 30 amino acids to about 50 amino acids, about 30 aminoacids to about 45 amino acids, about 30 amino acids to about 40 aminoacids, about 30 amino acids to about 35 amino acids, about 40 aminoacids to about 50 amino acids, about 40 amino acids to about 45 aminoacids, or about 45 amino acids to about 50 amino acids.

In some aspects, the amino acid linker has about 1, about 2, about 3,about 4, about 5, about 6, about 7, about 8, about 9, about 10, about11, about 12, about 13, about 14, about 15, about 16, about 17, about18, about 19, about 20, about 25, about 30, about 35, about 40, about45, or about 50 amino acids (e.g., one or more of L1, L2, L3, L4, L5,L6, L7, L8, L9, L10, L11 L12 etc. of an antigen binding polypeptidestructure described herein or a first, second, third, etc. polypeptideof an antigen binding polypeptide complex structure described herein).

In some aspects, the amino acid linker consists of one or more aminoacid residues (e.g., one or more of L1, L2, L3, L4, L5, L6, L7, L8, L9,L10, L11, L12 etc. of an antigen binding polypeptide structure describedherein or a first, second, third, etc. polypeptide of an antigen bindingpolypeptide complex structure described herein). In some aspects, theamino acid residues are selected from the group consisting of glycine,alanine, serine, threonine, cysteine, asparagine, glutamine, leucine,isoleucine, valine, proline, histidine, aspartic acid, glutamic acid,lysine, arginine, methionine, phenylalanine, tryptophan, and tyrosine.

In some aspects, an amino acid linker of the invention isnon-immunogenic. In some aspects, the non-immunogenic linker consists ofserine, glycine and/or alanine residues, or consists of serine and/orglycine residues. In some aspects, an amino acid linker of the inventiondoes not contain a T cell epitope or consensus T cell epitope.

In some aspects, the amino acid linker consists of one or more residuesof alanine, cysteine, glycine, isoleucine, leucine, methionine,phenylalanine, proline, tryptophan, tyrosine, valine (e.g., one or moreof L1, L2, L3, L4, L5, L6, L7, L8, L9, L10, L11, L12 etc. of an antigenbinding polypeptide structure described herein or a first, second,third, etc. polypeptide of an antigen binding polypeptide complexstructure described herein).

Amino acid linker sequences that can be used with the antigen bindingpolypeptides and antigen binding polypeptide complexes (e.g., anantibody or antigen binding fragment thereof) of the invention are wellknown and can be incorporated into antigen binding polypeptides andantigen binding polypeptide complexes of the invention using routinemolecular biology and recombinant DNA techniques. See, e.g., Chen etal., Adv Drug Deliv Rev., 65(10):1357-1369, 2013; and Chichili et al.,Protein Sci., 22(2):153-167, 2013.

In some aspects, the amino acid linker (e.g., one or more of L1, L2, L3,L4, L5, L6, L7, L8, L9, L10, L11, L12 etc. of a first, second, third,etc. polypeptide of an antigen binding polypeptide or antigen bindingpolypeptide complex structure described herein) has the sequence of g,a, gss, asg, ggssg, gssgs, gtvaa, asggs, astgg, asggsg, ggsggssgss,sggsgssggs, ggsggsgsgggsasgsg, ggsggsgsggggsasgsg, gggssggggsggsgsggsgs,ggggsggsgsggggsasgsg, gggssggsgsggsgsggsgs, sggssggsgsggsgsggsgssg,gsgssggggsggsgsggsgssg, ggggsgsggsgggssggggsggggsggggsggggsggggs,ggggsggggsggggsggggsggggsggggsggggsggggs,ggggsgsggsgggssggggsggggsggggsggggsggggssss,ggggsgsggsgggssggggsggggsggggsggggsggggssssgs, ggsgg,gsggsagsgsggggsasgsg, ggggs, or gsggsggsgsggggsasgsg (SEQ ID NOs:1-19and 681-688), or a sequence having at least 50%, at least 60%, at least70%, at least 80%, at least 90%, at least 91%, at least 93%, at least93%, at least 94%, at least 95%, at least 96%, at least 97%, at least98%, at least 99% or 100% identity to any one of SEQ ID NOs:1-19 and681-688. For example, the amino acid linker (e.g., one or more of L1,L2, L3, L4, L5, L6, L7, L8, L9, L10, L11, L12 etc. of a first, second,third, etc. polypeptide of an antigen binding polypeptide or antigenbinding polypeptide complex structure described herein) may comprise theamino acid sequence of any one of SEQ ID NOs: 1-19 and 681-688.

In some aspects, the antigen binding polypeptide or antigen bindingpolypeptide complex comprises a polypeptide having a structurerepresented by VL1-L1-VL2-L2-VH2-L3-VH1 or VH1-L1-VH2-L2-VL2-L3-VL1,wherein L1 comprises the amino acid sequence of ggssg (SEQ ID NO:1) or asequence having at least 50%, at least 60%, at least 70%, at least 80%,at least 90% or at least 95% identity to SEQ ID NO:1; L2 comprises theamino acid sequence of ggggsggsgsggggsasgsg (SEQ ID NO:12) or a sequencehaving at least 50%, at least 60%, at least 70%, at least 80%, at least90% or at least 95% identity to SEQ ID NO:12, and L3 comprises the aminoacid sequence of ggssg (SEQ ID NO:1) or a sequence having at least 50%,at least 60%, at least 70%, at least 80%, at least 90% or at least 95%identity to SEQ ID NO:1. For example, the antigen binding polypeptide orantigen binding polypeptide complex comprising a polypeptide having astructure represented by VL1-L1-VL2-L2-VH2-L3-VH1 orVH1-L1-VH2-L2-VL2-L3-VL1 may comprise an L1 linker with the amino acidsequence of ggssg (SEQ ID NO:1), a L2 linker with the amino acidsequence of ggggsggsgsggggsasgsg (SEQ ID NO:12), and a L3 linker withthe amino acid sequence of ggssg (SEQ ID NO:1).

In some aspects, the antigen binding polypeptide or antigen bindingpolypeptide complex comprises a polypeptide having a structurerepresented by VL1-L1-VL2-L2-VH2-L3-VH1-L4 orVH1-L1-VH2-L2-VL2-L3-VL1-L4, wherein L1 comprises the amino acidsequence of ggssg (SEQ ID NO:1) or a sequence having at least 50%, atleast 60%, at least 70%, at least 80%, at least 90%, or at least 95%identity to SEQ ID NO:1, L2 comprises the amino acid sequence ofggggsggsgsggggsasgsg (SEQ ID NO:12) or a sequence having at least 50%,at least 60%, at least 70%, at least 80%, at least 90%, or at least 95%identity to SEQ ID NO:12, L3 comprises the amino acid sequence of ggssg(SEQ ID NO:1) or a sequence having at least 50%, at least 60%, at least70%, at least 80%, at least 90%, or at least 95% identity to SEQ IDNO:1, and L4 comprises the amino acid sequence of asggsg (SEQ ID NO:6)or a sequence having at least 50%, at least 60%, at least 70%, at least80%, at least 90%, or at least 95% identity to SEQ ID NO:6. For example,the antigen binding polypeptide or antigen binding polypeptide complexcomprising a polypeptide having a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4 or VH1-L1-VH2-L2-VL2-L3-VL1-L4 may comprisea L1 linker with the amino acid sequence of ggssg (SEQ ID NO:1), a L2linker with the amino acid sequence of ggggsggsgsggggsasgsg (SEQ IDNO:12), a L3 linker with the amino acid sequence of ggssg (SEQ ID NO:1)and a L4 linker with the amino acid sequence of asggsg (SEQ ID NO:6).

In some aspects, the antigen binding polypeptide or antigen bindingpolypeptide complex comprises a polypeptide having a structurerepresented by VL1-L1-VL2-L2-VH2-L3-VH1-L4 orVH1-L1-VH2-L2-VL2-L3-VL1-L4, wherein L1 comprises the amino acidsequence of gtvaa (SEQ ID NO:3) or a sequence having at least 50%, atleast 60%, at least 70%, at least 80%, at least 90%, or at least 95%identity to SEQ ID NO:3, L2 comprises the amino acid sequence ofggggsggsgsggggsasgsg (SEQ ID NO:12) or a sequence having at least 50%,at least 60%, at least 70%, at least 80%, at least 90%, or at least 95%identity to SEQ ID NO:12, L3 comprises the amino acid sequence of astgg(SEQ ID NO:5) or a sequence having at least 50%, at least 60%, at least70%, at least 80%, at least 90%, or at least 95% identity to SEQ IDNO:5, and L4 comprises the amino acid sequence of asggsg (SEQ ID NO:6)or a sequence having at least 50%, at least 60%, at least 70%, at least80%, at least 90%, or at least 95% identity to SEQ ID NO:6. For example,the antigen binding polypeptide or antigen binding polypeptide complexcomprising a polypeptide having a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4 or VH1-L1-VH2-L2-VL2-L3-VL1-L4 may comprisea L1 linker with the amino acid sequence of gtvaa (SEQ ID NO:3), a L2linker with the amino acid sequence of ggggsggsgsggggsasgsg (SEQ IDNO:12), a L3 linker with the amino acid sequence of astgg (SEQ ID NO:5)and a L4 linker with the amino acid sequence of asggsg (SEQ ID NO:6).

In some aspects, the antigen binding polypeptide or antigen bindingpolypeptide complex comprising a polypeptide having a structurerepresented by VL1-L1-VL2-L2-VH2-L3-VH1-CL-L4-CH1 orVH1-L1-VH2-L2-VL2-L3-VL1-CL-L4-CH1, wherein L1 comprises the amino acidsequence of ggssg (SEQ ID NO:1) or a sequence having at least 50%, atleast 60%, at least 70%, at least 80%, at least 90%, or at least 95%identity to SEQ ID NO:1, L2 comprises the amino acid sequence ofggggsggsgsggggsasgsg (SEQ ID NO:12) or a sequence having at least 50%,at least 60%, at least 70%, at least 80%, at least 90%, or at least 95%identity to SEQ ID NO:12, L3 comprises the amino acid sequence of ggssg(SEQ ID NO:1) or a sequence having at least 50%, at least 60%, at least70%, at least 80%, at least 90%, or at least 95% identity to SEQ IDNO:1, and L4 comprises the amino acid sequence of ggggsggsgsggggsasgsg(SEQ ID NO:12) or a sequence having at least 50%, at least 60%, at least70%, at least 80%, at least 90%, or at least 95% identity to SEQ IDNO:12. For example, the antigen binding polypeptide or antigen bindingpolypeptide complex comprising a polypeptide having a structurerepresented by VL1-L1-VL2-L2-VH2-L3-VH1-CL-L4-CH1 orVH1-L1-VH2-L2-VL2-L3-VL1-CL-L4-CH1 may comprise a L1 linker with theamino acid sequence of ggssg (SEQ ID NO:1), a L2 linker with the aminoacid sequence of ggggsggsgsggggsasgsg (SEQ ID NO:12), a L3 linker withthe amino acid sequence of ggssg (SEQ ID NO:1) and a L4 linker with theamino acid sequence of ggggsggsgsggggsasgsg (SEQ ID NO:12).

In some aspects, the antigen binding polypeptide complex comprises asecond polypeptide having a structure represented by VL3-L4-VH3 orVH3-L4-VL3, wherein L4 comprises the amino acid sequence ofggggsggsgsggggsasgsg (SEQ ID NO:12) or a sequence having at least 50%,at least 60%, at least 70%, at least 80%, at least 90%, or at least 95%identity to SEQ ID NO:12. For example, the antigen binding polypeptidecomplex comprising a second polypeptide having a structure representedby VL3-L4-VH3 or VH3-L4-VL3 may comprise a L4 linker with the amino acidsequence of ggggsggsgsggggsasgsg (SEQ ID NO:12). In some aspects, theantigen binding polypeptide complex comprises a second polypeptidehaving a structure represented by VL3-L4-VH3-L5 or VH3-L4-L5, wherein L4comprises the amino acid sequence of ggggsggsgsggggsasgsg (SEQ ID NO:12)or a sequence having at least 50%, at least 60%, at least 70%, at least80%, at least 90%, or at least 95% identity to SEQ ID NO:12, and L5comprises the amino acid sequence of asggsg (SEQ ID NO:6) or a sequencehaving at least 50%, at least 60%, at least 70%, at least 80%, at least90%, or at least 95% identity to SEQ ID NO:6. For example, the antigenbinding polypeptide complex comprising a second polypeptide having astructure represented by VL3-L4-VH3-L5 or VH3-L4-L5 may comprise a L4linker with the amino acid sequence of ggggsggsgsggggsasgsg (SEQ IDNO:12) and a L5 linker with the amino acid sequence of asggsg (SEQ IDNO:6).

In some aspects, the antigen binding polypeptide or antigen bindingpolypeptide complex comprises a polypeptide having a structurerepresented by VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc-Fc orVH1-L1-VH2-L2-VL2-L3-VII-L4-Fc-Fc, wherein L1 comprises the amino acidsequence of ggssg (SEQ ID NO:1) or a sequence having at least 50%, atleast 60%, at least 70%, at least 80%, at least 90%, or at least 95%identity to SEQ ID NO:1, L2 comprises the amino acid sequence ofggggsggsgsggggsasgsg (SEQ ID NO:12) or a sequence having at least 50%,at least 60%, at least 70%, at least 80%, at least 90%, or at least 95%identity to SEQ ID NO:12, L3 comprises the amino acid sequence of ggssg(SEQ ID NO:1) or a sequence having at least 50%, at least 60%, at least70%, at least 80%, at least 90%, or at least 95% identity to SEQ IDNO:1, and L4 comprises the amino acid sequence of asggsg (SEQ ID NO:6)or a sequence having at least 50%, at least 60%, at least 70%, at least80%, at least 90%, or at least 95% identity to SEQ ID NO:6. For example,the antigen binding polypeptide or antigen binding polypeptide complexcomprising a polypeptide having a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc-Fc or VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc-Fcmay comprise a L1 linker with the amino acid sequence of ggssg (SEQ IDNO:1), a L2 linker with the amino acid sequence of ggggsggsgsggggsasgsg(SEQ ID NO:12), a L3 linker with the amino acid sequence of ggssg (SEQID NO:1) and a L4 linker with the amino acid sequence of asggsg (SEQ IDNO:6).

In some aspects, the antigen binding polypeptide or antigen bindingpolypeptide complex comprises a polypeptide having a structurerepresented by VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc-L5-Fc orVH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc-L5-Fc, wherein L1 comprises the aminoacid sequence of ggssg (SEQ ID NO:1) or a sequence having at least 50%,at least 60%, at least 70%, at least 80%, at least 90%, or at least 95%identity to SEQ ID NO:1, L2 comprises the amino acid sequence ofggggsggsgsggggsasgsg (SEQ ID NO:12) or a sequence having at least 50%,at least 60%, at least 70%, at least 80%, at least 90%, or at least 95%identity to SEQ ID NO:12, L3 comprises the amino acid sequence of ggssg(SEQ ID NO:1) or a sequence having at least 50%, at least 60%, at least70%, at least 80%, at least 90%, or at least 95% identity to SEQ IDNO:1, L4 comprises the amino acid sequence of asggsg (SEQ ID NO:6) or asequence having at least 50%, at least 60%, at least 70%, at least 80%,at least 90%, or at least 95% identity to SEQ ID NO:6, and L5 comprisesthe amino acid sequence of ggggsgsggsgggssggggsggggsggggsggggsggggssss(SEQ ID NO:18) or a sequence having at least 50%, at least 60%, at least70%, at least 80%, at least 90%, or at least 95% identity to SEQ IDNO:18. For example, the antigen binding polypeptide or antigen bindingpolypeptide complex comprising a polypeptide having a structurerepresented by VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc-L5-Fc orVH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc-L5-Fc may comprise a L1 linker with theamino acid sequence of ggssg (SEQ ID NO:1), a L2 linker with the aminoacid sequence of ggggsggsgsggggsasgsg (SEQ ID NO:12), a L3 linker withthe amino acid sequence of ggssg (SEQ ID NO:1), a L4 linker with theamino acid sequence of asggsg (SEQ ID NO:6), and a L5 linker with theamino acid sequence of ggggsgsggsgggssggggsggggsggggsggggsggggssss (SEQID NO:18).

In some aspects, the antigen binding polypeptide or antigen bindingpolypeptide complex comprises a polypeptide having a structurerepresented by VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc-L5-Fc orVH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc-L5-Fc, wherein L1 comprises the aminoacid sequence of ggssg (SEQ ID NO:1) or a sequence having at least 50%,at least 60%, at least 70%, at least 80%, at least 90%, or at least 95%identity to SEQ ID NO:1, L2 comprises the amino acid sequence ofggggsggsgsggggsasgsg (SEQ ID NO:12) or a sequence having at least 50%,at least 60%, at least 70%, at least 80%, at least 90%, or at least 95%identity to SEQ ID NO:12, L3 comprises the amino acid sequence of ggssg(SEQ ID NO:1) or a sequence having at least 50%, at least 60%, at least70%, at least 80%, at least 90%, or at least 95% identity to SEQ IDNO:1, L4 comprises the amino acid sequence of asggsg (SEQ ID NO:6) or asequence having at least 50%, at least 60%, at least 70%, at least 80%,at least 90%, or at least 95% identity to SEQ ID NO:6, and L5 comprisesthe amino acid sequence of ggggsgsggsgggssggggsggggsggggsggggsggggssssgs(SEQ ID NO:19) or a sequence having at least 50%, at least 60%, at least70%, at least 80%, at least 90%, or at least 95% identity to SEQ IDNO:19. For example, the antigen binding polypeptide or antigen bindingpolypeptide complex comprising a polypeptide having a structurerepresented by VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc-L5-Fc orVH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc-L5-Fc may comprise a L1 linker with theamino acid sequence of ggssg (SEQ ID NO:1), a L2 linker with the aminoacid sequence of ggggsggsgsggggsasgsg (SEQ ID NO:12), a L3 linker withthe amino acid sequence of ggssg (SEQ ID NO:1), a L4 linker with theamino acid sequence of asggsg (SEQ ID NO:6), and a L5 linker with theamino acid sequence of ggggsgsggsgggssggggsggggsggggsggggsggggssssgs(SEQ ID NO:19).

In some aspects, the antigen binding polypeptide or antigen bindingpolypeptide complex comprises a polypeptide having a structurerepresented by VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH3-L5-CH3 orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CH3-L5-CH3, wherein L1 comprises the aminoacid sequence of ggssg (SEQ ID NO:1) or a sequence having at least 50%,at least 60%, at least 70%, at least 80%, at least 90%, or at least 95%identity to SEQ ID NO:1, L2 comprises the amino acid sequence ofggggsggsgsggggsasgsg (SEQ ID NO:12) or a sequence having at least 50%,at least 60%, at least 70%, at least 80%, at least 90%, or at least 95%identity to SEQ ID NO:12, L3 comprises the amino acid sequence of ggssg(SEQ ID NO:1) or a sequence having at least 50%, at least 60%, at least70%, at least 80%, at least 90%, or at least 95% identity to SEQ IDNO:1, L4 comprises the amino acid sequence of asggsg (SEQ ID NO:6) or asequence having at least 50%, at least 60%, at least 70%, at least 80%,at least 90%, or at least 95% identity to SEQ ID NO:6, and L5 comprisesthe amino acid sequence of gggssggggsggsgsggsgs (SEQ ID NO:11) or asequence having at least 50%, at least 60%, at least 70%, at least 80%,at least 90%, or at least 95% identity to SEQ ID NO:11. For example, theantigen binding polypeptide or antigen binding polypeptide complexcomprising a polypeptide having a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CH3-L5-CH3 orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CH3-L5-CH3 may comprise a L1 linker with theamino acid sequence of ggssg (SEQ ID NO:1), a L2 linker with the aminoacid sequence of ggggsggsgsggggsasgsg (SEQ ID NO:12), a L3 linker withthe amino acid sequence of ggssg (SEQ ID NO:1), a L4 linker with theamino acid sequence of asggsg (SEQ ID NO:6), and a L5 linker with theamino acid sequence of gggssggggsggsgsggsgs (SEQ ID NO:11).

In some aspects, the antigen binding polypeptide or antigen bindingpolypeptide complex comprises a polypeptide having a structurerepresented by VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH3-L5-CH3 orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CH3-L5-CH3, wherein L1 comprises the aminoacid sequence of ggssg (SEQ ID NO:1) or a sequence having at least 50%,at least 60%, at least 70%, at least 80%, at least 90%, or at least 95%identity to SEQ ID NO:1, L2 comprises the amino acid sequence ofggggsggsgsggggsasgsg (SEQ ID NO:12) or a sequence having at least 50%,at least 60%, at least 70%, at least 80%, at least 90%, or at least 95%identity to SEQ ID NO:12, L3 comprises the amino acid sequence of ggssg(SEQ ID NO:1) or a sequence having at least 50%, at least 60%, at least70%, at least 80%, at least 90%, or at least 95% identity to SEQ IDNO:1, L4 comprises the amino acid sequence of asggsg (SEQ ID NO:6) or asequence having at least 50%, at least 60%, at least 70%, at least 80%,at least 90%, or at least 95% identity to SEQ ID NO:6, and L5 comprisesthe amino acid sequence of gggssggggsggsgsggsgs (SEQ ID NO:11) or asequence having at least 50%, at least 60%, at least 70%, at least 80%,at least 90%, or at least 95% identity to SEQ ID NO:11. For example, theantigen binding polypeptide or antigen binding polypeptide complexcomprising a polypeptide having a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CH3-L5-CH3 orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CH3-L5-CH3 may comprise a L1 linker with theamino acid sequence of ggssg (SEQ ID NO:1), a L2 linker with the aminoacid sequence of ggggsggsgsggggsasgsg (SEQ ID NO:12), a L3 linker withthe amino acid sequence of ggssg (SEQ ID NO:1), a L4 linker with theamino acid sequence of asggsg (SEQ ID NO:6), and a L5 linker with theamino acid sequence of gggssggggsggsgsggsgs (SEQ ID NO:11).

In some aspects, the antigen binding polypeptide or antigen bindingpolypeptide complex comprises a polypeptide having a structurerepresented by VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH3-L5-CH3 orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CH3-L5-CH3, wherein L1 comprises the aminoacid sequence of ggssg (SEQ ID NO:1) or a sequence having at least 50%,at least 60%, at least 70%, at least 80%, at least 90%, or at least 95%identity to SEQ ID NO:1, L2 comprises the amino acid sequence ofggggsggsgsggggsasgsg (SEQ ID NO:12) or a sequence having at least 50%,at least 60%, at least 70%, at least 80%, at least 90%, or at least 95%identity to SEQ ID NO:12, L3 comprises the amino acid sequence of ggssg(SEQ ID NO:1) or a sequence having at least 50%, at least 60%, at least70%, at least 80%, at least 90%, or at least 95% identity to SEQ IDNO:1, L4 comprises the amino acid sequence of asggsg (SEQ ID NO:6) or asequence having at least 50%, at least 60%, at least 70%, at least 80%,at least 90%, or at least 95% identity to SEQ ID NO:6, and L5 comprisesthe amino acid sequence of gsgssggggsggsgsggsgssg (SEQ ID NO:15) or asequence having at least 50%, at least 60%, at least 70%, at least 80%,at least 90%, or at least 95% identity to SEQ ID NO:15. For example, theantigen binding polypeptide or antigen binding polypeptide complexcomprising a polypeptide having a structure represented byVL1-L1-VL2-L2-VH2-L3-VH1-L4-CH3-L5-CH3 orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CH3-L5-CH3 may comprise a L1 linker with theamino acid sequence of ggssg (SEQ ID NO:1), a L2 linker with the aminoacid sequence of ggggsggsgsggggsasgsg (SEQ ID NO:12), a L3 linker withthe amino acid sequence of ggssg (SEQ ID NO:1), a L4 linker with theamino acid sequence of asggsg (SEQ ID NO:6), and a L5 linker with theamino acid sequence of gsgssggggsggsgsggsgssg (SEQ ID NO:15).

In some aspects, the antigen binding polypeptide or antigen bindingpolypeptide complex comprises a polypeptide having a structurerepresented by VL1-L1-VL2-L2-VH2-L3-VH1-CL-L4-CH1-Fc-L5-Fc orVH1-L1-VH2-L2-VL2-L3-VL1-CL-L4-CH1-Fc-L5-Fc, wherein L1 comprises theamino acid sequence of ggssg (SEQ ID NO:1) or a sequence having at least50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least95% identity to SEQ ID NO:1, L2 comprises the amino acid sequence ofggggsggsgsggggsasgsg (SEQ ID NO:12) or a sequence having at least 50%,at least 60%, at least 70%, at least 80%, at least 90%, or at least 95%identity to SEQ ID NO:12, L3 comprises the amino acid sequence of ggssg(SEQ ID NO:1) or a sequence having at least 50%, at least 60%, at least70%, at least 80%, at least 90%, or at least 95% identity to SEQ IDNO:1, L4 comprises the amino acid sequence of ggggsggsgsggggsasgsg (SEQID NO:12) or a sequence having at least 50%, at least 60%, at least 70%,at least 80%, at least 90%, or at least 95% identity to SEQ ID NO:12,and L5 comprises the amino acid sequence ofggggsgsggsgggssggggsggggsggggsggggsggggs (SEQ ID NO:16) or a sequencehaving at least 50%, at least 60%, at least 70%, at least 80%, at least90%, or at least 95% identity to SEQ ID NO:16. For example, the antigenbinding polypeptide or antigen binding polypeptide complex comprising apolypeptide having a structure represented byVIA-L1-VL2-L2-VH2-L3-VH1-CL-L4-CH1-Fc-L5-Fc orVH1-L1-VH2-L2-VL2-L3-VL1-CL-L4-CH1-Fc-L5-Fc may comprise a L1 linkerwith the amino acid sequence of ggssg (SEQ ID NO:1), a L2 linker withthe amino acid sequence of ggggsggsgsggggsasgsg (SEQ ID NO:12), a L3linker with the amino acid sequence of ggssg (SEQ ID NO:1), a L4 linkerwith the amino acid sequence of ggggsggsgsggggsasgsg (SEQ ID NO:12), anda L5 linker with the amino acid sequence ofggggsgsggsgggssggggsggggsggggsggggsggggs (SEQ ID NO:16).

In some aspects of an antigen binding polypeptide or antigen bindingpolypeptide complex of the invention, L1 comprises the amino acidsequence of ggssg (SEQ ID NO:1) or an amino acid sequence having atleast 90% identity or at least 95% identity to SEQ ID NO:1; L2 comprisesthe amino acid sequence of ggggsggsgsggggsasgsg (SEQ ID NO:12) or anamino acid sequence having at least 90% identity or at least 95%identity to SEQ ID NO:12; L3 comprises the amino acid sequence of SEQ IDNO:1 or an amino acid sequence having at least 90% identity or at least95% identity to SEQ ID NO:1; and L4 comprises the amino acid sequence ofasggsg (SEQ ID NO:6) or an amino acid sequence having at least 90%identity or at least 95% identity to SEQ ID NO:6. For example, theantigen binding polypeptide or antigen binding polypeptide complex maycomprise a L1 linker with the amino acid sequence of ggssg (SEQ IDNO:1), a L2 linker with the amino acid sequence of ggggsggsgsggggsasgsg(SEQ ID NO:12), a L3 linker with the amino acid sequence of ggssg (SEQID NO:1), and a L4 linker with the amino acid sequence of asggsg (SEQ IDNO:6).

In another aspect, the invention is directed to an antigen bindingpolypeptide complex comprising a first polypeptide and a secondpolypeptide; wherein the first polypeptide has a structure representedby VL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1; orVH1-L1-VH2-L2-VL2-L3-VL1; wherein the second polypeptide has a structurerepresented by VL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3;VL3-L4-VL4-L5-VH4-L6-VH3; or VH3-L4-VH4-L5-VL4-L6-VL3; wherein VL1 is afirst immunoglobulin light chain variable region that specifically bindsto an HIV protein; VL2 is a second immunoglobulin light chain variableregion that specifically binds to an HIV protein; VL3 is a thirdimmunoglobulin light chain variable region that specifically binds to anHIV protein; VL4 is a fourth immunoglobulin light chain variable regionthat specifically binds to an HIV protein; VH1 is a first immunoglobulinheavy chain variable region that specifically binds to an HIV protein;VH2 is a second immunoglobulin heavy chain variable region thatspecifically binds to an HIV protein; VH3 is a third immunoglobulinheavy chain variable region that specifically binds to an HIV protein;VH4 is a fourth immunoglobulin heavy chain variable region thatspecifically binds to an HIV protein; L1, L2, L3, L4, L5 and L6 areamino acid linkers; L1 comprises the amino acid sequence of ggssg (SEQID NO:1) or an amino acid sequence having at least 90% identity or atleast 95% identity to SEQ ID NO:1; L2 comprises the amino acid sequenceof ggggsggsgsggggsasgsg (SEQ ID NO:12) or an amino acid sequence havingat least 90% identity or at least 95% identity to SEQ ID NO:12; L3comprises the amino acid sequence of SEQ ID NO:1 or an amino acidsequence having at least 90% identity or at least 95% identity to SEQ IDNO:1; and L4 comprises the amino acid sequence of asggsg (SEQ ID NO:6)or an amino acid sequence having at least 90% identity or at least 95%identity to SEQ ID NO:6. For example, the antigen binding polypeptidecomplex comprising a first polypeptide having a structure represented byVL1-VL2-VH2-VH1; VH1-VH2-VL2-VL1; VL1-L1-VL2-L2-VH2-L3-VH1; orVH1-L1-VH2-L2-VL2-L3-VL1; and a second polypeptide having a structurerepresented by VL3-VL4-VH4-VH3; VH3-VH4-VL4-VL3;VL3-L4-VL4-L5-VH4-L6-VH3; or VH3-L4-VH4-L5-VL4-L6-VL3 may comprise a L1linker with the amino acid sequence of ggssg (SEQ ID NO:1), a L2 linkerwith the amino acid sequence of ggggsggsgsggggsasgsg (SEQ ID NO:12), aL3 linker with the amino acid sequence of ggssg (SEQ ID NO:1), and a L4linker with the amino acid sequence of asggsg (SEQ ID NO:6).

Detectable Labels and Drug Conjugates

In some aspects, an antigen binding polypeptide or antigen bindingpolypeptide complex (e.g., an antibody or antigen binding fragmentthereof) of the invention comprises one or more detectable labels. Anantigen binding polypeptide or antigen binding polypeptide complex(e.g., an antibody or antigen binding fragment thereof) containing adetectable label is useful in therapeutic, diagnostic, imaging (e.g.,radioimaging), or basic research applications.

In some aspects, the detectable label is a radioactive label. Examplesof a radioactive label include, but are not limited to, the isotopes ³H,¹⁴C, ³²P, ³⁵S, ³⁶Cl, ⁵⁷Cr, ⁵⁷Co, ⁵⁸Co, ⁵⁹Fe, ⁹⁰Y, ¹²¹I, ¹²⁴I, ¹²⁵I,¹³¹I, ¹¹¹In, ¹¹⁷Lu, ²¹¹At, ¹⁹⁸Au, ⁶⁷Cu, ²²⁵AC, ²¹³Bi, ⁹⁹TC, ¹⁸⁶Re and⁸⁹Zr.

In some aspects, the detectable label is a chemiluminescent label,fluorescent label, enzyme, biotin, or a combination thereof.

In some aspects, the detectable label is a peptide tag. In some aspects,the peptide tag is located at the N-terminus of the polypeptide orpolypeptide complex. In some aspects, the peptide tag is located at theC-terminus of the polypeptide or polypeptide complex. In some aspects,the peptide tag is an affinity tag or fusion tag.

In some aspects, the detectable label is a polyhistidine tag,polyarginine tag, glutathione-S-transferase (GST), maltose bindingprotein (MBP), chitin binding protein (CBP), Strep-tag, thioredoxin(TRX), poly(NANP), FLAG tag, ALFA-tag, V5-tag, Myc-tag, hemagglutinin(HA) tag, Spot tag, T7 tag, NE tag, or green fluorescence protein (GFP),or a combination thereof. In some aspects, the polyhistidine tagconsists of from about 4 to about 10 histidine residues. In someaspects, the polyhistidine tag consists of about 4, about 5, about 6,about 7, about 8, about 9, or about 10 histidine residues.

Additional examples of detectable labels and methods for introducingdetectable labels into a polypeptide are known and include routinechemical, molecular biology and recombinant DNA techniques. See, e.g.,Hnatowich et al., Science, 220(4597):613-615, 1983; Yao et al., Int. J.Mol. Sci., 17(2):194, 2016; Kimple et al., Curr. Protoc. Protein Sci.,73:Unit 9.9, 2013; Sambrook J, Fritsch E F. Molecular Cloning: ALaboratory Manual. Cold Spring Harbor Laboratory Press; Cold SpringHarbor, N.Y.: 1989; Molecular Cell Biology, 4^(th) edition, Section 3.5,Purifying, Detecting and Characterizing Proteins; and Mahmoodi et al.,Cogent Biology, 5(1):DOI: 10/1080/23312025.2019.1665406.

In some aspects, an antigen binding polypeptide or antigen bindingpolypeptide complex (e.g., an antibody or antigen binding fragmentthereof) of the invention is conjugated to an agent as an antibody-drugconjugate (ADC). An ADC of the invention is useful in therapeutic,diagnostic, imaging (e.g., radioimaging), or basic researchapplications.

In some aspects, an antigen binding polypeptide or antigen bindingpolypeptide complex (e.g., an antibody or antigen binding fragmentthereof) of the invention is conjugated to a cytotoxic agent,immunomodulating agent, imaging agent, or therapeutic protein, typicallyvia a linker. The linker can comprise a cleavable unit or can benon-cleavable. Cleavable units include, for example, disulfidecontaining linkers that are cleavable through disulfide exchange,acid-labile linkers that are cleavable at acidic pH, and linkers thatare cleavable by hydrolases, esterases, peptidases, and glucuronidases(e.g., peptide linkers and glucuronide linkers). Non-cleavable linkersare believed to release drug via a proteolytic antibody degradationmechanism.

Methods for making an ADC are known and include, but are not limited to,conjugation via thiols, amides, aldehydes, or azides, as well as otherroutine chemical, molecular biology and recombinant DNA techniques. See,e.g., Yao et al., Int. J. Mol. Sci., 17(2):194, 2016; Sambrook J,Fritsch E F. Molecular Cloning: A Laboratory Manual. Cold Spring HarborLaboratory Press; Cold Spring Harbor, N.Y.: 1989; Molecular CellBiology, 4th edition, Section 3.5, Purifying, Detecting andCharacterizing Proteins; and Mahmoodi et al., Cogent Biology, 5(1):DOI:10/1080/23312025.2019.1665406.

Modifications

In some aspects, the invention is directed to an antigen bindingpolypeptide or antigen binding polypeptide complex (e.g., an antibody orantigen binding fragment thereof) comprising an effector functionmutation or half-life extension mutation.

Effector functions are an important part of the humoral immune responseand form an link between innate and adaptive immunity. Most effectorfunctions are induced via the Fc region of an antibody, which caninteract with complement proteins and specialized Fc receptors. As usedherein, an “effector function mutation,” refers to a change in the aminoacid sequence, typically in the Fc region, which can increase ordecrease effector function, for example, increase binding affinity of Fcfor specific Fc receptors, or increase antibody-dependent cellularcytotoxicity (ADCC) activity.

“Half-life” of a pharmaceutically active substance is the time it takesfor the amount of the substance, once administered to the body, toreduce by half. A “half-life extension mutation” of an antigen bindingpolypeptide or antigen binding polypeptide complex of the inventionrefers to a change in the amino acid sequence, typically in the Fcregion, which increases the half-life of the antigen binding polypeptideor antigen binding polypeptide complex (e.g., by increasing Fc receptorbinding affinity, slowing off-rate for Fc and Fc receptors, and/orincreased sialylation).

Examples of effector function mutations that increase function include,but are not limited to, the following substitutions in the Fc region,based on the EU numbering scheme: S298A/E333A/K334A, S239D/I332E,S239D/A330L/I332E, and G236A/S239D/I332E. Examples of effector functionmutations that decrease function include, but are not limited to, thefollowing substitutions in the Fc region, based on the EU numberingscheme: N297A and L234A/L235A. Additional examples of effector functionmutations, half-life extension mutations and methods for incorporatingthe same into an amino acid sequence are known and described, forexample, in Saunders, “Conceptual Approaches to Modulating AntibodyEffector Functions and Circulation Half-Life,” Front. Immunol. Jun. 7,2019.

In some aspects, the invention is directed to an antigen bindingpolypeptide or antigen binding polypeptide complex (e.g., an antibody orantigen binding fragment thereof) comprising one or more knob-into-holemodifications.

The term “knob-into-hole modification” as used herein, refers to agenetic modification that directs the pairing of two polypeptides topromote heterodimerization. In some aspects, the modification introducesa protuberance (knob) into one polypeptide and a cavity (hole) into theother polypeptide at an interface in which the two polypeptidesinteract. In some aspects, a knob-into-hole modification can be createdby introducing only a hole modification, for example, by replacing anamino acid residue with a smaller side chain than the original aminoacid residue (e.g., a substitution of one or more serine, threonine,valine or alanine residues, or a combination thereof). In some aspects,a knob-into-hole modification can be created by introducing only a knobmodification, for example, by replacing an amino acid residue with alarger side chain than the original amino acid residue (e.g., asubstitution of one or more tryptophan or tyrosine residues, or acombination thereof).

In some aspects, the knob-into-hole modification is in the bindinginterface of two Fc regions, the binding interface of two CH2 regions,the binding interface of two CH3 regions, the binding interface of a CLregion and a CH1 region, or the binding interface of a VH region and aVL region. See, e.g., U.S. Pub. No. 2007/0178552, Int'l Pub. No. WO96/027011, Int'l Pub. No. WO 98/050431 and Zhu et al., Protein Science6:781-788, 1987.

In some aspects, the antigen binding polypeptide or antigen bindingpolypeptide complex comprises one, two, three, four, five, six, seven,eight, nine, ten, or more knob-into-hole modifications.

Knob-into-hole modifications are well known and can be incorporated intothe antigen binding polypeptides and antigen binding polypeptidecomplexes of the invention using routine molecular biology andrecombinant DNA techniques. See, e.g., U.S. Pub. No. 2003/0078385; Int'lPub. No. WO 96/027011; Ridgway et al., Protein Eng., 9:617-621, 1996;and Merchant et al., Nat. Biotechnol., 16:677-681, 1998.

In some aspects, the knob-into-hole modification is an amino acidsubstitution. As used herein, such a substitution is described based onthe EU numbering scheme of Kabat, which corresponds to the numbering inthe Protein Data Bank (PDB).

In some aspects, the knob-into-hole modification is a knob substitutionof S354C and/or T366W, based on the EU numbering scheme.

In some aspects, the knob-into-hole modification is a hole substitutionof Y349C, T366S, L368A, Y407V, L234A, L235A, P239A, M428L, N433S, M252Y,S254T, T256E, or any combination thereof, based on the EU numberingscheme.

In another aspect, the knob-into-hole modifications are holesubstitutions of Y349C, T366S, L368A and Y407V, based on the EUnumbering scheme. In some aspects, the knob-into-hole modifications area hole substitutions of L234A, L235A and P239A, based on the EUnumbering scheme. In some aspects, the knob-into-hole modifications arehole substitutions of L234A and L235A, based on the EU numbering scheme.In some aspects, the knob-into-hole modifications are hole substitutionsof M428L and N433S, based on the EU numbering scheme. In some aspects,the knob-into-hole modifications are hole substitutions of M252Y, S254Tand T256E, based on the EU numbering scheme.

In some aspects, an antigen binding polypeptide complex is an IgG1 orIgG4 antibody and the knob-into-hole modifications are knobsubstitutions of S354C and T366W and hole substitutions of Y349C, T366S,L368A and Y407V.

In some aspects, the antigen binding polypeptide complex is an IgG1 orIgG4 antibody and the knob-into-hole modifications are holesubstitutions of L234A, L235A and P239A.

In some aspects, the antigen binding polypeptide complex is an IgG1 orIgG4 antibody and the knob-into-hole modifications are holesubstitutions of L234A and L235A.

In some aspects, the antigen binding polypeptide complex is an IgG1 orIgG4 antibody and the knob-into-hole modifications are holesubstitutions of M428L and N433 S.

In some aspects, the antigen binding polypeptide complex is an IgG1 orIgG4 antibody and the knob-into-hole modifications are holesubstitutions of M252Y, S254T and T256E.

Chimeric Antigen Receptors

In some aspects of the invention, the antigen binding polypeptides andantigen binding polypeptide complexes can be used in chimeric antigenreceptor (CAR) therapy. In some aspects, the invention is directed to aCAR comprised of an antigen binding polypeptide or antigen bindingpolypeptide complex of the invention. In some aspects, a CAR of theinvention comprises an antigen binding polypeptide or antigen bindingpolypeptide complex of the invention and a transmembrane region. In someaspects, a CAR of the invention comprises an antigen binding polypeptideor antigen binding polypeptide complex of the invention, a transmembraneregion, and an intracellular region. In some aspects, the intracellularregion is comprised of a costimulatory region and/or an intracellularsignal transduction region. In another aspect, the intracellular regionis a T cell activation domain. In some aspects, the antigen bindingpolypeptide or antigen binding polypeptide complex of the invention isjoined to the transmembrane region by an immunoglobulin hinge.

Polypeptides, Polynucleotides, Vectors, Cells, and Protein ProductionMethods

In some aspects, the invention is directed to a polypeptide encoding anantigen binding polypeptide or antigen binding polypeptide complex(e.g., an antibody or antigen binding fragment thereof) describedherein.

In some aspects, the invention is directed to a polypeptide comprisingan amino acid sequence of one or more of SEQ ID NOs:32-43, 62-79,130-138, 633, 635, 637, 639, 641, 643, 645, 647, 649, 651, 653, 655,657, 659, 661, 663, 665, 667, 669, 671, 673, 675, 677, and 679, or anamino acid sequence having at least 90% identity or at least 95%identity to one or more of SEQ ID NOs:32-43, 62-79, 130-138, 633, 635,637, 639, 641, 643, 645, 647, 649, 651, 653, 655, 657, 659, 661, 663,665, 667, 669, 671, 673, 675, 677, and 679. For example, the polypeptidemay comprise an amino acid sequence having at least 90% (such as atleast 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity to one ormore of SEQ ID NOs:32-43, 62-79, 130-138, 633, 635, 637, 639, 641, 643,645, 647, 649, 651, 653, 655, 657, 659, 661, 663, 665, 667, 669, 671,673, 675, 677, and 679. For example, the polypeptide may comprise theamino acid sequence of one or more of SEQ ID NOs:32-43, 62-79, 130-138,633, 635, 637, 639, 641, 643, 645, 647, 649, 651, 653, 655, 657, 659,661, 663, 665, 667, 669, 671, 673, 675, 677, and 679. In some aspects,the invention is directed to a polypeptide comprising an amino acidsequence having at least 90% identity, at least 95% identity, or 100%identity to the amino acid sequence of SEQ ID NOs:32 or 33 that does notcontain the eight histidine residues at the C-terminus. For example, thepolypeptide may comprise an amino acid sequence having at least 90%(such as at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%)identity to the amino acid sequence of SEQ ID NOs:32 or 33 that does notcontain the eight histidine residues at the C-terminus. For example, thepolypeptide may comprise the amino acid sequence of SEQ ID NOs:32 or 33that does not contain the eight histidine residues at the C-terminus.

In some aspects, the invention is directed to a polypeptide comprisingan amino acid sequence encoded by one or more of SEQ ID NOs:44-55,80-97, 139-147, 634, 636, 638, 640, 642, 644, 646, 648, 650, 652, 654,656, 658, 660, 662, 664, 666, 668, 670, 672, 674, 676, 678, and 680, orencoded by a polynucleotide having at least 90% identity or at least 95%identity to one or more of SEQ ID NOs:44-55, 80-97, 139-147, 634, 636,638, 640, 642, 644, 646, 648, 650, 652, 654, 656, 658, 660, 662, 664,666, 668, 670, 672, 674, 676, 678, and 680. For example, the polypeptidemay comprise an amino acid sequence encoded by a polynucleotide havingat least 90% (such as at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%,or 99%) identity to one or more of SEQ ID NOs: 44-55, 80-97, 139-147,634, 636, 638, 640, 642, 644, 646, 648, 650, 652, 654, 656, 658, 660,662, 664, 666, 668, 670, 672, 674, 676, 678, and 680. For example, thepolypeptide may comprise an amino acid sequence encoded by thepolynucleotide shown in one or more of SEQ ID NOs:44-55, 80-97, 139-147,634, 636, 638, 640, 642, 644, 646, 648, 650, 652, 654, 656, 658, 660,662, 664, 666, 668, 670, 672, 674, 676, 678, and 680.

In some aspects, the invention is directed to a polypeptide comprisingan amino acid sequence of one or more of SEQ ID NOs:198-209, 346 and348, or an amino acid sequence having at least 90% identity or at least95% identity to one or more of SEQ ID NOs:198-209, 346 and 348. Forexample, the polypeptide may comprise an amino acid sequence having atleast 90% (such as at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or99%) identity to one or more of SEQ ID NOs:198-209, 346 and 348. Forexample, the polypeptide may comprise the amino acid sequence of one ormore of SEQ ID NOs:198-209, 346 and 348.

In some aspects, the invention is directed to a polypeptide comprisingan amino acid sequence encoded by one or more of SEQ ID NOs:347 and349-361, or encoded by a polynucleotide having at least 90% identity orat least 95% identity to one or more of SEQ ID NOs:347 and 349-361. Forexample, the polypeptide may comprise an amino acid sequence encoded bya polynucleotide having at least 90% (such as at least 91%, 92%, 93%,94%, 95%, 96%, 97%, 98%, or 99%) identity to one or more of SEQ ID NOs:347 and 349-361. For example, the polypeptide may comprise an amino acidsequence encoded by the polynucleotide shown in one or more of SEQ IDNOs: 347 and 349-361.

In some aspects, the invention is directed to a polynucleotide encodingan antigen binding polypeptide or antigen binding polypeptide complex(e.g., an antibody or antigen binding fragment thereof) describedherein. In other aspects, the invention is directed to a polynucleotideencoding a CAR described herein. As used herein, a “polynucleotide”includes DNA and RNA (e.g., mRNA).

In some aspects, the invention is directed to a polynucleotidecomprising a polynucleotide sequence of one or more of SEQ ID NOs:44-55,80-97, 139-147, 634, 636, 638, 640, 642, 644, 646, 648, 650, 652, 654,656, 658, 660, 662, 664, 666, 668, 670, 672, 674, 676, 678, and 680, ora polynucleotide having at least 90% identity or at least 95% identityto one or more of SEQ ID NOs:44-55, 80-97, 139-147, 634, 636, 638, 640,642, 644, 646, 648, 650, 652, 654, 656, 658, 660, 662, 664, 666, 668,670, 672, 674, 676, 678, and 680. For example, the polynucleotide mayhave at least 90% (such as at least 91%, 92%, 93%, 94%, 95%, 96%, 97%,98%, or 99%) identity to one or more of SEQ ID NOs:44-55, 80-97,139-147, 634, 636, 638, 640, 642, 644, 646, 648, 650, 652, 654, 656,658, 660, 662, 664, 666, 668, 670, 672, 674, 676, 678, and 680. Forexample, the polynucleotide may have the polynucleotide sequence shownin one or more of SEQ ID NOs:44-55, 80-97, 139-147, 634, 636, 638, 640,642, 644, 646, 648, 650, 652, 654, 656, 658, 660, 662, 664, 666, 668,670, 672, 674, 676, 678, and 680.

In some aspects, the invention is directed to a polynucleotide encodinga polypeptide of one or more of SEQ ID NOs:32-43, 62-79, 130-138, 633,635, 637, 639, 641, 643, 645, 647, 649, 651, 653, 655, 657, 659, 661,663, 665, 667, 669, 671, 673, 675, 677, and 679, or a polypeptide havingat least 90% identity or at least 95% identity to one or more of SEQ IDNOs:32-43, 62-79, 130-138, 633, 635, 637, 639, 641, 643, 645, 647, 649,651, 653, 655, 657, 659, 661, 663, 665, 667, 669, 671, 673, 675, 677,and 679. For example, the polynucleotide may encode a polypeptide havingat least 90% (such as at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%,or 99%) identity to one or more of SEQ ID NOs:32-43, 62-79, 130-138633,635, 637, 639, 641, 643, 645, 647, 649, 651, 653, 655, 657, 659, 661,663, 665, 667, 669, 671, 673, 675, 677, and 679. For example, thepolynucleotide may encode a polypeptide as shown in one or more of SEQID NOs:44-55, 80-97, 139-147, 634, 636, 638, 640, 642, 644, 646, 648,650, 652, 654, 656, 658, 660, 662, 664, 666, 668, 670, 672, 674, 676,678, and 680. In some aspects, the invention is directed topolynucleotide encoding a polypeptide comprising an amino acid sequencehaving at least 90% identity, at least 95% identity, or 100% identity tothe amino acid sequence of SEQ ID NOs:32 or 33 that does not contain theeight histidine residues at the C-terminus. For example, thepolynucleotide may encode a polypeptide having at least 90% (such as atleast 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity to theamino acid sequence of SEQ ID NOs:32 or 33 that does not contain theeight histidine residues at the C-terminus. For example, thepolynucleotide may encode a polypeptide as shown in SEQ ID NOs:32 or 33that does not contain the eight histidine residues at the C-terminus.

In some aspects, the invention is directed to a polynucleotide having asequence of one or more of SEQ ID NOs:347 and 349-361, or apolynucleotide having at least 90% identity or at least 95% identity toone or more of SEQ ID NOs:347 and 349-361. For example, thepolynucleotide may have at least 90% (such as at least 91%, 92%, 93%,94%, 95%, 96%, 97%, 98%, or 99%) identity to one or more of SEQ ID NOs:347 and 349-361. For example, the polynucleotide may have thepolynucleotide sequence shown in one or more of SEQ ID NOs: 347 and349-361.

In some aspects, the invention is directed to a polynucleotide encodinga polypeptide of one or more of SEQ ID NOs:198-209, 346 and 348, or apolynucleotide encoding a polypeptide having at least 90% identity or atleast 95% identity to one or more of SEQ ID NOs:198-209, 346 and 348.For example, the polynucleotide may encode a polypeptide having at least90% (such as at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%)identity to one or more of SEQ ID NOs:198-209, 346 and 348. For example,the polynucleotide may encode a polypeptide as shown in one or more ofSEQ ID NOs:198-209, 346 and 348.

In other aspects, the invention is directed to a vector comprising apolynucleotide described herein.

In yet other aspects, the invention is directed to a host cellcomprising a polynucleotide or vector described herein.

As used herein, the term “host cell” can be any type of cell, e.g., aprimary cell, a cell in culture, or a cell from a cell line. In someaspects, the term “host cell” refers to a cell containing a foreign gene[e.g., a cell subjected to gene delivery or transfected with apolynucleotide (e.g., DNA or mRNA) encoding the gene] transfected with apolynucleotide and the progeny or potential progeny of such a cell.Progeny of such a cell may not be identical to the parent celltransfected with the nucleic acid molecule, e.g., due to mutations orenvironmental influences that may occur in succeeding generations orintegration of the nucleic acid molecule into the host cell genome.

In other aspects, the invention is directed to an immune cell expressinga CAR of the invention or a polynucleotide or vector encoding a CAR ofthe invention. In some aspects, the immune cell is a neutrophil,eosinophil, basophil, mast cell, monocyte, macrophage, dendritic cell,natural killer cell, or lymphocyte (B cell or T cell).

Methods which are well known to those skilled in the art can be used toconstruct vectors encoding antigen binding polypeptides and antigenbinding polypeptide complexes (e.g., CDR, VH, VL, heavy chain and/orlight chain coding sequences and appropriate transcriptional andtranslational control signals). These methods include, for example, invitro recombinant DNA techniques, synthetic techniques, and in vivogenetic recombination.

A vector can be transferred to a host cell by conventional techniquesand the resulting cells can then be cultured by conventional techniquesto produce an antigen binding polypeptide or antigen binding polypeptidecomplex comprising, e.g., six CDRs, VH, VL, VH and VL, heavy chain,light chain, or heavy and light chain, or a domain thereof (e.g., one ormore CDRs, VH, VL, VH and VL, heavy chain, or light chain). Thus,provided herein are host cells containing a polynucleotide encoding anantigen binding polypeptide or antigen binding polypeptide complexcomprising, e.g., comprising six CDRs, VH, VL, VH and VL, heavy chain,light chain, or heavy and light chain, or a domain thereof (e.g., one ormore CDRs, VH, VL, VH and VL, heavy chain, or light chain), operablylinked to a promoter for expression of such sequences in the host cell.In some aspects, vectors encoding both heavy and light chains, or adomain thereof, individually, can be co-expressed in the host cell forexpression. In some aspects, a host cell contains a vector comprising apolynucleotide encoding both a heavy chain and light chain, or a domainthereof. In some aspects, a host cell contains two different vectors, afirst vector comprising a polynucleotide encoding a heavy chain or adomain thereof, and a second vector comprising a polynucleotide encodinga light chain or a domain thereof. In some aspects, a first host cellcomprises a first vector comprising a polynucleotide encoding a heavychain or a domain thereof, and a second host cell comprises a secondvector comprising a polynucleotide encoding a light chain or a domainthereof. In some aspects, provided herein is a population of host cellscomprising such a first host cell and such a second host cell.

In some aspects, provided herein is a population of vectors comprising afirst vector comprising a polynucleotide encoding a light chain ordomain thereof, and a second vector comprising a polynucleotide encodinga heavy chain or domain thereof. Alternatively, a single vector can beused which encodes, and is capable of expressing, both heavy and lightchain polypeptides or a domain thereof.

A variety of host-vector systems can be utilized to express thepolypeptides and polypeptide complexes described herein. Suchhost-vector systems represent vehicles by which the coding sequences ofinterest can be produced and subsequently purified, but also representcells which can, when transformed or transfected with the appropriatenucleotide coding sequences, express a polypeptide or polypeptidecomplex described herein in situ. These include but are not limited tomicroorganisms such as bacteria (e.g., E. coli and B. subtilis)transformed with recombinant bacteriophage DNA, plasmid DNA or cosmidDNA expression vectors containing antibody coding sequences; yeast(e.g., Saccharomyces pichia) transformed with recombinant yeastexpression vectors containing antibody coding sequences; insect cellsystems infected with recombinant virus expression vectors (e.g.,baculovirus) containing antibody coding sequences; plant cell systems(e.g., green algae such as Chlamydomonas reinhardtii) infected withrecombinant virus expression vectors (e.g., cauliflower mosaic virus,CaMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmidexpression vectors (e.g., Ti plasmid) containing antibody codingsequences; or mammalian cell systems (e.g., COS (e.g., COS1 or COS),CHO, BHK, MDCK, HEK 293, NS0, PER.C6, VERO, CRL7O3O, HsS78Bst, HeLa, andNIH 3T3, HEK-293T, HepG2, SP210, R1.1, B-W, L-M, BSC1, BSC40, YB/20, andBMT10 cells) harboring recombinant expression constructs containingpromoters derived from the genome of mammalian cells (e.g.,metallothionein promoter) or from mammalian viruses (e.g., theadenovirus late promoter; the vaccinia virus 7.5K promoter). In someaspects, cells for expressing polypeptide or polypeptide complexesdescribed herein are CHO cells, for example CHO cells from the CHO GSSystem™ (Lonza). In some aspects, cells for expressing polypeptides orpolypeptide complexes of the invention are human cells, e.g., human celllines. In some aspects, a mammalian expression vector is pOptiVEC™ orpcDNA3.3. In some aspects, bacterial cells such as Escherichia coli, oreukaryotic cells (e.g., mammalian cells) are used for the expression ofrecombinant polypeptides. For example, mammalian cells such as Chinesehamster ovary (CHO) cells in conjunction with a vector such as the majorintermediate early gene promoter element from human cytomegalovirus isan effective expression system for polypeptides (Foecking M K &Hofstetter H (1986) Gene 45: 101-105; and Cockett M I et al., (1990)Biotechnology 8: 662-667). In some aspects, polypeptides or polypeptidecomplexes described herein are produced by HEK-293T cells.

In addition, a host cell strain can be chosen which modulates theexpression of the inserted sequences, or modifies and processes the geneproduct in the specific fashion desired. Such modifications (e.g.,glycosylation) and processing (e.g., cleavage) of protein products cancontribute to the function of the protein. To this end, eukaryotic hostcells which possess the cellular machinery for proper processing of theprimary transcript, glycosylation, and phosphorylation of the geneproduct can be used. Such mammalian host cells include but are notlimited to CHO, VERO, BHK, Hela, MDCK, HEK 293, NIH 3T3, W138, BT483,Hs578T, HTB2, BT2O and T47D, NS0 (a murine myeloma cell line that doesnot endogenously produce any immunoglobulin chains), CRL7O3O, COS (e.g.,COS1 or COS), PER.C6, VERO, HsS78Bst, HEK-293T, HepG2, SP210, R1.1, B-W,L-M, BSC1, BSC40, YB/20, BMT10 and HsS78Bst cells.

Once a polypeptide or polypeptide complex described herein has beenproduced by recombinant expression, it can be purified by any methodknown in the art for purification of a protein or immunoglobulinmolecule, for example, by chromatography (e.g., ion exchange, affinity,particularly by affinity for the specific antigen after Protein A, andsize exclusion chromatography), centrifugation, differential solubility,or by any other standard technique for the purification of proteins.Further, the polypeptides or polypeptide complexes described herein canbe fused to heterologous polypeptide sequences described herein (e.g.,peptide tags) or otherwise known in the art to facilitate purification.

In some aspects, a polypeptide or polypeptide complex described hereinis isolated or purified. Generally, an isolated polypeptide orpolypeptide complex is one that is substantially free of otherpolypeptides or polypeptide complexes with different antigenicspecificities. For example, in some aspects, a preparation of apolypeptide or polypeptide complex described herein is substantiallyfree of cellular material and/or chemical precursors.

Pharmaceutical Compositions and Kits

In some aspects, the invention is directed to a pharmaceuticalcomposition comprising an antigen binding polypeptide, antigen bindingpolypeptide complex (e.g., antibody or antigen binding fragmentthereof), polypeptide, polynucleotide, vector, CAR or cell describedherein.

In some aspects, the invention is directed to a pharmaceuticalcomposition comprising (1) an antigen binding polypeptide, antigenbinding polypeptide complex (e.g., antibody or antigen binding fragmentthereof), polynucleotide, vector, CAR or cell described herein, and (2)a pharmaceutically acceptable carrier. The term “pharmaceuticallyacceptable carrier” includes any and all solvents, co-solvents,complexing agents, dispersion media, coatings, antibacterial andantifungal agents, isotonic and absorption delaying agents, and thelike, which are not biologically or otherwise undesirable. The use ofsuch media and agents for pharmaceutically active substances is known inthe art. Except insofar as any conventional media or agent isincompatible with the active ingredient, its use in the therapeuticformulations is contemplated. Supplementary active ingredients can alsobe incorporated into the pharmaceutical compositions of the invention.In addition, various excipients, such as are commonly used in the art,can be included. These and other such compounds are described in theliterature, e.g., in the Merck Index, Merck & Company, Rahway, N.J.Considerations for the inclusion of various components in pharmaceuticalcompositions are described, e.g., in Gilman et al. (Eds.) (2010);Goodman and Gilman's. The Pharmacological Basis of Therapeutics, 12thEd., The McGraw-Hill Companies. In some aspects, the pharmaceuticalcomposition is for parenteral, intravenous or subcutaneousadministration.

In some aspects, the invention is directed to a kit comprising anantigen binding polypeptide, antigen binding polypeptide complex (e.g.,antibody or antigen binding fragment thereof), polypeptide,polynucleotide, vector, cell, CAR or pharmaceutical compositiondescribed herein, or a combination thereof. Once a pharmaceuticalcomposition has been formulated, it can be stored in sterile vials as asolution, suspension, gel, emulsion, solid, crystal, or as a dehydratedor lyophilized powder. Such formulations may be stored either in aready-to-use form or in a form (e.g., lyophilized) that is reconstitutedprior to administration. In some aspects, the invention provides kitsfor producing a single-dose administration unit. In some aspects, thekits of the invention can contain both a first container having a driedprotein and a second container having an aqueous formulation. In someaspects, kits containing single and multi-chambered pre-filled syringes(e.g., liquid syringes and lyosyringes) are also provided. In someaspects, the kit contains components for intravenous or subcutaneousadministration.

Methods of Use

In some aspects, the invention is directed to certain methods of use ofan antigen binding polypeptide, antigen binding polypeptide complex(e.g., an antibody or antigen binding fragment thereof), polypeptide,polynucleotide, vector, cell, CAR, or pharmaceutical compositiondescribed herein, or a combination thereof. Any of the antigen bindingpolypeptide structures and any of the antigen binding polypeptidecomplex structures described herein targeting one or more of the targetsdescribed herein may be used in any of the methods and uses of theinvention.

In some aspects, the antigen binding polypeptides or antigen bindingpolypeptide complexes (e.g., antibodies or antigen binding fragmentsthereof) specifically binds to two, three or four of A2AR, APRIL,ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1, B7H2, B7H3,B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3, CCL4, CCL5,CCL7, CCL8, CCL11, CCL15, CCL17, CCL19, CCL20, CCL21, CCL25 CCR3, CCR4,CD3, CD16A, CD19, CD20, CD24, CD27, CD28, CD30, CD38, CD39, CD40, CD40L,CD47, CD52, CD70, CD80, CD86, CD123, CD133, CD137, CD137L, CD160, CD272,CEACAM5, CLEC9, CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4,CXCL12, CXCL13, CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin,EGFR, ENTPD1, EpCAM, FCER1, FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24,GITR, GITRL, GPR5, GP100, GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1,HVEM, IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2,IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O,IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23,IL25, IL7, IL33, IL35, ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHCclass II, MUC-1, MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L,PD-1, PD-L1, PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2,STEAP1, STEAP2, Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14,TIGIT, TIM3, TLR, TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55,TREM1, TSLP, TSLPR, TWEAK, VEGF, VISTA, Vstm3, and WUCAM. As describedherein, the VL1, VL2, VL3, VL4, VH1, VH2, VH3, and/or VH4 of the antigenbinding polypeptide or polypeptide comprised within the antigen bindingpolypeptide complex may specifically bind to one or more of A2AR, APRIL,ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1, B7H2, B7H3,B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3, CCL4, CCL5,CCL7, CCL8, CCL11, CCL15, CCL17, CCL19, CCL20, CCL21, CCL25 CCR3, CCR4,CD3, CD16A, CD19, CD20, CD24, CD27, CD28, CD30, CD38, CD39, CD40, CD40L,CD47, CD52, CD70, CD80, CD86, CD123, CD133, CD137, CD137L, CD160, CD272,CEACAM5, CLEC9, CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4,CXCL12, CXCL13, CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1, E-cadherin,EGFR, ENTPD1, EpCAM, FCER1, FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24,GITR, GITRL, GPR5, GP100, GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1,HVEM, IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2,IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O,IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23,IL25, IL7, IL33, IL35, ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHCclass II, MUC-1, MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1, OX40, OX40L,PD-1, PD-L1, PD-L2, PROM1, S152, SIRPalpha, SISP1, SLC, SPG64, ST2,STEAP1, STEAP2, Syk kinase, STEAP1, TROP2, TACI, TDO, TGFBETA, T14,TIGIT, TIM3, TLR, TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55,TREM1, TSLP, TSLPR, TWEAK, VEGF, VISTA, Vstm3, and WUCAM. For example,the antigen binding polypeptide or antigen binding polypeptide complex(e.g., antibodies or antigen binding fragments thereof) may specificallybind to CD3, CD28, CD38 and CD19. For example, the antigen bindingpolypeptide or antigen binding polypeptide complex (e.g., antibodies orantigen binding fragments thereof) may specifically bind to CD3, CD28,Trop2 and cMet. For example, the antigen binding polypeptide or antigenbinding polypeptide complex (e.g., antibodies or antigen bindingfragments thereof) may specifically bind to CD3, CD28, CD19 and CD20.Any of the antigen binding polypeptide structures and any of the antigenbinding polypeptide complex structures described herein may be used totarget one or more of the targets described herein in the methods anduses of the invention.

CD3 (Cluster of Differentiation 3) is a protein complex and T cellco-receptor that is involved in activating both the cytotoxic T cell(CD8+ naive T cells) and T helper cells (CD4+ naive T cells).

CD19 (Cluster of Differentiation 19, also known as B-Lymphocyte SurfaceAntigen B4, T Cell Surface Antigen Leu-12 and CVID3) is a transmembraneprotein expressed in all B lineage cells. CD19 plays two major roles inhuman B cells: on the one hand, it acts as an adaptor protein to recruitcytoplasmic signaling proteins to the membrane; on the other, it workswithin the CD19/CD21 complex to decrease the threshold for B cellreceptor signaling pathways. Due to its presence on all B cells, it is abiomarker for B lymphocyte development, lymphoma diagnosis and can beutilized as a target for leukemia immunotherapies.

CD28 (Cluster of Differentiation 28) is one of the proteins expressed onT cells that provide co-stimulatory signals required for T cellactivation and survival. T cell stimulation through CD28 in addition tothe T Cell Receptor (TCR) can provide a potent signal for the productionof various interleukins (IL-6 in particular).

CD38 (Cluster of Differentiation 38, also known as cyclic ADP ribosehydrolase) is a glycoprotein found on the surface of many immune cells(white blood cells), including CD4+, CD8+, B lymphocytes and naturalkiller cells. CD38 also functions in cell adhesion, signal transductionand calcium signaling.

Her2 (Human Epidermal Growth Factor Receptor 2, also known as Her2/neu,Erb-B2, or CD340) is a member of the human epidermal growth factorreceptor family. Amplification or overexpression of Her2 has been shownto play an important role in the development and progression of certaintypes of breast cancer.

cMet, also called membrane tyrosine-protein kinase Met or hepatocytegrowth factor receptor (HGFR), is a protein that in humans is encoded bythe MET gene. MET is a single pass tyrosine kinase receptor essentialfor embryonic development, organogenesis and wound healing. Abnormal METactivation in cancer correlates with poor prognosis, where aberrantlyactive MET triggers tumor growth, formation of new blood vessels(angiogenesis) that supply the tumor with nutrients, and cancer spreadto other organs (metastasis).

Tumor-associated calcium signal transducer 2 is also known as Trop2 andepithelial glycoprotein-1 antigen (EGP-1). It is a protein that inhumans is encoded by the TACSTD2 gene. Trop2 plays a role in tumorprogression by actively interacting with several key molecular signalingpathways traditionally associated with cancer development andprogression. Aberrant overexpression of Trop-2 has been described inseveral solid cancers, such as colorectal, renal, lung, and breastcancers. Trop-2 expression has also been described in some rare andaggressive malignancies, e.g., salivary duct, anaplastic thyroid,uterine/ovarian, and neuroendocrine prostate cancers.

B-lymphocyte antigen CD20 (CD20) is expressed on the surface of B cellsbeginning at the pro-B phase and progressively increasing inconcentration until maturity. In humans CD20 is encoded by the MS4A1gene. This gene encodes a member of the membrane-spanning 4A genefamily. It is found on B cell lymphomas, hairy cell leukemia, B cellchronic lymphocytic leukemia, and melanoma cancer stem cells.

Receptor tyrosine-protein kinase erbB-3, also known as Her3 (humanepidermal growth factor receptor 3), is a membrane bound protein that inhumans is encoded by the ERBB3 gene. EibB3 is a member of the epidermalgrowth factor receptor (EGFR/ERBB) family of receptor tyrosine kinasesErbB3 as a heterodimerization partner, most critically with ErbB2, isimplicated in growth, proliferation, chemotherapeutic resistance, andthe promotion of invasion and metastasis. ErbB3 is associated withtargeted therapeutic resistance in numerous cancers.

The adenosine A2A receptor, also known as A2AR or ADORA2A, is anadenosine receptor. This protein is a member of the G protein-coupledreceptor (GPCR) family which possess seven transmembrane alpha helices,as well as an extracellular N-terminus and an intracellular C-terminus.

A proliferation-inducing ligand (APRIL), also known as tumor necrosisfactor ligand superfamily member 13 (TNFSF13), is a protein of the TNFsuperfamily recognized by the cell surface receptor TACI. It is a memberof the tumor necrosis factor ligand (TNF) ligand family. This protein isa ligand for TNFRSF17/BCMA, a member of the TNF receptor family. Thisprotein and its receptor are both found to be important for B celldevelopment.

The epidermal growth factor receptor (EGFR; ErbB-1; HER1 in humans) is atransmembrane protein that is a receptor for members of the epidermalgrowth factor family (EGF family) of extracellular protein ligands. Theepidermal growth factor receptor is a member of the ErbB family ofreceptors, a subfamily of four closely related receptor tyrosinekinases. EGFR (ErbB-1), HER2/neu (EibB-2), Her 3 (ErbB-3) and Her 4(ErbB-4). In many cancer types, mutations affecting EGFR expression oractivity could result in cancer.

Fibroblast growth factor receptor (FGFR) is a receptor that binds tomembers of the fibroblast growth factor (FGF) family of proteins. TheFGF/FGFR signalling pathway is involved in a variety of cancers.

B-cell activating factor (BAFF), also known as tumor necrosis factorligand superfamily member 13B, is a protein that in humans is encoded bythe TNFSF13B gene. BAFF is also known as B Lymphocyte Stimulator (BLyS)and TNF- and APOL-related leukocyte expressed ligand (TALL-1) and theDendritic cell-derived TNF-like molecule (CD257 antigen; cluster ofdifferentiation 257). BAFF is a cytokine that belongs to the tumornecrosis factor (TNF) ligand family. This cytokine is a ligand forreceptors TNFRSF13B/TACI, TNFRSF17/BCMA, and TNFRSF13C/BAFF-R. Thiscytokine is expressed in B cell lineage cells, and acts as a potent Bcell activator. It has been also shown to play an important role in theproliferation and differentiation.

BAFF receptor (B-cell activating factor receptor, BAFF-R), also known astumor necrosis factor receptor superfamily member 13C (TNFRSF13C) andBLyS receptor 3 (BR3), is a membrane protein of the TNF receptorsuperfamily which recognizes BAFF, an essential factor for B cellmaturation and survival. In humans it is encoded by the TNFRSF13C gene.BAFF enhances B-cell survival in vitro and is a regulator of theperipheral B-cell population.

B-cell maturation antigen (BCMA or BCM), also known as tumor necrosisfactor receptor superfamily member 17 (TNFRSF17), is a protein that inhumans is encoded by the TNFRSF17 gene. TNFRSF17 is a cell surfacereceptor of the TNF receptor superfamily which recognizes BAFF. SerumB-cell maturation antigen (sBCMA) is the cleaved form of BCMA, found atlow levels in the serum of normal patients and generally elevated inpatients with multiple myeloma (MM).

Bruton's tyrosine kinase (BTK), also known as tyrosine-protein kinaseBTK, is a tyrosine kinase that is encoded by the BTK gene in humans BTKplays a crucial role in B cell development as it is required fortransmitting signals from the pre-B cell receptor that forms aftersuccessful immunoglobulin heavy chain rearrangement. It also has a rolein mast cell activation through the high-affinity IgE receptor.

B- and T-lymphocyte attenuator or BTLA (also known as cluster ofdifferentiation 272 or CD272) is a protein that belongs to the CD28immunoglobulin superfamily (IgSF) which is encoded by the BTLA gene. Itsdiscovered ligand herpes virus entry mediator or HVEM (also known astumour necrosis factor receptor superfamily member 14 or TNFRSF14)belongs to the tumor necrosis factor receptor superfamily (TNFRSF). Inmany cases BTLA expression is connected with unfavourable outcomes asit, for instance, inhibits the function of human CD8+ cancer-specific Tcells.

Programmed cell death 1 ligand 2 (also known as PDL2 or B7DC) is aprotein that in humans is encoded by the PDCD1LG2 gene. PDCD1LG2 hasalso been designated as CD273 (cluster of differentiation 273). PDCD1LG2is an immune checkpoint receptor ligand which plays a role in negativeregulation of the adaptive immune response. PD-L2 is one of two knownligands for Programmed cell death protein 1 (PD-1). PD-L2, PD-L1, andPD-1 expressions are important in the immune response to certaincancers.

Programmed death-ligand 1 (PD-L1) also known as cluster ofdifferentiation 274 (CD274) or B7 homolog 1 (B7-H1) is a protein that inhumans is encoded by the CD274 gene. It is a 40 kDa type 1 transmembraneprotein that has been speculated to play a major role in suppressing theadaptive arm of immune systems during particular events. The binding ofPD-L1 to the inhibitory checkpoint molecule PD-1 transmits an inhibitorysignal based on interaction with phosphatases (SHP-1 or SHP-2) viaImmunoreceptor Tyrosine-Based Switch Motif (ITSM). This reduces theproliferation of antigen-specific T-cells in lymph nodes, whilesimultaneously reducing apoptosis in regulatory T cells(anti-inflammatory, suppressive T cells)—further mediated by a lowerregulation of the gene Bcl-2. Upregulation of PD-L1 may allow cancers toevade the host immune system.

V-set domain-containing T-cell activation inhibitor 1 (also known asB7H4) is a protein that in humans is encoded by the VTCN1 gene. B7H4belongs to the B7 family of costimulatory proteins. These proteins areexpressed on the surface of antigen-presenting cells and interact withligands (e.g., CD28; MIM 186760) on T lymphocytes. B7H4 is an immunecheckpoint molecule.

Delta-like 3 (Drosophila), also known as DLL3, is a protein which inhumans is encoded by the DLL3 gene.

Ectonucleoside triphosphate diphosphohydrolase-1 (gene: ENTPD1; protein:NTPDase1), also known as CD39 (Cluster of Differentiation 39), is atypical cell surface enzyme with a catalytic site on the extracellularface. NTPDase1 is an ectonucleotidase that catalyse the hydrolysis of γ-and β-phosphate residues of triphospho- and diphosphonucleosides to themonophosphonucleoside derivative. NTPDase1 hydrolyzes P2 receptorligands, namely ATP, ADP, UTP and UDP with similar efficacy. NTPDase1can therefore affect P2 receptor activation and functions.

Fc fragment of IgE, high affinity I, receptor for; alpha polypeptide,also known as FCER1A, is a protein which in humans is encoded by theFCER1A gene. The high affinity IgE receptor plays a central role inallergic disease, coupling allergen and mast cell to initiate theinflammatory and immediate hypersensitivity responses that arecharacteristic of disorders such as hay fever and asthma.

The high-affinity IgE receptor, also known as FCER1, or Fc epsilon RI,is the high-affinity receptor for the Fc region of immunoglobulin E, anantibody isotype involved in the allergy disorder and parasites immunityFCER1 is a tetrameric receptor complex that binds Fc portion of the Eheavy chain of IgE. It is constitutively expressed on mast cells andbasophils and is inducible in eosinophils.

Arachidonate 5-lipoxygenase-activating protein also known as5-lipoxygenase activating protein, or FLAP, is a protein that in humansis encoded by the ALOX5AP gene. FLAP is necessary for the activation of5-lipoxygenase and therefore for the production of leukotrienes,5-hydroxyeicosatetraenoic acid, 5-oxo-eicosatetraenoic acid, andspecialized pro-resolving mediators of the lipoxin and resolvin classes.Leukotrienes, which need the FLAP protein to be made, have anestablished pathological role in allergic and respiratory diseases.

Glutamate carboxypeptidase II (GCPII), also known asN-acetyl-L-aspartyl-L-glutamate peptidase I (NAALADase I), NAAGpeptidase, or prostate-specific membrane antigen (PSMA) is an enzymethat in humans is encoded by the FOLH1 (folate hydrolase 1) gene. HumanGCPII contains 750 amino acids and weighs approximately 84 kDa. HumanFOLH1 is highly expressed in the prostate, roughly a hundred timesgreater than in most other tissues. In some prostate cancers, PSMA isthe second-most upregulated gene product, with an 8- to 12-fold increaseover levels in noncancerous prostate cells. In vitro studies usingprostate and breast cancer cell lines with decreased FOLH1 levels showeda significant decrease in the proliferation, migration, invasion,adhesion and survival of the cells.

Mucin 1, cell surface associated (MUC1), also called polymorphicepithelial mucin (PEM) or epithelial membrane antigen or EMA, is a mucinencoded by the MUC1 gene in humans. The ability of chemotherapeuticdrugs to access the cancer cells is inhibited by the heavy glycosylationin the extracellular domain of MUC1.

CD133 antigen, also known as prominin-1, is a glycoprotein that inhumans is encoded by the PROM1 gene. It is a member of pentaspantransmembrane glycoproteins, which specifically localize to cellularprotrusions. CD133 is expressed in hematopoietic stem cells, endothelialprogenitor cells, glioblastoma, neuronal and glial stem cells, variouspediatric brain tumors, as well as adult kidney, mammary glands,trachea, salivary glands, uterus, placenta, digestive tract, testes, andsome other cell types.

Mucin-16 (MUC-16), also known as Ovarian cancer-related tumor markerCA125, is a protein that in humans is encoded by the MUC16 gene. MUC-16is a member of the mucin family glycoproteins. MUC-16 has foundapplication as a tumor marker or biomarker that may be elevated in theblood of some patients with specific types of cancers, most notablyovarian cancer, or other conditions that are benign.

Lysosomal-associated membrane protein 1 (LAMP1) also known aslysosome-associated membrane glycoprotein 1 and CD107a (Cluster ofDifferentiation 107a), is a protein that in humans is encoded by theLAMP1 gene. LAMP1 is a type I transmembrane protein which is expressedat high or medium levels in many different normal tissue cell types. Itresides primarily across lysosomal membranes, and functions to provideselectins with carbohydrate ligands LAMP1 has also been shown to be amarker of degranulation on lymphocytes such as CD8+ and NK cells and mayalso play a role in tumor cell differentiation and metastasis.

Programmed death-ligand 1 (PD-L1), also known as cluster ofdifferentiation 274 (CD274) or B7 homolog 1 (B7-H1), is a protein thatin humans is encoded by the CD274 gene. Upregulation of PD-L1 may allowcancers to evade the host immune system.

Carcinoembryonic antigen-related cell adhesion molecule 1 (biliaryglycoprotein) (CEACAM1), also known as CD66a (Cluster of Differentiation66a), is a human glycoprotein, and a member of the carcinoembryonicantigen (CEA) gene family.

Metalloreductase STEAP1 is an enzyme that in humans is encoded by theSTEAP1 gene. This gene is predominantly expressed in prostate tissue,and is found to be upregulated in multiple cancer cell lines. The geneproduct is predicted to be a six-transmembrane protein, and was shown tobe a cell surface antigen significantly expressed at cell-celljunctions.

Epithelial cell adhesion molecule (EpCAM) is a transmembraneglycoprotein mediating calcium-independent homotypic cell-cell adhesionin epithelia. EpCAM is also involved in cell signaling, migration,proliferation, and differentiation Additionally, EpCAM has oncogenicpotential via its capacity to upregulate c-myc, e-fabp, and cyclins A &E. Since EpCAM is expressed exclusively in epithelia andepithelial-derived neoplasms, EpCAM can be used as diagnostic marker forvarious cancers.

In some aspects, the antigen binding polypeptides or antigen bindingpolypeptide complexes (e.g., antibodies or antigen binding fragmentsthereof) specifically bind a viral peptide, protein, polypeptide, or afragment thereof. In some aspects, the viral peptide, protein,polypeptide, or a fragment thereof is selected from influenza virusneuraminidase, influenza virus hemagglutinin, human respiratorysyncytial virus (RSV)-viral proteins, RSV F glycoprotein, RSV Gglycoprotein, herpes simplex virus (HSV) viral proteins, herpes simplexvirus glycoproteins gB, gC, gD, and gE, Chlamydia MOMP and PorBantigens, core protein, matrix protein or other protein of Dengue virus,measles virus hemagglutinin, herpes simplex virus type 2 glycoproteingB, poliovirus 1 VP1, envelope glycoproteins of HIV 1, hepatitis Bsurface antigen, diptheria toxin, Streptococcus 24M epitope, gonococcalpilin, pseudorabies virus g50 (gpD), pseudorabies virus II (gpB),pseudorabies virus III (gpC), pseudorabies virus glycoprotein H,pseudorabies virus glycoprotein E, transmissible gastroenteritisglycoprotein 195, transmissible gastroenteritis matrix protein, swinerotavirus glycoprotein 38, swine parvovirus capsid protein,Semulinahydodysenteriae protective antigen, bovine viral diarrheaglycoprotein 55, Newcastle disease virus hemagglutinin-neuraminidase,swine flu hemagglutinin, swine flu neuraminidase, foot and mouth diseasevirus, hog colera virus, swine influenza virus, African swine fevervirus, Mycoplasma liyopneutiioniae, infectious bovine rhinotracheitisvirus, infectious bovine rhinotracheitis virus glycoprotein E,glycoprotein G, infectious laryngotracheitis virus, infectiouslaryngotracheitis virus glycoprotein G or glycoprotein I, a glycoproteinof La Crosse virus, neonatal calf diarrhoea virus, Venezuelan equineencephalomyelitis virus, punta toro virus, murine leukemia virus, mousemammary tumor virus, hepatitis B virus core protein and hepatitis Bvirus surface antigen or a fragment or derivative thereof, antigen ofequine influenza virus or equine herpes virus, including equineinfluenza virus type A/Alaska 91 neuraminidase, equine influenza virustypeA/Miami 63 neuraminidase, equine influenza virus type A/Kentucky 81neuraminidase equine herpes virus type 1 glycoprotein B, and equineherpes virus type 1 glycoprotein D, antigen of bovine respiratorysyncytial virus or bovine parainfluenza virus, bovine respiratorysyncytial virus attachment protein (BRSV G), bovine respiratorysyncytial virus fusion protein (BRSV F), bovine respiratory syncytialvirus nucleocapsid protein (BRSVN), bovine parainfluenza virus type 3fusion protein, bovine parainfluenza virus type 3 hemagglutininneuraminidase, bovine E viral diarrhoea virus glycoprotein 48 andglycoprotein 53, glycoprotein E of Dengue virus, and glycoprotein ElE2of human hepatitis C virus. As described herein, the VL1, VL2, VL3, VL4,VH1, VH2, VH3, and/or VH4 of the antigen binding polypeptide orpolypeptide comprised within the antigen binding polypeptide complex mayspecifically bind to one or more viral peptide, protein, polypeptide, ora fragment thereof such as an influenza virus neuraminidase, influenzavirus hemagglutinin, human respiratory syncytial virus (RSV)-viralproteins, RSV F glycoprotein, RSV G glycoprotein, herpes simplex virus(HSV) viral proteins, herpes simplex virus glycoproteins gB, gC, gD, andgE, Chlamydia MOMP and PorB antigens, core protein, matrix protein orother protein of Dengue virus, measles virus hemagglutinin, herpessimplex virus type 2 glycoprotein gB, poliovirus 1 VP1, envelopeglycoproteins of HIV 1, hepatitis B surface antigen, diptheria toxin,Streptococcus 24M epitope, gonococcal pilin, pseudorabies virus g50(gpD), pseudorabies virus II (gpB), pseudorabies virus III (gpC),pseudorabies virus glycoprotein H, pseudorabies virus glycoprotein E,transmissible gastroenteritis glycoprotein 195, transmissiblegastroenteritis matrix protein, swine rotavirus glycoprotein 38, swineparvovirus capsid protein, Serpulinahydodysenteriae protective antigen,bovine viral diarrhea glycoprotein 55, Newcastle disease virushemagglutinin-neuraminidase, swine flu hemagglutinin, swine fluneuraminidase, foot and mouth disease virus, hog colera virus, swineinfluenza virus, African swine fever virus, Mycoplasma liyopneutiioniae,infectious bovine rhinotracheitis virus, infectious bovinerhinotracheitis virus glycoprotein E, glycoprotein G, infectiouslaryngotracheitis virus, infectious laryngotracheitis virus glycoproteinG or glycoprotein I, a glycoprotein of La Crosse virus, neonatal calfdiarrhoea virus, Venezuelan equine encephalomyelitis virus, punta torovirus, murine leukemia virus, mouse mammary tumor virus, hepatitis Bvirus core protein and hepatitis B virus surface antigen or a fragmentor derivative thereof, antigen of equine influenza virus or equineherpes virus, including equine influenza virus type A/Alaska 91neuraminidase, equine influenza virus typeA/Miami 63 neuraminidase,equine influenza virus type A/Kentucky 81 neuraminidase equine herpesvirus type 1 glycoprotein B, and equine herpes virus type 1 glycoproteinD, antigen of bovine respiratory syncytial virus or bovine parainfluenzavirus, bovine respiratory syncytial virus attachment protein (BRSV G),bovine respiratory syncytial virus fusion protein (BRSV F), bovinerespiratory syncytial virus nucleocapsid protein (BRSVN), bovineparainfluenza virus type 3 fusion protein, bovine parainfluenza virustype 3 hemagglutinin neuraminidase, bovine E viral diarrhoea virusglycoprotein 48 and glycoprotein 53, glycoprotein E of Dengue virus,glycoprotein ElE2 of human hepatitis C virus or a combination thereof.Any of the antigen binding polypeptide structures and any of the antigenbinding polypeptide complex structures described herein may be used totarget one or more of the viral targets described herein in the methodsand uses of the invention. In some aspects, the antigen bindingpolypeptide or antigen binding polypeptide complex (e.g., antibodies orantigen binding fragments thereof) specifically binds to a viralpeptide, protein, polypeptide, or a fragment of influenza virusneuraminidase. In some aspects, the antigen binding polypeptide orantigen binding polypeptide complex (e.g., antibodies or antigen bindingfragments thereof) specifically binds to a viral peptide, protein,polypeptide, or a fragment of influenza virus hemagglutinin. In someaspects, the antigen binding polypeptide or antigen binding polypeptidecomplex (e.g., antibodies or antigen binding fragments thereof)specifically binds to a viral peptide, protein, polypeptide, or afragment of a human respiratory syncytial virus (RSV)-viral protein. Insome aspects, the antigen binding polypeptide or antigen bindingpolypeptide complex (e.g., antibodies or antigen binding fragmentsthereof) specifically binds to a viral peptide, protein, polypeptide, ora fragment of RSV F glycoprotein. In some aspects, the antigen bindingpolypeptide or antigen binding polypeptide complex (e.g., antibodies orantigen binding fragments thereof) specifically binds to a viralpeptide, protein, polypeptide, or a fragment of RSV G glycoprotein. Insome aspects, the antigen binding polypeptide or antigen bindingpolypeptide complex (e.g., antibodies or antigen binding fragmentsthereof) specifically binds to a viral peptide, protein, polypeptide, ora fragment of a herpes simplex virus (HSV) viral protein. In someaspects, the antigen binding polypeptide or antigen binding polypeptidecomplex (e.g., antibodies or antigen binding fragments thereof)specifically binds to a viral peptide, protein, polypeptide, or afragment of the herpes simplex virus glycoprotein gB, gC, gD, or gE. Insome aspects, the antigen binding polypeptide or antigen bindingpolypeptide complex (e.g., antibodies or antigen binding fragmentsthereof) specifically binds to a viral peptide, protein, polypeptide, ora fragment of Chlamydia MOMP. In some aspects, the antigen bindingpolypeptide or antigen binding polypeptide complex (e.g., antibodies orantigen binding fragments thereof) specifically binds to a viralpeptide, protein, polypeptide, or a fragment of a PorB antigen. In someaspects, the antigen binding polypeptide or antigen binding polypeptidecomplex (e.g., antibodies or antigen binding fragments thereof)specifically binds to a viral peptide, protein, polypeptide, or afragment of core protein, matrix protein or other protein of Denguevirus. In some aspects, the antigen binding polypeptide or antigenbinding polypeptide complex (e.g., antibodies or antigen bindingfragments thereof) specifically binds to a viral peptide, protein,polypeptide, or a fragment of measles virus hemagglutinin. In someaspects, the antigen binding polypeptide or antigen binding polypeptidecomplex (e.g., antibodies or antigen binding fragments thereof)specifically binds to a viral peptide, protein, polypeptide, or afragment of simplex virus type 2 glycoprotein gB. In some aspects, theantigen binding polypeptide or antigen binding polypeptide complex(e.g., antibodies or antigen binding fragments thereof) specificallybinds to a viral peptide, protein, polypeptide, or a fragment ofpoliovirus 1 VP1. In some aspects, the antigen binding polypeptide orantigen binding polypeptide complex (e.g., antibodies or antigen bindingfragments thereof) specifically binds to a viral peptide, protein,polypeptide, or a fragment of an envelope glycoprotein of HIV 1. In someaspects, the antigen binding polypeptide or antigen binding polypeptidecomplex (e.g., antibodies or antigen binding fragments thereof)specifically binds to a viral peptide, protein, polypeptide, or afragment of hepatitis B surface antigen. In some aspects, the antigenbinding polypeptide or antigen binding polypeptide complex (e.g.,antibodies or antigen binding fragments thereof) specifically binds to aviral peptide, protein, polypeptide, or a fragment of diptheria toxin.In some aspects, the antigen binding polypeptide or antigen bindingpolypeptide complex (e.g., antibodies or antigen binding fragmentsthereof) specifically binds to a viral peptide, protein, polypeptide, ora fragment of Streptococcus 24M epitope. In some aspects, the antigenbinding polypeptide or antigen binding polypeptide complex (e.g.,antibodies or antigen binding fragments thereof) specifically binds to aviral peptide, protein, polypeptide, or a fragment of gonococcal pilin.In some aspects, the antigen binding polypeptide or antigen bindingpolypeptide complex (e.g., antibodies or antigen binding fragmentsthereof) specifically binds to a viral peptide, protein, polypeptide, ora fragment of pseudorabies virus g50 (gpD). In some aspects, the antigenbinding polypeptide or antigen binding polypeptide complex (e.g.,antibodies or antigen binding fragments thereof) specifically binds to aviral peptide, protein, polypeptide, or a fragment of pseudorabies virusII (gpB). In some aspects, the antigen binding polypeptide or antigenbinding polypeptide complex (e.g., antibodies or antigen bindingfragments thereof) specifically binds to a viral peptide, protein,polypeptide, or a fragment of pseudorabies virus III (gpC). In someaspects, the antigen binding polypeptide or antigen binding polypeptidecomplex (e.g., antibodies or antigen binding fragments thereof)specifically binds to a viral peptide, protein, polypeptide, or afragment of pseudorabies virus glycoprotein H. In some aspects, theantigen binding polypeptide or antigen binding polypeptide complex(e.g., antibodies or antigen binding fragments thereof) specificallybinds to a viral peptide, protein, polypeptide, or a fragment ofpseudorabies virus glycoprotein E. In some aspects, the antigen bindingpolypeptide or antigen binding polypeptide complex (e.g., antibodies orantigen binding fragments thereof) specifically binds to a viralpeptide, protein, polypeptide, or a fragment of transmissiblegastroenteritis glycoprotein 195. In some aspects, the antigen bindingpolypeptide or antigen binding polypeptide complex (e.g., antibodies orantigen binding fragments thereof) specifically binds to a viralpeptide, protein, polypeptide, or a fragment of transmissiblegastroenteritis matrix protein. In some aspects, the antigen bindingpolypeptide or antigen binding polypeptide complex (e.g., antibodies orantigen binding fragments thereof) specifically binds to a viralpeptide, protein, polypeptide, or a fragment of swine rotavirusglycoprotein 38. In some aspects, the antigen binding polypeptide orantigen binding polypeptide complex (e.g., antibodies or antigen bindingfragments thereof) specifically binds to a viral peptide, protein,polypeptide, or a fragment of swine parvovirus capsid protein. In someaspects, the antigen binding polypeptide or antigen binding polypeptidecomplex (e.g., antibodies or antigen binding fragments thereof)specifically binds to a viral peptide, protein, polypeptide, or afragment of Serpulinahydodysenteriae protective antigen. In someaspects, the antigen binding polypeptide or antigen binding polypeptidecomplex (e.g., antibodies or antigen binding fragments thereof)specifically binds to a viral peptide, protein, polypeptide, or afragment of bovine viral diarrhea glycoprotein 55. In some aspects, theantigen binding polypeptide or antigen binding polypeptide complex(e.g., antibodies or antigen binding fragments thereof) specificallybinds to a viral peptide, protein, polypeptide, or a fragment ofNewcastle disease virus hemagglutinin-neuraminidase. In some aspects,the antigen binding polypeptide or antigen binding polypeptide complex(e.g., antibodies or antigen binding fragments thereof) specificallybinds to a viral peptide, protein, polypeptide, or a fragment of swineflu hemagglutinin. In some aspects, the antigen binding polypeptide orantigen binding polypeptide complex (e.g., antibodies or antigen bindingfragments thereof) specifically binds to a viral peptide, protein,polypeptide, or a fragment of swine flu neuraminidase. In some aspects,the antigen binding polypeptide or antigen binding polypeptide complex(e.g., antibodies or antigen binding fragments thereof) specificallybinds to a viral peptide, protein, polypeptide, or a fragment of footand mouth disease virus. In some aspects, the antigen bindingpolypeptide or antigen binding polypeptide complex (e.g., antibodies orantigen binding fragments thereof) specifically binds to a viralpeptide, protein, polypeptide, or a fragment of hog colera virus. Insome aspects, the antigen binding polypeptide or antigen bindingpolypeptide complex (e.g., antibodies or antigen binding fragmentsthereof) specifically binds to a viral peptide, protein, polypeptide, ora fragment of swine influenza virus. In some aspects, the antigenbinding polypeptide or antigen binding polypeptide complex (e.g.,antibodies or antigen binding fragments thereof) specifically binds to aviral peptide, protein, polypeptide, or a fragment of African swinefever virus. In some aspects, the antigen binding polypeptide or antigenbinding polypeptide complex (e.g., antibodies or antigen bindingfragments thereof) specifically binds to a viral peptide, protein,polypeptide, or a fragment of Mycoplasma liyopneutiioniae. In someaspects, the antigen binding polypeptide or antigen binding polypeptidecomplex (e.g., antibodies or antigen binding fragments thereof)specifically binds to a viral peptide, protein, polypeptide, or afragment of. In some aspects, the antigen binding polypeptide or antigenbinding polypeptide complex (e.g., antibodies or antigen bindingfragments thereof) specifically binds to a viral peptide, protein,polypeptide, or a fragment of infectious bovine rhinotracheitis virus.In some aspects, the antigen binding polypeptide or antigen bindingpolypeptide complex (e.g., antibodies or antigen binding fragmentsthereof) specifically binds to a viral peptide, protein, polypeptide, ora fragment of infectious bovine rhinotracheitis virus glycoprotein E. Insome aspects, the antigen binding polypeptide or antigen bindingpolypeptide complex (e.g., antibodies or antigen binding fragmentsthereof) specifically binds to a viral peptide, protein, polypeptide, ora fragment of glycoprotein G. In some aspects, the antigen bindingpolypeptide or antigen binding polypeptide complex (e.g., antibodies orantigen binding fragments thereof) specifically binds to a viralpeptide, protein, polypeptide, or a fragment of infectiouslaryngotracheitis virus. In some aspects, the antigen bindingpolypeptide or antigen binding polypeptide complex (e.g., antibodies orantigen binding fragments thereof) specifically binds to a viralpeptide, protein, polypeptide, or a fragment of an infectiouslaryngotracheitis virus glycoprotein G or glycoprotein I. In someaspects, the antigen binding polypeptide or antigen binding polypeptidecomplex (e.g., antibodies or antigen binding fragments thereof)specifically binds to a viral peptide, protein, polypeptide, or afragment of a glycoprotein of La Crosse virus. In some aspects, theantigen binding polypeptide or antigen binding polypeptide complex(e.g., antibodies or antigen binding fragments thereof) specificallybinds to a viral peptide, protein, polypeptide, or a fragment ofneonatal calf diarrhoea virus. In some aspects, the antigen bindingpolypeptide or antigen binding polypeptide complex (e.g., antibodies orantigen binding fragments thereof) specifically binds to a viralpeptide, protein, polypeptide, or a fragment of Venezuelan equineencephalomyelitis virus. In some aspects, the antigen bindingpolypeptide or antigen binding polypeptide complex (e.g., antibodies orantigen binding fragments thereof) specifically binds to a viralpeptide, protein, polypeptide, or a fragment of punta toro virus. Insome aspects, the antigen binding polypeptide or antigen bindingpolypeptide complex (e.g., antibodies or antigen binding fragmentsthereof) specifically binds to a viral peptide, protein, polypeptide, ora fragment of murine leukemia virus. In some aspects, the antigenbinding polypeptide or antigen binding polypeptide complex (e.g.,antibodies or antigen binding fragments thereof) specifically binds to aviral peptide, protein, polypeptide, or a fragment of mouse mammarytumor virus. In some aspects, the antigen binding polypeptide or antigenbinding polypeptide complex (e.g., antibodies or antigen bindingfragments thereof) specifically binds to a viral peptide, protein,polypeptide, or a fragment of hepatitis B virus core protein orhepatitis B virus surface antigen. In some aspects, the antigen bindingpolypeptide or antigen binding polypeptide complex (e.g., antibodies orantigen binding fragments thereof) specifically binds to a viralpeptide, protein, polypeptide, or a fragment of equine influenza virusor equine herpes virus, such as equine influenza virus type A/Alaska 91neuraminidase, equine influenza virus typeA/Miami 63 neuraminidase,equine influenza virus type A/Kentucky 81 neuraminidase equine herpesvirus type 1 glycoprotein B, and equine herpes virus type 1 glycoproteinD. In some aspects, the antigen binding polypeptide or antigen bindingpolypeptide complex (e.g., antibodies or antigen binding fragmentsthereof) specifically binds to a viral peptide, protein, polypeptide, ora fragment of bovine respiratory syncytial virus or bovine parainfluenzavirus. In some aspects, the antigen binding polypeptide or antigenbinding polypeptide complex (e.g., antibodies or antigen bindingfragments thereof) specifically binds to a viral peptide, protein,polypeptide, or a fragment of bovine respiratory syncytial virusattachment protein (BRSV G). In some aspects, the antigen bindingpolypeptide or antigen binding polypeptide complex (e.g., antibodies orantigen binding fragments thereof) specifically binds to a viralpeptide, protein, polypeptide, or a fragment of bovine respiratorysyncytial virus fusion protein (BRSV F). In some aspects, the antigenbinding polypeptide or antigen binding polypeptide complex (e.g.,antibodies or antigen binding fragments thereof) specifically binds to aviral peptide, protein, polypeptide, or a fragment of bovine respiratorysyncytial virus nucleocapsid protein (BRSVN). In some aspects, theantigen binding polypeptide or antigen binding polypeptide complex(e.g., antibodies or antigen binding fragments thereof) specificallybinds to a viral peptide, protein, polypeptide, or a fragment of bovineparainfluenza virus type 3 fusion protein. In some aspects, the antigenbinding polypeptide or antigen binding polypeptide complex (e.g.,antibodies or antigen binding fragments thereof) specifically binds to aviral peptide, protein, polypeptide, or a fragment of ovineparainfluenza virus type 3 hemagglutinin neuraminidase. In some aspects,the antigen binding polypeptide or antigen binding polypeptide complex(e.g., antibodies or antigen binding fragments thereof) specificallybinds to a viral peptide, protein, polypeptide, or a fragment of bovineE viral diarrhoea virus glycoprotein 48 or glycoprotein 53. In someaspects, the antigen binding polypeptide or antigen binding polypeptidecomplex (e.g., antibodies or antigen binding fragments thereof)specifically binds to a viral peptide, protein, polypeptide, or afragment of glycoprotein E of Dengue virus. In some aspects, the antigenbinding polypeptide or antigen binding polypeptide complex (e.g.,antibodies or antigen binding fragments thereof) specifically binds to aviral peptide, protein, polypeptide, or a fragment of glycoprotein ElE2of human hepatitis C virus. Accordingly, In some aspects, the inventionis directed to a method of modulating T cell activation, comprisingadministering to a subject in need thereof an antigen bindingpolypeptide, antigen binding polypeptide complex (e.g., antibody orantigen binding fragment thereof), polypeptide, polynucleotide, vector,cell, CAR or pharmaceutical composition described herein, or acombination thereof. In another aspect, the invention is directed to amethod of modulating T cell activation, comprising administering to asubject in need thereof a therapeutically effective amount of an antigenbinding polypeptide, antigen binding polypeptide complex (e.g., antibodyor antigen binding fragment thereof), polypeptide, polynucleotide,vector, cell, CAR or pharmaceutical composition described herein, or acombination thereof.

In some aspects, the invention is directed to a method of modulatingcell proliferation, comprising administering to a subject in needthereof an antigen binding polypeptide, antigen binding polypeptidecomplex (e.g., antibody or antigen binding fragment thereof),polypeptide, polynucleotide, vector, cell, CAR or pharmaceuticalcomposition described herein, or a combination thereof. In anotheraspect, the invention is directed to a method of modulating cellproliferation, comprising administering to a subject in need thereof atherapeutically effective amount of an antigen binding polypeptide,antigen binding polypeptide complex (e.g., antibody or antigen bindingfragment thereof), polypeptide, polynucleotide, vector, cell, CAR orpharmaceutical composition described herein, or a combination thereof.

As used herein, the term “modulating” means an increase or decrease in agiven property. For example, “modulating T cell activation” means anincrease or decrease in T cell activation and “modulating cellproliferation” means an increase or decrease in cell proliferation.

As used herein, the term “subject” means a human or a non-human mammal,e.g., a dog, a cat, a mouse, a rat, a cow, a sheep, a pig, a goat, anon-human primate or a bird, e.g., a chicken, as well as any othervertebrate or invertebrate. In some aspects, the subject is a human. Insome aspects, the subject is a veterinary animal. In some aspects, thesubject is a mammal.

As used herein, the terms “treat” or “treatment” refer to therapeutic orpalliative measures. Beneficial or desired clinical results include, butare not limited to, alleviation, in whole or in part, of symptomsassociated with a disease or disorder or condition, diminishment of theextent of disease, stabilized (i.e., not worsening) state of disease,delay or slowing of disease progression, amelioration or palliation ofthe disease state (e.g., one or more symptoms of the disease), andremission (whether partial or total), whether detectable orundetectable. “Treatment” can also mean prolonging survival as comparedto expected survival if not receiving treatment.

As used herein, the terms “prevent” or “preventing” refer to theprevention of the onset, recurrence or spread, in whole or in part, of adisease or condition described herein, or a symptom thereof.

As used herein, a “therapeutically effective amount” is an amount of anantigen binding polypeptide or antigen binding polypeptide complex(e.g., an antibody or antigen binding fragment thereof) that issufficient to achieve the desired effect and can vary according to thenature and severity of the disease condition, and the potency of thepolypeptide or polypeptide complex. In some aspects, an antigen bindingpolypeptide or antigen binding polypeptide complex of the invention canbe delivered by administering a polynucleotide, vector, CAR or cell thatencodes the antigen binding polypeptide or antigen binding polypeptidecomplex. In some aspects, an antigen binding polypeptide or antigenbinding polypeptide complex thereof can be delivered by administering apharmaceutical composition containing the polypeptide or polypeptidecomplex. A therapeutic effect is the relief, to some extent, of one ormore of the symptoms of the disease, and can include curing a disease.“Curing” means that the symptoms of active disease are eliminated.However, certain long-term or permanent effects of the disease can existeven after a cure is obtained.

T cell activation can be measured using scientific methods that are wellknown in the art. For example, T cell activation can be determined bydetecting activation of T cells in response to a stimulus by measuring acharacteristic response, such as cytokine secretion, or by analyzingcells by the specificity of their T cell receptor. Specific techniquesinclude, but are not limited to, limiting dilutions culture, ELISPOT(enzyme-linked immunospot), intracellular staining, cytokine capture,tetramer staining, and spectratyping and biosensor assays.

Cell proliferation can be measured using scientific methods that arewell known in the art. Such methods include, but are not limited to,metabolic activity assays (e.g., measuring absorbance of formazan dye),cell proliferation marker assays (e.g., Ki-68 antibody), ATPconcentration assays (e.g., luciferase luminescence), and DNA synthesisassays (e.g., ³H-thymine or bromodeoxyuridine (BrdU)).

In some aspects, the invention is directed to a method of neutralizingviral infection, comprising administering to a subject in need thereofan antigen binding polypeptide, antigen binding polypeptide complex(e.g., antibody or antigen binding fragment thereof), polypeptide,polynucleotide, vector, cell, CAR or pharmaceutical compositiondescribed herein, or a combination thereof. In another aspect, theinvention is directed to a method of neutralizing viral infection,comprising administering to a subject in need thereof a therapeuticallyeffective amount of an antigen binding polypeptide, antigen bindingpolypeptide complex (e.g., antibody or antigen binding fragmentthereof), polypeptide, polynucleotide, vector, cell, CAR orpharmaceutical composition described herein, or a combination thereof.In some aspects, the viral infection is not human immunodeficiency virus(HIV) and/or severe acute respiratory syndrome (SARS).

In some aspects, the invention is directed to a method of treating orpreventing a disease or condition, comprising administering to a subjectin need thereof an antigen binding polypeptide, antigen bindingpolypeptide complex (e.g., antibody or antigen binding fragmentthereof), polypeptide, polynucleotide, vector, cell, CAR orpharmaceutical composition described herein, or a combination thereof.In some aspects, the invention is directed to a method of treating orpreventing a disease or condition, comprising administering to a subjectin need thereof a therapeutically effective amount of an antigen bindingpolypeptide, antigen binding polypeptide complex (e.g., antibody orantigen binding fragment thereof), polypeptide, polynucleotide, vector,cell, CAR or pharmaceutical composition described herein, or acombination thereof. The present invention further provides an antigenbinding polypeptide, antigen binding polypeptide complex (e.g., antibodyor antigen binding fragment thereof), polypeptide, polynucleotide,vector, cell, CAR or pharmaceutical composition described herein, or acombination thereof, for use in treating or preventing a disease orcondition in a subject. The present invention further provides the useof an antigen binding polypeptide, antigen binding polypeptide complex(e.g., antibody or antigen binding fragment thereof), polypeptide,polynucleotide, vector, cell, CAR or pharmaceutical compositiondescribed herein, or a combination thereof in the manufacture of amedicament for the treatment or prevention of a disease or condition ina subject.

In another aspect, the invention is directed to a method of treating orpreventing a virus infection, wherein the virus is influenza virus,respiratory syncytial virus (RSV), Chlamydia, adenovirdiae, mastadenovirus, aviadenovirus, herpesviridae, herpes simplex virus 1, herpessimplex virus 2, herpes simplex virus 5, herpes simplex virus 6,leviviridae, levivirus, enterobacteria phase MS2, allolevirus,poxviridae, chordopoxvirinae, parapoxvirus, avipoxvirus, capripoxvirus,leporiipoxvirus, suipoxvirus, molluscipoxvirus, entomopoxvirinae,papovaviridae, polyomavirus, papillomavirus, paramyxoviridae,paramyxovirus, parainfluenza virus 1, mobillivirus, measles virus,rubulavirus, mumps virus, pneumonovirinae, pneumovirus, me tapneumovirus, avian pneumovirus, human metapneumovirus, picornaviridae,enterovirus, rhinovirus, hepatovirus, human hepatitis A virus,cardiovirus, andaptho virus, reoviridae, orthoreovirus, orbivirus,rotavirus, cypovirus, fijivirus, phytoreovirus, oryzavirus,retroviridae, mammalian type B retroviruses, mammalian type Cretroviruses, avian type C retroviruses, type D retrovirus group,BLV-HTLV retroviruses, lentivirus, human immunodeficiency virus 1, humanimmunodeficiency virus 2, HTLV-I and -II viruses, SARS coronavirus,herpes simplex E virus, Epstein Barr virus, cytomegalovirus, hepatitisvirus (HCV, HAV, HBV, HDV, HEV), Toxoplasma gondii virus, Treponemapallidium virus, human T-lymphotrophic virus, encephalitis virus, WestNile virus, Dengue virus, Varicella Zoster Virus, rubeola, mumps,rubella, spumavirus, flaviviridae, hepatitis C virus, hepadnaviridae,hepatitis B virus, togaviridae, alphavirus sindbis virus, rubivirus,rubella virus, rhabdoviridae, vesiculovirus, lyssavirus, ephemerovirus,cytorhabdo virus, necleorhabdo virus, arenaviridae, arenavirus,lymphocytic choriomeningitis virus, Ippy virus, lassa virus,coronaviridae, coronavirus or torovirus. The present invention furtherprovides an antigen binding polypeptide, antigen binding polypeptidecomplex (e.g., antibody or antigen binding fragment thereof),polypeptide, polynucleotide, vector, cell, CAR or pharmaceuticalcomposition described herein, or a combination thereof, for use intreating or preventing a virus infection in a subject. The presentinvention further provides the use of an antigen binding polypeptide,antigen binding polypeptide complex (e.g., antibody or antigen bindingfragment thereof), polypeptide, polynucleotide, vector, cell, CAR orpharmaceutical composition described herein, or a combination thereof inthe manufacture of a medicament for the treatment or prevention of avirus infection in a subject. The virus may be selected from: influenzavirus, respiratory syncytial virus (RSV), Chlamydia, adenovirdiae,mastadeno virus, aviadenovirus, herpesviridae, herpes simplex virus 1,herpes simplex virus 2, herpes simplex virus 5, herpes simplex virus 6,leviviridae, levivirus, enterobacteria phase MS2, allolevirus,poxviridae, chordopoxvirinae, parapoxvirus, avipoxvirus, capripoxvirus,leporiipoxvirus, suipoxvirus, molluscipoxvirus, entomopoxvirinae,papovaviridae, polyomavirus, papillomavirus, paramyxoviridae,paramyxovirus, parainfluenza virus 1, mobillivirus, measles virus,rubulavirus, mumps virus, pneumonovirinae, pneumovirus, me tapneumovirus, avian pneumovirus, human metapneumovirus, picomaviridae,enterovirus, rhinovirus, hepatovirus, human hepatitis A virus,cardiovirus, andaptho virus, reoviridae, orthoreovirus, orbivirus,rotavirus, cypovirus, fijivirus, phytoreovirus, oryzavirus,retroviridae, mammalian type B retroviruses, mammalian type Cretroviruses, avian type C retroviruses, type D retrovirus group,BLV-HTLV retroviruses, lentivirus, human immunodeficiency virus 1, humanimmunodeficiency virus 2, HTLV-I and -II viruses, SARS coronavirus,herpes simplex E virus, Epstein Barr virus, cytomegalovirus, hepatitisvirus (HCV, HAV, HBV, HDV, HEV), Toxoplasma gondii virus, Treponemapallidium virus, human T-lymphotrophic virus, encephalitis virus, WestNile virus, Dengue virus, Varicella Zoster Virus, rubeola, mumps,rubella, spumavirus, flaviviridae, hepatitis C virus, hepadnaviridae,hepatitis B virus, togaviridae, alphavirus sindbis virus, rubivirus,rubella virus, rhabdoviridae, vesiculovirus, lyssavirus, ephemerovirus,cytorhabdo virus, necleorhabdo virus, arenaviridae, arenavirus,lymphocytic choriomeningitis virus, Ippy virus, lassa virus,coronaviridae, coronavirus and torovirus.

In some aspects, the invention is directed to a method of treating orpreventing a cancer, comprising administering to a subject in needthereof an antigen binding polypeptide, antigen binding polypeptidecomplex (e.g., antibody or antigen binding fragment thereof),polypeptide, polynucleotide, vector, cell, CAR or pharmaceuticalcomposition described herein, or a combination thereof. In anotheraspect, the invention is directed to a method of treating or preventinga cancer, comprising administering to a subject in need thereof atherapeutically effective amount of an antigen binding polypeptide,antigen binding polypeptide complex (e.g., antibody or antigen bindingfragment thereof), polypeptide, polynucleotide, vector, cell, CAR orpharmaceutical composition described herein, or a combination thereof.The present invention further provides an antigen binding polypeptide,antigen binding polypeptide complex (e.g., antibody or antigen bindingfragment thereof), polypeptide, polynucleotide, vector, cell, CAR orpharmaceutical composition described herein, or a combination thereof,for use in treating or preventing a cancer in a subject. The presentinvention further provides the use of an antigen binding polypeptide,antigen binding polypeptide complex (e.g., antibody or antigen bindingfragment thereof), polypeptide, polynucleotide, vector, cell, CAR orpharmaceutical composition described herein, or a combination thereof inthe manufacture of a medicament for the treatment or prevention of acancer in a subject.

In some aspects, the invention is directed to a method of neutralizingHIV infection, comprising administering to a subject in need thereof anantigen binding polypeptide, antigen binding polypeptide complex (e.g.,antibody or antigen binding fragment thereof), polypeptide,polynucleotide, vector, CAR, cell or pharmaceutical compositiondescribed herein, or a combination thereof. In some aspects, theinvention is directed to a method of neutralizing HIV infection,comprising administering to a subject in need thereof a therapeuticallyeffective amount of an antigen binding polypeptide, antigen bindingpolypeptide complex (e.g., antibody or antigen binding fragmentthereof), polypeptide, polynucleotide, vector, CAR, cell orpharmaceutical composition described herein, or a combination thereof.

In some aspects, the invention is directed to a method of treating orpreventing HIV infection, comprising administering to a subject in needthereof an antigen binding polypeptide, antigen binding polypeptidecomplex (e.g., antibody or antigen binding fragment thereof),polypeptide, polynucleotide, vector, CAR, cell or pharmaceuticalcomposition described herein, or a combination thereof. In some aspects,the invention is directed to a method of treating or preventing HIVinfection, comprising administering to a subject in need thereof atherapeutically effective amount of an antigen binding polypeptide,antigen binding polypeptide complex (e.g., antibody or antigen bindingfragment thereof), polypeptide, polynucleotide, vector, CAR, cell orpharmaceutical composition described herein, or a combination thereof.The present invention further provides an antigen binding polypeptide,antigen binding polypeptide complex (e.g., antibody or antigen bindingfragment thereof), polypeptide, polynucleotide, vector, cell, CAR orpharmaceutical composition described herein, or a combination thereof,for use in treating or preventing HIV infection in a subject. Thepresent invention further provides the use of an antigen bindingpolypeptide, antigen binding polypeptide complex (e.g., antibody orantigen binding fragment thereof), polypeptide, polynucleotide, vector,cell, CAR or pharmaceutical composition described herein, or acombination thereof in the manufacture of a medicament for the treatmentor prevention of HIV infection in a subject.

In some aspects, the invention is directed to a method of treating orpreventing acquired immunodeficiency syndrome (AIDS), comprisingadministering to a subject in need thereof an antigen bindingpolypeptide, antigen binding polypeptide complex (e.g., antibody orantigen binding fragment thereof), polypeptide, polynucleotide, vector,CAR, cell or pharmaceutical composition described herein, or acombination thereof. In some aspects, the invention is directed to amethod of treating or preventing AIDS, comprising administering to asubject in need thereof a therapeutically effective amount of an antigenbinding polypeptide, antigen binding polypeptide complex (e.g., antibodyor antigen binding fragment thereof), polypeptide, polynucleotide,vector, CAR, cell or pharmaceutical composition described herein, or acombination thereof. The present invention further provides an antigenbinding polypeptide, antigen binding polypeptide complex (e.g., antibodyor antigen binding fragment thereof), polypeptide, polynucleotide,vector, cell, CAR or pharmaceutical composition described herein, or acombination thereof, for use in treating or preventing AIDS in asubject. The present invention further provides the use of an antigenbinding polypeptide, antigen binding polypeptide complex (e.g., antibodyor antigen binding fragment thereof), polypeptide, polynucleotide,vector, cell, CAR or pharmaceutical composition described herein, or acombination thereof in the manufacture of a medicament for the treatmentor prevention of AIDS in a subject.

AIDS-related complex (ARC) is prodromal phase of HIV infection thatpresents certain symptoms that include, but are not limited to, lowgrade fever, unexplained weight loss, diarrhea, HIV-relatedopportunistic infections and generalized lymphadenopathy. In someaspects, the invention is directed to a method of treating or preventingARC, comprising administering to a subject in need thereof an antigenbinding polypeptide, antigen binding polypeptide complex (e.g., antibodyor antigen binding fragment thereof), polypeptide, polynucleotide,vector, CAR, cell or pharmaceutical composition described herein, or acombination thereof. In some aspects, the invention is directed to amethod of treating or preventing ARC, comprising administering to asubject in need thereof a therapeutically effective amount of an antigenbinding polypeptide, antigen binding polypeptide complex (e.g., antibodyor antigen binding fragment thereof), polypeptide, polynucleotide,vector, CAR, cell or pharmaceutical composition described herein, or acombination thereof. The present invention further provides an antigenbinding polypeptide, antigen binding polypeptide complex (e.g., antibodyor antigen binding fragment thereof), polypeptide, polynucleotide,vector, cell, CAR or pharmaceutical composition described herein, or acombination thereof, for use in treating or preventing ARC in a subject.The present invention further provides the use of an antigen bindingpolypeptide, antigen binding polypeptide complex (e.g., antibody orantigen binding fragment thereof), polypeptide, polynucleotide, vector,cell, CAR or pharmaceutical composition described herein, or acombination thereof in the manufacture of a medicament for the treatmentor prevention of ARC in a subject.

HIV-related opportunistic infections are illnesses that occur morefrequently and/or more severely in subjects infected with HIV, due totheir compromised immune systems. Examples of HIV-related opportunisticinfections include, but are not limited to, candidiasis, invasivecervical cancer, coccidioidomycosis, cryptococcosis, cryptosporidiosis(Crypto), cystoisosporiasis, cytomegalovirus (CMV) infection,encephalopathy, herpes simplex virus (HSV) infection, histoplasmosis,Kaposi's sarcoma (KS), lymphoma, tuberculosis, Mycobacterium aviumcomplex (MAC), Pneumocystis pneumonia (PCP), pneumonia, progressivemultifocal leukoencephalopathy, Salmonella septicemia, toxoplasmosis, orwasting syndrome.

In some aspects, the invention is directed to a method of treating orpreventing an HIV-related opportunistic infection, comprisingadministering to a subject in need thereof an antigen bindingpolypeptide, antigen binding polypeptide complex (e.g., antibody orantigen binding fragment thereof), polypeptide, polynucleotide, vector,CAR, cell or pharmaceutical composition described herein, or acombination thereof. In some aspects, the invention is directed to amethod of treating or preventing an HIV-related opportunistic infection,comprising administering to a subject in need thereof a therapeuticallyeffective amount of an antigen binding polypeptide, antigen bindingpolypeptide complex (e.g., antibody or antigen binding fragmentthereof), polypeptide, polynucleotide, vector, CAR, cell orpharmaceutical composition described herein, or a combination thereof.The present invention further provides an antigen binding polypeptide,antigen binding polypeptide complex (e.g., antibody or antigen bindingfragment thereof), polypeptide, polynucleotide, vector, cell, CAR orpharmaceutical composition described herein, or a combination thereof,for use in treating or preventing an HIV-related opportunistic infectionin a subject. The present invention further provides the use of anantigen binding polypeptide, antigen binding polypeptide complex (e.g.,antibody or antigen binding fragment thereof), polypeptide,polynucleotide, vector, cell, CAR or pharmaceutical compositiondescribed herein, or a combination thereof in the manufacture of amedicament for the treatment or prevention of an HIV-relatedopportunistic infection in a subject.

In some aspects of any of the methods and uses disclosed herein, the HIVis HIV-1 or HIV-2.

Clauses Relating to Aspects of the Invention

-   -   1. An antigen binding polypeptide having a structure represented        by:    -   VL1-VL2-VH2-VH1;    -   VH1-VH2-VL2-VL1;    -   VL1-L1-VL2-L2-VH2-L3-VH1; or    -   VH1-L1-VH2-L2-VL2-L3-VL1;    -   wherein:    -   VL1 is a first immunoglobulin light chain variable region;    -   VL2 is a second immunoglobulin light chain variable region;    -   VH1 is a first immunoglobulin heavy chain variable region;    -   VH2 is a second immunoglobulin heavy chain variable region; and    -   L1, L2 and L3 are amino acid linkers.    -   2. The C antigen binding polypeptide of clause 1, wherein the        polypeptide has a structure represented by:    -   VL1-VL2-VH2-VH1-Fc;    -   VH1-VH2-VL2-VL1-Fc;    -   VL1-L1-VL2-L2-VH2-L3-VH1-Fc;    -   VH1-L1-VH2-L2-VL2-L3-VL1-Fc;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc; or    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc;    -   wherein:    -   VL1 is a first immunoglobulin light chain variable region;    -   VL2 is a second immunoglobulin light chain variable region;    -   VH1 is a first immunoglobulin heavy chain variable region;    -   VH2 is a second immunoglobulin heavy chain variable region;    -   Fc is a region comprising an immunoglobulin heavy chain constant        region 2 (CH2), an immunoglobulin heavy chain constant region 3        (CH3), and optionally, an immunoglobulin hinge; and    -   L1, L2, L3 and L4 are amino acid linkers.    -   3. The C antigen binding polypeptide of clause 1, wherein the        polypeptide has a structure represented by:    -   VL1-VL2-VH2-VH1-CH1-CL;    -   VH1-VH2-VL2-VL1-CH1-CL;    -   VL1-VL2-VH2-VH1-CL-CH1;    -   VH1-VH2-VL2-VL1-CL-CH1;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-CL;    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-CL;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-CH1;    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-CH1;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; or    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1;    -   wherein:    -   VL1 is a first immunoglobulin light chain variable region;    -   VL2 is a second immunoglobulin light chain variable region;    -   VH1 is a first immunoglobulin heavy chain variable region;    -   VH2 is a second immunoglobulin heavy chain variable region;    -   CH1 is an immunoglobulin heavy chain constant region 1;    -   CL is an immunoglobulin light chain constant region; and    -   L1, L2, L3, L4 and L5 are amino acid linkers.    -   4. The antigen binding polypeptide of clause 1, wherein the        polypeptide has a structure represented by:    -   VL1-VL2-VH2-VH1-CH1-CL-Fc;    -   VH1-VH2-VL2-VL1-CH1-CL-Fc;    -   VL1-VL2-VH2-VH1-CL-CH1-Fc;    -   VH1-VH2-VL2-VL1-CL-CH1-Fc;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc;    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fc;    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6-Fc;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6-Fc; or    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc;    -   wherein:    -   VL1 is a first immunoglobulin light chain variable region;    -   VL2 is a second immunoglobulin light chain variable region;    -   VH1 is a first immunoglobulin heavy chain variable region;    -   VH2 is a second immunoglobulin heavy chain variable region;    -   CH1 is an immunoglobulin heavy chain constant region 1;    -   CL is an immunoglobulin light chain constant region; and    -   Fc is a region comprising an immunoglobulin heavy chain constant        region 2 (CH2), an immunoglobulin heavy chain constant region 3        (CH3), and optionally, an immunoglobulin hinge; and    -   L1, L2, L3, L4, L5 and L6 are amino acid linkers.    -   5. The antigen binding polypeptide of clause 1, wherein the        polypeptide has a structure represented by:    -   VL1-VL2-VH2-VH1-Fc-Fc;    -   VH1-VH2-VL2-VL1-Fc-Fc;    -   VL1-L1-VL2-L2-VH2-L3-VH1-Fc-Fc;    -   VH1-L1-VH2-L2-VL2-L3-VL1-Fc-Fc;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc-Fc;    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc-Fc;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc-L5-Fc; or    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc-L5-Fc;    -   wherein:    -   VL1 is a first immunoglobulin light chain variable region;    -   VL2 is a second immunoglobulin light chain variable region;    -   VH1 is a first immunoglobulin heavy chain variable region;    -   VH2 is a second immunoglobulin heavy chain variable region;    -   Fc is a region comprising an immunoglobulin heavy chain constant        region 2 (CH2), an immunoglobulin heavy chain constant region 3        (CH3), and optionally, an immunoglobulin hinge; and    -   L1, L2, L3, L4 and L5 are amino acid linkers.    -   6. The antigen binding polypeptide of clause 1, wherein the        polypeptide has a structure represented by:    -   VL1-VL2-VH2-VH1-CH3;    -   VH1-VH2-VL2-VL1-CH3;    -   VL1-L1-VL2-L2-VH2-L3-VH1-CH3;    -   VH1-L1-VH2-L2-VL2-L3-VL1-CH3;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH3;    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH3;    -   VL1-VL2-VH2-VH1-CH3-CH3;    -   VH1-VH2-VL2-VL1-CH3-CH3;    -   VL1-L1-VL2-L2-VH2-L3-VH1-CH3-CH3;    -   VH1-L1-VH2-L2-VL2-L3-VL1-CH3-CH3;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH3-CH3;    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH3-CH3;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH3-L5-CH3; or    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH3-L5-CH3;    -   wherein:    -   VL1 is a first immunoglobulin light chain variable region;    -   VL2 is a second immunoglobulin light chain variable region;    -   VH1 is a first immunoglobulin heavy chain variable region;    -   VH2 is a second immunoglobulin heavy chain variable region;    -   CH3 is an immunoglobulin heavy chain constant region 3; and    -   L1, L2, L3, L4 and L5 are amino acid linkers.    -   7. The antigen binding polypeptide of clause 1, wherein the        polypeptide has at least 90% identity to any one of SEQ ID        NOs:32-43, 62-79, 130-138, 633, 635, 637, 639, 641, 643, 645,        647, 649, 651, 653, 655, 657, 659, 661, 663, 665, 667, 669, 671,        673, 675, 677, and 679, optionally wherein the polypeptide has        at least 95% or 100% identity to any one of SEQ ID NOs:32-43,        62-79, 130-138, 633, 635, 637, 639, 641, 643, 645, 647, 649,        651, 653, 655, 657, 659, 661, 663, 665, 667, 669, 671, 673, 675,        677, and 679; or wherein the polypeptide has at least 90%        identity to the amino acid sequence of SEQ ID NOs:32 or 33 that        does not contain the eight histidine residues at the C-terminus,        optionally wherein the polypeptide has at least 95% or 100%        identity to the amino acid sequence of SEQ ID Nos:32 or 33 that        does not contain the eight histidine residues at the C-terminus.    -   8. The antigen binding polypeptide of clause 7, wherein the        polypeptide is encoded by a polynucleotide having at least 90%        identity to any one of SEQ ID NOs:44-55, 80-97, 139-147, 634,        636, 638, 640, 642, 644, 646, 648, 650, 652, 654, 656, 658, 660,        662, 664, 666, 668, 670, 672, 674, 676, 678, and 680, optionally        wherein the polypeptide is encoded by a polynucleotide having at        least 95% or 100% identity to any one of SEQ ID NOs:44-55,        80-97, 139-147, 634, 636, 638, 640, 642, 644, 646, 648, 650,        652, 654, 656, 658, 660, 662, 664, 666, 668, 670, 672, 674, 676,        678, and 680.    -   9. The antigen binding polypeptide of clause 1, wherein the        polypeptide has at least 90% identity to any one of SEQ ID        NOs:198-209, 346 and 348, optionally wherein the polypeptide has        at least 95% or 100% identity to any one of SEQ ID NOs:198-209,        346 and 348.    -   10. The antigen binding polypeptide of clause 9, wherein the        polypeptide is encoded by a polynucleotide having at least 90%        identity to any one of SEQ ID Nos:347 and 349-361, optionally        wherein the polypeptide is encoded by a polynucleotide having at        least 95% or 100% identity to any one of SEQ ID Nos:347 and        349-361.    -   11. An antigen binding polypeptide complex comprising:    -   (i) a first polypeptide and a second polypeptide, wherein the        first polypeptide has a structure represented by:    -   VL1-VL2-VH2-VH1;    -   VH1-VH2-VL2-VL1;    -   VL1-L1-VL2-L2-VH2-L3-VH1; or    -   VH1-L1-VH2-L2-VL2-L3-VL1; and    -   the second polypeptide has a structure represented by:    -   VL1-VL2-VH2-VH1;    -   VH1-VH2-VL2-VL1;    -   VL1-L1-VL2-L2-VH2-L3-VH1;    -   VH1-L1-VH2-L2-VL2-L3-VL1;    -   VL3-VL4-VH4-VH3;    -   VH3-VH4-VL4-VL3;    -   VL3-L4-VL4-L5-VH4-L6-VH3; or    -   VH3-L4-VH4-L5-VL4-L6-VL3;    -   (ii) a first polypeptide and a second polypeptide, wherein the        first polypeptide has a structure represented by:    -   VL1-VL2-VH2-VH1-Fc;    -   VH1-VH2-VL2-VL1-Fc;    -   VL1-L1-VL2-L2-VH2-L3-VH1-Fc;    -   VH1-L1-VH2-L2-VL2-L3-VL1-Fc;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; or    -   and    -   the second polypeptide has a structure represented by:    -   Fc;    -   VL1-VL2-VH2-VH1-Fc;    -   VH1-VH2-VL2-VL1-Fc;    -   VL1-L1-VL2-L2-VH2-L3-VH1-Fc;    -   VH1-L1-VH2-L2-VL2-L3-VL1-Fc    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc;    -   VL3-VL4-VH4-VH3-Fc;    -   VH3-VH4-VL4-VL3-Fc;    -   VL3-L5-VL4-L6-VH4-L7-VH3-Fc;    -   VH3-L5-VH4-L6-VL4-L7-VL3-Fc;    -   VL3-L5-VL4-L6-VH4-L7-VH3-L8-Fc; or    -   VH3-L5-VH4-L6-VL4-L7-VL3-L8-Fc;    -   or    -   (iii) a polypeptide as defined in clause 5 or clause 6;    -   wherein:    -   VL1 is a first immunoglobulin light chain variable region;    -   VL2 is a second immunoglobulin light chain variable region;    -   VL3 is a third immunoglobulin light chain variable region;    -   VL4 is a fourth immunoglobulin light chain variable region;    -   VH1 is a first immunoglobulin heavy chain variable region;    -   VH2 is a second immunoglobulin heavy chain variable region;    -   VH3 is a third immunoglobulin heavy chain variable region;    -   VH4 is a fourth immunoglobulin heavy chain variable region;    -   Fc is a region comprising an immunoglobulin heavy chain constant        region 2 (CH2), an immunoglobulin heavy chain constant region 3        (CH3), and optionally, an immunoglobulin hinge; and    -   L1, L2, L3, L4, L5, L6, L7 and L8 are amino acid linkers.    -   12. The antigen binding polypeptide complex of clause 11(i),        wherein the first polypeptide has a structure represented by:    -   VL1-VL2-VH2-VH1;    -   VH1-VH2-VL2-VL1;    -   VL1-L1-VL2-L2-VH2-L3-VH1; or    -   VH1-L1-VH2-L2-VL2-L3-VL1; and    -   the second polypeptide has a structure represented by:    -   VL1-VL2-VH2-VH1;    -   VH1-VH2-VL2-VL1;    -   VL1-L1-VL2-L2-VH2-L3-VH1;    -   VH1-L1-VH2-L2-VL2-L3-VL1;    -   wherein:    -   VL1 is a first immunoglobulin light chain variable region;    -   VL2 is a second immunoglobulin light chain variable region;    -   VH1 is a first immunoglobulin heavy chain variable region;    -   VH2 is a second immunoglobulin heavy chain variable region; and    -   L1, L2 and L3 are amino acid linkers.    -   13. The antigen binding polypeptide complex of clause 11(i),    -   wherein the first polypeptide has a structure represented by:    -   VL1-VL2-VH2-VH1;    -   VH1-VH2-VL2-VL1;    -   VL1-L1-VL2-L2-VH2-L3-VH1; or    -   VH1-L1-VH2-L2-VL2-L3-VL1; and    -   wherein the second polypeptide has a structure represented by:    -   VL3-VL4-VH4-VH3;    -   VH3-VH4-VL4-VL3;    -   VL3-L4-VL4-L5-VH4-L6-VH3; or    -   VH3-L4-VH4-L5-VL4-L6-VL3;    -   wherein:    -   VL1 is a first immunoglobulin light chain variable region;    -   VL2 is a second immunoglobulin light chain variable region;    -   VL3 is a third immunoglobulin light chain variable region;    -   VL4 is a fourth immunoglobulin light chain variable region;    -   VH1 is a first immunoglobulin heavy chain variable region;    -   VH2 is a second immunoglobulin heavy chain variable region;    -   VH3 is a third immunoglobulin heavy chain variable region;    -   VH4 is a fourth immunoglobulin heavy chain variable region; and    -   L1, L2, L3, L4, L5 and L6 are amino acid linkers.    -   14. The antigen binding polypeptide complex of clause 11(ii),        wherein the first polypeptide has a structure represented by:    -   VL1-VL2-VH2-VH1-Fc;    -   VH1-VH2-VL2-VL1-Fc;    -   VL1-L1-VL2-L2-VH2-L3-VH1-Fc;    -   VH1-L1-VH2-L2-VL2-L3-VL1-Fc;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc; or    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc;    -   and    -   wherein the second polypeptide has a structure represented by:    -   Fc;    -   VL1-VL2-VH2-VH1-Fc;    -   VH1-VH2-VL2-VL1-Fc;    -   VL1-L1-VL2-L2-VH2-L3-VH1-Fc;    -   VH1-L1-VH2-L2-VL2-L3-VL1-Fc    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc;    -   wherein:    -   VL1 is a first immunoglobulin light chain variable region;    -   VL2 is a second immunoglobulin light chain variable region;    -   VH1 is a first immunoglobulin heavy chain variable region;    -   VH2 is a second immunoglobulin heavy chain variable region;    -   Fc is a region comprising an immunoglobulin heavy chain constant        region 2 (CH2), an immunoglobulin heavy chain constant region 3        (CH3), and optionally, an immunoglobulin hinge; and    -   L1, L2, L3 and L4 are amino acid linkers.    -   15. The antigen binding polypeptide complex of clause 11(ii),    -   wherein the first polypeptide has a structure represented by:    -   VL1-VL2-VH2-VH1-Fc;    -   VH1-VH2-VL2-VL1-Fc;    -   VL1-L1-VL2-L2-VH2-L3-VH1-Fc;    -   VH1-L1-VH2-L2-VL2-L3-VL1-Fc;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc; or    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; and    -   wherein the second polypeptide has a structure represented by:    -   VL3-VL4-VH4-VH3-Fc;    -   VH3-VH4-VL4-VL3-Fc;    -   VL3-L5-VL4-L6-VH4-L7-VH3-Fc;    -   VH3-L5-VH4-L6-VL4-L7-VL3-Fc;    -   VL3-L5-VL4-L6-VH4-L7-VH3-L8-Fc; or    -   VH3-L5-VH4-L6-VL4-L7-VL3-L8-Fc;    -   wherein:    -   VL1 is a first immunoglobulin light chain variable region;    -   VL2 is a second immunoglobulin light chain variable region;    -   VL3 is a third immunoglobulin light chain variable region;    -   VL4 is a fourth immunoglobulin light chain variable region;    -   VH1 is a first immunoglobulin heavy chain variable region;    -   VH2 is a second immunoglobulin heavy chain variable region;    -   VH3 is a third immunoglobulin heavy chain variable region;    -   VH4 is a fourth immunoglobulin heavy chain variable region;    -   Fc is a region comprising an immunoglobulin heavy chain constant        region 2 (CH2), an immunoglobulin heavy chain constant region 3        (CH3), and optionally, an immunoglobulin hinge; and    -   L1, L2, L3, L4, L5, L6, L7 and L8 are amino acid linkers.    -   16. The antigen binding polypeptide complex of clause 11(i),        wherein the first polypeptide has a structure represented by:    -   VL1-VL2-VH2-VH1-CH1;    -   VH1-VH2-VL2-VL1-CH1;    -   VL1-VL2-VH2-VH1-CL;    -   VH1-VH2-VL2-VL1-CL;    -   VL1-VL2-VH2-VH1-CH1-CL;    -   VH1-VH2-VL2-VL1-CH1-CL;    -   VL1-VL2-VH2-VH1-CL-CH1;    -   VH1-VH2-VL2-VL1-CL-CH1;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; or    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; and    -   wherein the second polypeptide has a structure represented by:    -   VL1-VL2-VH2-VH1-CH1;    -   VL1-VL2-VH2-VH1-CH1;    -   VH1-VH2-VL2-VL1-CH1;    -   VL1-VL2-VH2-VH1-CL;    -   VH1-VH2-VL2-VL1-CL;    -   VL1-VL2-VH2-VH1-CH1-CL;    -   VH1-VH2-VL2-VL1-CH1-CL;    -   VL1-VL2-VH2-VH1-CL-CH1;    -   VH1-VH2-VL2-VL1-CL-CH1;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; or    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1;    -   wherein:    -   VL1 is a first immunoglobulin light chain variable region;    -   VL2 is a second immunoglobulin light chain variable region;    -   VH1 is a first immunoglobulin heavy chain variable region;    -   VH2 is a second immunoglobulin heavy chain variable region;    -   CH1 is an immunoglobulin heavy chain constant region 1;    -   CL is an immunoglobulin light chain constant region; and    -   L1, L2, L3, L4 and L5 are amino acid linkers.    -   17. The antigen binding polypeptide complex of clause 11(i),    -   wherein the first polypeptide has a structure represented by:    -   VL1-VL2-VH2-VH1-CH1;    -   VH1-VH2-VL2-VL1-CH1;    -   VL1-VL2-VH2-VH1-CL;    -   VH1-VH2-VL2-VL1-CL;    -   VL1-VL2-VH2-VH1-CH1-CL;    -   VH1-VH2-VL2-VL1-CH1-CL;    -   VL1-VL2-VH2-VH1-CL-CH1;    -   VH1-VH2-VL2-VL1-CL-CH1;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1; or    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1; and    -   wherein the second polypeptide has a structure represented by:    -   VL3-VL4-VH4-VH3-CH1;    -   VH3-VH4-VL4-VL3-CH1;    -   VL3-VL4-VH4-VH3-CL;    -   VH3-VH4-VL4-VL3-CL;    -   VL3-VL4-VH4-VH3-CH1-CL;    -   VH3-VH4-VL4-VL3-CH1-CL;    -   VL3-VL4-VH4-VH3-CL-CH1;    -   VH3-VH4-VL4-VL3-CL-CH1;    -   VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1;    -   VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1;    -   VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL;    -   VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL;    -   VL3-L6-VL4-L7-VH4-L8-VH3-L9-CH1-L10-CL;    -   VH3-L6-VH4-L7-VL4-L8-VL3-L9-CH1-L10-CL;    -   VL3-L6-VL4-L7-VH4-L8-VH3-L9-CL-L10-CH1; or    -   VH3-L6-VH4-L7-VL4-L8-VL3-L9-CL-L10-CH1;    -   wherein    -   VL1 is a first immunoglobulin light chain variable region;    -   VL2 is a second immunoglobulin light chain variable region;    -   VL3 is a third immunoglobulin light chain variable region;    -   VL4 is a fourth immunoglobulin light chain variable region;    -   VH1 is a first immunoglobulin heavy chain variable region;    -   VH2 is a second immunoglobulin heavy chain variable region;    -   VH3 is a third immunoglobulin heavy chain variable region;    -   VH4 is a fourth immunoglobulin heavy chain variable region;    -   CH1 is an immunoglobulin heavy chain constant region 1;    -   CL is an immunoglobulin light chain constant region; and    -   L1, L2, L3, L4, L5, L6, L7, L8, L9 and L10 are amino acid        linkers.    -   18. The antigen binding polypeptide complex of clause 11(ii),        wherein the first polypeptide has a structure represented by:        -   VL1-VL2-VH2-VH1-CH1-Fc;        -   VH1-VH2-VL2-VL1-CH1-Fc;        -   VL1-VL2-VH2-VH1-CL-Fc;        -   VH1-VH2-VL2-VL1-CL-Fc;        -   VL1-VL2-VH2-VH1-CH1-CL-Fc;        -   VH1-VH2-VL2-VL1-CH1-CL-Fc;        -   VL1-VL2-VH2-VH1-CL-CH1-Fc;        -   VH1-VH2-VL2-VL1-CL-CH1-Fc;        -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc;        -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;        -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc;        -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;        -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;        -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;        -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc;        -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc;        -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fc;        -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6-Fc;        -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6-Fc; or        -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc; and        -   wherein the second polypeptide has a structure represented            by:        -   Fc;        -   VL1-VL2-VH2-VH1-CH1-Fc;        -   VH1-VH2-VL2-VL1-CH1-Fc;        -   VL1-VL2-VH2-VH1-CL-Fc;        -   VH1-VH2-VL2-VL1-CL-Fc;        -   VL1-VL2-VH2-VH1-CH1-CL-Fc;        -   VH1-VH2-VL2-VL1-CH1-CL-Fc;        -   VL1-VL2-VH2-VH1-CL-CH1-Fc;        -   VH1-VH2-VL2-VL1-CL-CH1-Fc;        -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc;        -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;        -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc;        -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;        -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;        -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;        -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc; or        -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc;        -   wherein:        -   VL1 is a first immunoglobulin light chain variable region;        -   VL2 is a second immunoglobulin light chain variable region;        -   VH1 is a first immunoglobulin heavy chain variable region;        -   VH2 is a second immunoglobulin heavy chain variable region;        -   CH1 is an immunoglobulin heavy chain constant region 1;        -   CL is an immunoglobulin light chain constant region;    -   Fc is a region comprising an immunoglobulin heavy chain constant        region 2 (CH2), an immunoglobulin heavy chain constant region 3        (CH3), and optionally, an immunoglobulin hinge; and        -   L1, L2, L3, L4, L5 and L6 are amino acid linkers.    -   19. The antigen binding polypeptide complex of clause 11(ii),    -   wherein the first polypeptide has a structure represented by:    -   VL1-VL2-VH2-VH1-CH1-Fc;    -   VH1-VH2-VL2-VL1-CH1-Fc;    -   VL1-VL2-VH2-VH1-CL-Fc;    -   VH1-VH2-VL2-VL1-CL-Fc;    -   VL1-VL2-VH2-VH1-CH1-CL-Fc;    -   VH1-VH2-VL2-VL1-CH1-CL-Fc;    -   VL1-VL2-VH2-VH1-CL-CH1-Fc;    -   VH1-VH2-VL2-VL1-CL-CH1-Fc;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc;    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc;    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc;    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-Fc;    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-Fc;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-Fc;    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-Fc;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fc;    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6-Fc;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6-Fc; or    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc; and    -   wherein the second polypeptide has a structure represented by:    -   VL3-VL4-VH4-VH3-CH1-Fc;    -   VH3-VH4-VL4-VL3-CH1-Fc;    -   VL3-VL4-VH4-VH3-CL-Fc;    -   VH3-VH4-VL4-VL3-CL-Fc;    -   VL3-VL4-VH4-VH3-CH1-CL-Fc;    -   VH3-VH4-VL4-VL3-CH1-CL-Fc;    -   VL3-VL4-VH4-VH3-CL-CH1-Fc;    -   VH3-VH4-VL4-VL3-CL-CH1-Fc;    -   VL3-L7-VL4-L8-VH4-L9-VH3-L10-CH1-Fc;    -   VH3-L7-VH4-L8-VL4-L9-VL3-L10-CH1-Fc;    -   VL3-L7-VL4-L8-VH4-L9-VH3-L10-CL-Fc;    -   VH3-L7-VH4-L8-VL4-L9-VL3-L10-CL-Fc;    -   VL3-L7-VL4-L8-VH4-L9-VH3-L10-CH1-L11-CL-Fc;    -   VH3-L7-VH4-L8-VL4-L9-VL3-L10-CH1-L11-CL-Fc;    -   VL3-L7-VL4-L8-VH4-L9-VH3-L10-CL-L11-CH1-Fc;    -   VH3-L7-VH4-L8-VL4-L9-VL3-L10-CL-L11-CH1-Fc;    -   VL3-L7-VL4-L8-VH4-L9-VH3-L10-CH1-L11-Fc;    -   VH3-L7-VH4-L8-VL4-L9-VL3-L10-CH1-L11-Fc;    -   VL3-L7-VL4-L8-VH4-L9-VH3-L10-CL-L11-Fc;    -   VH3-L7-VH4-L8-VL4-L9-VL3-L10-CL-L11-Fc;    -   VL3-L7-VL4-L8-VH4-L9-VH3-L10-CH1-L11-CL-L12-Fc;    -   VH3-L7-VH4-L8-VL4-L9-VL3-L10-CH1-L11-CL-L12-Fc;    -   VL3-L7-VL4-L8-VH4-L9-VH3-L10-CL-L11-CH1-L12-Fc; or    -   VH3-L7-VH4-L8-VL4-L9-VL3-L10-CL-L11-CH1-L12-Fc;    -   wherein:    -   VL1 is a first immunoglobulin light chain variable region;    -   VL2 is a second immunoglobulin light chain variable region;    -   VL3 is a third immunoglobulin light chain variable region;    -   VL4 is a fourth immunoglobulin light chain variable region;    -   VH1 is a first immunoglobulin heavy chain variable region;    -   VH2 is a second immunoglobulin heavy chain variable region;    -   VH3 is a third immunoglobulin heavy chain variable region;    -   VH4 is a fourth immunoglobulin heavy chain variable region;    -   Fc is a region comprising an immunoglobulin heavy chain constant        region 2 (CH2), an immunoglobulin heavy chain constant region 3        (CH3), and optionally, an immunoglobulin hinge;    -   CH1 is an immunoglobulin heavy chain constant region 1;    -   CL is an immunoglobulin light chain constant region; and    -   L1, L2, L3, L4, L5, L6, L7, L8, L9, L10, L11 and L12 are amino        acid linkers.    -   20. The antigen binding polypeptide complex of clause 11(i) or        clause 11(ii), wherein the first polypeptide has a structure        represented by:    -   VL1-VL2-VH2-VH1;    -   VH1-VH2-VL2-VL1;    -   VL1-VL2-VH2-VH1-Fc;    -   VH1-VH2-VL2-VL1-Fc;    -   VL1-VL2-VH2-VH1-CH1;    -   VH1-VH2-VL2-VL1-CH1;    -   VL1-VL2-VH2-VH1-CL;    -   VH1-VH2-VL2-VL1-CL;    -   VL1-VL2-VH2-VH1-CH1-CL;    -   VH1-VH2-VL2-VL1-CH1-CL;    -   VL1-VL2-VH2-VH1-CL-CH1;    -   VH1-VH2-VL2-VL1-CL-CH1;    -   VL1-VL2-VH2-VH1-CH1-Fc;    -   VH1-VH2-VL2-VL1-CH1-Fc;    -   VL1-VL2-VH2-VH1-CL-Fc;    -   VH1-VH2-VL2-VL1-CL-Fc;    -   VL1-VL2-VH2-VH1-CH1-CL-Fc;    -   VH1-VH2-VL2-VL1-CH1-CL-Fc;    -   VL1-VL2-VH2-VH1-CL-CH1-Fc;    -   VH1-VH2-VL2-VL1-CL-CH1-Fc;    -   VL1-L1-VL2-L2-VH2-L3-VH1;    -   VH1-L1-VH2-L2-VL2-L3-VL1;    -   VL1-L1-VL2-L2-VH2-L3-VH1-Fc;    -   VH1-L1-VH2-L2-VL2-L3-VL1-Fc;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc;    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc;    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc;    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-Fc;    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-Fc;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-Fc;    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-Fc;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fc;    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6-Fc;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6-Fc; or    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc; and    -   wherein the second polypeptide has a structure represented by:    -   VL3-VL4-VH4-VH3;    -   VH3-VH4-VL4-VL3;    -   VL3-VL4-VH4-VH3-Fc;    -   VH3-VH4-VL4-VL3-Fc;    -   VL3-VL4-VH4-VH3-CH1;    -   VH3-VH4-VL4-VL3-CH1;    -   VL3-VL4-VH4-VH3-CL;    -   VH3-VH4-VL4-VL3-CL;    -   VL3-VL4-VH4-VH3-CH1-CL;    -   VH3-VH4-VL4-VL3-CH1-CL;    -   VL3-VL4-VH4-VH3-CL-CH1;    -   VH3-VH4-VL4-VL3-CL-CH1;    -   VL3-VL4-VH4-VH3-CH1-Fc;    -   VH3-VH4-VL4-VL3-CH1-Fc;    -   VL3-VL4-VH4-VH3-CL-Fc;    -   VH3-VH4-VL4-VL3-CL-Fc;    -   VL3-VL4-VH4-VH3-CH1-CL-Fc;    -   VH3-VH4-VL4-VL3-CH1-CL-Fc;    -   VL3-VL4-VH4-VH3-CL-CH1-Fc;    -   VH3-VH4-VL4-VL3-CL-CH1-Fc;    -   VL3-L7-VL4-L8-VH4-L9-VH3;    -   VH3-L7-VH4-L8-VL4-L9-VL3;    -   VL3-L7-VL4-L8-VH4-L9-VH3-Fc;    -   VH3-L7-VH4-L8-VL4-L9-VL3-Fc;    -   VL3-L7-VL4-L8-VH4-L9-VH3-L10-Fc;    -   VH3-L7-VH4-L8-VL4-L9-VL3-L10-Fc;    -   VL3-L7-VL4-L8-VH4-L9-VH3-L10-CH1;    -   VH3-L7-VH4-L8-VL4-L9-VL3-L10-CH1;    -   VL3-L7-VL4-L8-VH4-L9-VH3-L10-CL;    -   VH3-L7-VH4-L8-VL4-L9-VL3-L10-CL;    -   VL3-L7-VL4-L8-VH4-L9-VH3-L10-CH1-L11-CL;    -   VH3-L7-VH4-L8-VL4-L9-VL3-L10-CH1-L11-CL;    -   VL3-L7-VL4-L8-VH4-L9-VH3-L10-CL-L11-CH1;    -   VH3-L7-VH4-L8-VL4-L9-VL3-L10-CL-L11-CH1;    -   VL3-L7-VL4-L8-VH4-L9-VH3-L10-CH1-Fc;    -   VH3-L7-VH4-L8-VL4-L9-VL3-L10-CH1-Fc;    -   VL3-L7-VL4-L8-VH4-L9-VH3-L10-CL-Fc;    -   VH3-L7-VH4-L8-VL4-L9-VL3-L10-CL-Fc;    -   VL3-L7-VL4-L8-VH4-L9-VH3-L10-CH1-L11-CL-Fc;    -   VH3-L7-VH4-L8-VL4-L9-VL3-L10-CH1-L11-CL-Fc;    -   VL3-L7-VL4-L8-VH4-L9-VH3-L10-CL-L11-CH1-Fc;    -   VH3-L7-VH4-L8-VL4-L9-VL3-L10-CL-L11-CH1-Fc;    -   VL3-L7-VL4-L8-VH4-L9-VH3-L10-CH1-L11-Fc;    -   VH3-L7-VH4-L8-VL4-L9-VL3-L10-CH1-L11-Fc;    -   VL3-L7-VL4-L8-VH4-L9-VH3-L10-CL-L11-Fc;    -   VH3-L7-VH4-L8-VL4-L9-VL3-L10-CL-L11-Fc;    -   VL3-L7-VL4-L8-VH4-L9-VH3-L10-CH1-L11-CL-L12-Fc;    -   VH3-L7-VH4-L8-VL4-L9-VL3-L10-CH1-L11-CL-L12-Fc;    -   VL3-L7-VL4-L8-VH4-L9-VH3-L10-CL-L11-CH1-L12-Fc; or    -   VH3-L7-VH4-L8-VL4-L9-VL3-L10-CL-L11-CH1-L12-Fc;    -   wherein:    -   VL1 is a first immunoglobulin light chain variable region;    -   VL2 is a second immunoglobulin light chain variable region;    -   VL3 is a third immunoglobulin light chain variable region;    -   VL4 is a fourth immunoglobulin light chain variable region;    -   VH1 is a first immunoglobulin heavy chain variable region;    -   VH2 is a second immunoglobulin heavy chain variable region;    -   VH3 is a third immunoglobulin heavy chain variable region;    -   VH4 is a fourth immunoglobulin heavy chain variable region;    -   Fc is a region comprising an immunoglobulin heavy chain constant        region 2 (CH2), an immunoglobulin heavy chain constant region 3        (CH3), and optionally, an immunoglobulin hinge;    -   CH1 is an immunoglobulin heavy chain constant region 1;    -   CL is an immunoglobulin light chain constant region; and    -   L1, L2, L3, L4, L5, L6, L7, L8, L9, L10, L11 and L12 are amino        acid linkers.    -   21. The antigen binding polypeptide complex of clause 11(i) or        clause 11(ii), wherein the first polypeptide has a structure        represented by:    -   VL1-VL2-VH2-VH1;    -   VH1-VH2-VL2-VL1;    -   VL1-L1-VL2-L2-VH2-L3-VH1;    -   VH1-L1-VH2-L2-VL2-L3-VL1;    -   VL1-VL2-VH2-VH1-Fc;    -   VH1-VH2-VL2-VL1-Fc;    -   VL1-L1-VL2-L2-VH2-L3-VH1-Fc;    -   VH1-L1-VH2-L2-VL2-L3-VL1-Fc;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc;    -   VL1-VL2-VH2-VH1-CH1;    -   VH1-VH2-VL2-VL1-CH1;    -   VL1-VL2-VH2-VH1-CL;    -   VH1-VH2-VL2-VL1-CL;    -   VL1-VL2-VH2-VH1-CH1-CL;    -   VH1-VH2-VL2-VL1-CH1-CL;    -   VL1-VL2-VH2-VH1-CL-CH1;    -   VH1-VH2-VL2-VL1-CL-CH1;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1;    -   VL1-VL2-VH2-VH1-CH1-Fc;    -   VH1-VH2-VL2-VL1-CH1-Fc;    -   VL1-VL2-VH2-VH1-CL-Fc;    -   VH1-VH2-VL2-VL1-CL-Fc;    -   VL1-VL2-VH2-VH1-CH1-CL-Fc;    -   VH1-VH2-VL2-VL1-CH1-CL-Fc;    -   VL1-VL2-VH2-VH1-CL-CH1-Fc;    -   VH1-VH2-VL2-VL1-CL-CH1-Fc;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc;    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc;    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc;    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-Fc;    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-Fc;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-Fc;    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-Fc;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fc;    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6-Fc;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6-Fc; or    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc; and    -   wherein the second polypeptide has a structure represented by:    -   Fc;    -   VL1-VL2-VH2-VH1;    -   VH1-VH2-VL2-VL1;    -   VL1-L1-VL2-L2-VH2-L3-VH1;    -   VH1-L1-VH2-L2-VL2-L3-VL1;    -   VL1-VL2-VH2-VH1-Fc;    -   VH1-VH2-VL2-VL1-Fc;    -   VL1-L1-VL2-L2-VH2-L3-VH1-Fc;    -   VH1-L1-VH2-L2-VL2-L3-VL1-Fc;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc;    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc;    -   VL1-VL2-VH2-VH1-CH1;    -   VH1-VH2-VL2-VL1-CH1;    -   VL1-VL2-VH2-VH1-CL;    -   VH1-VH2-VL2-VL1-CL;    -   VL1-VL2-VH2-VH1-CH1-CL;    -   VH1-VH2-VL2-VL1-CH1-CL;    -   VL1-VL2-VH2-VH1-CL-CH1;    -   VH1-VH2-VL2-VL1-CL-CH1;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1;    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL;    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL;    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1;    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1;    -   VL1-VL2-VH2-VH1-CH1-Fc;    -   VH1-VH2-VL2-VL1-CH1-Fc;    -   VL1-VL2-VH2-VH1-CL-Fc;    -   VH1-VH2-VL2-VL1-CL-Fc;    -   VL1-VL2-VH2-VH1-CH1-CL-Fc;    -   VH1-VH2-VL2-VL1-CH1-CL-Fc;    -   VL1-VL2-VH2-VH1-CL-CH1-Fc;    -   VH1-VH2-VL2-VL1-CL-CH1-Fc;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc;    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc;    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc;    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-Fc;    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-Fc;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-Fc;    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-Fc;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fc;    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6-Fc;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6-Fc; or    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc;    -   wherein:    -   VL1 is a first immunoglobulin light chain variable region;    -   VL2 is a second immunoglobulin light chain variable region;    -   VH1 is a first immunoglobulin heavy chain variable region;    -   VH2 is a second immunoglobulin heavy chain variable region;    -   CH1 is an immunoglobulin heavy chain constant region 1;    -   CL is an immunoglobulin light chain constant region;    -   Fc is a region comprising an immunoglobulin heavy chain constant        region 2 (CH2), an immunoglobulin heavy chain constant region 3        (CH3), and optionally, an immunoglobulin hinge; and    -   L1, L2, L3, L4, L5 and L6 are amino acid linkers.    -   22. The antigen binding polypeptide complex of clause 11(ii),        wherein the first polypeptide has a structure represented by:    -   VL1-VL2-VH2-VH1-CH1-Fc;    -   VH1-VH2-VL2-VL1-CH1-Fc;    -   VL1-VL2-VH2-VH1-CL-Fc;    -   VH1-VH2-VL2-VL1-CL-Fc;    -   VL1-VL2-VH2-VH1-CH1-CL-Fc;    -   VH1-VH2-VL2-VL1-CH1-CL-Fc;    -   VL1-VL2-VH2-VH1-CL-CH1-Fc;    -   VH1-VH2-VL2-VL1-CL-CH1-Fc;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc;    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc;    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc;    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-Fc;    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-Fc;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-Fc;    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-Fc;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fc;    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6-Fc;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6-Fc; or    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc;    -   wherein the second polypeptide has a structure represented by:    -   Fc;    -   VL1-VL2-VH2-VH1-CH1-Fc;    -   VH1-VH2-VL2-VL1-CH1-Fc;    -   VL1-VL2-VH2-VH1-CL-Fc;    -   VH1-VH2-VL2-VL1-CL-Fc;    -   VL1-VL2-VH2-VH1-CH1-CL-Fc;    -   VH1-VH2-VL2-VL1-CH1-CL-Fc;    -   VL1-VL2-VH2-VH1-CL-CH1-Fc;    -   VH1-VH2-VL2-VL1-CL-CH1-Fc;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc;    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc;    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc;    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-Fc;    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-Fc;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-Fc;    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-Fc;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fc;    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6-Fc;    -   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6-Fc; or    -   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc;    -   wherein:    -   VL1 is a first immunoglobulin light chain variable region;    -   VL2 is a second immunoglobulin light chain variable region;    -   VH1 is a first immunoglobulin heavy chain variable region;    -   VH2 is a second immunoglobulin heavy chain variable region;    -   CH1 is an immunoglobulin heavy chain constant region 1;    -   CL is an immunoglobulin light chain constant region;    -   Fc is a region comprising an immunoglobulin heavy chain constant        region 2 (CH2), an immunoglobulin heavy chain constant region 3        (CH3), and optionally, an immunoglobulin hinge; and    -   L1, L2, L3, L4, L5 and L6 are amino acid linkers.    -   23. The antigen binding polypeptide or the antigen binding        polypeptide complex of any one of clauses 1-22, wherein VL1,        VL2, VH1 and/or VH2 specifically binds to at least one epitope        on at least one antigen selected from the group consisting of        A2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC,        B7H1, B7H2, B7H3, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5,        CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19,        CCL20, CCL21, CCL25, CCR3, CCR4, CD3, CD16A, CD19, CD20, CD24,        CD27, CD28, CD30, CD38, CD39, CD40, CD40L, CD47, CD52, CD70,        CD80, CD86, CD123, CD133, CD137, CD137L, CD160, CD272, CEACAM5,        CLEC9, CLEC91, CRTH2, CSF-1, CSF-2, CSF-3, CXCL1, CXCL2, CXCL4,        CXCL12, CXCL13, CXCR3, cMet, CTLA4, DLL3, DLL4, DNGR-1,        E-cadherin, EGFR, ENTPD1, EpCAM, FCER1, FCER1A, FCER2, FGFR,        FLAP, FOLH1, Gi24, GITR, GITRL, GPR5, GP100, GPRC5D, HER2, HER3,        ICOSL, ICOS, HHLA2, HMGB1, HVEM, IDO, IFNa, IgE, IGF1R,        IL2Rbeta, IL1, ILIA, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R,        IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL1O, IL12, IL13,        IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb, IL18, IL22, IL23, IL25,        IL7, IL33, IL35, ITGB4, ITK, KIR, LAG3, LAMP1, leptin, LPFS2,        MHC class II, MUC-1, MUC-16, NCR3LG1, NKG2D, NKp46, NTPDase-1,        OX40, OX40L, PD-1, PD-L1, PD-L2, PROM1, S152, SIRPalpha, SISP1,        SLC, SPG64, ST2, STEAP1, STEAP2, Syk kinase, STEAP1, TROP2,        TACI, TDO, TGFBETA, T14, TIGIT, TIM3, TLR, TLR2, TLR4, TLR5,        TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP, TSLPR, TWEAK,        VEGF, VISTA, Vstm3, and WUCAM;    -   optionally wherein    -   VL1, VL2, VL3, VL4, VH1, VH2, VH3 and/or VH4 specifically binds        to at least one epitope on at least one antigen selected from        the group consisting of A2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA,        BlyS, BTK, BTLA, B7DC, B7H1, B7H2, B7H3, B7H4, B7H5, B7H6, B7H7,        B7RP1, B7-4, C3, C5, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL11,        CCL15, CCL17, CCL19, CCL20, CCL21, CCL25, CCR3, CCR4, CD3,        CD16A, CD19, CD20, CD24, CD27, CD28, CD30, CD38, CD39, CD40,        CD40L, CD47, CD52, CD70, CD80, CD86, CD123, CD133, CD137,        CD137L, CD160, CD272, CEACAM5, CLEC9, CLEC91, CRTH2, CSF-1,        CSF-2, CSF-3, CXCL1, CXCL2, CXCL4, CXCL12, CXCL13, CXCR3, cMet,        CTLA4, DLL3, DLL4, DNGR-1, E-cadherin, EGFR, ENTPD1, EpCAM,        FCER1, FCER1A, FCER2, FGFR, FLAP, FOLH1, Gi24, GITR, GITRL,        GPR5, GP100, GPRC5D, HER2, HER3, ICOSL, ICOS, HHLA2, HMGB1,        HVEM, IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1, ILIA, IL1B, IL1F10,        IL2, IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8, IL9, IL9R,        IL10, rhIL1O, IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb,        IL18, IL22, IL23, IL25, IL7, IL33, IL35, ITGB4, ITK, KIR, LAG3,        LAMP1, leptin, LPFS2, MHC class II, MUC-1, MUC-16, NCR3LG1,        NKG2D, NKp46, NTPDase-1, OX40, OX40L, PD-1, PD-L1, PD-L2, PROM1,        S152, SIRPalpha, SISP1, SLC, SPG64, ST2, STEAP1, STEAP2, Syk        kinase, STEAP1, TROP2, TACI, TDo, TGFBETA, T14, TIGIT, TIM3,        TLR, TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1,        TSLP, TSLPR, TWEAK, VEGF, VISTA, Vstm3, and WUCAM.    -   24. The antigen binding polypeptide or antigen binding        polypeptide complex of clause 23, wherein:        -   (i) VH1 and VL1 specifically bind to CD28 and VH2 and VL2            specifically bind to CD3;        -   (ii) VH1 and VL1 specifically bind to CD3 and VH2 and VL2            specifically bind to CD28;        -   (iii) VH1 and VL1 specifically bind to CD19 and VH2 and VL2            specifically bind to CD38;        -   (iv) VH1 and VL1 specifically bind to CD38 and VH2 and VL2            specifically bind to CD19;        -   (v) VH1 and VL1 specifically bind to CD3 and VH2 and VL2            specifically bind to CD19;        -   (vi) VH1 and VL1 specifically bind to CD19 and VH2 and VL2            specifically bind to CD3;        -   (vii) VH1 and VL1 specifically bind to CD3 and VH2 and VL2            specifically bind to CD38;        -   (viii) VH1 and VL1 specifically bind to CD38 and VH2 and VL2            specifically bind to CD3;        -   (ix) VH1 and VL1 specifically bind to CD19 and VH2 and VL2            specifically bind to CD28;        -   (x) VH1 and VL1 specifically bind to CD28 and VH2 and VL2            specifically bind to CD19;        -   (xi) VH1 and VL1 specifically bind to CD28 and VH2 and VL2            specifically bind to CD38;        -   (xii) VH1 and VL1 specifically bind to CD38 and VH2 and VL2            specifically bind to CD28;        -   (xiii) VH1 and VL1 specifically bind to CD3 and VH2 and VL2        -   specifically bind to Her2; or        -   (xiv) VH1 and VL1 specifically bind to Her2 and VH2 and VL2            specifically bind to CD3.    -   25. The antigen binding polypeptide or antigen binding        polypeptide complex of clause 23 or clause 24, wherein:    -   (i) VH1 and VL1 specifically bind to CD3; VH2 and VL2        specifically bind to CD28; VH3 and VL3 specifically bind to        CD19; and VH4 and VL4 specifically bind to CD38;    -   (ii) VH1 and VL1 specifically bind to CD3; VH2 and VL2        specifically bind to CD28; VH3 and VL3 specifically bind to        CD38; and VH4 and VL4 specifically bind to CD19;    -   (iii) VH1 and VL1 specifically bind to CD28; VH2 and VL2        specifically bind to CD3; VH3 and VL3 specifically bind to CD19;        and VH4 and VL4 specifically bind to CD38; or    -   (iv) VH1 and VL1 specifically bind to CD28; VH2 and VL2        specifically bind to CD3; VH3 and VL3 specifically bind to CD38;        and VH4 and VL4 specifically bind to CD19.    -   26. The antigen binding polypeptide or antigen binding        polypeptide complex of any one of clauses 1-22, which        specifically binds to a viral peptide, protein, polypeptide, or        a fragment thereof, optionally wherein the VL1, VL2, VL3, VL4,        VH1, VH2, VH3 and/or VH4 specifically binds to at least one        epitope on at least one antigen of a viral peptide, protein,        polypeptide, or a fragment thereof.    -   27. The antigen binding polypeptide or antigen binding        polypeptide complex of clause 26, wherein the viral peptide,        protein, polypeptide, or a fragment is from: influenza virus        neuraminidase, influenza virus hemagglutinin, human respiratory        syncytial virus (RSV)-viral proteins, RSV F glycoprotein, RSV G        glycoprotein, herpes simplex virus (HSV) viral proteins, herpes        simplex virus glycoproteins gB, gC, gD, and gE, Chlamydia MOMP        and PorB antigens, core protein, matrix protein or other protein        of Dengue virus, measles virus hemagglutinin, herpes simplex        virus type 2 glycoprotein gB, poliovirus 1 VP1, envelope        glycoproteins of HIV 1, hepatitis B surface antigen, diptheria        toxin, Streptococcus 24M epitope, gonococcal pilin, pseudorabies        virus g50 (gpD), pseudorabies virus II (gpB), pseudorabies virus        III (gpC), pseudorabies virus glycoprotein H, pseudorabies virus        glycoprotein E, transmissible gastroenteritis glycoprotein 195,        transmissible gastroenteritis matrix protein, swine rotavirus        glycoprotein 38, swine parvovirus capsid protein,        Serpulinahydodysenteriae protective antigen, bovine viral        diarrhea glycoprotein 55, Newcastle disease virus        hemagglutinin-neuraminidase, swine flu hemagglutinin, swine flu        neuraminidase, foot and mouth disease virus, hog colera virus,        swine influenza virus, African swine fever virus, Mycoplasma        liyopneutiioniae, infectious bovine rhinotracheitis virus,        infectious bovine rhinotracheitis virus glycoprotein E,        glycoprotein G, infectious laryngotracheitis virus, infectious        laryngotracheitis virus glycoprotein G or glycoprotein I, a        glycoprotein of La Crosse virus, neonatal calf diarrhoea virus,        Venezuelan equine encephalomyelitis virus, punta toro virus,        murine leukemia virus, mouse mammary tumor virus, hepatitis B        virus core protein and hepatitis B virus surface antigen or a        fragment or derivative thereof, antigen of equine influenza        virus or equine herpes virus, including equine influenza virus        type A/Alaska 91 neuraminidase, equine influenza virus        typeA/Miami 63 neuraminidase, equine influenza virus type        A/Kentucky 81 neuraminidase equine herpes virus type 1        glycoprotein B, and equine herpes virus type 1 glycoprotein D,        antigen of bovine respiratory syncytial virus or bovine        parainfluenza virus, bovine respiratory syncytial virus        attachment protein (BRSV G), bovine respiratory syncytial virus        fusion protein (BRSV F), bovine respiratory syncytial virus        nucleocapsid protein (BRSVN), bovine parainfluenza virus type 3        fusion protein, bovine parainfluenza virus type 3 hemagglutinin        neuraminidase, bovine E viral diarrhoea virus glycoprotein 48        and glycoprotein 53, glycoprotein E of Dengue virus, or        glycoprotein ElE2 of human hepatitis C virus.    -   28. The antigen binding polypeptide or the antigen binding        polypeptide complex of any one of clauses 1-22, wherein VL1,        VL2, VH1 and/or VH2 specifically binds to an HIV protein;    -   optionally wherein VL1, VL2, VL3, VL4, VH1, VH2, VH3 and/or VH4        specifically binds to an HIV protein.    -   29. The antigen binding polypeptide or antigen binding        polypeptide complex of clause 28, wherein VH1, VH2, VH3 and/or        VH4 specifically bind to different HIV proteins or to different        epitopes on the same HIV protein.    -   30. The antigen binding polypeptide or antigen binding        polypeptide complex of clause 28 or clause 29, wherein VL1, VL2,        VL3 and/or VL4 specifically bind to different HIV proteins or to        different epitopes on the same HIV protein.    -   31. The antigen binding polypeptide or antigen binding        polypeptide complex of any one of clauses 28-30, wherein the HIV        protein is an HIV envelope protein, an HIV structural protein,        an HIV functional protein, or an HIV accessory protein.    -   32. The antigen binding polypeptide or antigen binding        polypeptide complex of clause 31, wherein the HIV envelope        protein is HIV envelope glycoprotein (Env), HIV envelope        glycoprotein gp160, HIV envelope surface glycoprotein gp120, or        HIV transmembrane envelope protein gp41.    -   33. The antigen binding polypeptide or antigen binding        polypeptide complex of clause 31, wherein the HIV structural        protein is p17, p24, p7 or p55.    -   34. The antigen binding polypeptide or antigen binding        polypeptide complex of clause 31, wherein the HIV functional        protein is p66, HIV-1 protease (PR) or p31.    -   35. The antigen binding polypeptide or antigen binding        polypeptide complex of clause 31, wherein the HIV accessory        protein is Nef, Tat, Rev, Vif, Vpr or Vpu.    -   36. The antigen binding polypeptide or antigen binding        polypeptide complex of any one of clauses 28-35, wherein VH1 is        a first immunoglobulin heavy chain variable region that        specifically binds to at least one epitope on at least one        antigen selected from the group consisting of Env, gp160, gp120,        gp41, p17, p24, p7, p55, p66, p31, Nef, Tat, Rev, Vif, Vpr and        Vpu; VH2 is a second immunoglobulin heavy chain variable region        that specifically binds to at least one epitope on at least one        antigen selected from the group consisting of Env, gp160, gp120,        gp41, p17, p24, p7, p55, p66, p31, Nef, Tat, Rev, Vif, Vpr and        Vpu; VH3 is a third immunoglobulin heavy chain variable region        that specifically binds to at least one epitope on at least one        antigen selected from the group consisting of Env, gp160, gp120,        gp41, p17, p24, p7, p55, p66, p31, Nef, Tat, Rev, Vif, Vpr and        Vpu; VH4 is a fourth immunoglobulin heavy chain variable region        that specifically binds to at least one epitope on at least one        antigen selected from the group consisting of Env, gp160, gp120,        gp41, p17, p24, p7, p55, p66, p31, Nef, Tat, Rev, Vif, Vpr and        Vpu; VL1 is a first immunoglobulin light chain variable region        that specifically binds to at least one epitope on at least one        antigen selected from the group consisting of Env, gp160, gp120,        gp41, p17, p24, p7, p55, p66, p31, Nef, Tat, Rev, Vif, Vpr and        Vpu; VL2 is a second immunoglobulin light chain variable region        that specifically binds to at least one epitope on at least one        antigen selected from the group consisting of Env, gp160, gp120,        gp41, p17, p24, p7, p55, p66, p31, Nef, Tat, Rev, Vif, Vpr and        Vpu; VL3 is a third immunoglobulin light chain variable region        that specifically binds to at least one epitope on at least one        antigen selected from the group consisting of Env, gp160, gp120,        gp41, p17, p24, p7, p55, p66, p31, Nef, Tat, Rev, Vif, Vpr and        Vpu; and/or VL4 is a fourth immunoglobulin light chain variable        region that specifically binds to at least one epitope on at        least one antigen selected from the group consisting of Env,        gp160, gp120, gp41, p17, p24, p7, p55, p66, p31, Nef, Tat, Rev,        Vif, Vpr and Vpu.    -   37. The antigen binding polypeptide or antigen binding        polypeptide complex of clause 28-35, wherein    -   VL1 is a first immunoglobulin light chain variable region that        specifically binds to at least one epitope on at least one        antigen selected from the group consisting of Env, gp160, gp120,        gp41, p17, p24, p7, p55, p66, p31, Nef, Tat, Rev, Vif, Vpr and        Vpu;    -   VL2 is a second immunoglobulin light chain variable region that        specifically binds to at least one epitope on at least one        antigen selected from the group consisting of Env, gp160, gp120,        gp41, p17, p24, p7, p55, p66, p31, Nef, Tat, Rev, Vif, Vpr and        Vpu;    -   VH1 is a first immunoglobulin heavy chain variable region that        specifically binds to at least one epitope on at least one        antigen selected from the group consisting of Env, gp160, gp120,        gp41, p17, p24, p7, p55, p66, p31, Nef, Tat, Rev, Vif, Vpr and        Vpu; and/or    -   VH2 is a second immunoglobulin heavy chain variable region that        specifically binds to at least one epitope on at least one        antigen selected from the group consisting of Env, gp160, gp120,        gp41, p17, p24, p7, p55, p66, p31, Nef, Tat, Rev, Vif, Vpr and        Vpu.    -   38. The antigen binding polypeptide or antigen binding        polypeptide complex of any one of clauses 28-37, wherein one or        more of VH1, VH2, VH3, and VH4 comprises an amino acid sequence        having at least 90% identity to any one of SEQ ID NOs:338-341,        optionally wherein one or more of VH1, VH2, VH3, and VH4        comprises an amino acid sequence having at least 95% or 100%        identity to any one of SEQ ID NOs:338-341.    -   39. The antigen binding polypeptide or antigen binding        polypeptide complex of any one of clauses 28-38, wherein one or        more of VL1, VL2, VL3 and VL4 comprises an amino acid sequence        having at least 90% identity to any one of SEQ ID NOs:342-345,        optionally wherein one or more of VL1, VL2, VL3 and VL4        comprises an amino acid sequence having at least 95% identity,        or 100% identity to any one of SEQ ID NOs:342-345.    -   40. The antigen binding polypeptide or antigen binding        polypeptide complex of any one of clauses 1-39, wherein the        immunoglobulin hinge comprises an upper hinge region, a middle        hinge region, a lower hinge region, or a combination thereof.    -   41. The antigen binding polypeptide of any one of clauses 1-10        and 23-40, wherein linkers L1, L2, L3, L4, L5, L6, L7, L8, L9,        L10, L11 and/or L12 have a length of from about 1 amino acid to        about 50 amino acids.    -   42. The antigen binding polypeptide complex of any one of        clauses 11-40, wherein linkers L1, L2, L3, L4, L5, L6, L7, L8,        L9, L10, L11 and/or L12 of the first polypeptide and/or the        second polypeptide have a length of from about 1 amino acid to        about 50 amino acids.    -   43. The antigen binding polypeptide or antigen binding        polypeptide complex of any one of clauses 1-42, wherein linkers        L1, L2, L3, L4, L5, L6, L7, L8, L9, L10, L11 and/or L12 comprise        the amino acid sequence of g, a, gss, asg, ggssg, gssgs, gtvaa,        asggs, astgg, asggsg, ggsggssgss, sggsgssggs, ggsggsgsgggsasgsg,        ggsggsgsggggsasgsg, gggssggggsggsgsggsgs, ggggsggsgsggggsasgsg,        gggssggsgsggsgsggsgs, sggssggsgsggsgsggsgssg,        gsgssggggsggsgsggsgssg,        ggggsgsggsgggssggggsggggsggggsggggsggggs,        ggggsggggsggggsggggsggggsggggsggggsggggs,        ggggsgsggsgggssggggsggggsggggsggggsggggssss,        ggggsgsggsgggssggggsggggsggggsggggsggggssssgs, ggsgg,        gsggsagsgsggggsasgsg, ggggs, or gsggsggsgsggggsasgsg (SEQ ID        NOs:1-19 and 681-688) or a sequence having at least 50%, at        least 60%, at least 70%, at least 80%, at least 90%, or at least        95% identity to any one of SEQ ID NOs:1-19 and 681-688.    -   44. The antigen binding polypeptide or antigen binding        polypeptide complex of any one of clauses 1-43, wherein the        amino acid linkers are non-immunogenic.    -   45. The antigen binding polypeptide or antigen binding        polypeptide complex of any one of clauses 1-44, wherein the        amino acid linkers do not contain a consensus T cell epitope.    -   46. The antigen binding polypeptide or antigen binding        polypeptide complex of any one of clauses 1-45, wherein the Fc        region comprises at least one knob-into-hole modification.    -   47. The antigen binding polypeptide complex of claim 46, wherein        the antigen binding polypeptide complex is an IgG1 or IgG4        antibody and the knob-into-hole modification comprises:    -   (i) knob substitutions of S354C and T366W and hole substitutions        of Y349C, T366S, L368A and Y407V;    -   (ii) hole substitutions of L234A, L235A and P239A;    -   (iii) hole substitutions of L234A and L235A;    -   (iv) hole substitutions of M428L and N433S;    -   (v) hole substitutions of M252Y, S254T and T256E; or    -   (vi) a combination thereof;    -   based on the EU numbering scheme.    -   48. The antigen binding polypeptide or antigen binding        polypeptide complex of any one of clauses 1-47, wherein the        antigen binding polypeptide or antigen binding polypeptide        complex comprises a detectable label.    -   49. The antigen binding polypeptide or antigen binding        polypeptide complex of clause 48, wherein the detectable label        is a radioactive label, chemiluminescent label, fluorescent        label, enzyme, or peptide tag, or a combination thereof.    -   50. The antigen binding polypeptide or antigen binding        polypeptide complex of clause 49, wherein the peptide tag is a        polyhistidine tag consisting of from about 4 to about 10        histidine residues.    -   51. The antigen binding polypeptide or antigen binding        polypeptide complex of clause 50, wherein the polyhistidine tag        consists of about 8 histidine residues.    -   52. The antigen binding polypeptide or antigen binding        polypeptide complex of any one of clauses 1-51, wherein the        polypeptide or polypeptide complex is conjugated to an agent as        an antibody-drug conjugate (ADC).    -   53. The antigen binding polypeptide or antigen binding        polypeptide complex of clause 52, wherein the agent is a        cytotoxic agent, immunomodulating agent, imaging agent, or        therapeutic protein, or a combination thereof.    -   54. The antigen binding polypeptide or antigen binding        polypeptide complex of any one of clauses 1-53 that binds to an        antigen with an equilibrium dissociation constant (KD) of from        about 10 μM to about 1 pM; optionally wherein the antigen        binding polypeptide or antigen binding polypeptide complex binds        to an HIV protein with an equilibrium dissociation constant (KD)        of from about 10 μM to about 1 pM.    -   55. An antibody or antigen binding fragment thereof comprising        the antigen binding polypeptide or antigen binding polypeptide        complex of any one of clauses 1-54.    -   56. The antibody or antigen binding fragment thereof of clause        55, wherein the antibody is IgG, IgM, IgE, IgA or IgD.    -   57. The antibody or antigen binding fragment thereof of clause        56, wherein the IgG is IgG1, IgG2, IgG3 or IgG4.    -   58. The antibody or antigen binding fragment thereof of clause        55, wherein the antigen binding fragment is a Fab, scFab, Fab′,        F(ab′)2, Fv, or scFv.    -   59. The antibody or antigen binding fragment thereof of clause        55, wherein the antibody is human or humanized    -   60. A polynucleotide encoding the antigen binding polypeptide or        antigen binding polypeptide complex of any one of clauses 1-54.    -   61. The polynucleotide of clause 60, wherein the polynucleotide        has at least 90% identity to any one of SEQ ID NOs:44-55, 80-97,        139-147, 634, 636, 638, 640, 642, 644, 646, 648, 650, 652, 654,        656, 658, 660, 662, 664, 666, 668, 670, 672, 674, 676, 678, and        680; optionally wherein the polynucleotide has at least 95% or        100% identity to any one of SEQ ID NOs:44-55, 80-97, 139-147,        634, 636, 638, 640, 642, 644, 646, 648, 650, 652, 654, 656, 658,        660, 662, 664, 666, 668, 670, 672, 674, 676, 678, and 680.    -   62. The polynucleotide of clause 60 or clause 61, wherein the        polynucleotide encodes a polypeptide having at least 90%        identity to any one of SEQ ID NOs:32-43, 62-79, 130-138, 633,        635, 637, 639, 641, 643, 645, 647, 649, 651, 653, 655, 657, 659,        661, 663, 665, 667, 669, 671, 673, 675, 677, and 679, optionally        wherein the polynucleotide encodes a polypeptide having at least        95% or 100% identity to any one of SEQ ID NOs:32-43, 62-79,        130-138, 633, 635, 637, 639, 641, 643, 645, 647, 649, 651, 653,        655, 657, 659, 661, 663, 665, 667, 669, 671, 673, 675, 677, and        679; or wherein the polynucleotide encodes a polypeptide having        at least 90% identity to the amino acid sequence of SEQ ID        Nos:32 or 33 that does not contain the eight histidine residues        at the C-terminus, optionally wherein the polynucleotide encodes        a polypeptide having at least 95% or 100% identity to the amino        acid sequence of SEQ ID Nos:32 or 33 that does not contain the        eight histidine residues at the C-terminus.    -   63. The polynucleotide of clause 60, wherein the polynucleotide        has at least 90% identity to any one of SEQ ID NOs:347 and        349-361, optionally wherein the polynucleotide has at least 95%        identity, or 100% identity to any one of SEQ ID NOs:347 and        349-361.    -   64. The polynucleotide of clause 60 or clause 63, wherein the        polynucleotide encodes a polypeptide having at least 90%        identity to any one of SEQ ID NOs:198-209, 346 and 348,        optionally wherein the polynucleotide encodes a polypeptide        having at least 95% or 100% identity to any one of SEQ ID        NOs:198-209, 346 and 348.    -   65. A vector comprising the polynucleotide of any one of clauses        60-64.    -   66. A host cell comprising the polynucleotide of any one of        clauses 60-64 or the vector of clause 65.    -   67. A chimeric antigen receptor (CAR) comprising the antigen        binding polypeptide or antigen binding polypeptide complex of        any one of clauses 1-54.    -   68. An immune cell comprising the CAR of clause 67.    -   69. A pharmaceutical composition comprising (i) the antigen        binding polypeptide or antigen binding polypeptide complex of        any one of clauses 1-54, the antibody or antigen binding        fragment thereof of any one of clauses 55-59, the polynucleotide        of any one of clauses 60-64, the vector of clause 65, the host        cell of clause 66, the CAR of clause 67, the immune cell of        clause 68, or a combination thereof, and (ii) a pharmaceutically        acceptable carrier.    -   70. A kit comprising the antigen binding polypeptide or antigen        binding polypeptide complex of any one of clauses 1-54, the        antibody or antigen binding fragment thereof of any one of        clauses 55-59, the polynucleotide of any one of clauses 60-64,        the vector of clause 65, the host cell of clause 66, the CAR of        clause 67, the immune cell of clause 68, or a combination        thereof.    -   71. An antigen binding polypeptide or antigen binding        polypeptide complex according to any one of clauses 1-54, an        antibody or antigen binding fragment according to any one of        clauses 55-59, a polynucleotide according to any one of clauses        60-64, a vector according to clause 65, a host cell according to        clause 66, a CAR according to clause 67, an immune cell        according to clause 68, a pharmaceutical composition according        to clause 69, or a combination thereof for use in treating or        preventing a disease in a subject in need thereof.    -   72. The antigen binding polypeptide, antigen binding polypeptide        complex, antibody or antigen binding fragment, polynucleotide,        vector, host cell, CAR, immune cell or pharmaceutical        composition for use according to clause 71, wherein the disease        is human immunodeficiency virus (HIV) infection, acquired immune        deficiency syndrome (AIDS), AIDS-related complex (ARC), or        HIV-related opportunistic infection, optionally wherein the        antigen binding polypeptide or antigen binding polypeptide        complex is as defined in any one of clauses 27-38.    -   73. The antigen binding polypeptide, antigen binding polypeptide        complex, antibody or antigen binding fragment, polynucleotide,        vector, host cell, CAR, immune cell or pharmaceutical        composition for use according to clause 72, wherein the disease        is human immunodeficiency virus (HIV) infection caused by HIV-1.    -   74. The antigen binding polypeptide, antigen binding polypeptide        complex, antibody or antigen binding fragment, polynucleotide,        vector, host cell, CAR, immune cell or pharmaceutical        composition for use according to clause 71, wherein the disease        is cancer, optionally wherein the antigen binding polypeptide or        antigen binding polypeptide complex is as defined in any one of        clauses 23-26.    -   75. The antigen binding polypeptide, antigen binding polypeptide        complex, antibody or antigen binding fragment, polynucleotide,        vector, host cell, CAR, immune cell or pharmaceutical        composition for use according to clause 71, wherein the disease        is caused by virus infection; optionally wherein the virus is        influenza virus, respiratory syncytial virus (RSV), Chlamydia,        adenovirdiae, mastadeno virus, aviadenovirus, herpesviridae,        herpes simplex virus 1, herpes simplex virus 2, herpes simplex        virus 5, herpes simplex virus 6, leviviridae, levivirus,        enterobacteria phase MS2, allolevirus, poxviridae,        chordopoxvirinae, parapoxvirus, avipoxvirus, capripoxvirus,        leporiipoxvirus, suipoxvirus, molluscipoxvirus,        entomopoxvirinae, papovaviridae, polyomavirus, papillomavirus,        paramyxoviridae, paramyxovirus, parainfluenza virus 1,        mobillivirus, measles virus, rubulavirus, mumps virus,        pneumonovirinae, pneumovirus, me tapneumo virus, avian        pneumovirus, human metapneumovirus, picornaviridae, enterovirus,        rhinovirus, hepatovirus, human hepatitis A virus, cardiovirus,        andaptho virus, reoviridae, orthoreovirus, orbivirus, rotavirus,        cypovirus, fijivirus, phytoreovirus, oryzavirus, retroviridae,        mammalian type B retroviruses, mammalian type C retroviruses,        avian type C retroviruses, type D retrovirus group, BLV-HTLV        retroviruses, lentivirus, human immunodeficiency virus 1, human        immunodeficiency virus 2, HTLV-I and -II viruses, SARS        coronavirus, herpes simplex E virus, Epstein Barr virus,        cytomegalovirus, hepatitis virus (HCV, HAV, HBV, HDV, HEV),        Toxoplasma gondii virus, Treponema pallidium virus, human        T-lymphotrophic virus, encephalitis virus, West Nile virus,        Dengue virus, Varicella Zoster Virus, rubeola, mumps, rubella,        spumavirus, flaviviridae, hepatitis C virus, hepadnaviridae,        hepatitis B virus, togaviridae, alphavirus sindbis virus,        rubivirus, rubella virus, rhabdoviridae, vesiculovirus,        lyssavirus, ephemerovirus, cytorhabdo virus, necleorhabdo virus,        arenaviridae, arenavirus, lymphocytic choriomeningitis virus,        Ippy virus, lassa virus, coronaviridae, coronavirus, or        torovirus.

EXAMPLES

The following examples are provided to further illustrate aspects of thedisclosure, and are not meant to constrain the disclosure to anyparticular application or theory of operation.

Example 1 Design of Bispecific and Tetraspecific Antibody Constructs

Non-limiting examples of bispecific and tetraspecific antibodyconfigurations are shown in FIGS. 1A-1F, FIG. 8A-8C and FIGS. 16A-16D.Antibody heavy chain variable domain (VH) and light chain variabledomain (VL) sequences targeting human CD3, CD28, CD38, CD19 and Her2were selected from publicly available databases (e.g., GenBank) orpatents to illustrate the feasibility of constructing exemplarybispecific and tetraspecific antibodies of the invention. Linkers ofvarious length and sequence connecting VH and VL regions in differentorders and orientations were tested, with and without different motifsof constant domains (e.g., CL, CH1, CH2, CH3). “Knob” and “hole”substitutions were integrated into respective halves of the antibody Fcregion when Fc heterodimerization was needed. Effector function orhalf-life extension mutations can also be incorporated into Fc regionswhen needed. Once the amino acid sequences for each bispecific ortetraspecific antibody molecule were assembled, DNA encoding thesesequences were codon optimized, synthesized (Cambridge Biologics, LLC,Brookline, Mass.), and cloned into a eukaryotic expression vector.

Example 2 Antibody Expression and Purification

Bispecific and tetraspecific antibodies were produced by transienttransfection of 1 or 2 expression plasmids into Expi293F cells at adensity of 2.5-3.0×10⁶/ml using polyethylenimine (PEI; Polyscience).Plasmid DNA and PEI were diluted in OPTi-MEM (LifeTech) separately andmixed later. The plasmid/PEI mixture, at a ratio of 1:3 (w:w), was addedto the cell culture 10 minutes after mixing. Valproic acid and sodiumpropionate were added to final concentrations of 0.5 mM and 5 mM,respectively, 16-20 hours post transfection. Supernatant was harvested 5days post transfection, and filtered through a 0.45 um filter.Bispecific and tetraspecific antibodies were then purified first byaffinity chromatography using either nickel-charged affinity resin(Ni-NTA, if His-tagged) or Protein A (if contained Fc) in batch modeaccording to the manufacture's standard procedures. After antibodieswere eluted by either 500 mM imidazole (if His-tagged) from Ni-NTA, orusing IgG elusion buffer (Thermo Fischer Scientific) from protein A,they were dialyzed into 10 mM Histidine (pH6.0)+25 mM NaCl overnight.Antibodies were further purified by size exclusion chromatography usingHiload 16/600 Superdex 200 PG or Superdex 200 Increase 10/300 GL (CytivaLifesciences). Fractions with the correct elusion profile were collectedand concentrated for further characterization by SD S-PAGE.

FIG. 2 shows SDS-PAGE results of Ni-NTA purified bispecific moleculeswith histidine tags, as depicted in FIG. 1A.

FIG. 4 shows SDS-PAGE results of protein A purified bispecific,tetravalent molecules with LALAPA Fc, as depicted in FIG. 1B.

Example 3 ELISA Binding Assay

An ELISA binding assay was used to test binding of bispecific andtetraspecific antibodies to their target antigens. Target protein foreach binding site of bispecific and tetraspecific antibodies was coatedin the wells of 96-well Immuno Plates (Thermo Fisher Scientific)overnight at 4° C. Coated plates were blocked using 5% skim milk+2%bovine serum albumin (BSA) in phosphate buffered saline (PBS)+0.25%Tween for one hour at room temperature, then washed three times withPBS+0.25% Tween 20. Serial diluted antibodies and control molecules wereadded to the plate and incubated at room temperature for 1 hr. Plateswere washed three times with PBS+0.25% Tween 20, incubated withhorseradish peroxidase (HPR) conjugated detection antibody for one hourat room temperature, washed again, and then developed with PeroxidaseSubstrate (KPL, Gaithersburg, Md., USA). After the reaction wasterminated by adding 100 μl of KPL TMB BlueSTOP solution, plates wereread at OD₆₅₀ using a plate reader and data analyzed in GraphPad Prism.

FIGS. 3A-3B show ELISA results of bispecific molecule aCD19aCD38-His orisotype control (Control IgG) binding to CD19 (FIG. 3A) and CD38 (FIG.3B).

FIGS. 5A-5B show ELISA results of bispecific, tetravalentaCD28aCD3LALAPAFc, aCD3aCD28LALAPAFc, or isotype control (Control IgG)binding to CD3 (FIG. 5A) and CD28 (FIG. 5B).

FIGS. 7A-7B show ELISA results of bispecific aCD28aCD3LALAPAFc oraCD3aCD28LALAPAFc, or isotype control (Control IgG) binding to CD3 (FIG.7A) and CD28 (FIG. 7B).

FIGS. 9A-9D show ELISA results of tetraspecificaCD28aCD3CD19CD38LALAPAFc, aCD3aCD28CD19CD38LALAPAFc,aCD28aCD3CD19CD38LALAPAFc, or aCD28aCD3CD38CD19LALAPAFc, or isotypecontrol (Control IgG) binding to CD3 (FIG. 9A), CD28 (FIG. 9B), CD19(FIG. 9C), and CD38 (FIG. 9D).

FIG. 12 shows both orientation and linker can affect expression oftetraspecific molecules.

FIGS. 13A-13D show ELISA results of tetraspecificaCD28aCD3CD19CD38LALAPAFc with different linker lengths as depicted inFIG. 12 , or isotype control (Control IgG) binding to CD3 (FIG. 13A),CD28 (FIG. 13B), CD19 (FIG. 13C), and CD38 (FIG. 13D).

FIGS. 14A-14D show ELISA results of tetraspecificaCD28aCD3CH1/CD19CD38CL LALAPAFc with different linkers as depicted inFIG. 8B, or isotype control (Control IgG) binding to CD3 (FIG. 14A),CD28 (FIG. 14B), CD38 (FIG. 14C), and CD19 (FIG. 14D).

FIGS. 15A-15D show ELISA results of tetraspecificaCD28aCD3CD38CD19LALAPAFc, aCD28aCD3CD38CD19LALAPAFc,aCD28aCD3CD38CD19LALAPAFc, or aCD3aCD28CD19CD38LALAPAFc, or isotypecontrol (Control IgG) binding to CD3 (FIG. 15A), CD28 (FIG. 15B), CD38(FIG. 15C), and CD19 (FIG. 15D).

FIGS. 15E-15H show ELISA results of tetraspecificaCD28aCD3L1/aCD38aCD19L1HHLL, aCD28aCD3L1/aCD19aCD38L1_HHLL,aCD3aCD28L1/aCD38aCD19L1_HHLL, aCD3aCD28L1/aCD19aCD38L1_HHLL, or isotypecontrol (Control HuIgG) binding to CD3 (FIG. 15E), CD28 (FIG. 15F), CD38(FIG. 15G), and CD19 (FIG. 15H).

Example 4 T Cell Activation Assay

T cell activation by bispecific and tetraspecific antibodies was testedusing an in vitro T cell activation assay. Purified human peripheralblood mononuclear cells (PBMCs, Blood Research Component, Brookline,Mass., USA) were resuspended in culture medium (RPMI1640 with 10% FBSand supplemented with Penicillin Streptomycin)(Gibco) (2.5×10⁵cells/ml). Serial diluted bispecific, tetraspecific and controlantibodies were first coated onto 96-well flat-bottom culture plates byincubating 2-4 hours in a 37° C. tissue culture incubator. PBMCs (200μL) were then added to each well containing the antibodies and incubatedfor 16-24 hours in a 37° C. tissue culture incubator. The cells werecentrifuged, stained with fluorescent labeled antibodies for T cellmarkers, such as CD3, CD4, CD8, activation marker CD69, and analyzed byan Attune flow cytometer (Thermo Fisher Scientific, USA). Data wereanalyzed using FlowJo software.

FIGS. 11A-11B show activation (CD69+) by tetraspecific moleculesaCD28aCD3/aCD19CD38L1LALAPAFc or aCD3aCD28/CD19CD38L1LALAPAFc, oranti-CD3 mAb, of CD4+(FIG. 11A) or CD8+(FIG. 11B) T cells from threedifferent donors.

Example 5 NFkB Luciferase Reporter Assay

The function of bispecific and tetraspecific antibody constructs wasfurther analyzed using a nuclear factor kappa B (NFkB) luciferasereporter assay. For this assay, Luciferase Reporter Jurkat Stable CellLine (Signosis, Calif., USA) and Jurkat-Lucia™ NFAT Cells (InvivoGen,Calif., USA) were prepared according to manufacturer's protocol.Briefly, cells were thawed for 2 min in a 37° C. water bath and gentlytransferred to a 15 mL conical centrifuge tube containing 10 mLpre-warmed R10 media. Cells were pelleted at 300 g for 5 min at roomtemperature. After removing the supernatant, cells were resuspended in20 mL pre-warmed culture media and transferred to a 75 cm² cultureflask, followed by incubation in a mammalian tissue culture incubatoruntil cells were growing and stable (“3-4 days). Cells were maintainedin culture media+selective antibiotics and normally used 7 days afterthawing.

For antibody stimulation, bispecific, tetraspecific or controlantibodies were serially diluted in PBS and coated onto 96-wellflat-bottom culture plates by incubating 2-4 hours in a 37° C. tissueculture incubator. NFkB Luciferase Reporter Jurkat Stable Cells wereresuspended to 2×10⁶ cells/mL, with 100 μl of cells added to each wellcontaining the antibodies and incubated in a mammalian incubator for 24hours. Assay plates were then taken out and allowed to equilibrate toambient temperature (10-15 min). Bio-Glo™ Reagent (Promega Cat #G7941)(ambient temperature) was added at 50 μl for each well of the assayplate. After 5 minutes, luminescence activity was measured usingVarioskan microplate reader (Thermo Fisher). Data were plotted usingGraphPad Prism software. Jurkat-Lucia™ NFAT Cells were resuspended to7.5×10⁵ cells/mL, with 200 μl of cells added to each well containing theantibodies and incubated in a mammalian incubator for 24 hours. 20 uL ofthe cell culture supernatant was pipetted into a new 96-wellwhite-walled microtiter plate. 50 uL of Quanti-Luc solution (InvivoGen)was then added to each well before luminescence activity was measuredusing Varioskan microplate reader (Thermo Fisher). Data were plottedusing GraphPad Prism software.

FIG. 6 shows NFKB pathway activation by bispecific, tetravalentaCD28aCD3L1LALAPAFc or aCD3aCD28L1LALAPAFc.

FIG. 10 shows NFKB pathway activation by tetraspecificaCD28aCD3/aCD19CD38L1LALAPAFc or aCD3aCD28/CD19CD38L1LALAPAFc.

Example 6 Design of Trispecific Antibody Constructs

Non-limiting examples of additional trispecific antibody configurationsare shown in FIGS. 17A-17E. Such examples include, but are not limitedto, an antigen binding polypeptide complex comprising a firstpolypeptide having an amino acid sequence of SEQ ID NOs:148-166, 180 or181, and a second polypeptide having an amino acid sequence of SEQ IDNOs:167-179.

Antibody heavy chain variable domain (VH) and light chain variabledomain (VL) sequences targeting human CD3, CD28, CD38 and CD19 wereselected from publicly available databases (e.g., GenBank) or patents toillustrate the feasibility of constructing various formats oftrispecific antibodies. Linkers in various length and sequenceconnecting VH and VL regions in different orders and orientations weretested, with and without different motifs of the constant domains (e.g.,CL, CH1, CH2, CH3). “Knob” and “hole” mutations were integrated intorespective halves of the antibody Fc region when Fc heterodimerizationwas needed. Effector function or half-life extension mutations can alsobe incorporated into the Fc sequences when needed. Once the amino acidsequences for each trispecific antibody molecule were assembled, DNAencoding these sequences were codon optimized, synthesized (CambridgeBiologics, LLC, Brookline, Mass.), and cloned into a eukaryoticexpression vector.

Example 7 Trispecific Antibody Expression and Purification

Trispecific antibodies were produced by transient transfection ofexpression plasmids into Expi293F cells at density of 2.5-3.0×10⁶/mlusing polyethylenimine (PEI; Poly science). Plasmid DNA and PEI werediluted in OPTi-MEM (LifeTech) separately and mixed later. Theplasmid/PEI mixture, at a ratio of 1:3 (w:w), was added to the cellculture 10 minutes after mixing. Valproic acid and sodium propionatewere added to final concentrations of 0.5 mM and 5 mM, respectively,16-20 hours post transfection. Supernatant was harvested 5 days posttransfection, and filtered through a 0.45 um filter. Trispecificantibodies were then purified first by affinity chromatography usingProtein A resins in batch mode according to manufacturer's standardprocedures. After antibodies were eluted using IgG elusion buffer(Thermo Fischer Scientific) from protein A, they were dialyzed into 10mM Histidine (pH6.0)+25 mM NaCl overnight. Antibodies were furtherpurified by size exclusion chromatography using Hiload 16/600 Superdex200 PG or Superdex 200 Increase 10/300 GL (Cytiva Lifesciences).Fractions with the correct elusion profile were collected andconcentrated for further characterization.

Example 8 Trispecific Antibody ELISA Binding Analysis

An ELISA binding assay was used to test binding of trispecificantibodies to their target antigens. Target protein for each bindingsite of the trispecific antibodies was coated in the wells of 96-wellImmuno Plates (Thermo Fisher Scientific) overnight at 4° C. Coatedplates were blocked using 5% skim milk+2% bovine serum albumin (BSA) inphosphate buffered saline (PBS)+0.25% Tween for one hour at roomtemperature, then washed three times with PBS+0.25% Tween 20. Serialdiluted trispecific antibodies and control molecules were added to theplates and incubated at room temperature for 1 hr. Plates were washedthree times with PBS+0.25% Tween 20, incubated with horseradishperoxidase (HPR) conjugated detection antibody for one hour at roomtemperature, washed again, and then developed with Peroxidase Substrate(KPL, Gaithersburg, Md., USA). After the reaction was terminated byadding 100 μl of KPL TMB BlueSTOP solution, plates were read at OD₆₅₀using a plate reader and data analyzed in GraphPad Prism.

FIGS. 18A-18C show ELISA results of trispecific aCD28aCD3/aCD38scFv,aCD28aCD3/aCD38Fab, aCD28aCD3/aCD38scFab, aCD28aCD3/aCD38CLCH1, orisotype control (Control IgG) binding to CD3 (FIG. 18A), CD28 (FIG.18B), and CD38 (FIG. 18C).

FIGS. 21A-21D show ELISA results of trispecificaCD28aCD3CL1CH1/aCD38scFvCL, aCD28aCD3CL1CH1/aCD19scFvCL or isotypecontrol (Control IgG) binding to CD3 (FIG. 21A), CD28 (FIG. 21B), CD19(FIG. 21C), and CD38 (FIG. 21D).

Example 9 T Cell Activation Assay

T cell activation by trispecific antibodies was tested using an in vitroT cell activation assay. Purified human peripheral blood mononuclearcells (PBMCs, Blood Research Component, Brookline, Mass., USA) wereresuspended in culture medium (RPMI1640 with 10% fetal bovine serum(FBS) and supplemented with Penicillin Streptomycin) (Gibco) (2.5×10⁵cells/ml). Serial diluted trispecific and control antibodies were firstcoated onto 96-well flat-bottom culture plates by incubating 2-4 hoursin a 37° C. tissue culture incubator. PBMCs (200 μL) were then added toeach well containing the antibodies and incubated for 16-24 hours in a37° C. tissue culture incubator. The cells were centrifuged, stainedwith fluorescent labeled antibodies for T cell markers, such as CD3,CD4, CD8, activation marker CD69, and analyzed by an Attune flowcytometer (Thermo Fisher Scientific, USA). Data were analyzed usingFlowJo software.

FIG. 19 shows the activation (CD69+) by trispecific antibodiesaCD28aCD3L1/aCD38scFv, aCD3aCD28/aCD38scFv, aCD28aCD3/aCD38scFab,aCD3aCD28/aCD38scFab, PMA/IO positive or negative isotype (Control IgG)control, of CD2+ T cells from three different donors.

Example 10 In Vitro Cytolytic Assay

Cytolysis of lymphoma tumor cells Z-138 by T cells mediated bytrispecific antibodies was determined using an in vitro cytolytic assay.PBMCs were isolated from normal human donors by Ficoll separation.Target lymphoma cancer cells Z-138 were labeled with the membrane dyePKH-26 (Sigma-Aldrich) and co-cultured for 16 h in a 37° C. tissueculture incubator with human PBMCs as effector cells at aneffector-to-target (E:T) ratio of 10:1. Titrations of trispecificantibodies were added to the cells at the start of the incubation. Afterthe incubation cells were spun down and then stained with FixableViability dye (Invitrogen). Cells were washed and then run on an Attuneflow cytometer (Thermo Fisher Scientific, USA), followed by analysisusing the FlowJo software. The percentage of killing is calculated bygating on PKH-26+ tumor cells and determining percentage of dying cellsthat stain positive for Fixable Viability dye.

FIGS. 20A-20C show cytolysis of lymphoma tumor cells by T cells mediatedby trispecific antibodies aCD28aCD3L1/aCD38scFv, aCD3aCD28/aCD38scFv,aCD28aCD3/aCD38scFab, aCD3aCD28/aCD38scFab, PMA/IO or isotype (ControlIgG) control from three different donors (FIGS. 20A-20C, respectively).

Example 11 Design of Trispecific Antibody Constructs

Non-limiting examples of multispecific antibody configurations are shownin FIG. 22 . Such examples include, but are not limited to, an antigenbinding polypeptide complex comprising a first polypeptide having anamino acid sequence of SEQ ID NOs:182-195, and a second polypeptidehaving an amino acid sequence of SEQ ID NOs:196 or 197.

Antibody heavy chain variable domains (VH) and light chain variabledomains (VL) targeting human CD3, CD19, CD20, CD28 and CD38 wereselected from publicly available databases (e.g., GenBank) or patents toillustrate the feasibility of constructing various formats oftrispecific antibodies. Linkers in various length and sequenceconnecting VH and VL regions in different orders and orientations weretested, with and without different motifs of the constant domains (e.g.,CL, CH1, CH2, CH3). “Knob” and “hole” mutations were integrated intorespective halves of the antibody Fc region when Fc heterodimerizationwas needed. Effector function or half-life extension mutations can alsobe incorporated into the Fc sequences when needed. Once the amino acidsequences for each multispecific antibody molecule were assembled, DNAencoding these sequences was codon optimized, synthesized (CambridgeBiologics, LLC, Brookline, Mass.), and cloned into a eukaryoticexpression vector.

Example 12 Multispecific Antibody Expression and Purification

Multispecific antibodies were produced by transient transfection ofexpression plasmids into Expi293F cells at density of 2.5-3.0×10⁶/mlusing polyethylenimine (PEI; Poly science). Plasmid DNA and PEI werediluted in OPTi-MEM (LifeTech) separately and mixed later. Theplasmid/PEI mixture, at a ratio of 1:3 (w:w), was added to the cellculture 10 minutes after mixing. Valproic acid and sodium propionatewere added to final concentrations of 0.5 mM and 5 mM, respectively,16-20 hours post transfection. Supernatant was harvested 5 days posttransfection, and filtered through a 0.45 um filter. Multispecificantibodies were then purified first by affinity chromatography usingProtein A resins in batch mode according to the manufacture's standardprocedures. After antibodies were eluted using IgG elusion buffer(Thermo Fischer Scientific) from protein A, they were dialyzed into 10mM Histidine (pH6.0)+25 mM NaCl overnight Antibodies were furtherpurified by size exclusion chromatography using Hiload 16/600 Superdex200 PG or Superdex 200 Increase 10/300 GL (Cytiva Lifesciences).Fractions with the correct elusion profile were collected andconcentrated for further characterization.

Example 13 Multispecific Antibody ELISA Binding Analysis

An ELISA binding assay was used to test binding of multispecificantibodies to their target antigens. Target protein for each bindingsite of the multispecific antibodies was coated in the wells of 96-wellImmuno Plates (Thermo Fisher Scientific) overnight at 4° C. Coatedplates were blocked using 5% skim milk+2% bovine serum albumin (BSA) inphosphate buffered saline (PBS)+0.25% Tween for one hour at roomtemperature, then washed three times with PBS+0.25% Tween 20. Serialdiluted multispecific antibodies and control molecules were added to theplate and incubated at room temperature for 1 hr. Plates were washedthree times with PBS+0.25% Tween 20, incubated with horseradishperoxidase (HPR) conjugated detection antibody for one hour at roomtemperature, washed again, and then developed with Peroxidase Substrate(KPL, Gaithersburg, Md., USA). After the reaction was terminated byadding 100 μl of KPL TMB BlueSTOP solution, the plate was read at OD₆₅₀using a plate reader and data analyzed in GraphPad Prism.

FIGS. 23A-23D show ELISA results of tetraspecificaCD28aCD3LHaCD38/aCD19aCD20, aCD28aCD3LHaCD38/aCD20aCD19,aCD28aCD3HLaCD38/aCD19aCD20, aCD28aCD3HLaCD38/aCD20aCD19, or isotypecontrol (Control IgG) binding to CD3 (FIG. 23A), CD28 (FIG. 23B), CD38(FIG. 23C), and CD19 (FIG. 23D).

Example 14 Design of Additional Antibody Constructs

Non-limiting examples of additional antibody configurations are shown inFIG. 24 . Such examples include, but are not limited to, an antigenbinding polypeptide complex comprising a first polypeptide having anamino acid sequence of any one of SEQ ID NOs:198-209, and a secondpolypeptide having an amino acid sequence of any one of SEQ IDNOs:198-209.

Example 15 Design of Masked Multispecific Molecules

Non-limiting examples of masked tetraspecific antibody configurationsare shown in FIGS. 25-26 and 31 . Such examples include, but are notlimited to, an antigen binding polypeptide complex comprising two orthree polypeptides, each having the sequence of any one of SEQ IDNOs:210-326. In FIG. 25 , variable domains (Fv) of the antibody areshown as heavy chain/light chain pairs, with Fv1-Fv3 targeting tumorassociated antigens (TAAs) or immune costimulatory receptors, and afourth Fv targeting CD3 (aCD3 or aCD3). In some aspects, linkers betweenFv3 and aCD3 contain one or more protease recognition sites. In someaspects, three of the Fvs target human Trop2 (aTROP2), cMet (acMET), andCD28 (aCD28) and a fourth Fv targets CD3. See FIGS. 26 and 31 .

Antibody heavy chain variable domain (VH) and light chain variabledomain (VL) sequences targeting human CD3, CD28, Trop2, and cMet wereselected from publicly available databases (e.g., GenBank) or patents toillustrate the feasibility of constructing various formats oftrispecific antibodies. Linkers in various length and sequenceconnecting VH and VL regions in different orders and orientations weretested, with and without different motifs of the constant domains (e.g.,CL, CH1, CH2, CH3). “Knob” and “hole” mutations were integrated intorespective halves of the antibody Fc region when Fc heterodimerizationwas needed. Effector function or half-life extension mutations can alsobe incorporated into the Fc sequences when needed. Once the amino acidsequences for each trispecific antibody molecule were assembled, DNAencoding these sequences were codon optimized, synthesized (CambridgeBiologics, LLC, Brookline, Mass.), and cloned into a eukaryoticexpression vector.

Example 16 Expression and Purification of Masked and Non-MaskedMultispecific Molecules

Masked and non-masked antibodies were produced by transient transfectionof expression plasmids into Expi293F cells at density of 2.5-3.0×10⁶ perml using PEI (Polyscience). Plasmid DNA and PEI were diluted in OPTi-MEM(LifeTech) separately and mixed later. The plasmid/PEI mixture, at aratio of 1:3 (w:w), was added to the cell culture 10 minutes aftermixing. Valproic acid and sodium propionate were added to finalconcentrations of 0.5 mM and 5 mM, respectively, 16-20 hours posttransfection. Supernatant was harvested 5 days post transfection, andfiltered through a 0.45 μm filter. Multispecific antibodies were thenpurified first by affinity chromatography using Protein A resins inbatch mode according to manufacture's standard procedures. Afterantibodies were eluted using IgG elusion buffer (Thermo FischerScientific) from protein A, they were dialyzed into 10 mM Histidine(pH6.0)+25 mM NaCl overnight Antibodies were further purified by sizeexclusion chromatography using Hiload 16/600 Superdex 200 PG or Superdex200 Increase 10/300 GL (Cytiva Lifesciences). Fractions with the correctelusion profile were collected and concentrated for furthercharacterization.

Example 17 In Vitro Protease Treatment of Masked Multispecific Molecules

Purified masked multispecific molecules at 1 μg/ml were incubated with0.2 μg/ml activated Matriptase (MTP) (R & D systems, Cat #3946-SEB) or0.4 μg/ml MMP9 (R & D system, Cat #911_MP) at 37° C. for 4 hours. 2 μgof digested proteins were run on SDS-PAGE.

FIG. 26 shows SDS-PAGE results of in vitro cleavage of exemplary maskedtetraspecific molecules as depicted. Molecules were treated with eitherMTP or MMP9 protease as specified. GS:non-cleavable linker sequences areon both light chain (LC) and heavy chain (HC). LC_mmp:MMP2 sensitivelinker sequences are on LC, and non-cleavable linker sequences are onHC. HC_mtp:MTP sensitive linker sequences are on HC, and non-cleavablelinker sequences are on LC.

Example 18 ELISA Binding Analysis of Masked and Non-Masked MultispecificMolecules

An ELISA binding assay was used to test binding of multispecificmolecules to their target antigens. Target protein for each binding siteof the multispecific molecules was coated in the wells of 96-well ImmunoPlate (Thermo Fisher Scientific) overnight at 4° C. Coated plates wereblocked using 5% skim milk+2% BSA in PBS+0.25% Tween for one hour atroom temperature, then washed with PBS+0.25% Tween 20 for three times.Serial diluted multispecific molecules and control molecules were addedto the plate and incubated at room temperature for 1 hour. Plates werewashed three times with PBS+0.25% Tween 20, incubated with HPRconjugated detection antibody for one hour at room temperature, washedagain, and then developed with Peroxidase Substrate (KPL, Gaithersburg,Md., USA). After the reaction was terminated by adding 100 μl of KPL TMBBlueSTOP solution, the plate was read at OD₆₅₀ using a plate reader anddata analyzed in GraphPad Prism.

FIG. 27 shows ELISA binding results of exemplary masked tetraspecificmolecules as depicted in FIG. 26 , or negative isotype (Control IgG1),with or without protease treatment. Molecules cleaved or not cleaved byMTP or MMP9 as specified were tested for binding affinity to Trop2 andcMet. Affinities to these two targets were not affected by proteasetreatment.

FIG. 28 shows ELISA binding results of exemplary masked tetraspecificmolecules as depicted in FIG. 26 , or negative isotype (Control IgG1),with or without protease treatment. Molecules cleaved or not cleaved byMTP or MMP9 as specified were tested for binding affinity to CD28.Affinities to these two targets were not affected by protease treatment.

FIG. 29 shows ELISA binding results of exemplary masked tetraspecificmolecules as depicted in FIG. 26 , or negative isotype (Control IgG1),with or without protease treatment. Molecules cleaved or not cleaved byMTP or MMP9 as specified were tested for binding affinity to CD3.

FIG. 31 shows ELISA binding results of exemplary non-maskedtetraspecific molecules as depicted, or negative isotype (hIgG1LALPA)control, to their respective targets of hTrop2, hcMet, hCD28, and hCD3.

Example 19 T Cell Activation Assay

T cell activation by multispecific molecules was tested using an invitro T cell activation assay. Purified human PBMCs (Blood ResearchComponent, Brookline, Mass., USA) were resuspended in culture medium(RPMI1640 with 10% FBS and supplemented with PenicillinStreptomycin)(Gibco) (2.5×10⁵ cells/ml). Serial diluted multispecificand control molecules were first coated onto 96-well flat-bottom cultureplates by incubating for 2-4 hours in a 37° C. tissue culture incubator.PBMCs (200 μL) were then added to each well containing the molecules andincubated for 16-24 hours in a 37° C. tissue culture incubator. Thecells were spun down, stained with florescent labeled antibodies for Tcell activation marker CD69, and analyzed by an Attune flow cytometer(Thermo Fisher Scientific, USA). Data was analyzed using FlowJosoftware.

FIG. 32 shows CD69+ activation by exemplary non-masked tetraspecificmolecules, or negative isotype (IgG1LALPA) control, of CD2+ T cells fromPBMCs of two different donors.

Example 20 In Vitro Cytolytic Assay

Cytolysis of lymphoma tumor cells Z-138 by T cells mediated bytrispecific antibodies was determined using an in vitro cytolytic assay.PBMCs were isolated from normal human donors by Ficoll separation. Invitro cytotoxicity assay was real-time monitored of cellular phenotypicchanges by measurement of electrical impedance using theAgilent×CELLigence RTCA MP system. The system measures impedance usinginterdigitated microelectrodes integrated into the bottom of each wellof the tissue culture E-Plates 96. Briefly, tumor cell HCC1954 wereseeded into an E-plate 96 as target cells (T) at 20K/well culture at 37°C. for overnight, followed by the addition of human PBMC cells as immuneeffector cells (E) at 200K/well, in the presence of the 5-fold seriallydiluted multispecific antibody or human IgG1 isotype control. Cellimpedance (measured as the cell index) was normalized when the effectorcells were added and monitored continuously every 30 min for a durationof up to 160 hours. The cytotoxicity was calculated as Lysis%=100−(experimental normalized cell index/average of control antibodygroup normalized cell index at same concentration)×100.

FIG. 30 shows cytolysis of HCC1954 tumor cells by PBMCs (E:T:10:1)mediated by exemplary masked tetraspecific molecules as depicted in FIG.26 , or negative isotype (Control IgG1), from PBMCs of two donors(KP63250 and KP63251).

Example 21 Design of Additional Antibody Constructs

A further non-limiting example of an additional antibody configurationis shown in FIG. 33 . Variable domains (Fv) of the antibody are shown asheavy chain/light chain pairs, along with Fc domain. Also shown (TNF) isa trimer of extracellular domains of a tumor necrosis factor superfamily(TNFSF) ligand (e.g., 4-1BBL or OX-40L). TNF can be present on both armsof the antibody (shown in FIG. 33 ) or present on one arm and not theother. This example includes, but is not limited to, an antigen bindingpolypeptide complex comprising a first polypeptide having an amino acidsequence of any one of SEQ ID NOs:327-337, and a second polypeptidehaving an amino acid sequence of any one of SEQ ID NOs:327-337.

Example 22 BLI and Flow Cytometry Analysis of Additional AntibodyConstructs

A further non-limiting example of an tetravalent, bispecific antibodyconfiguration is shown in FIG. 34A, called MX846 (SEQ ID NOs:633-636).Other examples that were made include MX847 (SEQ ID NOs:637-640), MX850(SEQ ID NOs:641-644), MX852 (SEQ ID NOs:649-652), and MX854 (SEQ IDNO:657-660). MX846 was analyzed for binding to CD3 by biolayerinterferometry (BLI) (FIG. 34B), and to CD20 by flow cytometry (FIG.34C) as follows.

Binding Kinetic Analyses by Biolayer Interferometry

On the Octet® R8 (Sartorius), recombinant His-tagged CD3, BMCA, or CD28was loaded by His-tag capture onto HIS1K biosensors (100 nM ligand, 300seconds, 1000 RPM). After baseline step (100 seconds, 1000 RPM),association with each test molecule as indicated (100 nM analyte) wasmonitored (300 seconds, 1000 RPM). Dissociation was then monitored (300seconds, 1000 RPM).

All assay steps occurred in 1×kinetic buffer (1×PBS pH 7.4; 0.1% BSA;0.02% Tween-20) at 24 degrees. Prior to each kinetic cycle, the HIS1Kbiosensors were regenerated in 1.5 pH glycine (5 seconds, 1000 RPM) andneutralized in 1×kinetic buffer (5 seconds, 1000 RPM) 5 consecutivetimes and then equilibrated back to 1×kinetic buffer (100 seconds; 1000RPM).

Binding model fit assumed a 1:1 binding model and fit the associationand dissociation together. Baseline was determined by mean of last fiveseconds of baseline step.

In Vitro Cell Surface Binding by Flow Cytometry

Expi293 cells transfected hCD20 were seeded in 96 U-bottom plate at1×10e5 cells/well. The TASER antibody or human IgG1 isotype control wereadded at final concentration 1-10 μg/ml and incubated on ice or at 4° C.for 20-30 minutes. Then, cells were spun down and stained withanti-human Fc PE (Jackson Immuno Research Cat #109-115-098) andviability dye (Invitrogen Cat #65-0864-14). Stained cells were analyzedby flow cytometry and the binding ability were presented as PE positivepopulation among total live cells.

The results in FIGS. 34B and 34C show that MX846 bound to CD3 and CD20.

Example 23 BLI and Flow Cytometry Analysis of Additional AntibodyConstructs

A further non-limiting example of a tetravalent, trispecific antibodyconfiguration is shown in FIG. 35A, called MX855 (SEQ ID NOs:661-664).MX855 was analyzed for binding to CD3 and CD28 by biolayerinterferometry (BLI) (FIG. 35B), and to CD20 by flow cytometry (FIG.35C), using the methods explained above. The results in FIGS. 35B and35C show that MX855 bound to CD3, CD28 and CD20.

Example 24 BLI and Flow Cytometry Analysis of Additional AntibodyConstructs

A further non-limiting example of a tetraspecific antibody configurationis shown in FIG. 36A, called MX851 (SEQ ID NOs:645-648). MX851 wasanalyzed for binding to CD3, CD28 and BCMA by biolayer interferometry(BLI) (FIG. 36B), and to CD20 by flow cytometry (FIG. 36C), using themethods explained above. The results in FIGS. 36B and 36C show thatMX851 bound to CD3, CD28, BCMA and CD20.

Example 25 BLI and Flow Cytometry Analysis of Additional AntibodyConstructs

A further non-limiting example of a tetraspecific antibody configurationis shown in FIG. 37A, called MX853 (SEQ ID NOs:653-656). MX853 wasanalyzed for binding to CD3, CD28 and BCMA by biolayer interferometry(BLI) (FIG. 37B), and to CD20 by flow cytometry (FIG. 37C), using themethods explained above. The results in FIGS. 37B and 37C show thatMX853 bound to CD3, CD28, BCMA and CD20.

Example 26 Killing of Mantle Cell Lymphoma with Additional AntibodyConstructs

In vitro killing of Z-138 tumor cells by T cells mediated bytetravalent, tetraspecific MX851 and tetravalent, trispecific MX855 wasanalyzed. B-lymphoma Z-138 was pre-labeled with PKH26 (Sigma Cat#PKH26GL-1KT) and seeded into a 96-well U-bottom plate as target cells(T) at 20K/well), in the presence of the 5-fold serially diluted TASERantibody or human IgG1 isotype control (hIgG1LALAPA). Human Pan-T cellsisolated from healthy donor PBMC with Dynabeads® Untouched™ Human TCells kit (Invitrogen Cat #11344D) were added as immune effector cells(E) at 60K/well (E:T=3:1) and incubated at 37° C. for 24-48 hours. Thecells were spun down and stained with Viability Dye eFluor™ 660(Invitrogen Cat #65-0864-14) after incubation. Stained cells wereanalyzed by flow cytometry for live cell counts. The cytotoxicity wascalculated as Lysis %=100-(experimental live cell number/average ofcontrol antibody group live cell number at same concentration)*100.

The results in FIGS. 38A-38B show that both MX851 (FIG. 38A) and MX855(FIG. 38B) mediated killing of Z-138 tumor cells.

Example 27 BLI Analysis of Additional Antibody Constructs

A further non-limiting example of a trispecific antibody configurationis shown in FIG. 39A, called MX894 (SEQ ID NOs:665-668;VRC01scFv/PGT121×10e8v4L1IgG1LS). MX894 was analyzed for binding to 10e8fusion peptide, and CD4 site-dependent and CD4 site-independent HIVspike protein by biolayer interferometry (BLI) as follows.

Binding Kinetic Analyses by Biolayer Interferometry

On the Octet® R8 (Sartorius), recombinant His-tagged HIV RCS3, HIVgp140ACD4, or HIV 10e8 peptide was loaded by His-tag capture onto HIS1Kbiosensors (100 nM ligand, 300 seconds, 1000 RPM). After baseline step(100 seconds, 1000 RPM), association with each test molecule asindicated (100 nM analyte) was monitored (300 seconds, 1000 RPM).Dissociation was then monitored (300 seconds, 1000 RPM).

All assay steps occurred in 1× kinetic buffer (1×PBS pH 7.4; 0.1% BSA;0.02% Tween-20) at 24 degrees C. Prior to each kinetic cycle, the HIS1Kbiosensors were regenerated in 1.5 pH glycine (5 seconds, 1000 RPM) andneutralized in 1×kinetic buffer (5 seconds, 1000 RPM) 5 consecutivetimes and then equilibrated back to 1×kinetic buffer (100 seconds; 1000RPM).

Binding model fit assumed a 1:1 binding model and fit the associationand dissociation together. Baseline was determined by mean of last fiveseconds of baseline step.

The results in FIGS. 39B-39D show that MX894 bound to 10e8 fusionpeptide (FIG. 39B), and CD4 site-dependent (FIG. 39C) and CD4site-independent (FIG. 39D) HIV spike protein.

Example 28 BLI Analysis of Additional Antibody Constructs

A further non-limiting example of a tetraspecific antibody configurationis shown in FIG. 40A, called MX873 (SEQ ID NOs:669-672;VRC26.25×10-1074L9/VRC01×PGT121L1 IgG1LS). MX873 was analyzed forbinding to CD4 site-dependent and CD4 site-independent HIV spike proteinby biolayer interferometry (BLI) as described above.

The results in FIGS. 40B-40C show that MX873 bound to CD4 site-dependent(FIG. 40B) and CD4 site-independent (FIG. 40C) HIV spike protein.

Example 29 BLI Analysis of Additional Antibody Constructs

A further non-limiting example of a tetraspecific antibody configurationis shown in FIG. 41A, called MX875 (SEQ ID NOs:673-676;10-1074×VRC26.25L9/VRC01×PGT121L1 IgG1LS). MX875 was analyzed forbinding to CD4 site-dependent and CD4 site-independent HIV spike proteinby biolayer interferometry (BLI) as described above.

The results in FIGS. 41B-41C show that MX875 bound to CD4 site-dependent(FIG. 41B) and CD4 site-independent (FIG. 41C) HIV spike protein.

Example 30 BLI Analysis of Additional Antibody Constructs

A further non-limiting example of a tetraspecific antibody configurationis shown in FIG. 42A, called MX877 (SEQ ID NOs:677-680;STAR_VRC26.25×PGT128L9/STAR_VRC01×PGT121L1 IgG1LS). MX877 was analyzedfor binding to CD4 site-dependent and CD4 site-independent HIV spikeprotein by biolayer interferometry (BLI) as described above.

The results in FIGS. 42B-42C show that MX877 bound to CD4 site-dependent(FIG. 42B) and CD4 site-independent (FIG. 42C) HIV spike protein.

All publications, patents and patent applications mentioned in thisapplication are herein incorporated in their entirety by reference intothe specification, to the same extent as if each individual publication,patent or patent application was specifically and individually indicatedto be incorporated herein by reference. In addition, citation oridentification of any reference in this application shall not beconstrued as an admission that such reference is available as prior artto the present invention. To the extent that section headings are used,they should not be construed as necessarily limiting.

1-127. (canceled)
 128. An antigen binding polypeptide complex comprisinga first polypeptide and a second polypeptide; wherein the firstpolypeptide has a structure represented by: VL1-VL2-VH2-VH1-Fc;VH1-VH2-VL2-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc; wherein the second polypeptide has astructure represented by: VL3-VL4-VH4-VH3-Fc; VH3-VH4-VL4-VL3-Fc;VL3-L5-VL4-L6-VH4-L7-VH3-Fc; VH3-L5-VH4-L6-VL4-L7-VL3-Fc;VL3-L5-VL4-L6-VH4-L7-VH3-L8-Fc; or VH3-L5-VH4-L6-VL4-L7-VL3-L8-Fc; andwherein: VL1 is a first immunoglobulin light chain variable region; VL2is a second immunoglobulin light chain variable region; VL3 is a thirdimmunoglobulin light chain variable region; VL4 is a fourthimmunoglobulin light chain variable region; VH1 is a firstimmunoglobulin heavy chain variable region; VH2 is a secondimmunoglobulin heavy chain variable region; VH3 is a thirdimmunoglobulin heavy chain variable region; VH4 is a fourthimmunoglobulin heavy chain variable region; Fc is a region comprising animmunoglobulin heavy chain constant region 2 (CH2), an immunoglobulinheavy chain constant region 3 (CH3), and optionally, an immunoglobulinhinge; and L1, L2, L3, L4, L5, L6, L7 and L8 are amino acid linkers.129. The antigen binding polypeptide complex of claim 128, wherein thefirst polypeptide has a structure represented by:VL1-VL2-VH2-VH1-CH1-Fc; VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc;VH1-VH2-VL2-VL1-CL-Fc; VL1-VL2-VH2-VH1-CH1-CL-Fc;VH1-VH2-VL2-VL1-CH1-CL-Fc; VL1-VL2-VH2-VH1-CL-CH1-Fc;VH1-VH2-VL2-VL1-CL-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc; VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc; wherein the secondpolypeptide has a structure represented by: VL3-VL4-VH4-VH3-CH1-Fc;VH3-VH4-VL4-VL3-CH1-F c; VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-F c;VL3-VL4-VH4-VH3-CH1-CL-Fc; VH3-VH4-VL4-VL3-CH1-CL-F c;VL3-VL4-VH4-VH3-CL-CH1-Fc; VH3-VH4-VL4-VL3-CL-CH1-F c;VL3-L7-VL4-L8-VH4-L9-VH3-L10-CH1-Fc; VH3-L7-VH4-L8-VL4-L9-VL3-L10-CH1-Fc; VL3-L7-VL4-L8-VH4-L9-VH3-L10-CL-Fc;VH3-L7-VH4-L8-VL4-L9-VL3-L10-CL-Fc;VL3-L7-VL4-L8-VH4-L9-VH3-L10-CH1-L11-CL-Fc;VH3-L7-VH4-L8-VL4-L9-VL3-L10-CH1-L11-CL-F c;VL3-L7-VL4-L8-VH4-L9-VH3-L10-CL-L11-CH1-Fc;VH3-L7-VH4-L8-VL4-L9-VL3-L10-CL-L11-CH1-F c;VL3-L7-VL4-L8-VH4-L9-VH3-L10-CH1-L11-CL-L12-Fc;VH3-L7-VH4-L8-VL4-L9-VL3-L10-CH1-L11-CL-L12-Fc;VL3-L7-VL4-L8-VH4-L9-VH3-L10-CL-L11-CH1-L12-Fc; orVH3-L7-VH4-L8-VL4-L9-VL3-L10-CL-L11-CH1-L12-F c; and wherein: CH1 is animmunoglobulin heavy chain constant region 1; CL is an immunoglobulinlight chain constant region; and L1, L2, L3, L4, L5, L6, L7, L8, L9,L10, L11 and L12 are amino acid linkers.
 130. An antigen bindingpolypeptide complex comprising a first polypeptide and a secondpolypeptide; wherein the first polypeptide has a structure representedby: VL1-VL2-VH2-VH1-Fc; VH1-VH2-VL2-VL1-Fc; VL1-VL2-VH2-VH1-CH1-Fc;VH1-VH2-VL2-VL1-CH1-Fc; VL1-VL2-VH2-VH1-CL-Fc; VH1-VH2-VL2-VL1-CL-Fc;VL1-VL2-VH2-VH1-CH1-CL-Fc; VH1-VH2-VL2-VL1-CH1-CL-Fc;VL1-VL2-VH2-VH1-CL-CH1-Fc; VH1-VH2-VL2-VL1-CL-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc; VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fc;VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6-Fc;VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6-Fc; orVH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc; wherein the secondpolypeptide has a structure represented by: VL3-VL4-VH4-VH3-Fc;VH3-VH4-VL4-VL3-F c; VL3-VL4-VH4-VH3-CH1-Fc; VH3-VH4-VL4-VL3-CH1-F c;VL3-VL4-VH4-VH3-CL-Fc; VH3-VH4-VL4-VL3-CL-F c;VL3-VL4-VH4-VH3-CH1-CL-Fc; VH3-VH4-VL4-VL3-CH1-CL-F c;VL3-VL4-VH4-VH3-CL-CH1-Fc; VH3-VH4-VL4-VL3-CL-CH1-F c;VL3-L7-VL4-L8-VH4-L9-VH3-Fc; VH3-L7-VH4-L8-VL4-L9-VL3-F c;VL3-L7-VL4-L8-VH4-L9-VH3-L10-Fc; VH3-L7-VH4-L8-VL4-L9-VL3-L10-Fc;VL3-L7-VL4-L8-VH4-L9-VH3-L10-CH1-Fc; VH3-L7-VH4-L8-VL4-L9-VL3-L10-CH1-Fc; VL3-L7-VL4-L8-VH4-L9-VH3-L10-CL-Fc;VH3-L7-VH4-L8-VL4-L9-VL3-L10-CL-Fc;VL3-L7-VL4-L8-VH4-L9-VH3-L10-CH1-L11-CL-Fc;VH3-L7-VH4-L8-VL4-L9-VL3-L10-CH1-L11-CL-F c;VL3-L7-VL4-L8-VH4-L9-VH3-L10-CL-L11-CH1-Fc;VH3-L7-VH4-L8-VL4-L9-VL3-L10-CL-L11-CH1-F c;VL3-L7-VL4-L8-VH4-L9-VH3-L10-CH1-L11-CL-L12-Fc;VH3-L7-VH4-L8-VL4-L9-VL3-L10-CH1-L11-CL-L12-Fc;VL3-L7-VL4-L8-VH4-L9-VH3-L10-CL-L11-CH1-L12-Fc; orVH3-L7-VH4-L8-VL4-L9-VL3-L10-CL-L11-CH1-L12-F c; and wherein: VL1 is afirst immunoglobulin light chain variable region; VL2 is a secondimmunoglobulin light chain variable region; VL3 is a thirdimmunoglobulin light chain variable region; VL4 is a fourthimmunoglobulin light chain variable region; VH1 is a firstimmunoglobulin heavy chain variable region; VH2 is a secondimmunoglobulin heavy chain variable region; VH3 is a thirdimmunoglobulin heavy chain variable region; VH4 is a fourthimmunoglobulin heavy chain variable region; Fc is a region comprising animmunoglobulin heavy chain constant region 2 (CH2), an immunoglobulinheavy chain constant region 3 (CH3), and optionally, an immunoglobulinhinge; CH1 is an immunoglobulin heavy chain constant region 1; CL is animmunoglobulin light chain constant region; and L1, L2, L3, L4, L5, L6,L7, L8, L9, L10, L11 and L12 are amino acid linkers.
 131. The antigenbinding polypeptide complex of claim 128, wherein VH1, VL1, VH3 and VL3bind to the same antigen.
 132. The antigen binding polypeptide complexof claim 128, wherein VH2, VL2, VH4 and VL4 bind to the same antigen.133. The antigen binding polypeptide complex of claim 128, wherein VH1,VH2, VH3 and VH4 each bind to different antigens, and VL1, VL2, VL3 andVL4 each bind to different antigens.
 134. The antigen bindingpolypeptide complex of claim 128, wherein linkers L1, L2, L3, L4, L5,L6, L7 and L8 each comprise the amino acid sequence of any one of SEQ IDNOs:1-19 and 681-688, or a sequence having at least 95% identity to anyone of SEQ ID NOs:1-19 and 681-688.
 135. The antigen binding polypeptidecomplex of claim 129, wherein linkers L1, L2, L3, L4, L5, L6, L7, L8,L9, L10, L11 and L12 each comprise the amino acid sequence of any one ofSEQ ID NOs:1-19 and 681-688, or a sequence having at least 95% identityto any one of SEQ ID NOs:1-19 and 681-688.
 136. The antigen bindingpolypeptide complex of claim 130, wherein linkers L1, L2, L3, L4, L5,L6, L7, L8, L9, L10, L11 and L12 each comprise the amino acid sequenceof any one of SEQ ID NOs:1-19 and 681-688, or a sequence having at least95% identity to any one of SEQ ID NOs:1-19 and 681-688.
 137. The antigenbinding polypeptide complex of claim 128, wherein the Fc regioncomprises at least one knob-into-hole modification.
 138. The antigenbinding polypeptide complex claim 129, wherein the Fc region comprisesat least one knob-into-hole modification.
 139. The antigen bindingpolypeptide complex of claim 130, wherein the Fc region comprises atleast one knob-into-hole modification.
 140. An antibody or antigenbinding fragment thereof comprising the antigen binding polypeptidecomplex of claim
 128. 141. The antibody or antigen binding fragmentthereof of claim 140, wherein the antigen binding fragment is a Fab,scFab, Fab′, F(ab′)2, Fv, or scFv.
 142. The antibody or antigen bindingfragment thereof of claim 140, wherein the antibody is human orhumanized.
 143. A polypeptide having at least 95% identity to any one ofSEQ ID NOs:32-43, 62-79, 130-138, 633, 635, 637, 639, 641, 643, 645,647, 649, 651, 653, 655, 657, 659, 661, 663, 665, 667, 669, 671, 673,675, 677, and 679, or having at least 95% identity to the amino acidsequence of SEQ ID NOs:32 or 33 that does not contain the eighthistidine residues at the C-terminus.
 144. A polynucleotide having atleast 95% identity to any one of SEQ ID NOs:44-55, 80-97, 139-147, 634,636, 638, 640, 642, 644, 646, 648, 650, 652, 654, 656, 658, 660, 662,664, 666, 668, 670, 672, 674, 676, 678, and
 680. 145. A vectorcomprising the polynucleotide of claim
 144. 146. A host cell comprisingthe polynucleotide of claim
 144. 147. A pharmaceutical compositioncomprising (i) the antigen binding polypeptide complex of claim 128, and(ii) a pharmaceutically acceptable carrier.
 148. A pharmaceuticalcomposition comprising (i) a polynucleotide encoding the antigen bindingpolypeptide complex of claim 128, and (ii) a pharmaceutically acceptablecarrier.
 149. A method of treating or preventing a cancer, comprisingadministering to a subject in need thereof a therapeutically effectiveamount of the antigen binding polypeptide complex of claim
 128. 150. Amethod of treating or preventing a virus infection, comprisingadministering to a subject in need thereof a therapeutically effectiveamount of the antigen binding polypeptide complex of claim 128.